<SEC-DOCUMENT>0001551152-22-000030.txt : 20220804
<SEC-HEADER>0001551152-22-000030.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804155733
ACCESSION NUMBER:		0001551152-22-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Inc.
		CENTRAL INDEX KEY:			0001551152
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				320375147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35565
		FILM NUMBER:		221136347

	BUSINESS ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
		BUSINESS PHONE:		(847) 932-7900

	MAIL ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abbv-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee,d:8040488224cd40d194fd225edca967d2--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:abbv="http://www.abbvie.com/20220630" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abbv-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8xLTEtMS0xLTk3NjE2_8dfc04f4-30a1-4f1e-80ea-57afc8d8bca4">0001551152</ix:nonNumeric><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8yLTEtMS0xLTk3NjE2_5b248bfa-f1e4-409a-8ab8-2b2b0a2b827e">false</ix:nonNumeric><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8zLTEtMS0xLTk3NjE2_95bd13fa-26cf-4cbd-9eea-b91d4df8f60c">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl80LTEtMS0xLTk3NjE2_a9d447b6-a64b-407f-ae82-14467625c236">2022</ix:nonNumeric><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl81LTEtMS0xLTk3NjE2_836b28e1-6bdf-4a08-9a23-0d15f419a12d">Q2</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xMDAvZnJhZzpiMTBlYzkxZmU4MTU0YTAyODQ1YzdhN2FiNDFiYjBlMS90YWJsZTpkMmQzZmYyZGMxMjA0ZDU3YjZhZTYyMDkxNTlmZDkzZC90YWJsZXJhbmdlOmQyZDNmZjJkYzEyMDRkNTdiNmFlNjIwOTE1OWZkOTNkXzEtMS0xLTEtOTc2MTY_602ac02c-1c11-436b-b4b4-155ff770bb7f">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abbv-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3edc6e25d594992851f6063814f5231_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d97026aba9492bbb24ab4366e9ed1b_I20220727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5695becc3594da099d28f6bd485f543_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca39d7498d64a07bc02cb92ab8980b5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bba3be992d1453a87a14f0fc2f2e003_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd10bb64fb74478ca8debe7969144471_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae5bbb2ee744272bd95a22daad94e1f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23011746e9d454494e543e106a64681_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331646900637403aaa44f99b19a7e033_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b62204439a646a58b785ecf93877432_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id749deebcb704c62b8d4183e0bcd069a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5349780f1cf74c438be36b3034549e8a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c48f78d5eb442ea02eb2415d1ad543_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2313112557e4fc19d7b91b3581dbfc8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21c67498e334a7c8353b31179d82f98_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i648a34fc11d2459da8234225c63c7180_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcf2868925d4b4c8aa4037dcd0e5af4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3515fb6a244df8a64a70f4a299d580_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b5b734cf6ca4161852ec96132b5b371_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa65e7da4134abaaff3c9854cd90499_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2e3d15040b43b680868217bfddc553_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0c1adb73294f28ae198cc2a832474e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43cafd566d444139ef47736b216cfb1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63689aa1556b43cd941eb0a471e03f21_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd8b399923342659954704e5a03ca81_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0fc5d280fb74f1eb96d3958d3310a50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c4079c9e0b47618569cdc1a099cb9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c496813ec4c4dce8734e3932b3a401d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18ec1eab6f64c5b8ad244778c1a7e89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a455a093e74bb9ba124f24699eed85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744bb82611c44753ad6906f397e5e897_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1816b7eac954956b4765afd462e3f73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b644de3252423c91efecac801ba901_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925631283eb246fca0b6016ff6e36dcd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5aa927ee5d642738ac384f97cdb27ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7be7b002a544fc89aa3eff960ce4c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c423a29ebb405295d44e99550f4888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143fa36216244880b463624089eaba3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b4a2ace56f474f9eb07fc6b9af67c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3894668cb74143f090cddbd16341590c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b72292beef4cbf9fac74da6779e3fb_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59db14e384674164aab7d20a75d7554b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JuvisePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b7b50a66b144149f8c1287ceec7314_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JuvisePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98df2b43008404b90c33af8edee6dd2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d7c4579b3144d4a545b08d34ae8d8f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied44bd1369ed4bdb88cabc67622ac9dd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia760c3d64fb74371a378c6623497a7ee_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92651b474c794e5ca8ac957b8b9b0e59_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1717a97362f94154b97a937865fbff42_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf29d7b949e14095835b529dec0be4b4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6eb92d83444f61b91925e0d7f8ff5a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7107caab25d347ebaae1ee759946b263_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe6e878897e14d5ea3dc67ebfd22e441_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1955ccecde54928aa0c73f282a2340a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d666e53ce1843c38b0611e7ba387246_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i520d59c123c940099b7566525c161f63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1be3d4d92e4a689787ce9b5a84b41a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17953cb362654702ad658e6a13cfb987_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895042247e154437ae780eab2540751d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fcaf1fd7b534884b238ec95d10826b7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439ea03a9e384ea8baf9310fdfda9c21_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a65557623304acba06de330a83ee93d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4361107b3034a3c94e481eec57cf68a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c025272d3c4c2194f440828c692e80_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9175130fd841a5a84a0d431d286267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f7ec1f596843529dece3b7b59c127d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7df08664994f12aca1518baebbe045_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88c1ac3f5e440e784ff845b1c57c6e7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812ac0d2871a40f1aafd158554ed5422_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc63ba180b3456d81d30cf250f754f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fce41091494b70b87e4d7af3546c7d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8022aceb9c14776b862ea4d4d6d6439_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab97e9e01f14b32910efe469af4e78e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8d8f7d150e4296aee9bf18bd08cc12_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a5b6a497ea346abad95173f039d362e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb1e9d02bf34f17b2a0eed52a00027a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcd977a37754942a73c727470b4f98f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ccfe28417c469f8af551c99b927b19_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a05939f8244a33897e7422c89f7126_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e74bcc52335423cbc3f7f772ff0e679_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id282193bd524451fb438bb7e138e29ac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e30abb6a7a486f885ad340a96c5778_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6915f306024be09472c7f5080f0fa1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6899f65d669d4afea3cd976e00ecbe6f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e1c3dc13f54e42a2d2dc2c62ec8e91_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d0d44f11db4eb99c11417e2743e862_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87cf8b8c10db40639f8c71e5fa2e3818_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f4c1493f0542bf83279f44f2ec5342_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e06ca0731cf4d6a8f878bc559195695_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1654b4f6b905425eb698282a6331007e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871d07741b564eae82a08aa0199ea0cd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37c40029abd4cb58eba88c002702a40_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb8785d8ad7402c9c7f7eb39826f245_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7570209272a04303b295e10fbfbaa969_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6ef1b50dd847ef8aafa94acba4e841_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b456e53d96948d096132c028d6d6d45_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf06b1b60dd7473091c775a625e20ee8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4df6c592544227855270f51208be85_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie235947ffd0b4fd494f966cfa005097d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib759084aea2f4496bf0b655de783f845_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf0ce88a8a04b83934728dac91cf848_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9690c3dd790403b890e9214d1dca483_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca60bffa3784e57811f6fbbdf1b19bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641166a797c04452b983f67696448927_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93c2d6ffcd9446ca4da0534ab40b4da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96b0b1b9688402b88d483caeec8f26e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebc83f6b36448f796534e54e707d893_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ca5c0ed3734cb0b0a99ad300871adb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae698ca482024ce3b8216d18a4baf683_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4524aeddacca4e89affea472fd4d9845_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2528382e46b44d108bf6d00b5efc76b8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ea8e2e6bee41e29619c4f66c42dbe3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa7cb14d24744b7acd20b1e031fb6b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba71512b143247428f9ba4531e9ff25d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910af4ba6c4148dead70c8fa5c3026a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a19c3fd69054e33b86e0c727461ec6d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i1a04bf70fbd049c193fbd17df553937c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea76646782af496e869aa248190a44f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icadd7ee0185740f48c4b33bcf2366cfa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie930d15d61914f70acd5df79dc6f905b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bd044943e9493c89b9abd3d5e526a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea75dcf12dd4babada42fe684de9583_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50577511b38f48d9809921e16e47f00e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4006483b344921a0461483796c88d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0ed5cfd5e041159ae295f44339cf2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fdb8595f8fc429f8bcbb4158edd7889_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3b1067e45a4422969dfe03a89a0497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i315f4ccb8fbd487f8663eb19701710d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b21adb7b594e90b42f8a6d7c1542b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a9fc635cec47649c6b29ca40ecc4f4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10501d2d359c448ab6d314b187853a21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1fd48dad064b5dbbcfd0c6de9a08b1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c14573e31f4f1faeb7cb5d171e2310_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739c681a88d742ad8f180ae17ea5b87e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebe4f90c08a4455a7f43925dbdae635_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6801e00c9ec84d40ab46635262d0eaf2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3baae219b314a4b9cda87196725e47a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386f36745a614aa0bfef448277833331_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71872c61ab7c46989f11583bf3a1dabc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5156cbd23c04971a5dd83142a3d49dd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f9ab36c47243cb97c7b0b729b87202_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i755cc2dfdc554f1aa804588740a5c249_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52aaa9318c7c4b838df81129cb70fa97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e16a7b014ce47f1b67466b07472b8a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98e8e4a49ca14f008f133fdd5954827f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709556ab9a9f465bade302574846826c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffcc1ea976042a3b863cd853e3615c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b69cc0d9c0a4003bff5b8b142db53cb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3858f900834806a5d8b1b8a4ab8060_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321bab6a8ec644378bbfac816a7f1529_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1da7424536451694dbf819f1ad1afe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2887c0ea8ed429e81e55af1fe19ba49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9c65ce995c41569b56cea1f111c6c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice9147234a7c47909a827383e386fa41_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50774814001e48ec956e2b9c5f605ec5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fff8515f5964feaada59a50074f36b6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2242a34258674da88852f8da26f482ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b9c1a3268b4e8490a003cc3c407a54_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c18991cb0745f7bfde8bb5e68396df_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f3be30283c469288d3b140fb14f38f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fa7e393d853413e8c347f6adc293a09_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e974e271de4652b5cda15919ce55ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b2022fd9784fa1800afc801df52ab4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93653ba690e49d188298eb65d621889_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7672ac59d1eb40d889784fa7661a5dff_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ba4ee6e978452e8a1317fb1eefa4ab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014cf1d076d344b3a853244e7ff6f7e2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92b470b9e9b4e9099e15d58a841ffa9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585d1d66efc44ae9819fbf2a01450a74_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708a87d51a194373a7ae0cfd26e60f16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1576b42347bd40ac95a968ddb28a8b73_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9466c79412984d2eb3f7d8ac357eecc5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42fdbf024af844d29c32652264e478ee_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da9ec9481dd4073920e0859a42702c6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ce7ad10c8f4e0e8549ad2454dcf4f4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cc41372ed3492cbdd0b1794bfc39fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a5b327aee6478ca6d36a047ef148de_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6806c0a00d42728328e0c191cb6c46_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b17ef4e01764ead8e46800fa43600f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e376f561464510bf004ff1475b3177_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3967d0c84ef4ab5b092b438c43a6bb9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica001ccafca24ec1b40518c87036cbc3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916d4573e04c4ebb82df425498689123_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c5f2e4fd04481eb9c96733c3ab6282_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6d1c3a9b9b43ed888b26722a1ef814_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81835d73a8d24f9fbf352588b381f229_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14b54f083414973b49fd17c21639430_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e90fc724a5a42e48ee6a1d195f84ab8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ada3a46921346fd865f1babab324aeb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5306df8c08e44da98c277f0e759fd1ae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0873fa6f786493d98f649f5b8df8913_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6789fba1c748ce81e02fec0c7a1680_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374e011a12484720b013a8ebf2f11a07_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia351d42f430a4ed8b308f667517d9671_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb37261f9244543bd3e42841c253c3d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870123ed29d24decb0df38ca4b783ed5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de815be0be44e778d9f2b95394472e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b79104cfa54b9abca4b24b661bea9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b5a23680db6467891252a20dcb977d8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5130a9a2788493194f69310dd5fb80a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0856d184c09c4cb990892955581e79dc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac4c3858d334f249fad7fb813cec175_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eae17c36c184345887eaf72ceb217e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb9b6002b78431987a6b16d086053e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48db75cf5be84dcebf25c3be860e8891_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8175f7411740adaed89dd39b020a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5da0605afd0403a91a86f6fc2935d5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad384a1ae084ceb824d660b0d1c00c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06facb13108b44fdb65aac8490d55d79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebba20d42aa84545b03550839e4d1ff6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06c67c0260e9410f924a9a9f01b3ccc6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f761535955494a9972245ac0bfc828_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50f71d020d2441aead5e84026b2c81c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2acaa96ed3e4d86ba6f80df2d1d23bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314e59ebff154934a9005087b9a2e107_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09bf75182a24ca78e3c58dda4a972f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9667464bea64d7bad769b8345f8228a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0bd307199034ef2b862a230a13fa5ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed7fba9444e4475a8d1d1fe03296f36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i618ae073cb994907a536ff425fc537bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01319674f9d40b28d7f32e4d0729277_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2fb100f05394ac080c865b058757667_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db82b411f6d44028dadc73a81fbddce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8e7e2cafe6f4f15bc1374d8dcb0e6b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f97658421c74a6883a23a2e06b3ea74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9facac76db04d889e4a084485f7e2e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc5716897864f0c9cc862e142a2ef79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb4215fa5f64baaaaf01df3d5b4e8c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0da0e73d4249789bbdb7acc456ca25_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939b4297b7084062a87e128f885293a2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e05916e33146c8ae338e992f86d223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb38cc669ce545e9bfccb54b2b798037_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889c9bd592d04c6ebb6f06b0687977ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic282be83b0124b8e836b6f16a56eda8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1927254a0845d7a42c9414c93e995c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286cd5a8d73f41ecbe7fec3a2ee10763_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876bd774408e4212b518335222b57f15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cba587881ea4be1a6fcd26255e217ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630843de12c0427290cca6b9829cfc34_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaef6f99af86488d838a3ce30fbf6f87_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9692678e8ae94f98873e8e482dbe735a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83a0493fb014bfb876176f16f9cb06e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd887f1676e449bba91f5fac45a6b160_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e5774a49944c5ab537c8ac3146f7c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641a3f2e695f488cb5096a3ed75f5c70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>abbv:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i986059b4f35d4a8daa2894ea55ad12ea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599b7447e0804132a06303bb0b4a837b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d41cc6c1144c0eb773b14b0f419c16_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9583131a11e44e7aa0e4827ce3a411c0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9e7fa9be3843a7a5bf54dd5d8ac7a9_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf34cf7670534dd3897946050fdaea95_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704e3023cf64424fb2e548f19872b22b_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd94ae07eaed40088bbf3d7cfc1781e6_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0fa7a03c79447e8db8a5d601b5fc8c_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77710e9c10447af9cd57b70a76e9850_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotes2.30PercentDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb78cb6f6ae44cb296ba20fe69d1e6a2_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotes2.30PercentDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c46c9af7913451184bb8271e2852db1_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorEuroNotesDue2021At0.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2610045aa69e4030bc8c18d427b52b41_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorEuroNotesDue2021At0.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0483da2eaea4022985712c39ea59d19_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDueInMay2021AtFloatingRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70516d291c55477c878b4b846af7180a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4a5e696cef44729310622ff60e2500_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b10bd565e94cdbad34d4b699a9c302_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8541a3fbd04b4aa7b0c71db6c67624_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd274134e874c458ac8bb198e697455_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39ddc4d4f8b4a60ae8112fec8a02ca0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215a3d4557c14afebf2687d536e46e9b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84cd19c9ee4e484da629710856ae0ec6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4aeffb4bf7740e693e0cf853abfe9cc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c76652aba54b3cb73c859bfcc92d58_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73323fc2811c4815be8a6fa8d6f92ebf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74c227e50b7440cb0bf2fe1f16077a8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3113d83c8f491b941990950d5919dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebba8edab23541ff89c8b58adf3e8a76_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca53a8519264b5a8bf940cc274a106a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29287228cbed45f6968865ac190732da_D20220623-20220623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-23</xbrli:startDate><xbrli:endDate>2022-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea99297cee64545990d63d337e0bd15_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a2a526c6f543e48795a4f1d12639ad_D20220217-20220217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1d6f16dc8f42568eb8061858ff99c8_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb37ae95313d475593909c6970fed474_D20210617-20210617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-17</xbrli:startDate><xbrli:endDate>2021-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82eba66f65734def83204d704d5b47ea_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b5f6d04f0a4544845c676987a1eeed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cd460fb97a943bea7eab54ac965aa60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce33acdbe974160ad9b3dfc07ae39d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia710a25cb0c047998dd58eb85bc213f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae61288e27a24ce39bded79de1bf4095_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f81fb701254285a4a206a18828b567_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed8396560c44007a9c95309d6d3a6a2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73a09f43445463abe6438c2b68a40d0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie041d69136f64b3a8a27ad04a132c273_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec6491fd6214350bcd0866f550aa297_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05002d950604d46a192beaa49081fc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35fed5ff539e43798107045d15730636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403c50879b1c4e05a4a20ace89fd4c22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d626d0838c74271a9d49423686e77f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e42ad98a314ebeb3aade819088d66a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if950e8b5b2df42df96087980787dec24_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7698dc329628476c963cdee26aa2812e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3822e99b0a044b3bb3488101e174bb2d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995a19a6da744643b9b86cc7f1216901_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97760527e754306a1191c6bc2573b87_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4d976678cf4540afbc6dc51554a787_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb0ed41b4e649d2a7d806f7497e41a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d84e38a2994c878bdc69755243817d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ccb01751b304c18af28a34833388cf8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic191f46d7d8e4caba4afd72c543fbcd4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3853f87f21c434890d33f2f2b77b72c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfb160d4b1643648262fd6a0eaae478_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b9ff182e8741859555b210dca9a32b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02110886faa542a89965a36d12b1be28_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4767839908e4c3c981b0e75e52a508d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51ac81d02ae4bb4bb4b631a36857242_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48cb26fc77245da81fea6fc298e2334_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608d6972b6ff4f3d8c222972b983496e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb4fc0c623c4f1ea81b83cb3bdba9ac_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c0a79aa3464c16a02968bd63694f55_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia174e4331257480796e6106ea2a76cce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:NiaspanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>abbv:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="class_action"><xbrli:measure>abbv:class_action</xbrli:measure></xbrli:unit><xbrli:unit id="direct_purchaser"><xbrli:measure>abbv:direct_purchaser</xbrli:measure></xbrli:unit><xbrli:unit id="end_payor_purchaser"><xbrli:measure>abbv:end_payor_purchaser</xbrli:measure></xbrli:unit><xbrli:context id="icfa3a17240a84a5fb4378a6e0964580e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>abbv:company</xbrli:measure></xbrli:unit><xbrli:context id="i7334ba57c4e449f59500bd93a416fe9f_D20190301-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a36967092e4074bf4a78063e79132b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:BystolicAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8cb2800eae14237a93a3936c9e32a27_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>abbv:claim</xbrli:measure></xbrli:unit><xbrli:context id="i48ac34a8b8274cc9af2a8d06028995a6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e04db914dad47f5b3d445d36e86ac46_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d8e2a0e62b4729b3abeb9e927196d9_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="investment_fund"><xbrli:measure>abbv:investment_fund</xbrli:measure></xbrli:unit><xbrli:context id="id7c685b4419c4e248155b129a874cf5a_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76475932981417e8c60761ee84327e0_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e751a39abb44d69bf6dde5f62f5da1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18bfd7270ee4f79a082b091a1d91241_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc2260464184105897c45f4f42c8c13_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf34e3dc9a54da193a3b587af7498e0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3665d816d7a49f7b2a2c250380955e0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id772f9666c5c4b569bff7bcce7ec09b4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2789587e0039409e85ee53a0e676e039_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a7736453da40babfdf09cafbc6d8d7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab62c95758e45988052a829d4196a90_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7dea9d6f70d4ec98a1e472f35d5c5e7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc046d2283c4b17b9218d96bfe9f744_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85dd0c7934dc4d97bade1ff5347b0cbb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613d7817d5e44951867e1c6db534f048_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3925d88e2c564017be693e4f33dc9fef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fab7cbaef51414aaaf8cf3add2b35cf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bb12764f7504661af49974aecf799fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691d9600e9b043098e5c276598fee110_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a4b28633f342598240cdb0c3efa237_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i560e85f5cfab4fc3ac49d453b66f47fc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768c6e087bc94398bcebcdec93f187ee_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6c8a9d73f14855aeed15aaa74afcff_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b51a1c66954d9aaa0187e550ad0413_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ea89bc103144a5958d2f2a66fe8098_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8bd49f99be462b96189ff1b51b483f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874093c1c0ae4f308272c783ac24326f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e6208b6b4f4a0388ca9ada2c7cc625_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd758e6d37b4bc59135caf3c0de84d6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d868053bd8748d3bf614376fe813cb8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c02e7957b24efd9ccb2368a2201c6e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f955f09f26347a4b61f9e1d792d9c52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a3befe2196456aa7304c27b18e62b0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c352b7e3b4a46d4ac9b0c8ae253c346_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacefee9559c84a7f8fe1b97854abae81_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf6107ac310458ca74734c319137631_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4786d948d133499db74a085616fa1875_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d29d5d87b2d4ba492379977f9b5ab22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a916779feaf471db9c3dd44f2d0f9e4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636fc0eccf124d9a800dd95dc70ad820_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2b0f551bc049d6abd5b17ecbfd5a7c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436d40cfe964413fbcbf9f712fc800e0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0416b6fe5a4a28ad14a534ffeaf36c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c20efa76564198871cbde27c4f3770_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a3090d63854077932361ea0cda6045_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8046e68b530144f7bb14542e2e179616_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a43659878c5400aadd92c3684016238_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc5e412e1f94776bc76d6999c9445a6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a45a226af5241fa94c7236e40243ed4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67c8e799778495794ae8022dd02b919_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90678a4b1d64aa5a5d8b7d3d0f183f9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac78ef5437840d1851a7bb8a12f61ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b338d203ed4ed48104fb83314e02d9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c74555cc18a4bc1bd636f5aab45af28_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb374613bd8a41a8bf753c1018b7cb7c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017973a311a149579a6e2d7f0bf65764_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84118bab402a49e5b84833a66c174d12_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21226e99e14c4ddbac60ef91e89cc530_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbbf979d6cd4eccb6057977d03291df_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae072cee9e51472198a5efde9ab867c3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64aebd25af841f1b7229554bc01f412_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f15191fe14b4cfa89c7a4ae3911fe49_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c81ab58c08424a9e69f6265e734d0f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0605eac069cf4d81b845fd844cb58c8a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6eafd7ccb9f4f629d0ad43895286c38_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4567b8412c0f40aca0ba3ae7d82676bb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdc471eaf3645a69aa7fd3af900fa42_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86af501659bb429a93b12bc11b5044ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34627b0f80bc47d4b2ee036c078502fa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if389f2dd00e545d28d559a5e75ab3f64_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic865d7480948423580adca162837e77c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id886288666fb48ccb61718e61df34b35_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cddde0247f443b9b340a36d7ca29a0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cbb654aee284bde985e29ed2a417187_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9b4bcd3c344d4caa8accace369889c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6f7a1a1f1d4823b6772df289977ce9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9240ee581cc94c809d2e9975585d0e32_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e9f078ec864353b22c3fdd238993cb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e70fb16dfd04148a41903925eb90981_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a3b9cd19a14173a8c66d72c61e2b31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07be0755a0ce42f09fbc795069473e02_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2de83259a6941d8bd633aabc6f46bc0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275a2f367c8e496799ea036748f953a9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id42a239b714e4f67893f359965c39442_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c169ef01f945ee87a73716291f5111_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ee77d1be804cf485a2836eb7067c67_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3df4a45fab4f4c9278ca1bfce58738_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d432d522a94fed8847f371bc5981f2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84165bbb1f1347e897f9eab39bb8ea94_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efa50552eb2412c8ac12c30f21c490f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b03fece4c047a99bd000932229b9de_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea32020dfa4649129801589297294e8d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaffe79a5455443aa04784d34e6c64ba_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb2fecdd608d4d54b39f0ea275388289_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e6ceaa8895481db504ab1693ffb3fa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ad21c8d5d444f39b0047d67697123f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffaa78a8e1142b288e6e354c460254c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9128c44b088f4cab95566ad9edc2a8ee_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d523156e124aa2ab5e04ddb64884bf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7f58287b6145d5a6823247454ddc45_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf6ab07195a4cca93acbe6ceb203e73_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df2818c56ef42baaa8eb76d1b384c0f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638a5ee6ee4c42fca17c06b8857fb5c6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1065d539abeb4072b769ab2d71e8944b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d1768636d746b4bab2547e1b9c9ce1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f61f08f40d4da3a4256963bc6f1384_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8781577e0c4483a640bac78e68df6e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f260375e939438fb809d92be390d888_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3461140986e4666a08f4efef9f1b613_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dc2f0df2044b08beb63c5086eb5739_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1888ed0d9b0e438c8de2757d768f23f6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3305a5ca26ca4e7ea948f6a5cb50efa8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5cab0be8af14785bd28c582835b0cc4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeefd3642f924fffbc846fad74fdad8c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e881c96a7684c80b5f00b2c241ce2ca_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf09146bec940c49881c105e2fde2a5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061d2a55e7174d83b68a055cd5e369b1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451984d626294d03858200463c69ceb7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc95ef169d984d27b48f3e697f6f4d3d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04dcb0e5c7634daa8fd3b1024c048528_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3628e0cef99d4acc818a521eb8fa79fd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a341dab3c8b46f780c38988862e144d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d827902a8b74349b77862bc1ae1fe1d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7877be381ff54eeebefba91654c5bec8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d561bc963364eb3b42dc2bb43967bfc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c9d7c0c1954f4a827422d7ddb71e44_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib009e9f4ccbc4aabb0abf813ff1b9b9d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91980ca8bba425dbf5ec17c1e6c8260_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66976616df8f45e4a0233eabd261afb9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5efcdbc4d1cf44e6b7ae58e964d94349_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63415011c3e645908f7ec388df1bb966_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a378f983e24296878b4a51a9ce87bc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3650cb2a09d0454bb935da1c661555e1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id488c5c2f38b4d9c87b2dd5a3c14dd52_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0aa8affc324889ba63c424cf09ade4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d3ccb3b6564bcab939ffb027584e3c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8319fb8317f64500af0908643ad0632a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486d629919554591943fc705452e1ffd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i910a16d51cdf46e69ab2f11998279fce_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5ee0b393444da28b3de9ccb5848abc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1c2e9044134fb283858ebe2b7015a4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efe769f8be14215a0a43d2955581c8b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie341a38ca0504923bb7a4212d96ae509_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0338fe30ecfb43c2bb594866b36d0c38_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8baf06e41cac46ca890ff77bbde002de_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if334fd6f6ced463191edffdfc673820e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae918b7a7fec4e0f884db97d43014c3d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6361dbeea1084098930ecf34e1a2cd74_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie802121280734295adc561cdb0a46110_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1d8a4f5a10492bb4bd12e2b4c064e8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37fe742fa0946ea9ef53a300a8b5681_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082bdbf7ba954da5b6a638b5ff634bd0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d2dc14539945b28da637cec2804a59_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065d8379e1cc41b4ad8f7251eaeeb1c2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b0f0ce20724b90a4f7647bb9a8ef1a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd74e66f1b04b9ea3d575b51adf1c05_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed7b5a1ebea48f093da2b0ff29eb4b7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id123036947d949b3b27454b60e9bb03d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06cad72124104e83a37813c7ca4d58bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b70cb0e5c7147579fa25e09acbf6291_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79667b913ce74f5dbebec3fe976825ff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d10096f8a24fccb83511987f26c69a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2d4201e5e747079eb77993bb61fba3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711eb0534e014c01be59768e65562deb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec21debfbe341cdad1aac7ebf721a99_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad19468cf9d346b28980e07a20d6f5db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15fbf82d23f3402dacdf01e8cf69b44a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1716e275a0412aa55aeb45b7eb6c31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf40dd1d09234507952e167d1479045e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3682c7c9fc8d4e37870dd6d2a55fffa6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a5fbce24694e669e94f977e23e2355_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c7d12ad2714a6ea184eada5e3b70a0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dea495dc74647a89c9c075bf46494aa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a900fadd404c10ad147fafe8f4deb4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b4ab1ba4784671a896ead7cb8313b0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8173b604f62e4076a3617362c1136935_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e86aea9a594dbeb0b923716d380818_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ae3512f1eb4610aca3449ed15dd8d1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1412de7cca3427fa94e528b2abb50ea_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201933aab6584d7ca5b8dbf08dbbac04_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedaedd5de554534991638c4456c25b3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b9bd9ac4d044d5860a53c8b0380a1e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9e048450024856b06b4e78059095d1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd1758c8b804a44b870604e3de47893_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3067379f7643989c5c6a9f5aa57e51_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b1aa17325b4c23ac4029b80c3b95d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959da824f08a41469fcef4982237f0ad_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9ca253be174199be0d0235e1eb2f23_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335cd00f529e4f93912c67b5c142472f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a7e51d8bb049719a805c96ee4e3371_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i904652ab5bb343df953e359f58983c26_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f642aa7c52d4beca6b8434dd4031490_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0dc83404ae74a8097d23417e7af22df_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53336e17dd6a40f1990e05073d8317b5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aeae0c651354131b671fc904166fb25_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e57842484a485991d62e03a01d8e38_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158d06c961ab4b84ac67732c15bd9b13_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16f064354b64f688d1bff104fcffb76_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fc70faba5c40f2b7c77bb2f65b318d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a52d243b364ceebafddad56040e1d4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b345afd17164d7d917c60019900d02c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7baadf51bd904370a6d282562978b306_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba200322b8f4fcb86619a36931e9175_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88385ff780be4c28851e5dde7a7375aa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3842eb65438141e288a8210b375b0e59_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67b59d6f5054f0f9504c3b750eb3e0f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb25c770cdcd4b8a84b4d8984b516ea3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7846dcf271946ef9f581063d57b1d32_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be1c9ae69774509942fb2c801e8e0b4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5411bdc1d3b46c5a26a274c0c49de78_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe1ad8786cd4ec9b518879507cdeefc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43669c40e73a46afb5e6f704a10e6d1e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9a8730959ce4f028d5538a29f222423_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id215663e03264d678a32b5af7a72e4d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1f55c4f4fa4a0f87dd08291588f95f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18902dc3bd7b4eb2bf8e70464f318c7d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f331549442e46038a09afa23765f532_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia689063c9a8d4f47ad065d4cd5c51cce_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a165da7515149dc9f2231f0452f276b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa0784d769c47b1b61138f07a799e92_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b632bb7a6f44b95a3ba9242b438a9b1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35991f95fd64801a6f989d5186073d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676449a933204a9cb64a6f54570b2d60_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8f4a95cb1b4c99b4bb5f312cef5b00_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5611e12d1194636a4cdc0e36968dd1a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe1892fc3014e6b8f3d56ee7c617da9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>abbv:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6 id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i8040488224cd40d194fd225edca967d2_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQw_8ee58896-be3b-4ce0-995a-e170d5da672d">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQy_5e4e8e40-3a91-43c0-aa40-143d9de4d424">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMjU_48a6f8bb-8aeb-4cbb-8687-6197891a03b8">June 30, 2022</ix:nonNumeric></span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ2_475d6fd3-6518-4123-81b3-71a6b627e415">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;to </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQx_365d7218-b037-49c2-afe3-e5d33a4af12c">001-35565</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><img src="abbv-20220630_g1.jpg" alt="abbv-20220630_g1.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQz_1b9804e9-4151-4798-9b27-56ba8a8219a1">AbbVie Inc.</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6ZjU5YzNiZTNhNjc3NGZhZGFmMTg3YzU4OWJjNzI4ZjUvdGFibGVyYW5nZTpmNTljM2JlM2E2Nzc0ZmFkYWYxODdjNTg5YmM3MjhmNV8xLTAtMS0xLTk3NjE2_3c27e32b-13c7-475a-a797-92175ceb04aa">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6ZjU5YzNiZTNhNjc3NGZhZGFmMTg3YzU4OWJjNzI4ZjUvdGFibGVyYW5nZTpmNTljM2JlM2E2Nzc0ZmFkYWYxODdjNTg5YmM3MjhmNV8xLTItMS0xLTk3NjE2_63b79131-af62-4eaa-8a77-004ddb489bb8">32-0375147</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. employer identification number)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></div></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ3_7b4fd2c6-e1e9-4b63-99ec-29b7d97e59be">1 North Waukegan Road</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ4_d9ee3f26-de06-47f1-a7c9-3eeb043fcdf6">North Chicago</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ0_9a08bffe-fb53-4678-934e-2b2599810e22">Illinois</ix:nonNumeric> <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUx_63d4f2cd-d26b-4be0-8779-5fc811732fd2">60064-6400</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Telephone: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ1_727715cd-a582-4d67-baee-93cc1a49ea34">847</ix:nonNumeric>) <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUy_72c46a82-61a7-47c0-b5c2-9e00a44f4a82">932-7900</ix:nonNumeric> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUz_f8159a4b-994f-4a72-a635-b5a6f1f47a75">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ5_fabec1f8-b4a2-4092-b02f-bc6d37f4a8cf">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8wLTAtMS0xLTk3NjE2_f19e2410-485c-45f3-bc6a-1a0e93627f53">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8xLTMtMS0xLTk3NjE2_84ae3fd4-de03-4d99-835e-2680a2076708">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8yLTMtMS0xLTk3NjE2_06ceb342-5876-44b7-9f39-ad0d4fd5a742">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTU1_0cbe4a47-9155-412f-8c32-025adc38cc9d">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTAtMS0xLTk3NjE2_b410f95f-b6a9-403a-b8f1-edc0ba445f75"><ix:nonNumeric contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTAtMS0xLTk3NjE2_e53544c0-dabe-4796-86db-0730081d46cc">Common Stock, par value $0.01 per share</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTItMS0xLTk3NjE2_18aaa252-be8d-4a50-85d2-43969ea6d15c"><ix:nonNumeric contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTItMS0xLTk3NjE2_4249663c-09b3-45b9-b815-58f0c6fd567f">ABBV</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTQtMS0xLTk3NjE2_d94f28a2-40b6-4bca-ae4f-f4eebc713d1f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8yLTQtMS0xLTk3NjE2_b7d792c9-e0f3-466e-a31c-2f634797e640">Chicago Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTAtMS0xLTk3NjE2_f26d19fe-eb79-4839-8ef2-55cb7aa4da2e">1.500% Senior Notes due 2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTItMS0xLTk3NjE2_845cac4d-bba3-44a2-91db-28ae3fafc3dc">ABBV23B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTQtMS0xLTk3NjE2_2a5fd6eb-3777-4a9f-a0c1-7faff89278fd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTAtMS0xLTk3NjE2_d3b0e1d5-f8e0-4f98-a15d-55ce65d5d961">1.375% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTItMS0xLTk3NjE2_0a4757f2-ff55-4ebd-9490-753131671e6c">ABBV24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTQtMS0xLTk3NjE2_7722e382-1405-46e8-9dca-1ae8b8daf6d8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTAtMS0xLTk3NjE2_eb41bd48-57f6-4c8f-8714-9f94bc93c057">1.250% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTItMS0xLTk3NjE2_70e207f9-ef4b-46ea-a696-8c110fe82db0">ABBV24B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTQtMS0xLTk3NjE2_2c1fb0b0-ce6a-4682-aa2b-a875140f09f9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTAtMS0xLTk3NjE2_f250438c-7b9e-4552-92c4-95f0301db2d8">0.750% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTItMS0xLTk3NjE2_04b09a87-a028-4455-a17a-f8b69483ac46">ABBV27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTQtMS0xLTk3NjE2_1641a08b-2f4b-45a4-9caa-d0a231a66768">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTAtMS0xLTk3NjE2_f2e08425-247d-43b4-aeee-1c05534e54fb">2.125% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTItMS0xLTk3NjE2_34a499fd-0d40-4ee9-abe7-35af1bc798c5">ABBV28</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTQtMS0xLTk3NjE2_98ddacc4-88d3-4f86-810c-42cdb467f918">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTAtMS0xLTk3NjE2_94625e7e-5cb8-41eb-a1f6-a3133e1ca925">2.625% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTItMS0xLTk3NjE2_01907a3b-93ea-4ebf-b428-3a8352637594">ABBV28B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTQtMS0xLTk3NjE2_e14432e9-8143-4fc4-b7b6-a062d5d95436">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTAtMS0xLTk3NjE2_cccfb16a-d684-4d33-b220-fe98f48f8bf7">2.125% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTItMS0xLTk3NjE2_965ea73b-1eb1-4d66-a9cf-6503d6a12614">ABBV29</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTQtMS0xLTk3NjE2_837642c5-65fb-4f56-9389-a53b13ec7b9d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC0wLTEtMS05NzYxNg_dbde003b-58cf-4bb2-bfa4-6b26b613a726">1.250% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC0yLTEtMS05NzYxNg_eaccf544-b997-4bd9-b2c4-c88d578f698f">ABBV31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC00LTEtMS05NzYxNg_f3429f4b-5ac7-42a9-a671-7ebee15885ed">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of July&#160;27, 2022, AbbVie Inc. had <ix:nonFraction unitRef="shares" contextRef="ia6d97026aba9492bbb24ab4366e9ed1b_I20220727" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMDgy_9e3d691b-499e-4bfd-8a9d-bced3e79c9fe">1,768,096,495</ix:nonFraction> shares of common stock at $0.01 par value outstanding.</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8040488224cd40d194fd225edca967d2_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_10">FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_13">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_103">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_103">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_103">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_142">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_142">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_142">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_145">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_145">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_145">35</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_148">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_148">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_151">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_151">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_151">37</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_157">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_157">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_157">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_160">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_160">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8040488224cd40d194fd225edca967d2_160">38</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div></div><div id="i8040488224cd40d194fd225edca967d2_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION </span></div><div id="i8040488224cd40d194fd225edca967d2_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="i8040488224cd40d194fd225edca967d2_16"></div><div style="margin-top:3pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings (unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;per&#160;share&#160;data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi0yLTEtMS05NzYxNg_a2039004-9895-4ba8-8a71-26661928514f">14,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi00LTEtMS05NzYxNg_e13538a6-b329-465c-be93-362d6ea1c1e0">13,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi02LTEtMS05NzYxNg_a56d15d6-ace8-4cee-8932-ddefbbbf4a28">28,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi04LTEtMS05NzYxNg_006cc40b-9a32-442c-8f55-72a3e4c4a2b7">26,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC0yLTEtMS05NzYxNg_aad12718-7181-4a26-992a-7790802966cc">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC00LTEtMS05NzYxNg_04e1a54d-6346-4f2f-928b-64eeeb67f7d6">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC02LTEtMS05NzYxNg_3bac7f8c-c638-47f3-a512-0d117cc75d0d">8,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC04LTEtMS05NzYxNg_5584c7a4-46f8-4378-bbb6-accf9dc77277">8,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS0yLTEtMS05NzYxNg_9bb716cd-f27e-40ab-ad35-e9d0075e99c1">5,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS00LTEtMS05NzYxNg_66009fdb-7fb4-40b0-89d9-afd300d28106">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS02LTEtMS05NzYxNg_dc32c5fa-cd71-46f9-b153-1e1026234bb9">8,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS04LTEtMS05NzYxNg_f3e50927-cd83-4733-ac80-8185a9f0ab69">6,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi0yLTEtMS05NzYxNg_5d35c895-768d-446f-b563-984269c6f51a">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi00LTEtMS05NzYxNg_4ba467c8-2659-4556-8ad0-2fac599d70a4">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi02LTEtMS05NzYxNg_b92480bc-9f9e-4dbe-8c92-8ee4508c8a46">3,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi04LTEtMS05NzYxNg_e5f8e273-afbe-4be7-88c1-1d5efac394c2">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy0yLTEtMS05NzYxNg_7b3fe2f3-9332-4df0-b224-d8effebee342">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy00LTEtMS05NzYxNg_b4fac5b3-0177-4563-acb0-f17555a1a161">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy02LTEtMS05NzYxNg_785e14e2-489d-44b7-8c73-90a1cd92df65">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy04LTEtMS05NzYxNg_0a1319e8-8a88-47ef-8e44-fbbc606d4e42">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC0yLTEtMS05NzYxNg_2706abe8-7966-4efd-beca-3e4e7b78df65">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC00LTEtMS05NzYxNg_75b5f5c7-7497-4f90-9a8f-380f0fc96258">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC02LTEtMS05NzYxNg_7e32c9af-ddc7-4447-a171-8820b88060f3">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC04LTEtMS05NzYxNg_fdf21a76-84a3-4873-964d-60d7c4175cdb">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS0yLTEtMS05NzYxNg_6cab7ca9-d5e3-45d3-b284-348b44c5b134">11,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS00LTEtMS05NzYxNg_56842ce7-3300-4047-9031-7a2d28a1cba9">9,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS02LTEtMS05NzYxNg_6fb3be44-5313-45a3-9192-2f859fc747ed">20,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS04LTEtMS05NzYxNg_ab396aaa-9996-4d31-a53c-ec5ccd708357">18,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtMi0xLTEtOTc2MTY_61b77116-86a4-40bb-be04-90423711f4a1">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtNC0xLTEtOTc2MTY_5ddc635b-3bdd-4bb1-bb80-e366f7e87a38">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtNi0xLTEtOTc2MTY_c9436d98-aac0-4fe1-9ea3-6e7f7fc3d3a2">8,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtOC0xLTEtOTc2MTY_4234a520-b591-45e6-a4bd-41597dd74756">8,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItMi0xLTEtOTc2MTY_e0ad69b5-2ad4-436b-9928-14afe7bf83af">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItNC0xLTEtOTc2MTY_6e2457a1-5de7-4d95-b689-23a41905101e">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItNi0xLTEtOTc2MTY_2f2b4b15-af46-4ade-8fc0-99194d1678db">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItOC0xLTEtOTc2MTY_139a4ff5-a827-4a18-a940-040db425cf6b">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtMi0xLTEtOTc2MTY_d7d7427f-a2e9-4307-91a7-f50a10775ef6">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtNC0xLTEtOTc2MTY_7f450690-4a10-4ceb-8dca-be30dd0783c0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtNi0xLTEtOTc2MTY_2d622c5b-cbd4-4428-814a-4f04cf035b97">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtOC0xLTEtOTc2MTY_5b21ef16-d619-420d-9923-98359ecb22f3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtMi0xLTEtOTc2MTY_55e5c11c-70c4-4df5-ab85-1da6dc4e98d7">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtNC0xLTEtOTc2MTY_118cae42-6454-49b0-ba96-38deea6ab3e0">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtNi0xLTEtOTc2MTY_4d88bb8f-34bf-4d0e-a456-6cd5e5d940d0">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtOC0xLTEtOTc2MTY_e4058584-cf15-46f8-b495-f4a134eba81d">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtMi0xLTEtOTc2MTY_dc34bc9e-c56b-4101-a6c2-87e7836857f2">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtNC0xLTEtOTc2MTY_a8140558-3d4b-4c27-807a-1530cfce7026">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtNi0xLTEtOTc2MTY_f4d411ee-a994-4b30-950c-4b5b5197cd3f">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtOC0xLTEtOTc2MTY_5179109e-bf40-4f59-b679-66bd65040bc3">5,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtMi0xLTEtOTc2MTY_bf418c32-75a3-42bb-bda9-8e2264bda994">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtNC0xLTEtOTc2MTY_2ac7796f-89c0-4cc1-bb76-cb08475dbff5">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtNi0xLTEtOTc2MTY_fe8dee4a-e663-4c6d-ab2d-9fb69088f42a">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtOC0xLTEtOTc2MTY_f2929141-3eb5-4ab4-a681-d851b7cea5dc">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctMi0xLTEtOTc2MTY_88281ca0-b770-4bc1-b6d3-704213300e11">928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctNC0xLTEtOTc2MTY_bf929520-6cc8-4b52-962c-d4c46b3062f6">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctNi0xLTEtOTc2MTY_f4cacc32-05f5-4b2e-8e3d-acbb86218d2c">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctOC0xLTEtOTc2MTY_14524416-9beb-4066-8147-07bb5076e5c3">4,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtMi0xLTEtOTc2MTY_00438504-9f1b-4125-876a-e8407e1bb358">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtNC0xLTEtOTc2MTY_573563f9-b9e9-4860-bdce-499efdbc13a0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtNi0xLTEtOTc2MTY_698e4db4-c409-42ad-b3f4-5a6792e949ee">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtOC0xLTEtOTc2MTY_48fc3c98-433a-422b-9a68-debfe07ef587">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktMi0xLTEtOTc2MTY_9ade95b0-1b8f-49fe-84ea-11f8bacfae97">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktNC0xLTEtOTc2MTY_fb9de274-2297-4d87-9539-27e8082f7db9">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktNi0xLTEtOTc2MTY_4c9fc1a0-7938-448a-9759-25a85c00cbe9">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktOC0xLTEtOTc2MTY_599519a5-c281-445c-b89a-acc43b77293c">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per share data</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItMi0xLTEtOTc2MTY_bf05e2fb-9067-4e2c-ac99-500ed150d1ed">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItNC0xLTEtOTc2MTY_18d7c75b-03a7-4bd6-b313-334bfc41234a">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItNi0xLTEtOTc2MTY_d9b495ed-bff8-461e-bd56-9e3bbd056fd5">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItOC0xLTEtOTc2MTY_af62ea5e-a4ff-4508-ad6e-45829f580763">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtMi0xLTEtOTc2MTY_3589b5ef-a2ad-4d05-affc-2dccad326316">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtNC0xLTEtOTc2MTY_79719a07-c2e4-43fc-b517-700a2d6ae81b">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtNi0xLTEtOTc2MTY_621a6f86-63d5-4d65-9f2f-a20871638b7a">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtOC0xLTEtOTc2MTY_44ec63b2-eda8-4ea5-a5a1-2bac18a1b7e3">2.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtMi0xLTEtOTc2MTY_03aa0070-ad88-45a0-8cbb-c3850f9c1225">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtNC0xLTEtOTc2MTY_ff4b3114-9865-4d33-b17f-deadd2c4bcec">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtNi0xLTEtOTc2MTY_ba22ac09-4fe5-4b54-bf6c-3cb57bc3f385">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtOC0xLTEtOTc2MTY_cb96d079-9b3d-4ff3-b8f5-7656e39e10ce">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtMi0xLTEtOTc2MTY_bdef9785-4f6c-430e-a35d-b4ef8cb7a94d">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtNC0xLTEtOTc2MTY_7bfd76d9-3175-4633-8687-ea70a778a210">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtNi0xLTEtOTc2MTY_72fd12d9-daf9-4788-8642-be5499bdc998">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtOC0xLTEtOTc2MTY_7c3cdfc3-514b-4a6f-9738-06632cc95f5c">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">1</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Statements of Comprehensive Income (unaudited) </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi0xLTEtMS05NzYxNg_6360e1d8-8447-4e72-a1ae-b3a31dae40cc">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi0zLTEtMS05NzYxNg_78ea868f-3f5e-4503-9ed0-8ba87534f448">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi01LTEtMS05NzYxNg_bc340364-dcab-4f55-93a7-5236da2697fe">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi03LTEtMS05NzYxNg_bb06d16c-7e3e-4f4e-b0f6-ab5d7e99c5d4">4,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net of tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzE2NDkyNjc0NDE4NDM_9683602c-28bf-4723-9354-0fd0bb92d188">12</ix:nonFraction>) for the three months and $(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzc5_aff4dafb-b4d8-4960-bffa-74f46e31f63f">19</ix:nonFraction>) for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzIxOTkwMjMyNTU3NDI_0684b794-fc30-4a9a-9d8d-49b8b50c8698">1</ix:nonFraction> for the three months and $(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzk3_c0ff6c4a-621c-434f-9471-8e14939b9dd1">24</ix:nonFraction>) for the six months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0xLTEtMS05NzYxNg_94314b1d-1676-4e78-a8fb-6d163d72699f">823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0zLTEtMS05NzYxNg_301726b5-5640-4748-b1cd-517e7c2301ba">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC01LTEtMS05NzYxNg_dc466c1e-23a1-4a4b-8c23-09eac7a0f979">1,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC03LTEtMS05NzYxNg_40025649-4832-48d5-b382-4eb3068902c9">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedging activities, net of tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5XzIxOTkwMjMyNTU3MzE_a58044c6-ff8f-4c5e-a261-94a64c9d29cf">146</ix:nonFraction> for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5Xzcx_1ccd4986-f4ae-47e0-b2ab-24bc9b1aff94">183</ix:nonFraction> for the six months ended June 30, 2022 and $(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5XzIxOTkwMjMyNTU3MjQ_650afba6-9cb2-4eba-bee6-9c50c9d6d086">31</ix:nonFraction>) for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5Xzg5_b7b74176-bdef-4cd5-ada1-23165e3fbce6">72</ix:nonFraction> for the six months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0xLTEtMS05NzYxNg_c8fd878d-5859-4e3d-a59b-f4501038f499">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0zLTEtMS05NzYxNg_b802e493-30e7-4a54-8d6a-c1f9108a11b4">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS01LTEtMS05NzYxNg_7cfed901-5605-4edc-a044-a57fee2c1481">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS03LTEtMS05NzYxNg_e4eb11d8-75d4-4e40-be92-cd858983ca7a">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-employment benefits, net of tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1XzIxOTkwMjMyNTU3MjM_d8c3508a-b1c2-4e90-b6a2-306d6c8edc0d">11</ix:nonFraction> for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1Xzc0_fde2a83e-b1a6-4ab3-88dc-6a07009fcdfe">21</ix:nonFraction> for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1XzIxOTkwMjMyNTU3MzU_6bd7ee17-8181-41f6-be3d-a74545b142d5">14</ix:nonFraction> for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1Xzky_cc23a128-bae1-4483-9e7a-b957e1151f82">33</ix:nonFraction> for the six months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0xLTEtMS05NzYxNg_2464ac7c-6a6b-4fca-a847-6b4ae4227afd">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0zLTEtMS05NzYxNg_30263cfa-6fdb-48a5-ae03-29b8f6633a34">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi01LTEtMS05NzYxNg_312910f9-5e87-483d-a357-35513c594e84">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi03LTEtMS05NzYxNg_22330252-793d-4150-ad07-3393bb84124d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedging activities, net of tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzIxOTkwMjMyNTU3MTU_bb460af0-d0f4-46da-8ffb-b34e9d2a0dbf">5</ix:nonFraction> for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzY2_2542d6e3-40ec-4019-9844-77c3b14c8c54">3</ix:nonFraction> for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzIxOTkwMjMyNTU3MjI_26b170fd-d21b-4af4-b4bb-c79379fe1edd">&#8212;</ix:nonFraction> for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzg0_b29f7731-03f6-42c5-8f8d-1766332e8bd7">3</ix:nonFraction> for the six months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0xLTEtMS05NzYxNg_2762cfd0-ac24-4729-b604-08502bbe9ac9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0zLTEtMS05NzYxNg_d09595c9-e709-469d-89dd-01ae9038440c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC01LTEtMS05NzYxNg_0b3ca9ab-f7fc-4a91-90d4-47e830d7cdee">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC03LTEtMS05NzYxNg_310abab3-5995-46a0-bf6f-b6a1812bfade">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS0xLTEtMS05NzYxNg_228c6d1e-1569-449f-9315-2e66e610c45c">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS0zLTEtMS05NzYxNg_150fd686-7a0d-428a-883c-a343a617258c">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS01LTEtMS05NzYxNg_65b013ea-6fb4-4214-a2f5-88dcdd91ba8b">297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS03LTEtMS05NzYxNg_df24e683-c9cc-4143-9f48-95c2591b6cdf">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtMS0xLTEtOTc2MTY_0e7bce97-1e99-4129-8efb-14188198f2db">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtMy0xLTEtOTc2MTY_33eee592-cdc9-45ad-aec0-4448bfc8d413">961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtNS0xLTEtOTc2MTY_202d7324-3953-4da5-9898-925f0ba55576">5,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtNy0xLTEtOTc2MTY_c29b7a75-cd9c-477a-96af-f0405cb445d5">4,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtMS0xLTEtOTc2MTY_bc5f79c5-5dbc-4603-945a-d18d6374ba30">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtMy0xLTEtOTc2MTY_98a27352-000d-453e-acda-df81b545c856">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtNS0xLTEtOTc2MTY_f390e436-c9f9-424e-b51e-e6cc74dfe315">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtNy0xLTEtOTc2MTY_afc27ed5-9d97-499e-8a3c-75b50336a761">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income attributable to AbbVie Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItMS0xLTEtOTc2MTY_6d120320-1c59-4ce0-8799-f937e682f66e">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItMy0xLTEtOTc2MTY_ee30185a-6596-4414-9168-2d21bba86985">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItNS0xLTEtOTc2MTY_330fe575-2e8c-4094-aa04-ec06df137480">5,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItNy0xLTEtOTc2MTY_1e33e671-600f-436f-bd17-79e0f3e857de">4,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">2</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Balance Sheets </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;share&#160;data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNC0xLTEtMS05NzYxNg_a07f98db-cbd7-4415-bd19-c45b67e1691a">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNC0zLTEtMS05NzYxNg_bc186d6b-3548-4df6-a8ec-1fc72dbf6a60">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNS0xLTEtMS05NzYxNg_3d8fef27-f8b6-4372-ada0-beff0b69f7d0">1,440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNS0zLTEtMS05NzYxNg_19df8528-75a3-4651-83c3-d3fb995806b2">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNi0xLTEtMS05NzYxNg_0cf2c294-c6d0-4efc-9421-19b5740ebf81">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNi0zLTEtMS05NzYxNg_68d3e698-66da-4eb2-8949-f0b49dc7c31e">9,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNy0xLTEtMS05NzYxNg_ef6031b4-f2ed-4760-a4c7-a9d11ed708b0">3,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNy0zLTEtMS05NzYxNg_f6bea658-a445-400a-9021-df3c3e2d24e9">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOC0xLTEtMS05NzYxNg_240d239e-9094-46f9-8498-8ef87483f3ba">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOC0zLTEtMS05NzYxNg_707e8a86-919e-4d69-a89a-6a90cb984572">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOS0xLTEtMS05NzYxNg_db37f34d-631c-452e-b206-696aa2ff390d">29,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOS0zLTEtMS05NzYxNg_dce48b95-987d-4ef2-b0e7-39c1bceefcc1">27,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTEtMS0xLTEtOTc2MTY_a4fdfb44-8584-4dce-9d63-4745ab060d59">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTEtMy0xLTEtOTc2MTY_0d22ae6f-f15b-43c0-84d8-1f331b13edc5">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTItMS0xLTEtOTc2MTY_1bb6a2e0-fe82-4aed-ac51-84c915101af9">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTItMy0xLTEtOTc2MTY_94a1cf21-8e0a-41e6-b7ac-41bda81e33f7">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTMtMS0xLTEtOTc2MTY_377d33cc-df70-400d-bb86-354e17350502">71,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTMtMy0xLTEtOTc2MTY_6d306640-c1de-4480-a7c9-c5a32e8f6ac9">75,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTQtMS0xLTEtOTc2MTY_8a989df1-7d43-4b31-9241-0e82cbbc8fa9">32,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTQtMy0xLTEtOTc2MTY_1449c5e0-cc9d-410b-be47-72cf8d3a2ea9">32,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTUtMS0xLTEtOTc2MTY_898c5757-e29f-499d-97e9-f1d48b1d6dad">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTUtMy0xLTEtOTc2MTY_f88d7473-4c14-4323-a5c5-d3cc3a36a15c">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTYtMS0xLTEtOTc2MTY_a269e77d-c4a1-43a2-b12f-cc6062c3e375">143,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTYtMy0xLTEtOTc2MTY_402d31e8-36ea-4dbe-84ce-786f684f1655">146,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjAtMS0xLTEtOTc2MTY_d2fd64c1-6faf-4640-bd7f-e49fbe6c10aa">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjAtMy0xLTEtOTc2MTY_36a9e02d-0ad5-41c4-b2a2-6548046172c4">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjEtMS0xLTEtOTc2MTY_da8041fb-f3d1-4b1d-98db-11f7edb8bb38">11,913</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjEtMy0xLTEtOTc2MTY_e86efddd-a997-487a-b3e0-c4660fa29808">12,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjItMS0xLTEtOTc2MTY_e920c2c7-1ad7-4c7a-ab4f-b9ca0bf931a1">22,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjItMy0xLTEtOTc2MTY_aef76514-c38b-43f9-bed2-8ddf4fa4f12a">22,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjMtMS0xLTEtOTc2MTY_8d52b450-1fc4-4c16-be8a-45186cf81b07">34,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjMtMy0xLTEtOTc2MTY_6cd43a8d-fbf7-4e01-a085-273ddadb63f3">35,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjUtMS0xLTEtOTc2MTY_0a2e1286-2bdc-4e2b-89a7-f573d2a61a4b">61,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjUtMy0xLTEtOTc2MTY_7e987439-8be3-49c7-a7f1-aefb6377db9a">64,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjYtMS0xLTEtOTc2MTY_74397eb3-d99a-4c8d-a109-6b10e9cd2575">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjYtMy0xLTEtOTc2MTY_39329da7-4592-44e7-9282-e3fde8bc651a">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjctMS0xLTEtOTc2MTY_aaa20c64-fdb7-4d97-b9be-0a897aa866fc">30,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjctMy0xLTEtOTc2MTY_bc4e4f92-cd3a-4db5-a1d6-7fd709cdbeb7">28,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjktMS0xLTEtOTc2MTY_c97acb6a-a452-47d1-8caf-2c426e4bb4bc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjktMy0xLTEtOTc2MTY_bf9cafd2-22b8-4b61-9ba0-0cae60e2563d"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8xOA_4eccd90d-f724-4e8c-b490-36221d72f991"><ix:nonFraction unitRef="usdPerShare" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8xOA_d5ffd944-285c-4da1-b43f-ed19696fc128">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8zMg_456dc0c9-07b9-49b4-a6da-b0bc67047fee"><ix:nonFraction unitRef="shares" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8zMg_6bd1a1c8-2108-436f-98f2-2dc770058bf9">4,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV81NA_76bf0d42-4a74-491f-b0f3-ced873f8394e">1,812,622,099</ix:nonFraction> shares issued as of June 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV84NA_0c945b07-b17c-4b32-a3a2-ed594aa536eb">1,803,195,293</ix:nonFraction> as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMS0xLTEtOTc2MTY_b34801c3-0c21-46b6-b1de-348363ba0bc8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMy0xLTEtOTc2MTY_4047dc69-f476-428a-8b41-a84aebd5ca1a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in treasury, at cost, <ix:nonFraction unitRef="shares" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjpmZmE3N2RiNzk3YmY0ZjFiODkwYjk2NTM4MTc2YjI1OF80NA_d366f1c7-345e-46f7-a088-2f352308b4df">44,595,448</ix:nonFraction> shares as of June 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjpmZmE3N2RiNzk3YmY0ZjFiODkwYjk2NTM4MTc2YjI1OF82Nw_2afa48b9-bfb1-480e-b3b8-adc2dfa56f4b">34,857,597</ix:nonFraction> as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMS0xLTEtOTc2MTY_0fb40ed7-676a-4d7f-9626-5badd8d0f449">4,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMy0xLTEtOTc2MTY_f20edd9a-02d8-498f-b0a3-1b0564f562ce">3,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzQtMS0xLTEtOTc2MTY_54ecaa99-d120-4fc7-9a71-13d16d820707">18,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzQtMy0xLTEtOTc2MTY_9632d0fe-44d4-48b4-990f-919a82589e34">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzUtMS0xLTEtOTc2MTY_c3187b0f-f308-4ff6-8f6d-ea9782c05517">3,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzUtMy0xLTEtOTc2MTY_75755daf-9119-45eb-9085-af74e8cba16d">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzYtMS0xLTEtOTc2MTY_14abd861-f690-4de0-a96f-a1f10da44363">3,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzYtMy0xLTEtOTc2MTY_853fd458-8003-46c0-a475-761a5500e76f">2,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzctMS0xLTEtOTc2MTY_6cbdfeca-9faf-4c69-a1e7-c8ccd6ab2694">14,653</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzctMy0xLTEtOTc2MTY_9be714dd-cd41-4940-920d-375d725a5912">15,408</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzgtMS0xLTEtOTc2MTY_d8d82e2c-799a-4dfc-b406-8235e268ec88">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzgtMy0xLTEtOTc2MTY_500adf41-392a-4958-9244-76d12977fa8a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzktMS0xLTEtOTc2MTY_6c1be6ba-6a36-4483-a646-3987038531c3">14,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzktMy0xLTEtOTc2MTY_a0a546b3-cc4b-48e3-8869-5c07eaaad0a9">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNDEtMS0xLTEtOTc2MTY_a042e605-711f-4fae-aef3-036fa1208485">143,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNDEtMy0xLTEtOTc2MTY_a23c1095-285d-4204-9283-5995a5133589">146,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">3</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries <br/>Condensed Consolidated Statements of Equity (unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xLTEtMS05NzYxNg_c4fdbc32-7ef3-488a-85c6-4473a89c3bc3">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0zLTEtMS05NzYxNg_e6f10908-a2d2-48fb-bbee-112ae0cb33cf">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibca39d7498d64a07bc02cb92ab8980b5_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS01LTEtMS05NzYxNg_1b5f7a5b-c5fd-4d1c-8741-24db5625c394">3,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bba3be992d1453a87a14f0fc2f2e003_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS03LTEtMS05NzYxNg_68c286eb-355e-40bc-8dd2-bb720d673658">17,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd10bb64fb74478ca8debe7969144471_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS05LTEtMS05NzYxNg_1e19c4f9-8ae0-4c1a-8298-622569cdf752">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieae5bbb2ee744272bd95a22daad94e1f_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xMS0xLTEtOTc2MTY_377f90ff-89a4-4374-8f54-9e86668c52a6">3,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23011746e9d454494e543e106a64681_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xMy0xLTEtOTc2MTY_53d3eaf1-d839-479b-be24-786e5498eab6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331646900637403aaa44f99b19a7e033_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xNS0xLTEtOTc2MTY_1deb814b-061c-4b81-b638-4b75d9f910d2">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0zLTEtMS05NzYxNg_0c90b226-6e87-47de-8a66-564cda567e2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy01LTEtMS05NzYxNg_89bee6bd-e11e-4134-b208-6503cca294e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy03LTEtMS05NzYxNg_0ea73bb9-c0f5-459a-bfff-4a905675aaed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy05LTEtMS05NzYxNg_1a25280f-4d2d-4d20-9b80-b34b0ebaef15">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xMS0xLTEtOTc2MTY_87431fa4-32f1-4541-a7ea-82ea750c666f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xMy0xLTEtOTc2MTY_1e7c9446-c62c-4483-8292-73dd811d1c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xNS0xLTEtOTc2MTY_afb7a8d4-2ad7-4077-a1a2-0cd30b1008eb">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0zLTEtMS05NzYxNg_33da4a28-9c01-474a-9607-914d747b5e96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC01LTEtMS05NzYxNg_ae1c6368-3281-4fca-addd-54d0e28a7b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC03LTEtMS05NzYxNg_58c1977c-785a-4af8-a67f-5baf7564f5b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC05LTEtMS05NzYxNg_ea633a62-5dae-4b21-9542-cd936be1129d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xMS0xLTEtOTc2MTY_3a77a409-eb09-472e-9dea-ac78d698f6e5">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xMy0xLTEtOTc2MTY_a8545dbb-4a4d-4ce5-881b-182aea15c388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xNS0xLTEtOTc2MTY_21f40824-48e4-4173-a352-64d2a4d0b17e">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0zLTEtMS05NzYxNg_3a48fd7f-6bb5-4e2c-8564-2b8ca3ff3826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS01LTEtMS05NzYxNg_37b28c0b-d686-4397-ace8-2f5af77c8bec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS03LTEtMS05NzYxNg_3d66d13f-b183-4efc-8b10-7b9a3d75c9d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS05LTEtMS05NzYxNg_8c80bc5c-1ed9-4296-81db-f6f822cfaf19">2,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xMS0xLTEtOTc2MTY_282c538f-0f24-441c-8085-3de081205be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xMy0xLTEtOTc2MTY_ad5ab9fc-757c-4f0a-ad5e-80bd0fd120bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xNS0xLTEtOTc2MTY_89927f6b-af91-4190-81d7-a05d01ba3ffa">2,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xLTEtMS05NzYxNg_bcad14ec-ebe8-4ed1-8c18-db8a7363012c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0zLTEtMS05NzYxNg_1cdaefd0-809c-4e43-95d8-d71a73c13748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy01LTEtMS05NzYxNg_3b521210-86a1-49e8-a253-906a5e201fbf">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy03LTEtMS05NzYxNg_876222c3-2b99-47fd-8139-440507ccd8cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy05LTEtMS05NzYxNg_97ae8233-3fd6-4b07-9463-7149e0d0fd70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xMS0xLTEtOTc2MTY_ebd236e1-a573-4fb9-a1f8-efad7b27a80e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xMy0xLTEtOTc2MTY_2da43918-6fe5-4245-8a3e-e05e490e200e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xNS0xLTEtOTc2MTY_da31fb92-4746-4bd2-ac6a-49775041891a">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xLTEtMS05NzYxNg_18d57812-0634-43d1-8308-88b214c967fd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0zLTEtMS05NzYxNg_1bfa3a48-f5a6-44ce-908e-786b7c468e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC01LTEtMS05NzYxNg_19627792-5411-4c90-b2f2-68fc92b5dd1e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC03LTEtMS05NzYxNg_b771e8fc-510f-41b2-ae86-88e0de0bbc9c">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC05LTEtMS05NzYxNg_108009a9-94e0-46b8-8ea8-5140493b505a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xMS0xLTEtOTc2MTY_f4e065e3-33ea-4800-95a0-eebae60669ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xMy0xLTEtOTc2MTY_9e735159-af8a-44f8-a3b8-9a2a9092ca57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xNS0xLTEtOTc2MTY_2ceaf008-5d2c-4efa-942a-e91b0d8a9235">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0zLTEtMS05NzYxNg_70f997b1-360a-4569-8088-cf11bfaf6e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS01LTEtMS05NzYxNg_2fbd6ef4-3ab4-44cf-8f9b-777e4314968e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS03LTEtMS05NzYxNg_945cc086-7f79-4752-b14d-104ac3b8bbfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS05LTEtMS05NzYxNg_bd7e184e-831c-47c3-a1b4-a13217f98297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xMS0xLTEtOTc2MTY_34d89e8f-2dd0-49c3-94b8-894fad600e79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xMy0xLTEtOTc2MTY_53585c43-966f-49d4-87e6-12cea94f193f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xNS0xLTEtOTc2MTY_beafbd63-bdb9-47b7-ac88-d6df4e3788ff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b62204439a646a58b785ecf93877432_I20210630" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMS0xLTEtOTc2MTY_b214bc21-7633-48df-9394-885247062d54">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b62204439a646a58b785ecf93877432_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMy0xLTEtOTc2MTY_a0cb9926-82a6-487f-be65-07aa4dcdc918">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id749deebcb704c62b8d4183e0bcd069a_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtNS0xLTEtOTc2MTY_ef869c52-602d-433d-8063-4d76065bb7ee">3,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5349780f1cf74c438be36b3034549e8a_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtNy0xLTEtOTc2MTY_fd94d4f8-3bad-4520-8c4f-779675799080">17,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48f78d5eb442ea02eb2415d1ad543_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtOS0xLTEtOTc2MTY_67a852d3-4e59-4a34-8a1f-104122b22c9f">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTEtMS0xLTk3NjE2_42f01f4a-ce1c-4b09-bea1-afa6ccf9833d">3,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2313112557e4fc19d7b91b3581dbfc8_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTMtMS0xLTk3NjE2_1259dfe8-9d24-46bd-bced-2c6896233a9d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTUtMS0xLTk3NjE2_02352a79-8b6f-48ae-a3b9-b9b4603e1870">12,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMS0xLTEtOTc2MTY_9b22fdf6-3fb3-4dbc-a002-7c042431fa17">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMy0xLTEtOTc2MTY_0ad86031-53ea-4cd6-a74b-25117d60c1e7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i648a34fc11d2459da8234225c63c7180_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItNS0xLTEtOTc2MTY_f82a04ef-f13b-4707-a7ab-422966490565">4,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcf2868925d4b4c8aa4037dcd0e5af4_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItNy0xLTEtOTc2MTY_c8b00378-9c24-4450-a24a-8f2303104ef7">18,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3515fb6a244df8a64a70f4a299d580_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItOS0xLTEtOTc2MTY_f5c5818b-42ed-4f2f-a2ba-fbbc1e95cb8e">5,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5b734cf6ca4161852ec96132b5b371_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTEtMS0xLTk3NjE2_bd3e9503-8c7d-4819-9457-55035d6e4a00">2,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa65e7da4134abaaff3c9854cd90499_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTMtMS0xLTk3NjE2_9927151b-ed3f-4cf9-9750-81b9c5087c19">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2e3d15040b43b680868217bfddc553_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTUtMS0xLTk3NjE2_a69b014e-b868-4763-ac71-6eba7eee84c1">16,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMy0xLTEtOTc2MTY_4796efbd-f6ce-4a88-a04a-318dc8303619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtNS0xLTEtOTc2MTY_035f234a-8c84-4d0c-b5ba-be75d68d12a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtNy0xLTEtOTc2MTY_5bcb54d4-d8f3-4c0a-bf1f-0ee9bca7f382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtOS0xLTEtOTc2MTY_267b7b22-3ad3-4ab8-824e-ba8794bfc08d">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTEtMS0xLTk3NjE2_96f367ec-6d2a-4833-b156-6a6f9655d8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTMtMS0xLTk3NjE2_a4f42ed0-6195-480c-80c1-fb34884b76fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTUtMS0xLTk3NjE2_91c422b1-ef9a-4289-b0f5-5321b0362e6e">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMy0xLTEtOTc2MTY_7c0d1c11-fadd-4735-9684-0d0a5fa988c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtNS0xLTEtOTc2MTY_73f1ad5c-b56b-49ac-b93e-b934a0e47d69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtNy0xLTEtOTc2MTY_b2146763-c763-4902-81f3-6be212e44eec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtOS0xLTEtOTc2MTY_f4012be2-d163-4d90-964d-6d4a9702bc5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTEtMS0xLTk3NjE2_d5412bc4-69ca-41c0-8419-beee6b21e93f">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTMtMS0xLTk3NjE2_1d29ad05-4016-4040-98e8-0a6e71e5ff3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTUtMS0xLTk3NjE2_578aa314-1b1d-4c91-a943-0857de22474f">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMy0xLTEtOTc2MTY_76956736-d191-4303-8350-2b5c138b046d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtNS0xLTEtOTc2MTY_9fbf52a5-7bd6-4e5a-8295-87749fefb066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtNy0xLTEtOTc2MTY_d3bcd14d-7741-451e-973c-a3c1ea5f3712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtOS0xLTEtOTc2MTY_24c63317-0237-4dbb-9a24-c81d7220f8b6">2,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTEtMS0xLTk3NjE2_f4f6ca33-2be4-4bbe-b892-cd960a930c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTMtMS0xLTk3NjE2_87923900-b0dc-4c97-984f-04fce265c1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTUtMS0xLTk3NjE2_96def73a-9dec-48ae-b803-2ec06317a89e">2,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMS0xLTEtOTc2MTY_8e3a2770-dd64-473f-9d21-8a27ad3ba6ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMy0xLTEtOTc2MTY_a6e94521-312f-41af-85ad-afcc59912d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtNS0xLTEtOTc2MTY_86b0070c-553a-4f87-bdba-3aad8009787f">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtNy0xLTEtOTc2MTY_8f858355-e5d3-4fa2-a06c-6b7a3dbe8e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtOS0xLTEtOTc2MTY_7587af19-9da8-45a4-a80d-2b9c5e150de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTEtMS0xLTk3NjE2_1080ded2-d469-4930-9434-58f5caa6967a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTMtMS0xLTk3NjE2_0e2dc666-d110-4974-91cd-b437a636c124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTUtMS0xLTk3NjE2_ee888579-5265-4052-80de-c672d1194387">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMS0xLTEtOTc2MTY_fbcd7144-6bf6-4ba8-93df-f5946080c8a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMy0xLTEtOTc2MTY_242e0bbc-5c22-4c78-b58a-331e067d9d0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktNS0xLTEtOTc2MTY_f0aad404-96f4-4c50-a94a-2c5ffbae57b9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktNy0xLTEtOTc2MTY_f4410d30-a655-4e4b-a40f-3bac792e4489">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktOS0xLTEtOTc2MTY_63e8b516-a9c2-470e-8fc7-953713e7ee78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTEtMS0xLTk3NjE2_14b3e324-5788-401b-860b-19d16e1fb07f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTMtMS0xLTk3NjE2_e97cec4c-57bc-400c-a7d2-8c3772197bf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTUtMS0xLTk3NjE2_a2c38341-79ee-4af5-8f57-bc600f030de9">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMy0xLTEtOTc2MTY_63ae7d55-c5da-41ce-9fdb-2946c987ff38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtNS0xLTEtOTc2MTY_56f6fd09-5ce0-4d02-8f1d-8d65ca1a96ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtNy0xLTEtOTc2MTY_eaf30898-f679-42e3-be8d-3f48686feab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtOS0xLTEtOTc2MTY_2a4a0bcb-ea4e-4a32-bd1c-1bd2fa1ceb00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTEtMS0xLTk3NjE2_b3b0e830-56e8-493b-8df4-beeda180073b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTMtMS0xLTk3NjE2_d144aaab-cb86-4dfd-83ea-a3d9502b4da7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTUtMS0xLTk3NjE2_90f4bda1-b072-428e-a4a2-bc74d4ebbd9a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMS0xLTEtOTc2MTY_d5e0d195-a74d-4b39-a86d-0169686471b3">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMy0xLTEtOTc2MTY_f35cfa6c-9733-4de0-b106-ee98bb9df013">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib43cafd566d444139ef47736b216cfb1_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtNS0xLTEtOTc2MTY_f4424ac3-3617-414e-ac0e-6ed21654dae6">4,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63689aa1556b43cd941eb0a471e03f21_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtNy0xLTEtOTc2MTY_11f88f4f-13db-400c-8b1b-5a3d55c62974">18,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd8b399923342659954704e5a03ca81_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtOS0xLTEtOTc2MTY_8613d92b-ab03-40b6-9e3e-10079255f220">3,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTEtMS0xLTk3NjE2_d454fd4e-f476-40c6-8199-f938956f4c19">3,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTMtMS0xLTk3NjE2_e3c40fa8-b3a9-4464-9e38-f73c4039703c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTUtMS0xLTk3NjE2_87a8711d-a215-4225-8407-3263dd3c4de1">14,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0fc5d280fb74f1eb96d3958d3310a50_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMS0xLTEtOTc2MTY_a22a92a1-89bd-487c-8447-726c61c4116c">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fc5d280fb74f1eb96d3958d3310a50_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMy0xLTEtOTc2MTY_efccc113-4c67-47e2-a82f-26c1e02bf822">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c4079c9e0b47618569cdc1a099cb9c_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtNS0xLTEtOTc2MTY_15c20cd9-a732-40af-a0f4-08b04ad188f0">2,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c496813ec4c4dce8734e3932b3a401d_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtNy0xLTEtOTc2MTY_b5bfa79b-0b0a-4749-bff3-56e2ac7846a8">17,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18ec1eab6f64c5b8ad244778c1a7e89_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtOS0xLTEtOTc2MTY_daf99927-8422-477c-909a-7485c73f2a65">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06a455a093e74bb9ba124f24699eed85_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTEtMS0xLTk3NjE2_2c85c8c3-3820-4d9c-aa19-ef0586bb37c1">3,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744bb82611c44753ad6906f397e5e897_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTMtMS0xLTk3NjE2_6e48c0ab-b674-4685-a9f7-22bb32e466f5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1816b7eac954956b4765afd462e3f73_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTUtMS0xLTk3NjE2_1b6b7fcf-a5d5-4860-b4b5-9b640a32659e">13,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMy0xLTEtOTc2MTY_a80ed9e5-b6b8-4000-814a-599fd51a870c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtNS0xLTEtOTc2MTY_d60d6ff7-e932-4a5f-9010-c37015b35f6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtNy0xLTEtOTc2MTY_c1974f32-27d2-45a9-b476-123d9dda61b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtOS0xLTEtOTc2MTY_8b874e2a-981f-4426-a110-4b0eac0f4eb2">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTEtMS0xLTk3NjE2_d4d39964-2eb7-4ea6-9980-ec098322d258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTMtMS0xLTk3NjE2_ba82e0ab-43a7-4a58-88cd-1e35124c005e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTUtMS0xLTk3NjE2_92457dab-5a6d-466c-acb1-b8031f566e5b">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMy0xLTEtOTc2MTY_965c130e-4037-4de0-8470-e631006ce24d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtNS0xLTEtOTc2MTY_3ae4b6eb-e260-4736-a612-f3f228bb7907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtNy0xLTEtOTc2MTY_ade920aa-516b-416e-a02b-eb1712e8a9b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtOS0xLTEtOTc2MTY_d181ca5f-e676-4921-955b-12d04959af12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTEtMS0xLTk3NjE2_4675aa28-a471-4610-9df8-8232bdaae543">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTMtMS0xLTk3NjE2_3e18dfe7-a785-4dbe-ba9f-c39e0e82d216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTUtMS0xLTk3NjE2_f0a601be-5eb5-49c8-b98a-487dbbc771f7">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMy0xLTEtOTc2MTY_a0aa0b45-a60e-4d32-8864-3c33d0d38808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctNS0xLTEtOTc2MTY_d60b755e-2f59-4a9d-bcf0-8c90c4e3efb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctNy0xLTEtOTc2MTY_8e4c97ec-f58c-40f8-b3b9-1aa2abfae3aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctOS0xLTEtOTc2MTY_6a1b713d-f533-46a3-8b98-7e051575a583">4,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTEtMS0xLTk3NjE2_990926d5-3fb3-43c0-ad1d-0bbb5a2a3bf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTMtMS0xLTk3NjE2_73d12d15-db33-47f7-80e7-d4c3654a2f52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTUtMS0xLTk3NjE2_607d2806-3455-4e7d-9a18-795ae0932049">4,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMS0xLTEtOTc2MTY_4c944c87-ab90-41f9-a3c0-c1b9640e8942">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMy0xLTEtOTc2MTY_2810fe77-e08f-46c2-957f-980b22c88d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktNS0xLTEtOTc2MTY_a1278728-613d-478a-ac43-cb0fcbed9583">797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktNy0xLTEtOTc2MTY_c11841a9-7ce1-401e-a656-6db3f7dbc5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktOS0xLTEtOTc2MTY_36d2ded6-b730-4389-9c9d-afce3d17569f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTEtMS0xLTk3NjE2_c21905b6-73d6-40c9-8bb0-271e4bbf23a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTMtMS0xLTk3NjE2_9830432b-aef1-42d3-b9a8-8fffe3978bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTUtMS0xLTk3NjE2_efe833d6-456d-43ca-a4e3-81236f32eb55">797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMS0xLTEtOTc2MTY_0e163e3b-0db1-46cf-8f08-5fc06467b633">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMy0xLTEtOTc2MTY_ce343bb6-b0ba-41e2-b965-51489f273ab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtNS0xLTEtOTc2MTY_e5c494a9-a458-4d84-85ec-ba37d49f1cfd">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtNy0xLTEtOTc2MTY_a712b58a-ab7a-4741-9987-1a4151186d54">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtOS0xLTEtOTc2MTY_03313678-e48e-4012-962d-0ceca9b1f921">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTEtMS0xLTk3NjE2_0f9c0eb6-2551-479a-843b-89f637233670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTMtMS0xLTk3NjE2_bcf65433-1c78-408a-9cba-2aec05326381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTUtMS0xLTk3NjE2_55969472-f7cb-4ccf-92d3-128f802db6dd">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMy0xLTEtOTc2MTY_44621147-0128-4132-90ce-d483ee3a4835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtNS0xLTEtOTc2MTY_e4770446-091c-4a63-98f0-8b08cc7246b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtNy0xLTEtOTc2MTY_be2e5f1d-85d4-4383-8fb9-95794db70bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtOS0xLTEtOTc2MTY_0e31d86c-e8b4-4667-8a86-8978a6bd26cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTEtMS0xLTk3NjE2_63db64fe-1206-4e2f-bb78-2e1e110a776c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTMtMS0xLTk3NjE2_89d1e2c4-8599-4461-9d8f-09146e0c359e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTUtMS0xLTk3NjE2_67d0eec4-1d57-49d5-9db5-2a5e188ed0fc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b62204439a646a58b785ecf93877432_I20210630" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMS0xLTEtOTc2MTY_f0cac12e-522b-4dff-9e06-f58a05a656e0">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b62204439a646a58b785ecf93877432_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMy0xLTEtOTc2MTY_67987734-130e-4174-b987-4c076b38c628">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id749deebcb704c62b8d4183e0bcd069a_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItNS0xLTEtOTc2MTY_867e4322-d6a2-483c-bf21-e21862e44cd1">3,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5349780f1cf74c438be36b3034549e8a_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItNy0xLTEtOTc2MTY_1034e82e-5f18-4328-a6eb-a40b8f83061c">17,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48f78d5eb442ea02eb2415d1ad543_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItOS0xLTEtOTc2MTY_db01ce23-2585-4429-9f34-85fdb87b407d">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTEtMS0xLTk3NjE2_a25442d8-647b-46ed-84ad-d70d7146ba92">3,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2313112557e4fc19d7b91b3581dbfc8_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTMtMS0xLTk3NjE2_eee2aad9-bcb2-43bb-a622-dc42c54da0c6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTUtMS0xLTk3NjE2_095a656c-597a-46a2-8aac-e1a6ca6856c2">12,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i925631283eb246fca0b6016ff6e36dcd_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMS0xLTEtOTc2MTY_fe753c98-5f93-4d57-8f94-bc90d486d250">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925631283eb246fca0b6016ff6e36dcd_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMy0xLTEtOTc2MTY_fed1e230-5851-4862-b11b-5bbf4a5e6a1d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5aa927ee5d642738ac384f97cdb27ae_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtNS0xLTEtOTc2MTY_455c86a5-e00e-4a25-94ae-e0b55d0e98eb">3,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7be7b002a544fc89aa3eff960ce4c9_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtNy0xLTEtOTc2MTY_9500cc8f-80c9-4fd2-8cf8-bc41d3939f19">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c423a29ebb405295d44e99550f4888_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtOS0xLTEtOTc2MTY_3e0c9e9e-83ae-489a-99de-c8dfb602ca68">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i143fa36216244880b463624089eaba3b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTEtMS0xLTk3NjE2_f29d6b56-16db-447f-8b80-d25ff192baaf">2,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b4a2ace56f474f9eb07fc6b9af67c8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTMtMS0xLTk3NjE2_bb086d7d-c1ec-4b9f-8cb1-bf7ab156190a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTUtMS0xLTk3NjE2_03e57fe7-7145-44c7-ae46-e49535bf2ecf">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMy0xLTEtOTc2MTY_1260604f-589d-4883-830d-4c57bba4b1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtNS0xLTEtOTc2MTY_5de8e06a-6b72-46c5-aa41-6d99d74351fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtNy0xLTEtOTc2MTY_979f0f60-4353-4588-b1c7-5e4394b8edad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtOS0xLTEtOTc2MTY_66897d46-c1a9-44ae-b748-3224407970dd">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTEtMS0xLTk3NjE2_52e4cd95-2e15-4eb0-abce-de81d91a5a7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTMtMS0xLTk3NjE2_646ec9c6-dd96-443c-afea-9b5f5d2f36b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTUtMS0xLTk3NjE2_5b626f2e-acf9-4ede-bf5c-a71aacf5f30a">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMy0xLTEtOTc2MTY_706dcf4d-6b4b-4e30-93e4-90dd562788aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtNS0xLTEtOTc2MTY_f45c4f60-e70c-4dc2-b1df-bf88c0723e98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtNy0xLTEtOTc2MTY_81823495-dd9e-485c-976c-0525da67af66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtOS0xLTEtOTc2MTY_28554a94-02e7-4f94-951f-27271c17e7f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTEtMS0xLTk3NjE2_eb70efff-82d3-4dcf-bfbf-eaf4fc473e2e">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTMtMS0xLTk3NjE2_b6243409-d4dc-405a-9d67-189c29cb2817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTUtMS0xLTk3NjE2_8412c73a-eb91-4558-a22e-50f1a6108377">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMy0xLTEtOTc2MTY_374a8452-8e4a-43a6-b21e-355be74e2dea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctNS0xLTEtOTc2MTY_73d167c7-0969-4e7b-a2e6-2e746f753ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctNy0xLTEtOTc2MTY_d9a3c24d-dbcc-4d6a-9888-07d537b6ea1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctOS0xLTEtOTc2MTY_3902750d-2b5c-4b40-adcb-63d505d403e6">5,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTEtMS0xLTk3NjE2_f8ef1a04-b29a-4b27-b36d-9410374fced7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTMtMS0xLTk3NjE2_0cbe6753-2087-4032-9cbd-32820dbc4bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTUtMS0xLTk3NjE2_adec0863-2df6-4d40-9d0c-52b2063f6270">5,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMS0xLTEtOTc2MTY_d82ef54c-03f5-4959-bfcf-7ab9d29f0101">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMy0xLTEtOTc2MTY_e90360b3-60fd-425d-aa57-7eb258332f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktNS0xLTEtOTc2MTY_ea803f37-1e8a-4b45-a1c7-cf6f166ceb4f">1,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktNy0xLTEtOTc2MTY_5d79eaa9-eeb3-40b0-ba19-304f668ba52e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktOS0xLTEtOTc2MTY_1be1fe40-9e7c-4ac9-8402-16f480c66415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTEtMS0xLTk3NjE2_a0cbc27f-44bb-4439-81a6-8f973c7c438e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTMtMS0xLTk3NjE2_3a3359aa-c747-4c5c-8738-34020fd97630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTUtMS0xLTk3NjE2_36187b07-3637-408b-a9c8-89979f19885c">1,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMS0xLTEtOTc2MTY_32ec0f83-d964-429b-9ed3-4f5ffef1f84c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMy0xLTEtOTc2MTY_cdbf19cd-5e93-4c06-8a1e-d0d3f13e7b38"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtNS0xLTEtOTc2MTY_1d035fdb-e520-4209-ab29-9851b954e6fd">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtNy0xLTEtOTc2MTY_fcdf4cc9-e6c6-4666-b9ff-be6c1f317202">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtOS0xLTEtOTc2MTY_05dbfaa2-4156-40d2-a4b8-9c866f273879"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTEtMS0xLTk3NjE2_4a1f2cb5-376e-49c1-9e65-d3184d991466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTMtMS0xLTk3NjE2_401e4619-573e-4010-a94c-6410d4aa1f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTUtMS0xLTk3NjE2_c5f0eef3-f213-4e22-a0be-fedcd7ec1173">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMy0xLTEtOTc2MTY_b0de06b8-413d-4c9d-997c-d64af0a4f41b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtNS0xLTEtOTc2MTY_c4a255d4-27c0-4589-8759-3c3048feb4c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtNy0xLTEtOTc2MTY_6878f28f-94b0-4414-aeaa-e7b4e26b89fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtOS0xLTEtOTc2MTY_da32be96-bc80-4b43-8498-d2faec7d0946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTEtMS0xLTk3NjE2_2bf95276-d71d-46e2-b7b2-5c78949480a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTMtMS0xLTk3NjE2_27a4f2fa-120c-430d-beef-950601a463dc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTUtMS0xLTk3NjE2_352fe742-4fb6-4381-87f4-c442e10bd8a2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMS0xLTEtOTc2MTY_e30117f8-a7d5-496d-9d5e-636756527e6f">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMy0xLTEtOTc2MTY_380ba1d2-0323-4a17-a1d7-6cd822cdda7a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib43cafd566d444139ef47736b216cfb1_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItNS0xLTEtOTc2MTY_21fba1bb-9a1e-4987-894f-c5feb8158d7b">4,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63689aa1556b43cd941eb0a471e03f21_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItNy0xLTEtOTc2MTY_4cb4a0a6-886e-4b58-bf59-05239ce11c62">18,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd8b399923342659954704e5a03ca81_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItOS0xLTEtOTc2MTY_2ef51291-8d03-4911-b3ce-4d975aab291e">3,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTEtMS0xLTk3NjE2_2276787e-5d1f-4207-99c4-f0b887bd9b08">3,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTMtMS0xLTk3NjE2_a65a8f3b-051c-460b-b1f7-7395da5a8ca4">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTUtMS0xLTk3NjE2_f0b26647-fac2-40d8-b053-b2d45ff986c8">14,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">4</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries<br/>Condensed Consolidated Statements of Cash Flows (unaudited) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)&#160;(brackets&#160;denote&#160;cash&#160;outflows)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMy0xLTEtMS05NzYxNg_19210008-5786-4ffe-9740-ad81fa1c790b">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMy0zLTEtMS05NzYxNg_43a470b6-60b2-4d6c-84b1-378d08cf51af">4,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to net cash from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNS0xLTEtMS05NzYxNg_ce729471-cbbf-470e-aca8-6be251ca2225">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNS0zLTEtMS05NzYxNg_781c56f1-a2c1-4d3d-a0cc-f4870a3f54e4">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNi0xLTEtMS05NzYxNg_8708618a-95a9-40b1-8805-cbd037858b07">3,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNi0zLTEtMS05NzYxNg_7dc76575-5275-4c2c-8089-1b3761c9a63e">4,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNy0xLTEtMS05NzYxNg_70365a30-2abb-4db6-803a-5951025d3863">794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNy0zLTEtMS05NzYxNg_b93605f1-6ce3-4350-9c75-e98e93b0f52b">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOC0xLTEtMS05NzYxNg_4e619f7b-4e3f-4560-9a80-9f691c7f07ba">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOC0zLTEtMS05NzYxNg_14d9b0a8-4696-4aca-bd59-5e0ccf5abab2">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOS0xLTEtMS05NzYxNg_a947f80d-0a13-4ba3-aa30-3d4bfd96e467">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOS0zLTEtMS05NzYxNg_f6d09e3e-a94a-40a5-9f4a-de926a8276d5">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTAtMS0xLTEtOTc2MTY_89ff5fc2-2560-48ea-9836-92b68a4b3274">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTAtMy0xLTEtOTc2MTY_27b7dbd3-29ad-4297-8968-78947d5ac463">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTEtMS0xLTEtMTAwNTAw_6ad1dd03-7ee0-4d8d-9d8c-93ba482593e9">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTEtMy0xLTEtOTkzNDM_2f9b6883-f58d-41db-ada7-1484d1988a06">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash litigation reserve adjustments, net of cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTMtMS0xLTEtOTc2MTY_69866a13-bffc-4439-be2e-aba8cfa334d9">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTMtMy0xLTEtOTc2MTY_0ca0ba6a-2ec7-4587-8c88-0b52f3e7b8ec">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTQtMS0xLTEtOTc2MTY_e866b92e-0455-4efc-a1e5-5e07431bb4aa">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTQtMy0xLTEtOTc2MTY_c1f9afcb-756e-45d0-89e8-339492a6dc69">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTYtMS0xLTEtOTc2MTY_f53ca716-3e59-45fd-b402-6cce4c612d70">1,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTYtMy0xLTEtOTc2MTY_961fe951-d266-47a5-890c-500279682389">1,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTctMS0xLTEtOTc2MTY_cc56065e-23e3-4e68-bf01-9ea88c5cf532">499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTctMy0xLTEtOTc2MTY_417d758c-c68e-43f0-8806-8067c81a79aa">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTgtMS0xLTEtOTc2MTY_b5934321-65b0-4b0f-8fea-2fccbd0c9b05">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTgtMy0xLTEtOTc2MTY_e68a4e8d-a97d-42a5-8a1b-31eda3f3f656">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTktMS0xLTEtOTc2MTY_6855820b-72b2-41e3-97aa-08684824e977">448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTktMy0xLTEtOTc2MTY_e239916e-f3e1-4e67-a6f2-8ba6c27bc6ba">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjAtMS0xLTEtOTc2MTY_93b7cab4-beab-4b7b-9c3a-2799a95b2546">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjAtMy0xLTEtOTc2MTY_bd79532b-5077-44ae-a3dc-0afb33953d2c">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjEtMS0xLTEtOTc2MTY_1eb1be6b-c849-42d1-8e5e-f5b9f1f4680f">9,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjEtMy0xLTEtOTc2MTY_65d0da24-7ff0-45a8-8532-4b7bcf1a6701">9,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjUtMS0xLTEtOTc2MTY_3ec288ae-d5a9-44eb-9512-9c47c2b45a12">394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjUtMy0xLTEtOTc2MTY_7c88a736-9a64-4d57-aabc-68cc44456277">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjYtMS0xLTEtOTc2MTY_eb440e0d-a091-477a-842c-895625c16bca">305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjYtMy0xLTEtOTc2MTY_4c175ed0-f8a4-4a31-92e7-75de42420434">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjctMS0xLTEtOTc2MTY_b59874b5-1da2-4fb9-9568-8003a109c7ed">1,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjctMy0xLTEtOTc2MTY_bddc7de5-4323-49b0-813a-5d8771666477">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjgtMS0xLTEtOTc2MTY_b9d0b3a7-777e-4d66-86ac-90ebe751d6cf">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjgtMy0xLTEtOTc2MTY_87d10c45-bf20-414e-8618-f543012cafc6">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzAtMS0xLTEtOTc2MTY_940a5846-ffa8-485b-b7c6-c673775c9865">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzAtMy0xLTEtOTc2MTY_9c7fd10f-1d78-4a99-a629-52d0341ceaf0">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzEtMS0xLTEtOTc2MTY_337238da-b9f2-4437-a541-7336bca13746">1,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzEtMy0xLTEtOTc2MTY_091c2da4-2f35-4458-9978-e6d101e82864">584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzctMS0xLTEtOTc2MTY_ece7f9fc-e56c-4d6f-a4ab-9827af0e2229">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt and finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzgtMS0xLTEtOTc2MTY_af824aca-e51c-48ac-8e36-283e6b20f949">4,881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzgtMy0xLTEtOTc2MTY_b33b5fb2-47be-44d6-a845-bbdd017faf91">3,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDAtMS0xLTEtOTc2MTY_ffea133c-2b64-487d-8ca6-863eab57c8e4">5,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDAtMy0xLTEtOTc2MTY_8ea9ecb3-873c-498b-b382-81c44eecc2f5">4,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDEtMS0xLTEtOTc2MTY_cc322db5-3163-4a14-b3c0-d31f2dff2b44">1,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDEtMy0xLTEtOTc2MTY_47dc01bd-1ad1-4960-9fad-5ce0a4728c19">797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDItMS0xLTEtOTc2MTY_80399773-6898-4245-9a3b-697fb647a752">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDItMy0xLTEtOTc2MTY_e5cf3ec8-9ff4-4ba8-8f71-2d25000c5f20">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDMtMS0xLTEtOTc2MTY_99972e69-4763-4cf1-a628-e070e8bfd863">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDMtMy0xLTEtOTc2MTY_8dff73a0-4a94-4f20-a85d-f7111a68f8f4">313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDQtMS0xLTEtOTc2MTY_61a93cc9-ea68-4d8c-959f-9644e8aefcaf">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDQtMy0xLTEtOTc2MTY_7a0433b3-5298-4d65-b494-4bdd2de8a75d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDUtMS0xLTEtOTc2MTY_6498aa0f-a6a2-48f0-b13e-fa9f751b19d3">9,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDUtMy0xLTEtOTc2MTY_1fb52194-0b23-4797-bc8b-31a560a29ead">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDYtMS0xLTEtOTc2MTY_b3a9049a-613d-44c4-877c-a8bd3b419abe">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDYtMy0xLTEtOTc2MTY_cd808c46-4c98-4f99-9cc5-77c08366121e">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDctMS0xLTEtOTc2MTY_74e95e89-1a92-456d-9ba2-ca862b47f8ae">1,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDctMy0xLTEtOTc2MTY_e27ee032-12bf-46b3-b82e-b1b0766a0455">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDgtMS0xLTEtOTc2MTY_4e93d1e7-883a-4268-ba98-d289396f2624">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1816b7eac954956b4765afd462e3f73_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDgtMy0xLTEtOTc2MTY_92e7cd46-7562-4158-8275-72313b03db8b">8,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and equivalents, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNTAtMS0xLTEtOTc2MTY_ea5ad3ad-f879-4a52-adcb-1bf82e2ea6f8">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNTAtMy0xLTEtOTc2MTY_7b8d3024-b2e5-448c-aa57-606c12cd22ff">8,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">5</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc. and Subsidiaries</span></div><div><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div id="i8040488224cd40d194fd225edca967d2_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 1 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMjIxNA_04e15f52-8c4d-4b5b-a0bd-a2a4dcdf0e0e" continuedAt="i3add76ba2fb54f5bbea25e80df8238ce" escape="true">Basis of Presentation </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i3add76ba2fb54f5bbea25e80df8238ce" continuedAt="i8720bc4a2b484db5983a017d8ef794bc">Basis of Historical Presentation </ix:continuation></span></div><ix:continuation id="i8720bc4a2b484db5983a017d8ef794bc" continuedAt="i4c462db4a9234b1bb77a218377952cfe"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#8217;s audited consolidated financial statements and notes included in the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#8217;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c462db4a9234b1bb77a218377952cfe">During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;D and milestones expense by $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA3Mg_847812d0-67d3-44fa-a686-e479b8c5383e"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA3Mg_b60e3f1f-24dd-49fa-b8d0-47751da89209">35</ix:nonFraction></ix:nonFraction>&#160;million for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA4OQ_3c8c058d-81c0-48a6-9c8a-52088903e799"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA4OQ_48627638-b8a4-444e-9c4f-1569e3e545b0">150</ix:nonFraction></ix:nonFraction>&#160;million for the six months ended June 30, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.</ix:continuation> </span></div><div id="i8040488224cd40d194fd225edca967d2_40"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 2 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTQ5_2685580c-1024-4f66-9756-c43ca619d6de" continuedAt="i17e6ffeecbb64c2b98d28a8830a1b858" escape="true">Supplemental Financial Information</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><ix:continuation id="i17e6ffeecbb64c2b98d28a8830a1b858" continuedAt="ia1b6970124b244f4a4b04c8400822271"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTMy_78ce1abe-3592-4f43-be53-9e25e9cf1fca" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi0yLTEtMS05NzYxNg_0cec2356-66e7-4834-922a-0cb45befd0ed">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi00LTEtMS05NzYxNg_002620d4-b9ad-420a-a4af-39f6c16b8a91">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi02LTEtMS05NzYxNg_99a11075-8827-41a0-942e-1f97211cf557">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi04LTEtMS05NzYxNg_5ae04cd0-eeca-4f90-843b-f5456cfce6df">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy0yLTEtMS05NzYxNg_2f74ffdc-3721-483d-b484-bb28b93a7fbd">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy00LTEtMS05NzYxNg_3c43040f-4723-4efd-b7e9-3ac9c3ca6e68">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy02LTEtMS05NzYxNg_a9e2922c-48ea-4336-ba05-86d019fdb2bf">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy04LTEtMS05NzYxNg_3241c2a9-0d76-4760-a341-0d8ad28f0b23">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC0yLTEtMS05NzYxNg_5277d662-6387-45b4-b828-752517855025">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC00LTEtMS05NzYxNg_3eaf50b2-3f5d-44cd-a507-5ac42ba2c32e">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC02LTEtMS05NzYxNg_beb241a4-df3f-4f39-9b86-d5694f5f3d19">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC04LTEtMS05NzYxNg_2d41c117-9c0c-4006-b76f-c7f6c00a83e0">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="ia1b6970124b244f4a4b04c8400822271" continuedAt="i2def69a74fcf4800969942a176d6c067"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTUw_b03763d6-7dde-4ffa-a5b8-c7638663bad1" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMS0xLTEtMS05NzYxNg_b4a1ccd2-afe1-4c2d-bb4f-839a46146cb0">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMS0zLTEtMS05NzYxNg_ca76b761-32ae-4f69-a215-35eabb949166">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMi0xLTEtMS05NzYxNg_f7c38e58-a643-4360-8721-f578ea2c5b10">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMi0zLTEtMS05NzYxNg_5770591a-3b1d-4dc5-a070-f9bbdaa87153">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMy0xLTEtMS05NzYxNg_d01d6a80-23d9-4b24-b137-c11d506f9ff4">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMy0zLTEtMS05NzYxNg_eed4f73e-73ad-46f1-850a-7a3cfe928eff">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfNC0xLTEtMS05NzYxNg_9b5a1824-39c0-4712-b99e-33a1cb1bc2b4">3,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfNC0zLTEtMS05NzYxNg_e04cc3b3-039e-41d4-8ec3-7a2615deed5c">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">6</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i2def69a74fcf4800969942a176d6c067"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTQ4_8f3837a8-8559-40fe-8d33-0f251e88a1e8" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMS0xLTEtMS05NzYxNg_e47a4a5f-62e7-4bce-9990-b8ecc5c52f64">10,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMS0zLTEtMS05NzYxNg_bf9563c4-5686-4383-9452-66b755089f1a">10,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMi0xLTEtMS05NzYxNg_cd088809-67aa-49ef-8b13-d28a2fe267ef">5,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMi0zLTEtMS05NzYxNg_c15b89e3-89f3-42fd-ab85-7bd768fc3de3">5,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMy0xLTEtMS05NzYxNg_32bee0a9-0630-44c3-abf6-c92fc6599cd1">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMy0zLTEtMS05NzYxNg_d96a2691-789d-4d79-b847-821352d811cc">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTY0OTI2NzQ0MTkwOQ_8924e009-207c-4504-8364-343fb30ee20d">203</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTAx_ce729471-cbbf-470e-aca8-6be251ca2225">401</ix:nonFraction> million for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTY0OTI2NzQ0MTkzMw_2f65fcd8-83cb-4df6-9d00-21320f67f7d7">201</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTE5_781c56f1-a2c1-4d3d-a0cc-f4870a3f54e4">407</ix:nonFraction> million for the six months ended June 30, 2021.</span></div></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_46"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 3 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RleHRyZWdpb246NTI1Njc1NDJlY2E3NDYzY2I4MDliOTIyNjI4MDlhMWFfNjQ3_f4119463-87ec-4045-a9fe-a0af5d0578b1" continuedAt="ia340d64f85664c71a64d53d778c986dc" escape="true">Earnings Per Share</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia340d64f85664c71a64d53d778c986dc" continuedAt="i9914d72048564de8b5c9f8264e51fd34">AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.</ix:continuation></span></div><ix:continuation id="i9914d72048564de8b5c9f8264e51fd34"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RleHRyZWdpb246NTI1Njc1NDJlY2E3NDYzY2I4MDliOTIyNjI4MDlhMWFfNjU2_d9604a67-da0f-4fa4-bcb7-4e8e17e9a23b" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy0yLTEtMS05NzYxNg_37146fb9-6500-4a5b-a19b-7b2f5b5fe053">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy00LTEtMS05NzYxNg_32440a73-6dc6-4019-8662-cf7a1d39f70b">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy02LTEtMS05NzYxNg_1983de8b-dd95-45cb-ace8-6747fc95d3a6">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy04LTEtMS05NzYxNg_9cdad053-08b6-4eb0-aa10-87fcf2d94506">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC0yLTEtMS05NzYxNg_98d38408-d7a2-498f-86d0-a9c7e0c1304a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC00LTEtMS05NzYxNg_92bdefb6-182c-4e15-90dd-f696ab81b141">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC02LTEtMS05NzYxNg_d7290f37-e1bc-4236-b5d5-6b210652f717">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC04LTEtMS05NzYxNg_bc644469-df4e-4ba3-93cb-6f6ef2cbe8a5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS0yLTEtMS05NzYxNg_505ea6f2-7735-4635-9c68-3f1f330a2587">913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS00LTEtMS05NzYxNg_312c238c-a94e-4fa4-b707-a20c64fd7168">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS02LTEtMS05NzYxNg_73e0bce4-28a4-4576-91ef-29ee1d3500bd">5,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS04LTEtMS05NzYxNg_d0e5bd10-e483-4c88-bc1e-b6d373dec7f8">4,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi0yLTEtMS05NzYxNg_75115a2f-6461-443d-95ca-6c69c0277405">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi00LTEtMS05NzYxNg_8ad16e4f-be9a-4f36-94d7-efa223625897">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi02LTEtMS05NzYxNg_fae4c8fa-7e81-4ba2-bbfd-1e126d260925">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi04LTEtMS05NzYxNg_8fa298db-481e-4dc6-a761-c4e12d49117f">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy0yLTEtMS05NzYxNg_65aae81b-aa05-4385-aa36-8c7d014b5df7">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy00LTEtMS05NzYxNg_20bbcb6c-e7bc-4bc5-bbb7-99d9aad4a780">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy02LTEtMS05NzYxNg_a5058de4-f681-4dd9-a52b-bf0a9fe082d1">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy04LTEtMS05NzYxNg_1a369a36-c02a-4269-86db-baf98fa13ff8">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtMi0xLTEtOTc2MTY_0b3f8f24-59ee-4f76-8411-23140dfa86f5">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtNC0xLTEtOTc2MTY_cd265164-7cd2-47fc-a236-409cfeb60530">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtNi0xLTEtOTc2MTY_76f63a78-356c-40d7-8f20-c2e665f81b9c">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtOC0xLTEtOTc2MTY_498a265b-b243-4a5a-94a6-936bb159e8ee">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtMi0xLTEtOTc2MTY_5df30677-e338-45cb-a886-0428cf173018">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtNC0xLTEtOTc2MTY_b34832b9-13a4-40b9-acdf-20bfa1b466e7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtNi0xLTEtOTc2MTY_e9bb9f66-50e1-4eaa-94c2-fc9d73c02f95">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtOC0xLTEtOTc2MTY_35de705e-e798-4477-b1fe-ce3e3c705154">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItMi0xLTEtOTc2MTY_5e2f6128-de1f-44f1-a3ad-840e42bf7368">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItNC0xLTEtOTc2MTY_3170e559-e17d-4908-906d-216e3d5aa9bb">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItNi0xLTEtOTc2MTY_c899c0ea-0c58-4fc3-900d-fcc9dd65a572">5,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItOC0xLTEtOTc2MTY_632dc574-7d90-4c4f-807d-0dba7d56dbea">4,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtMi0xLTEtOTc2MTY_5d166d1c-13b0-460f-af4e-375b25b1ba1f">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtNC0xLTEtOTc2MTY_25e420f4-9dd5-4e32-bb2f-9fe7a5f7bf03">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtNi0xLTEtOTc2MTY_49ac8c52-ced1-4d7e-a0f0-b6e125469b2f">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtOC0xLTEtOTc2MTY_7a23a0d5-e60a-4089-9fef-2492649733d2">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtMi0xLTEtOTc2MTY_e3894e3a-53e0-4346-8c91-eef1d29694a8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtNC0xLTEtOTc2MTY_fa15dfb8-3a8a-4970-97be-e05c7bb11bfe">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtNi0xLTEtOTc2MTY_ade7ea5c-9e9b-4b15-9a1a-1ced95c4d709">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtOC0xLTEtOTc2MTY_00d2b0a8-de83-483a-aaab-2bed2e7076f0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtMi0xLTEtOTc2MTY_a319a982-7cc0-46f8-99cf-4defa4ef56e2">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtNC0xLTEtOTc2MTY_590e06cf-c7b0-4bc0-ab4a-64280961f4f5">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtNi0xLTEtOTc2MTY_e5b73e62-1d58-41b2-a53b-cf4cf2f08841">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtOC0xLTEtOTc2MTY_d76377fc-b890-4c08-bf32-da643ab65b7e">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtMi0xLTEtOTc2MTY_691751cd-23e4-4156-a65f-892cf24fde24">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtNC0xLTEtOTc2MTY_e6b15e20-752d-4466-88dd-8c48786acf12">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtNi0xLTEtOTc2MTY_68a68a5c-2b50-491e-abc4-34d8f4aff4a4">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtOC0xLTEtOTc2MTY_b1c4fa8d-ad7e-45a2-a133-fbabc22a2966">2.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_49"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfODc5_55042e2c-79b8-4ff6-9a1f-650fa4c1ff69" continuedAt="icce123ea884f4fa98e22891c22da3559" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensing, Acquisitions and Other Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><ix:continuation id="icce123ea884f4fa98e22891c22da3559" continuedAt="i3b43fbee6a4a4581a57a77859a9b2c30"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflows related to acquisitions and investments totaled $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNDk_227d1594-5b5f-4448-a12f-8f9dc8867421">394</ix:nonFraction> million for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNjc_f08efd6b-f86e-4984-94b2-20319abb1406">345</ix:nonFraction> million for the six months ended June 30, 2021. AbbVie recorded acquired IPR&amp;D and milestones charges of $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTY0OTI2NzQ0MjcwNg_7b3fe2f3-9332-4df0-b224-d8effebee342">269</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTEy_785e14e2-489d-44b7-8c73-90a1cd92df65">414</ix:nonFraction> million for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTY0OTI2NzQ0Mjc1MA_b4fac5b3-0177-4563-acb0-f17555a1a161">132</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTMw_0a1319e8-8a88-47ef-8e44-fbbc606d4e42">317</ix:nonFraction>&#160;million for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Syndesi Therapeutics SA</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNjEz_7157db06-c503-4ddb-991a-3e022921ccf1">130</ix:nonFraction> million which was recorded to acquired IPR&amp;D and milestones expense in the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i3b43fbee6a4a4581a57a77859a9b2c30" continuedAt="i571edb4147c6425db57dc90b114e13b4"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib1b72292beef4cbf9fac74da6779e3fb_I20220228" decimals="-6" name="abbv:PotentialPaymentsUnderAgreementCertainMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNzk1_dc717643-9e9f-4e11-9b4a-de53ebaa34df">870</ix:nonFraction> million upon the achievement of certain development, regulatory and commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Juvise Pharmaceuticals</span></div></ix:continuation><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i571edb4147c6425db57dc90b114e13b4">In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i59db14e384674164aab7d20a75d7554b_D20220401-20220630" decimals="-6" name="us-gaap:ProceedsFromSaleOfOtherAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTA5OTUxMTYzMDQ3Mg_06b914ea-d5eb-4e8b-9dab-453569efe8ba">215</ix:nonFraction> million and recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i38b7b50a66b144149f8c1287ceec7314_D20220401-20220630" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTA5OTUxMTYzMDQ4OA_2cb7d27e-173c-423f-b3c1-10988e08c4a9">172</ix:nonFraction> million which was recorded in other operating income in the condensed consolidated statement of earnings in the second quarter of 2022.</ix:continuation> </span></div><div id="i8040488224cd40d194fd225edca967d2_55"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDI0MA_3cece7bb-a642-4c2d-9a61-f694d396bced" continuedAt="i732954e836814461bab8552b8ffea797" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaborations</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended June 30, 2022 and 2021.</span></ix:nonNumeric></div><ix:continuation id="i732954e836814461bab8552b8ffea797" continuedAt="ib198087ec013478ca9d3216f12ff357a"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Janssen Biotech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#8217;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630" decimals="-6" name="abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTM5Mw_6f820d84-3b79-414d-b592-425c90c314d7">200</ix:nonFraction> million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately <ix:nonFraction unitRef="number" contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630" decimals="2" name="abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTU3Mw_b8b380fc-f971-419f-b230-71e66160eacd">60</ix:nonFraction>% of collaboration development costs and AbbVie is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630" decimals="2" name="abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTY1NQ_a063e779-fee2-47db-8bab-ae5df91edec3">40</ix:nonFraction>% of collaboration development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDIzOQ_511052db-c424-4cee-840d-d897db5cc172" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d7c4579b3144d4a545b08d34ae8d8f_D20220401-20220630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi0yLTEtMS05NzYxNg_cd436447-818a-4b90-9ced-7068c5c626c9">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied44bd1369ed4bdb88cabc67622ac9dd_D20210401-20210630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi00LTEtMS05NzYxNg_2b58678b-df2e-4885-a8e2-b119466a92d8">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia760c3d64fb74371a378c6623497a7ee_D20220101-20220630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi02LTEtMS05NzYxNg_b03eacd6-b87d-4427-b466-1f3beb06da05">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92651b474c794e5ca8ac957b8b9b0e59_D20210101-20210630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi04LTEtMS05NzYxNg_7d8248f8-8d1b-4ef5-87f8-c2ac9d5fd47d">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1717a97362f94154b97a937865fbff42_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy0yLTEtMS05NzYxNg_1082f60a-fa41-4359-8539-bfc805bdba4d">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29d7b949e14095835b529dec0be4b4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy00LTEtMS05NzYxNg_ee060a9c-a5fc-45dc-b853-44cb5cef01f8">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6eb92d83444f61b91925e0d7f8ff5a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy02LTEtMS05NzYxNg_4a1f7914-544f-46b7-aaee-0e0754f59298">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7107caab25d347ebaae1ee759946b263_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy04LTEtMS05NzYxNg_23ffeb63-298f-4919-93e8-e81cb2c4f2f7">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6e878897e14d5ea3dc67ebfd22e441_D20220401-20220630" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC0yLTEtMS05NzYxNg_633de1bd-9dde-49e9-846e-93a3f364e41d">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1955ccecde54928aa0c73f282a2340a_D20210401-20210630" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC00LTEtMS05NzYxNg_09b5cb4f-4e85-4a6e-a2c7-2ee549d50679">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC02LTEtMS05NzYxNg_10658a99-5b4f-4f88-ab53-ea56cd4a0767">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d666e53ce1843c38b0611e7ba387246_D20210101-20210630" decimals="-6" name="abbv:OtherExpensesFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC04LTEtMS05NzYxNg_6fc8f9d2-0fde-4730-a86a-c61dd6efaab4">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s receivable from Janssen, included in accounts receivable, net, was $<ix:nonFraction unitRef="usd" contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjczMw_424aedcc-383b-4156-af01-5b67aa8ae9aa">310</ix:nonFraction> million at June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i520d59c123c940099b7566525c161f63_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjc0Ng_d5a3084e-af64-446b-b8e8-3efb93895375">294</ix:nonFraction> million at December 31, 2021. AbbVie&#8217;s payable to Janssen, included in accounts payable and accrued liabilities, was $<ix:nonFraction unitRef="usd" contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjg0Mw_7d1c7383-47eb-41a7-8b3a-23f9a3a2896b">389</ix:nonFraction> million at June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i520d59c123c940099b7566525c161f63_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjg1Ng_02caaf9f-617d-4474-a428-997d494cd066">509</ix:nonFraction> million at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Genentech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib198087ec013478ca9d3216f12ff357a" continuedAt="if42d1e8e7fe14e4797701eb39fcbee03"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#8217;s net revenues. Genentech&#8217;s share of United States profits is included in AbbVie&#8217;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;A) expenses and global development costs as part of research and development (R&amp;D) expenses, net of Genentech&#8217;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#8217;s cost of products sold.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="if42d1e8e7fe14e4797701eb39fcbee03"><ix:nonNumeric contextRef="i3a1be3d4d92e4a689787ce9b5a84b41a_D20220101-20220630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDIzMA_482ba8ea-e410-420b-81dd-0c98b3d631dc" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17953cb362654702ad658e6a13cfb987_D20220401-20220630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi0yLTEtMS05NzYxNg_8373f176-1a62-472d-94b3-bd91c76271fd">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi00LTEtMS05NzYxNg_3e6dc4d4-90a6-4dda-854e-e2ae99e706c2">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi02LTEtMS05NzYxNg_b1779986-f730-475c-b068-52dfe6f4b519">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895042247e154437ae780eab2540751d_D20210101-20210630" decimals="-6" name="abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi04LTEtMS05NzYxNg_7d0b87d9-b549-4de5-aa4b-db3f5a81342d">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcaf1fd7b534884b238ec95d10826b7_D20220401-20220630" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy0yLTEtMS05NzYxNg_321685c2-42b0-4203-a53c-78e0ac642425">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439ea03a9e384ea8baf9310fdfda9c21_D20210401-20210630" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy00LTEtMS05NzYxNg_a25584ec-4d4e-4ce3-9d6b-508afa097dde">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a65557623304acba06de330a83ee93d_D20220101-20220630" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy02LTEtMS05NzYxNg_17ebc28d-8bf9-4456-93f8-fe01e7950e23">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4361107b3034a3c94e481eec57cf68a_D20210101-20210630" decimals="-6" name="abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy04LTEtMS05NzYxNg_fb049d41-648d-439c-9970-897731059e46">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17953cb362654702ad658e6a13cfb987_D20220401-20220630" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC0yLTEtMS05NzYxNg_32539e79-c114-4d9b-a2e3-f32ad53bc48e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC00LTEtMS05NzYxNg_c986f9a7-b025-4cc1-83ac-9ec8805b2e04">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC02LTEtMS05NzYxNg_7674113d-1edb-498d-8451-271151f79790">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895042247e154437ae780eab2540751d_D20210101-20210630" decimals="-6" name="abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC04LTEtMS05NzYxNg_37c9fb9f-25f4-41fa-bb73-dab52b60183b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i8040488224cd40d194fd225edca967d2_58"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 6 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODcy_f7989389-7686-4541-91b6-c1df2c476c84" continuedAt="ic003b9e4ff794d9884c5e4bbcdc357f1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="ic003b9e4ff794d9884c5e4bbcdc357f1" continuedAt="if3841bbeeb8a4554b7ff9786903c09c1">Goodwill</ix:continuation></span></div><ix:continuation id="if3841bbeeb8a4554b7ff9786903c09c1" continuedAt="i3668574ccc384229b9caa90be2eeda9f"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODY4_01c8e8ab-ba09-48a0-a779-b912fa0294e0" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMS0xLTEtMS05NzYxNg_9f128b2a-848c-450e-97ec-3d75cc38902b">32,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMi0xLTEtMS05NzYxNg_e14f539c-f458-41dc-a190-ad4f40700d0e">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMy0xLTEtMS05NzYxNg_25cbfde2-5595-435e-92f9-baedcc7e6299">32,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2022, there were <ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMjQ5_c3c0774d-1984-41cb-a4f3-dc923454be6f">no</ix:nonFraction> accumulated goodwill impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODU3_0d3093ef-8def-471d-95fc-04e1b2121412" escape="true"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODc1_4339e603-a813-4086-9010-13a741e46ac6" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c025272d3c4c2194f440828c692e80_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0xLTEtMS05NzYxNg_d4730082-1652-4425-8acf-658ff27a5bc4">88,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32c025272d3c4c2194f440828c692e80_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0zLTEtMS05NzYxNg_b0e2c05c-61c1-4a80-8166-300346fa2f11">21,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c025272d3c4c2194f440828c692e80_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy01LTEtMS05NzYxNg_c14aea42-c908-4e70-9b56-2d76b3489478">66,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy03LTEtMS05NzYxNg_041b1fcf-531e-4041-ae6c-d7f59386f852">88,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy05LTEtMS05NzYxNg_e5fbcb13-f806-4068-8632-6374aec48817">18,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0xMS0xLTEtOTc2MTY_80b91642-75e8-4ce1-b8b8-324c7a2c6bad">70,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0xLTEtMS05NzYxNg_28e8379c-5f23-4841-9af0-7db3dc236de4">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0zLTEtMS05NzYxNg_a8fa0b92-db61-4035-b26b-0d10e96e9dce">4,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC01LTEtMS05NzYxNg_68410c9e-bf76-4680-a360-684a397f660f">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC03LTEtMS05NzYxNg_a670bf3a-7c68-4614-8605-fd9b56427f2a">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC05LTEtMS05NzYxNg_873fbdad-c95d-43f9-b45f-4c480259f8b8">3,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0xMS0xLTEtOTc2MTY_d6683703-dac7-4f26-9802-75a2f53eb9ff">4,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0xLTEtMS05NzYxNg_6b258bc9-2cef-478a-b64c-091b1227db9a">96,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0zLTEtMS05NzYxNg_ea8efac5-6ed9-44b4-98a9-7d126dfb607d">25,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS01LTEtMS05NzYxNg_854de169-85a1-4805-9a25-eead2a5197c3">71,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS03LTEtMS05NzYxNg_1c1d5a44-b864-402d-8f2b-aa4a4c65fd44">97,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS05LTEtMS05NzYxNg_419c2c11-da8f-4722-8b19-a435150b240f">22,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0xMS0xLTEtOTc2MTY_3fc39c54-191d-4fa2-9e85-b3776552a6ca">75,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi0xLTEtMS05NzYxNg_249c2d20-c4f5-40cb-91d8-979593cc8ac1">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi01LTEtMS05NzYxNg_100101ca-eb67-4fc0-8d22-9ceb0f6f1d8a">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi03LTEtMS05NzYxNg_b50995ad-2dee-4feb-91c6-552187c4bb3c">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi0xMS0xLTEtOTc2MTY_0db9e832-4ded-4b17-8ac4-0bc9971cc98b">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0xLTEtMS05NzYxNg_c8740b70-6c7e-4f06-b89f-8ac39ade8825">97,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0zLTEtMS05NzYxNg_809f3362-104a-43f7-ad98-7a0d0c431623">25,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy01LTEtMS05NzYxNg_f1883024-f5d4-4c18-a525-88da1c23a5c7">71,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy03LTEtMS05NzYxNg_4159002f-b647-44a3-b1e9-569e3156a26a">98,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy05LTEtMS05NzYxNg_205b9fdb-63fb-43d3-85b2-bc3168670b42">22,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0xMS0xLTEtOTc2MTY_ec32bc82-d275-438d-8e6e-83cff28a6e79">75,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMTY0OTI2NzQ0MjYwNA_d9858c00-27bd-45d6-8ea1-0ac0bd3acc54">1.8</ix:nonFraction> billion for the three months and $<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfNDI0_b657da08-725c-49b6-a578-7b7e2d0c6054">3.7</ix:nonFraction> billion for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMTY0OTI2NzQ0MjYyMQ_87b411ba-3e79-497e-b9d4-8eedbae7fddd">2.0</ix:nonFraction>&#160;billion for the three months and $<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfNDQy_38eb49c1-47f2-406d-9101-3a5b738b4f97">4.0</ix:nonFraction> billion for the six months ended June 30, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i3668574ccc384229b9caa90be2eeda9f"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.</span></div></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_64"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 7 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTcw_b7ff6739-4319-433b-a0ff-06a23af15df9" continuedAt="i87a7798c65cf4cbbb76321609d89def9" escape="true">Integration and Restructuring Plans</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i87a7798c65cf4cbbb76321609d89def9" continuedAt="ia916af46d4604d25a7f2709ccfb76e7d">Allergan Integration Plan </ix:continuation></span></div><ix:continuation id="ia916af46d4604d25a7f2709ccfb76e7d"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i2c7df08664994f12aca1518baebbe045_I20220630" decimals="-9" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMzEx_90066e3d-168d-44db-a5e5-bafcffc10e12">2</ix:nonFraction> billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTcy_27f27ae5-62e3-4d44-bd3a-b550e4c89c4b" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.372%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic88c1ac3f5e440e784ff845b1c57c6e7_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy01LTEtMS05NzYxNg_9fe5f03b-21fc-42eb-ae07-dfe5955fa5e6">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812ac0d2871a40f1aafd158554ed5422_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy03LTEtMS05NzYxNg_6e25bb52-860d-4e61-b82f-3d20cefa8fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fc63ba180b3456d81d30cf250f754f1_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy05LTEtMS05NzYxNg_617d13d3-2cf5-47e9-b6c3-b92b8a769382">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fce41091494b70b87e4d7af3546c7d_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xMS0xLTEtOTc2MTY_428afa82-35b7-4d7e-b3a9-21de59321199">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8022aceb9c14776b862ea4d4d6d6439_D20220401-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xNy0xLTEtOTc2MTY_db303e30-01fa-489c-8d91-ec95bc1b1a05">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab97e9e01f14b32910efe469af4e78e_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xOC0xLTEtOTc2MTY_2a543c47-f078-4282-8bb2-bef1277f867d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8d8f7d150e4296aee9bf18bd08cc12_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0yMC0xLTEtOTc2MTY_d321ff1b-bfe8-44b1-8d34-ff87cd1e5395">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5b6a497ea346abad95173f039d362e_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0yMi0xLTEtOTc2MTY_bb1842b8-c199-4751-bc88-ac9774ef7efc">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb1e9d02bf34f17b2a0eed52a00027a_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC01LTEtMS05NzYxNg_c3454b79-8351-46e9-950f-42fe1e423f92">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcd977a37754942a73c727470b4f98f_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC03LTEtMS05NzYxNg_0056b140-cc7e-428a-8e2b-76c436ef0c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ccfe28417c469f8af551c99b927b19_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC05LTEtMS05NzYxNg_9f8f24b2-cdac-4d0c-88e1-192f2e9ee967">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a05939f8244a33897e7422c89f7126_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xMS0xLTEtOTc2MTY_53c5d8ed-b7be-471f-bca6-2c18ef1f9c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74bcc52335423cbc3f7f772ff0e679_D20220401-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xNy0xLTEtOTc2MTY_cc300806-9af7-4d11-af67-c35ff1f1435e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id282193bd524451fb438bb7e138e29ac_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xOC0xLTEtOTc2MTY_89128a84-24d4-4880-be6f-56df197c9d60">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e30abb6a7a486f885ad340a96c5778_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0yMC0xLTEtOTc2MTY_71d0e9c7-e29e-452f-b75e-25740e56a56a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6915f306024be09472c7f5080f0fa1_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0yMi0xLTEtOTc2MTY_92908c0f-2d8a-4f4a-8d5c-94cf229ce24a">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6899f65d669d4afea3cd976e00ecbe6f_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS01LTEtMS05NzYxNg_4beb07dc-59f6-4c72-bca7-47ef2e55d1f7">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e1c3dc13f54e42a2d2dc2c62ec8e91_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS03LTEtMS05NzYxNg_6938dbfb-d666-4e6b-97f9-24a90e5ce9a6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d0d44f11db4eb99c11417e2743e862_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS05LTEtMS05NzYxNg_3ddf38bc-d276-4607-a8f0-a6e31a5e3129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87cf8b8c10db40639f8c71e5fa2e3818_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xMS0xLTEtOTc2MTY_b429060b-900a-4af9-86e6-9143a3a7891a">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f4c1493f0542bf83279f44f2ec5342_D20220401-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xNy0xLTEtOTc2MTY_c39c1d62-9d77-488d-abf2-b1bb9dcd880e">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e06ca0731cf4d6a8f878bc559195695_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xOC0xLTEtOTc2MTY_642612af-6240-4874-bdb3-cb9e74f634cc">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1654b4f6b905425eb698282a6331007e_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0yMC0xLTEtOTc2MTY_4f25244e-b29c-49a0-96df-752c6f196d51">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871d07741b564eae82a08aa0199ea0cd_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0yMi0xLTEtOTc2MTY_06218959-f3fa-4f88-b33a-a9739d7575a1">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges (benefits)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib37c40029abd4cb58eba88c002702a40_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi01LTEtMS05NzYxNg_b13d274c-377b-4f94-8f19-91f293e51460">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb8785d8ad7402c9c7f7eb39826f245_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi03LTEtMS05NzYxNg_459d8db2-de16-4249-b47b-92bbaf5e6aa9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi05LTEtMS05NzYxNg_6c901f41-e50d-48f6-bfc3-cbcf483489f6">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6ef1b50dd847ef8aafa94acba4e841_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xMS0xLTEtOTc2MTY_bc405da9-0bee-429c-8584-605ab8d47c88">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b456e53d96948d096132c028d6d6d45_D20220401-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xNy0xLTEtOTc2MTY_90cab837-a229-4ae8-8871-bf520beda558">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf06b1b60dd7473091c775a625e20ee8_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xOC0xLTEtOTc2MTY_a6074777-1a91-49d0-a0d7-38c4cbdfec94">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0yMC0xLTEtOTc2MTY_c8984ab6-b596-4002-a22e-d862c56de4da">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie235947ffd0b4fd494f966cfa005097d_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0yMi0xLTEtOTc2MTY_d73103b7-684a-4597-b9b9-057e583a9cf6">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTgx_3c8bc558-78c6-4363-8d76-a31f89b347a8" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the six months ended June 30, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib759084aea2f4496bf0b655de783f845_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMS0xLTEtMS05NzYxNg_7328b8e3-489b-4e4a-b44b-f90fbea5eeb8">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf0ce88a8a04b83934728dac91cf848_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMS0zLTEtMS05NzYxNg_6b53bfb8-aae6-4d5e-bc50-f86458d8225e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges (benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630" decimals="-6" sign="-" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMi0xLTEtMS05NzYxNg_0b7c669c-07c6-47e1-98d4-617f10ce82cd">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630" decimals="-6" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMi0zLTEtMS05NzYxNg_90fbe789-821b-452e-aba1-b4af63de533c">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNS0xLTEtMS05NzYxNg_6e5042d6-1282-4cb4-af6d-0091d84ceedd">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNS0zLTEtMS05NzYxNg_8f66fbe4-15cc-42ac-ad5c-638138436800">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9690c3dd790403b890e9214d1dca483_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNi0xLTEtMS05NzYxNg_fe222c8f-c69b-4ed8-8059-18b1d696b1b0">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca60bffa3784e57811f6fbbdf1b19bb_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNi0zLTEtMS05NzYxNg_f6963668-952a-4f59-8d9f-a3c7d7b30896">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Restructuring</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie recorded restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="i641166a797c04452b983f67696448927_D20220401-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfODQ1_038bc44d-d712-46f2-9fb4-752dd265e946">36</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMTY0OTI2NzQ0Mjc0MA_400357f8-13c4-45b5-9fb8-3455b51b5cde">93</ix:nonFraction> million for the six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ie93c2d6ffcd9446ca4da0534ab40b4da_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMTY0OTI2NzQ0Mjc2Mw_e86b80c3-207a-4c51-9dc4-964142655559">5</ix:nonFraction> million for the three months and $<ix:nonFraction unitRef="usd" contextRef="ib96b0b1b9688402b88d483caeec8f26e_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfODYz_7092185f-af41-411a-9e4d-02259a402bdf">43</ix:nonFraction> million for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTgz_f410ceaa-ce86-4897-b9bc-a011e5832ace" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebc83f6b36448f796534e54e707d893_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMS0xLTEtMS05NzYxNg_f198a1a8-829f-4a3a-bbe7-edbeb3569f5e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630" decimals="-6" name="abbv:RestructuringReserveCashSettledRestructuringGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMi0xLTEtMS05NzYxNg_115121e3-c901-45fc-b0e4-7e81df893ca9">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630" decimals="-6" name="abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMy0xLTEtMS05NzYxNg_8f2df836-269e-4c75-af10-587cb1b5e3ac">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ca5c0ed3734cb0b0a99ad300871adb_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfNC0xLTEtMS05NzYxNg_3d307867-27ea-46d2-84c1-37e747dd56f2">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_70"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 8 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:DerivativesAndFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTM_1ea2220c-aebc-4dbe-b4fa-aa782b8096b0" continuedAt="iad0731682f93403bbf7718f4c01a9ea5" escape="true">Financial Instruments and Fair Value Measures</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iad0731682f93403bbf7718f4c01a9ea5" continuedAt="iaed9edc3a79d45c58fb52be256364d74">Risk Management Policy</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaed9edc3a79d45c58fb52be256364d74" continuedAt="ib33c1b7a742d407581de15ff04fc78fa">See Note 11 to the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#8217;s risk management policy and use of derivative instruments.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib33c1b7a742d407581de15ff04fc78fa" continuedAt="ib3adb399fa7546499592075211aded30"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="iae698ca482024ce3b8216d18a4baf683_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNTM4_c86c5fc6-4533-4633-9d8b-15ea6ac3db16">1.7</ix:nonFraction> billion at June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i4524aeddacca4e89affea472fd4d9845_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNTUx_d661f281-feb5-4a02-abca-49863ba7f02e">1.1</ix:nonFraction> billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than <ix:nonNumeric contextRef="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNzAz_b5908299-3e8f-417e-a8d7-0d59f2d49985">18</ix:nonNumeric> months. Accumulated gains and losses as of June 30, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding <ix:nonNumeric contextRef="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630" name="us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODk4_177446da-16d9-4c92-a3a1-9c0c821ec89c">six months</ix:nonNumeric> from the date of settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i2528382e46b44d108bf6d00b5efc76b8_I20190930" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTA0Ng_763e7e83-50af-4c51-a415-a37b66f88f30">10.0</ix:nonFraction> billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i12ea8e2e6bee41e29619c4f66c42dbe3_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OQ_92fbaf3e-bc41-4780-b7b6-f96c54cfd3d0"><ix:nonFraction unitRef="usd" contextRef="i7aa7cb14d24744b7acd20b1e031fb6b5_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OQ_a0e76e63-97c6-4e4b-ad88-93ec19727133">750</ix:nonFraction></ix:nonFraction> million at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="iba71512b143247428f9ba4531e9ff25d_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjQyNA_fb01b324-949c-459c-a797-11135255d29a">7.2</ix:nonFraction> billion at June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i910af4ba6c4148dead70c8fa5c3026a9_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjQzNw_a779ef10-ecf2-4add-b783-ade1185de08e">8.2</ix:nonFraction> billion at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="i0a19c3fd69054e33b86e0c727461ec6d_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjc1NA_501efd62-68af-4ba5-855d-a06267230063">4.8</ix:nonFraction>&#160;billion at June 30, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i1a04bf70fbd049c193fbd17df553937c_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjA1MA_748f681c-1d7a-4356-ab11-17854a9005ab">4.3</ix:nonFraction> billion at December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#8364;<ix:nonFraction unitRef="eur" contextRef="iea76646782af496e869aa248190a44f5_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjg4Mg_b6a7b71d-9d63-4bd6-855e-91a42c5493e9"><ix:nonFraction unitRef="eur" contextRef="icadd7ee0185740f48c4b33bcf2366cfa_I20220630" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjg4Mg_f51f39f1-f721-4c0d-ad1e-240e929be666">5.9</ix:nonFraction></ix:nonFraction> billion at June 30, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="ie930d15d61914f70acd5df79dc6f905b_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzM4MQ_5256f2de-d6bc-46ca-909a-cf5872df00ee"><ix:nonFraction unitRef="usd" contextRef="i48bd044943e9493c89b9abd3d5e526a6_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzM4MQ_b64ff904-981e-4953-b942-6d755a03cab2">4.5</ix:nonFraction></ix:nonFraction> billion at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_83eafbf2-c5ed-43b1-8e82-8a3e339e81d8"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_8d6ff385-6bd6-45f9-902d-a17d47d8b6c8"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_a446347e-4969-463b-b295-b41a940371e9"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="INF" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_e804acc3-6795-4fba-ba66-a89ac7e67add">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib3adb399fa7546499592075211aded30" continuedAt="i76287e32b98c439fa3f7a9eac7264355"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyOTU_7369f69a-da97-4c0a-93e8-2844d2e07179" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea75dcf12dd4babada42fe684de9583_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy0yLTEtMS05NzYxNg_af6cbc73-d66d-49b9-a0b5-01a859791ff9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50577511b38f48d9809921e16e47f00e_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy0zLTEtMS05NzYxNg_6cef5034-f67c-4cdc-9da4-6020742d9f31">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4006483b344921a0461483796c88d1_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy02LTEtMS05NzYxNg_bd4a4164-42cd-4106-b43e-89781a435aed">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0ed5cfd5e041159ae295f44339cf2b_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy03LTEtMS05NzYxNg_331fbaa6-48c8-4f82-a0dd-c87934ded128">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb8595f8fc429f8bcbb4158edd7889_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC0yLTEtMS05NzYxNg_d3621d0d-0769-48cd-b221-50a1aaadab39">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3b1067e45a4422969dfe03a89a0497_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC0zLTEtMS05NzYxNg_24dd831b-a05c-441c-8af8-5617794a29a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i315f4ccb8fbd487f8663eb19701710d5_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC02LTEtMS05NzYxNg_9999b9f6-3fa0-419a-8cae-0757d6dd5023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b21adb7b594e90b42f8a6d7c1542b1_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC03LTEtMS05NzYxNg_5ee6b137-621d-42d5-a34a-e9b93ebde3cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a9fc635cec47649c6b29ca40ecc4f4_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS0yLTEtMS05NzYxNg_f9d35179-8f63-4f16-ad6b-396961863871">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10501d2d359c448ab6d314b187853a21_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS0zLTEtMS05NzYxNg_afef2ea9-5e20-4a1a-982b-ae2d36afff1b">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1fd48dad064b5dbbcfd0c6de9a08b1_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS02LTEtMS05NzYxNg_fb30368c-8da7-43c6-b26f-03e3f9c83f70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c14573e31f4f1faeb7cb5d171e2310_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS03LTEtMS05NzYxNg_4c08a46c-4b3e-44fb-bd0d-b1dee6c37c79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739c681a88d742ad8f180ae17ea5b87e_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi0yLTEtMS05NzYxNg_289bc242-6f9d-43b8-b99c-ff0e911277f7">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebe4f90c08a4455a7f43925dbdae635_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi0zLTEtMS05NzYxNg_7c8e9eb6-7a30-47f8-ba38-1c1456a2975f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6801e00c9ec84d40ab46635262d0eaf2_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi02LTEtMS05NzYxNg_ecfaeb8d-67cb-4672-94f6-1e5ade214614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3baae219b314a4b9cda87196725e47a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi03LTEtMS05NzYxNg_5aaabf2f-a63a-472f-bcb1-e06fa9e3ce2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386f36745a614aa0bfef448277833331_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy0yLTEtMS05NzYxNg_4cdc60f3-0860-4b5a-b65a-7ca5dede5857">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71872c61ab7c46989f11583bf3a1dabc_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy0zLTEtMS05NzYxNg_afd8888f-4330-469e-9d5c-842e333c5a1b">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5156cbd23c04971a5dd83142a3d49dd_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy02LTEtMS05NzYxNg_2d0059e7-cfe2-4986-bb56-41c2c5b7bcdc">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f9ab36c47243cb97c7b0b729b87202_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy03LTEtMS05NzYxNg_033c8a75-42cb-434a-b1a2-fb0c81c7da1e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755cc2dfdc554f1aa804588740a5c249_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS0yLTEtMS05NzYxNg_8068acf7-3681-48ea-8c70-8e7a4b37d09d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aaa9318c7c4b838df81129cb70fa97_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS0zLTEtMS05NzYxNg_ce370a39-ebd0-4edc-a602-5ed8fbffdc78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e16a7b014ce47f1b67466b07472b8a4_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS02LTEtMS05NzYxNg_32266bb0-69f2-486b-8e66-d7e6262d3ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e8e4a49ca14f008f133fdd5954827f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS03LTEtMS05NzYxNg_7c6f30ff-82f7-4ac6-9932-562b25e550a5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709556ab9a9f465bade302574846826c_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtMi0xLTEtOTc2MTY_f74eb5d5-c8ef-4c5b-a160-5967e12d0660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffcc1ea976042a3b863cd853e3615c2_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtMy0xLTEtOTc2MTY_23ec152b-3015-40b7-aa2a-5821f047a96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b69cc0d9c0a4003bff5b8b142db53cb_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtNi0xLTEtOTc2MTY_b38d69e6-c2cd-4fc1-983e-b6e85d4249a4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3858f900834806a5d8b1b8a4ab8060_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtNy0xLTEtOTc2MTY_466c89a8-b628-4d3d-939a-ccd8527b56f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321bab6a8ec644378bbfac816a7f1529_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItMi0xLTEtOTc2MTY_7eab817d-b153-4ce9-9fa9-092593c8787a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1da7424536451694dbf819f1ad1afe_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItMy0xLTEtOTc2MTY_2722492f-7762-4a0d-bac6-524216240036">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2887c0ea8ed429e81e55af1fe19ba49_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItNi0xLTEtOTc2MTY_e4b52d62-a946-4f0e-9dcb-9bc49a0ae340">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9c65ce995c41569b56cea1f111c6c2_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItNy0xLTEtOTc2MTY_285ac5a7-4b35-47c6-aab8-c7c1c67fc534">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtMi0xLTEtOTc2MTY_852c67cf-5d98-4c80-91fb-47a747e66e2c">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtMy0xLTEtOTc2MTY_d7358c6c-a4f4-4440-880f-9931be51dab5">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtNi0xLTEtOTc2MTY_64fc97ab-623c-44ad-953d-6ba80ff9ce26">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtNy0xLTEtOTc2MTY_4e3658cd-b94a-43b9-9d32-283dd26dc9f2">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with the company&#8217;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTY_e324d443-9899-425d-b170-7ab0fc10aaab" escape="true"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyOTE_6be19a31-ba0d-40aa-9ace-9b1850b7e713" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy0yLTEtMS05NzYxNg_4499ba70-50ff-4e96-ae6b-c8ba032d1c7a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy00LTEtMS05NzYxNg_648980a5-234c-4e02-8cb2-965a8a1fd525">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy02LTEtMS05NzYxNg_8f5db9af-f1dc-46cb-ae64-66793bcac427">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9147234a7c47909a827383e386fa41_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy04LTEtMS05NzYxNg_bc6f7eca-8e7e-4b84-b761-61a98cf9bd95">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC0yLTEtMS05NzYxNg_c4d6b905-bf86-42de-a6d3-257aa5237647">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC00LTEtMS05NzYxNg_ecaaf11d-2afc-46d0-b925-ce23f4907486">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC02LTEtMS05NzYxNg_976f1c49-aae3-4e65-87d9-68c62851efb6">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9147234a7c47909a827383e386fa41_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC04LTEtMS05NzYxNg_1c48c8bd-d011-4fa0-9cb0-72353030c6e5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50774814001e48ec956e2b9c5f605ec5_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS0yLTEtMS05NzYxNg_49a19bb3-f0c1-4c00-829c-53c98b81b208">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fff8515f5964feaada59a50074f36b6_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS00LTEtMS05NzYxNg_21158f72-aa24-44bb-a8af-63f56abbfc17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2242a34258674da88852f8da26f482ed_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS02LTEtMS05NzYxNg_b9b40ef8-809b-4c35-8fa9-83d04d4f599d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b9c1a3268b4e8490a003cc3c407a54_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS04LTEtMS05NzYxNg_7859643a-7271-41d9-ac66-61eeba2cb9f4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="ie3c18991cb0745f7bfde8bb5e68396df_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDI2MA_ac7b1abc-974c-4dba-beda-65fb08bbfff7">73</ix:nonFraction>&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="i34f3be30283c469288d3b140fb14f38f_I20220630" decimals="-6" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDMyNA_0161d188-a178-4819-85d4-5549f62e9dab">2</ix:nonFraction> million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="i34f3be30283c469288d3b140fb14f38f_I20220630" decimals="-6" name="abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDM5Mw_3e0f85ce-2d95-45be-86f9-b011d530b9f5">24</ix:nonFraction> million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to AbbVie&#8217;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="i4fa7e393d853413e8c347f6adc293a09_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjEzOQ_b859fd9e-a66e-4886-8965-84543da7ea79">402</ix:nonFraction> million for three months and pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="if2e974e271de4652b5cda15919ce55ec_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDYzMQ_827cc6a8-d046-4f6f-9109-0f9542dc0218">501</ix:nonFraction>&#160;million for the six months ended June 30, 2022 and pre-tax losses of $<ix:nonFraction unitRef="usd" contextRef="i60b2022fd9784fa1800afc801df52ab4_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDY2Mw_17d58a29-8486-443f-bb1f-7ec2e9ed3ae2">126</ix:nonFraction> million for the three months and pre-tax gains of $<ix:nonFraction unitRef="usd" contextRef="id93653ba690e49d188298eb65d621889_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjE1NQ_42cb51c8-9ad0-4883-b005-19cc825d2682">256</ix:nonFraction> million for the six months ended June 30, 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i76287e32b98c439fa3f7a9eac7264355" continuedAt="if54aa1dc6fff44e58c4d97af04602fca"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTc_73ed1f25-8e08-41e1-a1ce-ff479f9c22cb" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7672ac59d1eb40d889784fa7661a5dff_D20220401-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy0zLTEtMS05NzYxNg_8ba541d8-1ea5-43ee-9e54-fff9baa17dcf">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ba4ee6e978452e8a1317fb1eefa4ab_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy01LTEtMS05NzYxNg_a439cf18-57c9-4f12-9a8e-f1c1b03f9d19">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014cf1d076d344b3a853244e7ff6f7e2_D20220101-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy03LTEtMS05NzYxNg_53df2e10-640f-40e3-bce2-a0817ce89bad">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92b470b9e9b4e9099e15d58a841ffa9_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy05LTEtMS05NzYxNg_43329fe5-714a-4232-8349-771103a576ab">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585d1d66efc44ae9819fbf2a01450a74_D20220401-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC0zLTEtMS05NzYxNg_5ac6e852-5275-4a95-b2aa-14e13bf4f22b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708a87d51a194373a7ae0cfd26e60f16_D20210401-20210630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC01LTEtMS05NzYxNg_4516d19e-69fa-43e3-a593-8f61518e6716">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1576b42347bd40ac95a968ddb28a8b73_D20220101-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC03LTEtMS05NzYxNg_dd1974bf-490c-402b-a15e-f871cffa6fee">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9466c79412984d2eb3f7d8ac357eecc5_D20210101-20210630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC05LTEtMS05NzYxNg_7840e677-e3de-4f28-9c30-3bd57642d74e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42fdbf024af844d29c32652264e478ee_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS0zLTEtMS05NzYxNg_b01b869d-ce07-400d-a76f-0ec81752d3f1">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da9ec9481dd4073920e0859a42702c6_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS01LTEtMS05NzYxNg_0ea3ce66-dada-4be8-a074-297bfbea28fc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68ce7ad10c8f4e0e8549ad2454dcf4f4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS03LTEtMS05NzYxNg_f58bdfc8-79d9-459a-a38e-a6ce00821f75">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8cc41372ed3492cbdd0b1794bfc39fa_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS05LTEtMS05NzYxNg_10f12dc2-1440-4f5c-a776-3f5311e0fa9b">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a5b327aee6478ca6d36a047ef148de_D20220401-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi0zLTEtMS05NzYxNg_cbfcb11c-699f-4570-aa18-0e80e52b143e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6806c0a00d42728328e0c191cb6c46_D20210401-20210630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi01LTEtMS05NzYxNg_a7298e12-c356-4b50-80eb-ab5b6140e21f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b17ef4e01764ead8e46800fa43600f1_D20220101-20220630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi03LTEtMS05NzYxNg_ee63d773-6aac-4e99-95f7-c50a221dbdc3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e376f561464510bf004ff1475b3177_D20210101-20210630" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi05LTEtMS05NzYxNg_79b634b8-4c8f-46d8-abd5-d5427a1ab45a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3967d0c84ef4ab5b092b438c43a6bb9_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC0zLTEtMS05NzYxNg_fad94b7f-bb6c-4ab5-bf80-f64c5a611021">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica001ccafca24ec1b40518c87036cbc3_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC01LTEtMS05NzYxNg_5c2ee1d4-f9a8-4454-809b-eefe50ba7dfe">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i916d4573e04c4ebb82df425498689123_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC03LTEtMS05NzYxNg_b5fbf819-b626-4e85-a49d-ebcd6a2b7f58">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38c5f2e4fd04481eb9c96733c3ab6282_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC05LTEtMS05NzYxNg_230c13eb-13bd-4755-89c6-dd1c9342541a">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b6d1c3a9b9b43ed888b26722a1ef814_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS0zLTEtMS05NzYxNg_e9598eae-d186-46ec-a387-1ec398a5575d">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81835d73a8d24f9fbf352588b381f229_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS01LTEtMS05NzYxNg_b4c0acd0-8fea-4593-9044-9446feb49e39">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib14b54f083414973b49fd17c21639430_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS03LTEtMS05NzYxNg_2c4dee88-7dab-468a-b00b-8e7829161435">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e90fc724a5a42e48ee6a1d195f84ab8_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS05LTEtMS05NzYxNg_3429ecd8-769c-4a4d-84be-ffab2a9c2e01">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ada3a46921346fd865f1babab324aeb_D20220401-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtMy0xLTEtOTc2MTY_76af0bbc-38a7-4f30-b16a-aaacd3560894">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5306df8c08e44da98c277f0e759fd1ae_D20210401-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtNS0xLTEtOTc2MTY_5ff95616-8421-45ed-a81d-16470ea9dfee">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0873fa6f786493d98f649f5b8df8913_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtNy0xLTEtOTc2MTY_87913ff9-5748-436f-8eb2-6ec13def183e">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6789fba1c748ce81e02fec0c7a1680_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtOS0xLTEtOTc2MTY_cf2577e4-fccb-4123-8235-639e57231ff6">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 2 &#8211; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 3 &#8211; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#8217;s management about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNjk_691bdbe9-ce6b-443a-a53f-58cf8e3705e2" continuedAt="i4d2ee1416328439086ac3944e627b70c" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy0xLTEtMS05NzYxNg_98095244-c311-4aa3-9fb0-bb98f6f492bb">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy0zLTEtMS05NzYxNg_5b75fd93-6660-4b98-97b1-eb63d9d7b884">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy01LTEtMS05NzYxNg_ae9da209-43d0-4b27-9f06-906999bf5008">4,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy03LTEtMS05NzYxNg_80887d87-dfa6-4436-a992-a5d13b858cd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870123ed29d24decb0df38ca4b783ed5_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC0xLTEtMS05NzYxNg_d3b8eba0-2620-45a3-88bb-0c24c62768c3">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de815be0be44e778d9f2b95394472e4_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC0zLTEtMS05NzYxNg_0a61f3b6-cf84-4c81-8288-90fb16350594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b79104cfa54b9abca4b24b661bea9c_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC01LTEtMS05NzYxNg_d3eabc8b-571d-4e27-b8d5-d87f2b140fdb">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5a23680db6467891252a20dcb977d8_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC03LTEtMS05NzYxNg_90dd0218-fd64-4f9d-b397-203f340a5bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS0xLTEtMS05NzYxNg_b2d92b14-b734-40ea-8c45-47f85ff25417">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS0zLTEtMS05NzYxNg_7179ace4-0ea3-4807-ad53-c513732a6c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS01LTEtMS05NzYxNg_3446af62-3a03-4b62-a52f-8b8d22fab19a">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS03LTEtMS05NzYxNg_8ca8db30-8bca-4bdc-b3cd-3192202390f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi0xLTEtMS05NzYxNg_8654b5de-07b8-438d-992d-32d073e9655b">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi0zLTEtMS05NzYxNg_4912a6b8-df17-4d61-9e64-264f86e5c161">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi01LTEtMS05NzYxNg_e3bdb2d7-f41d-4b29-beea-802c817ec6fa">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi03LTEtMS05NzYxNg_41259d29-5f76-4599-bf9d-4822614f7684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy0xLTEtMS05NzYxNg_2ba879ff-104b-4e76-a898-e39867a93576">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy0zLTEtMS05NzYxNg_62e8bab4-0847-4ba5-a241-d9aa262def39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy01LTEtMS05NzYxNg_0b76c4e5-4991-4456-bc63-c60bfe07ea1c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy03LTEtMS05NzYxNg_0eeb6d5b-6faa-4039-a86d-73d24190d379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5130a9a2788493194f69310dd5fb80a_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC0xLTEtMS05NzYxNg_8098e67e-8662-4050-93ba-5a6c09858a8c">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0856d184c09c4cb990892955581e79dc_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC0zLTEtMS05NzYxNg_ff29223f-1ed6-465d-a99b-18e3df548bcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac4c3858d334f249fad7fb813cec175_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC01LTEtMS05NzYxNg_e4099c5d-babe-40df-a2e1-3f0ea9a046ec">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC03LTEtMS05NzYxNg_9448c568-5fa4-4bab-b0a9-2f4f5b96f3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtMS0xLTEtOTc2MTY_423ec9e0-b703-4e16-9776-022afea31b9f">10,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtMy0xLTEtOTc2MTY_f3cd3c2d-e3ba-409f-a227-d8b5ad49aa29">4,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtNS0xLTEtOTc2MTY_3ee31aaa-12fa-4949-aab8-bf181025755b">6,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtNy0xLTEtOTc2MTY_8fffb873-b16b-407c-a02d-47fdbfa4ca63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItMS0xLTEtOTc2MTY_49ae0764-6fce-44a7-ae98-5c8a2c5504e5">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItMy0xLTEtOTc2MTY_d3d91a69-6daf-4f0d-b9de-432b6a7c4b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItNS0xLTEtOTc2MTY_f588d54d-24f1-43b4-b6b2-57ed1e1eb046">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItNy0xLTEtOTc2MTY_60d4cd52-6903-4ce7-aace-c6a947721d50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5130a9a2788493194f69310dd5fb80a_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtMS0xLTEtOTc2MTY_44582c44-1c02-495a-9b1e-31faa11d41fc">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0856d184c09c4cb990892955581e79dc_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtMy0xLTEtOTc2MTY_5af5425f-bc19-4fa9-a777-6fa6883f69f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac4c3858d334f249fad7fb813cec175_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtNS0xLTEtOTc2MTY_2c69e26d-f59a-4b07-8173-d8fee38aad5e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtNy0xLTEtOTc2MTY_ed6b8496-79d9-4c81-87e3-5acff206071d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtMS0xLTEtOTc2MTY_781ae6e4-b0d5-49b8-935b-77f4e4c66dfe">15,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtMy0xLTEtOTc2MTY_5a7b5736-4cd5-4587-b0d2-06baaa6f85f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtNS0xLTEtOTc2MTY_bc3ee7da-584c-45f0-8838-b26ac46b6cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtNy0xLTEtOTc2MTY_0e845930-a066-4d64-a153-6355683cf076">15,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtMS0xLTEtOTc2MTY_85f38e1d-d41e-4113-ac78-94af0de03f8f">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtMy0xLTEtOTc2MTY_346a158e-c533-4598-a48f-295671fc39cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtNS0xLTEtOTc2MTY_388f90ec-6db1-4bbd-a078-35a17dd906ee">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtNy0xLTEtOTc2MTY_6c2cd8a7-c3a8-4c4a-bdca-7add14ea90ce">15,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if54aa1dc6fff44e58c4d97af04602fca" continuedAt="icab8e9037692491694b71206d7e13592"><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i4d2ee1416328439086ac3944e627b70c"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy0xLTEtMS05NzYxNg_2f804824-3ca1-44a8-9ab1-7e2534663119">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy0zLTEtMS05NzYxNg_0aee1297-21e5-431b-951a-12a08d9ce80a">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy01LTEtMS05NzYxNg_a440da8f-b088-424d-b258-d6b4c444359b">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy03LTEtMS05NzYxNg_9a4f6006-f2c4-469b-a1bd-09b315ac36ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48db75cf5be84dcebf25c3be860e8891_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC0xLTEtMS05NzYxNg_95495420-9347-4ad4-bed3-649fe0d9fbee">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8175f7411740adaed89dd39b020a8b_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC0zLTEtMS05NzYxNg_7eb9a2e3-f8b9-4af5-8f08-afb3a16111b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5da0605afd0403a91a86f6fc2935d5b_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC01LTEtMS05NzYxNg_5ac105c2-4f2b-4f30-9565-eca1dcfed5bb">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad384a1ae084ceb824d660b0d1c00c9_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC03LTEtMS05NzYxNg_7aee09f2-da3f-4e8d-a3df-7e48cee976d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS0xLTEtMS05NzYxNg_10eae950-4d98-4a18-88e4-65e688069aa0">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS0zLTEtMS05NzYxNg_9afbf466-f05f-4b5c-83fb-70cc769007ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS01LTEtMS05NzYxNg_01854a5b-383a-4ed5-9a19-cd84e97e512e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS03LTEtMS05NzYxNg_973e8092-08da-4685-8efd-7df30fe7cac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi0xLTEtMS05NzYxNg_14c4a2c4-63f4-444b-aa81-a7675fc58997">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi0zLTEtMS05NzYxNg_8cf3463b-4446-4d8c-9c60-88d96acd5bcf">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi01LTEtMS05NzYxNg_e783a4a5-6a57-4f0b-a8d5-1759d9cd2b0b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi03LTEtMS05NzYxNg_fdec86b1-3ee6-4153-9583-8fced9ca6ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy0xLTEtMS05NzYxNg_a80f7d20-962b-47cd-88f9-c9a5c60b859a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy0zLTEtMS05NzYxNg_dab04d89-2176-4c3c-9dd2-201ce7e971b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy01LTEtMS05NzYxNg_f59e9496-8aeb-40a8-99f1-4699e5b0458b">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy03LTEtMS05NzYxNg_eecae072-2d16-4b90-9dfc-b59e78d5cdd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC0xLTEtMS05NzYxNg_820f89e2-eecc-453a-92ca-0be8189890cd">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06facb13108b44fdb65aac8490d55d79_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC0zLTEtMS05NzYxNg_644982e5-0da2-4bde-a79c-b3b21915c442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC01LTEtMS05NzYxNg_d95f64fb-11af-4929-bba1-18cff0c6ad53">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC03LTEtMS05NzYxNg_094bfed1-89f9-478f-b4bf-c8fba4db8434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtMS0xLTEtOTc2MTY_36da393b-dd69-46fe-9dd5-3b507a9242c6">10,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtMy0xLTEtOTc2MTY_d6cc48f4-36e0-48f0-9317-c66da6ce3efc">4,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtNS0xLTEtOTc2MTY_5e1afe0b-06c7-41a5-911b-586a6cffce88">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtNy0xLTEtOTc2MTY_34f22ba3-805f-4550-b4bc-93c4f274377c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItMS0xLTEtOTc2MTY_c8ad1e66-9cb3-4d39-8a79-baf93102596d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItMy0xLTEtOTc2MTY_526f3bee-bcf8-4087-a2d1-1900b02ebaa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItNS0xLTEtOTc2MTY_86dea381-7d4d-4dd1-bdc7-275d9686c8da">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItNy0xLTEtOTc2MTY_336a4f8c-c3b7-4955-ba6a-1e69f0cf4cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtMS0xLTEtOTc2MTY_84661a7e-ca57-4601-99b5-f198cd4b71cd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06facb13108b44fdb65aac8490d55d79_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtMy0xLTEtOTc2MTY_8c73c61c-c5d8-40e1-961b-14b6c551a353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtNS0xLTEtOTc2MTY_42704efa-34f6-45f4-ad0e-e00e5d5a96e4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtNy0xLTEtOTc2MTY_993b91b9-d0e7-492d-8276-f4626205324c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtMS0xLTEtOTc2MTY_f115a378-b44c-4f5a-bec1-d35c9a3f3ed6">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtMy0xLTEtOTc2MTY_43651b98-0e0f-47db-ab9a-485f97b365fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtNS0xLTEtOTc2MTY_5d97e5df-c832-4be8-9eb9-20562447319a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtNy0xLTEtOTc2MTY_3c0a17b1-793a-4ad0-8e88-d0bba7abc73d">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtMS0xLTEtOTc2MTY_73f2c119-babc-4f61-b711-05159691553d">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtMy0xLTEtOTc2MTY_51f90691-6636-4f15-bcec-654be4733bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtNS0xLTEtOTc2MTY_5467070a-2d4e-4335-96dc-a2001b1547ad">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtNy0xLTEtOTc2MTY_d3593a3f-a90f-4551-85d2-ef872d70f784">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, probabilities of achieving the milestones, time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. </span></div><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODA_ca665da4-331c-4b11-bc3e-41fcba30be72" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebba20d42aa84545b03550839e4d1ff6_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjYxMzllMmJjM2I2MzRhNWY4MTlkOTlhMTVhOWY4MmNiXzQ_b1f1d050-1b0a-433b-8146-62888a9af1c3">2.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i06c67c0260e9410f924a9a9f01b3ccc6_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjYxMzllMmJjM2I2MzRhNWY4MTlkOTlhMTVhOWY4MmNiXzk_b0718a29-df9c-49db-b0ab-4cf47420dcbc">4.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0f761535955494a9972245ac0bfc828_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0">4.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50f71d020d2441aead5e84026b2c81c1_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmRjOTE5YzRkNDc1ODRlNGRiYzUyZGRjMDI1YzVmNWZiXzQ_23dc4b34-01a4-453a-a971-1694619fad82">0.2</ix:nonFraction>%- <ix:nonFraction unitRef="number" contextRef="ic2acaa96ed3e4d86ba6f80df2d1d23bc_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmRjOTE5YzRkNDc1ODRlNGRiYzUyZGRjMDI1YzVmNWZiXzg_f2798496-ed41-44f0-bf06-944af38ad346">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i314e59ebff154934a9005087b9a2e107_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie09bf75182a24ca78e3c58dda4a972f3_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjQxYTZlMzkxNjY4NTRkM2I4ZTc0ZTBiYWQxYjA5N2FlXzQ_3197b046-ab8c-41f6-8c03-4fcfb1b8bf63">89</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic9667464bea64d7bad769b8345f8228a_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjQxYTZlMzkxNjY4NTRkM2I4ZTc0ZTBiYWQxYjA5N2FlXzk_98008e62-fa0d-4648-92ae-20d10a3948bf">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0bd307199034ef2b862a230a13fa5ba_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716">95</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaed7fba9444e4475a8d1d1fe03296f36_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmY3MWI4ZjlhMmRiYjQ3ODU4MTgxMzA1YmIxZDhiNjlmXzQ_655a23ed-be60-48ba-be7e-304589734971">89</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i618ae073cb994907a536ff425fc537bc_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmY3MWI4ZjlhMmRiYjQ3ODU4MTgxMzA1YmIxZDhiNjlmXzk_fce19593-12ed-4fd2-962a-9bd10c6982f4">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if01319674f9d40b28d7f32e4d0729277_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa">90</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2fb100f05394ac080c865b058757667_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e">56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i0db82b411f6d44028dadc73a81fbddce_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8e7e2cafe6f4f15bc1374d8dcb0e6b7_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da">99</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f97658421c74a6883a23a2e06b3ea74_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6">56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib9facac76db04d889e4a084485f7e2e5_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18">100</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbc5716897864f0c9cc862e142a2ef79_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128">96</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcb4215fa5f64baaaaf01df3d5b4e8c2_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkMTVkOTA3NDUwMTQyYjhiMjg0ODExY2EyNGI3ZmFmXzQ_0b8b2c25-c1a8-4b7e-97f0-7f5753096f76">2022</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="iae0da0e73d4249789bbdb7acc456ca25_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkMTVkOTA3NDUwMTQyYjhiMjg0ODExY2EyNGI3ZmFmXzk_afd424c6-9f36-4f12-9c05-6ab95d2ef4ba">2034</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i939b4297b7084062a87e128f885293a2_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d">2027</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2e05916e33146c8ae338e992f86d223_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyNmEyOWIwZGI2MjQ5YzM5YzIzN2VhOWY3MGNjZjc5XzQ_596846ab-d06e-4559-9fb6-4026fdb144a9">2022</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="ieb38cc669ce545e9bfccb54b2b798037_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyNmEyOWIwZGI2MjQ5YzM5YzIzN2VhOWY3MGNjZjc5Xzk_ff5c88ba-feb4-478d-804a-f75226968e65">2034</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i889c9bd592d04c6ebb6f06b0687977ec_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0">2027</ix:nonFraction></span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" footnoteRole="http://www.xbrl.org/2003/role/footnote">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</ix:footnote></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b) Excluding approved indications, the estimated probability of payment ranged from <ix:nonFraction unitRef="number" contextRef="ic282be83b0124b8e836b6f16a56eda8f_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0d36de35-e35e-4faf-9566-d2931da1b051"><ix:nonFraction unitRef="number" contextRef="idb1927254a0845d7a42c9414c93e995c_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84">56</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i286cd5a8d73f41ecbe7fec3a2ee10763_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99"><ix:nonFraction unitRef="number" contextRef="i876bd774408e4212b518335222b57f15_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_f8338e58-64b8-4547-a026-88f77f9fd644">89</ix:nonFraction></ix:nonFraction>% at June 30, 2022 and December 31, 2021.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="icab8e9037692491694b71206d7e13592" continuedAt="ieebe245d5b0143cf994e89e72e1d866c"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_0f718875-1840-4908-9c19-035b9644bb37"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_24be8f45-ebbd-4383-a4c2-58910a394bcd"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_ac97a54f-0ae2-4983-91b0-3af187bff0ac"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_e55f3188-ec26-4085-bbb6-9ba25e8a5910">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDg_e9c4b106-6f5d-473c-a06f-69a7fb930d9a" continuedAt="i645edc447d984ad59ddfce89faeabcdd" escape="true">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:</ix:nonNumeric></span><ix:continuation id="i645edc447d984ad59ddfce89faeabcdd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMi0yLTEtMS05NzYxNg_a517a3b1-98fb-4c54-b0f7-4d01f923fdfb">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1816b7eac954956b4765afd462e3f73_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMi00LTEtMS05NzYxNg_025b9fd5-78f4-4582-bafa-9df73323e83b">12,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMy0yLTEtMS05NzYxNg_7a927ee9-a23a-4bd3-9e9c-d2df34dc6adb">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMy00LTEtMS05NzYxNg_685135e7-a810-4555-87fc-2bdab00621ab">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNC0yLTEtMS05NzYxNg_2d58860b-4958-4242-81ab-9ff2bd52271a">570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNC00LTEtMS05NzYxNg_08c21a1c-bd46-441b-86a2-e9fbb72b7337">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNS0yLTEtMS05NzYxNg_89874aa1-8340-4835-b696-73de73939334">15,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNS00LTEtMS05NzYxNg_97bd53ed-9e8d-4a11-a719-3a198b68b864">14,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial instruments are carried at historical cost or some basis other than fair value. <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNzE_3a835962-69e0-458b-ad2e-d3c07ac69ec8" continuedAt="i4ad471d4d54d480ebc713b02008c721c" escape="true">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2022 are shown in the table below:</ix:nonNumeric></span></div><ix:continuation id="i4ad471d4d54d480ebc713b02008c721c"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi0xLTEtMS05NzYxNg_e1d2a03b-ca4b-4b45-b5e6-8752ad9a3c67">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi0yLTEtMS05NzYxNg_d5a1fd10-b1e5-48ef-ad38-92f6228512a3">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630843de12c0427290cca6b9829cfc34_I20220630" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi00LTEtMS05NzYxNg_0478e6a5-afa0-408d-b4c9-41cdb3b745ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi02LTEtMS05NzYxNg_b5485abf-5c49-40b6-8ae4-98c7e5f3e12d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi04LTEtMS05NzYxNg_d2df51e7-041b-4d13-bd93-82aea25c3f48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy0xLTEtMS05NzYxNg_7577dfd1-a700-4c19-b5ae-6c307c99e68b">11,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy0yLTEtMS05NzYxNg_f8539308-cd35-47f5-b5a3-f65446238912">11,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy00LTEtMS05NzYxNg_e055d2fd-81fc-49f2-afed-f2ad2def6e35">11,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy02LTEtMS05NzYxNg_22a40f84-2302-404a-8d99-35a8c5e85142">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy04LTEtMS05NzYxNg_ce2f5f70-5458-46c1-9892-da2636dd68b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC0xLTEtMS05NzYxNg_2fbb35e6-4b2a-4566-a9e7-2491fa35ee17">61,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC0yLTEtMS05NzYxNg_4d8dd53c-d82b-4db3-b920-2fb1825df574">57,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC00LTEtMS05NzYxNg_bce914ea-9df9-4322-8786-bd8d4290e1a2">56,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC02LTEtMS05NzYxNg_5982f453-ef35-4fd8-96d0-8b45809e42dc">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC04LTEtMS05NzYxNg_31ce231b-891e-4185-b0cb-c3d8fa877273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS0xLTEtMS05NzYxNg_42fd2c7b-efe0-49af-bf26-ce8bcac272fb">73,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS0yLTEtMS05NzYxNg_12b8295c-da4a-45d5-a3d2-fe3a0cc9615e">69,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS00LTEtMS05NzYxNg_140b9979-3ef2-4590-9c22-c51eb53a663a">68,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS02LTEtMS05NzYxNg_8d50148a-d815-4390-a08b-f6950e5b0634">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS04LTEtMS05NzYxNg_83cc26b6-7ad9-42e6-9995-c6a13a8b12b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi0xLTEtMS05NzYxNg_b36d7d50-44da-4a4c-822f-08d0f7baf511">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi0yLTEtMS05NzYxNg_7d52a375-338e-4efa-af1f-429c318e4cee">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e5774a49944c5ab537c8ac3146f7c7_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi00LTEtMS05NzYxNg_8f5a9496-d887-45c1-8d02-83ae917c82e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi02LTEtMS05NzYxNg_66a318e8-51ac-463e-ad53-4293490f6152">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231" decimals="-6" name="us-gaap:ShorttermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi04LTEtMS05NzYxNg_417245c0-d301-4fe5-b8d6-0a3d593f4a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy0xLTEtMS05NzYxNg_f6dbd383-e09e-47bb-b9a9-5b63b13de313">12,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy0yLTEtMS05NzYxNg_1b87484f-e7cc-44fc-b314-8add9b3b8c8a">11,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy00LTEtMS05NzYxNg_83f1ecdf-3d4b-4aaf-b49b-f0c88d83130b">11,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy02LTEtMS05NzYxNg_4cf426d6-13bd-4ff5-b87f-068873d26a23">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy04LTEtMS05NzYxNg_155d3aa5-6a44-4c94-a3b8-eb0dda087094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC0xLTEtMS05NzYxNg_8f2b948b-4f51-4b3c-beba-fba7cc01cbf4">64,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC0yLTEtMS05NzYxNg_2fac798b-e9dc-4aef-9aa3-96d70d1616e9">71,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC00LTEtMS05NzYxNg_bc1264c4-971f-47a8-b725-ed62f50f0380">70,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC02LTEtMS05NzYxNg_fcbe0b9a-3955-4c2f-ac11-a1c0be3aec8e">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231" decimals="-6" name="abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC04LTEtMS05NzYxNg_a65da8b0-fe81-4c8d-a460-a8f7bfaa918e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS0xLTEtMS05NzYxNg_98ccca8c-8452-422d-bf5b-f60d6897b59b">76,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS0yLTEtMS05NzYxNg_01be99c6-b6cf-41a4-8acb-b82cca528ef2">83,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS00LTEtMS05NzYxNg_0ea0d3e4-9f92-40be-9d9d-ceb5dbf85f5d">82,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS02LTEtMS05NzYxNg_51567f20-e313-41bb-b3c2-9d31fe2c113c">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS04LTEtMS05NzYxNg_1cad6f30-e57e-4171-af4d-7b66ec4d43b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTA5OA_6e594fa3-ced3-490e-b454-bed18c233848">148</ix:nonFraction> million as of June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="id5695becc3594da099d28f6bd485f543_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTExNA_f3ad7dca-5a77-4b4d-a014-e8a4b570713a">149</ix:nonFraction> million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of total net accounts receivable, <ix:nonFraction unitRef="wholesaler" contextRef="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630" decimals="INF" name="abbv:NumberOfPrincipalUSCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTI5Mg_c53a3b91-02b7-4b66-a215-84a53fb082a6">three</ix:nonFraction> U.S. wholesalers accounted for <ix:nonFraction unitRef="number" contextRef="i986059b4f35d4a8daa2894ea55ad12ea_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTMyNg_b2929e52-50c3-4282-a951-0e8ad4ccd672">76</ix:nonFraction>% as of June 30, 2022 and <ix:nonFraction unitRef="number" contextRef="i599b7447e0804132a06303bb0b4a837b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTM0Mg_1d82ebda-221d-4039-a06e-436d5f5e28aa">75</ix:nonFraction>% as of December 31, 2021, and substantially all of AbbVie&#8217;s pharmaceutical product net revenues in the United States were to these <ix:nonFraction unitRef="wholesaler" contextRef="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630" decimals="INF" name="abbv:NumberOfPrincipalUSCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTQ2MA_c53a3b91-02b7-4b66-a215-84a53fb082a6">three</ix:nonFraction> wholesalers.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ieebe245d5b0143cf994e89e72e1d866c"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humira (adalimumab) is AbbVie&#8217;s single largest product and accounted for approximately <ix:nonFraction unitRef="number" contextRef="i32d41cc6c1144c0eb773b14b0f419c16_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTU2Mw_573b4830-5497-4acf-a228-bdfbad0664a7">36</ix:nonFraction>% of AbbVie&#8217;s total net revenues for the six months ended June 30, 2022 and <ix:nonFraction unitRef="number" contextRef="i9583131a11e44e7aa0e4827ce3a411c0_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTA5OTUxMTY0MDIxNg_7f60e00a-61a7-4a9d-8dec-cbf504d86011">37</ix:nonFraction>% for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the company repaid $<ix:nonFraction unitRef="usd" contextRef="i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTY5MA_0de06eb9-6718-46b9-8da9-3ccdca6adef7">2.9</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i8e9e7fa9be3843a7a5bf54dd5d8ac7a9_I20220131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTcyMw_50cd657a-671e-49b8-b75c-1f9af4a11e50">3.45</ix:nonFraction>% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the company refinanced its $<ix:nonFraction unitRef="usd" contextRef="ibf34cf7670534dd3897946050fdaea95_I20220228" decimals="-8" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTk1NQ_5d196296-39ed-48cb-af8a-eca86dc12c7a">2.0</ix:nonFraction> billion floating rate <ix:nonNumeric contextRef="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDI_a7d7f7e4-2082-40aa-a795-75978962971f">five-year</ix:nonNumeric> term loan. As part of the refinancing, the company repaid the existing $<ix:nonFraction unitRef="usd" contextRef="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAwNTE_a3a2c0f3-862b-4165-a2dd-30925b7c067f">2.0</ix:nonFraction> billion term loan due May 2025 and borrowed $<ix:nonFraction unitRef="usd" contextRef="i704e3023cf64424fb2e548f19872b22b_I20220228" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAwOTA_f57a98ac-2eff-44d8-820b-63ab3e4fa2bc">2.0</ix:nonFraction> billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the company repaid $<ix:nonFraction unitRef="usd" contextRef="idd94ae07eaed40088bbf3d7cfc1781e6_D20220701-20220731" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTIwOTQ2Mjc5MTcxODM_80f74593-4b1c-4b7d-bf03-c6054000ec52">1.7</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i6a0fa7a03c79447e8db8a5d601b5fc8c_I20220731" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTIwOTQ2Mjc5MTcyMTc_36692362-8197-40ea-b3a3-1ebcb4a3d1f4">3.25</ix:nonFraction>% senior notes that were scheduled to mature in October 2022. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the company repaid $<ix:nonFraction unitRef="usd" contextRef="ia77710e9c10447af9cd57b70a76e9850_D20210401-20210430" decimals="-8" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc0Ng_94961170-78b5-4002-b96b-5fef89e4852d">1.8</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ieb78cb6f6ae44cb296ba20fe69d1e6a2_I20210430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc1Mw_ec994b63-4ede-4b29-bd80-6b86a3a5190a">2.3</ix:nonFraction>% senior notes that were scheduled to mature in May 2021. In May 2021, the company repaid &#8364;<ix:nonFraction unitRef="eur" contextRef="i9c46c9af7913451184bb8271e2852db1_D20210501-20210531" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc1Nw_809da677-6ceb-4a37-935d-b34132459229">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2610045aa69e4030bc8c18d427b52b41_I20210531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc2Mg_4c4b690d-d597-42e9-af7d-5c60d42178b6">0.5</ix:nonFraction>% senior euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $<ix:nonFraction unitRef="usd" contextRef="ie0483da2eaea4022985712c39ea59d19_D20210501-20210531" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc2Ng_68b2214f-fe8c-4ab9-ba98-ea0b47acaf19">750</ix:nonFraction> million aggregate principal amount of floating rate senior notes at maturity in May 2021.</span></div></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_76"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RleHRyZWdpb246OTRmNTc1YWM5ZTE5NGI5Y2I2MzI0ZGRjMzUxMDI0YzhfMjQ0_a58392dc-ae32-489b-9e66-1c1fce4662e8" continuedAt="ib9eb3f018c964413a8a49977febe1aa1" escape="true"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Post-Employment Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RleHRyZWdpb246OTRmNTc1YWM5ZTE5NGI5Y2I2MzI0ZGRjMzUxMDI0YzhfMjQ2_bbd1cfba-2221-4a28-ac76-fb93e4e2d1b1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xLTEtMS05NzYxNg_8f774139-a282-4197-acd3-3c2c57037784">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0zLTEtMS05NzYxNg_461b8b64-a3f8-4fb1-aa2e-65e9c2aaf964">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy01LTEtMS05NzYxNg_06297e25-ac23-42a1-ae0a-33a839194a41">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy03LTEtMS05NzYxNg_85b1b300-6aa1-499f-995a-06326fadffb0">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy05LTEtMS05NzYxNg_065b7529-0e16-456d-9c8a-5d17979eab02">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xMS0xLTEtOTc2MTY_5cba41e9-398a-4b13-a5b7-e38ec0a631bc">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xMy0xLTEtOTc2MTY_b62ab35f-827e-4de2-9b22-34c94ea75873">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xNS0xLTEtOTc2MTY_d07dbfbf-9948-4b10-980d-4ab348de5c1f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xLTEtMS05NzYxNg_62645d01-0b3b-4c1e-b519-f2753126e212">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0zLTEtMS05NzYxNg_0896e60e-1b69-45be-8ac4-57fb1357d3f6">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC01LTEtMS05NzYxNg_9f780a1b-ea65-447b-aa06-7877d2ad790c">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC03LTEtMS05NzYxNg_1ba04185-a2df-49be-8453-66d12b9d0cea">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC05LTEtMS05NzYxNg_3cd5b007-be66-434e-a679-90cc55938b4f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xMS0xLTEtOTc2MTY_a39a7952-eb68-4250-be0b-5560879d42ff">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xMy0xLTEtOTc2MTY_4ac495f4-47b5-46f4-962b-5128b9a28019">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xNS0xLTEtOTc2MTY_f4e15604-b4d8-4fb2-9a7f-c8283bd7925f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xLTEtMS05NzYxNg_0a8f617b-8797-4753-b478-d831cdfcfaa1">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0zLTEtMS05NzYxNg_6156321f-68f8-456f-afad-4ab8ea9fb621">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS01LTEtMS05NzYxNg_e78264ab-bc90-4e3c-b688-f0b25320a7b9">359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS03LTEtMS05NzYxNg_bf71e333-13c6-48b6-ad7e-f89e2ef6a03c">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS05LTEtMS05NzYxNg_d91de2cd-1223-4e2d-ba70-0ccc304dae95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xMS0xLTEtOTc2MTY_c33a2c05-663d-48a7-8aeb-1689b420bcc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xMy0xLTEtOTc2MTY_2f013017-9c94-4b3c-bad0-725e1b51b138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xNS0xLTEtOTc2MTY_abd8dc02-5b48-4d96-baca-9b5af06eeff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xLTEtMS05NzYxNg_1da8e92c-dba8-4abb-93c8-d2459b4dc9de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0zLTEtMS05NzYxNg_752983c4-73b1-4ae6-bff9-b6bd61156042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi01LTEtMS05NzYxNg_d6b89f46-8e5c-4473-b0e4-100638e831b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi03LTEtMS05NzYxNg_7a468700-0add-4560-b9ce-311c03d9d809">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi05LTEtMS05NzYxNg_692468d4-4a82-428f-a0cc-bac39e41f96f">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xMS0xLTEtOTc2MTY_e411d1fa-d9dd-43f6-af03-96f4c9fd706b">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xMy0xLTEtOTc2MTY_5e37e5d3-3fb4-4094-a4ca-b89b2cecb756">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xNS0xLTEtOTc2MTY_1d1aea42-bd82-432b-8f96-7233fe3cfce0">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xLTEtMS05NzYxNg_a243cca0-6b9c-4091-9a18-267944157278">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0zLTEtMS05NzYxNg_60c5693e-2612-429f-89bd-cab20cb602e6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy01LTEtMS05NzYxNg_88dc7f5b-cd6a-4a58-b01e-40c5dc9f1309">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy03LTEtMS05NzYxNg_e736f13f-fe53-4cc1-8931-0dd3e964e2f5">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy05LTEtMS05NzYxNg_82dc66c7-4440-4d85-9c27-2922e6382dc1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xMS0xLTEtOTc2MTY_bb095aae-c186-4c54-bd43-ca56cb596126">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xMy0xLTEtOTc2MTY_110d1b04-95ff-48b8-a926-1535cddbea4d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" sign="-" name="abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xNS0xLTEtOTc2MTY_37a67c60-627e-42d2-a628-d047545eeb45">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xLTEtMS05NzYxNg_cee6bf2a-4b29-482c-ba3b-082cecfe94b8">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0zLTEtMS05NzYxNg_31115a07-76e6-465e-a50a-350c19436972">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC01LTEtMS05NzYxNg_ba850157-314e-4233-b926-dff386e037df">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC03LTEtMS05NzYxNg_a8e5996a-5634-4127-bd39-f2a23f3585f5">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC05LTEtMS05NzYxNg_3b35b779-ac2b-4f48-b3c3-19f91fd68355">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xMS0xLTEtOTc2MTY_c4b1520b-f865-45be-b991-cfa4de44de22">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xMy0xLTEtOTc2MTY_665141dc-ae12-4f98-8ec5-d2c9c16e3748">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xNS0xLTEtOTc2MTY_25dea66b-15e9-4f91-90b4-90c842560133">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9eb3f018c964413a8a49977febe1aa1">The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">16</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 10 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1MA_c2b0cc6d-d997-47ee-b2b0-d2cdc33d5562" continuedAt="i66cfbb805bd94254a27fb3f99c3ec0b5" escape="true">Equity</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i66cfbb805bd94254a27fb3f99c3ec0b5" continuedAt="i978e7e1c9bb040cab1263bde88320719">Stock-Based Compensation</ix:continuation></span></div><ix:continuation id="i978e7e1c9bb040cab1263bde88320719" continuedAt="i179e6a46841342dc84085fad48d2b7cd"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1Nw_41668d49-43ee-4638-87d0-7c8bc4323062" continuedAt="i498d1d8e3158410089895bd5227721f1" escape="true">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:</ix:nonNumeric></span><ix:continuation id="i498d1d8e3158410089895bd5227721f1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a5e696cef44729310622ff60e2500_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi0yLTEtMS05NzYxNg_bef65f9d-9b36-43ff-ac75-5cee3c015021">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b10bd565e94cdbad34d4b699a9c302_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi00LTEtMS05NzYxNg_9b7956c9-fd75-4638-a8d8-7c09ad5f8570">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8541a3fbd04b4aa7b0c71db6c67624_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi02LTEtMS05NzYxNg_3ebaa9ff-67db-4628-b775-dd7bf34a3916">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd274134e874c458ac8bb198e697455_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi04LTEtMS05NzYxNg_da1b73fd-7790-4b9f-9a08-df50af7bc47a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39ddc4d4f8b4a60ae8112fec8a02ca0_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy0yLTEtMS05NzYxNg_02b50c95-f7fb-45b2-8572-434398f58dc2">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215a3d4557c14afebf2687d536e46e9b_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy00LTEtMS05NzYxNg_54d6c619-3769-43de-8793-73aed427dc20">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84cd19c9ee4e484da629710856ae0ec6_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy02LTEtMS05NzYxNg_1cf985ff-52f5-4e2d-aec5-fcefd2549ec2">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4aeffb4bf7740e693e0cf853abfe9cc_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy04LTEtMS05NzYxNg_4c872ab9-c585-47b1-9405-9b9fbba4836c">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c76652aba54b3cb73c859bfcc92d58_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC0yLTEtMS05NzYxNg_347a6d00-0fc4-4ac9-887d-eb4b29275bd4">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73323fc2811c4815be8a6fa8d6f92ebf_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC00LTEtMS05NzYxNg_ce9a1770-a8cd-4827-8e68-18c091d6bde3">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74c227e50b7440cb0bf2fe1f16077a8_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC02LTEtMS05NzYxNg_db4fe38d-5672-4ba3-b29c-621c739d82e6">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3113d83c8f491b941990950d5919dd_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC04LTEtMS05NzYxNg_5605e03f-9a7e-4e6a-90b7-fe341e5d5e91">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS0yLTEtMS05NzYxNg_21f070ef-1dd6-4df2-a43a-2f246344d2a4">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS00LTEtMS05NzYxNg_2e6941e5-8ea0-4624-91de-7ea65835c722">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS02LTEtMS05NzYxNg_2326df41-eab2-4b59-a56f-4c4c3705cb9e">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS04LTEtMS05NzYxNg_215e0aa9-8a16-4ea9-85f4-7975e4844d26">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi0yLTEtMS05NzYxNg_c38124fa-beb8-4f42-9e97-b8764c7b76ca">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi00LTEtMS05NzYxNg_193165ec-06a5-4de6-b136-05d4b99ccb05">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi02LTEtMS05NzYxNg_31a62cf4-f213-4558-b5c6-ab74bfaf861a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi04LTEtMS05NzYxNg_d15a4bf5-ac6b-4692-a55d-da95a5d0d467">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy0yLTEtMS05NzYxNg_a3a9240d-996c-4c42-a6ae-8ae7370b7e72">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy00LTEtMS05NzYxNg_7f90063b-2773-43ef-8d37-fdc04a0af45c">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy02LTEtMS05NzYxNg_df5a60ab-f8f1-4dab-a8b2-4f79f3d271a7">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy04LTEtMS05NzYxNg_54af9790-63c6-4ec6-9a10-d9004b3b6681">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted <ix:nonFraction unitRef="shares" contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTEy_5af8e420-817e-4ffa-b1fd-b42e6e557884">0.9</ix:nonFraction>&#160;million stock options with a weighted-average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTc4_9fd8f6df-ff30-4832-8343-dc60d273758a">22.83</ix:nonFraction>. As of June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="iebba8edab23541ff89c8b58adf3e8a76_I20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTky_7cd7e5b3-870b-4215-af33-2bbd087b4b47">10</ix:nonFraction> million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNzIy_161da7ef-d327-41eb-b889-7eb22c1aa144">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs and Performance Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted <ix:nonFraction unitRef="shares" contextRef="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfODQx_d598a9ca-16b5-443f-a956-6d7a675d45c2">5.8</ix:nonFraction>&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca53a8519264b5a8bf940cc274a106a_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfOTIx_788a6d3d-4d4c-4938-99e1-0b776715d6ee">146.20</ix:nonFraction>. As of June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i5ca53a8519264b5a8bf940cc274a106a_I20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfOTM1_2529912e-3c01-4535-ac2b-f077f3c350c0">824</ix:nonFraction>&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTA3OQ_c1053bd8-3d3c-4673-be50-d122ce636768">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfDividendsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg4NQ_40f73324-01d5-46ae-a6cd-8d70fb40e701" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/23/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29287228cbed45f6968865ac190732da_D20220623-20220623" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMi00LTEtMS05NzYxNg_7fc0c58f-2bfb-48b1-856c-249cc8cad1d0">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ea99297cee64545990d63d337e0bd15_D20211029-20211029" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMi0xMC0xLTEtOTc2MTY_e187bbb7-e9a3-4cfd-86a1-6188522aa8db">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1a2a526c6f543e48795a4f1d12639ad_D20220217-20220217" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMy00LTEtMS05NzYxNg_526da670-9598-463f-af84-99a20b24ccdd">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac1d6f16dc8f42568eb8061858ff99c8_D20210910-20210910" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMy0xMC0xLTEtOTc2MTY_3c229516-b2a1-43e9-b53c-bcb87e63e8bc">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb37ae95313d475593909c6970fed474_D20210617-20210617" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfNC0xMC0xLTEtOTc2MTY_29797af1-d607-475f-ab7d-6e2153f6f4eb">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82eba66f65734def83204d704d5b47ea_D20210218-20210218" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfNS0xMC0xLTEtOTc2MTY_56ca1d70-2f9a-4446-adaa-4cbfd751fb68">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie repurchased <ix:nonFraction unitRef="shares" contextRef="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTYwOA_60c55929-844a-45f3-8e15-45c8d549feda">8</ix:nonFraction>&#160;million shares for $<ix:nonFraction unitRef="usd" contextRef="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTYyMg_92b1e4e0-0215-4ab8-83d5-229d76fecb45">1.1</ix:nonFraction>&#160;billion during the six months ended June 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTY0Mw_a6664546-098a-480a-b1a3-a30592184100">5</ix:nonFraction>&#160;million shares for $<ix:nonFraction unitRef="usd" contextRef="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTY1Nw_7d7d3a26-d676-4d32-9a46-46d78135f663">550</ix:nonFraction>&#160;million during the six months ended June 30, 2021. AbbVie's remaining stock repurchase authorization was approximately $<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTc0Mw_4fae8c58-6d81-42e8-95bc-a23b87720c4f">1.4</ix:nonFraction>&#160;billion as of June 30, 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i179e6a46841342dc84085fad48d2b7cd" continuedAt="ia047911777b246c1b1a78426ed51d6ab"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3Mg_1519fd1f-e7b3-493a-b134-f59fbfdf1b82" continuedAt="i0a480f8e862f435cb58345102685e344" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22b5f6d04f0a4544845c676987a1eeed_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0xLTEtMS05NzYxNg_fa9f9b32-bf94-490a-967d-aefd55d2da64">570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cd460fb97a943bea7eab54ac965aa60_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0zLTEtMS05NzYxNg_c5224d39-ea54-46e6-8bbd-26f9f5d97f63">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icce33acdbe974160ad9b3dfc07ae39d2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS01LTEtMS05NzYxNg_78b05413-8c32-4200-9b67-d3229e83760c">2,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia710a25cb0c047998dd58eb85bc213f9_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS05LTEtMS05NzYxNg_f2d6af93-905b-4da4-a483-64b968725bc1">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae61288e27a24ce39bded79de1bf4095_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0xMS0xLTEtOTc2MTY_31efdab3-082d-4216-891a-a67a46864ebd">2,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0xLTEtMS05NzYxNg_74033597-e3a4-4eac-ad44-049a30d538e6">1,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0zLTEtMS05NzYxNg_230d112d-b922-4919-bdf7-297c7ada9975">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi01LTEtMS05NzYxNg_ffe441a0-e5da-4316-9ce5-9e905e033647">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi05LTEtMS05NzYxNg_cbd87258-efb6-449f-94ce-7ec24a4c5dd0">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0xMS0xLTEtOTc2MTY_d5c62edb-88c9-4cd5-abff-2beff3d0fd86">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0xLTEtMS05NzYxNg_c7003c10-0b2a-4da0-b360-9ed638d63e61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0zLTEtMS05NzYxNg_39d1f8d8-c64c-45bd-b99a-17d58804b362">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy01LTEtMS05NzYxNg_af43ff48-5d1b-4ac6-8bbb-f13780417e27">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy05LTEtMS05NzYxNg_759978be-e9cf-444d-aae2-aaf44c0e8ad0">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0xMS0xLTEtOTc2MTY_32f514ad-a5a6-462c-ba63-4888ef0f1621">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0xLTEtMS05NzYxNg_6cf3577d-4be9-4827-941a-18438b23456a">1,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0zLTEtMS05NzYxNg_8ef38e57-df62-4334-902f-20922755533a">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC01LTEtMS05NzYxNg_46d634af-8917-49c2-9540-1a451818359e">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC05LTEtMS05NzYxNg_70b2ee86-4f4d-4ac5-a289-af0500eaf350">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0xMS0xLTEtOTc2MTY_a460b387-5ddf-48a7-9cbd-8c4460654afa">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7f81fb701254285a4a206a18828b567_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0xLTEtMS05NzYxNg_2903d814-7f65-4965-a600-0226a337be21">1,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed8396560c44007a9c95309d6d3a6a2_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0zLTEtMS05NzYxNg_7466e3e7-0070-4d5f-8a4d-8d5258d03cce">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a09f43445463abe6438c2b68a40d0_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS01LTEtMS05NzYxNg_eb933daa-4324-40db-9111-65179384553e">2,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie041d69136f64b3a8a27ad04a132c273_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS05LTEtMS05NzYxNg_6b7fef98-0d58-4db2-8919-6f42d27063a0">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ec6491fd6214350bcd0866f550aa297_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0xMS0xLTEtOTc2MTY_e0bf1527-3f83-4afd-b953-d3c063681b4c">3,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the six months ended June 30, 2022 included foreign currency translation adjustments totaling a loss of $<ix:nonFraction unitRef="usd" contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630" decimals="-8" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTkzNA_42888a5c-fcb2-455e-98cc-360f8e844681">1.1</ix:nonFraction> billion and the offsetting impact of net investment hedging activities totaling a gain of $<ix:nonFraction unitRef="usd" contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjAxNw_f555ad20-0dba-4b84-a67c-1ccb4be26f65">666</ix:nonFraction> million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i0a480f8e862f435cb58345102685e344"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05002d950604d46a192beaa49081fc9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0xLTEtMS05NzYxNg_395eb1f6-6558-46e4-a78b-f0a7eec364a3">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35fed5ff539e43798107045d15730636_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0zLTEtMS05NzYxNg_9bf8ea21-e464-4ddf-9a9d-3e5da631272b">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i403c50879b1c4e05a4a20ace89fd4c22_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS01LTEtMS05NzYxNg_b8ada3c6-9c7e-4078-94ba-dfe69e8e39b3">3,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d626d0838c74271a9d49423686e77f2_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS05LTEtMS05NzYxNg_1c16a6f2-9be4-466a-83a3-217bf48534f9">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e42ad98a314ebeb3aade819088d66a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0xMS0xLTEtOTc2MTY_db2b6148-5198-4896-b64a-43565e741992">3,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0xLTEtMS05NzYxNg_a82bcdd5-f1b7-438f-8e89-1e2684ef7939">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0zLTEtMS05NzYxNg_d8ffc803-4fad-4e13-9b7a-d10da19a912d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi01LTEtMS05NzYxNg_a57867ab-bab4-4798-a5b8-07bb641b57a7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi05LTEtMS05NzYxNg_235645e0-1cc7-4d2b-910c-fc702a72ba0d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0xMS0xLTEtOTc2MTY_c3b65fdb-6262-47cf-bbe8-3b060cda7a2d">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0xLTEtMS05NzYxNg_f2f1461b-2288-478e-8378-319b2979b4c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0zLTEtMS05NzYxNg_3880db92-6c55-4ad1-8365-d1c5fa202d83">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy01LTEtMS05NzYxNg_d0e274d1-3b83-41a6-bb29-9a64671edbd7">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy05LTEtMS05NzYxNg_70ae6d81-61d8-49c9-b542-e696986b367d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0xMS0xLTEtOTc2MTY_cb5c6bcc-858f-4af4-8e23-8bc30b1e2117">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0xLTEtMS05NzYxNg_b9b5d1ae-1cfd-4d72-9403-0dd1c4fd44f4">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0zLTEtMS05NzYxNg_a0554e5b-c561-4d83-92e6-c11ce717c46a">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC01LTEtMS05NzYxNg_025d34cd-db48-48e7-81ea-a8e771fe6570">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC05LTEtMS05NzYxNg_4e0e512f-815b-49ed-a001-9ec6d691b617">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0xMS0xLTEtOTc2MTY_1e0f5181-7c08-4ba3-839f-1409b57c0bcb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3822e99b0a044b3bb3488101e174bb2d_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0xLTEtMS05NzYxNg_e521acc8-de69-4aed-bc27-cf405a1a8c1a">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i995a19a6da744643b9b86cc7f1216901_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0zLTEtMS05NzYxNg_f7f14e8b-70c1-47d8-8e26-c8962f36f5d7">530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic97760527e754306a1191c6bc2573b87_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS01LTEtMS05NzYxNg_84bdafe7-f994-456b-9f37-f30b03232ef6">2,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4d976678cf4540afbc6dc51554a787_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS05LTEtMS05NzYxNg_cf12adde-63be-44f8-b862-6e55edb792f6">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb0ed41b4e649d2a7d806f7497e41a8_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0xMS0xLTEtOTc2MTY_ed72b362-5ea1-4917-b7a7-93df0b9a35c6">3,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income for the six months ended June 30, 2021 included foreign currency translation adjustments totaling a loss of $<ix:nonFraction unitRef="usd" contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjMyNg_212395d7-23ee-4a92-845d-5e385b458a75">433</ix:nonFraction> million and the offsetting impact of net investment hedging activities totaling a gain of $<ix:nonFraction unitRef="usd" contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTA5OTUxMTYzMDkyNg_73bed535-84f9-45a3-9283-1be01136000c">260</ix:nonFraction> million, which was principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia047911777b246c1b1a78426ed51d6ab"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjgzNg_c3f71c17-6a24-4e1a-b03c-6cf425244e64" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC0xLTEtMS05NzYxNg_5d02a065-8df5-48e7-890a-3f73018f2b67">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC0zLTEtMS05NzYxNg_9153ff70-549f-4458-bee8-5b04cdfc8076">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC01LTEtMS05NzYxNg_237a261e-1bf2-440c-8bb0-9a0d3e2f955e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC03LTEtMS05NzYxNg_957a5994-2a49-4c71-845f-52f4eaee5614">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS0xLTEtMS05NzYxNg_6a40b03c-517d-467c-a346-652d7a0006e5">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS0zLTEtMS05NzYxNg_8e550155-3a97-4fb7-a5be-9a30e4e05ed1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS01LTEtMS05NzYxNg_f071484a-e471-4efd-aaeb-fdca676db98a">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS03LTEtMS05NzYxNg_9a35bf4d-3356-4040-8e89-ab6267a694a1">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC0xLTEtMS05NzYxNg_d1837650-6e1b-4abe-a1e9-218164627826">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC0zLTEtMS05NzYxNg_d1e3c3a3-a103-49b8-b5c1-c2a6d98aa957">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC01LTEtMS05NzYxNg_8e9af11f-3229-4eca-9d8b-cf456978251e">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC03LTEtMS05NzYxNg_cba12039-db97-46d9-ae53-cac6e189edc2">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS0xLTEtMS05NzYxNg_839fdc5d-30a1-4867-97e9-eb6d1fd4ad16">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS0zLTEtMS05NzYxNg_a9eea189-bc15-4d4f-b72e-45174c92c634">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS01LTEtMS05NzYxNg_8184adb8-7119-4959-83c8-54e32bb3a169">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS03LTEtMS05NzYxNg_2ae717ed-fcc2-4b9e-a25e-d860854f0c7c">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ccb01751b304c18af28a34833388cf8_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic191f46d7d8e4caba4afd72c543fbcd4_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3853f87f21c434890d33f2f2b77b72c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfb160d4b1643648262fd6a0eaae478_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3b9ff182e8741859555b210dca9a32b_D20220401-20220630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02110886faa542a89965a36d12b1be28_D20210401-20210630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4767839908e4c3c981b0e75e52a508d_D20220101-20220630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie51ac81d02ae4bb4bb4b631a36857242_D20210101-20210630" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48cb26fc77245da81fea6fc298e2334_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d6972b6ff4f3d8c222972b983496e_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb4fc0c623c4f1ea81b83cb3bdba9ac_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c0a79aa3464c16a02968bd63694f55_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtMS0xLTEtOTc2MTY_8972a698-9af6-4b91-90cb-9d3324f66484">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia174e4331257480796e6106ea2a76cce_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtMy0xLTEtOTc2MTY_90c47a2f-6c94-40b4-9ceb-8a7008963183">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtNS0xLTEtOTc2MTY_646aa0ac-9186-4705-8967-567205b84ef7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtNy0xLTEtOTc2MTY_b1804aae-573d-4ef0-9d61-c4cd19a76643">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtMS0xLTEtOTc2MTY_d7f7f225-b498-4465-bdf2-0d5faa612188">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia174e4331257480796e6106ea2a76cce_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtMy0xLTEtOTc2MTY_6d720211-19cc-4d28-88f1-0fd8ce4a8894">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtNS0xLTEtOTc2MTY_a1837d16-c80f-4e6a-9ee9-3acd313035ea">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtNy0xLTEtOTc2MTY_8f14e6dd-5d85-4523-b7e1-c1ff3e145a74">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e" footnoteRole="http://www.xbrl.org/2003/role/footnote">(a)&#160;Amounts are included in interest expense, net (see Note 8)</ix:footnote>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</ix:footnote></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073" footnoteRole="http://www.xbrl.org/2003/role/footnote">(c) Amounts are included in cost of products sold (see Note 8).</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i8040488224cd40d194fd225edca967d2_88"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 11 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfODY3_ecc0c8d6-6192-4e9e-96ef-b42c82222637" continuedAt="id2cf2e2f22da4fe9a3a3f2153d381e3f" escape="true">Income Taxes </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><ix:continuation id="id2cf2e2f22da4fe9a3a3f2153d381e3f" continuedAt="i006a0fd8e3584a63807c80d7b5d8e72d"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjYxNg_22794a87-adb5-42e8-842c-c04b9378a74b">22</ix:nonFraction>% for the three months and <ix:nonFraction unitRef="number" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY0NQ_2b6897ab-c393-400a-8630-4adcaf8c199f">11</ix:nonFraction>% for the six months ended June 30, 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to <ix:nonFraction unitRef="number" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY3MA_f7d794b9-f804-4430-944c-6aade107b19e">34</ix:nonFraction>% for the three months and <ix:nonFraction unitRef="number" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY4Mg_3af8fced-f67e-44e4-9a79-95e7be1e76e2">14</ix:nonFraction>% for the six months ended June 30, 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate in each period differed from the U.S. statutory tax rate of <ix:nonFraction unitRef="number" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_36630c3f-3691-44b9-9fed-2d0568df4621"><ix:nonFraction unitRef="number" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_956b333d-1e5f-439d-bf23-d6c8c5690fa8"><ix:nonFraction unitRef="number" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_b04884a5-8fed-4795-8b12-61d262f5a9a2"><ix:nonFraction unitRef="number" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_bc0b4aa8-a59f-4d08-a7ac-b44214516693">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The decrease in the effective tax rate for the three and six months ended June 30, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings and accretion on contingent consideration.</span></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i006a0fd8e3584a63807c80d7b5d8e72d">Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#8217;s gross unrecognized tax benefits balance may change within the next 12 months by up to $<ix:nonFraction unitRef="usd" contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfODYy_86ec5403-eb08-4601-82bd-3c12626e5fa4">145</ix:nonFraction>&#160;million.</ix:continuation></span></div><div id="i8040488224cd40d194fd225edca967d2_94"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 12 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMTQxNDA_5e6262c4-3079-4c52-8262-7db4a7a13d4e" continuedAt="i9d0848afb97d463eab4e2c1098a8bb19" escape="true">Legal Proceedings and Contingencies </ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d0848afb97d463eab4e2c1098a8bb19" continuedAt="i49bd80df4f5646e3b467e9ad216e684d">AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#8217;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#8217;s consolidated financial position, results of operations or cash flows.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i49bd80df4f5646e3b467e9ad216e684d" continuedAt="i0d97798f6d54485cb7d977a6a184190f">Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i0d97798f6d54485cb7d977a6a184190f" continuedAt="i9664e73bed534724b0239ec77fed616e"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of <ix:nonFraction unitRef="lawsuit" contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630" decimals="INF" name="abbv:LossContingencyIndividualPlaintiffLawsuitsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjIwOQ_db395bb9-f778-46ab-8476-8943cc1543fb">four</ix:nonFraction> individual plaintiff lawsuits and <ix:nonFraction unitRef="class_action" contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630" decimals="INF" name="abbv:LossContingencyPurportedClassActionsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjI0Ng_ac5fdb8d-6d67-4b03-90b9-d73d3dd528d8">two</ix:nonFraction> consolidated purported class actions: <ix:nonFraction unitRef="direct_purchaser" contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjI4Nw_0e248786-7f8f-4e35-b8b2-25f7ec366d3c">one</ix:nonFraction> brought by Niaspan direct purchasers and <ix:nonFraction unitRef="end_payor_purchaser" contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjMzMQ_9ae7b6bb-0cbb-406c-b91d-4fa5d32ffb78">one</ix:nonFraction> brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Niaspan Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#8217;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#8217; fees. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with <ix:nonFraction unitRef="company" contextRef="icfa3a17240a84a5fb4378a6e0964580e_D20190801-20190831" decimals="INF" name="abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMzU3NQ_4641e0fe-9458-4bee-be8f-09cce82a8981">three</ix:nonFraction> generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#8217;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between March and May 2019, <ix:nonFraction unitRef="company" contextRef="i7334ba57c4e449f59500bd93a416fe9f_D20190301-20190531" decimals="INF" name="abbv:PutativeClassActionLawsuitIndividualNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNDI2Ng_c0a59244-1c4f-4467-b77c-017bb5ccd1a1">12</ix:nonFraction> putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Humira (Adalimumab) Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Namenda Indirect Purchaser Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#8217;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with <ix:nonFraction unitRef="company" contextRef="if3a36967092e4074bf4a78063e79132b_D20220101-20220630" decimals="INF" name="abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNjQ1NA_f2e65836-6955-46c2-81a4-566fc1274d3a">six</ix:nonFraction> generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Bystolic Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Proceedings</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately <ix:nonFraction unitRef="claim" contextRef="ie8cb2800eae14237a93a3936c9e32a27_I20220630" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNzEwNw_263ded6b-8598-42fd-8774-b7a29b0a2197">3,031</ix:nonFraction> matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i9664e73bed534724b0239ec77fed616e" continuedAt="if6ac71ce7007468891d2d715fbcd9886"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prescription Opiate Litigation, MDL No. 2804. Approximately <ix:nonFraction unitRef="claim" contextRef="i48ac34a8b8274cc9af2a8d06028995a6_I20220630" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNzM4MQ_3b89dd25-2ccb-4a37-9677-d68ced254da9">266</ix:nonFraction> matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In May and July 2022, Allergan reached settlements with the State of West Virginia and its political subdivisions and with the City and County of San Francisco, California, respectively. Allergan previously reached settlements with other plaintiffs. Allergan is engaged in negotiations with representatives for the remaining states, counties, cities, other municipal entities and Native American tribes regarding a potential settlement, with payments likely to be made over a number of years. While negotiations are on-going and definitive terms have not been reached, a framework for an agreement exists, including an estimate of a potential settlement amount based on maximum participation in the potential settlement. AbbVie recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i1e04db914dad47f5b3d445d36e86ac46_I20220630" decimals="-8" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMTA5OTUxMTY1NjI1NQ_257319f1-694a-498c-baea-15790df46b5c">2.1</ix:nonFraction> billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to this potential settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the New Mexico Attorney General filed a lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#8217;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. In July 2022, the parties reached an agreement in principle to settle this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder and Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by <ix:nonFraction unitRef="investment_fund" contextRef="i65d8e2a0e62b4729b3abeb9e927196d9_D20160601-20160630" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfODM4MQ_7679925f-1a70-44a1-8b71-6b8d77fab327">five</ix:nonFraction> investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of <ix:nonFraction unitRef="investment_fund" contextRef="id7c685b4419c4e248155b129a874cf5a_D20220201-20220228" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfODgwMw_cbe90a42-9c90-4930-b2b7-fdfdab647f81">three</ix:nonFraction> investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. <ix:nonFraction unitRef="investment_fund" contextRef="id76475932981417e8c60761ee84327e0_D20220101-20220131" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfOTA2OA_7b21aabd-5879-417b-b9bd-db5c9c168311">One</ix:nonFraction> of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, a federal securities lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Holwill v. AbbVie Inc., et al</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May 2022, a shareholder derivative lawsuit, Ranney v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that certain AbbVie directors and officers breached their fiduciary duties based on related allegations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Allergan plc Securities Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The plaintiffs generally seek compensatory damages and attorneys&#8217; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, a federal securities lawsuit, Nakata v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois against AbbVie and certain officers alleging misstatements regarding the potential effect that safety information about another company&#8217;s product would have on the Food and Drug Administration&#8217;s approval and labeling for AbbVie&#8217;s Rinvoq. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the same court, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties based on related allegations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and General Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, a qui tam lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Silbersher v. Allergan Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if6ac71ce7007468891d2d715fbcd9886"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allergan USA, Inc., Allergan Sales, LLC and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit. In May 2022, the parties settled the cases and they were dismissed without prejudice.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">22</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 13 <ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RleHRyZWdpb246NTgxMGY2MTEzY2YwNDBhOGFkZTFjYWU4MDk5NzJhOTlfMTEyMA_b0cb84cb-67ca-483b-9c3e-d5402cd818d9" continuedAt="i7be6ac9aa0a04f6c88a73056c18c2fd6" escape="true">Segment Information</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7be6ac9aa0a04f6c88a73056c18c2fd6" continuedAt="i5a73935c331a4252be84dfc3bc03d111">AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i5a73935c331a4252be84dfc3bc03d111" continuedAt="i60ccb784ad824665972c6936ad5200cd"><ix:nonNumeric contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RleHRyZWdpb246NTgxMGY2MTEzY2YwNDBhOGFkZTFjYWU4MDk5NzJhOTlfMTEyOQ_9f9e4c00-9867-40f7-b6ba-6f0c89fd57f7" continuedAt="i44a1a7df6a714b7599ad965043aac0d0" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e751a39abb44d69bf6dde5f62f5da1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC0yLTEtMS05NzYxNg_64a03693-7fe9-4d5b-aa29-3f85c68fa630">4,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18bfd7270ee4f79a082b091a1d91241_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC00LTEtMS05NzYxNg_e80a775e-399c-4605-a6c1-62fcdc66a456">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc2260464184105897c45f4f42c8c13_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC02LTEtMS05NzYxNg_c0f295bb-d909-4a1c-9484-ffe3d2b133d1">8,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf34e3dc9a54da193a3b587af7498e0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC04LTEtMS05NzYxNg_bb257d5c-1d40-42e3-9d54-0d3efab91f52">8,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3665d816d7a49f7b2a2c250380955e0_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS0yLTEtMS05NzYxNg_9971f27e-1f95-4b7e-add3-3b7024001b61">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id772f9666c5c4b569bff7bcce7ec09b4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS00LTEtMS05NzYxNg_226c5a16-a492-42e9-b30c-8c224188c0e1">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2789587e0039409e85ee53a0e676e039_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS02LTEtMS05NzYxNg_0d0b7b8d-5a26-4f6c-9d75-536e84736c11">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a7736453da40babfdf09cafbc6d8d7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS04LTEtMS05NzYxNg_78f426f4-6f03-4e76-855b-24400bb54c09">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab62c95758e45988052a829d4196a90_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi0yLTEtMS05NzYxNg_e77d827d-f969-4604-984a-1aae4e02a16d">5,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7dea9d6f70d4ec98a1e472f35d5c5e7_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi00LTEtMS05NzYxNg_39ad4eee-e58c-4390-9c1e-3db2d958e7a0">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc046d2283c4b17b9218d96bfe9f744_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi02LTEtMS05NzYxNg_fb477a0c-a4c3-4398-806c-8d1954f6059d">10,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dd0c7934dc4d97bade1ff5347b0cbb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi04LTEtMS05NzYxNg_2d726054-589d-49a3-9882-068312e8f1a2">9,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613d7817d5e44951867e1c6db534f048_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy0yLTEtMS05NzYxNg_ddef2b8f-67dd-43eb-8c34-38ac461de5b0">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3925d88e2c564017be693e4f33dc9fef_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy00LTEtMS05NzYxNg_9e8524dd-6ac8-4aa5-8bf6-cb0c0cac5c8a">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fab7cbaef51414aaaf8cf3add2b35cf_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy02LTEtMS05NzYxNg_71051ca7-5e97-4c69-afc5-cff2ec70bddb">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb12764f7504661af49974aecf799fa_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy04LTEtMS05NzYxNg_cdb7882c-8676-4a0f-9e0b-dc8ef6574822">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691d9600e9b043098e5c276598fee110_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC0yLTEtMS05NzYxNg_ea2c0f5a-a78e-42f6-8f9d-d14ecf824435">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a4b28633f342598240cdb0c3efa237_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC00LTEtMS05NzYxNg_abb99408-abcd-4c55-beaf-744b6b8a6dd4">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i560e85f5cfab4fc3ac49d453b66f47fc_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC02LTEtMS05NzYxNg_a543854e-45d8-4595-bc7a-5482f3c67ce7">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768c6e087bc94398bcebcdec93f187ee_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC04LTEtMS05NzYxNg_862e4d4c-403d-4192-92fd-79e533846f96">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6c8a9d73f14855aeed15aaa74afcff_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS0yLTEtMS05NzYxNg_26cfc1e3-c993-4c30-8bf6-65dced8c0b62">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b51a1c66954d9aaa0187e550ad0413_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS00LTEtMS05NzYxNg_0982f315-5c0d-4879-908b-ea16e4e05460">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea89bc103144a5958d2f2a66fe8098_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS02LTEtMS05NzYxNg_baf79386-7a27-45ad-967a-a02d964c3276">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8bd49f99be462b96189ff1b51b483f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS04LTEtMS05NzYxNg_68947207-aa8a-4e9d-a882-696bc81ee914">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874093c1c0ae4f308272c783ac24326f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtMi0xLTEtOTc2MTY_2f2da975-c4c3-4236-b101-9485168a0c3d">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e6208b6b4f4a0388ca9ada2c7cc625_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtNC0xLTEtOTc2MTY_528161ef-0818-459f-b3c4-e71c53e6f1ef">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd758e6d37b4bc59135caf3c0de84d6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtNi0xLTEtOTc2MTY_abfc70dd-89de-4024-b92c-9d345688506a">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d868053bd8748d3bf614376fe813cb8_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtOC0xLTEtOTc2MTY_bf12d5d0-f821-4670-833d-3be564ef2c7e">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c02e7957b24efd9ccb2368a2201c6e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtMi0xLTEtOTc2MTY_beb16ec3-2af9-458d-b938-c3103e957b76">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f955f09f26347a4b61f9e1d792d9c52_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtNC0xLTEtOTc2MTY_150c350a-3579-4aa3-b02c-a2838fb8e554">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a3befe2196456aa7304c27b18e62b0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtNi0xLTEtOTc2MTY_a0abf226-2c3e-46c0-ad51-5175b69bba36">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c352b7e3b4a46d4ac9b0c8ae253c346_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtOC0xLTEtOTc2MTY_f1a581e5-717d-4c2a-a428-7d3f4292d089">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacefee9559c84a7f8fe1b97854abae81_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItMi0xLTEtOTc2MTY_6f4a0cfe-707d-4890-a200-826edba6ab93">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf6107ac310458ca74734c319137631_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItNC0xLTEtOTc2MTY_3efb14f4-cafc-4f39-98cd-55c1f68e64a6">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4786d948d133499db74a085616fa1875_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItNi0xLTEtOTc2MTY_64b5d5d2-3030-4733-888b-53bdf1bf0f83">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d29d5d87b2d4ba492379977f9b5ab22_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItOC0xLTEtOTc2MTY_91ef78a1-1acc-413f-a5b0-73739d35d20c">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a916779feaf471db9c3dd44f2d0f9e4_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtMi0xLTEtOTc2MTY_2b6e76d5-fd19-40f7-aae2-46edb2eef231">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636fc0eccf124d9a800dd95dc70ad820_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtNC0xLTEtOTc2MTY_7cbd9483-29e9-447d-8328-325833b564c5">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2b0f551bc049d6abd5b17ecbfd5a7c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtNi0xLTEtOTc2MTY_299d5baa-667d-4bcd-91a8-8a87f795de34">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436d40cfe964413fbcbf9f712fc800e0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtOC0xLTEtOTc2MTY_9c3de0fd-125b-4e11-8acd-b3ff9a844a70">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0416b6fe5a4a28ad14a534ffeaf36c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtMi0xLTEtOTc2MTY_1c0ff8f2-5c6a-4a44-991b-33ca31f2a080">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c20efa76564198871cbde27c4f3770_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtNC0xLTEtOTc2MTY_0db03636-85b0-4e44-9c2c-f59e121c57a6">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a3090d63854077932361ea0cda6045_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtNi0xLTEtOTc2MTY_2ec09024-4955-4593-a199-2565dfea70c0">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8046e68b530144f7bb14542e2e179616_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtOC0xLTEtOTc2MTY_c6c7a34e-2914-4ef0-9cdf-9815e649ae67">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a43659878c5400aadd92c3684016238_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtMi0xLTEtOTc2MTY_fcaeb696-7562-40c1-904a-733b908ca825">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc5e412e1f94776bc76d6999c9445a6_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtNC0xLTEtOTc2MTY_2f7f0834-7870-4cc4-9a2b-08e0999e9062">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a45a226af5241fa94c7236e40243ed4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtNi0xLTEtOTc2MTY_2e0c277a-c85c-47ec-95e0-06f4fbd0b3d3">2,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67c8e799778495794ae8022dd02b919_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtOC0xLTEtOTc2MTY_71ddf78a-146d-4633-8f7c-2455bd36dde2">2,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90678a4b1d64aa5a5d8b7d3d0f183f9_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctMi0xLTEtOTc2MTY_66aee01a-80a9-41ed-bd63-de12bf5cbe35">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac78ef5437840d1851a7bb8a12f61ca_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctNC0xLTEtOTc2MTY_244e5549-d407-4cbc-9cc9-88113ef57df2">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b338d203ed4ed48104fb83314e02d9_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctNi0xLTEtOTc2MTY_4785691d-cc11-4242-a106-4def06657c1b">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c74555cc18a4bc1bd636f5aab45af28_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctOC0xLTEtOTc2MTY_c5213044-d0e6-4f21-b365-2556b5aa1c3f">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb374613bd8a41a8bf753c1018b7cb7c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtMi0xLTEtOTc2MTY_2d009d52-117c-4947-b83f-1116609d8148">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017973a311a149579a6e2d7f0bf65764_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtNC0xLTEtOTc2MTY_609428e5-1208-40b3-ba5d-04cde05b2507">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84118bab402a49e5b84833a66c174d12_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtNi0xLTEtOTc2MTY_7b943514-e9b7-4990-b3e0-8a294b3c4fc7">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21226e99e14c4ddbac60ef91e89cc530_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtOC0xLTEtOTc2MTY_1fcfd340-2522-4e6f-80aa-74f4143095a8">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbbf979d6cd4eccb6057977d03291df_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktMi0xLTEtOTc2MTY_c6e961d9-5a90-4fa4-870f-b8e3c52ee396">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae072cee9e51472198a5efde9ab867c3_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktNC0xLTEtOTc2MTY_d65d50e0-f030-45db-bcd9-73e1baf62811">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64aebd25af841f1b7229554bc01f412_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktNi0xLTEtOTc2MTY_53df3995-f9e3-4d89-9135-e7f289240c0b">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f15191fe14b4cfa89c7a4ae3911fe49_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktOC0xLTEtOTc2MTY_4349acaa-9a3f-44b4-b263-b4b0f8462e45">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c81ab58c08424a9e69f6265e734d0f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtMi0xLTEtOTc2MTY_2d568380-51e5-430c-8140-589378ce5368">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0605eac069cf4d81b845fd844cb58c8a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtNC0xLTEtOTc2MTY_0de6439f-aff3-41d0-af4a-019d0fcbe660">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6eafd7ccb9f4f629d0ad43895286c38_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtNi0xLTEtOTc2MTY_957dfead-e1eb-4ff1-8128-22c139fc84d4">862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4567b8412c0f40aca0ba3ae7d82676bb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtOC0xLTEtOTc2MTY_ee48a53c-29da-4c61-9ebb-13d47033a235">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdc471eaf3645a69aa7fd3af900fa42_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItMi0xLTEtOTc2MTY_337ac453-e3d0-4ed8-a916-a8b0348cc341">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86af501659bb429a93b12bc11b5044ca_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItNC0xLTEtOTc2MTY_198ec91f-e0a4-4e3b-990a-b764498e48f1">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34627b0f80bc47d4b2ee036c078502fa_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItNi0xLTEtOTc2MTY_c11c9287-161b-4687-9e0b-aaadb91243e8">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if389f2dd00e545d28d559a5e75ab3f64_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItOC0xLTEtOTc2MTY_0832755a-5211-41cc-bb45-1db21bba00d7">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic865d7480948423580adca162837e77c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtMi0xLTEtOTc2MTY_a10eea4c-478c-4b11-b20c-65e7b1b5caa9">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id886288666fb48ccb61718e61df34b35_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtNC0xLTEtOTc2MTY_341fc55e-29c1-4733-a42d-1f3cff4a133b">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cddde0247f443b9b340a36d7ca29a0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtNi0xLTEtOTc2MTY_294f180d-77b7-42b1-a881-1ab0f263233b">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cbb654aee284bde985e29ed2a417187_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtOC0xLTEtOTc2MTY_ad321713-c494-4504-9cb8-a8c065325510">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9b4bcd3c344d4caa8accace369889c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtMi0xLTEtOTc2MTY_6df3362a-f930-45f6-b128-f28f15501e6e">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6f7a1a1f1d4823b6772df289977ce9_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtNC0xLTEtOTc2MTY_ebd85f44-4b0b-48bf-b9e4-c55ee042e4f7">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9240ee581cc94c809d2e9975585d0e32_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtNi0xLTEtOTc2MTY_4547939c-9c39-4c27-a17c-b44b929f1d2d">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e9f078ec864353b22c3fdd238993cb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtOC0xLTEtOTc2MTY_ac18fd16-d926-4d34-b9c8-dd6961c46282">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e70fb16dfd04148a41903925eb90981_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtMi0xLTEtOTc2MTY_5e94f191-c207-407a-93bb-a3264b2cf47b">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a3b9cd19a14173a8c66d72c61e2b31_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtNC0xLTEtOTc2MTY_9d0faef8-28a3-4fd0-8d41-791e36c25164">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07be0755a0ce42f09fbc795069473e02_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtNi0xLTEtOTc2MTY_a7642394-3ef9-47d5-b045-276b3364e269">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2de83259a6941d8bd633aabc6f46bc0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtOC0xLTEtOTc2MTY_cf44d69d-8a34-4c88-bc67-aecd528e3459">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a2f367c8e496799ea036748f953a9_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtMi0xLTEtOTc2MTY_1de04a36-f8dc-487e-94a2-a579ceb42fe2">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42a239b714e4f67893f359965c39442_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtNC0xLTEtOTc2MTY_297d38e9-337c-4599-8405-0163d6c753a5">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c169ef01f945ee87a73716291f5111_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtNi0xLTEtOTc2MTY_80dea705-d37d-4aff-bb60-5d2fcf2dcebb">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee77d1be804cf485a2836eb7067c67_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtOC0xLTEtOTc2MTY_8576dd0f-f1ab-4f54-b087-d6ce60285477">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3df4a45fab4f4c9278ca1bfce58738_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctMi0xLTEtOTc2MTY_d98124e0-a535-4f16-be5e-4e55b7923e61">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75d432d522a94fed8847f371bc5981f2_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctNC0xLTEtOTc2MTY_2e97e84b-d8f6-4bc1-9944-b8c04cf48e6a">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84165bbb1f1347e897f9eab39bb8ea94_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctNi0xLTEtOTc2MTY_7a07df88-2fd1-4e5b-be7f-44c1d7fd18a3">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efa50552eb2412c8ac12c30f21c490f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctOC0xLTEtOTc2MTY_951bf74c-b856-4c06-88a3-65c75a79c726">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b03fece4c047a99bd000932229b9de_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtMi0xLTEtOTc2MTY_8b12a51b-4ccd-418a-a022-3d40e84676ff">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea32020dfa4649129801589297294e8d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtNC0xLTEtOTc2MTY_e34f0f82-d9b2-463f-ac8c-efeeb517c640">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaffe79a5455443aa04784d34e6c64ba_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtNi0xLTEtOTc2MTY_b759625d-a659-446a-9a97-e0d94ee48b26">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2fecdd608d4d54b39f0ea275388289_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtOC0xLTEtOTc2MTY_3aa28ee7-fed2-4a5b-abae-fb197ce469e5">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e6ceaa8895481db504ab1693ffb3fa_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktMi0xLTEtOTc2MTY_691f5a4a-d081-4785-b313-7ec951215156">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ad21c8d5d444f39b0047d67697123f_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktNC0xLTEtOTc2MTY_8106fac4-6153-49e9-a68f-10e506307e7b">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffaa78a8e1142b288e6e354c460254c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktNi0xLTEtOTc2MTY_31ea9902-d401-4658-a163-25d47bcb69d4">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9128c44b088f4cab95566ad9edc2a8ee_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktOC0xLTEtOTc2MTY_0b5accff-9a8c-412c-b349-49d805a2596b">765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d523156e124aa2ab5e04ddb64884bf_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtMi0xLTEtOTc2MTY_d8b59dc5-feca-420b-b9d1-b58ef14070d1">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7f58287b6145d5a6823247454ddc45_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtNC0xLTEtOTc2MTY_25826992-5f19-4a13-b684-6e0f4b7edd96">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf6ab07195a4cca93acbe6ceb203e73_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtNi0xLTEtOTc2MTY_e058be82-4031-402e-94ae-2cef92926c29">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df2818c56ef42baaa8eb76d1b384c0f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtOC0xLTEtOTc2MTY_86954eb3-274f-4c55-b933-4e6f4ba522cf">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638a5ee6ee4c42fca17c06b8857fb5c6_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItMi0xLTEtOTc2MTY_824b3f4d-24df-431f-be27-bd6f7aa08b7d">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1065d539abeb4072b769ab2d71e8944b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItNC0xLTEtOTc2MTY_01403eb3-e508-454c-86ea-3981b8795575">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d1768636d746b4bab2547e1b9c9ce1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItNi0xLTEtOTc2MTY_81c448e9-8cd2-4d0f-acab-f830412a9845">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f61f08f40d4da3a4256963bc6f1384_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItOC0xLTEtOTc2MTY_ff122fc9-a4fe-4ada-bda2-d46f76603219">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8781577e0c4483a640bac78e68df6e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtMi0xLTEtOTc2MTY_b7d4e55c-16f2-4e5b-b373-4d84225c4bd0">678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f260375e939438fb809d92be390d888_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtNC0xLTEtOTc2MTY_48dd492b-1969-4652-9740-b01ec141f7c6">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3461140986e4666a08f4efef9f1b613_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtNi0xLTEtOTc2MTY_9900f7ba-6a70-4778-8b88-619f850fe039">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07dc2f0df2044b08beb63c5086eb5739_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtOC0xLTEtOTc2MTY_9c12a026-8044-46c6-8b83-99033f538baa">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1888ed0d9b0e438c8de2757d768f23f6_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtMi0xLTEtOTc2MTY_14c5f67d-2ed5-4c61-8806-e90544341f75">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3305a5ca26ca4e7ea948f6a5cb50efa8_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtNC0xLTEtOTc2MTY_ac09a279-42e2-4dfe-a405-1c026ba86173">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5cab0be8af14785bd28c582835b0cc4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtNi0xLTEtOTc2MTY_8ef2d6df-0067-488f-bbdc-678986e89468">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeefd3642f924fffbc846fad74fdad8c_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtOC0xLTEtOTc2MTY_47817034-fef3-408a-9e8e-428fc4a392c4">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e881c96a7684c80b5f00b2c241ce2ca_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctMi0xLTEtOTc2MTY_733d5f19-8ed0-4514-bb6a-e477d4118a46">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf09146bec940c49881c105e2fde2a5_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctNC0xLTEtOTc2MTY_00a7fa44-cfc0-44ed-8734-9a5e5ced5d32">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061d2a55e7174d83b68a055cd5e369b1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctNi0xLTEtOTc2MTY_19152e1f-ab39-4462-8287-83f91a7fdee1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451984d626294d03858200463c69ceb7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctOC0xLTEtOTc2MTY_6ccf24ad-2330-480c-af82-da1710eccc77">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc95ef169d984d27b48f3e697f6f4d3d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtMi0xLTEtOTc2MTY_d04983f2-c696-4e29-b17a-688e46988c10">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04dcb0e5c7634daa8fd3b1024c048528_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtNC0xLTEtOTc2MTY_5af0c7ab-be13-4507-84c1-6ee4b2d1a1bb">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3628e0cef99d4acc818a521eb8fa79fd_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtNi0xLTEtOTc2MTY_50a6e5b6-fa4f-4085-851a-da7c3ac5c94d">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a341dab3c8b46f780c38988862e144d_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtOC0xLTEtOTc2MTY_f3730ee5-fc1f-42e1-a197-6788a5f2d713">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d827902a8b74349b77862bc1ae1fe1d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktMi0xLTEtOTc2MTY_3c185fc8-867e-4dd2-b2d5-9919ef5b52ec">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7877be381ff54eeebefba91654c5bec8_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktNC0xLTEtOTc2MTY_a68d78c9-4060-424a-aec1-7cb8b7099bf5">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d561bc963364eb3b42dc2bb43967bfc_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktNi0xLTEtOTc2MTY_96efa6cc-bb52-4c86-8530-6586d4ab76b4">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c9d7c0c1954f4a827422d7ddb71e44_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktOC0xLTEtOTc2MTY_17e1f0e9-a157-4d37-9af1-b9754bdffd42">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib009e9f4ccbc4aabb0abf813ff1b9b9d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtMi0xLTEtOTc2MTY_0c2e92b8-894a-4f5a-90c9-5d8fca0fd373">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91980ca8bba425dbf5ec17c1e6c8260_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtNC0xLTEtOTc2MTY_4e563549-6e19-46aa-bac1-c278e1d16add">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66976616df8f45e4a0233eabd261afb9_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtNi0xLTEtOTc2MTY_7e9585de-c223-4f1e-aa4a-5b03675b0c49">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efcdbc4d1cf44e6b7ae58e964d94349_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtOC0xLTEtOTc2MTY_f8865457-24e0-4c9b-84c5-9fad2b0ea455">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63415011c3e645908f7ec388df1bb966_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtMi0xLTEtMTAwNjY2_3c1f5e1f-5910-4ea9-9ee3-dbb6122eac91">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a378f983e24296878b4a51a9ce87bc_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtNC0xLTEtMTAxNDgz_61f9227d-184c-435d-8ac9-d671aaccecfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3650cb2a09d0454bb935da1c661555e1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtNi0xLTEtOTc2MTY_255311e1-d97b-4922-a917-65ec3402e957">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id488c5c2f38b4d9c87b2dd5a3c14dd52_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtOC0xLTEtOTc2MTY_cbe1cead-45ce-4e42-9eec-90032d5d0144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0aa8affc324889ba63c424cf09ade4_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtMi0xLTEtOTc2MTY_cb2a50c5-d7f9-462c-aaa9-21981e6311bd">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d3ccb3b6564bcab939ffb027584e3c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtNC0xLTEtOTc2MTY_5cc7b5b7-046d-4420-af9d-28cd96e3167a">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8319fb8317f64500af0908643ad0632a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtNi0xLTEtOTc2MTY_93d1f3c5-9b90-4cc5-b957-49ef6083d6f9">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486d629919554591943fc705452e1ffd_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtOC0xLTEtOTc2MTY_540758da-7ad2-48e6-8a4d-2ab98a799687">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910a16d51cdf46e69ab2f11998279fce_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtMi0xLTEtOTc2MTY_2aeb7d74-b0d5-4c09-aa0d-5a1944b4021b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5ee0b393444da28b3de9ccb5848abc_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtNC0xLTEtOTc2MTY_91e147c0-29a8-44c5-a0e5-bdc54b6e0a49">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1c2e9044134fb283858ebe2b7015a4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtNi0xLTEtOTc2MTY_b456e81e-f0ae-4209-92e6-53f97ff68c4f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efe769f8be14215a0a43d2955581c8b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtOC0xLTEtOTc2MTY_0d3560ed-116c-4d12-bc80-9b77bcf724bf">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie341a38ca0504923bb7a4212d96ae509_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtMi0xLTEtOTc2MTY_dfc13883-d883-4a0d-bcea-5a8ed0b37552">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0338fe30ecfb43c2bb594866b36d0c38_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtNC0xLTEtOTc2MTY_7db2268e-aca2-4a0b-9b5c-0a81f8471104">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8baf06e41cac46ca890ff77bbde002de_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtNi0xLTEtOTc2MTY_6c6143c3-19ea-4886-bc74-8d04e05ec5e9">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if334fd6f6ced463191edffdfc673820e_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtOC0xLTEtOTc2MTY_f4980fc2-6df9-4855-ac86-cfae59f1f055">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i60ccb784ad824665972c6936ad5200cd"><ix:continuation id="i44a1a7df6a714b7599ad965043aac0d0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae918b7a7fec4e0f884db97d43014c3d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtMi0xLTEtOTc2MTY_84b397ce-c7d1-4c4e-b379-36151d9141b6">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6361dbeea1084098930ecf34e1a2cd74_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtNC0xLTEtOTc2MTY_180c3519-14c9-4198-96c4-17a3675a9a58">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie802121280734295adc561cdb0a46110_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtNi0xLTEtOTc2MTY_d5823426-931e-46b3-9b5b-a6ba5db5a0c5">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e1d8a4f5a10492bb4bd12e2b4c064e8_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtOC0xLTEtOTc2MTY_b670cafb-87b8-4439-85bd-831ff006cf54">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37fe742fa0946ea9ef53a300a8b5681_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktMi0xLTEtOTc2MTY_e46348ad-8695-464e-9c16-7a2c040b84bc">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082bdbf7ba954da5b6a638b5ff634bd0_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktNC0xLTEtOTc2MTY_3ea2d10b-333a-46bd-b021-4d82bb77cf33">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d2dc14539945b28da637cec2804a59_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktNi0xLTEtOTc2MTY_6e68aab8-8d3a-479a-b910-499b965b9b1e">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065d8379e1cc41b4ad8f7251eaeeb1c2_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktOC0xLTEtOTc2MTY_0ed6f1c7-6d7d-4332-951c-3249f4ed92c5">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b0f0ce20724b90a4f7647bb9a8ef1a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtMi0xLTEtOTc2MTY_1de3c64a-b742-49ea-b000-c9cb39bbca5f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd74e66f1b04b9ea3d575b51adf1c05_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtNC0xLTEtOTc2MTY_3b612395-5959-46e8-9ad5-9849d8996832">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed7b5a1ebea48f093da2b0ff29eb4b7_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtNi0xLTEtOTc2MTY_7b86eeca-7169-4c66-80b7-8bf3dbc6285a">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id123036947d949b3b27454b60e9bb03d_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtOC0xLTEtOTc2MTY_800b1f28-bcb2-4375-a602-7e204838632c">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cad72124104e83a37813c7ca4d58bc_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtMi0xLTEtOTc2MTY_a8214fe1-5fa1-4f0b-953c-6cc7c27ae32d">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b70cb0e5c7147579fa25e09acbf6291_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtNC0xLTEtOTc2MTY_f065e199-917a-4078-90d8-fcf328b17432">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79667b913ce74f5dbebec3fe976825ff_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtNi0xLTEtOTc2MTY_2c0f0bd3-9467-43a6-bbb7-0b878ad47cb1">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d10096f8a24fccb83511987f26c69a_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtOC0xLTEtOTc2MTY_6bea63b5-7d6a-4ed3-923d-553da088f5b3">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2d4201e5e747079eb77993bb61fba3_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItMi0xLTEtOTc2MTY_a9e37ec1-471f-414e-8a57-fbca0a286d80">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711eb0534e014c01be59768e65562deb_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItNC0xLTEtOTc2MTY_c4384ef9-6b55-484e-8c1f-058ee8ac00fa">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec21debfbe341cdad1aac7ebf721a99_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItNi0xLTEtOTc2MTY_fab87913-11e8-4ebc-aeeb-da6cd63fa345">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad19468cf9d346b28980e07a20d6f5db_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItOC0xLTEtOTc2MTY_4310cd06-c9ca-49d8-bc0d-77e81403862e">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15fbf82d23f3402dacdf01e8cf69b44a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtMi0xLTEtOTc2MTY_7aa93c84-8a0f-4021-8de5-26549207a38d">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f1716e275a0412aa55aeb45b7eb6c31_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtNC0xLTEtOTc2MTY_2ee3f8d1-cba3-4f47-9c7a-d1b37c7e9136">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf40dd1d09234507952e167d1479045e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtNi0xLTEtOTc2MTY_24df0e3c-3a1a-43f2-ac9e-78f892874120">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3682c7c9fc8d4e37870dd6d2a55fffa6_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtOC0xLTEtOTc2MTY_d13bf133-829c-4573-8dce-15b557e2dd37">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a5fbce24694e669e94f977e23e2355_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtMi0xLTEtOTc2MTY_47c2aa33-9726-4a07-9a4a-0c7d68d6dae9">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c7d12ad2714a6ea184eada5e3b70a0_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtNC0xLTEtOTc2MTY_555f1a4c-459a-4730-89f9-bad1b8288188">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dea495dc74647a89c9c075bf46494aa_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtNi0xLTEtOTc2MTY_b2768cfb-7540-4f62-b944-f875a54740c6">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a900fadd404c10ad147fafe8f4deb4_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtOC0xLTEtOTc2MTY_d8d0524e-de86-4d1f-981f-345450fb9208">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b4ab1ba4784671a896ead7cb8313b0_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtMi0xLTEtOTc2MTY_0ae005f6-b15c-433e-9ef6-32767e236e03">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8173b604f62e4076a3617362c1136935_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtNC0xLTEtOTc2MTY_baa4e2a8-92b8-468b-8014-182547a60bd4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e86aea9a594dbeb0b923716d380818_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtNi0xLTEtOTc2MTY_b56f4f68-74f2-4799-9eb7-30bce652164d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ae3512f1eb4610aca3449ed15dd8d1_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtOC0xLTEtOTc2MTY_549451c7-ea49-4ad4-8ac5-c452095da368">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1412de7cca3427fa94e528b2abb50ea_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtMi0xLTEtOTc2MTY_4136a226-3e02-414e-88bc-6153ac8d553c">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201933aab6584d7ca5b8dbf08dbbac04_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtNC0xLTEtOTc2MTY_ebb311f7-1eba-4b7e-974a-2d73fc9c1c64">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedaedd5de554534991638c4456c25b3_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtNi0xLTEtOTc2MTY_798bf791-4c8c-4dc1-93e2-d0f1affa339e">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17b9bd9ac4d044d5860a53c8b0380a1e_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtOC0xLTEtOTc2MTY_6cf77d7f-32ef-4107-b696-da7d26f3c3be">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9e048450024856b06b4e78059095d1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctMi0xLTEtOTc2MTY_c87dbcd0-de65-419f-ab49-81724dd80a23">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd1758c8b804a44b870604e3de47893_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctNC0xLTEtOTc2MTY_31863350-4f26-41ab-a7b0-15fbca0c03df">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3067379f7643989c5c6a9f5aa57e51_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctNi0xLTEtOTc2MTY_2ad7f700-17ae-4440-8cc2-2e227f88c455">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b1aa17325b4c23ac4029b80c3b95d4_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctOC0xLTEtOTc2MTY_73b7df3c-327f-4f7c-b6ae-bf25e16263f8">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959da824f08a41469fcef4982237f0ad_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtMi0xLTEtOTc2MTY_7da863d3-b190-4e10-a1df-cd186bb2da25">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9ca253be174199be0d0235e1eb2f23_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtNC0xLTEtOTc2MTY_090e951b-0696-4059-8891-7b53df98dea1">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335cd00f529e4f93912c67b5c142472f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtNi0xLTEtOTc2MTY_58f0db2c-39f0-4f85-b2d1-5c9631727da4">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a7e51d8bb049719a805c96ee4e3371_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtOC0xLTEtOTc2MTY_428b08e0-ac21-46fc-a64b-8ed2c9414332">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904652ab5bb343df953e359f58983c26_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktMi0xLTEtOTc2MTY_40c16537-5f7f-4c66-8341-d8587462b307">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f642aa7c52d4beca6b8434dd4031490_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktNC0xLTEtOTc2MTY_b592dccc-7521-43a7-baaa-a64a54b404b4">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0dc83404ae74a8097d23417e7af22df_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktNi0xLTEtOTc2MTY_c89a6fdc-14ba-48e7-b310-990201a07d3e">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53336e17dd6a40f1990e05073d8317b5_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktOC0xLTEtOTc2MTY_22761a8a-e412-47f0-bc73-e104e943a76a">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aeae0c651354131b671fc904166fb25_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtMi0xLTEtOTc2MTY_fc754735-02a7-4036-a160-32a51cefe86d">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e57842484a485991d62e03a01d8e38_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtNC0xLTEtOTc2MTY_1e7a269f-b1d9-49ca-a1d7-3f70359caf61">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158d06c961ab4b84ac67732c15bd9b13_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtNi0xLTEtOTc2MTY_48a37d03-d476-487f-8a84-3d2bcd0721dc">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16f064354b64f688d1bff104fcffb76_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtOC0xLTEtOTc2MTY_ecf2c581-06de-4e79-aa17-bb9358656643">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24fc70faba5c40f2b7c77bb2f65b318d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItMi0xLTEtOTc2MTY_6b7e585f-2dff-4c5d-84d6-a042fac205d9">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a52d243b364ceebafddad56040e1d4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItNC0xLTEtOTc2MTY_21bfc808-502e-45f3-b42d-326a4661835b">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b345afd17164d7d917c60019900d02c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItNi0xLTEtOTc2MTY_c806dd80-513b-4411-a161-7748114f203b">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baadf51bd904370a6d282562978b306_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItOC0xLTEtOTc2MTY_6b8dbe44-f651-424b-baa5-09d0bcc686b6">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba200322b8f4fcb86619a36931e9175_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtMi0xLTEtOTc2MTY_32b01c59-4d4e-48bc-9a98-d2af2c1a4a8c">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88385ff780be4c28851e5dde7a7375aa_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtNC0xLTEtOTc2MTY_92c49cb8-7735-49c6-88b1-4df0799c6cbb">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3842eb65438141e288a8210b375b0e59_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtNi0xLTEtOTc2MTY_66872b25-76d8-4618-bb65-16b676afd549">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67b59d6f5054f0f9504c3b750eb3e0f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtOC0xLTEtOTc2MTY_cab17eb3-b59d-4213-bf82-88375584593c">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb25c770cdcd4b8a84b4d8984b516ea3_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtMi0xLTEtOTc2MTY_86272246-dbd8-45de-b651-06a1aad463f5">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7846dcf271946ef9f581063d57b1d32_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtNC0xLTEtOTc2MTY_4df0694e-c0b2-49cb-9d45-e23fcc06d790">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1c9ae69774509942fb2c801e8e0b4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtNi0xLTEtOTc2MTY_7d4f63e3-2520-4a64-ae77-6e16b425ef63">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5411bdc1d3b46c5a26a274c0c49de78_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtOC0xLTEtOTc2MTY_3f3f1a3d-74c1-4a26-86b2-f90641e38e4e">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe1ad8786cd4ec9b518879507cdeefc_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtMi0xLTEtOTc2MTY_8f348536-9351-478a-93aa-e4b716dc74e4">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43669c40e73a46afb5e6f704a10e6d1e_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtNC0xLTEtOTc2MTY_3edef42b-a298-4550-a824-ae34b10868b9">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a8730959ce4f028d5538a29f222423_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtNi0xLTEtOTc2MTY_aecb4700-43ca-44f2-aa6c-8f5e520a1b93">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id215663e03264d678a32b5af7a72e4d0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtOC0xLTEtOTc2MTY_c5b837e9-6f2d-4081-948c-e538b175f497">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1f55c4f4fa4a0f87dd08291588f95f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtMi0xLTEtOTc2MTY_2dc994d0-7a36-486f-bfd9-72c651434bb5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18902dc3bd7b4eb2bf8e70464f318c7d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtNC0xLTEtOTc2MTY_50cb69ca-bbe4-4eb5-92a6-f63c306f2d19">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f331549442e46038a09afa23765f532_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtNi0xLTEtOTc2MTY_c171edbf-ee82-446f-aeb8-4f68fa05ee8d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia689063c9a8d4f47ad065d4cd5c51cce_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtOC0xLTEtOTc2MTY_1f1fa58a-f9bd-49ef-952a-2d048af5a05b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a165da7515149dc9f2231f0452f276b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctMi0xLTEtOTc2MTY_dde84086-4c71-40bf-ba42-24626690ffc4">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa0784d769c47b1b61138f07a799e92_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctNC0xLTEtOTc2MTY_89a55987-d589-468d-bd3e-3709129c1ad3">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b632bb7a6f44b95a3ba9242b438a9b1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctNi0xLTEtOTc2MTY_aae6d916-f090-488a-8ae0-be87b4fb1937">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35991f95fd64801a6f989d5186073d6_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctOC0xLTEtOTc2MTY_552f7e24-2851-441b-9fb3-79d4b2dd27ef">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676449a933204a9cb64a6f54570b2d60_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtMi0xLTEtOTc2MTY_b2e79747-3e1b-463a-aa67-410486b7aa53">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8f4a95cb1b4c99b4bb5f312cef5b00_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtNC0xLTEtOTc2MTY_29bda50f-bbf9-4019-a007-b2c66ad6abe7">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5611e12d1194636a4cdc0e36968dd1a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtNi0xLTEtOTc2MTY_2e8765e5-59f1-4179-aa1d-1746061e743c">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe1892fc3014e6b8f3d56ee7c617da9_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtOC0xLTEtOTc2MTY_a24043f1-33f6-44e8-ad0d-ea31aa4a9c1a">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItMi0xLTEtOTc2MTY_6f3ea7c7-c6e2-4fb7-a2ac-6601a5d7df76">14,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItNC0xLTEtOTc2MTY_1f0c4e58-a1fb-420c-bd1f-c6d49dab4e3d">13,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItNi0xLTEtOTc2MTY_9102ac1c-7019-4a32-bf8d-2068cf2ab3eb">28,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItOC0xLTEtOTc2MTY_056eea93-0902-4683-8041-8be3da454228">26,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">24</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of June 30, 2022 and December 31, 2021 and the results of operations for the three and six months ended June 30, 2022 and 2021. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, &#8220;Financial Statements and Supplementary Data.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world&#8217;s most complex and serious diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies. AbbVie has approximately 50,000 employees. AbbVie operates as a single global business segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Strategic Objectives</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution. AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)&#160;growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)&#160;continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)&#160;expanding operating margins; and (v)&#160;returning cash to shareholders via a strong and growing dividend while also reducing debt. In addition, AbbVie anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months.</span></div><div id="i8040488224cd40d194fd225edca967d2_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's financial performance for the six months ended June 30, 2022 included delivering worldwide net revenues of $28.1&#160;billion, operating earnings of $8.0&#160;billion, diluted earnings per share of $3.03 and cash flows from operations of $9.9&#160;billion. Worldwide net revenues grew by 4% on a reported basis and 6% on a constant currency basis, reflecting growth across its immunology, neuroscience and aesthetics portfolios.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share was $3.03 for the six months ended June 30, 2022 and included the following after-tax costs:                     (i) $3.1&#160;billion related to the amortization of intangible assets; (ii) $1.9 billion for charges related to litigation matters; (iii) $875&#160;million for the change in fair value of contingent consideration liabilities; and (iv) $219&#160;million of acquisition and integration expenses. These costs were partially offset by an after-tax gain of $126 million related to the divestiture of Pylera. Additionally, financial results reflected continued funding to support all stages of AbbVie&#8217;s pipeline assets and continued investment in AbbVie&#8217;s on-market brands.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. The integration plan is expected to realize approximately $2.5 billion of annual cost synergies in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Global Events</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia/Ukraine</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the military conflict between Russia and Ukraine, the United States and other North Atlantic Treaty Organization member states, as well as certain non-member states, announced targeted economic sanctions and export controls on Russia and Belarus. These include restrictions on the export and transfer of products containing certain toxins, including Botox, to Russia and Belarus. With the exception of Botox, AbbVie is not prohibited to continue the sale of essential pharmaceutical products to help ensure patients receive an uninterrupted supply of their medicines. In March 2022, AbbVie announced the suspension of operations for all aesthetics products in Russia. In April 2022, AbbVie also announced that all profits from the sales of essential medicines in Russia will be donated to support direct humanitarian relief efforts in Ukraine. While the company&#8217;s operations in Russia, Belarus and Ukraine are not significant, if the conflict escalates and results in broader economic and political concerns, AbbVie&#8217;s business could be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the Coronavirus Disease 2019 (COVID-19)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing public health crisis posed by COVID-19, AbbVie continues to focus on ensuring the safety of employees. Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also continues to closely manage manufacturing and supply chain resources around the world to help ensure that patients continue to receive an uninterrupted supply of their medicines. Clinical trial sites are being monitored locally to protect the safety of study participants, staff and employees. While the impact of COVID-19 on AbbVie's operations to date has not been material, AbbVie continues to experience lower new patient starts in certain products and markets. AbbVie expects this matter could continue to negatively impact its results of operations throughout the duration of the pandemic. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may impact AbbVie's financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the effectiveness of vaccines and therapeutics.</span></div><div id="i8040488224cd40d194fd225edca967d2_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and innovation are the cornerstones of AbbVie&#8217;s business as a global biopharmaceutical company. AbbVie&#8217;s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s pipeline currently includes approximately 80 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care. Of these programs, more than 40 are in mid- and late-stage development. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sections summarize transitions of significant programs from mid-stage development to late-stage development as well as developments in significant late-stage and registration programs. AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Programs and Developments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Skyrizi</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, A</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bbVie announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi for the treatment of adults with active psoriatic arthritis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, AbbVie announced that the FDA approved Skyrizi for the treatment of adults with moderately to severely active Crohn&#8217;s disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rinvoq</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, AbbVie announced its submission of a supplemental New Drug Application (sNDA) to the FDA for Rinvoq for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, Ab</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bVie announced that the FDA approved Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In February 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AbbVie was notified that the European Commission (EC) is requesting the European Medicines Agency (EMA) to assess safety concerns associated with JAK inhibitor products authorized in inflammatory diseases and to evaluate the impact of these events on their benefit-risk balance. The assessment covers all JAK inhibitors approved for use in inflammatory diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie announced top-line results from its second Phase 3 induction study, U-Excel, for Rinvoq in patients with moderate to severe Crohn&#8217;s disease who had an inadequate response or were intolerant to conventional or biologic therapy met the primary and most key secondary endpoints.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie announced that the FDA approved Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In April 2022, AbbVie announced that the FDA approved Rinvoq for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2022, AbbVie announced positive top-line results from U-ENDURE, its Phase 3 maintenance study for Rinvoq in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy. The results showed that more patients treated with Rinvoq achieved the co-primary and secondary endpoints at one year compared to placebo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, AbbVie announced that the EC approved Rinvoq for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, AbbVie announced its submission of an sNDA to the FDA and a marketing authorization application (MAA) to the EMA for Rinvoq for the treatment of adult patients with moderately to severely active Crohn&#8217;s disease. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, AbbVie announced that the EC approved Rinvoq for the treatment of adult patients with active nr-axSpA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Teliso-V</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In May 2022, AbbVie initiated a Phase 3 clinical trial to evaluate Teliso-V versus docetaxel for the treatment of patients with previously treated c-Met overexpressing, epidermal growth factor receptor wild type, advanced/metastatic non-squamous non-small cell lung cancer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Imbruvica</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie submitted an sNDA to the FDA for Imbruvica for the treatment of pediatric and adolescent patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Epcoritamab</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, Genmab A/S (Genmab) announced that FDA granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody-CD3xCD20), for the treatment of follicular lymphoma. Genmab and AbbVie are co-developing epcoritamab and will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, AbbVie announced primary results from the large B-cell lymphoma expansion cohort in the EPCORE NHL-1 phase 2 clinical trial evaluating epcoritamab, an investigational subcutaneous bispecific antibody. In this study, epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy including chimeric antigen receptor T-cell therapy. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Juvederm Collection</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie announced that the FDA approved JUVEDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">BoNTE</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie initiated three Phase 3 clinical trials to evaluate the efficacy and safety of BoNTE (AGN-151586) for the treatment of glabellar lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuroscience</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vraylar</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, AbbVie submitted an sNDA to the FDA for Vraylar for the adjunctive treatment of major depressive disorder in patients who are receiving ongoing antidepressant therapy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Qulipta</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2022, AbbVie announced results from the Phase 3 PROGRESS trial for Qulipta in the preventive treatment of chronic migraine in adults met the primary endpoint and resulted in significant improvements in all secondary endpoints after adjustment for multiple comparisons.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, AbbVie submitted an sNDA to the FDA for Qulipta for the preventative treatment of chronic migraine in adults.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, AbbVie submitted an MAA to the EMA for Qulipta for the prophylactic treatment of migraine in adult patients who have at least four migraine days per month.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ABBV-951</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In May 2022, AbbVie submitted a New Drug Application to the FDA for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eye Care</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vuity</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">In April 2022, AbbVie announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of Vuity 1.25% in adults with presbyopia met its primary efficacy endpoint. </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In June 2022, AbbVie submitted an sNDA to the FDA for twice-daily administration of Vuity 1.25% in adults with presbyopia.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more comprehensive discussion of AbbVie&#8217;s products and pipeline, see the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">28</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div id="i8040488224cd40d194fd225edca967d2_118"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year&#8217;s foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company&#8217;s operations and can facilitate analysis of the company&#8217;s results of operations, particularly in evaluating performance from one period to another.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency&#160;rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency&#160;rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenues</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.102%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:14pt"><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;100.0 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vraylar</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.102%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent&#160;change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;actual <br/>currency rates</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At&#160;constant <br/>currency rates</span></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n/m &#8211; Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of AbbVie&#8217;s net revenues by product is presented on a constant currency basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Humira sales increased by 7% for the three months and 3% for the six months ended June 30, 2022 primarily driven by market growth across therapeutic categories, partially offset by direct biosimilar competition in certain international markets. In the United States, Humira sales increased by 10% for the three months and 6% for the six months ended June 30, 2022 primarily driven by market growth across all indications and favorable pricing. This increase was partially offset by lower market share following corresponding market share gains of Skyrizi and Rinvoq. Internationally, Humira revenues decreased by 7% for the three months and 13% for the six months ended June 30, 2022 primarily driven by direct biosimilar competition in certain international markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Skyrizi increased by 88% for the three months and 78% for the six months ended June 30, 2022 primarily driven by continued strong volume and market share uptake since launch as a treatment for plaque psoriasis as well as market growth. Net revenues for the three and six months ended June 30, 2022 were also favorably impacted by recent regulatory approvals and expansion of Skyrizi for the treatment of psoriatic arthritis. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Rinvoq increased by 61% for the three months and 59% for the six months ended June 30, 2022 primarily driven by continued strong volume and market share uptake since launch for the treatment of moderate to severe rheumatoid arthritis as well as market growth. Net revenues for the three and six months ended June 30, 2022 were also favorably impacted by recent regulatory approvals and expansion of Rinvoq for the treatment of psoriatic arthritis, atopic dermatitis, ankylosing spondylitis and ulcerative colitis. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie&#8217;s 50% share of Imbruvica profit. AbbVie's global Imbruvica revenues decreased by 17% for the three months and 13% for the six months ended June 30, 2022 as a result of decreased market demand and lower new patient starts in the United States. The decrease in net revenues for the six months ended June 30, 2022 was also partially offset by increased collaboration revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Venclexta increased by 21% for the three and six months ended June 30, 2022 primarily due to continued expansion of Venclexta for the treatment of patients with chronic lymphocytic leukemia (CLL), relapsed/refractory CLL and acute myeloid leukemia. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Botox Cosmetic used in facial aesthetics increased by 21% for the three months and 28% for the six months ended June 30, 2022 due to increased consumer demand driven by targeted brand investment. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Juvederm Collection used in facial aesthetics decreased by 16% for the three months ended June 30, 2022 due to COVID-19 restrictions in China and suspension of aesthetic operations in Russia. Net revenues for Juvederm Collection increased 4% for the six months ended June 30, 2022 due to market growth partially offset by COVID-19 restrictions in China and suspension of aesthetic operations in Russia. In the United States, net revenues for the three and six months ended June 30, 2022 were unfavorably impacted by higher revenues in the prior year due to a one-time promotion in the three months ended June 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Botox Therapeutic used primarily in neuroscience and urology therapeutic areas increased by 14% for the three months and 15% for the six months ended June 30, 2022 due to market growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Vraylar for the treatment of schizophrenia, bipolar I disorder and bipolar depression increased by 14% for the three months and 18% for the six months ended June 30, 2022 due to higher market share and market growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Ubrelvy for the acute treatment of migraine with or without aura in adults increased by 48% for the three months and 56% for the six months ended June 30, 2022 primarily due to increased market share uptake since launch.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for Mavyret decreased by 5% for the three and six months ended June 30, 2022 due to the continued disruption of global HCV markets due to the COVID-19 pandemic.</span></div><div id="i8040488224cd40d194fd225edca967d2_121"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,413</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,436</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,899</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,233</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percentage of net revenues increased for the three and six months ended June 30, 2022 compared to the prior year. Gross margin percentage for the three and six months ended June 30, 2022 was favorably impacted by changes in product mix and lower amortization of intangible assets associated with the Allergan acquisition.</span></div><div id="i8040488224cd40d194fd225edca967d2_124"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,164</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,539</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses as a percentage of net revenues increased for the three and six months ended June 30, 2022 compared to the prior year. SG&amp;A expense percentage for the three and six months ended June 30, 2022 was unfavorably impacted by litigation reserve charges of $2.2 billion for the three months and $2.4 billion for the six months ended June 30, 2022.</span></div><div id="i8040488224cd40d194fd225edca967d2_127"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development and Acquired IPR&amp;D and Milestones</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,106</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as a % of net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and milestones</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses as a percentage of net revenues decreased for the three and six months ended June 30, 2022 compared to the prior year. R&amp;D expense percentage was favorably impacted by the purchase of priority review vouchers from third parties during the three and six months ended June 30, 2021, increased scale of the combined company and synergies realized as well as lower integration costs related to the acquisition of Allergan.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and milestones expense represents upfront and subsequent development milestone payments incurred prior to regulatory approval to acquire rights to in-process R&amp;D projects through R&amp;D collaborations, licensing arrangements or other asset acquisitions. Acquired IPR&amp;D and milestones expense in the six months ended June 30, 2022 included a charge of $130 million as a result of acquiring Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118, which is being evaluated to target nerve terminals to enhance synaptic efficiency. There were no individually significant transactions during the three months ended June 30, 2022 and the three and six months ended June 30, 2021.</span></div><div id="i8040488224cd40d194fd225edca967d2_130"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income for the three and six months ended June 30, 2022 included $172 million of income related to the sale of worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. See Note 4 to the Condensed Consolidated Financial Statements for additional information. Other operating income for the three and six months ended June 30, 2021 included $68 million of income related to the sale of a biologics facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Expenses (Income)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net decreased for the three and six months ended June 30, 2022 compared to the prior year primarily due to a lower average debt balance as a result of deleveraging.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net included charges related to changes in fair value of contingent consideration liabilities of $1.6 billion for the three months and $861&#160;million for the six months ended June 30, 2022 and $2.7 billion for the three months and $2.3&#160;billion for the six months ended June 30, 2021. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three and six months ended June 30, 2022, the change in fair value represented higher estimated Skyrizi sales driven by stronger market share uptake, partially offset by higher discount rates. For the three and six months ended June 30, 2021, the change in fair value represented higher estimated Skyrizi sales driven by stronger market share uptake, favorable Skyrizi clinical trial results and lower discount rates. </span></div><div id="i8040488224cd40d194fd225edca967d2_136"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 22% for the three months and 11% for the six months ended June 30, 2022 compared to 34% for the three months and 14% for the six months ended June 30, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The decrease in the effective tax rate for the three and six months ended June 30, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings and accretion on contingent consideration.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">33</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,651)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,058)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows for the six months ended June 30, 2022 increased compared to the prior year primarily due to improved results of operations resulting from revenue growth, partially offset by the timing of working capital cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing cash flows for the six months ended June 30, 2022 included payments made for net purchases of investment securities totaling $1.4&#160;billion, acquisitions and investments of $394&#160;million and capital expenditures of $305&#160;million. Investing cash flows for the six months ended June 30, 2021 included capital expenditures of $383 million, payments made for acquisitions and investments of $345 million and net sales and maturities of investment securities totaling $9&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows for the six months ended June 30, 2022 included repayment of $2.9 billion aggregate principal amount of the company&#8217;s 3.45% senior notes. Additionally, financing cash flows included repayment of a $2.0 billion floating rate term loan due May 2025 and issuance of a new $2.0 billion floating rate term loan as part of the term loan refinancing in February 2022. Financing cash flows for the six months ended June 30, 2021 included repayment of $1.8 billion aggregate principal amount of the company&#8217;s 2.3% senior notes, &#8364;750 million aggregate principal amount of the company&#8217;s 0.5% senior euro notes and $750 million aggregate principal amount of floating rate senior notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows also included cash dividend payments of $5.0 billion for the six months ended June 30, 2022 and $4.6 billion for the six months ended June 30, 2021. The increase in cash dividend payments was primarily driven by the increase in the quarterly dividend rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;23, 2022, the company announced that its board of directors declared a quarterly cash dividend of $1.41 per share for stockholders of record at the close of business on July&#160;15, 2022, payable on August&#160;15, 2022. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie&#8217;s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie&#8217;s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the six months ended June 30, 2022 and 5&#160;million shares for $550&#160;million during the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility, Access to Capital and Credit Ratings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie currently has a $4.0 billion five-year revolving credit facility that matures in August 2024. This credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At June 30, 2022, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of June 30, 2022 and December 31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Capital</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt. The company&#8217;s ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company&#8217;s products or in the solvency of its customers or suppliers, deterioration in the company&#8217;s key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company&#8217;s growth objectives.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Ratings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Moody&#8217;s Investors Service (Moody&#8217;s) affirmed its Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. At the same time, Moody&#8217;s revised the outlook to positive from stable. Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company&#8217;s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company&#8217;s outstanding debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company&#8217;s significant accounting policies is included in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in AbbVie's Annual Report on Form&#160;10-K for the year ended December 31, 2021. There have been no significant changes in the company&#8217;s application of its critical accounting policies during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements in this quarterly report on Form&#160;10-Q may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.&#160;The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; and similar expressions, among others, generally identify forward-looking statements.&#160;AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.&#160;Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan, failure to promptly and effectively integrate Allergan's businesses, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.&#160;Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; in AbbVie&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021, which has been filed with the Securities and Exchange Commission.&#160;AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.</span></div><div id="i8040488224cd40d194fd225edca967d2_142"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="i8040488224cd40d194fd225edca967d2_145"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Chief Executive Officer, Richard A. Gonzalez, and the Chief Financial Officer, Scott T. Reents, evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie&#8217;s disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules&#160;and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Exchange Act is accumulated and communicated to AbbVie&#8217;s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in AbbVie&#8217;s internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting during the quarter ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AbbVie&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie&#8217;s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">36</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="i8040488224cd40d194fd225edca967d2_151"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information pertaining to legal proceedings is provided in Note 12 to the Condensed Consolidated Financial Statements and is incorporated by reference herein.</span></div><div id="i8040488224cd40d194fd225edca967d2_157"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:29.25pt"><span><br/></span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)&#160;Total <br/>Number&#160;of <br/>Shares&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Units) <br/>Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)&#160;Average <br/>Price&#160;Paid <br/>per&#160;Share <br/>(or&#160;Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number <br/>of&#160;Shares&#160;(or <br/>Units)&#160;Purchased <br/>as&#160;Part&#160;of&#160;Publicly <br/>Announced&#160;Plans <br/>or&#160;Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)&#160;Maximum <br/>Number&#160;(or <br/>Approximate <br/>Dollar&#160;Value)&#160;of <br/>Shares&#160;(or&#160;Units) <br/>that&#160;May&#160;Yet&#160;Be <br/>Purchased&#160;Under <br/>the&#160;Plans&#160;or <br/>Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022 - April 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$162.39</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1, 2022 - May 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.92</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022 - June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$146.78</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$161.60</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,393,714,917</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.92pt">In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan &#8211; 28,809 in April; 839 in May; and 989 in June.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">37</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_160"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt;margin-top:12pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be &#8220;filed&#8221; under the Securities Exchange Act of 1934.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex106.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex106.htm">AbbVie Non-Employee Directors&#8217; Fee Plan, as amended and restated</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex106.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex311.htm">Certification of Chief Executive Officer Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex312.htm">Certification of Chief Financial Officer Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex321.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20220630xex322.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2022, filed on August&#160;4, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)&#160;Condensed Consolidated Statements of Earnings; (ii)&#160;Condensed Consolidated Statements of Comprehensive Income; (iii)&#160;Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v)&#160;Condensed Consolidated Statements of Cash Flows; and (vi)&#160;the Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">38</span></div></td></tr></table></div></div></div><div id="i8040488224cd40d194fd225edca967d2_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ABBVIE INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott T. Reents</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott T. Reents</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;4, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">2022 Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> | </span><img src="abbv-20220630_g2.gif" alt="abbv-20220630_g2.gif" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">39</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>abbv-20220630xex106.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3623f8c192b544688d07839a359c5ac8_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit&#160;10.6</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ABBVIE NON-EMPLOYEE DIRECTORS&#8217; FEE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(Amended and Restated Effective as of May 6, 2022)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ABBVIE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NON-EMPLOYEE DIRECTORS&#8217; FEE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 1.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">PURPOSE</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This AbbVie Non-Employee Directors&#8217; Fee Plan (the &#8220;Plan&#8221;) is maintained by AbbVie Inc. (the &#8220;Company&#8221;) to attract and retain as members of its Board of Directors persons who are not full-time employees of the Company or any of its subsidiaries but whose business experience and judgment are valuable assets to the Company and its subsidiaries.  The Plan was originally adopted by the Company effective January 1, 2013, and was last amended and restated effective as of May 8, 2020.  The terms of the Plan set forth in this document shall be effective as of May 6, 2022 (the &#8220;Effective Date&#8221;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 2.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">DIRECTORS COVERED</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As used in the Plan, the term &#8220;Director&#8221; means any person serving on the Board of Directors of the Company on the Effective Date or at any time thereafter who is not a full-time employee of the Company or any of its subsidiaries.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 3.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">FEES PAYABLE TO DIRECTORS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.1&#160;&#160;&#160;&#160;Each Director shall be entitled to a deferred fee of $120,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position with the Company, excluding the month in which the Director is first elected to such position.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.2&#160;&#160;&#160;&#160;Lead Director and Executive Committee Chair Fees</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a) &#160;&#160;&#160;&#160;A Director who serves as Lead Director for the Board of Directors shall be entitled to a deferred fee of $50,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;A Director who serves as Chair of the Executive Committee of the Board of Directors shall be entitled to a deferred fee of $20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.3&#160;&#160;&#160;&#160;Audit Committee Fees</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;A Director who serves as Chair of the Audit Committee of the Board of Directors shall be entitled to a deferred fee of $30,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Each Director who serves on the Audit Committee of the Board of Directors (other than the Chair of the Audit Committee) shall be entitled to a deferred fee of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$10,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.4&#160;&#160;&#160;&#160;A Director who serves as Chair of the Compensation Committee of the Board of Directors shall be entitled to a deferred fee of $20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.5&#160;&#160;&#160;&#160;A Director who serves as Chair of the Nominations Committee of the Board of Directors shall be entitled to a deferred fee of $20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.6&#160;&#160;&#160;&#160;A Director who serves as Chair of any other Committee created by the Board of Directors shall be entitled to a deferred fee of $25,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.7&#160;&#160;&#160;&#160;A Director&#8217;s Deferred Fee Account shall be credited with interest annually. The rate of interest credited to deferred fees shall be equal to&#58; (a) the average of the &#8220;prime rate&#8221; of interest set forth on the Bloomberg Screen BTMM or comparable successor quotation service on the first business day of January and the last business day of each month of the fiscal year&#59; plus (b) two hundred twenty-five (225) basis points.  For purposes of this provision, the term &#8220;deferred fees&#8221; shall include &#8220;deferred monthly fees,&#8221; and &#8220;deferred meeting fees,&#8221; and shall also include any such interest credited thereon.  </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.8&#160;&#160;&#160;&#160;For purposes of Sections 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6, the automatic deferral of the fees specified therein shall be subject to a Director&#8217;s election to receive such fees currently pursuant to Section 4.1 or Section 8.1 of the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 4.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">PAYMENT OF DIRECTORS&#8217; FEES</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.1&#160;&#160;&#160;&#160;Any Director may, by written notice filed with the Secretary of the Company no later than December 31 in a calendar year, elect to receive current payment of all or any portion of the monthly and meeting fees earned by him in calendar years subsequent to the calendar year in which he files such notice, in which case such fees shall not be deferred but shall be paid quarterly as earned and no interest shall be credited thereon.  Such election shall be irrevocable as of December 31 of the year prior to the year in which the fees will be earned. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding the timing requirements described above, an individual who is newly elected as a Director may make the election described above by filing it with the Secretary of the Company within the thirty (30) day period immediately following the date he or she first becomes a Director eligible to participate in the Plan (and all plans that would be aggregated with the Plan pursuant to Treasury Regulation &#167;1.409A-1(c)(2)(i)), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">compensation subject to such election relates solely to services performed after the date of such election and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that such election shall become irrevocable on the thirtieth day following the date he or she first becomes a Director eligible to participate in the Plan.  In no event shall the fees subject to an election under this Section 4.1 be paid later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as such term is defined in Treasury Regulation &#167;1.409A-1(b)(4)(i)(A).  Any Director who has previously provided notice pursuant to this Section 4.1 may, by written notice filed with the Secretary of the Company no later than December 31 in a calendar year, elect to defer payment of all or a portion of the monthly and meeting fees earned by him in calendar years subsequent to the year in which he files such notice, in which case such fees shall be paid to him in accordance with Section 4.2 below.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.2&#160;&#160;&#160;&#160;A Director&#8217;s deferred fees earned pursuant to the Plan shall commence to be paid on the first day of the calendar month next following the earlier of his death or his attainment of age sixty-five (65) if he is not then serving as a Director, or the termination of his service as a Director if he serves as a Director after the attainment of age sixty-five (65).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.3&#160;&#160;&#160;&#160;A Director&#8217;s deferred fees that have commenced to be payable pursuant to Section 4.2 shall be payable in annual installments in the order in which they shall have been deferred (i.e., the deferred fees and earnings thereon for the earliest year of service as a Director will be paid on the date provided for in Section 4.2, the deferred fees for the next earliest year of service as a Director will be paid on the anniversary of the payment of the first installment, etc.).  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.4&#160;&#160;&#160;&#160;A Director&#8217;s deferred fees shall continue to be paid until all deferred fees which he is entitled to receive under the Plan shall have been paid to him (or, in case of his death, to his beneficiary).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.5&#160;&#160;&#160;&#160;If a Director incurs a termination of service as a Director within two (2) years following the occurrence of a Change in Control (as defined below), the aggregate unpaid balance of such Director&#8217;s deferred fees plus all unpaid interest credited thereon shall be paid to such Director in a lump sum within thirty (30) days following the date of such termination of service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that if such Change in Control does not constitute a &#8220;change in control event&#8221; (as defined in Treasury Regulation &#167;1.409A-3(i)(5)), then the aggregate unpaid balance of such Director&#8217;s deferred fees shall be paid in accordance with Sections 4.2 and 4.3.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding any other provision of the Plan, if a Director has made the alternative election set forth in Section 8.1, and if such Director incurs a termination of service as a Director within five (5) years following the occurrence of a Change in Control, the aggregate unpaid balance of such Director&#8217;s fees deposited to the Director&#8217;s Grantor Trust (as defined below) plus all unpaid interest credited thereon, shall be paid to such Director from the Director&#8217;s Grantor Trust in a lump sum within thirty (30) days following the date of such termination of service.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.6&#160;&#160;&#160;&#160;A &#8220;Change in Control&#8221; shall be deemed to have occurred on the earliest of the following dates&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;the date any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 20% or more of the combined voting power of the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (i) of paragraph (c) below&#59; or</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;the date the following individuals cease for any reason to constitute a majority of the number of directors then serving&#58; individuals who, on the Effective Date, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board of Directors or nomination for election by the Company&#8217;s stockholders was approved or recommended by a vote of at least two-thirds (2&#47;3) of the directors then still in office who either were directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended&#59; or</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;the date on which there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, other than (i) a merger or consolidation (A) immediately following which the individuals who comprise the Board of Directors immediately prior thereto constitute at least a majority of the Board of Directors of the Company, the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger or consolidation is then a subsidiary, the ultimate parent thereof and (B) which results in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 20% or more of the combined voting power of the Company&#8217;s then outstanding securities&#59; or</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;the date the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by stockholders of the Company, in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, in substantially the same proportions as their ownership of the Company immediately prior to such sale.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">immediately prior to such transaction or series of transactions continue to have</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For purposes of this Plan&#58; &#8220;Affiliate&#8221; shall have the meaning set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act&#59; &#8220;Beneficial Owner&#8221; shall have the meaning set forth in Rule 13d-3 under the Exchange Act&#59; &#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time&#59; and &#8220;Person&#8221; shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.7&#160;&#160;&#160;&#160;A &#8220;Potential Change in Control&#8221; shall exist during any period in which the circumstances described in paragraph (a), (b), (c) or (d), below, exist (provided, however, that a Potential Change in Control shall cease to exist not later than the occurrence of a Change in Control)&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;The Company enters into an agreement, the consummation of which would result in the occurrence of a Change in Control, provided that a Potential Change in Control described in this paragraph (a) shall cease to exist upon the expiration or other termination of all such agreements.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Any Person (without regard to the exclusions set forth in clauses (i) through (iv) of such definition) publicly announces an intention to take or to consider taking actions the consummation of which would constitute a Change in Control&#59; provided that a Potential Change in Control described in this paragraph (b) shall cease to exist upon the withdrawal of such intention, or upon a determination by the Board of Directors that there is no reasonable chance that such actions would be consummated.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 10% or more of either the then outstanding shares of common stock of the Company or the combined voting power of the Company&#8217;s then outstanding securities (not including any securities beneficially owned by such Person which are or were acquired directly from the Company or its Affiliates).</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;The Board of Directors adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control exists&#59; provided that a Potential Change in Control described in this paragraph (d) shall cease to exist upon a determination by the Board of Directors that the reasons that gave rise to the resolution providing for the existence of a Potential Change in Control have expired or no longer exist.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.8&#160;&#160;&#160;&#160;The provisions of Sections 4.5, 4.6, 4.7 and this Section 4.8 may not be amended or deleted, nor superseded by any other provision of this Plan, (i) during the pendency of a Potential Change in Control and (ii) during the period beginning on the date of a Change in Control and ending on the date five (5) years following such Change in Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 5.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">CONVERSION TO COMMON STOCK UNITS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.1&#160;&#160;&#160;&#160;Any Director who is then serving as a director may, by written notice filed with the Secretary of the Company, irrevocably elect to have all or any portion of deferred fees previously earned but not yet paid, transferred from the Director&#8217;s Deferred Fee Account to a stock account established under this Section 5 (&#8220;Stock Account&#8221;). Any election as to a portion of such fees shall be expressed as a percentage and the same percentage shall be applied to all such fees regardless of the calendar year in which earned or to all deferred fees earned in designated calendar years, as specified by the Director. A Director may make no more than one notional investment election under this Section 5.l in any calendar year. All such elections may apply only to deferred fees for which an election has not previously been made and shall be irrevocable.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.2&#160;&#160;&#160;&#160;Any Director may, by written notice filed with the Secretary of the Company, elect to have all or any portion of deferred fees earned subsequent to the date such notice is filed credited to a Stock Account established under this Section 5. Fees covered by such election shall be credited to such account at the end of each calendar quarter in, or for which, such fees are earned. Such election may be revoked or modified by such Director, by written notice filed with the Secretary of the Company, as to deferred fees to be earned in calendar years subsequent to the calendar year such notice is filed, but shall be irrevocable as to deferred fees earned prior to such year.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.3&#160;&#160;&#160;&#160;Deferred fees credited to a Stock Account under Section 5.1 shall be converted to Common Stock Units by dividing the deferred fees so credited by the closing price of common stock of the Company on the date the notice of election under Section 5 is received by the Company (or the next business day, if there are no sales on such date) as reported on the New York Stock Exchange Composite Reporting System. Deferred fees credited to a Stock Account under Section 5.2 shall be converted to Common Stock Units by dividing the deferred fees so credited by the closing price of common stock of the Company as of the last business day of the calendar quarter for which the credit is made, as reported on the New York Stock Exchange Composite Reporting System.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.4&#160;&#160;&#160;&#160;Each Common Stock Unit shall be credited with (or adjusted for) the same cash and stock dividends, stock splits and other distributions and adjustments as are received by or applicable to one share of common stock of the Company. All cash dividends and other cash distributions credited to Common Stock Units shall be converted to additional Common Stock Units by dividing each such dividend or distribution by the closing price of common stock of the Company on the payment date for such dividend or distribution, as reported by the New York Stock Exchange Composite Reporting System.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.5&#160;&#160;&#160;&#160;The value of the Common Stock Units credited each Director shall be paid to the Director in cash on the dates specified in Section 4.3 (or, if applicable, Section 4.5). The amount of each payment shall be determined by multiplying the Common Stock Units payable on each date specified in Section 4.3 (or, if applicable, Section 4.5) by the closing price of common stock of the Company on the day prior to the payment date (or the next preceding business day if there are no sales on such date), as reported by the New York Stock Exchange Composite Reporting System.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 6.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">MISCELLANEOUS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.1&#160;&#160;&#160;&#160;Each Director or former Director entitled to payment of deferred fees hereunder from time to time may name any person or persons (who may be named contingently or successively) to whom any deferred Director&#8217;s fees earned by him and payable to him are to be paid in case of his death before he receives any or all of such deferred Director&#8217;s fees.  Each designation will revoke all prior designations by the same Director or former Director, shall be in a form prescribed by the Company, and will be effective only when filed by the Director or former Director in writing with the Secretary of the Company during his lifetime. If a deceased Director or former Director shall have failed to name a beneficiary in the manner provided above, or if the beneficiary named by a deceased Director or former Director dies before him or before payment of all the Director&#8217;s or former Director&#8217;s deferred Directors&#8217; fees, the Company, in its discretion, may direct payment of the remaining installments required by Section 4.3 to either&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;any one or more or all of the next of kin (including the surviving spouse) of the Director or former Director, and in such proportions as the Company determines&#59; or</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;the legal representative or representatives of the estate of the last to die of the Director or former Director and his last surviving beneficiary.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The person or persons to whom any deceased Director&#8217;s or former Director&#8217;s deferred Directors&#8217; fees are payable under this Section will be referred to as his &#8220;beneficiary.&#8221;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.2&#160;&#160;&#160;&#160;Establishment of the Plan and coverage thereunder of any person shall not be construed to confer any right on the part of such person to be nominated for reelection to the Board of Directors of the Company, or to be reelected to the Board of Directors.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.3&#160;&#160;&#160;&#160;Payment of deferred Directors&#8217; fees will be made only to the person entitled thereto in accordance with the terms of the Plan, and deferred Directors&#8217; fees are not in any way subject to the debts or other obligations of persons entitled thereto, and may not be voluntarily or involuntarily sold, transferred or assigned. When a person entitled to a payment under the Plan is under legal disability or, in the Company&#8217;s opinion, is in any way incapacitated so as to be unable to manage his financial affairs, the Company may direct that payment be made to such person&#8217;s legal representative, or to a relative or friend of such person for his benefit. Any payment made in accordance with the preceding sentence shall be in complete discharge of the Company&#8217;s obligation to make such payment under the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.4&#160;&#160;&#160;&#160;Any action required or permitted to be taken by the Company under the terms of the Plan shall be by affirmative vote of a majority of the members of the Board of Directors then in office.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.5&#160;&#160;&#160;&#160;To the extent applicable, it is intended that the Plan comply with the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;Code Section 409A&#8221;).  The Plan will be administered and interpreted in a manner consistent with this intent, and any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">provision that would cause the Plan to fail to satisfy Code Section 409A will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent permitted by Code Section 409A).  Notwithstanding anything contained herein to the contrary, for all purposes of this Plan, a Director shall not be deemed to have had a termination of service as a Director until the Director has incurred a separation from service as defined in Treasury Regulation &#167;1.409A-1(h) and, to the extent required to avoid accelerated taxation and&#47;or tax penalties under Code Section 409A and applicable guidance issued thereunder, payment of the amounts payable under the Plan that would otherwise be payable during the six-month period after the date of termination shall instead be paid on the first business day after the expiration of such six-month period, plus interest thereon, at a rate equal to the rate specified in Section 8.8 (to the extent that such interest is not already provided to the Director under Section 8.10), from the respective dates on which such amounts would otherwise have been paid until the actual date of payment.  In addition, for purposes of the Plan, each amount to be paid and each installment payment shall be construed as a separate identified payment for purposes of Code Section 409A.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 7.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">AMENDMENT AND DISCONTINUANCE</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">While the Company expects to continue the Plan, it must necessarily reserve, and does hereby reserve, the right to amend or discontinue the Plan at any time&#59; provided, however, that any amendment or discontinuance of the Plan shall be prospective in operation only, and shall not affect the payment of any deferred Directors&#8217; fees theretofore earned by any Director, or the conditions under which any such fees are to be paid or forfeited under the Plan. Any discontinuance of the Plan by the Company shall comply with the requirements of Code Section 409A.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 8.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ALTERNATE PAYMENT OF FEES</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.1&#160;&#160;&#160;&#160;A Director who was first elected or appointed to the Board of Directors before January 1, 2016 may, by written notice filed with the Secretary of the Company prior to each calendar year, elect to receive all or a portion of his fees earned in the following calendar year in accordance with the provisions of Section 8.  An election under this Section 8.1 shall become irrevocable as of December 31 of the calendar year prior to the year in which such monthly and meeting fees will be earned (or, in the case of a new Director elected or appointed before January 1, 2016, on the 30th day following the Director&#8217;s first participation in the Plan and all plans that would be aggregated with the Plan pursuant to Treasury Regulation  &#167;1.409A-1(c)(2)(i), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> that the compensation subject to such election relates solely to services performed after the date of such election).  </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.2&#160;&#160;&#160;&#160;If payment of a Director&#8217;s fees is made pursuant to Section 8.1, such fees shall not be deferred and a portion of the gross amount of such fees shall be paid currently in cash for the Director directly to a &#8220;Grantor Trust&#8221; established by the Director, provided such trust is in a form determined by the Committee&#59; and the balance of the gross amount of such fees shall be paid currently in cash directly to the Director, provided that the portion paid directly to the Director shall be an amount equal to the aggregate federal, state and local individual income taxes attributable to the gross fees paid pursuant to this Section 8.2 (determined in accordance with Section 8.14).  In no event shall such fees be paid to the Grantor Trust or directly to the Director </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as such term is defined in Treasury Regulation &#167;1.409A-1(b)(4)(i)(A).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.3&#160;&#160;&#160;&#160;The Company will establish and maintain four separate accounts in the name of each Director who has made an election under Section 8.1 as follows&#58; a &#8220;Pre-Tax Fee Account,&#8221; an &#8220;After-Tax Fee Account,&#8221; a &#8220;Pre-Tax Stock Account&#8221; and an &#8220;After-Tax Stock Account&#8221; (collectively, the &#8220;Accounts&#8221;).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;The Pre-Tax Fee Account shall reflect the total amount of any fees paid in cash to a Director or deposited to a Director&#8217;s Grantor Trust, including the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2, and Interest to be credited to a Director pursuant to Section 8.8.  The After-Tax Fee Account shall reflect such gross amounts but shall be maintained on an after-tax basis. </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;The Pre-Tax Stock Account shall reflect the total amount of fees converted to Common Stock Units pursuant to Section 5, including the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2, and any adjustments made pursuant to Section 8.9. The After-Tax Stock Account shall reflect such gross amounts but shall be maintained on an after-tax basis. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;The Accounts established pursuant to this Section 8.3 are for the convenience of the administration of the Plan and no trust relationship with respect to such Accounts is intended or should be implied.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.4&#160;&#160;&#160;&#160;As of the end of each calendar year, the Company shall adjust each Director&#8217;s Pre-Tax Fee Account as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the distribution from the fee account maintained thereunder that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the gross amount of any fees paid for that year, not converted to Common Stock Units, that are paid to the Director (including the amount deposited in the Director&#8217;s Grantor Trust and the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2) according to Section 8.2&#59; and</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;FINALLY, credit an amount equal to the Interest earned for that year according to Section 8.8.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.5&#160;&#160;&#160;&#160;As of the end of each calendar year, the Company shall adjust each Director&#8217;s After-Tax Fee Account as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;FIRST, charge, in any year in which the Director is in receipt of a benefit distribution from his or her Grantor Trust, an amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3, multiplied by (ii) a fraction, the numerator of which is the balance in the Director&#8217;s After-Tax Fee Account as of the end of the prior fiscal year and the denominator of which is the balance of the Director&#8217;s Pre-Tax Fee Account as of that same date&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the fees not converted to Common Stock Units that are paid that year to the Director directly to the Director&#8217;s Grantor Trust according to Section 8.2&#59; and </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;FINALLY, credit an amount equal to the After-Tax Interest earned for that year according to Section 8.8. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.6&#160;&#160;&#160;&#160;As of the end of each calendar year, the Company shall adjust each Director&#8217;s Pre-Tax Stock Account as follows&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the distribution that would have been made to the Director if the aggregate amount of fees paid according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made under Section 5&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the total amount of any fees for that year that are converted to Common Stock Units and paid to the Director (including the amount deposited in the Director&#8217;s Grantor Trust and the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2) and allocated to the Stock Account maintained thereunder) according to Section 8.2&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the net earnings of the Director&#8217;s Grantor Trust for the year&#59; and</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.7&#160;&#160;&#160;&#160;As of the end of each calendar year, the Company shall adjust each Director&#8217;s After-Tax Stock Account as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made under Section 5, multiplied by (ii) a fraction, the numerator of which is the balance in the Director&#8217;s After-Tax Stock Account as of the end of the prior fiscal year and the denominator of which is the balance of the Director&#8217;s Pre-Tax Stock Account as of that same date&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the fees converted to Common Stock Units that are paid that year to the Director directly to the Director&#8217;s Grantor Trust and allocated to the Stock Account maintained thereunder according to Section 8.2&#59; and </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;NEXT, credit an amount equal to the net earnings of the Director&#8217;s Grantor Trust for the year&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9. </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.8&#160;&#160;&#160;&#160;The Director&#8217;s Pre-Tax Fee Account and After-Tax Fee Account shall be credited with interest as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;As of the end of each calendar year, a Director&#8217;s Pre-Tax Fee Account shall be credited with interest (&#8220;Interest&#8221;) at the following rate&#58;</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;the average of the &#8220;prime rate&#8221; of interest set forth on the Bloomberg Screen BTMM or comparable successor quotation service on the first business day of January and the last business day of each month of the fiscal year&#59; plus</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;two hundred twenty-five (225) basis points.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;As of the end of each calendar year, a Director&#8217;s After-Tax Fee Account shall be credited with the amount of Interest set forth above, multiplied by (one minus the aggregate of the applicable federal, state and local individual income tax rates and employment tax rate) (the &#8220;After-Tax Interest&#8221;).</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.9&#160;&#160;&#160;&#160;As of the end of each calendar year, a Director&#8217;s Pre-Tax Stock Account and After-Tax Stock Account shall be adjusted as provided in Section 5.4, to the extent applicable, and shall also be adjusted to reflect the increase or decrease in the fair market value of the Company&#8217;s common stock determined in accordance with Section 5.5, except that (i) any reference to the payment date in such Section shall mean December 31 of the applicable calendar year for purposes of this Section, and (ii) adjustments to the After-Tax Stock Account shall be made on an after-tax basis.  Such adjustments shall be referred to as &#8220;Book Value Adjustments.&#8221;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.10&#160;&#160;&#160;&#160;In addition to any fees paid to a Director&#8217;s Grantor Trust under Section 8.2 during the year, the Company shall also make a payment (an &#8220;Interest Payment&#8221;) with respect to each Director who has established a Grantor Trust for each year in which the Grantor Trust is in effect.  The Interest Payment shall equal the excess, if any, of the gross amount of the Interest credited to the Director (as defined in Section 8.8(a)), over the net earnings of the Director&#8217;s Grantor Trust for the year, and shall be paid within the thirty (30)-day period beginning April 1 of the following calendar year.  A portion of such gross Interest Payment, equal to the excess, if any, of the Net Interest Accrual over the net earnings of the Director&#8217;s Grantor Trust, shall be deposited in the Director&#8217;s Grantor Trust, with the balance paid to the Director&#59; provided, however, in the event that the net earnings of the Director&#8217;s Grantor Trust exceeds the Net Interest Accrual, a distribution from the Grantor Trust shall be required in accordance with Section 8.15.  A Director&#8217;s Net Interest Accrual for a year is an amount equal to the After-Tax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Interest credited to the Director&#8217;s After-Tax Fee Account for that year in accordance with Section 8.8(b).  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.11&#160;&#160;&#160;&#160;In addition to the fees paid under Section 8.2 during the year and the Interest Payment described above, the Company shall also make a payment (a &#8220;Principal Payment&#8221;) with respect to each Director who has established a Grantor Trust for each year in which the Grantor Trust is in effect, to be credited to the Stock Account maintained thereunder.   The Principal Payment shall equal the excess, if any, of 75 percent of the fair market value (as determined in accordance with Section 6.5) of the balance of the Director&#8217;s Pre-Tax Stock Account on December 31 over the balance in the Stock Account maintained under the Director&#8217;s Grantor Trust as of that same date, and shall be paid within the thirty (30)-day period beginning April 1 of the following calendar year.  For the calendar year in which the last installment distribution is made from the Director&#8217;s Grantor Trust (meaning, the year that is X years following the year of the event triggering the payments, where X is the same number of years served by the Director), the payment made under this Section 8.11 shall equal the excess, if any, of 100 percent of the balance of the Director&#8217;s After-Tax Stock Account over the balance in the Stock Account maintained under the Director&#8217;s Grantor Trust as of that same date.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.12&#160;&#160;&#160;&#160;Each Director&#8217;s Grantor Trust assets shall be invested solely in the instruments specified by investment guidelines established by the Committee.  Such investment guidelines, once established, may be changed by the Committee, provided that any change shall not take effect until the year following the year in which the change is made and provided further that the instruments specified shall be consistent with the provisions of Section 3(b) of the form of Grantor Trust established by the Committee.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.13&#160;&#160;&#160;&#160;For purposes of Section 8, a Director&#8217;s federal income tax rate shall be deemed to be the highest marginal rate of federal individual income tax in effect in the calendar year in which a calculation under this Section is to be made and state and local tax rates shall be deemed to be the highest marginal rates of individual income tax in effect in the state and locality of the Director&#8217;s residence on the date such a calculation is made, net of any federal tax benefits without a benefit for any net capital losses. Notwithstanding the preceding sentence, if a Director is not a citizen or resident of the United States, his or her income tax rates shall be deemed to be the highest marginal income tax rates actually imposed on the Director&#8217;s benefits under this Plan or earnings under his or her Grantor Trust without a benefit for any net capital losses.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.14&#160;&#160;&#160;&#160;If a portion of a Director&#8217;s fees have been paid to a Grantor Trust pursuant to Section 8.2, then those fees and earnings thereon shall be paid to him from the Grantor Trust in the order in which they were earned (i.e., the fees for the earliest year of service as a Director will be the first fees distributed from the Grantor Trust(s), the fees for the next earliest year of service as a Director will be paid on the anniversary of the payment of the first installment, etc.).  The distribution of a Director&#8217;s fees shall continue until all fees which the Director is entitled to receive under the Plan shall have been paid in accordance with the terms of the Grantor Trust(s).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.15     AbbVie, as the administrator of the Director&#8217;s Grantor Trust, may direct the trustee to distribute to the Director from the income of such Grantor Trust, a sum of money sufficient to pay the taxes on trust earnings for such year, to the extent a sufficient sum of money has not been paid to the Director pursuant to Section 8.10 or 8.11, as applicable.  The taxes shall be determined in accordance with Section 8.13.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.16     AbbVie, as the administrator of the Director&#8217;s Grantor Trust, may direct the trustee to pay the appropriate federal, state and local individual income taxes attributable to the fees and other payments paid to the Director pursuant to Sections 8.2, 8.10 and 8.11 to the applicable tax authorities on behalf of the Director.  The taxes shall be determined in accordance with Section 8.13.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>abbv-20220630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1ae694b0cc8147859906a357b63b24bf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a))</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard A. Gonzalez, certify that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of AbbVie Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for AbbVie and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in AbbVie&#8217;s internal control over financial reporting that occurred during AbbVie&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie&#8217;s auditors and the audit committee of AbbVie&#8217;s board of directors&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Gonzalez, Chairman of the Board</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>abbv-20220630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7d3d59635654481c9f91f57036b211bd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule&#160;13a-14(a)&#160;(17 CFR 240.13a-14(a))</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott T. Reents, certify that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of AbbVie Inc.&#59;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for AbbVie and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of AbbVie&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in AbbVie&#8217;s internal control over financial reporting that occurred during AbbVie&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;AbbVie&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie&#8217;s auditors and the audit committee of AbbVie&#8217;s board of directors&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott T. Reents</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott T. Reents, Senior Vice President,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>abbv-20220630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9eeac2a23764496cbf256693fa1d09ac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbbVie Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Gonzalez</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>abbv-20220630xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4ccb86e09904449296771388317a9ad3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbbVie Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, Scott T. Reents, Senior Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott T. Reents</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott T. Reents</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>abbv-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abbv="http://www.abbvie.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abbvie.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.abbvie.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarningsUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEquityUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.abbvie.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.abbvie.com/role/BasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformation">
        <link:definition>2103102 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationTables">
        <link:definition>2304301 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationDetails" roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails">
        <link:definition>2405402 - Disclosure - Supplemental Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.abbvie.com/role/EarningsPerShare">
        <link:definition>2106103 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.abbvie.com/role/EarningsPerShareTables">
        <link:definition>2307302 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.abbvie.com/role/EarningsPerShareDetails">
        <link:definition>2408403 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAcquisitionsandOtherArrangements" roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements">
        <link:definition>2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAcquisitionsandOtherArrangementsDetails" roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails">
        <link:definition>2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.abbvie.com/role/Collaborations">
        <link:definition>2111105 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsTables" roleURI="http://www.abbvie.com/role/CollaborationsTables">
        <link:definition>2312303 - Disclosure - Collaborations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsDetails" roleURI="http://www.abbvie.com/role/CollaborationsDetails">
        <link:definition>2413405 - Disclosure - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssets">
        <link:definition>2114106 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2315304 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillDetails" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails">
        <link:definition>2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails">
        <link:definition>2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlans" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlans">
        <link:definition>2118107 - Disclosure - Integration and Restructuring Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlansTables" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables">
        <link:definition>2319305 - Disclosure - Integration and Restructuring Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntegrationandRestructuringPlansDetails" roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails">
        <link:definition>2420408 - Disclosure - Integration and Restructuring Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasures" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures">
        <link:definition>2121108 - Disclosure - Financial Instruments and Fair Value Measures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresTables" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables">
        <link:definition>2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails">
        <link:definition>2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails">
        <link:definition>2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails">
        <link:definition>2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails">
        <link:definition>2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails">
        <link:definition>2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails">
        <link:definition>2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails">
        <link:definition>2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails">
        <link:definition>2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefits" roleURI="http://www.abbvie.com/role/PostEmploymentBenefits">
        <link:definition>2131109 - Disclosure - Post-Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsTables" roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsTables">
        <link:definition>2332307 - Disclosure - Post-Employment Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsDetails" roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails">
        <link:definition>2433417 - Disclosure - Post-Employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.abbvie.com/role/Equity">
        <link:definition>2134110 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.abbvie.com/role/EquityTables">
        <link:definition>2335308 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockBasedCompensationDetails" roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails">
        <link:definition>2436418 - Disclosure - Equity - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockOptionsDetails" roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails">
        <link:definition>2437419 - Disclosure - Equity - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityRSUsandPerformanceSharesDetails" roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails">
        <link:definition>2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityCashDividendsDetails" roleURI="http://www.abbvie.com/role/EquityCashDividendsDetails">
        <link:definition>2439421 - Disclosure - Equity - Cash Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockRepurchaseProgramDetails" roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails">
        <link:definition>2440422 - Disclosure - Equity - Stock Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.abbvie.com/role/IncomeTaxes">
        <link:definition>2143111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.abbvie.com/role/IncomeTaxesDetails">
        <link:definition>2444425 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsandContingencies" roleURI="http://www.abbvie.com/role/LegalProceedingsandContingencies">
        <link:definition>2145112 - Disclosure - Legal Proceedings and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsandContingenciesDetails" roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails">
        <link:definition>2446426 - Disclosure - Legal Proceedings and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.abbvie.com/role/SegmentInformation">
        <link:definition>2147113 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.abbvie.com/role/SegmentInformationTables">
        <link:definition>2348309 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>2449427 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDisaggregationofRevenueDetails" roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails">
        <link:definition>2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" abstract="true" name="AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" abstract="false" name="CollaborativeArrangementMilestoneMethodPaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_AllerganIntegrationPlanMember" abstract="true" name="AllerganIntegrationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SKYRIZIMember" abstract="true" name="SKYRIZIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_JuvisePharmaceuticalsMember" abstract="true" name="JuvisePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_BotoxCosmeticMember" abstract="true" name="BotoxCosmeticMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherKeyProductsMember" abstract="true" name="OtherKeyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_BystolicAntitrustLitigationMember" abstract="true" name="BystolicAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ElliottAssociatesL.P.Member" abstract="true" name="ElliottAssociatesL.P.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" abstract="false" name="RestructuringReservePeriodCashSettledAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" abstract="true" name="ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" abstract="false" name="AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abbv_AlphaganCombiganMember" abstract="true" name="AlphaganCombiganMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PrincipalUSCustomersMember" abstract="true" name="PrincipalUSCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" abstract="false" name="LossContingencyIndividualPlaintiffLawsuitsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_SeniorNotesDue2022At3.250PercentMember" abstract="true" name="SeniorNotesDue2022At3.250PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AestheticsMember" abstract="true" name="AestheticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_DuodopaMember" abstract="true" name="DuodopaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_MAVYRETMember" abstract="true" name="MAVYRETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1.250SeniorNotesdue2031Member" abstract="true" name="Sec1.250SeniorNotesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" abstract="false" name="ResearchAndDevelopmentExpenseFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" abstract="false" name="CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abbv_ImbruvicaMember" abstract="true" name="ImbruvicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherAestheticsMember" abstract="true" name="OtherAestheticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RINVOQMember" abstract="true" name="RINVOQMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SeniorNotesDue2022At3.450PercentMember" abstract="true" name="SeniorNotesDue2022At3.450PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec0.750SeniorNotesDue2027Member" abstract="true" name="Sec0.750SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" abstract="true" name="AccumulatedNetGainLossFromNetInvestmentHedgesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" abstract="false" name="TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_RestasisMember" abstract="true" name="RestasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec2625SeniorNotesDue2028Member" abstract="true" name="Sec2625SeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SeniorNotes2.30PercentDue2021Member" abstract="true" name="SeniorNotes2.30PercentDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SupplementalFinancialInformationDisclosureAbstract" abstract="true" name="SupplementalFinancialInformationDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_ProjectedYearofPaymentsMember" abstract="true" name="ProjectedYearofPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" abstract="false" name="OtherComprehensiveIncomeLossNetInvestmentHedgeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_NumberOfPrincipalUSCustomers" abstract="false" name="NumberOfPrincipalUSCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_LossContingencyPurportedClassActionsNumber" abstract="false" name="LossContingencyPurportedClassActionsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_JuvedermCollectionMember" abstract="true" name="JuvedermCollectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_UbrelvyMember" abstract="true" name="UbrelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec2.125SeniorNotesdue2028Member" abstract="true" name="Sec2.125SeniorNotesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" abstract="false" name="CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abbv_HematologicOncologyMember" abstract="true" name="HematologicOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_KeyProductPortfolioAxis" abstract="true" name="KeyProductPortfolioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abbv_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_EyeCareMember" abstract="true" name="EyeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1250SeniorNotesDue2024Member" abstract="true" name="Sec1250SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_QuliptaMember" abstract="true" name="QuliptaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_VraylarMember" abstract="true" name="VraylarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SeniorEuroNotesDue2021At0.500PercentMember" abstract="true" name="SeniorEuroNotesDue2021At0.500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_SyndesiMember" abstract="true" name="SyndesiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_NiaspanMember" abstract="true" name="NiaspanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LumiganGanfortMember" abstract="true" name="LumiganGanfortMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" abstract="false" name="ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" abstract="false" name="CostofGoodsAndServicesSoldFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" abstract="false" name="LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_December2018StockRepurchaseAuthorizationMember" abstract="true" name="December2018StockRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_Sec1.375SeniorNotesDue2024Member" abstract="true" name="Sec1.375SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforUnachievedMilestonesMember" abstract="true" name="ProbabilityofPaymentforUnachievedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_KeyProductPortfolioDomain" abstract="true" name="KeyProductPortfolioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" abstract="false" name="LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_PutativeClassActionLawsuitIndividualNumber" abstract="false" name="PutativeClassActionLawsuitIndividualNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abbv_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abbv_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" abstract="false" name="NonCashLitigationReserveAdjustmentsNetOfCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_Sec2125SeniorNotesDue2029Member" abstract="true" name="Sec2125SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" abstract="true" name="SeniorNotesDueInMay2021AtFloatingRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" abstract="true" name="HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" abstract="false" name="LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_OtherExpensesFromCollaborativeArrangements" abstract="false" name="OtherExpensesFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_BotoxTherapeuticMember" abstract="true" name="BotoxTherapeuticMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" abstract="true" name="PrescriptionDrugAbuseLitigationInStateCourtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_GenentechInc.Member" abstract="true" name="GenentechInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_CreonMember" abstract="true" name="CreonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherRestructuringPlansMember" abstract="true" name="OtherRestructuringPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_LinzessConstellaMember" abstract="true" name="LinzessConstellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" abstract="true" name="AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_FloatingRateTermLoanTrancheDueMay2025Member" abstract="true" name="FloatingRateTermLoanTrancheDueMay2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_HUMIRAMember" abstract="true" name="HUMIRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_VENCLEXTAMember" abstract="true" name="VENCLEXTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" abstract="false" name="ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_PrescriptionDrugAbuseLitigationMember" abstract="true" name="PrescriptionDrugAbuseLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" abstract="false" name="DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" abstract="true" name="FloatingRateTermLoanTrancheDueMay2025RefinancedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" abstract="true" name="ProbabilityofPaymentforRoyaltiesbyIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_OtherEyeCareMember" abstract="true" name="OtherEyeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_PotentialPaymentsUnderAgreementCertainMilestones" abstract="false" name="PotentialPaymentsUnderAgreementCertainMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_Sec1500SeniorNotesDue2023Member" abstract="true" name="Sec1500SeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abbv_RestructuringReserveCashSettledRestructuringGainsLosses" abstract="false" name="RestructuringReserveCashSettledRestructuringGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" abstract="false" name="SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>abbv-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofEarningsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de254bed-b3e9-45d1-9a18-7dd4343b582e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69188593-b666-4e8f-88a9-213c59b04974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_de254bed-b3e9-45d1-9a18-7dd4343b582e" xlink:to="loc_us-gaap_ProfitLoss_69188593-b666-4e8f-88a9-213c59b04974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4975810e-a1e2-4fdc-bb44-70a0b05ba286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_de254bed-b3e9-45d1-9a18-7dd4343b582e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4975810e-a1e2-4fdc-bb44-70a0b05ba286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c487e38-dd78-46d7-a30c-d492c9165a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5cfbe247-9564-4a70-8414-095b749758e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c487e38-dd78-46d7-a30c-d492c9165a7b" xlink:to="loc_us-gaap_OperatingIncomeLoss_5cfbe247-9564-4a70-8414-095b749758e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f711775a-45aa-46da-8430-96b56ece0045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c487e38-dd78-46d7-a30c-d492c9165a7b" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f711775a-45aa-46da-8430-96b56ece0045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f3122c99-18c4-49bd-8049-eb839d78c00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c487e38-dd78-46d7-a30c-d492c9165a7b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f3122c99-18c4-49bd-8049-eb839d78c00d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_acc4b934-aaec-487c-97c5-29ffa6615c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c487e38-dd78-46d7-a30c-d492c9165a7b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_acc4b934-aaec-487c-97c5-29ffa6615c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ec21e8b2-7d21-4864-b381-b533cfd8387c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b33b8d6b-1a4e-42cd-9411-37aafec1f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ec21e8b2-7d21-4864-b381-b533cfd8387c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b33b8d6b-1a4e-42cd-9411-37aafec1f6bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71199d62-d9a5-4de1-af1c-51a29b74b69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ec21e8b2-7d21-4864-b381-b533cfd8387c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71199d62-d9a5-4de1-af1c-51a29b74b69e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cf28077c-a717-48c5-83d9-d016b502384e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8c3d469a-eeed-44b0-a0be-d96a5ed65933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cf28077c-a717-48c5-83d9-d016b502384e" xlink:to="loc_us-gaap_CostsAndExpenses_8c3d469a-eeed-44b0-a0be-d96a5ed65933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e8a72b20-4d6b-4db0-a341-fe60c2c40fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cf28077c-a717-48c5-83d9-d016b502384e" xlink:to="loc_us-gaap_Revenues_e8a72b20-4d6b-4db0-a341-fe60c2c40fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8e82b9f8-d40b-4eb5-8604-104626147bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8e82b9f8-d40b-4eb5-8604-104626147bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94cab59a-5843-4782-8c9f-8c70102a672c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94cab59a-5843-4782-8c9f-8c70102a672c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e60dcff5-a1d3-467c-a204-aaff7af8e22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e60dcff5-a1d3-467c-a204-aaff7af8e22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ce916148-eefb-4342-8555-a92af94600ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ce916148-eefb-4342-8555-a92af94600ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_76fa570a-cd60-4842-bc34-46d7710c9fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b077a4a6-e987-4920-a517-28238bc5c733" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_76fa570a-cd60-4842-bc34-46d7710c9fdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_79959f57-3a84-4fde-8e4e-07554d9329be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_307e0730-0c32-4061-ab7d-3616b4953266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_79959f57-3a84-4fde-8e4e-07554d9329be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_307e0730-0c32-4061-ab7d-3616b4953266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b29df35d-b03d-43a5-a33e-467064025326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_79959f57-3a84-4fde-8e4e-07554d9329be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b29df35d-b03d-43a5-a33e-467064025326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4ff8a367-7fcd-4135-9ea5-c5218bfc5925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_79959f57-3a84-4fde-8e4e-07554d9329be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4ff8a367-7fcd-4135-9ea5-c5218bfc5925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_9f73f8ce-1a57-4ad4-a6a4-4932f8a94515" xlink:href="abbv-20220630.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_79959f57-3a84-4fde-8e4e-07554d9329be" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_9f73f8ce-1a57-4ad4-a6a4-4932f8a94515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_752fa676-7f92-4ede-81cb-40e50d99d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_77c5e6b8-9aa4-4709-8112-811362bc07d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_752fa676-7f92-4ede-81cb-40e50d99d83d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_77c5e6b8-9aa4-4709-8112-811362bc07d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_feb5afac-604d-4398-ac6a-64ffc171f28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_752fa676-7f92-4ede-81cb-40e50d99d83d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_feb5afac-604d-4398-ac6a-64ffc171f28b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd703787-ccb8-4cf8-9710-205496b0367f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5d509c33-922d-4149-bd29-c1fe3e65ba83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd703787-ccb8-4cf8-9710-205496b0367f" xlink:to="loc_us-gaap_ProfitLoss_5d509c33-922d-4149-bd29-c1fe3e65ba83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_470b1167-5e60-44df-a1ca-f9f40d8105f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd703787-ccb8-4cf8-9710-205496b0367f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_470b1167-5e60-44df-a1ca-f9f40d8105f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a09aa086-d969-41b8-8467-cdda60fafafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_LiabilitiesCurrent_a09aa086-d969-41b8-8467-cdda60fafafe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_175a05fb-013d-46ce-a339-032a5d32be01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_175a05fb-013d-46ce-a339-032a5d32be01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e10871a6-33fb-4e72-9428-8c0688ba0fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e10871a6-33fb-4e72-9428-8c0688ba0fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ddd8b6b3-2d05-43cb-b024-89f7d35be8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ddd8b6b3-2d05-43cb-b024-89f7d35be8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4eb4a8ea-00c9-42da-b479-1aaff63f64cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4eb4a8ea-00c9-42da-b479-1aaff63f64cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5662841-f675-4fc1-be87-826d5b22fdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c75f9e99-b741-451c-8652-fd3e45836af7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5662841-f675-4fc1-be87-826d5b22fdf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_317bfecf-7d6f-4744-b307-88d9fc34e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_317bfecf-7d6f-4744-b307-88d9fc34e22a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7467ffc8-7a73-43bf-88d5-1cb819691bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:to="loc_us-gaap_TreasuryStockValue_7467ffc8-7a73-43bf-88d5-1cb819691bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54be3648-67e4-4d61-ae0b-dc99dff9afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54be3648-67e4-4d61-ae0b-dc99dff9afa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_46ae2ad9-6350-4980-8d31-473768721c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_46ae2ad9-6350-4980-8d31-473768721c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e1e1f806-5ae8-4274-9615-b17aa0d15eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7713a094-b1fb-48f2-b3c4-c97135442e2e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e1e1f806-5ae8-4274-9615-b17aa0d15eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7a524d95-cc72-4e20-bc2e-0531e1b16b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_AssetsCurrent_7a524d95-cc72-4e20-bc2e-0531e1b16b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_eabd6a0d-6f0f-4381-bfc3-8d04d3350575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_LongTermInvestments_eabd6a0d-6f0f-4381-bfc3-8d04d3350575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c52a8d58-94b0-4846-9cea-8c7e694297c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c52a8d58-94b0-4846-9cea-8c7e694297c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40c5cd50-75d8-40b8-aa88-4bb4f5b71714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40c5cd50-75d8-40b8-aa88-4bb4f5b71714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c8998f83-a81d-458c-9b2e-d56ac60b92a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_Goodwill_c8998f83-a81d-458c-9b2e-d56ac60b92a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6777a7a7-e9fd-4de1-ae50-9538d6df464e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67685f51-244e-4aea-b54a-cfab3a295860" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6777a7a7-e9fd-4de1-ae50-9538d6df464e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c38d1932-dff8-46a5-9a0a-55c9763cd05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_a700d4a7-101d-4af5-9076-ed9c2b3d28c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c38d1932-dff8-46a5-9a0a-55c9763cd05a" xlink:to="loc_us-gaap_ShortTermBorrowings_a700d4a7-101d-4af5-9076-ed9c2b3d28c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5922b764-5b2c-4b7a-b801-027c68565dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c38d1932-dff8-46a5-9a0a-55c9763cd05a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5922b764-5b2c-4b7a-b801-027c68565dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5123b5d7-d93f-4f22-b13f-73aea3d90ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c38d1932-dff8-46a5-9a0a-55c9763cd05a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5123b5d7-d93f-4f22-b13f-73aea3d90ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6034a91f-095e-4fdc-8a20-680813d09dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6034a91f-095e-4fdc-8a20-680813d09dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_36de547c-9de9-4a33-bcf3-ae3325293f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:to="loc_us-gaap_ShortTermInvestments_36de547c-9de9-4a33-bcf3-ae3325293f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_186cbae8-aaae-4837-95cc-8b4ecd2e1cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_186cbae8-aaae-4837-95cc-8b4ecd2e1cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0ecf7492-94a4-42c1-812e-c89d14926441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:to="loc_us-gaap_InventoryNet_0ecf7492-94a4-42c1-812e-c89d14926441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_20a70d8d-ccd7-4c97-92eb-82177d92489a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b21b7b53-fe52-4d2b-844c-d8965ba72d11" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_20a70d8d-ccd7-4c97-92eb-82177d92489a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46d57301-1626-49e3-881f-394d9ed5c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b574f44-0e0f-44d5-b2d5-97702408ffde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46d57301-1626-49e3-881f-394d9ed5c40c" xlink:to="loc_us-gaap_StockholdersEquity_3b574f44-0e0f-44d5-b2d5-97702408ffde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_946daa5f-5e29-4ec0-84d0-c738cbf04591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46d57301-1626-49e3-881f-394d9ed5c40c" xlink:to="loc_us-gaap_MinorityInterest_946daa5f-5e29-4ec0-84d0-c738cbf04591" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6af4f5a2-2bff-4479-97e1-606f0a2059af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6af4f5a2-2bff-4479-97e1-606f0a2059af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_76fcd735-d44c-4ff4-9ec4-4b3bcef13edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_76fcd735-d44c-4ff4-9ec4-4b3bcef13edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_819e3d42-19a1-4661-bf79-709c726f6355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_819e3d42-19a1-4661-bf79-709c726f6355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c9449004-cbed-405b-8345-0e9c9951d152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c9449004-cbed-405b-8345-0e9c9951d152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5cd022e7-e0b7-44d3-8427-2a0a7469e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14e5ba98-e5ae-4c33-bda2-000db0b5c8bf" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5cd022e7-e0b7-44d3-8427-2a0a7469e0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93eb95ff-d2c3-41da-b94f-b84f54c2f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34c9a8a-deae-4eca-a355-46bf645cf01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93eb95ff-d2c3-41da-b94f-b84f54c2f7f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34c9a8a-deae-4eca-a355-46bf645cf01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5588a61-7f17-4396-b90e-4db5ae26c7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93eb95ff-d2c3-41da-b94f-b84f54c2f7f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5588a61-7f17-4396-b90e-4db5ae26c7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e6ae206c-5546-4bf1-8fbe-6a2970a1bf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93eb95ff-d2c3-41da-b94f-b84f54c2f7f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e6ae206c-5546-4bf1-8fbe-6a2970a1bf84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_06657b99-fc62-4850-9ef0-ac30d1a35b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93eb95ff-d2c3-41da-b94f-b84f54c2f7f4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_06657b99-fc62-4850-9ef0-ac30d1a35b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a246cd6-3a74-4c11-9bd6-9864f67bb779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a246cd6-3a74-4c11-9bd6-9864f67bb779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2739d8f9-fc97-416b-88ec-31fad0b02628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_Depreciation_2739d8f9-fc97-416b-88ec-31fad0b02628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c5b6ea2-6e67-4660-87e1-42226ed36075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_ProfitLoss_8c5b6ea2-6e67-4660-87e1-42226ed36075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_5fb61252-3c0c-4634-9ee0-750b0bd81287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_5fb61252-3c0c-4634-9ee0-750b0bd81287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_26c15225-9ec4-4055-b221-4a9aa09f6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_26c15225-9ec4-4055-b221-4a9aa09f6a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_acb5396d-28ef-4cda-b39d-3141189d4428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_acb5396d-28ef-4cda-b39d-3141189d4428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5477bb50-2318-4d77-8bcd-b6b565dfe465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5477bb50-2318-4d77-8bcd-b6b565dfe465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_399d7bf1-5eaf-4af2-bf3f-ddf01c4f0edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_399d7bf1-5eaf-4af2-bf3f-ddf01c4f0edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_b0aedb81-d0ff-41e1-a42a-385a6ded15ff" xlink:href="abbv-20220630.xsd#abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_b0aedb81-d0ff-41e1-a42a-385a6ded15ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_180ac395-4957-49ce-bb3d-56264e3c12e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_180ac395-4957-49ce-bb3d-56264e3c12e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e874190b-0d68-48b4-baec-a453a068b259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e874190b-0d68-48b4-baec-a453a068b259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b24829a0-c6fd-4dbb-a410-2f28be81bdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_ShareBasedCompensation_b24829a0-c6fd-4dbb-a410-2f28be81bdfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5268a794-6833-445c-86b8-b2ffeb79ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5268a794-6833-445c-86b8-b2ffeb79ebc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_acdd4ec6-53a5-4505-88b2-a8a7729de878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_acdd4ec6-53a5-4505-88b2-a8a7729de878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_abcdea0c-9259-4943-97cf-3465ed37ea84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_902a900a-9c3f-4d0d-b572-4b7f867acb3a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_abcdea0c-9259-4943-97cf-3465ed37ea84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_9eb47691-181b-4cfc-bb65-766880881016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_PaymentsOfDividends_9eb47691-181b-4cfc-bb65-766880881016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bea5d6fc-f294-4a0f-a39c-b725bab4ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bea5d6fc-f294-4a0f-a39c-b725bab4ba27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1c7bd36-1b4d-46d5-86ec-ceedf902b90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1c7bd36-1b4d-46d5-86ec-ceedf902b90d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_37d68c8b-943a-427e-9500-179a02f490ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_37d68c8b-943a-427e-9500-179a02f490ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_c3d6c670-a904-49d9-8117-8c8df8f7fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_c3d6c670-a904-49d9-8117-8c8df8f7fc64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95965284-6d94-4152-9acc-4ca94a4efcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95965284-6d94-4152-9acc-4ca94a4efcac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_111fbd1e-dd2f-4196-bcae-99aaa7cbb3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_036a5160-e0ba-4adb-bf38-dee7923dc984" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_111fbd1e-dd2f-4196-bcae-99aaa7cbb3bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#SupplementalFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a581905e-045a-49bd-b70c-f7a59677de55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_46c62b14-d6ef-4e43-85c5-09864e9cd438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a581905e-045a-49bd-b70c-f7a59677de55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_46c62b14-d6ef-4e43-85c5-09864e9cd438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1d550a-20c6-4fe4-a535-5929f44667c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a581905e-045a-49bd-b70c-f7a59677de55" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1d550a-20c6-4fe4-a535-5929f44667c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_12109317-a9b1-4e04-868c-3ca320c6beb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8ddb3b90-13ec-4661-b435-aa41ac74fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_12109317-a9b1-4e04-868c-3ca320c6beb2" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8ddb3b90-13ec-4661-b435-aa41ac74fe39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_837c5094-e3ed-4852-8746-d86b6449a007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_12109317-a9b1-4e04-868c-3ca320c6beb2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_837c5094-e3ed-4852-8746-d86b6449a007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3b043fb5-cd8f-488d-8c07-137b0d717f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_12109317-a9b1-4e04-868c-3ca320c6beb2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3b043fb5-cd8f-488d-8c07-137b0d717f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_41ffa1da-2e45-4fe7-b524-d95527fe4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b78c3757-8b17-42ab-9a48-a82b484dae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_41ffa1da-2e45-4fe7-b524-d95527fe4a90" xlink:to="loc_us-gaap_InterestExpense_b78c3757-8b17-42ab-9a48-a82b484dae0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_efd51544-3698-46f7-be3a-dbc1a1111db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_41ffa1da-2e45-4fe7-b524-d95527fe4a90" xlink:to="loc_us-gaap_InvestmentIncomeInterest_efd51544-3698-46f7-be3a-dbc1a1111db0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2267bd3f-b55c-401b-a8d9-5e8181c910fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6cfb5ba-9ba7-4740-898f-a78ae422d004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2267bd3f-b55c-401b-a8d9-5e8181c910fb" xlink:to="loc_us-gaap_NetIncomeLoss_e6cfb5ba-9ba7-4740-898f-a78ae422d004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_0dfb636f-ba28-4a01-b582-dee689222722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2267bd3f-b55c-401b-a8d9-5e8181c910fb" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_0dfb636f-ba28-4a01-b582-dee689222722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_925829e9-80c2-44d9-b6b6-ec9f8a202fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55e52e09-0bab-4d81-8b7c-0d6f171c0ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_925829e9-80c2-44d9-b6b6-ec9f8a202fba" xlink:to="loc_us-gaap_NetIncomeLoss_55e52e09-0bab-4d81-8b7c-0d6f171c0ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_a7dd1b15-758e-4e8b-82ea-a1d5eb802b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_925829e9-80c2-44d9-b6b6-ec9f8a202fba" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_a7dd1b15-758e-4e8b-82ea-a1d5eb802b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f1468ce-5213-4c81-a417-b30036c26861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2f72715-7356-4787-a16b-c6a5e9d640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f1468ce-5213-4c81-a417-b30036c26861" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2f72715-7356-4787-a16b-c6a5e9d640e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_43f98b8d-b458-431f-ad5c-41c0a2e0a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f1468ce-5213-4c81-a417-b30036c26861" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_43f98b8d-b458-431f-ad5c-41c0a2e0a0ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a776773a-4c15-4108-b207-f16f26b64e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a9be2c93-281b-4cf7-8ab0-664164f9f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a776773a-4c15-4108-b207-f16f26b64e07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a9be2c93-281b-4cf7-8ab0-664164f9f3c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8c9a5af-063c-4b53-84ac-e0eed6242a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a776773a-4c15-4108-b207-f16f26b64e07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8c9a5af-063c-4b53-84ac-e0eed6242a2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91a65fb7-1555-4f82-9117-add6f9d4e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91a65fb7-1555-4f82-9117-add6f9d4e60e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b302b4e4-beec-42c1-a954-80212a99444a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b302b4e4-beec-42c1-a954-80212a99444a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4874b9db-933b-4c03-a61c-3596f5d5d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4874b9db-933b-4c03-a61c-3596f5d5d4ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_4aa192bc-fefe-4f8d-ab28-1c7c8c630ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_4aa192bc-fefe-4f8d-ab28-1c7c8c630ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_570f4b80-9329-4097-86d8-d9dcf73c75a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b9e8c5d-3433-4fc8-8694-041fecd69069" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_570f4b80-9329-4097-86d8-d9dcf73c75a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_9b3db730-774b-40fc-bb31-77e6b6442ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_ab7472f4-12e4-4931-8c77-8778a85e3bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9b3db730-774b-40fc-bb31-77e6b6442ddc" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_ab7472f4-12e4-4931-8c77-8778a85e3bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b2c9d961-1e0d-4278-b208-1e8154c37022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9b3db730-774b-40fc-bb31-77e6b6442ddc" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b2c9d961-1e0d-4278-b208-1e8154c37022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3f54766d-873c-4d60-a50f-0cd8be6813bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9b3db730-774b-40fc-bb31-77e6b6442ddc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3f54766d-873c-4d60-a50f-0cd8be6813bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_78eaac41-cef1-475c-acf7-5b36363c414b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_7e96b3a0-03c8-4089-b266-5549b33ab67f" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_78eaac41-cef1-475c-acf7-5b36363c414b" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_7e96b3a0-03c8-4089-b266-5549b33ab67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_a3ba1cd1-6eae-415e-af24-5fad85623f54" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_78eaac41-cef1-475c-acf7-5b36363c414b" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_a3ba1cd1-6eae-415e-af24-5fad85623f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_6ca04e05-d5f9-4ab2-91d3-bfee1e5151fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_78eaac41-cef1-475c-acf7-5b36363c414b" xlink:to="loc_us-gaap_ShorttermDebtFairValue_6ca04e05-d5f9-4ab2-91d3-bfee1e5151fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#PostEmploymentBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_67d10f74-2ebe-4ab6-bfdc-7ec0efe2623e" xlink:href="abbv-20220630.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_67d10f74-2ebe-4ab6-bfdc-7ec0efe2623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_a5d037a9-e25b-4ac0-8733-a666ad1e10b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_a5d037a9-e25b-4ac0-8733-a666ad1e10b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dce82299-70ac-4e3b-b33b-bc5241b2386c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dce82299-70ac-4e3b-b33b-bc5241b2386c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6436b48c-ecef-4d6a-8577-4e459f9d7246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6436b48c-ecef-4d6a-8577-4e459f9d7246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_13dbe1e3-0896-4aef-a586-6f852d1fee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7ca737ba-92fc-425e-afbf-5407e1184c3a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_13dbe1e3-0896-4aef-a586-6f852d1fee76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f7965eca-5c81-4f27-a92f-6d781edecdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e142f38b-1d1c-4939-9c5b-f2e4fbc00de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f7965eca-5c81-4f27-a92f-6d781edecdcf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e142f38b-1d1c-4939-9c5b-f2e4fbc00de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a0fcd146-bbc6-4c23-8743-b2d05b42814b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f7965eca-5c81-4f27-a92f-6d781edecdcf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a0fcd146-bbc6-4c23-8743-b2d05b42814b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0918033d-7f34-42e9-84b5-ecf2ee941cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7ec90d2b-c30d-4edd-8d5f-702a0df41479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0918033d-7f34-42e9-84b5-ecf2ee941cf3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7ec90d2b-c30d-4edd-8d5f-702a0df41479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_33d50869-7b5e-41af-80b6-e3319697ceda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0918033d-7f34-42e9-84b5-ecf2ee941cf3" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_33d50869-7b5e-41af-80b6-e3319697ceda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80be696a-7336-4df2-8516-0788628ee475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_3b9686f8-a007-4c50-9b39-4eb9f0156a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80be696a-7336-4df2-8516-0788628ee475" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_3b9686f8-a007-4c50-9b39-4eb9f0156a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3bbce8b0-1c52-46b9-8cc5-96acc205ea2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80be696a-7336-4df2-8516-0788628ee475" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3bbce8b0-1c52-46b9-8cc5-96acc205ea2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8be78f9-d355-4240-8d7b-535fbe79e635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_84295e77-4e74-4cf3-8698-bdf8c950b970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e8be78f9-d355-4240-8d7b-535fbe79e635" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_84295e77-4e74-4cf3-8698-bdf8c950b970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70458f49-614e-4726-83e3-4f43f7811410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e8be78f9-d355-4240-8d7b-535fbe79e635" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70458f49-614e-4726-83e3-4f43f7811410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8b5555a3-a9ea-4d0c-bd9f-06e30f487dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e8be78f9-d355-4240-8d7b-535fbe79e635" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8b5555a3-a9ea-4d0c-bd9f-06e30f487dac" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>abbv-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="abbv-20220630.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="extended" id="ic26ca211a1794178a6623c1d8d37f9ab_DocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6f02a35-735d-4917-a73b-c11d821e2af3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentType_f6f02a35-735d-4917-a73b-c11d821e2af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9fb45195-951b-4137-885a-8af850be04ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentQuarterlyReport_9fb45195-951b-4137-885a-8af850be04ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_11c71680-807c-42bb-8a69-86d77e775d98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentPeriodEndDate_11c71680-807c-42bb-8a69-86d77e775d98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_07bb9eaa-afad-4108-a8e9-4fc4ae287e54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentTransitionReport_07bb9eaa-afad-4108-a8e9-4fc4ae287e54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f77570b4-ded8-4dd0-94c9-07630a648750" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityFileNumber_f77570b4-ded8-4dd0-94c9-07630a648750" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_00b75f4b-9676-4f98-982d-43218e0c4cae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityRegistrantName_00b75f4b-9676-4f98-982d-43218e0c4cae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e5b9b84e-a9ec-43fc-959f-4f196fe24bfd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCentralIndexKey_e5b9b84e-a9ec-43fc-959f-4f196fe24bfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_89bf6ca5-7601-4cc0-993d-45e7d4a6d6a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentFiscalYearFocus_89bf6ca5-7601-4cc0-993d-45e7d4a6d6a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6ee9c25b-6599-419d-9170-5b4fbde2cf9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6ee9c25b-6599-419d-9170-5b4fbde2cf9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_679d7dff-d74e-4a04-9992-fd60fa883cee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_AmendmentFlag_679d7dff-d74e-4a04-9992-fd60fa883cee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2666cd30-1912-431c-b4fd-2647475ba8c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_CurrentFiscalYearEndDate_2666cd30-1912-431c-b4fd-2647475ba8c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d79cf3ce-c396-4a88-8fa1-8ddbbc2e3b9a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d79cf3ce-c396-4a88-8fa1-8ddbbc2e3b9a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b9b80d81-cc34-44f0-af0a-b3e01ee7824c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityTaxIdentificationNumber_b9b80d81-cc34-44f0-af0a-b3e01ee7824c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a687bb8e-2eaf-4e77-a06f-7e6e138dd2c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressAddressLine1_a687bb8e-2eaf-4e77-a06f-7e6e138dd2c6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_56036972-d5ce-4e99-b61d-ef3dbbf26231" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressCityOrTown_56036972-d5ce-4e99-b61d-ef3dbbf26231" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8bbd34dc-8cca-4c97-bd19-753f6e7d4959" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressStateOrProvince_8bbd34dc-8cca-4c97-bd19-753f6e7d4959" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9edaa5f9-7ed4-4255-a0fc-c9de4f7749bf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressPostalZipCode_9edaa5f9-7ed4-4255-a0fc-c9de4f7749bf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c7aa545b-c87f-442c-a592-15f29119b34a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_CityAreaCode_c7aa545b-c87f-442c-a592-15f29119b34a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63f81d81-1f92-4707-8816-ddc00325aaa2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_LocalPhoneNumber_63f81d81-1f92-4707-8816-ddc00325aaa2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c2f0598-94ad-4fa5-97a5-1c5677508d54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCurrentReportingStatus_9c2f0598-94ad-4fa5-97a5-1c5677508d54" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f7f9b469-8211-48d1-b52a-e988c84b4aa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityInteractiveDataCurrent_f7f9b469-8211-48d1-b52a-e988c84b4aa8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0b40dea1-f685-4003-b611-03120f489cdd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityFilerCategory_0b40dea1-f685-4003-b611-03120f489cdd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_88bf0309-68a6-4196-924b-5e441b0835bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntitySmallBusiness_88bf0309-68a6-4196-924b-5e441b0835bb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_539220ea-1aae-4b22-956a-9c4e75d8aa28" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityEmergingGrowthCompany_539220ea-1aae-4b22-956a-9c4e75d8aa28" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4465c734-476c-4091-b177-0030583b3f3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityShellCompany_4465c734-476c-4091-b177-0030583b3f3c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_26970612-adaa-4aa0-86d6-00ec11297dc2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_SecurityExchangeName_26970612-adaa-4aa0-86d6-00ec11297dc2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e25e0368-52d9-44bc-8405-d731d067ac02" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_Security12bTitle_e25e0368-52d9-44bc-8405-d731d067ac02" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a9feccae-1ab5-4253-b635-07419da9e884" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_TradingSymbol_a9feccae-1ab5-4253-b635-07419da9e884" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fb985ae1-a37c-44e6-95c5-419ad3f5ac41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fb985ae1-a37c-44e6-95c5-419ad3f5ac41" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:to="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_cebd187b-d520-4554-b4fb-45c004a54bd9_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:to="loc_dei_ExchangeDomain_cebd187b-d520-4554-b4fb-45c004a54bd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:to="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_b4f3a4b4-6575-4c9f-ba5f-d2c5768e13ae" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:to="loc_exch_XNYS_b4f3a4b4-6575-4c9f-ba5f-d2c5768e13ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_c986ce31-28b7-4423-8a37-73dbce690ac5" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:to="loc_exch_XCHI_c986ce31-28b7-4423-8a37-73dbce690ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73987b57-0d85-45cd-b782-ab8cf3516e21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:to="loc_us-gaap_ClassOfStockDomain_73987b57-0d85-45cd-b782-ab8cf3516e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:to="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e880391a-16eb-4797-81e5-c0a6f3fe03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_us-gaap_CommonStockMember_e880391a-16eb-4797-81e5-c0a6f3fe03d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_e4089ee6-eb1d-4e80-a18c-7d9fc20b9908" xlink:href="abbv-20220630.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_e4089ee6-eb1d-4e80-a18c-7d9fc20b9908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_27cb870b-d867-4e1f-8718-a51d311d388b" xlink:href="abbv-20220630.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_27cb870b-d867-4e1f-8718-a51d311d388b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_d65eaaf2-7408-4312-aee1-70994d92d154" xlink:href="abbv-20220630.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_d65eaaf2-7408-4312-aee1-70994d92d154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_874c5c22-45d4-4ff3-999e-2fb50829f5b2" xlink:href="abbv-20220630.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_874c5c22-45d4-4ff3-999e-2fb50829f5b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_92d727b0-87c0-41d9-bf7c-b16dd509f503" xlink:href="abbv-20220630.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_92d727b0-87c0-41d9-bf7c-b16dd509f503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_ed0b05ed-ace8-443c-8b7a-e947c2a7161c" xlink:href="abbv-20220630.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_ed0b05ed-ace8-443c-8b7a-e947c2a7161c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_d72d9f6d-2154-4d6d-b984-ee2d30e964bf" xlink:href="abbv-20220630.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_d72d9f6d-2154-4d6d-b984-ee2d30e964bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_8fd95350-8841-4ca7-a41b-17abe396e8a0" xlink:href="abbv-20220630.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_8fd95350-8841-4ca7-a41b-17abe396e8a0" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="extended" id="i400a1dfcc84548fd99d1fbd43f270167_CondensedConsolidatedStatementsofEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffea2223-fd5d-4a94-b027-ee21593ede97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffea2223-fd5d-4a94-b027-ee21593ede97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_36a5c944-8fdc-4be0-b0fc-e10c5cb7e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_SharesOutstanding_36a5c944-8fdc-4be0-b0fc-e10c5cb7e9aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39e5e472-edef-4f87-b96d-d1e601fef5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_NetIncomeLoss_39e5e472-edef-4f87-b96d-d1e601fef5ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f9f5c06-fa2d-4bce-a42f-828f5a71f7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f9f5c06-fa2d-4bce-a42f-828f5a71f7fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_54b90963-a0d5-4b20-b6a0-6f09d711e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_DividendsCommonStockCash_54b90963-a0d5-4b20-b6a0-6f09d711e35e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccc023d4-c34c-4cdf-bc60-de2ebd3d6b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccc023d4-c34c-4cdf-bc60-de2ebd3d6b7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b5ec07b3-e301-41fb-9e03-ae1c85786de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b5ec07b3-e301-41fb-9e03-ae1c85786de0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_49afc516-6e32-4c2b-856f-fb0b0a6e3bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_49afc516-6e32-4c2b-856f-fb0b0a6e3bb4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b4b6001-1c99-4167-bf63-b368d0c224d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b4b6001-1c99-4167-bf63-b368d0c224d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_c03b74ce-9270-4b8b-ab8d-380e49c57b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_c03b74ce-9270-4b8b-ab8d-380e49c57b73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf915eb4-c8f5-4664-b502-eb229f8d496b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_625b24fd-14db-4ff3-91aa-8dc80b2554de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:to="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:to="loc_us-gaap_EquityComponentDomain_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:to="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_377bdb32-13af-479c-be62-a67a937dc607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_CommonStockMember_377bdb32-13af-479c-be62-a67a937dc607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9538672a-178c-49ee-b765-655fd6968d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_TreasuryStockMember_9538672a-178c-49ee-b765-655fd6968d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e62807d-30c5-4424-967c-18ced0e74b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e62807d-30c5-4424-967c-18ced0e74b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1f098e9e-a400-4621-89a3-09a372dd22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_RetainedEarningsMember_1f098e9e-a400-4621-89a3-09a372dd22ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6499928b-5507-47a3-a904-8817dea1f170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6499928b-5507-47a3-a904-8817dea1f170" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_60da4aee-01ac-4cc9-b205-e498f1b1ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_NoncontrollingInterestMember_60da4aee-01ac-4cc9-b205-e498f1b1ebec" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#LicensingAcquisitionsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="extended" id="ifb74e4276181492ca292e3cd13544378_LicensingAcquisitionsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_de2ae66f-1757-42c1-8b00-f920b4b45e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_de2ae66f-1757-42c1-8b00-f920b4b45e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d2b7dde-1a3f-44fb-8d01-834dc683a850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d2b7dde-1a3f-44fb-8d01-834dc683a850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_ec70fe2e-66bc-4457-858c-74b52f88125c" xlink:href="abbv-20220630.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_ec70fe2e-66bc-4457-858c-74b52f88125c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_ac58d657-4990-4df5-bad8-234ada009598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_ac58d657-4990-4df5-bad8-234ada009598" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_18ab0058-d702-4d80-aa09-e1ab3aaa6d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_18ab0058-d702-4d80-aa09-e1ab3aaa6d4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c0c39ce-6189-4a8d-bd31-fbd62af695f0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c0c39ce-6189-4a8d-bd31-fbd62af695f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember_7eecfda7-3d76-480c-bbd3-df2d7589e8fa" xlink:href="abbv-20220630.xsd#abbv_SyndesiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:to="loc_abbv_SyndesiMember_7eecfda7-3d76-480c-bbd3-df2d7589e8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvisePharmaceuticalsMember_f617237f-0c05-4134-a3a0-109040504e4a" xlink:href="abbv-20220630.xsd#abbv_JuvisePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:to="loc_abbv_JuvisePharmaceuticalsMember_f617237f-0c05-4134-a3a0-109040504e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23120c13-595d-4529-8761-f1f43bc68a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23120c13-595d-4529-8761-f1f43bc68a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_98acd18d-56ac-4c4f-952d-0c8fd14fb541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_98acd18d-56ac-4c4f-952d-0c8fd14fb541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1830c47b-db33-48e0-b4bf-757cc0fa57ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:to="loc_srt_RangeMember_1830c47b-db33-48e0-b4bf-757cc0fa57ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:to="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7c5b125-7be9-48f7-9726-a8ea23f8f644" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:to="loc_srt_MaximumMember_b7c5b125-7be9-48f7-9726-a8ea23f8f644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_adc067b5-6e72-47f0-86b9-2aba2250c228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_adc067b5-6e72-47f0-86b9-2aba2250c228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_656ab4e1-a6f4-4fd5-a979-c6958f14ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_656ab4e1-a6f4-4fd5-a979-c6958f14ab7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_582da57e-2a77-4186-bad0-9106c11311fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_582da57e-2a77-4186-bad0-9106c11311fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#CollaborationsTables"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CollaborationsTables" xlink:type="extended" id="i5bfd19a7da9d46858b01d3b879ae75ee_CollaborationsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_41734336-4020-47c1-b861-99788eff858d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_41734336-4020-47c1-b861-99788eff858d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:to="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b07742da-36a2-40aa-8a5f-3c33b7273def_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b07742da-36a2-40aa-8a5f-3c33b7273def_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_87901879-1c61-4f60-b67f-1e051c788024" xlink:href="abbv-20220630.xsd#abbv_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:to="loc_abbv_JanssenBiotechIncMember_87901879-1c61-4f60-b67f-1e051c788024" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_2443f7f9-ab7c-445c-a66e-2d199325ccde" xlink:href="abbv-20220630.xsd#abbv_GenentechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:to="loc_abbv_GenentechInc.Member_2443f7f9-ab7c-445c-a66e-2d199325ccde" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#CollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="extended" id="i9697cb5a2cf74dc18290805dbd81bc9f_CollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_153530cc-f4f6-4640-86ce-661cb39af109" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_153530cc-f4f6-4640-86ce-661cb39af109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_d1c0d17b-cf1a-4879-80c2-540cac5a3ce9" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_d1c0d17b-cf1a-4879-80c2-540cac5a3ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_76eb0d4e-874a-4b11-9e25-3c0ad0e28869" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_76eb0d4e-874a-4b11-9e25-3c0ad0e28869" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_84b541e6-5362-4f89-b7a6-62282e442baa" xlink:href="abbv-20220630.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_84b541e6-5362-4f89-b7a6-62282e442baa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_784c26f6-2767-4dba-86ed-fbbb955d79b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_784c26f6-2767-4dba-86ed-fbbb955d79b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements_a891e146-527d-4eb2-842f-4466a3c27cc0" xlink:href="abbv-20220630.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_OtherExpensesFromCollaborativeArrangements_a891e146-527d-4eb2-842f-4466a3c27cc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e089339-9fef-4254-96a6-0dc3224631d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6e089339-9fef-4254-96a6-0dc3224631d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3d0d04b3-b82d-4196-91db-e9f35516146a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3d0d04b3-b82d-4196-91db-e9f35516146a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_6708faf3-0563-4ac0-b4b2-378c8f743055" xlink:href="abbv-20220630.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_6708faf3-0563-4ac0-b4b2-378c8f743055" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_fa1eb7fb-1b6d-4f80-b89f-52d0c6918c88" xlink:href="abbv-20220630.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_fa1eb7fb-1b6d-4f80-b89f-52d0c6918c88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa749a37-071e-490c-be9c-1e51dd050685_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa749a37-071e-490c-be9c-1e51dd050685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_b1a04e7d-3eb3-44e3-8e54-d1b3ed390f65" xlink:href="abbv-20220630.xsd#abbv_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:to="loc_abbv_JanssenBiotechIncMember_b1a04e7d-3eb3-44e3-8e54-d1b3ed390f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_52fb377c-d1ca-49af-9734-652df3821303" xlink:href="abbv-20220630.xsd#abbv_GenentechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:to="loc_abbv_GenentechInc.Member_52fb377c-d1ca-49af-9734-652df3821303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e28fbafe-5bc9-43e1-9f4b-25423a45dee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e28fbafe-5bc9-43e1-9f4b-25423a45dee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b595e4a8-9323-45f9-a517-180b81a31d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b595e4a8-9323-45f9-a517-180b81a31d1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:to="loc_srt_SegmentGeographicalDomain_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:to="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dac678c6-2180-437e-ae03-6c4b2380599e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:to="loc_country_US_dac678c6-2180-437e-ae03-6c4b2380599e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_63b9db89-3050-408f-99ae-7556c697d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:to="loc_us-gaap_NonUsMember_63b9db89-3050-408f-99ae-7556c697d1b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended" id="i06cdb9c5d2554cb6a46bcdaeae73b5ff_GoodwillandIntangibleAssetsIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e61b6d71-32be-4372-8017-54923b0d4d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e61b6d71-32be-4372-8017-54923b0d4d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dd28d36-2545-4753-9336-529a5bfa0729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dd28d36-2545-4753-9336-529a5bfa0729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_386f00ef-ec3a-47ea-bdd6-56317b5bc791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_386f00ef-ec3a-47ea-bdd6-56317b5bc791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7a073f1a-0d79-43b7-a737-646330b5a35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7a073f1a-0d79-43b7-a737-646330b5a35d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bf422be8-ecb4-4ef9-89e0-f8deda867d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bf422be8-ecb4-4ef9-89e0-f8deda867d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9acabc74-fb83-4f6a-9ea2-efb830771721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9acabc74-fb83-4f6a-9ea2-efb830771721" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1e76011-60fb-4cf3-9adf-5276288cf120_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1e76011-60fb-4cf3-9adf-5276288cf120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_362ea9ce-a865-4f44-b3f0-3e91c5f634ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_362ea9ce-a865-4f44-b3f0-3e91c5f634ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5d056c99-7c29-4569-a89a-5dff70b6b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:to="loc_us-gaap_LicensingAgreementsMember_5d056c99-7c29-4569-a89a-5dff70b6b7e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#IntegrationandRestructuringPlansTables"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="extended" id="ie0e40a8012e24d4f8249d11bb234e0fe_IntegrationandRestructuringPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_76e56872-068d-4fbd-b565-3ae61a5c43f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_76e56872-068d-4fbd-b565-3ae61a5c43f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5574e673-be9b-4459-a37f-6fcc9e426e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5574e673-be9b-4459-a37f-6fcc9e426e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:to="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_24fa607a-15c3-4da3-9c27-50de65b71cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:to="loc_us-gaap_RestructuringPlanDomain_24fa607a-15c3-4da3-9c27-50de65b71cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:to="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_88bbf3dc-8c5b-436e-8262-e37d4cbd5ff2" xlink:href="abbv-20220630.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:to="loc_abbv_AllerganIntegrationPlanMember_88bbf3dc-8c5b-436e-8262-e37d4cbd5ff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_20960846-2569-40b4-a8e3-50b54ae4c5d9" xlink:href="abbv-20220630.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:to="loc_abbv_OtherRestructuringPlansMember_20960846-2569-40b4-a8e3-50b54ae4c5d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#IntegrationandRestructuringPlansDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="extended" id="i879844f14a824b7e8487be3b0384344f_IntegrationandRestructuringPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_413a5aaf-0951-4bd9-9bb1-893f29ae1190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_413a5aaf-0951-4bd9-9bb1-893f29ae1190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e915ea2e-2d07-4bd5-a336-3074b9ac74d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e915ea2e-2d07-4bd5-a336-3074b9ac74d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_31007642-bba3-47cb-ad56-d8e382c1b489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_us-gaap_RestructuringReserve_31007642-bba3-47cb-ad56-d8e382c1b489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_05931788-6026-41dc-a30a-983d9a8f889f" xlink:href="abbv-20220630.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_05931788-6026-41dc-a30a-983d9a8f889f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_732d3856-f61a-42e9-a0f3-76fc2c807a2d" xlink:href="abbv-20220630.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_732d3856-f61a-42e9-a0f3-76fc2c807a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6ea6e973-32fb-4900-aeea-9949f6a78391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_73d9d472-e5f1-4689-9864-e242b0e2124c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:to="loc_us-gaap_RestructuringPlanDomain_73d9d472-e5f1-4689-9864-e242b0e2124c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:to="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_5523146a-d100-413b-9973-cf2052a1769f" xlink:href="abbv-20220630.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:to="loc_abbv_AllerganIntegrationPlanMember_5523146a-d100-413b-9973-cf2052a1769f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_db1066f8-b8d5-4f25-8050-770d0adea62b" xlink:href="abbv-20220630.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:to="loc_abbv_OtherRestructuringPlansMember_db1066f8-b8d5-4f25-8050-770d0adea62b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a32b892f-3509-4158-9d23-d17f44e1a0aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a32b892f-3509-4158-9d23-d17f44e1a0aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ba5a8987-1b82-49f5-afd9-9ee2d1d47871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ba5a8987-1b82-49f5-afd9-9ee2d1d47871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_e2c61455-de06-46fd-8b01-7d098923fbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:to="loc_us-gaap_OtherRestructuringMember_e2c61455-de06-46fd-8b01-7d098923fbda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c52176ca-b1ac-4865-acb6-9c82acb5ebab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c52176ca-b1ac-4865-acb6-9c82acb5ebab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6eaa1da2-8374-4a06-8d9e-cf38eb92797f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_CostOfSalesMember_6eaa1da2-8374-4a06-8d9e-cf38eb92797f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358f1630-b6ac-46d8-90dd-3abd5f0882df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358f1630-b6ac-46d8-90dd-3abd5f0882df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80330eaa-0724-4bcc-931d-6dbacc2ed7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80330eaa-0724-4bcc-931d-6dbacc2ed7b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="extended" id="icf90eef4cb5444068851b30221e83bad_FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0d8497a7-5da7-4bb0-9bc6-0bc39810b4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0d8497a7-5da7-4bb0-9bc6-0bc39810b4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_90b22769-17e8-48a6-ba34-e4f149992833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeTermOfContract_90b22769-17e8-48a6-ba34-e4f149992833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_80e7da92-4de7-435f-a38f-23c60f6af5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_80e7da92-4de7-435f-a38f-23c60f6af5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_414b6964-16f7-43df-8682-25d350570505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_414b6964-16f7-43df-8682-25d350570505" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_cc78dfa2-d595-472e-ac40-09334506e0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_cc78dfa2-d595-472e-ac40-09334506e0b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_a2fae81a-3010-41da-864b-5246162cca48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_a2fae81a-3010-41da-864b-5246162cca48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_297b76f6-80a5-4595-9c14-da72407274ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_297b76f6-80a5-4595-9c14-da72407274ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_24926d79-6c95-4475-9d2a-85060fccf936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_24926d79-6c95-4475-9d2a-85060fccf936" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8358efab-84a6-4428-8700-6fb101bea40b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:to="loc_us-gaap_HedgingDesignationDomain_8358efab-84a6-4428-8700-6fb101bea40b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:to="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_45350cea-a964-4e1b-a16a-6cf77e075201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_45350cea-a964-4e1b-a16a-6cf77e075201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_31ae71bb-cdb7-447e-9a6d-1fbf966cb1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:to="loc_us-gaap_NondesignatedMember_31ae71bb-cdb7-447e-9a6d-1fbf966cb1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_352fd255-aa3c-488a-8417-c8c49bee4ece_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_352fd255-aa3c-488a-8417-c8c49bee4ece_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_37d1c428-2be2-4c92-ac26-82e57dcfa1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_37d1c428-2be2-4c92-ac26-82e57dcfa1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_56ae7ab9-b69e-430a-a99d-78752a67a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_TreasuryLockMember_56ae7ab9-b69e-430a-a99d-78752a67a13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_960dffac-8e78-42e9-b351-062b2ce4354d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_InterestRateSwapMember_960dffac-8e78-42e9-b351-062b2ce4354d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b52ff1af-6d9c-402a-856a-494139e0ec50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b52ff1af-6d9c-402a-856a-494139e0ec50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_af0fb602-58de-4115-938a-9516a9606ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_CashFlowHedgingMember_af0fb602-58de-4115-938a-9516a9606ea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_658ffbd6-5c6f-4b65-a070-33a724defad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_658ffbd6-5c6f-4b65-a070-33a724defad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e5484bee-dca7-418a-bfbf-c09c77dc391f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_FairValueHedgingMember_e5484bee-dca7-418a-bfbf-c09c77dc391f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bf438df1-189a-4351-bf00-6886dd372bc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bf438df1-189a-4351-bf00-6886dd372bc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9b38a8c8-84a1-4b60-8bdf-33454928b51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:to="loc_us-gaap_SeniorNotesMember_9b38a8c8-84a1-4b60-8bdf-33454928b51c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_65da8559-98ae-4fd5-8eab-512ebf22a413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_65da8559-98ae-4fd5-8eab-512ebf22a413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f0e066e2-6a97-41f5-a052-529518de82b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f0e066e2-6a97-41f5-a052-529518de82b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2a0289aa-e6b7-4c55-8171-8d38d6d5a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2a0289aa-e6b7-4c55-8171-8d38d6d5a42e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_d6963e20-e1d4-407d-81b8-b98f3a4f3131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_OtherLiabilitiesMember_d6963e20-e1d4-407d-81b8-b98f3a4f3131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b99baf7-bf63-438f-be3b-2028e32a47d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b99baf7-bf63-438f-be3b-2028e32a47d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_44edfd0e-dabd-4499-bb20-708606d9d2bb" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDueInMay2021AtFloatingRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:to="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_44edfd0e-dabd-4499-bb20-708606d9d2bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="extended" id="i0bda4b0046124142a6d0a6b335b88551_FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3808bc29-f665-4b2a-8f26-f2720a887b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3808bc29-f665-4b2a-8f26-f2720a887b82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2f1eac69-eec3-4ca8-937f-c9ae768816a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2f1eac69-eec3-4ca8-937f-c9ae768816a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1de3005b-c43b-4893-b5ea-d73122bd800e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1de3005b-c43b-4893-b5ea-d73122bd800e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_5fde4ae2-dbea-4a06-aaa8-50b7d4a38e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_5fde4ae2-dbea-4a06-aaa8-50b7d4a38e05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_db96d8c9-2b7f-4047-bc5d-3d24041e92c9" xlink:href="abbv-20220630.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_db96d8c9-2b7f-4047-bc5d-3d24041e92c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_08ca66f7-b2c1-4803-906f-a2ba1ac5affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_08ca66f7-b2c1-4803-906f-a2ba1ac5affa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_080e2ea4-2407-4046-99e5-9d96779c1fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_080e2ea4-2407-4046-99e5-9d96779c1fb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d46d9699-84e7-4097-96c0-2712de9d6037_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d46d9699-84e7-4097-96c0-2712de9d6037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_0fb47ca6-1ab0-4718-8a46-a623e1c69428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_0fb47ca6-1ab0-4718-8a46-a623e1c69428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a8bdbc9d-923f-4405-811a-13ac63676cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_InterestRateSwapMember_a8bdbc9d-923f-4405-811a-13ac63676cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_384b9f97-76d0-4a33-b7b1-5cbe0b120f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_TreasuryLockMember_384b9f97-76d0-4a33-b7b1-5cbe0b120f9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_77adc61d-a049-4861-bf20-37b0986c4776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:to="loc_us-gaap_HedgingDesignationDomain_77adc61d-a049-4861-bf20-37b0986c4776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:to="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5326e2b-0a3c-453b-b6f5-0d06b9b7df13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5326e2b-0a3c-453b-b6f5-0d06b9b7df13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_29eb677d-a344-4ffa-9ebd-02911d59a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:to="loc_us-gaap_NondesignatedMember_29eb677d-a344-4ffa-9ebd-02911d59a481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b4b5ff17-88b8-4699-954e-6be96266bfe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b4b5ff17-88b8-4699-954e-6be96266bfe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_78252b49-d527-4cdc-ac84-9612e8926235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_CostOfSalesMember_78252b49-d527-4cdc-ac84-9612e8926235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_a601d034-a925-40a9-bccc-f4247d5db0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_InterestExpenseMember_a601d034-a925-40a9-bccc-f4247d5db0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember_44970d0b-1e14-455c-8c8c-a5027f7fc79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_ForeignCurrencyGainLossMember_44970d0b-1e14-455c-8c8c-a5027f7fc79a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce3fecfc-e212-499f-876a-9a5a946c2886_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce3fecfc-e212-499f-876a-9a5a946c2886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4772ea95-6684-41f6-98fc-42de0e741547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:to="loc_us-gaap_SeniorNotesMember_4772ea95-6684-41f6-98fc-42de0e741547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:to="loc_us-gaap_HedgingRelationshipDomain_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:to="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9203e4a0-24bb-471c-a492-a76a05d88a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_CashFlowHedgingMember_9203e4a0-24bb-471c-a492-a76a05d88a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c333cd61-0fff-4e99-a9ab-29bcdb5cce42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c333cd61-0fff-4e99-a9ab-29bcdb5cce42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_716795f2-e360-447b-add6-9118d91d3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_FairValueHedgingMember_716795f2-e360-447b-add6-9118d91d3b1b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended" id="i097b8ac1a42147f6bc2229a6cfc8528c_FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5a4f1e7f-6d43-4bd5-847e-289a9d944259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5a4f1e7f-6d43-4bd5-847e-289a9d944259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5e64d274-0a97-47bc-b6e2-6799eaeaafda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5e64d274-0a97-47bc-b6e2-6799eaeaafda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_984cbce7-50eb-49c0-b878-5d16a2ed4be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_984cbce7-50eb-49c0-b878-5d16a2ed4be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e3397153-c98e-4d52-b874-5b6bc8656ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e3397153-c98e-4d52-b874-5b6bc8656ed2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ab4194b8-7b2f-4412-9c8b-1b2f80962b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ab4194b8-7b2f-4412-9c8b-1b2f80962b46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2e72fdfc-2b04-41ef-89c0-0ed6a4636fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2e72fdfc-2b04-41ef-89c0-0ed6a4636fdf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f083c335-57da-4c51-be5f-8d5ff7174404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f083c335-57da-4c51-be5f-8d5ff7174404" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_226f500d-3496-4ae0-8695-a4b2d5c512ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_226f500d-3496-4ae0-8695-a4b2d5c512ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbd7fb0e-38cf-42b5-9e0d-99c93d8c442d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbd7fb0e-38cf-42b5-9e0d-99c93d8c442d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_933f50c4-ce69-4d9c-b837-4fde468e924a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_933f50c4-ce69-4d9c-b837-4fde468e924a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40ba9d32-d360-4c0b-8c6b-ad4939fd9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40ba9d32-d360-4c0b-8c6b-ad4939fd9e37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_05952b6d-54be-449f-821c-e5e92682dda4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_05952b6d-54be-449f-821c-e5e92682dda4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_224d2bc0-5bce-454a-87bb-ba9bdd6638c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_224d2bc0-5bce-454a-87bb-ba9bdd6638c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3695eef6-9d4d-466c-ac16-ff2c7faa3380_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3695eef6-9d4d-466c-ac16-ff2c7faa3380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e033266d-6ad1-4863-a66a-1b9d1e3bed6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e033266d-6ad1-4863-a66a-1b9d1e3bed6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d208acda-96bf-42e1-9fa9-f396f6b8e364_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d208acda-96bf-42e1-9fa9-f396f6b8e364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3373e616-f156-44f3-b543-fbcc06f94c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3373e616-f156-44f3-b543-fbcc06f94c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c08fd885-9b73-46a2-8530-79a36411b7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c08fd885-9b73-46a2-8530-79a36411b7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e99fda61-0ce9-478e-b979-f36fad92bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e99fda61-0ce9-478e-b979-f36fad92bca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_59631552-2f6e-4674-b471-d417d7168950_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_59631552-2f6e-4674-b471-d417d7168950_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0d6adc2f-3e2c-473a-bf63-cd5483eb21bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0d6adc2f-3e2c-473a-bf63-cd5483eb21bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="extended" id="i2817434f16004a948a287a34ce309b97_FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_aabc58d4-9fe0-44b8-8da6-95fce27b6970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_aabc58d4-9fe0-44b8-8da6-95fce27b6970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:to="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2385773-76d5-4a36-86b9-ffd4fa9eed0d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:to="loc_srt_RangeMember_c2385773-76d5-4a36-86b9-ffd4fa9eed0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:to="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_56b08263-54ac-4f90-aa14-0ff728459823" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_WeightedAverageMember_56b08263-54ac-4f90-aa14-0ff728459823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bec6b039-2388-46b4-90ea-6d354d9961ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_MinimumMember_bec6b039-2388-46b4-90ea-6d354d9961ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dd09073-3489-46c7-8e20-08b855de6eb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_MaximumMember_6dd09073-3489-46c7-8e20-08b855de6eb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_870b5d78-a4d2-48d6-8472-6832989b6b51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_870b5d78-a4d2-48d6-8472-6832989b6b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8bb34b54-1478-4ff0-aed7-3dec7659d13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8bb34b54-1478-4ff0-aed7-3dec7659d13a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_db96dbaa-b26c-478a-ba60-e1d41f53f6f7" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_db96dbaa-b26c-478a-ba60-e1d41f53f6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_1a4f8bef-6877-40a1-a12f-3d9b3ae58489" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_1a4f8bef-6877-40a1-a12f-3d9b3ae58489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember_95ee7ce6-bb4c-49e8-ac0e-95f410167f0d" xlink:href="abbv-20220630.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProjectedYearofPaymentsMember_95ee7ce6-bb4c-49e8-ac0e-95f410167f0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a777a81f-7bd2-4ca7-bb83-4a717fdce19f" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a777a81f-7bd2-4ca7-bb83-4a717fdce19f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended" id="i9c77c894e3f5449e9451565b3cc1bbce_FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_8de33768-7580-4c96-b99a-4f9f95bd2111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_us-gaap_ShorttermDebtFairValue_8de33768-7580-4c96-b99a-4f9f95bd2111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_95035f6f-6c8b-4ea6-9d32-60754ae86fa7" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_95035f6f-6c8b-4ea6-9d32-60754ae86fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_843c419b-801d-4bf9-a334-f4ef3494a3d6" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_843c419b-801d-4bf9-a334-f4ef3494a3d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_46c007f6-bb4a-45f3-b855-587bbd84e89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_46c007f6-bb4a-45f3-b855-587bbd84e89a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5a05bc4a-5af0-448e-81e9-fe2ea3559682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5a05bc4a-5af0-448e-81e9-fe2ea3559682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cf6d4db2-250c-4b38-810e-2db1de7edabc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cf6d4db2-250c-4b38-810e-2db1de7edabc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8eec17a-3c8d-4132-8df8-c4b10af3299a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8eec17a-3c8d-4132-8df8-c4b10af3299a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e392a532-c0ee-4dd3-9f78-fa6a41e46f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e392a532-c0ee-4dd3-9f78-fa6a41e46f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c13251e-199e-4a2c-9ed1-d9135c52c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c13251e-199e-4a2c-9ed1-d9135c52c7da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddec9ea7-8685-4458-ba33-51a2487638a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddec9ea7-8685-4458-ba33-51a2487638a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d58efb7c-1ef5-4d26-a993-2b9b61473aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d58efb7c-1ef5-4d26-a993-2b9b61473aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_57287bc6-622a-4de7-b44d-70947bc27d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_57287bc6-622a-4de7-b44d-70947bc27d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_da2e0cad-a4b1-49e0-a696-ad42f28445df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_da2e0cad-a4b1-49e0-a696-ad42f28445df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="extended" id="i22450b7fee0c4903929b21ce00401d1d_FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers_271c03cb-ea15-4e3d-8120-125dbdbf04b8" xlink:href="abbv-20220630.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:to="loc_abbv_NumberOfPrincipalUSCustomers_271c03cb-ea15-4e3d-8120-125dbdbf04b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c5e75515-69b9-4d59-b58f-1c15ed1b709d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c5e75515-69b9-4d59-b58f-1c15ed1b709d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:to="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_412ad0b8-d9b9-471e-aad6-94ca1ebf21f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:to="loc_us-gaap_AccountsReceivableMember_412ad0b8-d9b9-471e-aad6-94ca1ebf21f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_24c062cc-d27f-4ff3-b404-9421a9729dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:to="loc_us-gaap_SalesRevenueNetMember_24c062cc-d27f-4ff3-b404-9421a9729dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0287c3ea-ee3c-4708-8cff-ec4d5beb4758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0287c3ea-ee3c-4708-8cff-ec4d5beb4758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_912373cc-e8e2-4389-82fb-08983e3e7d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_912373cc-e8e2-4389-82fb-08983e3e7d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_c4bd35d6-6929-423a-a470-261489c01de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_c4bd35d6-6929-423a-a470-261489c01de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27cc9df2-7f82-4c65-9a2d-7731414b7fb7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:to="loc_srt_ProductsAndServicesDomain_27cc9df2-7f82-4c65-9a2d-7731414b7fb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:to="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_47a2d89d-d41b-49a4-8e33-8785830e9aa0" xlink:href="abbv-20220630.xsd#abbv_HUMIRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:to="loc_abbv_HUMIRAMember_47a2d89d-d41b-49a4-8e33-8785830e9aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_005c50bb-a083-415c-808e-6041629fce43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:to="loc_srt_NameOfMajorCustomerDomain_005c50bb-a083-415c-808e-6041629fce43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember_c7dd8d2f-7e8c-49fd-94fb-efb81246d6f0" xlink:href="abbv-20220630.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:to="loc_abbv_PrincipalUSCustomersMember_c7dd8d2f-7e8c-49fd-94fb-efb81246d6f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="extended" id="i50d18d0f92c241349107c7b944ea0cfc_FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_689b86e3-5d2a-4cab-b1ac-32fd7d9e3427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_689b86e3-5d2a-4cab-b1ac-32fd7d9e3427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05e4793a-91d7-4376-bc67-52bfedc2f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05e4793a-91d7-4376-bc67-52bfedc2f28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_9262ca83-3224-4447-8aaf-9f98463941d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_9262ca83-3224-4447-8aaf-9f98463941d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_effc6477-9561-40ef-abbc-47ea1c9a0bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_effc6477-9561-40ef-abbc-47ea1c9a0bb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0158f0ec-797c-4e92-866f-865c75858be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_LongTermDebt_0158f0ec-797c-4e92-866f-865c75858be6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eb6a019e-99bd-4c85-b341-0e605b62fb73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eb6a019e-99bd-4c85-b341-0e605b62fb73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember_a277ba69-c47d-4895-9142-9e7a86db9903" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDue2022At3.450PercentMember_a277ba69-c47d-4895-9142-9e7a86db9903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_d6a6248a-029d-479f-bfae-4db0aac15931" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_d6a6248a-029d-479f-bfae-4db0aac15931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_dde64712-7094-411c-8b6b-497ef3154c6c" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_dde64712-7094-411c-8b6b-497ef3154c6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.250PercentMember_26456e95-1038-4b1c-bcc4-2a76d344f6f3" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDue2022At3.250PercentMember_26456e95-1038-4b1c-bcc4-2a76d344f6f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotes2.30PercentDue2021Member_7c24af99-897d-4427-937c-4daad6c5a27c" xlink:href="abbv-20220630.xsd#abbv_SeniorNotes2.30PercentDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotes2.30PercentDue2021Member_7c24af99-897d-4427-937c-4daad6c5a27c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember_6c7b8283-02ee-46e3-879a-a9bd91d2e12c" xlink:href="abbv-20220630.xsd#abbv_SeniorEuroNotesDue2021At0.500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember_6c7b8283-02ee-46e3-879a-a9bd91d2e12c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_8b54d38c-b5c5-4bcc-9fdb-a547d118f4ea" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDueInMay2021AtFloatingRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_8b54d38c-b5c5-4bcc-9fdb-a547d118f4ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e9a761dd-084a-428c-9973-edf29f67aabd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e9a761dd-084a-428c-9973-edf29f67aabd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3c793033-ff8a-4fdd-af96-d5f2b7377851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:to="loc_us-gaap_SeniorNotesMember_3c793033-ff8a-4fdd-af96-d5f2b7377851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4de46ff4-2135-4e50-b90e-05c7e5214dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:to="loc_us-gaap_LoansPayableMember_4de46ff4-2135-4e50-b90e-05c7e5214dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d842600c-d05c-4835-972a-367a8e2ba395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:to="loc_us-gaap_SubsequentEventMember_d842600c-d05c-4835-972a-367a8e2ba395" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#PostEmploymentBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended" id="i28482f89fc3a44b1b541a5bb5d717874_PostEmploymentBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_069118a9-d330-44ab-a3fb-b8acebac15e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_069118a9-d330-44ab-a3fb-b8acebac15e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_4c5c1a7a-0ad6-40fd-8879-5ba3d1462c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_4c5c1a7a-0ad6-40fd-8879-5ba3d1462c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5fc0d60f-0698-4485-838c-dd9784f72f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5fc0d60f-0698-4485-838c-dd9784f72f42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dfd9afe0-4e4e-404a-a312-5d3a50820918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dfd9afe0-4e4e-404a-a312-5d3a50820918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_2bcc0ed0-3a41-4196-bfce-0e03213bee29" xlink:href="abbv-20220630.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_2bcc0ed0-3a41-4196-bfce-0e03213bee29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a3e661b-5332-4628-9a15-aefa8ff4e131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a3e661b-5332-4628-9a15-aefa8ff4e131" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8a908594-e6a8-40ec-b5ad-9ca28efc4654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8a908594-e6a8-40ec-b5ad-9ca28efc4654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d72c1f20-4109-4f54-a95c-4efe68832788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d72c1f20-4109-4f54-a95c-4efe68832788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2709b6e6-5556-4277-83ce-ee228f8734b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2709b6e6-5556-4277-83ce-ee228f8734b8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended" id="ieb5171c98152491692dbedf3bf2d8af1_EquityStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28996676-258e-4b04-bb21-2004803f4b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28996676-258e-4b04-bb21-2004803f4b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5c680c47-9c43-43f5-b64d-dbbfadfb4f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5c680c47-9c43-43f5-b64d-dbbfadfb4f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_435b478f-07f4-415f-ae8a-0eab120671b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_435b478f-07f4-415f-ae8a-0eab120671b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69169afa-9bf4-4bb2-9d0f-7a497cdab807_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69169afa-9bf4-4bb2-9d0f-7a497cdab807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_95802860-1322-4489-bffc-7db7ee07cfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_CostOfSalesMember_95802860-1322-4489-bffc-7db7ee07cfd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699ca783-c3a7-419c-8d52-9c729ab3a2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699ca783-c3a7-419c-8d52-9c729ab3a2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_34e77f0d-ba8a-47c4-86c6-694a03802508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_34e77f0d-ba8a-47c4-86c6-694a03802508" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="extended" id="i9160469e491e4845a85626ec98ff27d5_EquityStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a92f75f-934c-4ec0-8d86-9e9667f19da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a92f75f-934c-4ec0-8d86-9e9667f19da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_887b3a51-8774-4417-ab30-56fa1650651e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_887b3a51-8774-4417-ab30-56fa1650651e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d328bcf3-d33f-450b-a031-3dec408ceb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d328bcf3-d33f-450b-a031-3dec408ceb8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_483cab86-b2f6-4ebd-aa0f-2eec7a2560d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_483cab86-b2f6-4ebd-aa0f-2eec7a2560d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:to="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1f960f9-edc3-4d4d-9723-0bdf22b294ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1f960f9-edc3-4d4d-9723-0bdf22b294ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78a236aa-9e5f-4654-84c0-1e14d924c603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78a236aa-9e5f-4654-84c0-1e14d924c603" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityRSUsandPerformanceSharesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="extended" id="i14413b1bf86b4fbfabb1038de1634287_EquityRSUsandPerformanceSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8686d14-de00-479f-86a8-bbc731f84efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8686d14-de00-479f-86a8-bbc731f84efe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_182aa17b-5925-4b6d-b197-87b7c98441fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_182aa17b-5925-4b6d-b197-87b7c98441fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_737949b6-6572-4629-88d2-e94228df0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_737949b6-6572-4629-88d2-e94228df0d4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5d80a42d-c38e-4f92-b941-4cdb07d0bac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5d80a42d-c38e-4f92-b941-4cdb07d0bac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:to="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b52b0777-5017-47ec-8377-4a89c044236a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b52b0777-5017-47ec-8377-4a89c044236a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_2301430e-35f1-493e-877b-e0a8cfe12297" xlink:href="abbv-20220630.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:to="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_2301430e-35f1-493e-877b-e0a8cfe12297" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockRepurchaseProgramDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="extended" id="if07216504f464ff0896c37626ba1bb12_EquityStockRepurchaseProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d3bfe460-c884-4b9b-aab9-2fb1b5c3cd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d3bfe460-c884-4b9b-aab9-2fb1b5c3cd6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7b3d87dd-4bb0-4d1d-87e1-0ed7202688db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7b3d87dd-4bb0-4d1d-87e1-0ed7202688db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a453c20e-93fc-4001-97e8-e3d81f0712bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a453c20e-93fc-4001-97e8-e3d81f0712bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7283c9fa-a5fa-4bd1-9232-a315242b4969_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7283c9fa-a5fa-4bd1-9232-a315242b4969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember_f8628c3d-20a9-425b-9096-26ecfdf6fb2a" xlink:href="abbv-20220630.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:to="loc_abbv_December2018StockRepurchaseAuthorizationMember_f8628c3d-20a9-425b-9096-26ecfdf6fb2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i02252a9fc60f4522b7e8ea307de983c0_EquityAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b39b7bab-9796-4912-b4f1-0c1a511494e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b39b7bab-9796-4912-b4f1-0c1a511494e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a0687e4c-5843-43be-9d22-13cdb48e849b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a0687e4c-5843-43be-9d22-13cdb48e849b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_553a79d9-6940-4200-915e-f217dbeebbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_553a79d9-6940-4200-915e-f217dbeebbad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0931b71e-061c-4e54-9bc2-2568454649cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0931b71e-061c-4e54-9bc2-2568454649cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b327c4f4-b213-442f-a03b-fec8d1138231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa53337d-3523-4158-b92c-266728f5a39c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:to="loc_us-gaap_EquityComponentDomain_aa53337d-3523-4158-b92c-266728f5a39c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:to="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2e7d626d-f836-40b2-9b3e-764addedbf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2e7d626d-f836-40b2-9b3e-764addedbf6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_dec344f0-1fbc-410e-b432-e0d62bc87691" xlink:href="abbv-20220630.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_dec344f0-1fbc-410e-b432-e0d62bc87691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7d557d6b-cc32-4aa9-b6f5-6856982d8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7d557d6b-cc32-4aa9-b6f5-6856982d8e43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37a36873-f35f-4890-91ac-e4ba86616cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37a36873-f35f-4890-91ac-e4ba86616cdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01c10c74-dff7-494a-a369-d8b5166bc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01c10c74-dff7-494a-a369-d8b5166bc15c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="ib7bedb58a789486c83a822b3e7e68cd8_EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fbb6565-6df5-4f2d-86e4-035a6b4c5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fbb6565-6df5-4f2d-86e4-035a6b4c5d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_947026ab-0c71-4d23-804d-569e5f75490d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_947026ab-0c71-4d23-804d-569e5f75490d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24089b48-7a04-4126-aa32-7808b74452e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_NetIncomeLoss_24089b48-7a04-4126-aa32-7808b74452e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2519c3f2-f20e-4029-9085-1938158fdaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2519c3f2-f20e-4029-9085-1938158fdaa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_c82f55e7-475e-40db-9858-429f746f2729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_c82f55e7-475e-40db-9858-429f746f2729" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_17880b7d-4846-469a-b0f6-74db4779d6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_17880b7d-4846-469a-b0f6-74db4779d6d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d7864610-0eee-459a-9547-f5bf7424099e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d7864610-0eee-459a-9547-f5bf7424099e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_770027d7-91a6-4a24-a77d-b70f1b23326f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_770027d7-91a6-4a24-a77d-b70f1b23326f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_89d3abba-4871-4d8e-a0fe-9c3f4db15f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_89d3abba-4871-4d8e-a0fe-9c3f4db15f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_288f41d8-2564-46d7-a6a0-88e97b9a25ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_TreasuryLockMember_288f41d8-2564-46d7-a6a0-88e97b9a25ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_97864738-7f6c-416f-9b8e-7e94e657f3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_InterestRateSwapMember_97864738-7f6c-416f-9b8e-7e94e657f3c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8884ec9b-2368-4deb-af91-7effc975dbbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8884ec9b-2368-4deb-af91-7effc975dbbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_37efae2f-b011-46bf-a873-1342bc03b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_37efae2f-b011-46bf-a873-1342bc03b6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_010864ac-61ab-4d7d-97cc-e82a954809e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_010864ac-61ab-4d7d-97cc-e82a954809e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ea513007-a25a-4bd9-b40b-0f031245c074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ea513007-a25a-4bd9-b40b-0f031245c074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5159db2-4412-4911-b287-0938d37896d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:to="loc_us-gaap_EquityComponentDomain_c5159db2-4412-4911-b287-0938d37896d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:to="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_30ad685c-6cbe-49a2-91da-304af35e5f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_30ad685c-6cbe-49a2-91da-304af35e5f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ab6846d3-3b5c-491c-926d-58fc281b2074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ab6846d3-3b5c-491c-926d-58fc281b2074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_155c3d42-c97c-4fb6-9542-029c41e71b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_155c3d42-c97c-4fb6-9542-029c41e71b0a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#LegalProceedingsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="extended" id="ib57945ff69474a01ac5d1e38bb045139_LegalProceedingsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_b463abf0-e0e0-4a74-99a9-5d2ea71524be" xlink:href="abbv-20220630.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_b463abf0-e0e0-4a74-99a9-5d2ea71524be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber_c51db00b-5aae-4879-a961-4ccdc9550d96" xlink:href="abbv-20220630.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyPurportedClassActionsNumber_c51db00b-5aae-4879-a961-4ccdc9550d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e9b2653e-b1c1-4564-89c9-26cef4ea6f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e9b2653e-b1c1-4564-89c9-26cef4ea6f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_b99c1461-612e-41e9-a78e-066fff1e8fb4" xlink:href="abbv-20220630.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_b99c1461-612e-41e9-a78e-066fff1e8fb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber_051f58b1-cdee-4569-81ce-6692fa8cf09f" xlink:href="abbv-20220630.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_PutativeClassActionLawsuitIndividualNumber_051f58b1-cdee-4569-81ce-6692fa8cf09f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9e0ca539-9ea6-4ef3-96f2-ce99e3f64456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9e0ca539-9ea6-4ef3-96f2-ce99e3f64456" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_28f17282-3a93-4647-8c2d-4f0a77279e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_28f17282-3a93-4647-8c2d-4f0a77279e84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d42d3329-a917-46c9-945d-550791b7ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d42d3329-a917-46c9-945d-550791b7ab96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_5d426199-e69c-41a0-b3e2-64d26c2d7d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_5d426199-e69c-41a0-b3e2-64d26c2d7d2c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:to="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:to="loc_srt_LitigationCaseTypeDomain_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:to="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember_2c239ba9-4151-4f6e-bb1b-ef739b4164f4" xlink:href="abbv-20220630.xsd#abbv_NiaspanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_NiaspanMember_2c239ba9-4151-4f6e-bb1b-ef739b4164f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_52bc7fbc-b3df-473e-a661-ee2ea81dca2c" xlink:href="abbv-20220630.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_52bc7fbc-b3df-473e-a661-ee2ea81dca2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_a3d65f36-90ef-4fde-93d2-e857632cf809" xlink:href="abbv-20220630.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_a3d65f36-90ef-4fde-93d2-e857632cf809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember_b48ea73f-ce74-4878-a4bb-b3702c07b512" xlink:href="abbv-20220630.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_BystolicAntitrustLitigationMember_b48ea73f-ce74-4878-a4bb-b3702c07b512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember_88682535-ea9d-4563-a9c7-3a537bd4e1f0" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationMember_88682535-ea9d-4563-a9c7-3a537bd4e1f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_2ab93c9f-2c0d-4e7a-9922-3eed08d30ad9" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_2ab93c9f-2c0d-4e7a-9922-3eed08d30ad9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member_e8f73926-8843-4124-b9bb-ac770fe7666e" xlink:href="abbv-20220630.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_ElliottAssociatesL.P.Member_e8f73926-8843-4124-b9bb-ac770fe7666e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a32e7090-0de2-4937-ba7a-acf45a3bb2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a32e7090-0de2-4937-ba7a-acf45a3bb2b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#SegmentInformationDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="extended" id="i739b738dd67f4ee584f2d2799f745025_SegmentInformationDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f4e3ec-1484-48bd-b343-964716d3d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f4e3ec-1484-48bd-b343-964716d3d2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_4b834ecb-91ec-444f-b139-1604741ffa70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_4b834ecb-91ec-444f-b139-1604741ffa70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07258b39-00dd-4d16-9a0a-2e8457d633e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_Revenues_07258b39-00dd-4d16-9a0a-2e8457d633e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_7f59b1fe-f975-492b-a72f-99515448eb08_default" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:to="loc_abbv_KeyProductPortfolioDomain_7f59b1fe-f975-492b-a72f-99515448eb08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:to="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember_bd948191-61d4-4dee-aeeb-1d40537f6905" xlink:href="abbv-20220630.xsd#abbv_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_ImmunologyMember_bd948191-61d4-4dee-aeeb-1d40537f6905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember_d0ac5402-ce22-4a4f-be72-d482caa40584" xlink:href="abbv-20220630.xsd#abbv_HematologicOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_HematologicOncologyMember_d0ac5402-ce22-4a4f-be72-d482caa40584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember_65d51cbb-724b-4c27-8c51-22573912bbfa" xlink:href="abbv-20220630.xsd#abbv_AestheticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_AestheticsMember_65d51cbb-724b-4c27-8c51-22573912bbfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember_4f41bef2-34bc-4872-ac19-ef1dd1e3e1b2" xlink:href="abbv-20220630.xsd#abbv_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_NeuroscienceMember_4f41bef2-34bc-4872-ac19-ef1dd1e3e1b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember_e793e681-e282-4ede-8e23-e3494184ec75" xlink:href="abbv-20220630.xsd#abbv_EyeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_EyeCareMember_e793e681-e282-4ede-8e23-e3494184ec75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember_8a51d10c-d846-4bd1-b51c-67fe05677aaf" xlink:href="abbv-20220630.xsd#abbv_OtherKeyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_OtherKeyProductsMember_8a51d10c-d846-4bd1-b51c-67fe05677aaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73047e4d-2f5d-496a-942e-25b3f110229a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:to="loc_srt_ProductsAndServicesDomain_73047e4d-2f5d-496a-942e-25b3f110229a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:to="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_e3fd2f17-2ae5-404d-bc45-b01ce7929412" xlink:href="abbv-20220630.xsd#abbv_HUMIRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_HUMIRAMember_e3fd2f17-2ae5-404d-bc45-b01ce7929412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember_22b2b7f1-c0fa-466f-9796-da1a40b6e335" xlink:href="abbv-20220630.xsd#abbv_SKYRIZIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_SKYRIZIMember_22b2b7f1-c0fa-466f-9796-da1a40b6e335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember_7ba76d5d-e2db-4aa4-a0a9-9cdb69408be6" xlink:href="abbv-20220630.xsd#abbv_RINVOQMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_RINVOQMember_7ba76d5d-e2db-4aa4-a0a9-9cdb69408be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember_8a85882f-c2bf-4e47-b104-2d804d6dc1da" xlink:href="abbv-20220630.xsd#abbv_ImbruvicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_ImbruvicaMember_8a85882f-c2bf-4e47-b104-2d804d6dc1da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember_f1683550-a950-4d31-ac1e-4b489caabe83" xlink:href="abbv-20220630.xsd#abbv_VENCLEXTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_VENCLEXTAMember_f1683550-a950-4d31-ac1e-4b489caabe83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember_d4817169-aaeb-4469-a206-e2284d75477f" xlink:href="abbv-20220630.xsd#abbv_BotoxCosmeticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_BotoxCosmeticMember_d4817169-aaeb-4469-a206-e2284d75477f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember_6a5d5a6a-7673-4fc0-9328-61b034b1bb87" xlink:href="abbv-20220630.xsd#abbv_JuvedermCollectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_JuvedermCollectionMember_6a5d5a6a-7673-4fc0-9328-61b034b1bb87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember_88e0c753-7be9-462b-b084-2306eb0647ef" xlink:href="abbv-20220630.xsd#abbv_OtherAestheticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherAestheticsMember_88e0c753-7be9-462b-b084-2306eb0647ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember_e607e17c-4d6d-4a94-a9d6-5c4eb3e070da" xlink:href="abbv-20220630.xsd#abbv_BotoxTherapeuticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_BotoxTherapeuticMember_e607e17c-4d6d-4a94-a9d6-5c4eb3e070da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember_20d47da0-6320-42fc-85fc-9bfc5ba02105" xlink:href="abbv-20220630.xsd#abbv_VraylarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_VraylarMember_20d47da0-6320-42fc-85fc-9bfc5ba02105" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember_5667a951-bc04-4f63-9214-f09e61fd277f" xlink:href="abbv-20220630.xsd#abbv_DuodopaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_DuodopaMember_5667a951-bc04-4f63-9214-f09e61fd277f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember_36bff0f1-a488-49b3-9312-bbd9557d4e56" xlink:href="abbv-20220630.xsd#abbv_UbrelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_UbrelvyMember_36bff0f1-a488-49b3-9312-bbd9557d4e56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember_432c21d6-a41f-4382-8084-d686d18566f6" xlink:href="abbv-20220630.xsd#abbv_QuliptaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_QuliptaMember_432c21d6-a41f-4382-8084-d686d18566f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember_105fe386-a137-4a71-bfd1-804c3e7c4b6b" xlink:href="abbv-20220630.xsd#abbv_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherNeuroscienceMember_105fe386-a137-4a71-bfd1-804c3e7c4b6b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember_46800765-03c5-416c-aee3-6ba9f3956b94" xlink:href="abbv-20220630.xsd#abbv_LumiganGanfortMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_LumiganGanfortMember_46800765-03c5-416c-aee3-6ba9f3956b94" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember_84005984-1fdd-40d0-9a3f-4494b83074df" xlink:href="abbv-20220630.xsd#abbv_AlphaganCombiganMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_AlphaganCombiganMember_84005984-1fdd-40d0-9a3f-4494b83074df" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember_e164f5e1-9f25-4ed2-b190-9ac3028efacf" xlink:href="abbv-20220630.xsd#abbv_RestasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_RestasisMember_e164f5e1-9f25-4ed2-b190-9ac3028efacf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember_63f72989-66f1-45e3-b646-e9885e038b0a" xlink:href="abbv-20220630.xsd#abbv_OtherEyeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherEyeCareMember_63f72989-66f1-45e3-b646-e9885e038b0a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember_1c628d18-af5d-4094-baea-d50b46ffaf6c" xlink:href="abbv-20220630.xsd#abbv_MAVYRETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_MAVYRETMember_1c628d18-af5d-4094-baea-d50b46ffaf6c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember_50bbc732-42da-41db-bc7e-2a0ebba678fa" xlink:href="abbv-20220630.xsd#abbv_CreonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_CreonMember_50bbc732-42da-41db-bc7e-2a0ebba678fa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember_bb14ed7c-fa58-458d-a717-911ca4f32518" xlink:href="abbv-20220630.xsd#abbv_LinzessConstellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_LinzessConstellaMember_bb14ed7c-fa58-458d-a717-911ca4f32518" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember_39578051-9cb7-4f8e-bbb1-d3fb3bc915f0" xlink:href="abbv-20220630.xsd#abbv_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherProductsMember_39578051-9cb7-4f8e-bbb1-d3fb3bc915f0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:to="loc_srt_SegmentGeographicalDomain_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:to="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1b42a469-9685-4fd7-a095-d8a4c37a5592" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:to="loc_country_US_1b42a469-9685-4fd7-a095-d8a4c37a5592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5bdeecd7-da1c-41ad-811c-973c7e5a9453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:to="loc_us-gaap_NonUsMember_5bdeecd7-da1c-41ad-811c-973c7e5a9453" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>abbv-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_exch_XCHI_e7f3eeab-b5b0-4acc-aead-8511203a844e_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_2c0b2abb-32cb-4dcd-91e9-2cc8768410f1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_434944e4-a160-4a6c-8c18-e5b48970c88d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_dae9e8b0-d5dc-476d-bc2f-e3c9623ce663_terseLabel_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected year of payments</link:label>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_label_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Year of Payments [Member]</link:label>
    <link:label id="lab_abbv_ProjectedYearofPaymentsMember_documentation_en-US" xlink:label="lab_abbv_ProjectedYearofPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents projected year of payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember" xlink:href="abbv-20220630.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProjectedYearofPaymentsMember" xlink:to="lab_abbv_ProjectedYearofPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_a9ff0108-b3a4-40ea-b1bf-ed7cf11e223e_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings and Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2d1ce437-0db5-49d2-be26-25b3fbd0fd0e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_51af4737-4bc5-4456-8722-db7bf4f57a0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of actuarial losses and other</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e56e0088-8d2e-4a95-b4d4-8347a954e96d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9d96caaf-70e7-4b34-9b0e-d5d1916aa704_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4f1b93a5-88a9-4d56-af41-d4f78e8d35f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f9bae1e8-851f-4d8e-a3db-a472d451e280_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c36e41b0-c845-41e6-809b-2ef5b8bc8edb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_b1090c70-f423-431c-8b6a-e605700fa24a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5a570624-2dcf-4e2d-869d-e51c29265bc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6e651199-884d-4957-9332-656a98fae3d8_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_220e2b39-ebcd-461f-b1e2-35533835c4e7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_80a02ac7-7d90-4349-b717-ceae223d7928_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_61e7e529-2ab5-4059-a23b-99a62d8fa51e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_17b509ea-5020-41ad-94af-405c38c7ae79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_df67873a-13b2-410b-bffb-3565b5de9b74_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_400a5bcb-c5b0-4760-b61d-533b9ea3a8c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7499f795-089e-4d8f-9d6e-28546865452a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5a9202c5-50fa-48c2-bf3d-d2d2316c59d8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_c2272b57-bb27-47d0-89d6-155b5f3d83c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_e4611dcc-5ce4-4fcf-acbf-86c2924a4cd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets or liabilities between the fair value measurement levels</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f5ce714e-fc34-4cc7-9876-bce8d4380062_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9335062-73a1-48e8-93c0-3137415d0de1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_8a39b1f5-a2db-4d04-929e-7b988a36cf82_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_03907f91-6534-4301-bdb5-be5cdb2cf6d4_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and milestones</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_abeceecc-ec93-4470-abac-b86e80f61f2b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ac63342-c240-4d75-a28b-eb3402ae9f38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b78aa198-ef30-4668-aaf8-bc7aa11f6cfb_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in net earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_128104d9-c9ae-4e4c-ac1a-270705794d39_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_f704e191-2d66-4619-abac-352b1899237d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7da547cd-3a88-4048-9aec-18cb332fb5cb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_5a47f4b4-947a-41c0-9c42-0d4a796c5fba_terseLabel_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_label_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:href="abbv-20220630.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:to="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_8c68cb8c-d6be-4576-8624-f834bdf0e778_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ea650aba-9891-45d2-9ca2-edfad9547fbb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65587f7c-2d2e-48cb-b2f3-c7bd835fcfd9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_dc4861fb-0503-43c2-affc-2291837c3f55_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_11d30735-691f-42b4-84e4-9239fcac9c2d_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6e53b8ae-8191-4a31-b989-e4282730d2ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of cash activity in the restructuring reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4f5bf784-7e85-4e45-92b7-bedbcb5a44d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining share repurchase authorization amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_DuodopaMember_35fd198f-0098-409c-aa42-5fbebd90aa7d_terseLabel_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duodopa</link:label>
    <link:label id="lab_abbv_DuodopaMember_label_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duodopa [Member]</link:label>
    <link:label id="lab_abbv_DuodopaMember_documentation_en-US" xlink:label="lab_abbv_DuodopaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Duodopa, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember" xlink:href="abbv-20220630.xsd#abbv_DuodopaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_DuodopaMember" xlink:to="lab_abbv_DuodopaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_67c4bd18-2752-4908-9934-6406e6e7a759_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_68998587-ce6b-4f40-a5a2-a48534b2ead5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8b0b3cfc-030e-41a1-b272-9d82be7d19d1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_467cff9f-bd3a-4a11-9040-82cc8aa94a7b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from the assessment of effectiveness for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:to="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_d3b3dbe7-ca96-413a-96c9-457da0437426_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_JanssenBiotechIncMember_113235b4-d176-45b6-afc6-c49a21427d3d_terseLabel_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_abbv_JanssenBiotechIncMember_label_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_abbv_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_abbv_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertains to the entity Janssen Biotech Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember" xlink:href="abbv-20220630.xsd#abbv_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_JanssenBiotechIncMember" xlink:to="lab_abbv_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b6dff1f4-d6fd-4d8c-9d94-0a538b475a1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_809c727f-9536-4d9c-aa6f-ef7b514154a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_90d8caa6-9c13-4da0-9381-c7c53ead3342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3766abb9-8811-4eb3-aae1-0dd03deb906c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_a280ac29-3099-4e85-8634-3db18e3f8a65_terseLabel_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elliott Associates, L.P.</link:label>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_label_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elliott Associates, L.P. [Member]</link:label>
    <link:label id="lab_abbv_ElliottAssociatesL.P.Member_documentation_en-US" xlink:label="lab_abbv_ElliottAssociatesL.P.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Elliot Associates, LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member" xlink:href="abbv-20220630.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ElliottAssociatesL.P.Member" xlink:to="lab_abbv_ElliottAssociatesL.P.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f4e58c44-a40a-47c3-a0f5-8d00373818f1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International - AbbVie's share of profits (included in net revenues)</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_0a7c9934-cd6b-4779-bab1-60579268722b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_35448f69-2dd2-45b9-9336-ebf17b6ef01b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_de7eebc4-7f77-49a5-844d-1aeff1f9311a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_af469267-209c-42f7-9cd7-26995cc0269f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c396c806-6d4a-48f0-9a03-413534a0521f_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential change in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55238c90-d740-48eb-b701-4402046805b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_05636263-ad59-4b20-8b76-78da8d71f5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c7edf888-19e1-40ac-be20-e1c7b0958ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0f0afa5b-9e2d-4c73-ba0e-bd349a02012d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5f30e0a5-787e-4298-80ad-1f72411f7614_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e917d394-de3a-4d53-9833-3445c7af72d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0d4098ec-5879-4e37-a235-07727e147146_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a765955-f925-48c9-b453-a7eb03e82db0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesAndFairValueTextBlock_43393b8e-be28-42d7-8ae7-7d06139aa274_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Fair Value Measures</link:label>
    <link:label id="lab_us-gaap_DerivativesAndFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesAndFairValueTextBlock" xlink:to="lab_us-gaap_DerivativesAndFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_51536111-e619-413d-b7ad-28f2df5011e3_terseLabel_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring</link:label>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_label_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Plans [Member]</link:label>
    <link:label id="lab_abbv_OtherRestructuringPlansMember_documentation_en-US" xlink:label="lab_abbv_OtherRestructuringPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents other restructuring plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember" xlink:href="abbv-20220630.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherRestructuringPlansMember" xlink:to="lab_abbv_OtherRestructuringPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d9c4e679-75ec-4e8a-993b-ee71eda9a941_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ImbruvicaMember_7822433b-9635-432f-8421-4536047abc64_terseLabel_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:label id="lab_abbv_ImbruvicaMember_label_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica [Member]</link:label>
    <link:label id="lab_abbv_ImbruvicaMember_documentation_en-US" xlink:label="lab_abbv_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Imbruvica, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember" xlink:href="abbv-20220630.xsd#abbv_ImbruvicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ImbruvicaMember" xlink:to="lab_abbv_ImbruvicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0ef097d3-3b51-4f91-a407-6032322a4b66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable input for contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f9cae4f2-dd89-4854-9094-f0f353c6c065_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a44239f-4ab1-44c9-a070-77927a62982b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8f01bc36-ec8d-46b6-890a-f0f4ead1c8cf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_JuvisePharmaceuticalsMember_41d562a8-c93e-49d9-a26a-baa900d0b675_terseLabel_en-US" xlink:label="lab_abbv_JuvisePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvise Pharmaceuticals</link:label>
    <link:label id="lab_abbv_JuvisePharmaceuticalsMember_label_en-US" xlink:label="lab_abbv_JuvisePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvise Pharmaceuticals [Member]</link:label>
    <link:label id="lab_abbv_JuvisePharmaceuticalsMember_documentation_en-US" xlink:label="lab_abbv_JuvisePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvise Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvisePharmaceuticalsMember" xlink:href="abbv-20220630.xsd#abbv_JuvisePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_JuvisePharmaceuticalsMember" xlink:to="lab_abbv_JuvisePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c187ae9f-dc74-444b-803a-400d702e591b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_068dc0e9-50f8-4d82-881e-fe392c826a70_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_08a208ed-e685-44b8-b606-85abac9440b2_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual plaintiff lawsuits</link:label>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_label_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Individual Plaintiff Lawsuits Number</link:label>
    <link:label id="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_documentation_en-US" xlink:label="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:href="abbv-20220630.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:to="lab_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_893b0504-e5fe-4b7c-a712-8748155eb1c6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_66061ac8-2906-4b6b-a7e4-2220a85d70d7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ed703042-6a3b-4445-b6ba-f5d1d8bb53e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_b9148ae8-326d-4097-b9eb-864b98a6e2d1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_923d163e-e7ad-4784-b1b5-b47653a88124_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits, net of tax expense (benefit) of $11 for the three months and $21 for the six months ended June 30, 2022 and $14 for the three months and $33 for the six months ended June 30, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_393f1151-8c5c-46e0-a0d8-9c2e48ed99e1_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of generic companies with whom certain litigation related agreements were entered into</link:label>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_label_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws</link:label>
    <link:label id="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_documentation_en-US" xlink:label="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:href="abbv-20220630.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:to="lab_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_490fd8ab-16fb-49d0-adab-1a0721a85eec_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_82ddf614-680c-42a7-8f2b-4d3ff368ca94_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1d774d3c-eaa3-4d1f-bdc3-0fd4158d219b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_11f471d6-b9dc-49e5-812a-c9fcab3f095c_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of collaboration development costs responsible by Janssen (as a percent)</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:to="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0f437ca0-e92c-49ea-9123-857208d30c53_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8efda634-6505-4bf0-9c66-83a09719831a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of worldwide net revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_182c4fcd-66d8-4949-9811-4f27687bdb29_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_d79935c5-4428-43fc-8c77-b31205f85baf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4994559a-b7bb-45b3-a2f3-d5ee88a4d082_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_MAVYRETMember_3423cfdb-f47c-457f-bb32-56c06ffde07b_terseLabel_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mavyret</link:label>
    <link:label id="lab_abbv_MAVYRETMember_label_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAVYRET [Member]</link:label>
    <link:label id="lab_abbv_MAVYRETMember_documentation_en-US" xlink:label="lab_abbv_MAVYRETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to MAVYRET, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember" xlink:href="abbv-20220630.xsd#abbv_MAVYRETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_MAVYRETMember" xlink:to="lab_abbv_MAVYRETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_f5ad2212-3681-43b8-a36e-3b64c204b60e_terseLabel_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating rate notes due 2025</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_label_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025 [Member]</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member_documentation_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:to="lab_abbv_FloatingRateTermLoanTrancheDueMay2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_aabb0592-217e-48ca-819a-1a229b299c72_terseLabel_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan integration plan</link:label>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_label_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Integration Plan [Member]</link:label>
    <link:label id="lab_abbv_AllerganIntegrationPlanMember_documentation_en-US" xlink:label="lab_abbv_AllerganIntegrationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Allergan integration plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember" xlink:href="abbv-20220630.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AllerganIntegrationPlanMember" xlink:to="lab_abbv_AllerganIntegrationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_84c1b905-dff7-477c-9fd3-46308a40ca71_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_76a1f1e7-05ab-447b-a96f-c5173b6e5c06_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value - Derivatives in asset position</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_592f01b6-b00a-413f-a74f-b153ab8b628a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_120f854c-3744-4758-994e-47660f6f1377_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of healthcare benefit providers acting as plaintiff in lawsuit</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_717596c0-4c89-410e-8898-235a73c67a9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_5601499e-4fde-4610-9679-8e511bdb7827_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_0b791ec1-71e6-4709-9c86-f43eaa0d9035_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7f8d3f2c-591a-4aff-8d68-53e194500ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_fbf73b6c-5568-4dcd-82d4-b8e239c1deae_terseLabel_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense from research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:href="abbv-20220630.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:to="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ddf613b9-6a29-4bcd-bd14-9db97a538d17_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_062afc59-3fa2-437d-9546-e9ab323ce73d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_af4495f9-ccfe-41ce-9847-4caf07f080ba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt obligations, gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6c11147b-f129-4591-8b81-ff20f54e523d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bc81920b-07a4-4335-8cd9-646568f53baf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_bafa34ed-cb91-49b5-a9dc-a2799a1d9e5d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_15715085-e7af-499f-a0c0-d4acc264aca4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_a239339a-9a99-4da0-88a6-90d14313e51f_terseLabel_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_label_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:href="abbv-20220630.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:to="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8acffc3-f3c0-4385-b3f3-550b5742bd38_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6908eb74-f6de-47a1-80b3-682de42d79f0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5083c0e6-e743-48a2-9946-9d119212c15e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities, net of tax expense (benefit) of $5 for the three months and $3 for the six months ended June 30, 2022 and $&#8212; for the three months and $3 for the six months ended June 30, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_UbrelvyMember_6497478f-7445-4a4e-b56c-6c55cb5cdbf0_terseLabel_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ubrelvy</link:label>
    <link:label id="lab_abbv_UbrelvyMember_label_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ubrelvy [Member]</link:label>
    <link:label id="lab_abbv_UbrelvyMember_documentation_en-US" xlink:label="lab_abbv_UbrelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Ubrelvy, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember" xlink:href="abbv-20220630.xsd#abbv_UbrelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_UbrelvyMember" xlink:to="lab_abbv_UbrelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_3920d369-e30a-4f5b-abce-17dc8654b193_terseLabel_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription drug abuse litigation in state courts</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_label_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation In State Courts [Member]</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_documentation_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation In State Courts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:to="lab_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NeuroscienceMember_b89fffa1-952f-4461-b722-3191cfdf257a_terseLabel_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_abbv_NeuroscienceMember_label_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_abbv_NeuroscienceMember_documentation_en-US" xlink:label="lab_abbv_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Neuroscience, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember" xlink:href="abbv-20220630.xsd#abbv_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NeuroscienceMember" xlink:to="lab_abbv_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7e5fdeb3-9049-46fa-982e-f2b8a7f6a348_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_abacefc4-cde3-4e77-ad3d-e522a154cb83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_885e9cb1-fb19-4be6-a5af-34aaae2f96a8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_9b76b853-2022-4684-a56a-7815cf4a3256_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_dd9c54ee-adc2-44ee-960b-d5205b892696_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b0a698a1-d7d8-44f2-be7a-68aaeddc5425_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as fair value hedges</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_f782a38d-04d9-44da-b035-482b3c9ebf6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherAestheticsMember_ccbc87ac-8624-4ef5-ac11-c4a5ca136c29_terseLabel_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Aesthetics</link:label>
    <link:label id="lab_abbv_OtherAestheticsMember_label_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Aesthetics [Member]</link:label>
    <link:label id="lab_abbv_OtherAestheticsMember_documentation_en-US" xlink:label="lab_abbv_OtherAestheticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Aesthetics products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember" xlink:href="abbv-20220630.xsd#abbv_OtherAestheticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherAestheticsMember" xlink:to="lab_abbv_OtherAestheticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_22f5daa7-fe03-4231-9506-8bffa8942c5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of liabilities into Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_fdec375d-8960-4f28-85bb-379bd9f74165_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve rollforward</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_343b6a99-6f1d-4931-8eb8-4f4798b7d5b7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0f9ab3c5-8bf5-4f91-ba6b-8a84dc38db7a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's payable to Janssen</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NiaspanMember_722a0c80-78da-4ce7-92f5-471eac892a02_terseLabel_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Niaspan</link:label>
    <link:label id="lab_abbv_NiaspanMember_label_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Niaspan [Member]</link:label>
    <link:label id="lab_abbv_NiaspanMember_documentation_en-US" xlink:label="lab_abbv_NiaspanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Niaspan, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember" xlink:href="abbv-20220630.xsd#abbv_NiaspanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NiaspanMember" xlink:to="lab_abbv_NiaspanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_2ec25d93-d8f2-4c48-a98e-5f8312410444_terseLabel_en-US" xlink:label="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating senior notes due 2021</link:label>
    <link:label id="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_label_en-US" xlink:label="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due in May 2021 At Floating Rates [Member]</link:label>
    <link:label id="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_documentation_en-US" xlink:label="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due in May 2021 At Floating Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDueInMay2021AtFloatingRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:to="lab_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_c2cd3f16-988e-4d5a-be4d-61ce52ffda42_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_bad7106c-f44d-42bf-9d73-82f6767ae617_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8a755eb9-9265-44fc-9c90-a065b9a7ad63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b48824db-03bb-4a58-ac62-6d661136d28a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_650eb1e5-e718-498d-a02f-7adb27974d52_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_bca20b00-a706-4ea7-ae80-775159176b67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a6822dce-bd5d-4fa5-9005-e7e3cbc7236c_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for royalties excluding early stage or approved indications</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Royalties Excluding Approved Indications [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents estimated probability of payment for royalties excluding approved indications.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:to="lab_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_013ebd91-3177-428c-86f5-7f796ad5eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_32fb10f1-cf48-4dbc-8ca2-7b9d0da7d3dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f82760e3-7c19-466a-b06b-38d0adc6fe9b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b94bc31f-c063-491d-9e18-aa19c182ab89_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6f1260be-e0cf-4029-b26e-01640a19abfa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_453545a1-d0f4-4949-b863-7b504aeab53b_terseLabel_en-US" xlink:label="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash litigation reserve adjustments, net of cash payments</link:label>
    <link:label id="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_label_en-US" xlink:label="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash litigation reserve adjustments, net of cash payments</link:label>
    <link:label id="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_documentation_en-US" xlink:label="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash litigation reserve adjustments, net of cash payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:href="abbv-20220630.xsd#abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:to="lab_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_61498205-9ec6-4200-84d2-95eb6b02ae31_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_345fd92d-c79a-49e6-943b-767ed0d9181f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5e8ca965-4d50-482d-9a22-46cfe7123b48_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_362b1d70-9a91-420f-b743-27f1a1b8a627_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AlphaganCombiganMember_308d78d6-574b-4617-8ee8-48e9a7d6ec7a_terseLabel_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphagan/Combigan</link:label>
    <link:label id="lab_abbv_AlphaganCombiganMember_label_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphagan/Combigan [Member]</link:label>
    <link:label id="lab_abbv_AlphaganCombiganMember_documentation_en-US" xlink:label="lab_abbv_AlphaganCombiganMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Alphagan/Combigan, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember" xlink:href="abbv-20220630.xsd#abbv_AlphaganCombiganMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AlphaganCombiganMember" xlink:to="lab_abbv_AlphaganCombiganMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_77859d72-d491-4af0-8e24-f4cf9d9baf2f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from the assessment of effectiveness for fair value hedges</link:label>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:to="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherNeuroscienceMember_b941df89-ed97-46ad-bddc-d9424bb93226_terseLabel_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_abbv_OtherNeuroscienceMember_label_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_abbv_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_abbv_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Neuroscience products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember" xlink:href="abbv-20220630.xsd#abbv_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherNeuroscienceMember" xlink:to="lab_abbv_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BotoxTherapeuticMember_59ffb2e5-966e-49f7-b181-5d2a215a49ba_terseLabel_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Therapeutic</link:label>
    <link:label id="lab_abbv_BotoxTherapeuticMember_label_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Therapeutic [Member]</link:label>
    <link:label id="lab_abbv_BotoxTherapeuticMember_documentation_en-US" xlink:label="lab_abbv_BotoxTherapeuticMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Botox Therapeutic, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember" xlink:href="abbv-20220630.xsd#abbv_BotoxTherapeuticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BotoxTherapeuticMember" xlink:to="lab_abbv_BotoxTherapeuticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1ac67657-d0b0-4dc2-b887-9db86cf8d499_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7d582c84-0638-4a61-a640-efaea54901cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance beginning of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7f248635-8815-46a0-bf23-b751a3372bc9_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance end of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f39d6d8e-2f79-46bf-91c6-724fb9702e7f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_5a898976-0197-4753-a730-4914949478d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cf4ea729-3922-4d53-adc0-f8df72358241_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_8c3e0c4c-f9e2-4fb6-9576-8bcbeea7c0c5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HematologicOncologyMember_a98e046b-878c-4632-8b06-0cc61b9ae932_terseLabel_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hematologic Oncology</link:label>
    <link:label id="lab_abbv_HematologicOncologyMember_label_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hematologic Oncology [Member]</link:label>
    <link:label id="lab_abbv_HematologicOncologyMember_documentation_en-US" xlink:label="lab_abbv_HematologicOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember" xlink:href="abbv-20220630.xsd#abbv_HematologicOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HematologicOncologyMember" xlink:to="lab_abbv_HematologicOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_17a4c9db-7114-4040-90bb-9926be7907b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_10cc1064-3d42-4f13-ba0c-50cdc7f394d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_13a6afec-675b-415b-bd85-9947395e4412_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other integration</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8424ed3f-0ff7-41f8-8108-4103db37a7cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_9112abf7-0d1c-48d4-bbaf-6d6699906a74_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_aa0b7288-5c6c-4448-9998-1568d3896c8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_995bceb7-fd88-49bb-af89-595d953671de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_048fc1a8-7f82-43ca-b262-29f4ee3eed03_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_f3d767f0-4bc6-4e77-8cb2-197a7beedd30_negatedLabel_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of actuarial loss</link:label>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_label_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)</link:label>
    <link:label id="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_documentation_en-US" xlink:label="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:href="abbv-20220630.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:to="lab_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_229b6714-dfdb-46ee-adb9-c56da1b9df97_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_d4301402-568e-4b5c-afda-9dcc85b7e3cb_terseLabel_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities</link:label>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_label_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) From Net Investment Hedges [Member]</link:label>
    <link:label id="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_documentation_en-US" xlink:label="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) From Net Investment Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:href="abbv-20220630.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:to="lab_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_853eabd8-90de-406b-84e2-138745aa25db_terseLabel_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription drug abuse litigation</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_label_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Abuse Litigation [Member]</link:label>
    <link:label id="lab_abbv_PrescriptionDrugAbuseLitigationMember_documentation_en-US" xlink:label="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to prescription drug abuse litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrescriptionDrugAbuseLitigationMember" xlink:to="lab_abbv_PrescriptionDrugAbuseLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_70e8097a-d8d2-442a-8054-3d251e4a3820_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_73838f07-9318-4763-a2b0-79928a3ec6bc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ca70e56a-ff3c-424d-809c-1928e156d89e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_6cd16b6a-b795-45a9-aeb2-6e8b15df63b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_640eb8ba-5900-464f-a2e9-49508392a52d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84448f8c-6611-461f-98aa-0ef37bc2059a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of awards vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_b3175d9d-51b7-4b1b-9802-18420fe12a25_terseLabel_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_label_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:href="abbv-20220630.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:to="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5b7da29f-e185-472d-bf53-1a949a3a17ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other post-employment plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5b964f1b-1e1e-46c0-bd77-6df677489766_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherKeyProductsMember_9f1bff9c-4d74-4a02-aded-dd5618aafaf0_terseLabel_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Key Products</link:label>
    <link:label id="lab_abbv_OtherKeyProductsMember_label_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Key Products [Member]</link:label>
    <link:label id="lab_abbv_OtherKeyProductsMember_documentation_en-US" xlink:label="lab_abbv_OtherKeyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to other key products of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember" xlink:href="abbv-20220630.xsd#abbv_OtherKeyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherKeyProductsMember" xlink:to="lab_abbv_OtherKeyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_061576ac-1c28-4947-a13a-36b7ac159d2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_f084dd7f-4522-42dc-9aaa-5c3113085b8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of book values, approximate fair values and bases used to measure certain financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f6925f55-0023-4496-993d-88116f51f8a7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Two Class Method [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_ce0942de-9362-433e-a6c0-0e19f8fb4e39_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a30b6fe4-e8a4-474f-a629-63f0d47e0836_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_e7e29988-66e0-432a-8ef9-cf72f58384ab_terseLabel_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_label_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:href="abbv-20220630.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:to="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_3d3cc4dd-590d-46de-b317-163fe9005a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HUMIRA</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_a5ca4400-4f55-499b-9e57-25be2f4d4bfd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5211dafc-f7bb-431c-a462-f07c40d63438_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_GenentechInc.Member_1cede682-c026-46b2-a516-69c116c7c514_verboseLabel_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:label id="lab_abbv_GenentechInc.Member_label_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. [Member]</link:label>
    <link:label id="lab_abbv_GenentechInc.Member_documentation_en-US" xlink:label="lab_abbv_GenentechInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member" xlink:href="abbv-20220630.xsd#abbv_GenentechInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_GenentechInc.Member" xlink:to="lab_abbv_GenentechInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90446f18-58d5-420f-a0ba-b40f41a0748a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_dfdf115d-7257-4319-b977-42664e6cfa32_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_a28980a8-7f85-47f1-a525-a75ce815802e_terseLabel_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purported class actions</link:label>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_label_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Purported Class Actions Number</link:label>
    <link:label id="lab_abbv_LossContingencyPurportedClassActionsNumber_documentation_en-US" xlink:label="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of purported class actions filed, pertaining to a loss contingency during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber" xlink:href="abbv-20220630.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LossContingencyPurportedClassActionsNumber" xlink:to="lab_abbv_LossContingencyPurportedClassActionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f84f8590-600d-4e07-8b60-9ff8d17664db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e827f694-e898-44c8-94eb-72b40c990bc9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6f90ab9a-1190-491d-9bc4-609c671ed8f0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_f4e1a3fb-ca31-4341-9cf1-20a4462f577f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock held in treasury, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e4da24da-b9a3-4552-a30d-c0259ceb3025_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_c511c44f-3126-4b80-b469-bb54c6e95add_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Long-term Debt and Capital Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2395c0d4-7baf-4d47-b0db-a53efa64e68d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_8c4fafca-5677-4512-a791-fb1ebcc07ccb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e21c1427-c6cb-4bfe-b02f-8a7319afb307_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2e25cb3-b28c-4984-a2c5-d00a5da22686_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_8a3ba464-7c4e-481f-8146-cbf1714b98d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ffd06112-1f48-40f1-b554-8cbe0b99ea81_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_6f259099-997e-4872-9ed9-7decea9a5a1f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_cd11432e-1bf1-44f1-b23a-5ccafff68396_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:to="lab_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c4c21e14-aa2d-4d0b-b574-7d427dbad5b7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CreonMember_000ccca7-27a1-47ed-bc21-add9706e5c36_terseLabel_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creon</link:label>
    <link:label id="lab_abbv_CreonMember_label_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creon [Member]</link:label>
    <link:label id="lab_abbv_CreonMember_documentation_en-US" xlink:label="lab_abbv_CreonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Creon, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember" xlink:href="abbv-20220630.xsd#abbv_CreonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CreonMember" xlink:to="lab_abbv_CreonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_780b57ba-b66f-4f93-9b3f-c2e5189deebc_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebe85677-76db-492c-bf46-fd13a791361f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_a29f3ff9-edf1-4080-ae50-326ea5b63e29_terseLabel_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating rate notes due 2025, refinanced</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_label_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member]</link:label>
    <link:label id="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_documentation_en-US" xlink:label="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Term Loan Tranche Due May 2025, Refinanced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:to="lab_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_e53bbf5e-aeef-4c91-8cec-f6c77dde823e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_a29c793d-1d26-42b7-b514-7bc398949dca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d21e91ad-dc93-4abf-813c-b2153ef00ae5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_9934f2df-97b2-4ef7-bafe-32cc38521fa2_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_62c53f5d-7766-4435-adac-e134369c3ed2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d88c64e2-0b1a-48e7-acc5-cd94a6437bbd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_604ec762-4bf9-45fd-930b-ead5e7fa8688_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ff4a45c4-a31a-4b75-a5c5-f333a408f7b5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ImmunologyMember_3e4e0fe6-26b3-4ebb-90d0-c5ef1ed951fd_terseLabel_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_abbv_ImmunologyMember_label_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_abbv_ImmunologyMember_documentation_en-US" xlink:label="lab_abbv_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Immunology, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember" xlink:href="abbv-20220630.xsd#abbv_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ImmunologyMember" xlink:to="lab_abbv_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_842f1260-53a0-41f2-9d2c-aaf3cf639865_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9d74bde6-0a84-46fe-b73d-840af3f358fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3ae0764b-7c62-4107-97d8-43a0e47f33c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_88c84323-a1b6-417a-9667-6527ed2d5114_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and Restructuring Plans</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_30ddd0a8-907a-4e8d-9c81-11a2469ff77f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_668ede48-96a7-42cc-804f-6f7c709d0cff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflows related to acquisitions and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_43169767-f14a-4971-bd94-afce2e08591c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets out of Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6dacbb62-9c11-4f9b-b499-4a827caf922a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3ff80e3-16d6-4089-ab26-cdcd7b43f01a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_20aabcda-b411-491b-b17d-e89800498049_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_47dd2a8d-339e-490a-b9b7-8a9ae08370d0_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_be8bfef3-b10e-4f54-9d8e-35f8a3819db4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SKYRIZIMember_f350d75f-abbf-403b-a63a-2bd47ddd9dcf_terseLabel_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skyrizi</link:label>
    <link:label id="lab_abbv_SKYRIZIMember_label_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SKYRIZI [Member]</link:label>
    <link:label id="lab_abbv_SKYRIZIMember_documentation_en-US" xlink:label="lab_abbv_SKYRIZIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to SKYRIZI, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember" xlink:href="abbv-20220630.xsd#abbv_SKYRIZIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SKYRIZIMember" xlink:to="lab_abbv_SKYRIZIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_a6a1b5c6-b8b2-450d-9d3c-ae0ebd36d2c3_terseLabel_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</link:label>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General And Administrative Expense From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:href="abbv-20220630.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:to="lab_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a402686e-72a1-41df-97c0-f462fd01a56b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d54c48b7-f8bf-42cf-b1b2-95fee524f8cb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_383b5e5d-a960-43ea-9339-2d7cd39b767a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_9d749aad-3a01-4090-b93a-da75d7b210b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_189da01c-276c-41a6-887d-dcb262e5cae8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_30acd6d3-5ed1-48b0-ac40-36d62dd07f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and milestones</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_99d35f43-bf39-4e6a-ae96-09cfdd6c892d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45272753-a5dd-40f8-9042-a428362134ba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_67c1c9e7-d4bb-463a-9fe7-80821692ae81_terseLabel_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months</link:label>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_documentation_en-US" xlink:label="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:href="abbv-20220630.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:to="lab_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_40001090-9519-41a6-ba4a-57bb0dcaf2fd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_d347aeba-89ff-4e94-aad2-861fe1696c6b_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_60ee11de-10d8-4eb4-828a-7f73e61f7086_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of profit and cost sharing relationship</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LumiganGanfortMember_d4d84010-927e-4deb-a87c-aa3dc9534cad_terseLabel_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumigan/Ganfort</link:label>
    <link:label id="lab_abbv_LumiganGanfortMember_label_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumigan/Ganfort [Member]</link:label>
    <link:label id="lab_abbv_LumiganGanfortMember_documentation_en-US" xlink:label="lab_abbv_LumiganGanfortMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Lumigan/Ganfort, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember" xlink:href="abbv-20220630.xsd#abbv_LumiganGanfortMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LumiganGanfortMember" xlink:to="lab_abbv_LumiganGanfortMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_7805690b-a72c-4fa3-a7a2-2b6c619fdf9c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_033ac24e-4c2b-461c-ae70-0f1841d07299_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0ca20ae8-004b-43d2-8db9-c4c5d46701c5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f278dd1c-03d6-41c4-ac66-6ab4ad209810_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShorttermDebtFairValue_d198a7ca-5424-46a0-af02-387284ba2538_terseLabel_en-US" xlink:label="lab_us-gaap_ShorttermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ShorttermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_ShorttermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShorttermDebtFairValue" xlink:to="lab_us-gaap_ShorttermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_59dc3475-bbbd-4e5e-b6c7-f3ba80bc8a72_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Milestone Method Payments Receivable</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:to="lab_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.250PercentMember_3a4cbe7c-b644-4a7d-9545-3b0d25a79876_terseLabel_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% senior notes due 2022</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.250PercentMember_label_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.250 Percent [Member]</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.250PercentMember_documentation_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.250 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.250PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:to="lab_abbv_SeniorNotesDue2022At3.250PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_74a7b66f-85c1-441f-8d0d-a474fa624c48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fd5ffef9-0557-4464-bd38-a5f411b05a0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fa6cee25-27d0-422a-a339-e6de6beb863d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_9c81a08a-b9e8-44fc-a740-97e2a2af0338_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AestheticsMember_de053a76-aeba-44db-b8ac-bec5723ec2a9_terseLabel_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aesthetics</link:label>
    <link:label id="lab_abbv_AestheticsMember_label_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aesthetics [Member]</link:label>
    <link:label id="lab_abbv_AestheticsMember_documentation_en-US" xlink:label="lab_abbv_AestheticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Aesthetics, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember" xlink:href="abbv-20220630.xsd#abbv_AestheticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AestheticsMember" xlink:to="lab_abbv_AestheticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50d70bfa-e6d8-464f-85fd-5af8762f7233_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDividendsPayableTextBlock_d3492ae2-935a-433e-9cfe-b170f9872569_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of quarterly cash dividends</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDividendsPayableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dividends Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDividendsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDividendsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_36272736-af2c-423e-90f8-bb7288665a0b_terseLabel_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</link:label>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_label_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member]</link:label>
    <link:label id="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_documentation_en-US" xlink:label="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:href="abbv-20220630.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:to="lab_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ced8afa1-c2b6-450c-b0fe-55661077edcf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b6623d2f-0fff-4316-b3b2-9547621c8c46_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_947a37d2-5016-4388-a719-296c71ce7760_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in balances of each component of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5d69ad7-450b-4252-88c6-9d03e89efdc7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_036fc880-aebd-469b-9f68-6062838fdd94_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_e3342b20-dc5e-4d15-bf16-3ac314c22663_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8106e674-579e-4533-bcc2-d8ffe6cb4c6b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_478c9a86-5226-45a8-b464-6da1656df6f2_terseLabel_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities, net of tax expense (benefit) of $146 for the three months and $183 for the six months ended June 30, 2022 and $(31) for the three months and $72 for the six months ended June 30, 2021</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_label_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_documentation_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:href="abbv-20220630.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:to="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4c1901af-7fac-4048-89ac-5c284b260e93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ab18ace1-703e-40ed-8224-d9a54fd0fcbc_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of unsecured senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2a1b51da-fe7b-42ff-928f-3cba095650e8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_90392e34-776c-4e11-adf0-d907d403633a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c195c934-b323-4f78-af55-22a7cdc47a30_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_4dd0ccf1-4aa4-45f8-abbb-f57307d20ed5_terseLabel_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</link:label>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods And Services Sold From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:href="abbv-20220630.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:to="lab_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_JuvedermCollectionMember_ad4370d6-898c-4d79-87f3-121a23068b38_terseLabel_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvederm Collection</link:label>
    <link:label id="lab_abbv_JuvedermCollectionMember_label_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juvederm Collection [Member]</link:label>
    <link:label id="lab_abbv_JuvedermCollectionMember_documentation_en-US" xlink:label="lab_abbv_JuvedermCollectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Juvederm Collection, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember" xlink:href="abbv-20220630.xsd#abbv_JuvedermCollectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_JuvedermCollectionMember" xlink:to="lab_abbv_JuvedermCollectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_51edd349-1c95-4599-9361-2998875be049_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5c6625a0-5cfe-433b-b113-216ade251464_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6a454bb4-9877-4948-ac1e-8203370252ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_464ccf64-1892-4dfc-99f0-ad435b10f214_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_986ac931-685c-411b-81bd-451cfa72860a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9e343cd7-f10c-47db-a893-6c55084decff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_39102348-23d8-4564-8a9c-6fde987706c1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments, notional amount and fair value</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_44dfa588-d495-4c08-9f54-a3d07f312231_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0bea897d-f21d-46d8-83ce-b6ada1e22839_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_457e4e9e-172b-4ab4-885d-f95899e346fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_fcf13792-e2ce-43fb-a0bf-175fe16b2516_terseLabel_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global - AbbVie's share of other costs (included in respective line items)</link:label>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_OtherExpensesFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements" xlink:href="abbv-20220630.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherExpensesFromCollaborativeArrangements" xlink:to="lab_abbv_OtherExpensesFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_48206262-3b64-43c1-a9fb-9bf32cc9f2f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c5c7da13-2664-4c41-abed-03949f648058_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_4b449763-ce34-4d6c-9976-37dd439fc246_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a7a50515-c7d9-41e7-829d-973d459547c9_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_a46f903c-b9a1-4464-85da-340a049740ae_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0c39507e-f846-4b34-a548-93eb05ea72bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in fair value of Level 3 inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_dad37ffe-2096-464b-a1e4-97efaa18740b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9480ee5d-2f76-41db-8d6d-62038ffa98dc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_24735cba-8c05-45b3-aa7b-f5570296fc31_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a941ca34-5093-4fad-80a4-9a0147d59154_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_87198721-b0c2-4771-b6c1-fa7c93368de1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_623680c9-a6d3-4416-8a2e-547df6ea9ef1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ceb9cd9-e832-4cba-9826-01b72df55988_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cdad805-e9a3-4d3a-9cf7-51f90da6fc45_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd2f73ec-55dd-400d-889c-693d10bf4f48_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_581ae245-d546-48ae-877b-c963406a2fb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cf110dcb-8508-423f-b013-d28bb526f09f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_f4aa1d9a-feec-407f-a217-a391c115d534_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4692d06c-4a71-4d27-89f5-0b02bf49029a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_77d9ac50-1e08-4fd4-b0d9-40a6d7d79f89_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's receivable from Janssen</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fc314db6-a363-478e-a55a-d1daac634cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_383aa031-3d96-426d-9087-acdb34e6c955_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiff claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2ce89c29-2cfb-4285-b170-e4a9121fcc13_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e59dabb4-c3e6-42c3-88b6-f42f9468d3c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_66cf2b9d-f3a1-4326-b36d-8896d93bbb19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_46461f8b-0494-4f93-b521-6ba02984a424_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f73a89e8-174c-4a43-9a90-513724ab2c5c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherProductsMember_7eabc86c-1dd5-47cf-95a1-6601f8b30cb7_terseLabel_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_abbv_OtherProductsMember_label_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_abbv_OtherProductsMember_documentation_en-US" xlink:label="lab_abbv_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to other products of the entity not specified anywhere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember" xlink:href="abbv-20220630.xsd#abbv_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherProductsMember" xlink:to="lab_abbv_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_23e6b74d-2f3e-43be-8443-c3424d4a60d8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5428dd5d-5695-4fb3-977b-d42450b7b022_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_81cb23a0-5175-47b6-a9b7-eeb530d69b9a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_55df305d-f221-43c8-9d85-fd525b4417b5_verboseLabel_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and finance lease obligations, excluding fair value hedges</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_label_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Fair Value Disclosure</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_documentation_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:to="lab_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0a1afef3-f922-49cc-91ca-2ff3d550bcc1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1745e5e4-e336-4f73-ae46-a142fcabff36_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4cff04ee-0857-4095-bb1a-1eddc4b1cc13_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88275f29-83d1-4471-aaba-cf674e7e0118_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, asset and liability measures</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3db99f97-a32d-491a-bfbf-b3f37c409d4a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bases used to measure the approximate fair values of the financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a6137602-9267-472d-9ca7-6f395ad02fde_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f5dd8d55-327d-46d7-be98-45d925651f26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1 for the three months and $(24) for the six months ended June 30, 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SupplementalFinancialInformationDisclosureAbstract_010a83be-8027-4621-8298-119ecc8152a7_terseLabel_en-US" xlink:label="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_abbv_SupplementalFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:href="abbv-20220630.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:to="lab_abbv_SupplementalFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1292bd56-986e-4b2d-a2fb-c7299dfe28ce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6cdee916-7d33-4b5f-bf5f-2fe44d0dc0dd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_49f42468-e088-403d-b342-19167f1e2dfc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_38b5cf1b-06b7-4a9f-a272-e2938ee99460_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_d8c668c7-3b81-4e6d-907e-f56a718d0160_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_58e08e39-bac7-4579-ae13-07a8217e3236_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_58e04032-dfa4-4041-8710-22087c021f22_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0aa4d81e-39bb-49f4-a9f1-1ea4fcce63a6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of investments in equity securities that do not have readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestasisMember_5f3627e3-8fb5-4133-8d1b-1d7f533c84fc_terseLabel_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restasis</link:label>
    <link:label id="lab_abbv_RestasisMember_label_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restasis [Member]</link:label>
    <link:label id="lab_abbv_RestasisMember_documentation_en-US" xlink:label="lab_abbv_RestasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Restasis, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember" xlink:href="abbv-20220630.xsd#abbv_RestasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestasisMember" xlink:to="lab_abbv_RestasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d6f47c4-f97f-4203-ad44-0181c898a42b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryLockMember_c0d1c522-5777-45d3-ac14-b3990b8ab6d9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury rate lock agreements</link:label>
    <link:label id="lab_us-gaap_TreasuryLockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryLockMember" xlink:to="lab_us-gaap_TreasuryLockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_c0ae1d91-7573-4da3-87b5-77509a4280a4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c81f494-cf01-4c3c-b503-53f28498e4fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of the stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1000eb3d-2558-49d6-8cbb-aa82896fdaf4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2be26ecc-7e5a-4698-9cd7-e0c783da162e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation plans and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember_f01330ff-6042-4920-86f6-72e862991c05_terseLabel_en-US" xlink:label="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% senior euro notes due 2021</link:label>
    <link:label id="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember_label_en-US" xlink:label="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Euro Notes Due 2021 At 0.500 Percent [Member]</link:label>
    <link:label id="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember_documentation_en-US" xlink:label="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Euro Notes Due 2021 At 0.500 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:href="abbv-20220630.xsd#abbv_SeniorEuroNotesDue2021At0.500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:to="lab_abbv_SeniorEuroNotesDue2021At0.500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_3fe462d6-e7e2-4537-8019-f2a435a1ba66_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_76eab509-f511-42e3-a643-02c17675c493_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ae1be226-3d0a-45b6-bfb2-71175729775d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_d4bf0942-9326-4508-9c5f-6b8f48307de4_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for unachieved milestones</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Unachieved Milestones [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the probability of payment for unachieved milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:to="lab_abbv_ProbabilityofPaymentforUnachievedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_896f7cda-09c9-40f7-9a1b-03c63e2279c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges associated with integration or restructuring plans</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79f3ef51-e22a-4163-a228-674670c122ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_64a0e542-d8d2-4128-8be1-c3a5c1c26768_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8fdec9dc-f284-4503-aa2b-26cd76f49d1a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d31f8f43-8dde-42bd-810f-e41970bc124b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a6a226b7-3c15-4331-8637-3554436e2d76_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3b98456a-e9e7-402a-984b-9a6caf6cf845_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_4371918b-618c-4cea-80f4-f51fb572e1e2_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9466d852-17a1-49b5-9800-d7cab5a83f94_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_422a5a01-623c-4188-9d69-969b4849a008_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_fb8e7cef-ad8b-44ee-95e3-9341f78d45fa_terseLabel_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% senior notes due 2022</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_label_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.450 Percent [Member]</link:label>
    <link:label id="lab_abbv_SeniorNotesDue2022At3.450PercentMember_documentation_en-US" xlink:label="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 At 3.450 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:to="lab_abbv_SeniorNotesDue2022At3.450PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_461a41bb-11fa-4e22-9d1e-4f110c96819d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_46ac1430-be93-4fb6-9010-2eb7f21a9cdc_terseLabel_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:href="abbv-20220630.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cd5619cd-6f61-496a-85a0-630893ae5fc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LinzessConstellaMember_495d84a6-df79-43c5-ada9-a2d3e67bcf73_terseLabel_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Linzess/Constella</link:label>
    <link:label id="lab_abbv_LinzessConstellaMember_label_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Linzess/Constella [Member]</link:label>
    <link:label id="lab_abbv_LinzessConstellaMember_documentation_en-US" xlink:label="lab_abbv_LinzessConstellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Linzess/Constella, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember" xlink:href="abbv-20220630.xsd#abbv_LinzessConstellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LinzessConstellaMember" xlink:to="lab_abbv_LinzessConstellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_91a78090-0ddb-417b-bc4e-01067864cccd_terseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_19078e65-a77f-48d7-8eeb-e4fcae6c98af_verboseLabel_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure</link:label>
    <link:label id="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:to="lab_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_a0ed07a5-bea2-4038-ab34-05ab11d63ba3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_41b7c7f6-6604-410e-b72f-f6cb53b6e44b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_be8ca354-ed5e-4a82-8986-f133fc650d3f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_183d8a0f-399c-4086-bc0f-8a9aeebe31e0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_2b7e6c36-1387-41d0-a1c4-e3a6773aebcf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d7ad9fa-3d6f-4b58-921b-3bb7114fd90d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7febff70-0b5e-4d92-b87f-2f5feba4919d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic and diluted earnings per share, impact of two-class method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bf41850a-ca15-40c3-9b1b-3de5742aaf19_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c79094da-354b-4a08-abea-c2df83cc57f9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6a82dbbe-9ef2-42a9-9bf2-0593dc6a024f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_QuliptaMember_dceb5ebb-1fd3-4442-80f2-797d14cedc18_terseLabel_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta</link:label>
    <link:label id="lab_abbv_QuliptaMember_label_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta [Member]</link:label>
    <link:label id="lab_abbv_QuliptaMember_documentation_en-US" xlink:label="lab_abbv_QuliptaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qulipta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember" xlink:href="abbv-20220630.xsd#abbv_QuliptaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_QuliptaMember" xlink:to="lab_abbv_QuliptaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_44ed613a-bfb7-4998-9079-63b13ab6e162_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Two Class Method [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_879d18bf-2c1a-447c-9ccb-2b55e230c86e_terseLabel_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie's share of development costs (included in R&amp;D)</link:label>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_label_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense From Collaborative Arrangements</link:label>
    <link:label id="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_documentation_en-US" xlink:label="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:href="abbv-20220630.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:to="lab_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2ef7bf2b-fbd2-4d8f-9356-163ef551bca1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0e9f2710-fba3-4710-a7ea-1485876be68f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_01fda96f-da87-41c7-b1ed-a27723fb4aaf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration related costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1971717a-fc58-45fb-8924-fffe72eadd8e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3b6c4751-972c-4f6f-b74d-a074866558e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31aafe2f-d7b3-4e19-a997-a309f27f41da_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_edadf7a0-4ef0-400d-964e-5705c6122a8f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e9824288-b8ec-466f-bed1-79751209c68b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and post-employment benefits</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_652d9138-7c92-4f68-af01-63665c40bc6c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_00e8d802-fe7c-439c-b5e3-7c6a69de0f03_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5b14ac59-969f-4269-b3e9-835afdf1ce5d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d1621356-d773-4da9-b2c1-9f7ceeda8a1c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_87378c26-6152-42a9-93cd-d0ea79f82879_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9fd0f03-9611-41d4-83cd-289e8046366a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d5b364d6-2c60-495d-8153-3fab69a8d7d2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2fe8adc3-9cf9-459a-bf5b-683a1456270f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_0d3f2f70-1774-4e8c-ba01-4c40e90a8b22_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c93fa4b5-8dbe-41e6-a212-8e59cbcc6543_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ca47fe1-5210-46e1-a27a-5396915528c8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_a3978083-75dd-4d17-bf48-5233d9973a94_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_c7fc4139-b715-4baf-842a-eb862bdee2fa_terseLabel_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual putative class action lawsuits</link:label>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_label_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative Class Action Lawsuit Individual Number</link:label>
    <link:label id="lab_abbv_PutativeClassActionLawsuitIndividualNumber_documentation_en-US" xlink:label="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents number of the number of individual putative class action lawsuit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:href="abbv-20220630.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:to="lab_abbv_PutativeClassActionLawsuitIndividualNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_ed25e6ba-4047-442c-a055-0e02c17224e0_terseLabel_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and Performance Shares</link:label>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Shares [Member]</link:label>
    <link:label id="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="abbv-20220630.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_abbv_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_129cc085-2f31-409c-b660-84aebc78af24_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f1652da3-5ddf-409e-a81a-cd013c1deed2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7d3ce1d0-37ed-4067-b1c5-60b7d9481e33_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a2eda533-dcee-4b14-b056-172f5a0e7032_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_b64cb2b3-2783-4045-b91d-0a29af6f1841_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of liabilities out of Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a8ad734-d6c0-481b-898a-014bd76898aa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99f35873-77a9-4510-aacf-760670f252f6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c5839da6-249b-40a7-83ea-6c139ba2e364_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_f12c78d6-8d3e-47be-aa3c-0fbff8d866ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_702594cf-20f0-4546-90a5-106ec0cf8680_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_10193e4e-7341-48c1-b75c-e8245b4feea2_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_25c79cae-d10b-4616-8de1-ac1544c711a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssets1_2503ffc7-a015-464b-92bc-f58f41834eb2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssets1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_a5c3958d-6275-4c81-ae6f-2471e438b02b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_c0da81b9-965d-416e-901a-0f4fc4a25597_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c78f5f00-8918-4de3-8159-e333fae7becd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7774005-4406-4b28-91b8-f7e139824152_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_31fc65af-cdb5-4c97-96d5-2b7506558580_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to AbbVie Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_0e27afed-f194-48ff-8d86-77f7e5fea03c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_15eac69a-fc9d-4a17-99f3-d714f123da77_terseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_63e631dc-fb37-46a3-af8a-26f4f3959fd1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_4e6ea836-e64f-4334-a4d8-2b13ffabc796_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock held in treasury, at cost, 44,595,448 shares as of June 30, 2022 and 34,857,597 as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RINVOQMember_01852263-f715-400a-936b-d62916784596_terseLabel_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rinvoq</link:label>
    <link:label id="lab_abbv_RINVOQMember_label_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RINVOQ [Member]</link:label>
    <link:label id="lab_abbv_RINVOQMember_documentation_en-US" xlink:label="lab_abbv_RINVOQMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to RINVOQ, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember" xlink:href="abbv-20220630.xsd#abbv_RINVOQMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RINVOQMember" xlink:to="lab_abbv_RINVOQMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_63403777-7d72-42ef-9e28-e8950778b3ef_terseLabel_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bystolic antitrust litigation</link:label>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_label_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bystolic Antitrust Litigation [Member]</link:label>
    <link:label id="lab_abbv_BystolicAntitrustLitigationMember_documentation_en-US" xlink:label="lab_abbv_BystolicAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Bystolic antitrust litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember" xlink:href="abbv-20220630.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BystolicAntitrustLitigationMember" xlink:to="lab_abbv_BystolicAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ddd1b959-f56b-49d2-a34a-7798bbd00aec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_bd178713-2912-45ae-817a-dd53cdd2babc_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_a22c5774-a60f-4cc6-945a-4f4779aaa319_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on divestitures</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_bb445941-4735-4076-ae6c-7817daea38a2_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gain recognized on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b64f3e45-e374-4f53-8f31-92b0637a50e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_be375707-52b0-43df-88fd-087bd07ddd73_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e22d2a98-a160-4751-84ee-7caf7dd56ddc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f514ac1c-f21b-4bab-801f-620551c0c4da_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_669b1705-6eeb-48c3-b121-d079ba2108d4_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherEyeCareMember_e3dc0e82-4497-405b-8f05-12f4023a8093_terseLabel_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Eye Care</link:label>
    <link:label id="lab_abbv_OtherEyeCareMember_label_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Eye Care [Member]</link:label>
    <link:label id="lab_abbv_OtherEyeCareMember_documentation_en-US" xlink:label="lab_abbv_OtherEyeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Other Eye Care products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember" xlink:href="abbv-20220630.xsd#abbv_OtherEyeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherEyeCareMember" xlink:to="lab_abbv_OtherEyeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_BotoxCosmeticMember_22c7e950-c7a1-4d06-881e-80c0c95cd822_terseLabel_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Cosmetic</link:label>
    <link:label id="lab_abbv_BotoxCosmeticMember_label_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Botox Cosmetic [Member]</link:label>
    <link:label id="lab_abbv_BotoxCosmeticMember_documentation_en-US" xlink:label="lab_abbv_BotoxCosmeticMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Botox Cosmetic, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember" xlink:href="abbv-20220630.xsd#abbv_BotoxCosmeticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_BotoxCosmeticMember" xlink:to="lab_abbv_BotoxCosmeticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2be8124-64a1-4be3-af7a-5de432303800_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d16c0330-e860-4902-9853-81d732cd5f66_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_cd804ce2-afb0-4e98-8280-6926a0922158_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of charges associated with integration plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_02578257-bd3b-49d0-8a04-34e9bed77866_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of collaboration development costs responsible by the entity (as a percent)</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Percentage Of Share Of Development Costs</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:to="lab_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_bf880ed2-af01-4efb-a714-0dab4937522b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets into Level 3 of the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_56b5161a-88f9-4d0e-88c4-3f1ae698ea13_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_17fb7138-939a-400c-b9ac-3bcdc89514ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_c2981f8b-3775-498a-aa08-1618bfcd45b4_terseLabel_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing, Acquisitions, and Other Arrangements</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_label_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]</link:label>
    <link:label id="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for acquisitions, collaborations and other arrangements of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:href="abbv-20220630.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:to="lab_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_91fd8fc0-d2b1-4303-84d1-d1923ba45f6e_terseLabel_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Axis]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_label_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Axis]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioAxis_documentation_en-US" xlink:label="lab_abbv_KeyProductPortfolioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information concerning the company's portfolios of key products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_KeyProductPortfolioAxis" xlink:to="lab_abbv_KeyProductPortfolioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_faed8e0c-276a-4571-9a5e-e1f67c8a8e6e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_cd62948f-7ba3-49d9-9f1e-9f1e2ba884e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b3903819-1197-46f0-829e-cc483b062541_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses (gains) on foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_20bfed6e-972d-402e-87b3-a4ba7b717ee4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_682bf18f-6d80-4e87-894e-a58e8ad2cec8_terseLabel_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Domain]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_label_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Product Portfolio [Domain]</link:label>
    <link:label id="lab_abbv_KeyProductPortfolioDomain_documentation_en-US" xlink:label="lab_abbv_KeyProductPortfolioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Information concerning the company's portfolios of key products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_KeyProductPortfolioDomain" xlink:to="lab_abbv_KeyProductPortfolioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a0c1cd5a-bf64-40cb-95c5-accb0e28b955_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_11620005-26bb-401f-a8b3-ffc514e7ba37_terseLabel_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US customers</link:label>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_label_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US Customers [Member]</link:label>
    <link:label id="lab_abbv_PrincipalUSCustomersMember_documentation_en-US" xlink:label="lab_abbv_PrincipalUSCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal US Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember" xlink:href="abbv-20220630.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PrincipalUSCustomersMember" xlink:to="lab_abbv_PrincipalUSCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HUMIRAMember_38da8099-a5d2-4b8b-845d-ae40c8cf4077_terseLabel_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira</link:label>
    <link:label id="lab_abbv_HUMIRAMember_label_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H U M I R A [Member]</link:label>
    <link:label id="lab_abbv_HUMIRAMember_documentation_en-US" xlink:label="lab_abbv_HUMIRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to HUMIRA, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember" xlink:href="abbv-20220630.xsd#abbv_HUMIRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HUMIRAMember" xlink:to="lab_abbv_HUMIRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_4bcc8df4-4051-4fc5-9512-a523c95093ed_terseLabel_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:href="abbv-20220630.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d211837b-1807-452f-b96d-379a79feedbf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cbfa243e-c8a5-4120-b336-0944e3afc491_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_c59a53cc-b122-4fd9-92cc-a466670ac5c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ea0a2d9d-f356-47ec-a5af-c3ed8b3da3a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_9aaa69f7-33dd-47d9-be44-966f15977329_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and time deposits</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_5301f5b6-14c9-4ec6-be98-56d0dbe13876_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_530324d9-6cca-4601-aede-a25bad675b02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_665b4a90-0958-469a-832f-06461d6ab831_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0da913ad-0519-4fca-a11d-4ff6f9341cbe_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7bf30f93-a55e-41d9-b0a4-c8ee83088ca9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_5ca160e6-0851-4028-9808-cd8731cbc4bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8360c132-6be0-49d0-9cda-e17ce672ee81_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5b9dee2c-6f16-4d69-a2bd-c28ad1fdab68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_dab0abe7-9807-401f-8023-7cf3c2128e02_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_76234c3c-a34f-4baa-a360-e1f21e8e4327_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_01c8a474-e59c-4399-b13c-a57260c5ea14_negatedLabel_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_label_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Period Cash Settled and Other Adjustments</link:label>
    <link:label id="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_documentation_en-US" xlink:label="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:href="abbv-20220630.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:to="lab_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8f8ef822-f795-44bb-ab68-7e85fed90a1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_406c67da-3ff3-48c7-bb45-83fe1ecb242a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_12123192-f425-49da-b687-b5af83be28a2_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_338977f8-6693-4b72-9e2f-9995afa3a821_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1266d89c-ef2e-49dd-b797-f81f43601d73_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedging activities</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d8e1318e-3618-4b55-9544-5e8f6dcd9d5f_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_736fe5a6-ea34-4926-9393-7d3a5b583626_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_7b8510e6-e23b-4167-8d0c-e354a2915bd6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fb41a491-93b4-4925-9e2a-2b68d60f29c2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7f7ea6fe-db4b-4b18-ad88-4494cc65327c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_3b7a1b08-9252-4850-b6e5-f0d8b41f6350_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_4a669c00-88a4-4b45-9f95-a76c8097d2a0_terseLabel_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment for royalties by indication</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_label_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Payment for Royalties by Indication [Member]</link:label>
    <link:label id="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_documentation_en-US" xlink:label="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents probability of payment for royalties by indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:to="lab_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_769633d5-8c54-4d21-9c56-ae0715ca42f3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2842cbb8-8826-4a84-8a0c-9a0ddbef3c8a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_7959355e-3c00-462b-a357-5442cb46f83f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share data</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4c387217-8385-4e13-8e5d-e6d327d2688e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d9a70d44-4be7-466b-9941-e30c186d9e20_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_e9b692e8-ca71-4ed9-a512-54d868485850_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation charge related to potential settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a3eb7f1e-2ce9-4e3c-86c7-e2ed430a6090_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f248e41b-ebbb-40b2-ba3f-4aaca031534a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fb094812-1dec-4f81-989f-946507ca3157_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_de1a2e71-73a2-454d-9f54-37bdc8471fb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1731c6ae-9b67-4843-b825-6113e1b20f63_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_190562a6-6406-4934-a516-1d9d33dd7f05_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46b0de18-4275-4380-8a01-7f072b6172bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16099571-0b9d-4aeb-b5f8-79f100945d97_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_2dd244b3-413b-4bb1-9566-762b03b25648_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3bfc2a74-4d32-4b6d-aefc-a922f1188138_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0efb0f08-5b77-4848-baf5-ae86309fd130_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_ea0506f5-e280-4fba-b473-bb78a6f68b3c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit and other post-employment plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_d3fedaf4-e173-48b8-85dd-09a7c227aaa8_terseLabel_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_label_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:href="abbv-20220630.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:to="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8c909903-fbb4-453f-9814-e5f8fb66cbb1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf3956bb-a29f-4293-bfbb-2c358ce5314a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5101ccbb-bc67-490e-b0a6-f5b8964b89b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a152f167-9e2c-4612-97ce-862b86193667_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_00453095-6991-4200-911c-6c6e85550d1e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_24acafc5-4609-4de7-a027-890529b6745b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_490e830c-fa1f-443c-9292-497b038372ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d16473bc-7cdc-456d-abfb-a72d23cff8f3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1f716084-a883-4d31-8c61-9c9c9379fea8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9772db1b-f9d8-4ec0-a0cf-4b7f51665337_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_c4bca6ed-a36b-4caa-b120-f01b350cb39f_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_45710510-e1ca-403b-8acc-ece4fe259a1b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_2b766357-69ce-4d20-8c7d-21bcbb64cb48_terseLabel_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of principal customers</link:label>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_label_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Principal US Customers</link:label>
    <link:label id="lab_abbv_NumberOfPrincipalUSCustomers_documentation_en-US" xlink:label="lab_abbv_NumberOfPrincipalUSCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of principal U.S. customers of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers" xlink:href="abbv-20220630.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_NumberOfPrincipalUSCustomers" xlink:to="lab_abbv_NumberOfPrincipalUSCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5560209a-c5cd-4be5-b460-f3b521fbfe38_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e78ce8e9-5171-464a-870f-6cd3a09ec186_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c465e40c-0dc2-4fe6-acfe-3e6e21c9263e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3dc45d59-f486-4899-a305-370bba9f60ab_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b9b46cbe-ef57-4172-82d8-dd49d2b5af4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_VraylarMember_10cca0e9-6105-4472-8bb0-93f91417afea_terseLabel_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vraylar</link:label>
    <link:label id="lab_abbv_VraylarMember_label_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vraylar [Member]</link:label>
    <link:label id="lab_abbv_VraylarMember_documentation_en-US" xlink:label="lab_abbv_VraylarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Vraylar, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember" xlink:href="abbv-20220630.xsd#abbv_VraylarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_VraylarMember" xlink:to="lab_abbv_VraylarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_680903a7-2722-4758-9a51-729cf3f175b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6d356f8d-9a49-4217-8f36-52755cc8b818_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5823c92e-b44d-4aad-a2c0-55841bcb5716_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7db777be-6790-4f6b-b3b9-e94a2b3fc035_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueOrExpenseNetAbstract_ba6af9bb-7e6e-43e1-8044-72b07104fa76_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Net</link:label>
    <link:label id="lab_us-gaap_InterestRevenueOrExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueOrExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:to="lab_us-gaap_InterestRevenueOrExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_0453a3de-4ef4-4477-9ad2-7b4f21dd1fa1_terseLabel_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_abbv_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_abbv_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_CollaborativeArrangementsAbstract" xlink:to="lab_abbv_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SyndesiMember_fe00703c-af8c-41aa-b8e0-8304a80bc6d3_terseLabel_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi</link:label>
    <link:label id="lab_abbv_SyndesiMember_label_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi [Member]</link:label>
    <link:label id="lab_abbv_SyndesiMember_documentation_en-US" xlink:label="lab_abbv_SyndesiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndesi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember" xlink:href="abbv-20220630.xsd#abbv_SyndesiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SyndesiMember" xlink:to="lab_abbv_SyndesiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_7da78e6f-fa05-4bc1-9c8b-d4d82d9dbf6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_c3daa8c4-ac9d-4dd1-b83d-121b7e116dba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_045f5708-0541-493d-9f50-07ea3379b66f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_b7411d0b-1504-4a16-b9df-b330771d07aa_terseLabel_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_label_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:href="abbv-20220630.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:to="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyGainLossMember_f6f01266-047d-41e3-978b-a82e14666d28_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyGainLossMember_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Gain (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyGainLossMember" xlink:to="lab_us-gaap_ForeignCurrencyGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_SeniorNotes2.30PercentDue2021Member_29369bd9-5b25-4f12-acbe-03d607d52ce0_terseLabel_en-US" xlink:label="lab_abbv_SeniorNotes2.30PercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.30% senior notes due 2021</link:label>
    <link:label id="lab_abbv_SeniorNotes2.30PercentDue2021Member_label_en-US" xlink:label="lab_abbv_SeniorNotes2.30PercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 2.30 Percent Due 2021 [Member]</link:label>
    <link:label id="lab_abbv_SeniorNotes2.30PercentDue2021Member_documentation_en-US" xlink:label="lab_abbv_SeniorNotes2.30PercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2.30% Unsecured Senior Notes Due 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotes2.30PercentDue2021Member" xlink:href="abbv-20220630.xsd#abbv_SeniorNotes2.30PercentDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_SeniorNotes2.30PercentDue2021Member" xlink:to="lab_abbv_SeniorNotes2.30PercentDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_3336b67c-92f6-4e5d-9cd0-51012f2b4660_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_5b0ebe78-e48a-4b33-b83f-5ad45838240c_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedges</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_adc98d97-bf22-4a29-91ad-d7e5cf8c9557_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bea71841-b39f-4d9b-97ad-2d421494c217_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b0ef5204-16b0-4917-904d-fc4333420104_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at fair value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ede3df56-ec98-4cab-a1c5-8533f7750586_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_238bb1b4-230c-4f6e-aa69-16c15d60fc08_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_aecced94-f3f1-4148-ba56-dd3e8fde5ea5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6f9d747d-0e3a-4330-81c4-0082ece270e5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_ffd756f8-a01c-4d7b-81ac-fac740522e4a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_8f4413a0-6eb4-4389-b6de-f6c507e829be_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_fe74727d-8b20-4d49-b930-b8ed8a0a3667_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant amounts reclassified out of each component of AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3ced93aa-022c-4661-8f75-711d23a53d6b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and time deposits</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_09174a59-dfae-41a7-9f75-d7339a223b61_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3902bbe3-29c2-4988-97f9-ad96a7f42681_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_a455e10b-07e3-4be7-8336-7a183eaab26d_terseLabel_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization</link:label>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization [Member]</link:label>
    <link:label id="lab_abbv_December2018StockRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember" xlink:href="abbv-20220630.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_December2018StockRepurchaseAuthorizationMember" xlink:to="lab_abbv_December2018StockRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5faac52d-3a79-4b3b-bfa0-8ba89b740f89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_e8d151a1-1e66-4976-acfe-f2fec607e5e9_terseLabel_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense to IPR&amp;D and milestones expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_label_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of development milestone expense to IPR&amp;D and milestones expense</link:label>
    <link:label id="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_documentation_en-US" xlink:label="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:href="abbv-20220630.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:to="lab_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_110e5299-89e5-4e15-a2ca-d3dab9e294a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e50a9a9f-6b2b-46f1-917e-3cb841124af5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_13216448-88d9-4afd-b875-41634b34be91_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3309828b-fb02-4ffa-a977-b3dda0c2642c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87263b1d-92d5-4219-adc6-af6b83e3409f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d24ec5c9-959c-4989-aa21-2eef336fdeb4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_7db2441b-0a35-4ef5-9e48-40f1e7dec0ad_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties to lawsuit (in investment funds)</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1f41c7f2-97c2-42ec-ab81-cc5741910060_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_fb9b61cc-0c4f-4598-8ed1-ee0cca4aab70_terseLabel_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payments under agreement certain milestones</link:label>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_label_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payments under Agreement Certain Milestones</link:label>
    <link:label id="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones_documentation_en-US" xlink:label="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:href="abbv-20220630.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:to="lab_abbv_PotentialPaymentsUnderAgreementCertainMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_4fa800f7-d674-4a34-bb2b-eb02651717b8_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value - Derivatives in liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_d453647b-de45-4bac-bf7f-bf7c84679948_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_63d10a8d-d81f-4433-a9ff-e92da7f6221a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0413c1b2-87eb-45c4-96c1-c01c01d4535d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_23f1ebde-d549-4d60-9a78-257dab1b8364_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_329503ca-2c47-41e8-9170-5a3673e2e197_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_91f212d0-fa95-4b3c-9fad-7991c762fcab_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_c1c5109f-f0c0-48d0-b54b-f3a7432b70f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_783f05bc-383a-4ae5-b215-9ea53b71b307_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_29c5f6aa-3b92-4455-94eb-ae2cb291f47b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_40dbd225-d581-407b-b7ef-b29014c2c504_terseLabel_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation</link:label>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_label_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Antitrust Litigation, In re: Humira (Adalimumab) Antitrust Litigation [Member]</link:label>
    <link:label id="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_documentation_en-US" xlink:label="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to lawsuits filed alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:href="abbv-20220630.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:to="lab_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_4dbdf919-8ac4-4ec7-932c-80fee6e465d8_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1eeb00db-c7f7-4652-926b-d79475dbe4d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant level 3 unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_fe7d9026-bf20-4168-ba83-70de254f8a17_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_VENCLEXTAMember_9d78e320-dab3-4d05-b3ed-92197223fc57_terseLabel_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Venclexta</link:label>
    <link:label id="lab_abbv_VENCLEXTAMember_label_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VENCLEXTA [Member]</link:label>
    <link:label id="lab_abbv_VENCLEXTAMember_documentation_en-US" xlink:label="lab_abbv_VENCLEXTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to VENCLEXTA, a product of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember" xlink:href="abbv-20220630.xsd#abbv_VENCLEXTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_VENCLEXTAMember" xlink:to="lab_abbv_VENCLEXTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_63f130c1-ff6e-431d-b7ee-3bb56539e232_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time Hedged in Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:to="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_4b850f29-ff52-4f8e-9b78-c905a9b4fc07_terseLabel_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_label_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_documentation_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:href="abbv-20220630.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:to="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_ba07aa59-82a2-4ef6-b178-ff4f7c75895c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_1b807516-a5bd-4504-8a7d-af0ab1a4c4db_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_370e7df3-55be-4863-b52c-6af1504791d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_f8b9d5c7-0bc0-447f-a88b-fd7be41cf81b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,622,099 shares issued as of June 30, 2022 and 1,803,195,293 as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_fa9d74bd-fb23-4546-a938-6730d4cc40ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts and location of derivatives on the condensed consolidated balance sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_33e6243d-aadb-46e6-bdc8-ca3df81caf71_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_EyeCareMember_6f50f464-7c36-4b24-979d-86589ddefcc6_terseLabel_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eye Care</link:label>
    <link:label id="lab_abbv_EyeCareMember_label_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eye Care [Member]</link:label>
    <link:label id="lab_abbv_EyeCareMember_documentation_en-US" xlink:label="lab_abbv_EyeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Eye Care, a key product portfolio of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember" xlink:href="abbv-20220630.xsd#abbv_EyeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_EyeCareMember" xlink:to="lab_abbv_EyeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_bdc3929e-6d0c-4e62-a2b9-87a00338b50e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_d8293e0b-6ee6-4a49-bc0e-d144937a3d2b_verboseLabel_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_label_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Cash Settled Restructuring Gains (Losses)</link:label>
    <link:label id="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_documentation_en-US" xlink:label="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:href="abbv-20220630.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:to="lab_abbv_RestructuringReserveCashSettledRestructuringGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_5fc535d6-9a5f-497d-97c0-ff969622c950_terseLabel_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedging activities, tax expense (benefit)</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_label_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Tax</link:label>
    <link:label id="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_documentation_en-US" xlink:label="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:href="abbv-20220630.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:to="lab_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_217ca20c-6e7b-4060-87d2-e7472bf8536c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_533ffa63-ece0-4174-92e0-cb55942cd6ab_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and license agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c1e9540e-32d1-407a-9c4e-e75f3523e3a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0149f5fc-9307-43e7-a7c3-a3e0f1dd5f07_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>abbv-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:582bdcbd-df81-4562-98a1-f070e0ab5f69,g:2db432dd-589c-4867-9656-372b50c315ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="abbv-20220630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_71eda92d-c593-4d0b-a399-eb93b27a906c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_71eda92d-c593-4d0b-a399-eb93b27a906c" xlink:to="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:to="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_cebd187b-d520-4554-b4fb-45c004a54bd9" xlink:to="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_b4f3a4b4-6575-4c9f-ba5f-d2c5768e13ae" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:to="loc_exch_XNYS_b4f3a4b4-6575-4c9f-ba5f-d2c5768e13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_c986ce31-28b7-4423-8a37-73dbce690ac5" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_a14b9fe0-13fb-4ab7-8e5d-be4dd188797e" xlink:to="loc_exch_XCHI_c986ce31-28b7-4423-8a37-73dbce690ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73987b57-0d85-45cd-b782-ab8cf3516e21" xlink:to="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e880391a-16eb-4797-81e5-c0a6f3fe03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_us-gaap_CommonStockMember_e880391a-16eb-4797-81e5-c0a6f3fe03d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_e4089ee6-eb1d-4e80-a18c-7d9fc20b9908" xlink:href="abbv-20220630.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_e4089ee6-eb1d-4e80-a18c-7d9fc20b9908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_27cb870b-d867-4e1f-8718-a51d311d388b" xlink:href="abbv-20220630.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_27cb870b-d867-4e1f-8718-a51d311d388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_d65eaaf2-7408-4312-aee1-70994d92d154" xlink:href="abbv-20220630.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_d65eaaf2-7408-4312-aee1-70994d92d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_874c5c22-45d4-4ff3-999e-2fb50829f5b2" xlink:href="abbv-20220630.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_874c5c22-45d4-4ff3-999e-2fb50829f5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_92d727b0-87c0-41d9-bf7c-b16dd509f503" xlink:href="abbv-20220630.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_92d727b0-87c0-41d9-bf7c-b16dd509f503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_ed0b05ed-ace8-443c-8b7a-e947c2a7161c" xlink:href="abbv-20220630.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_ed0b05ed-ace8-443c-8b7a-e947c2a7161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_d72d9f6d-2154-4d6d-b984-ee2d30e964bf" xlink:href="abbv-20220630.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_d72d9f6d-2154-4d6d-b984-ee2d30e964bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_8fd95350-8841-4ca7-a41b-17abe396e8a0" xlink:href="abbv-20220630.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9178202-3a1c-4f19-8e3b-aa172e782122" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_8fd95350-8841-4ca7-a41b-17abe396e8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_eedabe6c-1a47-4bb5-8c8b-964c3d4e803e" xlink:to="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6f02a35-735d-4917-a73b-c11d821e2af3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentType_f6f02a35-735d-4917-a73b-c11d821e2af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9fb45195-951b-4137-885a-8af850be04ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentQuarterlyReport_9fb45195-951b-4137-885a-8af850be04ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_11c71680-807c-42bb-8a69-86d77e775d98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentPeriodEndDate_11c71680-807c-42bb-8a69-86d77e775d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_07bb9eaa-afad-4108-a8e9-4fc4ae287e54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentTransitionReport_07bb9eaa-afad-4108-a8e9-4fc4ae287e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f77570b4-ded8-4dd0-94c9-07630a648750" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityFileNumber_f77570b4-ded8-4dd0-94c9-07630a648750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_00b75f4b-9676-4f98-982d-43218e0c4cae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityRegistrantName_00b75f4b-9676-4f98-982d-43218e0c4cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e5b9b84e-a9ec-43fc-959f-4f196fe24bfd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCentralIndexKey_e5b9b84e-a9ec-43fc-959f-4f196fe24bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_89bf6ca5-7601-4cc0-993d-45e7d4a6d6a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentFiscalYearFocus_89bf6ca5-7601-4cc0-993d-45e7d4a6d6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6ee9c25b-6599-419d-9170-5b4fbde2cf9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6ee9c25b-6599-419d-9170-5b4fbde2cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_679d7dff-d74e-4a04-9992-fd60fa883cee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_AmendmentFlag_679d7dff-d74e-4a04-9992-fd60fa883cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2666cd30-1912-431c-b4fd-2647475ba8c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_CurrentFiscalYearEndDate_2666cd30-1912-431c-b4fd-2647475ba8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d79cf3ce-c396-4a88-8fa1-8ddbbc2e3b9a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d79cf3ce-c396-4a88-8fa1-8ddbbc2e3b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b9b80d81-cc34-44f0-af0a-b3e01ee7824c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityTaxIdentificationNumber_b9b80d81-cc34-44f0-af0a-b3e01ee7824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a687bb8e-2eaf-4e77-a06f-7e6e138dd2c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressAddressLine1_a687bb8e-2eaf-4e77-a06f-7e6e138dd2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_56036972-d5ce-4e99-b61d-ef3dbbf26231" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressCityOrTown_56036972-d5ce-4e99-b61d-ef3dbbf26231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8bbd34dc-8cca-4c97-bd19-753f6e7d4959" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressStateOrProvince_8bbd34dc-8cca-4c97-bd19-753f6e7d4959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9edaa5f9-7ed4-4255-a0fc-c9de4f7749bf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityAddressPostalZipCode_9edaa5f9-7ed4-4255-a0fc-c9de4f7749bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c7aa545b-c87f-442c-a592-15f29119b34a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_CityAreaCode_c7aa545b-c87f-442c-a592-15f29119b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63f81d81-1f92-4707-8816-ddc00325aaa2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_LocalPhoneNumber_63f81d81-1f92-4707-8816-ddc00325aaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c2f0598-94ad-4fa5-97a5-1c5677508d54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCurrentReportingStatus_9c2f0598-94ad-4fa5-97a5-1c5677508d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f7f9b469-8211-48d1-b52a-e988c84b4aa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityInteractiveDataCurrent_f7f9b469-8211-48d1-b52a-e988c84b4aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0b40dea1-f685-4003-b611-03120f489cdd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityFilerCategory_0b40dea1-f685-4003-b611-03120f489cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_88bf0309-68a6-4196-924b-5e441b0835bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntitySmallBusiness_88bf0309-68a6-4196-924b-5e441b0835bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_539220ea-1aae-4b22-956a-9c4e75d8aa28" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityEmergingGrowthCompany_539220ea-1aae-4b22-956a-9c4e75d8aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4465c734-476c-4091-b177-0030583b3f3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityShellCompany_4465c734-476c-4091-b177-0030583b3f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_26970612-adaa-4aa0-86d6-00ec11297dc2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_SecurityExchangeName_26970612-adaa-4aa0-86d6-00ec11297dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e25e0368-52d9-44bc-8405-d731d067ac02" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_Security12bTitle_e25e0368-52d9-44bc-8405-d731d067ac02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a9feccae-1ab5-4253-b635-07419da9e884" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_TradingSymbol_a9feccae-1ab5-4253-b635-07419da9e884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fb985ae1-a37c-44e6-95c5-419ad3f5ac41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_525702d9-dcaf-41f6-b9da-74c04f50a862" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fb985ae1-a37c-44e6-95c5-419ad3f5ac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofEarningsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_008a5ece-b8bf-4078-beee-4ec402f5b25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_Revenues_008a5ece-b8bf-4078-beee-4ec402f5b25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dc42432d-05cb-4df6-b33d-9bb19619526e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dc42432d-05cb-4df6-b33d-9bb19619526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bbf669da-bf42-4fa3-8e31-8637be047c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bbf669da-bf42-4fa3-8e31-8637be047c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5897a3a0-32f2-4c41-b873-6cf897433d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5897a3a0-32f2-4c41-b873-6cf897433d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_dfe02760-2965-4678-9b78-6e4bf7cb56dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_dfe02760-2965-4678-9b78-6e4bf7cb56dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_b55e2957-42ed-4c92-8f72-df40a8fedb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_b55e2957-42ed-4c92-8f72-df40a8fedb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0e09207b-eba7-4dc0-b42d-3673e3b4bf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_CostsAndExpenses_0e09207b-eba7-4dc0-b42d-3673e3b4bf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5da7c041-c35d-4de5-86e5-123651ea9b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_OperatingIncomeLoss_5da7c041-c35d-4de5-86e5-123651ea9b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c1c636b8-9f82-4fea-9974-5f66d3ab8cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c1c636b8-9f82-4fea-9974-5f66d3ab8cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3d3a9ae6-e086-4776-bfdd-0852dcff4142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3d3a9ae6-e086-4776-bfdd-0852dcff4142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_74c2e81f-0934-4520-826d-e0515127c590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_74c2e81f-0934-4520-826d-e0515127c590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3bbca5d-5fa1-4220-92b4-52f798f6ce0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3bbca5d-5fa1-4220-92b4-52f798f6ce0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fb866b50-5c23-455a-8ece-a880ceaef71a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fb866b50-5c23-455a-8ece-a880ceaef71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b24be010-1db6-41a1-8156-aec90f2e2381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_ProfitLoss_b24be010-1db6-41a1-8156-aec90f2e2381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_35b423a1-b2d9-48eb-92db-4d2cc01ed3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_35b423a1-b2d9-48eb-92db-4d2cc01ed3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6edd7281-f897-47ec-96b6-19dc14994fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_NetIncomeLoss_6edd7281-f897-47ec-96b6-19dc14994fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f26ba15e-1898-4131-ad1e-3cf8fd4d627b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f26ba15e-1898-4131-ad1e-3cf8fd4d627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_33e067fd-40d1-4806-9e6a-afd53b04d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f26ba15e-1898-4131-ad1e-3cf8fd4d627b" xlink:to="loc_us-gaap_EarningsPerShareBasic_33e067fd-40d1-4806-9e6a-afd53b04d3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2ebbb2fe-e1ba-491d-8d22-1e997edd509e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f26ba15e-1898-4131-ad1e-3cf8fd4d627b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2ebbb2fe-e1ba-491d-8d22-1e997edd509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f579b93d-fcd4-4bb8-8a0d-2aab108ac4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f579b93d-fcd4-4bb8-8a0d-2aab108ac4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43691591-70cb-4a58-83d6-f057fa5b29a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3da2f69-1b3e-411d-91ae-9951db876dba" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43691591-70cb-4a58-83d6-f057fa5b29a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f6b33787-f974-48ff-8059-6aa499b834cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_ProfitLoss_f6b33787-f974-48ff-8059-6aa499b834cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4e292b3d-1b0d-4e7a-b801-cb4ee701abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4e292b3d-1b0d-4e7a-b801-cb4ee701abf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_dee2ed4b-5d5e-4699-a666-5493d67a2cfc" xlink:href="abbv-20220630.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax_dee2ed4b-5d5e-4699-a666-5493d67a2cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1d2d594a-3c3b-4dce-9a34-e1c186d3fd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1d2d594a-3c3b-4dce-9a34-e1c186d3fd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0d0b99b9-6826-4c18-b4e4-96205636678c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0d0b99b9-6826-4c18-b4e4-96205636678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a209463-94a3-4cdd-a747-9ea30361fc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a209463-94a3-4cdd-a747-9ea30361fc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e069b85f-c215-47f3-b8a0-75b53c75dcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e069b85f-c215-47f3-b8a0-75b53c75dcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9bd0ab7a-0396-4e06-bf13-dd0463d872d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9bd0ab7a-0396-4e06-bf13-dd0463d872d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_82204d2c-dfa9-49ae-aaa7-19f4ecb3b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1940403d-80e8-4e54-9ffb-21c0ebf40cec" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_82204d2c-dfa9-49ae-aaa7-19f4ecb3b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0fe7087-6325-47ea-a932-c568610f2b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0fe7087-6325-47ea-a932-c568610f2b12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0dcd3769-b3b4-4ad8-bb77-098193323ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0dcd3769-b3b4-4ad8-bb77-098193323ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_3c681bd4-23b4-4f09-a7de-521b0d71534e" xlink:href="abbv-20220630.xsd#abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:to="loc_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax_3c681bd4-23b4-4f09-a7de-521b0d71534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_521ba420-6206-4042-bb06-d48cd4ba9304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_521ba420-6206-4042-bb06-d48cd4ba9304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2f41371b-cd7b-4e21-aafd-28cfa6b7cb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract_107b10c4-f3e1-4d1f-962c-8e224ff0eacc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2f41371b-cd7b-4e21-aafd-28cfa6b7cb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a7bdab87-5c08-4201-8ff7-665435987e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7bdab87-5c08-4201-8ff7-665435987e8b" xlink:to="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6bbf4c4-863a-48b1-a000-1b9a87385479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6bbf4c4-863a-48b1-a000-1b9a87385479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_7a83fbff-9840-444a-9620-84d83b4cf530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_ShortTermInvestments_7a83fbff-9840-444a-9620-84d83b4cf530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_71b4839e-c087-4608-a6a4-3f5fd0c0cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_71b4839e-c087-4608-a6a4-3f5fd0c0cfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4584d709-97ea-4556-aa0f-d6d247cce341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_InventoryNet_4584d709-97ea-4556-aa0f-d6d247cce341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_c76c0740-9f57-400e-b433-c57d1d0c5752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_c76c0740-9f57-400e-b433-c57d1d0c5752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6d07b1e2-6f57-44e9-b252-87bbb25cf8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3c33b5ba-bcfb-4407-8334-570765944e29" xlink:to="loc_us-gaap_AssetsCurrent_6d07b1e2-6f57-44e9-b252-87bbb25cf8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1c2e0dcf-9a3f-4c65-b1af-b7dd2c1d5b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_LongTermInvestments_1c2e0dcf-9a3f-4c65-b1af-b7dd2c1d5b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b474c7fe-55a8-4879-908b-96b3963f2849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b474c7fe-55a8-4879-908b-96b3963f2849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ff56a6fd-09f5-4514-978e-520e415c0b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ff56a6fd-09f5-4514-978e-520e415c0b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc84a7ba-8b0b-4112-a28a-027ab8a6dd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_Goodwill_dc84a7ba-8b0b-4112-a28a-027ab8a6dd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_09dc33bb-e79f-4a25-ab9b-99847ffd6c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_09dc33bb-e79f-4a25-ab9b-99847ffd6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5e2a9726-c8a9-4f80-8d11-339d20bc792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d932a888-d32a-40ce-8bf6-345cf564ad6a" xlink:to="loc_us-gaap_Assets_5e2a9726-c8a9-4f80-8d11-339d20bc792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7bdab87-5c08-4201-8ff7-665435987e8b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_93970ea7-15f5-49c3-b9b5-9ea9d35b36e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:to="loc_us-gaap_ShortTermBorrowings_93970ea7-15f5-49c3-b9b5-9ea9d35b36e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f67719e3-027b-4839-b752-280198fec8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f67719e3-027b-4839-b752-280198fec8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbab1e39-8e03-4254-981f-975934da8aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbab1e39-8e03-4254-981f-975934da8aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d91c8e16-49b6-4339-932e-bfffa0fbf8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54ad5b33-e5fe-419b-bc73-6e6a6d67b600" xlink:to="loc_us-gaap_LiabilitiesCurrent_d91c8e16-49b6-4339-932e-bfffa0fbf8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_475cfc4b-7b49-4974-871f-46b8a71685ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_475cfc4b-7b49-4974-871f-46b8a71685ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_26ff641f-0081-4e39-a74c-965704a90f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_26ff641f-0081-4e39-a74c-965704a90f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e19b6253-82df-42eb-aa94-6b6821c92192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e19b6253-82df-42eb-aa94-6b6821c92192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f52d8c88-9a0b-4449-ad0e-d23a9b0fd6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f52d8c88-9a0b-4449-ad0e-d23a9b0fd6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_254ddb43-44e3-43d8-9c27-ff77dde5c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_CommonStockValueOutstanding_254ddb43-44e3-43d8-9c27-ff77dde5c3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d19a061d-dadf-471f-9a1d-287c7ed92532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_TreasuryStockValue_d19a061d-dadf-471f-9a1d-287c7ed92532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ec96a2ee-67b7-424f-a7d3-693f6b7d9483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ec96a2ee-67b7-424f-a7d3-693f6b7d9483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5956f9a-001e-4933-a6e0-b39b142d1a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5956f9a-001e-4933-a6e0-b39b142d1a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8451281-2a39-41c9-95ee-ea66d90fdd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8451281-2a39-41c9-95ee-ea66d90fdd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d087f7bb-04e8-46a1-af1a-71866abcfd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ed51775-e1b4-44d7-b37d-b2b0aaf9087d" xlink:to="loc_us-gaap_StockholdersEquity_d087f7bb-04e8-46a1-af1a-71866abcfd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_207dcf50-6d8e-40be-810a-3fd83677e735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_MinorityInterest_207dcf50-6d8e-40be-810a-3fd83677e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bfb58e3b-9970-4285-8f26-8038f5ae06b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bfb58e3b-9970-4285-8f26-8038f5ae06b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e8655be-c0cf-47e7-b110-1123ff8b0eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc6194f-74e7-4789-a657-8d01c577cfce" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e8655be-c0cf-47e7-b110-1123ff8b0eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3de67f43-ead2-49c5-b7ee-d5b03d2ee1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4b679524-5305-4b76-99fa-274c7e5e78de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3de67f43-ead2-49c5-b7ee-d5b03d2ee1db" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4b679524-5305-4b76-99fa-274c7e5e78de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c8032a6a-c543-4bc9-a652-aba72af010fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3de67f43-ead2-49c5-b7ee-d5b03d2ee1db" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c8032a6a-c543-4bc9-a652-aba72af010fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_37a38884-7e28-4e6b-97be-020f8509ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3de67f43-ead2-49c5-b7ee-d5b03d2ee1db" xlink:to="loc_us-gaap_CommonStockSharesIssued_37a38884-7e28-4e6b-97be-020f8509ef97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_b9cc73c6-4b26-445f-965f-faf714c35c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3de67f43-ead2-49c5-b7ee-d5b03d2ee1db" xlink:to="loc_us-gaap_TreasuryStockShares_b9cc73c6-4b26-445f-965f-faf714c35c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b40206c5-62dd-46bf-bb13-0830ae29f191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b40206c5-62dd-46bf-bb13-0830ae29f191" xlink:to="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e78b235-e394-4ce6-83c8-8d16cb9e4d8a" xlink:to="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_377bdb32-13af-479c-be62-a67a937dc607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_CommonStockMember_377bdb32-13af-479c-be62-a67a937dc607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9538672a-178c-49ee-b765-655fd6968d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_TreasuryStockMember_9538672a-178c-49ee-b765-655fd6968d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e62807d-30c5-4424-967c-18ced0e74b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e62807d-30c5-4424-967c-18ced0e74b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1f098e9e-a400-4621-89a3-09a372dd22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_RetainedEarningsMember_1f098e9e-a400-4621-89a3-09a372dd22ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6499928b-5507-47a3-a904-8817dea1f170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6499928b-5507-47a3-a904-8817dea1f170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_60da4aee-01ac-4cc9-b205-e498f1b1ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33a71bf8-6475-4a58-afc3-145475a02633" xlink:to="loc_us-gaap_NoncontrollingInterestMember_60da4aee-01ac-4cc9-b205-e498f1b1ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57f5d7e4-7d5b-4846-8ca5-68fadbc1953e" xlink:to="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b2da9093-b3ab-4355-8a1c-96c937eaa970" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffea2223-fd5d-4a94-b027-ee21593ede97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffea2223-fd5d-4a94-b027-ee21593ede97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_36a5c944-8fdc-4be0-b0fc-e10c5cb7e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_SharesOutstanding_36a5c944-8fdc-4be0-b0fc-e10c5cb7e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39e5e472-edef-4f87-b96d-d1e601fef5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_NetIncomeLoss_39e5e472-edef-4f87-b96d-d1e601fef5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f9f5c06-fa2d-4bce-a42f-828f5a71f7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f9f5c06-fa2d-4bce-a42f-828f5a71f7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_54b90963-a0d5-4b20-b6a0-6f09d711e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_DividendsCommonStockCash_54b90963-a0d5-4b20-b6a0-6f09d711e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccc023d4-c34c-4cdf-bc60-de2ebd3d6b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccc023d4-c34c-4cdf-bc60-de2ebd3d6b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b5ec07b3-e301-41fb-9e03-ae1c85786de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b5ec07b3-e301-41fb-9e03-ae1c85786de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_49afc516-6e32-4c2b-856f-fb0b0a6e3bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_49afc516-6e32-4c2b-856f-fb0b0a6e3bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b4b6001-1c99-4167-bf63-b368d0c224d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b4b6001-1c99-4167-bf63-b368d0c224d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_c03b74ce-9270-4b8b-ab8d-380e49c57b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_c03b74ce-9270-4b8b-ab8d-380e49c57b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf915eb4-c8f5-4664-b502-eb229f8d496b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf915eb4-c8f5-4664-b502-eb229f8d496b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_625b24fd-14db-4ff3-91aa-8dc80b2554de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51d3d398-cc0f-4ad0-8317-3cfeda9fedd7" xlink:to="loc_us-gaap_SharesOutstanding_625b24fd-14db-4ff3-91aa-8dc80b2554de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="abbv-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d4f1569f-6a6e-47db-940e-962614079c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_ProfitLoss_d4f1569f-6a6e-47db-940e-962614079c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1cfff14a-07d6-4064-a38b-b16295e49eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1cfff14a-07d6-4064-a38b-b16295e49eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1cfff14a-07d6-4064-a38b-b16295e49eb7" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_db645961-f0c8-40c1-809c-29575ae33bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_Depreciation_db645961-f0c8-40c1-809c-29575ae33bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_baf16b86-5498-42c6-a346-72daeba6e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_baf16b86-5498-42c6-a346-72daeba6e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05798acb-330a-4d18-a0bd-0f7b31c086d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05798acb-330a-4d18-a0bd-0f7b31c086d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e6335a36-a6c5-4643-9ff8-5a54278ea317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e6335a36-a6c5-4643-9ff8-5a54278ea317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7564750-6eac-47c4-adf2-d217f9fd2ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_ShareBasedCompensation_a7564750-6eac-47c4-adf2-d217f9fd2ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5faf495e-9e18-4aa5-87d4-9d60d7911820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5faf495e-9e18-4aa5-87d4-9d60d7911820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5d0254b0-b6f2-493a-a434-a22b896a5688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5d0254b0-b6f2-493a-a434-a22b896a5688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_1ac83d86-8fe7-4d76-b0f8-91a5ad04ec83" xlink:href="abbv-20220630.xsd#abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments_1ac83d86-8fe7-4d76-b0f8-91a5ad04ec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dfe41cbe-3b66-4119-8a86-ae62f09b708d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dfe41cbe-3b66-4119-8a86-ae62f09b708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3a4183f-9f32-4716-971f-fde8af6d1541" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcd14928-f303-4ff3-b266-9b4d5d283d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcd14928-f303-4ff3-b266-9b4d5d283d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_61636aa9-fb28-482f-8ee8-f2fce602be51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_61636aa9-fb28-482f-8ee8-f2fce602be51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2cb0202c-8a58-454c-9537-0ed62d18d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2cb0202c-8a58-454c-9537-0ed62d18d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c1f86b74-3ef9-492b-9fd3-b2205b888122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c1f86b74-3ef9-492b-9fd3-b2205b888122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_fb2d2389-214d-4d00-8fc3-0336543c7f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff25231a-7c56-433c-8b93-2dd9f606483e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_fb2d2389-214d-4d00-8fc3-0336543c7f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9603f8-a4cf-4bea-9d30-0a385379f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1cfff14a-07d6-4064-a38b-b16295e49eb7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9603f8-a4cf-4bea-9d30-0a385379f7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_b2b58418-43f4-42de-b24a-ba3802126f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_b2b58418-43f4-42de-b24a-ba3802126f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d9b1be6-1db7-4dc2-ae25-a97ce5704a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d9b1be6-1db7-4dc2-ae25-a97ce5704a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ec6cdf53-ff74-46d8-993d-352450c6bb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ec6cdf53-ff74-46d8-993d-352450c6bb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5555376d-949d-44ea-b191-8c2f3a571dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5555376d-949d-44ea-b191-8c2f3a571dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d89857c1-8673-42c5-ae7d-d886023cc14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d89857c1-8673-42c5-ae7d-d886023cc14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee890c9e-842a-4423-8e1a-b8cc33a1d180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7a22245c-3a07-43ee-adf6-0753e93e7a91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee890c9e-842a-4423-8e1a-b8cc33a1d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3302dbc5-2665-4949-9ec5-80e032381871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3302dbc5-2665-4949-9ec5-80e032381871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_f1619f16-08d1-437d-af43-a40889fa70b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_f1619f16-08d1-437d-af43-a40889fa70b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_0efad02b-b85b-4f87-bed4-115563e3704a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_PaymentsOfDividends_0efad02b-b85b-4f87-bed4-115563e3704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_350dfc43-6e7c-41c1-b453-9c217caafc80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_350dfc43-6e7c-41c1-b453-9c217caafc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2001c948-3b43-4683-a234-6ee6b5bc1b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2001c948-3b43-4683-a234-6ee6b5bc1b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_fc8ebf8f-ad53-4a29-9b38-32296b45aca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_fc8ebf8f-ad53-4a29-9b38-32296b45aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e078337e-c051-4da3-8bb9-059bb5cf6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e078337e-c051-4da3-8bb9-059bb5cf6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_908d242f-0be7-4bc7-b989-f56bf3dcef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_eb3758e1-e727-49e1-929b-2bcfcaba710a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_908d242f-0be7-4bc7-b989-f56bf3dcef6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_cf3a0fce-e8d4-41a9-bd81-c792362ae0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_cf3a0fce-e8d4-41a9-bd81-c792362ae0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7af303d-44f4-453d-8626-91e0e15a4153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7af303d-44f4-453d-8626-91e0e15a4153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daac1c70-e79b-427b-b586-498b86438d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daac1c70-e79b-427b-b586-498b86438d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98285952-46a3-4eff-b18b-6cb490e7152d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e7c76c6-3ebe-41fd-8e34-ca18a478683a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98285952-46a3-4eff-b18b-6cb490e7152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/BasisofPresentation" xlink:type="simple" xlink:href="abbv-20220630.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0bf82b1-5271-4d4d-9443-bee454562e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c4b0ce7a-ae4a-4e65-95a8-be4814a2d78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0bf82b1-5271-4d4d-9443-bee454562e26" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c4b0ce7a-ae4a-4e65-95a8-be4814a2d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf0933fd-e888-4d15-ad42-7673774240be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_8ac242b4-dc4f-4961-9b21-d8480bfdbe39" xlink:href="abbv-20220630.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf0933fd-e888-4d15-ad42-7673774240be" xlink:to="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense_8ac242b4-dc4f-4961-9b21-d8480bfdbe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_7556099c-17d9-416a-a1c6-8aea12494eeb" xlink:href="abbv-20220630.xsd#abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf0933fd-e888-4d15-ad42-7673774240be" xlink:to="loc_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense_7556099c-17d9-416a-a1c6-8aea12494eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="abbv-20220630.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_5dfaff7c-9f74-4bf2-9604-032cdf7402e7" xlink:href="abbv-20220630.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_055ca848-4511-43a5-aa69-3b5ed46410b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_5dfaff7c-9f74-4bf2-9604-032cdf7402e7" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_055ca848-4511-43a5-aa69-3b5ed46410b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_1e1681f2-8551-41d4-b2dd-ff5bb8fed462" xlink:href="abbv-20220630.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_a2dcf498-4015-49f4-84c7-f72bcbef9968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_1e1681f2-8551-41d4-b2dd-ff5bb8fed462" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_a2dcf498-4015-49f4-84c7-f72bcbef9968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3202f737-d5e6-476c-829c-508171a8dbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_1e1681f2-8551-41d4-b2dd-ff5bb8fed462" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3202f737-d5e6-476c-829c-508171a8dbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_611028ff-8d23-4573-9942-a7bd6012c038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_1e1681f2-8551-41d4-b2dd-ff5bb8fed462" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_611028ff-8d23-4573-9942-a7bd6012c038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#SupplementalFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SupplementalFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_b95c8e3a-2d31-4712-8ab3-65ffc0ac01d5" xlink:href="abbv-20220630.xsd#abbv_SupplementalFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_398e1e1b-b648-4d74-9e1f-24d35b4b38eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueOrExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_b95c8e3a-2d31-4712-8ab3-65ffc0ac01d5" xlink:to="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_398e1e1b-b648-4d74-9e1f-24d35b4b38eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_de682cfa-a142-4ab9-8b31-14aed96814a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_398e1e1b-b648-4d74-9e1f-24d35b4b38eb" xlink:to="loc_us-gaap_InterestExpense_de682cfa-a142-4ab9-8b31-14aed96814a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0ffb5ca5-90ff-41a5-b4b4-4da7815d313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_398e1e1b-b648-4d74-9e1f-24d35b4b38eb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0ffb5ca5-90ff-41a5-b4b4-4da7815d313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_afd3c5c4-65db-41ce-b253-fb491cb432a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRevenueOrExpenseNetAbstract_398e1e1b-b648-4d74-9e1f-24d35b4b38eb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_afd3c5c4-65db-41ce-b253-fb491cb432a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_b95c8e3a-2d31-4712-8ab3-65ffc0ac01d5" xlink:to="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_949536cb-7773-4150-9756-ba6e5fbccb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_949536cb-7773-4150-9756-ba6e5fbccb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0ccc536a-5d35-4001-8b1a-1c79a1ff5436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0ccc536a-5d35-4001-8b1a-1c79a1ff5436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ccfff09d-c420-48da-af23-5acc0763e1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ccfff09d-c420-48da-af23-5acc0763e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_30623599-097e-4575-a11f-ed644f59acde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9d97bbb1-3f30-4bd2-b020-43276de0effb" xlink:to="loc_us-gaap_InventoryNet_30623599-097e-4575-a11f-ed644f59acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_SupplementalFinancialInformationDisclosureAbstract_b95c8e3a-2d31-4712-8ab3-65ffc0ac01d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c36aab66-2c1b-475e-bad1-3fb2a6b63cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c36aab66-2c1b-475e-bad1-3fb2a6b63cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_888dae76-6690-4ce2-9a53-1621e1bb17f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_888dae76-6690-4ce2-9a53-1621e1bb17f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0dd8e7b1-ca49-4cf3-a5a2-0a56f72f8820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0dd8e7b1-ca49-4cf3-a5a2-0a56f72f8820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_53f2512b-4973-43d1-82e3-3761619896c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_cf56fc44-f012-4b50-bbc3-81b41ca4b60d" xlink:to="loc_us-gaap_Depreciation_53f2512b-4973-43d1-82e3-3761619896c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShare" xlink:type="simple" xlink:href="abbv-20220630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a009eb25-bece-4c3b-8ea2-b01110e24ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b16a361c-809d-4247-9cd9-5b300c9da59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a009eb25-bece-4c3b-8ea2-b01110e24ec7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b16a361c-809d-4247-9cd9-5b300c9da59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_18049187-50b2-4ba8-b80b-09790867db71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_47120e9d-93bf-4513-bd88-d2223d2f019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_18049187-50b2-4ba8-b80b-09790867db71" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_47120e9d-93bf-4513-bd88-d2223d2f019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ac43555e-eb1a-4a95-9bd6-5f2d294081fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac43555e-eb1a-4a95-9bd6-5f2d294081fd" xlink:to="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2be13cd-e00f-47c2-a3e2-00c434cbb916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:to="loc_us-gaap_NetIncomeLoss_d2be13cd-e00f-47c2-a3e2-00c434cbb916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_7e5681b0-8b44-410e-bb23-0ae77394d192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_7e5681b0-8b44-410e-bb23-0ae77394d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2c1deab5-ffe4-4fcb-920f-d02d46e3b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2c1deab5-ffe4-4fcb-920f-d02d46e3b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_caa06222-cb6e-4266-a02b-b9a6e47714c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_caa06222-cb6e-4266-a02b-b9a6e47714c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_64d59a4a-347f-4779-b226-b27fc417266c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_6a3b6f8a-4455-4a4f-a41e-30b19f6fc23d" xlink:to="loc_us-gaap_EarningsPerShareBasic_64d59a4a-347f-4779-b226-b27fc417266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac43555e-eb1a-4a95-9bd6-5f2d294081fd" xlink:to="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_790c9b0f-6ad0-4860-9b9a-804ae1cc41e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_NetIncomeLoss_790c9b0f-6ad0-4860-9b9a-804ae1cc41e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_5aa79491-b5fb-4a8c-8f67-639d425e22a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_5aa79491-b5fb-4a8c-8f67-639d425e22a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0509c507-7700-49c4-a007-d70e8bdf3955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0509c507-7700-49c4-a007-d70e8bdf3955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48595ea3-f1ae-42f2-abcc-b9c901b30fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48595ea3-f1ae-42f2-abcc-b9c901b30fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7a9a37e6-ee4d-4736-abcb-ba24d453b658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7a9a37e6-ee4d-4736-abcb-ba24d453b658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_934f9a01-e944-4c3d-873f-a78a3be3ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_934f9a01-e944-4c3d-873f-a78a3be3ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_77d33fe1-e981-45f0-8866-289f03af46a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract_f324e555-e590-40b7-b44e-29fceb1a36fa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_77d33fe1-e981-45f0-8866-289f03af46a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements" xlink:type="simple" xlink:href="abbv-20220630.xsd#LicensingAcquisitionsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_6a0cf7a9-3bd3-45f5-9b80-e9155ebc8816" xlink:href="abbv-20220630.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_4b73ef0e-d491-4d03-a639-dc4db1691a94" xlink:href="abbv-20220630.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_6a0cf7a9-3bd3-45f5-9b80-e9155ebc8816" xlink:to="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock_4b73ef0e-d491-4d03-a639-dc4db1691a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#LicensingAcquisitionsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_2dc14884-17f7-459b-8d7a-d4f87f7f97ed" xlink:href="abbv-20220630.xsd#abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract_2dc14884-17f7-459b-8d7a-d4f87f7f97ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3c0c39ce-6189-4a8d-bd31-fbd62af695f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SyndesiMember_7eecfda7-3d76-480c-bbd3-df2d7589e8fa" xlink:href="abbv-20220630.xsd#abbv_SyndesiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:to="loc_abbv_SyndesiMember_7eecfda7-3d76-480c-bbd3-df2d7589e8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvisePharmaceuticalsMember_f617237f-0c05-4134-a3a0-109040504e4a" xlink:href="abbv-20220630.xsd#abbv_JuvisePharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae53f96f-4546-43b0-a37b-8cccb6fe2602" xlink:to="loc_abbv_JuvisePharmaceuticalsMember_f617237f-0c05-4134-a3a0-109040504e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_23120c13-595d-4529-8761-f1f43bc68a26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_98acd18d-56ac-4c4f-952d-0c8fd14fb541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b0e6cd-821b-4488-8569-94e6d2969c9d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_98acd18d-56ac-4c4f-952d-0c8fd14fb541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1830c47b-db33-48e0-b4bf-757cc0fa57ed" xlink:to="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7c5b125-7be9-48f7-9726-a8ea23f8f644" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c0ff49b-78da-4676-bb75-d3ece71e664b" xlink:to="loc_srt_MaximumMember_b7c5b125-7be9-48f7-9726-a8ea23f8f644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_adc067b5-6e72-47f0-86b9-2aba2250c228" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_656ab4e1-a6f4-4fd5-a979-c6958f14ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_656ab4e1-a6f4-4fd5-a979-c6958f14ab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_582da57e-2a77-4186-bad0-9106c11311fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e72a7b49-560f-45d9-bec1-d1f196332e65" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_582da57e-2a77-4186-bad0-9106c11311fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb35774d-fc5f-4ce2-8818-e68335d3da0d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_de2ae66f-1757-42c1-8b00-f920b4b45e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_de2ae66f-1757-42c1-8b00-f920b4b45e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d2b7dde-1a3f-44fb-8d01-834dc683a850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d2b7dde-1a3f-44fb-8d01-834dc683a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_ec70fe2e-66bc-4457-858c-74b52f88125c" xlink:href="abbv-20220630.xsd#abbv_PotentialPaymentsUnderAgreementCertainMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_abbv_PotentialPaymentsUnderAgreementCertainMilestones_ec70fe2e-66bc-4457-858c-74b52f88125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_ac58d657-4990-4df5-bad8-234ada009598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_ac58d657-4990-4df5-bad8-234ada009598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_18ab0058-d702-4d80-aa09-e1ab3aaa6d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9cf654d4-a7c9-415d-baf2-cce87497039b" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_18ab0058-d702-4d80-aa09-e1ab3aaa6d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/Collaborations" xlink:type="simple" xlink:href="abbv-20220630.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_e3cdd4d6-0d3d-4eda-a88c-c3adf037da4d" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9520013-8d74-41ec-b185-56613da6d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_e3cdd4d6-0d3d-4eda-a88c-c3adf037da4d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9520013-8d74-41ec-b185-56613da6d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#CollaborationsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CollaborationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_27bd2df2-e68b-4f22-94b4-8b0fa698ed77" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_27bd2df2-e68b-4f22-94b4-8b0fa698ed77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:to="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b07742da-36a2-40aa-8a5f-3c33b7273def" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_87901879-1c61-4f60-b67f-1e051c788024" xlink:href="abbv-20220630.xsd#abbv_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:to="loc_abbv_JanssenBiotechIncMember_87901879-1c61-4f60-b67f-1e051c788024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_2443f7f9-ab7c-445c-a66e-2d199325ccde" xlink:href="abbv-20220630.xsd#abbv_GenentechInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f8849f8-2aa4-407b-b25c-61f12ad11dd7" xlink:to="loc_abbv_GenentechInc.Member_2443f7f9-ab7c-445c-a66e-2d199325ccde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef4d3d28-20e0-4470-a273-a2196fefe8f1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_41734336-4020-47c1-b861-99788eff858d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_236a0b0b-3315-48df-9a27-3ee148664fa4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_41734336-4020-47c1-b861-99788eff858d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#CollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/CollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsAbstract_8ebee455-921c-4bcd-b4e2-90bd4bcb260a" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_CollaborativeArrangementsAbstract_8ebee455-921c-4bcd-b4e2-90bd4bcb260a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aa749a37-071e-490c-be9c-1e51dd050685" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JanssenBiotechIncMember_b1a04e7d-3eb3-44e3-8e54-d1b3ed390f65" xlink:href="abbv-20220630.xsd#abbv_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:to="loc_abbv_JanssenBiotechIncMember_b1a04e7d-3eb3-44e3-8e54-d1b3ed390f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_GenentechInc.Member_52fb377c-d1ca-49af-9734-652df3821303" xlink:href="abbv-20220630.xsd#abbv_GenentechInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9249899-251e-4da6-94ba-3c3922b304a9" xlink:to="loc_abbv_GenentechInc.Member_52fb377c-d1ca-49af-9734-652df3821303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e28fbafe-5bc9-43e1-9f4b-25423a45dee5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b595e4a8-9323-45f9-a517-180b81a31d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d2b746f-acc6-4862-b564-44135116b213" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b595e4a8-9323-45f9-a517-180b81a31d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_70e85a75-b7a7-444f-a6fd-ea9b1a040dc6" xlink:to="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dac678c6-2180-437e-ae03-6c4b2380599e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:to="loc_country_US_dac678c6-2180-437e-ae03-6c4b2380599e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_63b9db89-3050-408f-99ae-7556c697d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b4ebcca6-854e-42b0-bd3f-6b0c0425978b" xlink:to="loc_us-gaap_NonUsMember_63b9db89-3050-408f-99ae-7556c697d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e595ab-9af1-4992-aa24-3ee3e6a0278f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_153530cc-f4f6-4640-86ce-661cb39af109" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable_153530cc-f4f6-4640-86ce-661cb39af109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_d1c0d17b-cf1a-4879-80c2-540cac5a3ce9" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty_d1c0d17b-cf1a-4879-80c2-540cac5a3ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_76eb0d4e-874a-4b11-9e25-3c0ad0e28869" xlink:href="abbv-20220630.xsd#abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts_76eb0d4e-874a-4b11-9e25-3c0ad0e28869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_84b541e6-5362-4f89-b7a6-62282e442baa" xlink:href="abbv-20220630.xsd#abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements_84b541e6-5362-4f89-b7a6-62282e442baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_784c26f6-2767-4dba-86ed-fbbb955d79b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_784c26f6-2767-4dba-86ed-fbbb955d79b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherExpensesFromCollaborativeArrangements_a891e146-527d-4eb2-842f-4466a3c27cc0" xlink:href="abbv-20220630.xsd#abbv_OtherExpensesFromCollaborativeArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_OtherExpensesFromCollaborativeArrangements_a891e146-527d-4eb2-842f-4466a3c27cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e089339-9fef-4254-96a6-0dc3224631d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6e089339-9fef-4254-96a6-0dc3224631d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3d0d04b3-b82d-4196-91db-e9f35516146a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3d0d04b3-b82d-4196-91db-e9f35516146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_6708faf3-0563-4ac0-b4b2-378c8f743055" xlink:href="abbv-20220630.xsd#abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements_6708faf3-0563-4ac0-b4b2-378c8f743055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_fa1eb7fb-1b6d-4f80-b89f-52d0c6918c88" xlink:href="abbv-20220630.xsd#abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb6ace50-8858-4500-bb64-ab576e670fe9" xlink:to="loc_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements_fa1eb7fb-1b6d-4f80-b89f-52d0c6918c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1353332b-8ac8-4280-bb47-848870eb5412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8029f692-eca5-42f2-8e5c-c5b589948389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1353332b-8ac8-4280-bb47-848870eb5412" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8029f692-eca5-42f2-8e5c-c5b589948389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a17f8b1c-1f81-47c1-a285-db74c67feb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d360f62c-c117-4286-925e-7c83bf346a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a17f8b1c-1f81-47c1-a285-db74c67feb5e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d360f62c-c117-4286-925e-7c83bf346a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c10e9d3c-3649-49a6-a83a-6c2106baafb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a17f8b1c-1f81-47c1-a285-db74c67feb5e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c10e9d3c-3649-49a6-a83a-6c2106baafb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_33ca6ae8-6f38-4ceb-addb-a8901625fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a17f8b1c-1f81-47c1-a285-db74c67feb5e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_33ca6ae8-6f38-4ceb-addb-a8901625fc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b1fc4da-80ac-47d5-bb31-2b85571a2cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ca49f6af-90da-46ec-9a2a-fd65fa09e110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b1fc4da-80ac-47d5-bb31-2b85571a2cdd" xlink:to="loc_us-gaap_GoodwillRollForward_ca49f6af-90da-46ec-9a2a-fd65fa09e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4aaf8e9-3912-4165-aecc-f5edb30f0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca49f6af-90da-46ec-9a2a-fd65fa09e110" xlink:to="loc_us-gaap_Goodwill_c4aaf8e9-3912-4165-aecc-f5edb30f0e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_77536ad9-093d-431b-88c4-1cbe8f7bb24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca49f6af-90da-46ec-9a2a-fd65fa09e110" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_77536ad9-093d-431b-88c4-1cbe8f7bb24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4dc1eed7-c63c-42bd-b05c-257deec80f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca49f6af-90da-46ec-9a2a-fd65fa09e110" xlink:to="loc_us-gaap_Goodwill_4dc1eed7-c63c-42bd-b05c-257deec80f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_2bfe7e6a-0939-4bed-b8eb-e32b25976a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b1fc4da-80ac-47d5-bb31-2b85571a2cdd" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_2bfe7e6a-0939-4bed-b8eb-e32b25976a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f4ff47c5-8086-4d16-8f56-406c695027bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_2bfe7e6a-0939-4bed-b8eb-e32b25976a74" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f4ff47c5-8086-4d16-8f56-406c695027bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa17a12-9d9d-4dc2-a7d0-ca268cb21740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa17a12-9d9d-4dc2-a7d0-ca268cb21740" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1e76011-60fb-4cf3-9adf-5276288cf120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_362ea9ce-a865-4f44-b3f0-3e91c5f634ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_362ea9ce-a865-4f44-b3f0-3e91c5f634ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5d056c99-7c29-4569-a89a-5dff70b6b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148a887b-889c-4db7-bdac-5483d2e1eac4" xlink:to="loc_us-gaap_LicensingAgreementsMember_5d056c99-7c29-4569-a89a-5dff70b6b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4e4f7ce4-a09d-4a94-b04b-c740a326240d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e61b6d71-32be-4372-8017-54923b0d4d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e61b6d71-32be-4372-8017-54923b0d4d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dd28d36-2545-4753-9336-529a5bfa0729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dd28d36-2545-4753-9336-529a5bfa0729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_386f00ef-ec3a-47ea-bdd6-56317b5bc791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_386f00ef-ec3a-47ea-bdd6-56317b5bc791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7a073f1a-0d79-43b7-a737-646330b5a35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7a073f1a-0d79-43b7-a737-646330b5a35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bf422be8-ecb4-4ef9-89e0-f8deda867d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bf422be8-ecb4-4ef9-89e0-f8deda867d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9acabc74-fb83-4f6a-9ea2-efb830771721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c3bef078-6880-4280-898d-695ae2216db5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9acabc74-fb83-4f6a-9ea2-efb830771721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0ba4a461-28f2-48ce-ba43-70c6c9b98f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa17a12-9d9d-4dc2-a7d0-ca268cb21740" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0ba4a461-28f2-48ce-ba43-70c6c9b98f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlans" xlink:type="simple" xlink:href="abbv-20220630.xsd#IntegrationandRestructuringPlans"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a04b1026-5890-497d-a5c2-d85914379770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0e4eae48-c018-4bf1-84ec-dfb3e75e02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a04b1026-5890-497d-a5c2-d85914379770" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0e4eae48-c018-4bf1-84ec-dfb3e75e02ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#IntegrationandRestructuringPlansTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fe7630be-1bd4-4cb9-b038-270429a6d16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fe7630be-1bd4-4cb9-b038-270429a6d16d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:to="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_24fa607a-15c3-4da3-9c27-50de65b71cb6" xlink:to="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_88bbf3dc-8c5b-436e-8262-e37d4cbd5ff2" xlink:href="abbv-20220630.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:to="loc_abbv_AllerganIntegrationPlanMember_88bbf3dc-8c5b-436e-8262-e37d4cbd5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_20960846-2569-40b4-a8e3-50b54ae4c5d9" xlink:href="abbv-20220630.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0bc763d2-f5e7-4b85-b1b7-7d805709c916" xlink:to="loc_abbv_OtherRestructuringPlansMember_20960846-2569-40b4-a8e3-50b54ae4c5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b3132b60-d388-4736-a75a-a4a190e47f58" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_76e56872-068d-4fbd-b565-3ae61a5c43f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_76e56872-068d-4fbd-b565-3ae61a5c43f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5574e673-be9b-4459-a37f-6fcc9e426e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d87d3c3-6b15-43e7-aa0e-973ef3695b08" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5574e673-be9b-4459-a37f-6fcc9e426e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#IntegrationandRestructuringPlansDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_955498f7-3a59-4200-a5d9-7b4e865e90bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_955498f7-3a59-4200-a5d9-7b4e865e90bf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_73d9d472-e5f1-4689-9864-e242b0e2124c" xlink:to="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AllerganIntegrationPlanMember_5523146a-d100-413b-9973-cf2052a1769f" xlink:href="abbv-20220630.xsd#abbv_AllerganIntegrationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:to="loc_abbv_AllerganIntegrationPlanMember_5523146a-d100-413b-9973-cf2052a1769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherRestructuringPlansMember_db1066f8-b8d5-4f25-8050-770d0adea62b" xlink:href="abbv-20220630.xsd#abbv_OtherRestructuringPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3dd7611e-7459-41e1-b389-0bb9136f5f0a" xlink:to="loc_abbv_OtherRestructuringPlansMember_db1066f8-b8d5-4f25-8050-770d0adea62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a32b892f-3509-4158-9d23-d17f44e1a0aa" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ba5a8987-1b82-49f5-afd9-9ee2d1d47871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ba5a8987-1b82-49f5-afd9-9ee2d1d47871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_e2c61455-de06-46fd-8b01-7d098923fbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9985b6f6-7bc2-4890-bf7c-e7f18dfa841e" xlink:to="loc_us-gaap_OtherRestructuringMember_e2c61455-de06-46fd-8b01-7d098923fbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c52176ca-b1ac-4865-acb6-9c82acb5ebab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6eaa1da2-8374-4a06-8d9e-cf38eb92797f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_CostOfSalesMember_6eaa1da2-8374-4a06-8d9e-cf38eb92797f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358f1630-b6ac-46d8-90dd-3abd5f0882df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358f1630-b6ac-46d8-90dd-3abd5f0882df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80330eaa-0724-4bcc-931d-6dbacc2ed7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa0cbd03-fb9a-4558-8b38-12bb60c23d22" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80330eaa-0724-4bcc-931d-6dbacc2ed7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_417bb5b7-0c62-4c8b-aee0-26b70401e12b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_413a5aaf-0951-4bd9-9bb1-893f29ae1190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_413a5aaf-0951-4bd9-9bb1-893f29ae1190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e915ea2e-2d07-4bd5-a336-3074b9ac74d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e915ea2e-2d07-4bd5-a336-3074b9ac74d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75251cb9-04c6-48ab-9f9e-7d7be1958a85" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_31007642-bba3-47cb-ad56-d8e382c1b489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_us-gaap_RestructuringReserve_31007642-bba3-47cb-ad56-d8e382c1b489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_05931788-6026-41dc-a30a-983d9a8f889f" xlink:href="abbv-20220630.xsd#abbv_RestructuringReserveCashSettledRestructuringGainsLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_abbv_RestructuringReserveCashSettledRestructuringGainsLosses_05931788-6026-41dc-a30a-983d9a8f889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_732d3856-f61a-42e9-a0f3-76fc2c807a2d" xlink:href="abbv-20220630.xsd#abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments_732d3856-f61a-42e9-a0f3-76fc2c807a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6ea6e973-32fb-4900-aeea-9949f6a78391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0b2406cc-fd83-41a9-a682-b4a2eec1c948" xlink:to="loc_us-gaap_RestructuringReserve_6ea6e973-32fb-4900-aeea-9949f6a78391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasures"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b50a9d8-112c-49aa-b491-e345512bed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock_e7e58712-74ae-471c-853f-9a63df811c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b50a9d8-112c-49aa-b491-e345512bed61" xlink:to="loc_us-gaap_DerivativesAndFairValueTextBlock_e7e58712-74ae-471c-853f-9a63df811c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_2d968ee6-8ce4-4454-9588-4aea4a529145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_2d968ee6-8ce4-4454-9588-4aea4a529145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_641487cf-1a72-4447-b34e-b98c564a7d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_641487cf-1a72-4447-b34e-b98c564a7d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b6d130a3-b129-455e-919a-b72b4b647ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b6d130a3-b129-455e-919a-b72b4b647ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a9af0b20-ea26-47e8-9507-5a2207f73828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a9af0b20-ea26-47e8-9507-5a2207f73828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fb7fbb6a-24f1-46a9-87a6-abd7b2c57aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fb7fbb6a-24f1-46a9-87a6-abd7b2c57aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f49ba1aa-b30b-49e3-93aa-5a25b43aa270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f49ba1aa-b30b-49e3-93aa-5a25b43aa270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff512b0b-47fd-4fc9-bad0-96e23bf41572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff512b0b-47fd-4fc9-bad0-96e23bf41572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1849b584-bf4b-409c-bc35-1e49ddf589e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f44936ed-c52b-4943-9a2d-691e53fe5e77" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1849b584-bf4b-409c-bc35-1e49ddf589e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15b22f7c-d3bb-4b72-99d8-53088c279ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15b22f7c-d3bb-4b72-99d8-53088c279ac9" xlink:to="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8358efab-84a6-4428-8700-6fb101bea40b" xlink:to="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_45350cea-a964-4e1b-a16a-6cf77e075201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_45350cea-a964-4e1b-a16a-6cf77e075201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_31ae71bb-cdb7-447e-9a6d-1fbf966cb1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3991d50a-766c-458b-9456-5c98c7be44ea" xlink:to="loc_us-gaap_NondesignatedMember_31ae71bb-cdb7-447e-9a6d-1fbf966cb1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_352fd255-aa3c-488a-8417-c8c49bee4ece" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_37d1c428-2be2-4c92-ac26-82e57dcfa1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_37d1c428-2be2-4c92-ac26-82e57dcfa1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_56ae7ab9-b69e-430a-a99d-78752a67a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_TreasuryLockMember_56ae7ab9-b69e-430a-a99d-78752a67a13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_960dffac-8e78-42e9-b351-062b2ce4354d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2a0130af-43e5-4d7e-ab04-605a24b2ce67" xlink:to="loc_us-gaap_InterestRateSwapMember_960dffac-8e78-42e9-b351-062b2ce4354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b52ff1af-6d9c-402a-856a-494139e0ec50" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_af0fb602-58de-4115-938a-9516a9606ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_CashFlowHedgingMember_af0fb602-58de-4115-938a-9516a9606ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_658ffbd6-5c6f-4b65-a070-33a724defad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_658ffbd6-5c6f-4b65-a070-33a724defad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e5484bee-dca7-418a-bfbf-c09c77dc391f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a25d21-444e-4f0b-badf-dc6fe9d8f8b2" xlink:to="loc_us-gaap_FairValueHedgingMember_e5484bee-dca7-418a-bfbf-c09c77dc391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf438df1-189a-4351-bf00-6886dd372bc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9b38a8c8-84a1-4b60-8bdf-33454928b51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fecc4003-d89b-48a4-8b2e-8ee346ca62e7" xlink:to="loc_us-gaap_SeniorNotesMember_9b38a8c8-84a1-4b60-8bdf-33454928b51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf77272-7e0b-4954-b2b1-8eb2aa7eb94f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_65da8559-98ae-4fd5-8eab-512ebf22a413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_65da8559-98ae-4fd5-8eab-512ebf22a413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f0e066e2-6a97-41f5-a052-529518de82b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_f0e066e2-6a97-41f5-a052-529518de82b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2a0289aa-e6b7-4c55-8171-8d38d6d5a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2a0289aa-e6b7-4c55-8171-8d38d6d5a42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_d6963e20-e1d4-407d-81b8-b98f3a4f3131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5c344ce-f1f5-4a3d-94c5-17d58017083a" xlink:to="loc_us-gaap_OtherLiabilitiesMember_d6963e20-e1d4-407d-81b8-b98f3a4f3131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b99baf7-bf63-438f-be3b-2028e32a47d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_44edfd0e-dabd-4499-bb20-708606d9d2bb" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDueInMay2021AtFloatingRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a3e3a9c7-cc39-4dde-a4c4-77661003cbc6" xlink:to="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_44edfd0e-dabd-4499-bb20-708606d9d2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e091a06-1119-43a1-867a-b03848e034a0" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0d8497a7-5da7-4bb0-9bc6-0bc39810b4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0d8497a7-5da7-4bb0-9bc6-0bc39810b4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_90b22769-17e8-48a6-ba34-e4f149992833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeTermOfContract_90b22769-17e8-48a6-ba34-e4f149992833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_80e7da92-4de7-435f-a38f-23c60f6af5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_80e7da92-4de7-435f-a38f-23c60f6af5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_414b6964-16f7-43df-8682-25d350570505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_414b6964-16f7-43df-8682-25d350570505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_cc78dfa2-d595-472e-ac40-09334506e0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet_cc78dfa2-d595-472e-ac40-09334506e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_a2fae81a-3010-41da-864b-5246162cca48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_a2fae81a-3010-41da-864b-5246162cca48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_297b76f6-80a5-4595-9c14-da72407274ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_297b76f6-80a5-4595-9c14-da72407274ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_24926d79-6c95-4475-9d2a-85060fccf936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55dd49cf-c506-4f86-89c4-d5af2810708e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_24926d79-6c95-4475-9d2a-85060fccf936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35f20c62-3279-4a1f-b127-1696e21400dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35f20c62-3279-4a1f-b127-1696e21400dc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d46d9699-84e7-4097-96c0-2712de9d6037" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_0fb47ca6-1ab0-4718-8a46-a623e1c69428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_0fb47ca6-1ab0-4718-8a46-a623e1c69428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a8bdbc9d-923f-4405-811a-13ac63676cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_InterestRateSwapMember_a8bdbc9d-923f-4405-811a-13ac63676cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_384b9f97-76d0-4a33-b7b1-5cbe0b120f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_062ab22f-7d0d-4192-816a-7d16578ccb36" xlink:to="loc_us-gaap_TreasuryLockMember_384b9f97-76d0-4a33-b7b1-5cbe0b120f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_77adc61d-a049-4861-bf20-37b0986c4776" xlink:to="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5326e2b-0a3c-453b-b6f5-0d06b9b7df13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5326e2b-0a3c-453b-b6f5-0d06b9b7df13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_29eb677d-a344-4ffa-9ebd-02911d59a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_84d1ab26-d295-42ed-92e4-72cd8eada514" xlink:to="loc_us-gaap_NondesignatedMember_29eb677d-a344-4ffa-9ebd-02911d59a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4b5ff17-88b8-4699-954e-6be96266bfe4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_78252b49-d527-4cdc-ac84-9612e8926235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_CostOfSalesMember_78252b49-d527-4cdc-ac84-9612e8926235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_a601d034-a925-40a9-bccc-f4247d5db0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_InterestExpenseMember_a601d034-a925-40a9-bccc-f4247d5db0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyGainLossMember_44970d0b-1e14-455c-8c8c-a5027f7fc79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b0f462a6-f585-4908-b186-29094705c819" xlink:to="loc_us-gaap_ForeignCurrencyGainLossMember_44970d0b-1e14-455c-8c8c-a5027f7fc79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ce3fecfc-e212-499f-876a-9a5a946c2886" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4772ea95-6684-41f6-98fc-42de0e741547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41375f1b-4178-410b-87e1-14f43341b736" xlink:to="loc_us-gaap_SeniorNotesMember_4772ea95-6684-41f6-98fc-42de0e741547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_def5dd0a-3aa2-47dc-ba4d-739c7a51aa47" xlink:to="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9203e4a0-24bb-471c-a492-a76a05d88a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_CashFlowHedgingMember_9203e4a0-24bb-471c-a492-a76a05d88a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c333cd61-0fff-4e99-a9ab-29bcdb5cce42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c333cd61-0fff-4e99-a9ab-29bcdb5cce42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_716795f2-e360-447b-add6-9118d91d3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_967e865e-a015-4daa-9fcf-befe9b1ea7c2" xlink:to="loc_us-gaap_FairValueHedgingMember_716795f2-e360-447b-add6-9118d91d3b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b46bbba8-5a5a-4f07-9d21-012e3ca7d1f9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3808bc29-f665-4b2a-8f26-f2720a887b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3808bc29-f665-4b2a-8f26-f2720a887b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2f1eac69-eec3-4ca8-937f-c9ae768816a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2f1eac69-eec3-4ca8-937f-c9ae768816a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1de3005b-c43b-4893-b5ea-d73122bd800e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1de3005b-c43b-4893-b5ea-d73122bd800e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_5fde4ae2-dbea-4a06-aaa8-50b7d4a38e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_5fde4ae2-dbea-4a06-aaa8-50b7d4a38e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_db96d8c9-2b7f-4047-bc5d-3d24041e92c9" xlink:href="abbv-20220630.xsd#abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet_db96d8c9-2b7f-4047-bc5d-3d24041e92c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_08ca66f7-b2c1-4803-906f-a2ba1ac5affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_08ca66f7-b2c1-4803-906f-a2ba1ac5affa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_080e2ea4-2407-4046-99e5-9d96779c1fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_344cbc61-6e74-4335-8daf-725546af532b" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1_080e2ea4-2407-4046-99e5-9d96779c1fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f426bde3-e51f-4f9a-89e1-e5960671bdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f426bde3-e51f-4f9a-89e1-e5960671bdb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_05952b6d-54be-449f-821c-e5e92682dda4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_224d2bc0-5bce-454a-87bb-ba9bdd6638c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_afbd02c3-b7cb-44af-9870-1e5197c56e3a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_224d2bc0-5bce-454a-87bb-ba9bdd6638c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3695eef6-9d4d-466c-ac16-ff2c7faa3380" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e033266d-6ad1-4863-a66a-1b9d1e3bed6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d8ba5ab-669e-434a-ab59-5d6ea97fef6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e033266d-6ad1-4863-a66a-1b9d1e3bed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d208acda-96bf-42e1-9fa9-f396f6b8e364" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3373e616-f156-44f3-b543-fbcc06f94c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3373e616-f156-44f3-b543-fbcc06f94c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c08fd885-9b73-46a2-8530-79a36411b7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c08fd885-9b73-46a2-8530-79a36411b7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e99fda61-0ce9-478e-b979-f36fad92bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5afbbe-b133-4270-89de-5218b26ef729" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e99fda61-0ce9-478e-b979-f36fad92bca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_59631552-2f6e-4674-b471-d417d7168950" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0d6adc2f-3e2c-473a-bf63-cd5483eb21bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ff0d9fe3-095a-409a-bd01-882fd90fde4f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0d6adc2f-3e2c-473a-bf63-cd5483eb21bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a300afac-0132-41b0-a94d-46151925bc4d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5a4f1e7f-6d43-4bd5-847e-289a9d944259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5a4f1e7f-6d43-4bd5-847e-289a9d944259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5e64d274-0a97-47bc-b6e2-6799eaeaafda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5e64d274-0a97-47bc-b6e2-6799eaeaafda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_984cbce7-50eb-49c0-b878-5d16a2ed4be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_984cbce7-50eb-49c0-b878-5d16a2ed4be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e3397153-c98e-4d52-b874-5b6bc8656ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e3397153-c98e-4d52-b874-5b6bc8656ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ab4194b8-7b2f-4412-9c8b-1b2f80962b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ab4194b8-7b2f-4412-9c8b-1b2f80962b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2e72fdfc-2b04-41ef-89c0-0ed6a4636fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2e72fdfc-2b04-41ef-89c0-0ed6a4636fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f083c335-57da-4c51-be5f-8d5ff7174404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_43be9811-0de0-47c3-9278-6302f9ef0071" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f083c335-57da-4c51-be5f-8d5ff7174404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95da255f-0c14-4462-84ba-1d4fb01dbfb4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_226f500d-3496-4ae0-8695-a4b2d5c512ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_226f500d-3496-4ae0-8695-a4b2d5c512ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbd7fb0e-38cf-42b5-9e0d-99c93d8c442d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbd7fb0e-38cf-42b5-9e0d-99c93d8c442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_933f50c4-ce69-4d9c-b837-4fde468e924a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_933f50c4-ce69-4d9c-b837-4fde468e924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40ba9d32-d360-4c0b-8c6b-ad4939fd9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24fb3991-0389-4f54-aae6-15943c5d5b8a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40ba9d32-d360-4c0b-8c6b-ad4939fd9e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_854d599a-9ba7-42be-9334-87ae05380545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_854d599a-9ba7-42be-9334-87ae05380545" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:to="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c2385773-76d5-4a36-86b9-ffd4fa9eed0d" xlink:to="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_56b08263-54ac-4f90-aa14-0ff728459823" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_WeightedAverageMember_56b08263-54ac-4f90-aa14-0ff728459823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bec6b039-2388-46b4-90ea-6d354d9961ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_MinimumMember_bec6b039-2388-46b4-90ea-6d354d9961ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dd09073-3489-46c7-8e20-08b855de6eb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_131e2e25-1e0e-4380-85d6-b2df33d268a7" xlink:to="loc_srt_MaximumMember_6dd09073-3489-46c7-8e20-08b855de6eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_870b5d78-a4d2-48d6-8472-6832989b6b51" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8bb34b54-1478-4ff0-aed7-3dec7659d13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8bb34b54-1478-4ff0-aed7-3dec7659d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_db96dbaa-b26c-478a-ba60-e1d41f53f6f7" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforUnachievedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforUnachievedMilestonesMember_db96dbaa-b26c-478a-ba60-e1d41f53f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_1a4f8bef-6877-40a1-a12f-3d9b3ae58489" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember_1a4f8bef-6877-40a1-a12f-3d9b3ae58489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProjectedYearofPaymentsMember_95ee7ce6-bb4c-49e8-ac0e-95f410167f0d" xlink:href="abbv-20220630.xsd#abbv_ProjectedYearofPaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProjectedYearofPaymentsMember_95ee7ce6-bb4c-49e8-ac0e-95f410167f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a777a81f-7bd2-4ca7-bb83-4a717fdce19f" xlink:href="abbv-20220630.xsd#abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72c10d18-d722-4fe3-9af1-b706e26e957c" xlink:to="loc_abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember_a777a81f-7bd2-4ca7-bb83-4a717fdce19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cd061970-7b18-45ae-9d2c-3b2364017987" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_aabc58d4-9fe0-44b8-8da6-95fce27b6970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_90bb1b51-e93a-46cb-ba00-adce8dd7274e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_aabc58d4-9fe0-44b8-8da6-95fce27b6970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_165e9989-44a0-4de7-b5f3-d1da3df644a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_d7e754d4-0881-4b0b-a74d-9e84f346d54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_165e9989-44a0-4de7-b5f3-d1da3df644a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_d7e754d4-0881-4b0b-a74d-9e84f346d54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_89c12a69-4a77-46a2-ad38-3e12c2a63ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_d7e754d4-0881-4b0b-a74d-9e84f346d54f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_89c12a69-4a77-46a2-ad38-3e12c2a63ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_82a8c297-becd-4833-8953-80e856aa6afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_d7e754d4-0881-4b0b-a74d-9e84f346d54f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_82a8c297-becd-4833-8953-80e856aa6afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_4903dfe0-96a9-449d-98e0-26709a81f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_165e9989-44a0-4de7-b5f3-d1da3df644a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_4903dfe0-96a9-449d-98e0-26709a81f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_3220f1fa-a45d-4472-bdf3-82196270968e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_4903dfe0-96a9-449d-98e0-26709a81f2d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_3220f1fa-a45d-4472-bdf3-82196270968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_763e6639-ca0f-4455-a1e1-3f82dbf0f661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract_4903dfe0-96a9-449d-98e0-26709a81f2d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_763e6639-ca0f-4455-a1e1-3f82dbf0f661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_165e9989-44a0-4de7-b5f3-d1da3df644a1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e3b60306-c743-443b-938c-fb55207fabc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e3b60306-c743-443b-938c-fb55207fabc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fa98482-4e9e-4c9c-aa8b-cde000205c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fa98482-4e9e-4c9c-aa8b-cde000205c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_682d4b26-9db3-4bf6-8ef9-6a4bafdfdb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_682d4b26-9db3-4bf6-8ef9-6a4bafdfdb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6e34933e-69b2-4121-8918-5121a373ca60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eeff9049-62fb-4c69-9e5b-153ea8c92fc0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6e34933e-69b2-4121-8918-5121a373ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38d85f84-738c-4327-949c-b7dc525df1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38d85f84-738c-4327-949c-b7dc525df1d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_cf6d4db2-250c-4b38-810e-2db1de7edabc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8eec17a-3c8d-4132-8df8-c4b10af3299a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8eec17a-3c8d-4132-8df8-c4b10af3299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e392a532-c0ee-4dd3-9f78-fa6a41e46f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e392a532-c0ee-4dd3-9f78-fa6a41e46f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c13251e-199e-4a2c-9ed1-d9135c52c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_751b05ac-a533-4cbd-abc2-dffcb85beed2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c13251e-199e-4a2c-9ed1-d9135c52c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddec9ea7-8685-4458-ba33-51a2487638a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d58efb7c-1ef5-4d26-a993-2b9b61473aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d58efb7c-1ef5-4d26-a993-2b9b61473aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_57287bc6-622a-4de7-b44d-70947bc27d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_57287bc6-622a-4de7-b44d-70947bc27d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_da2e0cad-a4b1-49e0-a696-ad42f28445df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8ee43e28-1a88-497d-9240-8fdf471d5ca4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_da2e0cad-a4b1-49e0-a696-ad42f28445df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1269fac3-9c75-4f62-a756-612823bcde9e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtFairValue_8de33768-7580-4c96-b99a-4f9f95bd2111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShorttermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_us-gaap_ShorttermDebtFairValue_8de33768-7580-4c96-b99a-4f9f95bd2111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_95035f6f-6c8b-4ea6-9d32-60754ae86fa7" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure_95035f6f-6c8b-4ea6-9d32-60754ae86fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_843c419b-801d-4bf9-a334-f4ef3494a3d6" xlink:href="abbv-20220630.xsd#abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure_843c419b-801d-4bf9-a334-f4ef3494a3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_46c007f6-bb4a-45f3-b855-587bbd84e89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d18f9ac-beac-4790-b980-a03bfa9015cb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_46c007f6-bb4a-45f3-b855-587bbd84e89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5a05bc4a-5af0-448e-81e9-fe2ea3559682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638abe13-dd9c-42a7-8610-f87790a3a263" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5a05bc4a-5af0-448e-81e9-fe2ea3559682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b04e9b3a-d80d-404f-8be7-9842647525c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b04e9b3a-d80d-404f-8be7-9842647525c3" xlink:to="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cdc3a258-6bdb-4c8d-8a56-71b1c7ef61e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_412ad0b8-d9b9-471e-aad6-94ca1ebf21f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:to="loc_us-gaap_AccountsReceivableMember_412ad0b8-d9b9-471e-aad6-94ca1ebf21f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_24c062cc-d27f-4ff3-b404-9421a9729dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa26a325-e8e1-43a7-b531-65784e67eefc" xlink:to="loc_us-gaap_SalesRevenueNetMember_24c062cc-d27f-4ff3-b404-9421a9729dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0287c3ea-ee3c-4708-8cff-ec4d5beb4758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_912373cc-e8e2-4389-82fb-08983e3e7d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_912373cc-e8e2-4389-82fb-08983e3e7d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_c4bd35d6-6929-423a-a470-261489c01de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69c3a888-8fa7-48b9-81e1-75e28975815b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_c4bd35d6-6929-423a-a470-261489c01de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_27cc9df2-7f82-4c65-9a2d-7731414b7fb7" xlink:to="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_47a2d89d-d41b-49a4-8e33-8785830e9aa0" xlink:href="abbv-20220630.xsd#abbv_HUMIRAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2e932e30-c00f-41eb-a480-2290c8056ab0" xlink:to="loc_abbv_HUMIRAMember_47a2d89d-d41b-49a4-8e33-8785830e9aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_005c50bb-a083-415c-808e-6041629fce43" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrincipalUSCustomersMember_c7dd8d2f-7e8c-49fd-94fb-efb81246d6f0" xlink:href="abbv-20220630.xsd#abbv_PrincipalUSCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d87eb67-eda7-4446-a4ca-c5b9448f8c87" xlink:to="loc_abbv_PrincipalUSCustomersMember_c7dd8d2f-7e8c-49fd-94fb-efb81246d6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd4a66e6-f182-417b-9cca-1f2fb3e961dc" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NumberOfPrincipalUSCustomers_271c03cb-ea15-4e3d-8120-125dbdbf04b8" xlink:href="abbv-20220630.xsd#abbv_NumberOfPrincipalUSCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:to="loc_abbv_NumberOfPrincipalUSCustomers_271c03cb-ea15-4e3d-8120-125dbdbf04b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c5e75515-69b9-4d59-b58f-1c15ed1b709d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10690a6a-f286-4ab0-96b7-035da2d25124" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c5e75515-69b9-4d59-b58f-1c15ed1b709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cd6f67d8-6a40-4daf-ab27-b5b59e09e0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd6f67d8-6a40-4daf-ab27-b5b59e09e0b2" xlink:to="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb6a019e-99bd-4c85-b341-0e605b62fb73" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.450PercentMember_a277ba69-c47d-4895-9142-9e7a86db9903" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.450PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDue2022At3.450PercentMember_a277ba69-c47d-4895-9142-9e7a86db9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_d6a6248a-029d-479f-bfae-4db0aac15931" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025Member_d6a6248a-029d-479f-bfae-4db0aac15931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_dde64712-7094-411c-8b6b-497ef3154c6c" xlink:href="abbv-20220630.xsd#abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember_dde64712-7094-411c-8b6b-497ef3154c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDue2022At3.250PercentMember_26456e95-1038-4b1c-bcc4-2a76d344f6f3" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDue2022At3.250PercentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDue2022At3.250PercentMember_26456e95-1038-4b1c-bcc4-2a76d344f6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotes2.30PercentDue2021Member_7c24af99-897d-4427-937c-4daad6c5a27c" xlink:href="abbv-20220630.xsd#abbv_SeniorNotes2.30PercentDue2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotes2.30PercentDue2021Member_7c24af99-897d-4427-937c-4daad6c5a27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember_6c7b8283-02ee-46e3-879a-a9bd91d2e12c" xlink:href="abbv-20220630.xsd#abbv_SeniorEuroNotesDue2021At0.500PercentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorEuroNotesDue2021At0.500PercentMember_6c7b8283-02ee-46e3-879a-a9bd91d2e12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_8b54d38c-b5c5-4bcc-9fdb-a547d118f4ea" xlink:href="abbv-20220630.xsd#abbv_SeniorNotesDueInMay2021AtFloatingRatesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862a4e8a-db20-4ade-b023-89b2f70d8d05" xlink:to="loc_abbv_SeniorNotesDueInMay2021AtFloatingRatesMember_8b54d38c-b5c5-4bcc-9fdb-a547d118f4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9a761dd-084a-428c-9973-edf29f67aabd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3c793033-ff8a-4fdd-af96-d5f2b7377851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:to="loc_us-gaap_SeniorNotesMember_3c793033-ff8a-4fdd-af96-d5f2b7377851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4de46ff4-2135-4e50-b90e-05c7e5214dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05170348-8e64-4bd9-a748-f1eed881f199" xlink:to="loc_us-gaap_LoansPayableMember_4de46ff4-2135-4e50-b90e-05c7e5214dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90fa4ac5-cbe3-4efa-b5e7-84511fcd0fed" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d842600c-d05c-4835-972a-367a8e2ba395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e1d43806-06c4-4c3d-944f-53b96f7448a4" xlink:to="loc_us-gaap_SubsequentEventMember_d842600c-d05c-4835-972a-367a8e2ba395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c01fb513-19f2-4015-91ac-5f0ae2414ae3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_689b86e3-5d2a-4cab-b1ac-32fd7d9e3427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_689b86e3-5d2a-4cab-b1ac-32fd7d9e3427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05e4793a-91d7-4376-bc67-52bfedc2f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05e4793a-91d7-4376-bc67-52bfedc2f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_9262ca83-3224-4447-8aaf-9f98463941d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_9262ca83-3224-4447-8aaf-9f98463941d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_effc6477-9561-40ef-abbc-47ea1c9a0bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_effc6477-9561-40ef-abbc-47ea1c9a0bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0158f0ec-797c-4e92-866f-865c75858be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e5e8b7f-8209-4761-908d-0628806eb8f8" xlink:to="loc_us-gaap_LongTermDebt_0158f0ec-797c-4e92-866f-865c75858be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefits" xlink:type="simple" xlink:href="abbv-20220630.xsd#PostEmploymentBenefits"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_f7d1ba25-254b-491f-8245-1ff555f2e0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_552dc8aa-0fca-4d87-81e2-07f12a5059fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_f7d1ba25-254b-491f-8245-1ff555f2e0db" xlink:to="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_552dc8aa-0fca-4d87-81e2-07f12a5059fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#PostEmploymentBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_ebd42a6c-acfc-47e6-b637-15ffd2f08020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0059b0c5-d3dc-4ed7-abc8-c6a388b59887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_ebd42a6c-acfc-47e6-b637-15ffd2f08020" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0059b0c5-d3dc-4ed7-abc8-c6a388b59887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#PostEmploymentBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_defc93ab-b2c1-4dda-94f6-b8eda7bfe7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_defc93ab-b2c1-4dda-94f6-b8eda7bfe7e8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8a908594-e6a8-40ec-b5ad-9ca28efc4654" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d72c1f20-4109-4f54-a95c-4efe68832788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d72c1f20-4109-4f54-a95c-4efe68832788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2709b6e6-5556-4277-83ce-ee228f8734b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fbf2db5b-4d5d-419c-9f3c-70c6e1a2fbdd" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2709b6e6-5556-4277-83ce-ee228f8734b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b741c86-f57c-4ba9-9ca3-e50b5e75802d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_069118a9-d330-44ab-a3fb-b8acebac15e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_069118a9-d330-44ab-a3fb-b8acebac15e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_4c5c1a7a-0ad6-40fd-8879-5ba3d1462c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_4c5c1a7a-0ad6-40fd-8879-5ba3d1462c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5fc0d60f-0698-4485-838c-dd9784f72f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5fc0d60f-0698-4485-838c-dd9784f72f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dfd9afe0-4e4e-404a-a312-5d3a50820918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dfd9afe0-4e4e-404a-a312-5d3a50820918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_2bcc0ed0-3a41-4196-bfce-0e03213bee29" xlink:href="abbv-20220630.xsd#abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit_2bcc0ed0-3a41-4196-bfce-0e03213bee29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a3e661b-5332-4628-9a15-aefa8ff4e131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_287eafea-39cc-4d3f-abd4-7aeb76110f7f" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a3e661b-5332-4628-9a15-aefa8ff4e131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/Equity" xlink:type="simple" xlink:href="abbv-20220630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_bd31fb36-a80d-4923-b175-15cf7161064c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_074d5299-5a12-440a-a057-a1644362f874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_bd31fb36-a80d-4923-b175-15cf7161064c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_074d5299-5a12-440a-a057-a1644362f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5b31d051-8d57-4ade-828b-172fa693324f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_75e17ae7-a611-46f8-b958-1c5d8c90a235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5b31d051-8d57-4ade-828b-172fa693324f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_75e17ae7-a611-46f8-b958-1c5d8c90a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDividendsPayableTextBlock_c8d0224b-bd39-4bdc-8aca-94a9214d8a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDividendsPayableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5b31d051-8d57-4ade-828b-172fa693324f" xlink:to="loc_us-gaap_ScheduleOfDividendsPayableTextBlock_c8d0224b-bd39-4bdc-8aca-94a9214d8a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_78864447-1315-496d-807a-8a4d18f818cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5b31d051-8d57-4ade-828b-172fa693324f" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_78864447-1315-496d-807a-8a4d18f818cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f1adeddb-73b3-4218-95b0-398556b4c78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5b31d051-8d57-4ade-828b-172fa693324f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f1adeddb-73b3-4218-95b0-398556b4c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c346dbfe-7040-4f70-8482-1f9317a334bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c346dbfe-7040-4f70-8482-1f9317a334bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69169afa-9bf4-4bb2-9d0f-7a497cdab807" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_95802860-1322-4489-bffc-7db7ee07cfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_CostOfSalesMember_95802860-1322-4489-bffc-7db7ee07cfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699ca783-c3a7-419c-8d52-9c729ab3a2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699ca783-c3a7-419c-8d52-9c729ab3a2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_34e77f0d-ba8a-47c4-86c6-694a03802508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0648ae5-4346-4217-afde-0afba8ab3541" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_34e77f0d-ba8a-47c4-86c6-694a03802508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72a26ca8-1bb1-4ca9-9796-609755a39dac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28996676-258e-4b04-bb21-2004803f4b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28996676-258e-4b04-bb21-2004803f4b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5c680c47-9c43-43f5-b64d-dbbfadfb4f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5c680c47-9c43-43f5-b64d-dbbfadfb4f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_435b478f-07f4-415f-ae8a-0eab120671b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456796ce-be89-4974-a85c-cd0e8257ee38" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_435b478f-07f4-415f-ae8a-0eab120671b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_03d2553e-6d1a-4c22-a2c6-d7990f64628a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_03d2553e-6d1a-4c22-a2c6-d7990f64628a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:to="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c1f960f9-edc3-4d4d-9723-0bdf22b294ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78a236aa-9e5f-4654-84c0-1e14d924c603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b292667e-8487-4e77-818b-ffd05763ef89" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78a236aa-9e5f-4654-84c0-1e14d924c603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa10895e-836d-45a8-82cd-3e6a33c41801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a92f75f-934c-4ec0-8d86-9e9667f19da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a92f75f-934c-4ec0-8d86-9e9667f19da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_887b3a51-8774-4417-ab30-56fa1650651e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_887b3a51-8774-4417-ab30-56fa1650651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d328bcf3-d33f-450b-a031-3dec408ceb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d328bcf3-d33f-450b-a031-3dec408ceb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_483cab86-b2f6-4ebd-aa0f-2eec7a2560d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8a98db6-e5f1-4d8e-b0fb-5388745d1f07" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_483cab86-b2f6-4ebd-aa0f-2eec7a2560d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityRSUsandPerformanceSharesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0782f138-a30d-47d1-afca-d5f65c15173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0782f138-a30d-47d1-afca-d5f65c15173c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:to="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b52b0777-5017-47ec-8377-4a89c044236a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_2301430e-35f1-493e-877b-e0a8cfe12297" xlink:href="abbv-20220630.xsd#abbv_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4da25db9-7dd2-43f7-8ee4-fbb2ea8ceedd" xlink:to="loc_abbv_RestrictedStockUnitsAndPerformanceSharesMember_2301430e-35f1-493e-877b-e0a8cfe12297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec4cb48e-a63d-4aaf-9c8f-43569c3e6a53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8686d14-de00-479f-86a8-bbc731f84efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8686d14-de00-479f-86a8-bbc731f84efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_182aa17b-5925-4b6d-b197-87b7c98441fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_182aa17b-5925-4b6d-b197-87b7c98441fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_737949b6-6572-4629-88d2-e94228df0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_737949b6-6572-4629-88d2-e94228df0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5d80a42d-c38e-4f92-b941-4cdb07d0bac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f97f7b5a-1ae3-41d8-b517-358916a4370c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5d80a42d-c38e-4f92-b941-4cdb07d0bac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityCashDividendsDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityCashDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityCashDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cff94364-4c06-4ecd-b30d-9fffb4735a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_715bc325-e2a3-47c2-8376-d0de0f1f188f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cff94364-4c06-4ecd-b30d-9fffb4735a47" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_715bc325-e2a3-47c2-8376-d0de0f1f188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityStockRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_71d8cffc-a082-481b-a243-82c226c9ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_71d8cffc-a082-481b-a243-82c226c9ac59" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7283c9fa-a5fa-4bd1-9232-a315242b4969" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_December2018StockRepurchaseAuthorizationMember_f8628c3d-20a9-425b-9096-26ecfdf6fb2a" xlink:href="abbv-20220630.xsd#abbv_December2018StockRepurchaseAuthorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0879d486-05f0-437a-8db1-941825293c32" xlink:to="loc_abbv_December2018StockRepurchaseAuthorizationMember_f8628c3d-20a9-425b-9096-26ecfdf6fb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8ef632f7-fc9a-446d-a1ec-611a12945ce7" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d3bfe460-c884-4b9b-aab9-2fb1b5c3cd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d3bfe460-c884-4b9b-aab9-2fb1b5c3cd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7b3d87dd-4bb0-4d1d-87e1-0ed7202688db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7b3d87dd-4bb0-4d1d-87e1-0ed7202688db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a453c20e-93fc-4001-97e8-e3d81f0712bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9f932d63-3b29-4dc7-9fa4-acd7b50c6c2a" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a453c20e-93fc-4001-97e8-e3d81f0712bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8549da4f-f98e-4105-abf1-8bf299a786a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8549da4f-f98e-4105-abf1-8bf299a786a0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa53337d-3523-4158-b92c-266728f5a39c" xlink:to="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2e7d626d-f836-40b2-9b3e-764addedbf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2e7d626d-f836-40b2-9b3e-764addedbf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_dec344f0-1fbc-410e-b432-e0d62bc87691" xlink:href="abbv-20220630.xsd#abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember_dec344f0-1fbc-410e-b432-e0d62bc87691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7d557d6b-cc32-4aa9-b6f5-6856982d8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7d557d6b-cc32-4aa9-b6f5-6856982d8e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37a36873-f35f-4890-91ac-e4ba86616cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37a36873-f35f-4890-91ac-e4ba86616cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01c10c74-dff7-494a-a369-d8b5166bc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_605a31bd-f04f-4f11-a024-8b4873d8d945" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01c10c74-dff7-494a-a369-d8b5166bc15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dbe854e7-bac9-4344-9ee3-b7d179399f4b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8f4c680f-0c59-4b50-85e3-3ea74ec18ea7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b39b7bab-9796-4912-b4f1-0c1a511494e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b39b7bab-9796-4912-b4f1-0c1a511494e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a0687e4c-5843-43be-9d22-13cdb48e849b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a0687e4c-5843-43be-9d22-13cdb48e849b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_553a79d9-6940-4200-915e-f217dbeebbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_553a79d9-6940-4200-915e-f217dbeebbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0931b71e-061c-4e54-9bc2-2568454649cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0931b71e-061c-4e54-9bc2-2568454649cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b327c4f4-b213-442f-a03b-fec8d1138231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b009586f-7bc3-4aa7-9258-2dd4ae7a1501" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b327c4f4-b213-442f-a03b-fec8d1138231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_68ffb64a-893a-417a-a01e-fcfbe5754d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_68ffb64a-893a-417a-a01e-fcfbe5754d48" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_770027d7-91a6-4a24-a77d-b70f1b23326f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_89d3abba-4871-4d8e-a0fe-9c3f4db15f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_89d3abba-4871-4d8e-a0fe-9c3f4db15f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_288f41d8-2564-46d7-a6a0-88e97b9a25ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_TreasuryLockMember_288f41d8-2564-46d7-a6a0-88e97b9a25ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_97864738-7f6c-416f-9b8e-7e94e657f3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4c87828-4ec4-43e4-bd3e-080c943d0d8f" xlink:to="loc_us-gaap_InterestRateSwapMember_97864738-7f6c-416f-9b8e-7e94e657f3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8884ec9b-2368-4deb-af91-7effc975dbbf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_37efae2f-b011-46bf-a873-1342bc03b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_458fe9e9-3a74-4eb5-8891-80956aa2af9b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_37efae2f-b011-46bf-a873-1342bc03b6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_010864ac-61ab-4d7d-97cc-e82a954809e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ea513007-a25a-4bd9-b40b-0f031245c074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2aaf62f1-806a-41b1-976f-abf5615b047c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ea513007-a25a-4bd9-b40b-0f031245c074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5159db2-4412-4911-b287-0938d37896d8" xlink:to="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_30ad685c-6cbe-49a2-91da-304af35e5f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_30ad685c-6cbe-49a2-91da-304af35e5f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ab6846d3-3b5c-491c-926d-58fc281b2074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ab6846d3-3b5c-491c-926d-58fc281b2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_155c3d42-c97c-4fb6-9542-029c41e71b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0243f02b-ee1e-4345-998e-d49ae61bcca7" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_155c3d42-c97c-4fb6-9542-029c41e71b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9eea6250-9c9e-4541-bb8b-fd89bd1dd60f" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fbb6565-6df5-4f2d-86e4-035a6b4c5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fbb6565-6df5-4f2d-86e4-035a6b4c5d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_947026ab-0c71-4d23-804d-569e5f75490d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_947026ab-0c71-4d23-804d-569e5f75490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24089b48-7a04-4126-aa32-7808b74452e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_NetIncomeLoss_24089b48-7a04-4126-aa32-7808b74452e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2519c3f2-f20e-4029-9085-1938158fdaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2519c3f2-f20e-4029-9085-1938158fdaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_c82f55e7-475e-40db-9858-429f746f2729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_c82f55e7-475e-40db-9858-429f746f2729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_17880b7d-4846-469a-b0f6-74db4779d6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_17880b7d-4846-469a-b0f6-74db4779d6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d7864610-0eee-459a-9547-f5bf7424099e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_006fd58e-ab2e-4876-ba2b-7aa925e79cc4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d7864610-0eee-459a-9547-f5bf7424099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IncomeTaxes" xlink:type="simple" xlink:href="abbv-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8ee073b5-0f43-4b76-aba9-6804298762cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3fbffae2-1599-4628-81a1-8b6645f3015a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ee073b5-0f43-4b76-aba9-6804298762cb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3fbffae2-1599-4628-81a1-8b6645f3015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_816052fe-3eb6-466e-937f-e91ddafdb054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d6a82857-ba73-4728-aa09-a94b5296ba54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_816052fe-3eb6-466e-937f-e91ddafdb054" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d6a82857-ba73-4728-aa09-a94b5296ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_de5dd2cf-8fcf-44ab-bf5c-b097713c98a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_816052fe-3eb6-466e-937f-e91ddafdb054" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_de5dd2cf-8fcf-44ab-bf5c-b097713c98a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_80bdd12c-2f61-49ac-8aba-6568ab7bbc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_816052fe-3eb6-466e-937f-e91ddafdb054" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_80bdd12c-2f61-49ac-8aba-6568ab7bbc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingencies" xlink:type="simple" xlink:href="abbv-20220630.xsd#LegalProceedingsandContingencies"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c541bd1-9d93-4dba-b553-a3de99062f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5feb8992-4d20-4311-8e04-442e9f28e799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c541bd1-9d93-4dba-b553-a3de99062f30" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5feb8992-4d20-4311-8e04-442e9f28e799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#LegalProceedingsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49644486-7116-4945-a70b-53975439bf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49644486-7116-4945-a70b-53975439bf9b" xlink:to="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:to="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ad082d3b-a61a-416b-aa30-c7b5c7d8aa75" xlink:to="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NiaspanMember_2c239ba9-4151-4f6e-bb1b-ef739b4164f4" xlink:href="abbv-20220630.xsd#abbv_NiaspanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_NiaspanMember_2c239ba9-4151-4f6e-bb1b-ef739b4164f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_52bc7fbc-b3df-473e-a661-ee2ea81dca2c" xlink:href="abbv-20220630.xsd#abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember_52bc7fbc-b3df-473e-a661-ee2ea81dca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_a3d65f36-90ef-4fde-93d2-e857632cf809" xlink:href="abbv-20220630.xsd#abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember_a3d65f36-90ef-4fde-93d2-e857632cf809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BystolicAntitrustLitigationMember_b48ea73f-ce74-4878-a4bb-b3702c07b512" xlink:href="abbv-20220630.xsd#abbv_BystolicAntitrustLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_BystolicAntitrustLitigationMember_b48ea73f-ce74-4878-a4bb-b3702c07b512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationMember_88682535-ea9d-4563-a9c7-3a537bd4e1f0" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationMember_88682535-ea9d-4563-a9c7-3a537bd4e1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_2ab93c9f-2c0d-4e7a-9922-3eed08d30ad9" xlink:href="abbv-20220630.xsd#abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember_2ab93c9f-2c0d-4e7a-9922-3eed08d30ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ElliottAssociatesL.P.Member_e8f73926-8843-4124-b9bb-ac770fe7666e" xlink:href="abbv-20220630.xsd#abbv_ElliottAssociatesL.P.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c34130e6-43be-4c47-b17f-62b85a277a54" xlink:to="loc_abbv_ElliottAssociatesL.P.Member_e8f73926-8843-4124-b9bb-ac770fe7666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8e82d91-0c8a-4bd7-b3e5-ec1847a292fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a32e7090-0de2-4937-ba7a-acf45a3bb2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4e91684-68dc-4f07-b370-f1791d1b0d5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a32e7090-0de2-4937-ba7a-acf45a3bb2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_49aaaa3b-5786-4355-80bf-2acc31f4edfd" xlink:to="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_b463abf0-e0e0-4a74-99a9-5d2ea71524be" xlink:href="abbv-20220630.xsd#abbv_LossContingencyIndividualPlaintiffLawsuitsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber_b463abf0-e0e0-4a74-99a9-5d2ea71524be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyPurportedClassActionsNumber_c51db00b-5aae-4879-a961-4ccdc9550d96" xlink:href="abbv-20220630.xsd#abbv_LossContingencyPurportedClassActionsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyPurportedClassActionsNumber_c51db00b-5aae-4879-a961-4ccdc9550d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e9b2653e-b1c1-4564-89c9-26cef4ea6f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e9b2653e-b1c1-4564-89c9-26cef4ea6f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_b99c1461-612e-41e9-a78e-066fff1e8fb4" xlink:href="abbv-20220630.xsd#abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws_b99c1461-612e-41e9-a78e-066fff1e8fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_PutativeClassActionLawsuitIndividualNumber_051f58b1-cdee-4569-81ce-6692fa8cf09f" xlink:href="abbv-20220630.xsd#abbv_PutativeClassActionLawsuitIndividualNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_abbv_PutativeClassActionLawsuitIndividualNumber_051f58b1-cdee-4569-81ce-6692fa8cf09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9e0ca539-9ea6-4ef3-96f2-ce99e3f64456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9e0ca539-9ea6-4ef3-96f2-ce99e3f64456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_28f17282-3a93-4647-8c2d-4f0a77279e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_28f17282-3a93-4647-8c2d-4f0a77279e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d42d3329-a917-46c9-945d-550791b7ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d42d3329-a917-46c9-945d-550791b7ab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_5d426199-e69c-41a0-b3e2-64d26c2d7d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1cc5e66f-64dd-4a5a-a706-cf3e859cb690" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_5d426199-e69c-41a0-b3e2-64d26c2d7d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformation" xlink:type="simple" xlink:href="abbv-20220630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aef58bda-859c-47c3-a733-30e923ed6a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_882969d0-4fa2-4318-8063-e3403909b61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aef58bda-859c-47c3-a733-30e923ed6a68" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_882969d0-4fa2-4318-8063-e3403909b61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="abbv-20220630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_964ed2b7-071e-4cc2-8c3b-ed099cce5b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d91b73ca-93b7-454f-9381-ea084aabac57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_964ed2b7-071e-4cc2-8c3b-ed099cce5b1c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d91b73ca-93b7-454f-9381-ea084aabac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b6e0065e-86f4-41c9-93a7-aac4bf139eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7f27e1d0-994c-4a5e-bd7a-5105c2244ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b6e0065e-86f4-41c9-93a7-aac4bf139eab" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7f27e1d0-994c-4a5e-bd7a-5105c2244ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="abbv-20220630.xsd#SegmentInformationDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d5f21b-256e-4afc-bbea-5e9ce2bc5657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d5f21b-256e-4afc-bbea-5e9ce2bc5657" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:href="abbv-20220630.xsd#abbv_KeyProductPortfolioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioAxis_7f59b1fe-f975-492b-a72f-99515448eb08" xlink:to="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImmunologyMember_bd948191-61d4-4dee-aeeb-1d40537f6905" xlink:href="abbv-20220630.xsd#abbv_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_ImmunologyMember_bd948191-61d4-4dee-aeeb-1d40537f6905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HematologicOncologyMember_d0ac5402-ce22-4a4f-be72-d482caa40584" xlink:href="abbv-20220630.xsd#abbv_HematologicOncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_HematologicOncologyMember_d0ac5402-ce22-4a4f-be72-d482caa40584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AestheticsMember_65d51cbb-724b-4c27-8c51-22573912bbfa" xlink:href="abbv-20220630.xsd#abbv_AestheticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_AestheticsMember_65d51cbb-724b-4c27-8c51-22573912bbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_NeuroscienceMember_4f41bef2-34bc-4872-ac19-ef1dd1e3e1b2" xlink:href="abbv-20220630.xsd#abbv_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_NeuroscienceMember_4f41bef2-34bc-4872-ac19-ef1dd1e3e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_EyeCareMember_e793e681-e282-4ede-8e23-e3494184ec75" xlink:href="abbv-20220630.xsd#abbv_EyeCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_EyeCareMember_e793e681-e282-4ede-8e23-e3494184ec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherKeyProductsMember_8a51d10c-d846-4bd1-b51c-67fe05677aaf" xlink:href="abbv-20220630.xsd#abbv_OtherKeyProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abbv_KeyProductPortfolioDomain_22d6a45f-a4e0-4eb7-9f6a-fa917d742a04" xlink:to="loc_abbv_OtherKeyProductsMember_8a51d10c-d846-4bd1-b51c-67fe05677aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73047e4d-2f5d-496a-942e-25b3f110229a" xlink:to="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_HUMIRAMember_e3fd2f17-2ae5-404d-bc45-b01ce7929412" xlink:href="abbv-20220630.xsd#abbv_HUMIRAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_HUMIRAMember_e3fd2f17-2ae5-404d-bc45-b01ce7929412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_SKYRIZIMember_22b2b7f1-c0fa-466f-9796-da1a40b6e335" xlink:href="abbv-20220630.xsd#abbv_SKYRIZIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_SKYRIZIMember_22b2b7f1-c0fa-466f-9796-da1a40b6e335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RINVOQMember_7ba76d5d-e2db-4aa4-a0a9-9cdb69408be6" xlink:href="abbv-20220630.xsd#abbv_RINVOQMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_RINVOQMember_7ba76d5d-e2db-4aa4-a0a9-9cdb69408be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_ImbruvicaMember_8a85882f-c2bf-4e47-b104-2d804d6dc1da" xlink:href="abbv-20220630.xsd#abbv_ImbruvicaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_ImbruvicaMember_8a85882f-c2bf-4e47-b104-2d804d6dc1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VENCLEXTAMember_f1683550-a950-4d31-ac1e-4b489caabe83" xlink:href="abbv-20220630.xsd#abbv_VENCLEXTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_VENCLEXTAMember_f1683550-a950-4d31-ac1e-4b489caabe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxCosmeticMember_d4817169-aaeb-4469-a206-e2284d75477f" xlink:href="abbv-20220630.xsd#abbv_BotoxCosmeticMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_BotoxCosmeticMember_d4817169-aaeb-4469-a206-e2284d75477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_JuvedermCollectionMember_6a5d5a6a-7673-4fc0-9328-61b034b1bb87" xlink:href="abbv-20220630.xsd#abbv_JuvedermCollectionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_JuvedermCollectionMember_6a5d5a6a-7673-4fc0-9328-61b034b1bb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherAestheticsMember_88e0c753-7be9-462b-b084-2306eb0647ef" xlink:href="abbv-20220630.xsd#abbv_OtherAestheticsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherAestheticsMember_88e0c753-7be9-462b-b084-2306eb0647ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_BotoxTherapeuticMember_e607e17c-4d6d-4a94-a9d6-5c4eb3e070da" xlink:href="abbv-20220630.xsd#abbv_BotoxTherapeuticMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_BotoxTherapeuticMember_e607e17c-4d6d-4a94-a9d6-5c4eb3e070da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_VraylarMember_20d47da0-6320-42fc-85fc-9bfc5ba02105" xlink:href="abbv-20220630.xsd#abbv_VraylarMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_VraylarMember_20d47da0-6320-42fc-85fc-9bfc5ba02105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_DuodopaMember_5667a951-bc04-4f63-9214-f09e61fd277f" xlink:href="abbv-20220630.xsd#abbv_DuodopaMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_DuodopaMember_5667a951-bc04-4f63-9214-f09e61fd277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_UbrelvyMember_36bff0f1-a488-49b3-9312-bbd9557d4e56" xlink:href="abbv-20220630.xsd#abbv_UbrelvyMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_UbrelvyMember_36bff0f1-a488-49b3-9312-bbd9557d4e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_QuliptaMember_432c21d6-a41f-4382-8084-d686d18566f6" xlink:href="abbv-20220630.xsd#abbv_QuliptaMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_QuliptaMember_432c21d6-a41f-4382-8084-d686d18566f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherNeuroscienceMember_105fe386-a137-4a71-bfd1-804c3e7c4b6b" xlink:href="abbv-20220630.xsd#abbv_OtherNeuroscienceMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherNeuroscienceMember_105fe386-a137-4a71-bfd1-804c3e7c4b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LumiganGanfortMember_46800765-03c5-416c-aee3-6ba9f3956b94" xlink:href="abbv-20220630.xsd#abbv_LumiganGanfortMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_LumiganGanfortMember_46800765-03c5-416c-aee3-6ba9f3956b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_AlphaganCombiganMember_84005984-1fdd-40d0-9a3f-4494b83074df" xlink:href="abbv-20220630.xsd#abbv_AlphaganCombiganMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_AlphaganCombiganMember_84005984-1fdd-40d0-9a3f-4494b83074df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_RestasisMember_e164f5e1-9f25-4ed2-b190-9ac3028efacf" xlink:href="abbv-20220630.xsd#abbv_RestasisMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_RestasisMember_e164f5e1-9f25-4ed2-b190-9ac3028efacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherEyeCareMember_63f72989-66f1-45e3-b646-e9885e038b0a" xlink:href="abbv-20220630.xsd#abbv_OtherEyeCareMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherEyeCareMember_63f72989-66f1-45e3-b646-e9885e038b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_MAVYRETMember_1c628d18-af5d-4094-baea-d50b46ffaf6c" xlink:href="abbv-20220630.xsd#abbv_MAVYRETMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_MAVYRETMember_1c628d18-af5d-4094-baea-d50b46ffaf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_CreonMember_50bbc732-42da-41db-bc7e-2a0ebba678fa" xlink:href="abbv-20220630.xsd#abbv_CreonMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_CreonMember_50bbc732-42da-41db-bc7e-2a0ebba678fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_LinzessConstellaMember_bb14ed7c-fa58-458d-a717-911ca4f32518" xlink:href="abbv-20220630.xsd#abbv_LinzessConstellaMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_LinzessConstellaMember_bb14ed7c-fa58-458d-a717-911ca4f32518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_OtherProductsMember_39578051-9cb7-4f8e-bbb1-d3fb3bc915f0" xlink:href="abbv-20220630.xsd#abbv_OtherProductsMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7157dc49-64cc-4069-9b74-1ea7a1ffffef" xlink:to="loc_abbv_OtherProductsMember_39578051-9cb7-4f8e-bbb1-d3fb3bc915f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5d4a2d5f-eea6-45ed-b4c2-ed86a5e35057" xlink:to="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1b42a469-9685-4fd7-a095-d8a4c37a5592" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:to="loc_country_US_1b42a469-9685-4fd7-a095-d8a4c37a5592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5bdeecd7-da1c-41ad-811c-973c7e5a9453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48da5ab9-74b0-4300-b6ef-1438e90b5c35" xlink:to="loc_us-gaap_NonUsMember_5bdeecd7-da1c-41ad-811c-973c7e5a9453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ef07ffcc-627d-4a21-bbc0-5695f45d30e5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f4e3ec-1484-48bd-b343-964716d3d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f4e3ec-1484-48bd-b343-964716d3d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_4b834ecb-91ec-444f-b139-1604741ffa70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_4b834ecb-91ec-444f-b139-1604741ffa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07258b39-00dd-4d16-9a0a-2e8457d633e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6930354f-bd57-4538-a43f-9b828916b60f" xlink:to="loc_us-gaap_Revenues_07258b39-00dd-4d16-9a0a-2e8457d633e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>abbv-20220630_g1.jpg
<TEXT>
begin 644 abbv-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$!&0$9  #__@ R35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]53D-/051?4$U37TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ . %$ P$B  (1
M 0,1 ?_$ !\   (" P # 0$            *"0L"!P@!!08$ __$ $T0   &
M 0," P((!PH/ 0    $" P0%!@< " D1$@H3(10Q%1HB05%88=<6,G%R@9&8
M%Q@C)S-)E[&RLSE"4E598G:)E*&WR-'3\(?_Q  < 0 " P$! 0$
M   &!P,$!0((  '_Q  _$0 " @(! P($! ,#"0D    ! @,$!1$& !(A$S$'
M(D%1%",R815Q@4)RH187,U1C@I&4\$-%559B9972U/_:  P# 0 "$0,1 #\
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MMIA'(M): LE<P[B^4B91@N & J[9VV3,)%"*(KI"HW<)JH*JIFM L/6Y[?\
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MK.%RM>% 2\LV.MQ1J -DM(\*JH \[) UU)#F<18<1P93'32,0%CBNUI'8DZ
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M_?2]^M6E'A6SD_DVK;S-PS<[PHD]D1!W!Y:FE4FRH>9[2N+-=9$0)Y+=8!,
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M6,LNS3@Y%;0UM"Y6\12\@OQ5LC>QK,J];7,RVF&4W#O$'$!2.(?Y!OL^8?>
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M#V\[RC/T$MS5<<,A9L9 Q-HR".U(L,8'L9&+N%+;"+WN5;04KE83\(_O-N<
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MV5)&P3U#)X@Z&?P_+OO?;ODBD5DK#0IEH4A^\%F$U@;&R[ _=VE[3JDZE.0
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M._53?_M X)^]?1\7>YG?JIO_ -H'!/WKZM* ,F/N,0?R"4?ZM>?D?ZO_ "T
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M40B*BCHT-3_A-RHGW&CX%R<R:9S1K%Y#=@XG0FNX3$86K86(D,F/2/W^YKM
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MA],"A(\JRL =E>UCOJ,*F;T>938\5SCB)RSO<PFTJZ!&BF/\CUB^RD-66H)
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M7&QDN0MM<Q/N(JTA6UEF,;G_ &FO;O;*U)Q)CD.FY;V[%)"V>,AGWR3&A[W
M5Y8JP&1>PY52_*-&I>$<OS%22+!.U>[C)>Y5K7H3.(%8@LD+"1"(VV?RG,D0
M))5%)),?*^-8RRK98+-5OHT8-BI*(6DV0H:4=C!G ]G 5C_:+#QU]9#<X'-K
MC,48IQN>S415NP"/3:9&PI09^1!!JX$AEUE;CB125=OR+I';N)-VNX>',55!
MPN=0#@'T'Q@[FP^LU8/V;\*?=%HT:>$6#X_,BR/Q[!%G\L?X54\G:CZQD_\
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92?U7,$?=)(B-(YTFV=M#N8[.SKR3OK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>abbv-20220630_g2.gif
<TEXT>
begin 644 abbv-20220630_g2.gif
M1TE&.#EA9  3 (0  $56=^_Q]-#4W<'&T39(:Z*JNN#CZ&1RCB8Y8)*<KU5D
M@G2 F;&XQN'DZ>OM\-_BZ.;H[>/EZN+EZN#BZ.+DZ>7H[!<K5(..I <=2?__
M_P                       "'_"TY%5%-#05!%,BXP P$!   A^00
M "P     9  3   (_P S"!Q(L&!! P(,*BPX(,#"AQ C2IQ(,<,%# <J"L1@
MP8#&CP(9 "@ LJ3 BP ^8L PP&1%E"Y!PM2XLF5,B0P()+@YT$&$!PT@+)PI
MT"=0H0IK$C0:E.=$ID@7%E! 8*55"P N>!R(,D " !:LKD2@H(##@34''*@J
M%NL"CP8L6,@X<8%< Q<L,"#H%0 "L59'$A3 %G!;DB<Q( AK6"R"A!L5-P9\
M(0.#E0LD)EBY]Z*"@0,83UY9.4, Q@<:$AR0@+'-BRLM7+ I,,  NQRWBCW
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<->VO"T%5D;E/_=0410;$>FX%$DP % 51!00 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911558816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AbbVie Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001551152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0375147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 North Waukegan Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">North Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60064-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">932-7900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,096,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.500 Senior Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Senior Notes due 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV23B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.375 Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 0.750 Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.625 Senior Notes Due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XCHI', window );">CHICAGO STOCK EXCHANGE, INC | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908029088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues</a></td>
<td class="nump">$ 14,583<span></span>
</td>
<td class="nump">$ 13,959<span></span>
</td>
<td class="nump">$ 28,121<span></span>
</td>
<td class="nump">$ 26,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">4,170<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">8,222<span></span>
</td>
<td class="nump">8,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,412<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">8,539<span></span>
</td>
<td class="nump">6,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
<td class="nump">3,106<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">11,288<span></span>
</td>
<td class="nump">9,518<span></span>
</td>
<td class="nump">20,109<span></span>
</td>
<td class="nump">18,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">4,441<span></span>
</td>
<td class="nump">8,012<span></span>
</td>
<td class="nump">8,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange loss</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income tax expense</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">5,421<span></span>
</td>
<td class="nump">4,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net earnings attributable to noncontrolling interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 5,414<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908043632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="nump">$ 4,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1 for the three months and $(24) for the six months ended June 30, 2021</a></td>
<td class="num">(823)<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax', window );">Net investment hedging activities, net of tax expense (benefit) of $146 for the three months and $183 for the six months ended June 30, 2022 and $(31) for the three months and $72 for the six months ended June 30, 2021</a></td>
<td class="nump">536<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Pension and post-employment benefits, net of tax expense (benefit) of $11 for the three months and $21 for the six months ended June 30, 2022 and $14 for the three months and $33 for the six months ended June 30, 2021</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Cash flow hedging activities, net of tax expense (benefit) of $5 for the three months and $3 for the six months ended June 30, 2022 and $&#8212; for the three months and $3 for the six months ended June 30, 2021</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to AbbVie Inc.</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 5,117<span></span>
</td>
<td class="nump">$ 4,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909089488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract', window );"><strong>Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, tax expense (benefit)</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax', window );">Net investment hedging activities, tax expense (benefit)</a></td>
<td class="nump">146<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Pension and post-employment benefits, tax expense (benefit)</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Cash flow hedging activities, tax expense (benefit)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908090720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 8,521<span></span>
</td>
<td class="nump">$ 9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">11,237<span></span>
</td>
<td class="nump">9,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="nump">27,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">71,823<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,028<span></span>
</td>
<td class="nump">32,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,186<span></span>
</td>
<td class="nump">146,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt and finance lease obligations</a></td>
<td class="nump">11,913<span></span>
</td>
<td class="nump">12,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">22,543<span></span>
</td>
<td class="nump">22,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,473<span></span>
</td>
<td class="nump">35,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt and finance lease obligations</a></td>
<td class="nump">61,002<span></span>
</td>
<td class="nump">64,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,768<span></span>
</td>
<td class="nump">28,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,622,099 shares issued as of June 30, 2022 and 1,803,195,293 as of December 31, 2021</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common stock held in treasury, at cost, 44,595,448 shares as of June 30, 2022 and 34,857,597 as of December 31, 2021</a></td>
<td class="num">(4,591)<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">18,906<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">3,516<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,196)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">14,653<span></span>
</td>
<td class="nump">15,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">14,688<span></span>
</td>
<td class="nump">15,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 143,186<span></span>
</td>
<td class="nump">$ 146,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562913909488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,812,622,099<span></span>
</td>
<td class="nump">1,803,195,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common stock held in treasury, at cost (in shares)</a></td>
<td class="nump">44,595,448<span></span>
</td>
<td class="nump">34,857,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562904963808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Equity (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 13,097<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (2,264)<span></span>
</td>
<td class="nump">$ 17,384<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="num">$ (3,117)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">4,319<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,319<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(4,634)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,634)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(797)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">12,594<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,022)<span></span>
</td>
<td class="nump">17,936<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="num">(3,103)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">13,733<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,017)<span></span>
</td>
<td class="nump">17,712<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
<td class="num">(3,295)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(2,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">12,594<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,022)<span></span>
</td>
<td class="nump">17,936<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="num">(3,103)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">15,436<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">5,414<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,414<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(5,025)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,025)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(1,479)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,479)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">14,688<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(4,591)<span></span>
</td>
<td class="nump">18,906<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
<td class="num">(3,196)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(4,585)<span></span>
</td>
<td class="nump">18,731<span></span>
</td>
<td class="nump">5,103<span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(2,511)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,511)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation plans and other</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 14,688<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (4,591)<span></span>
</td>
<td class="nump">$ 18,906<span></span>
</td>
<td class="nump">$ 3,516<span></span>
</td>
<td class="num">$ (3,196)<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562907949056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="nump">$ 4,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">3,704<span></span>
</td>
<td class="nump">4,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on divestitures</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments', window );">Non-cash litigation reserve adjustments, net of cash payments</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(499)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(448)<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income tax assets and liabilities, net</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">9,913<span></span>
</td>
<td class="nump">9,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Acquisitions and investments</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisitions of property and equipment</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investment securities</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales and maturities of investment securities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="num">(584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt and finance lease obligations</a></td>
<td class="num">(4,881)<span></span>
</td>
<td class="num">(3,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(5,033)<span></span>
</td>
<td class="num">(4,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,479)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="num">(9,651)<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and equivalents</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and equivalents</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents, beginning of period</a></td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">8,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents, end of period</a></td>
<td class="nump">$ 8,521<span></span>
</td>
<td class="nump">$ 8,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash litigation reserve adjustments, net of cash payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909696016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation Basis of Historical Presentation <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#8217;s audited consolidated financial statements and notes included in the company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#8217;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. </span></div>During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;D and milestones expense by $35&#160;million for the three months and $150&#160;million for the six months ended June 30, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909786656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SupplementalFinancialInformationDisclosureAbstract', window );"><strong>Supplemental Financial Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text">Supplemental Financial Information<span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $203 million for the three months and $401 million for the six months ended June 30, 2022 and $201 million for the three months and $407 million for the six months ended June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SupplementalFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SupplementalFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909944256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909786656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing, Acquisitions and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract', window );"><strong>Licensing, Acquisitions, and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock', window );">Licensing, Acquisitions, and Other Arrangements</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensing, Acquisitions and Other Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflows related to acquisitions and investments totaled $394 million for the six months ended June 30, 2022 and $345 million for the six months ended June 30, 2021. AbbVie recorded acquired IPR&amp;D and milestones charges of $269 million for the three months and $414 million for the six months ended June 30, 2022 and $132 million for the three months and $317&#160;million for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Syndesi Therapeutics SA</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&amp;D and milestones expense in the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Juvise Pharmaceuticals</span></div>In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the condensed consolidated statement of earnings in the second quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for acquisitions, collaborations and other arrangements of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909841760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaborations</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended June 30, 2022 and 2021.</span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Janssen Biotech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#8217;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie&#8217;s receivable from Janssen, included in accounts receivable, net, was $310 million at June 30, 2022 and $294 million at December 31, 2021. AbbVie&#8217;s payable to Janssen, included in accounts payable and accrued liabilities, was $389 million at June 30, 2022 and $509 million at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration with Genentech, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#8217;s net revenues. Genentech&#8217;s share of United States profits is included in AbbVie&#8217;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;A) expenses and global development costs as part of research and development (R&amp;D) expenses, net of Genentech&#8217;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#8217;s cost of products sold.</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909986448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2022, there were no accumulated goodwill impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $1.8 billion for the three months and $3.7 billion for the six months ended June 30, 2022 and $2.0&#160;billion for the three months and $4.0 billion for the six months ended June 30, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911453568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Integration and Restructuring Plans</a></td>
<td class="text">Integration and Restructuring PlansAllergan Integration Plan <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.372%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.240%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges (benefits)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the six months ended June 30, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges (benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Restructuring</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie recorded restructuring charges of $36 million for the three months and $93 million for the six months ended June 30, 2022 and $5 million for the three months and $43 million for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910006480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Financial Instruments and Fair Value Measures</a></td>
<td class="text">Financial Instruments and Fair Value MeasuresRisk Management PolicySee Note 11 to the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#8217;s risk management policy and use of derivative instruments.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.7 billion at June 30, 2022 and $1.1 billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of June 30, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $750 million at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.2 billion at June 30, 2022 and $8.2 billion at December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#8364;4.8&#160;billion at June 30, 2022 and &#8364;4.3 billion at December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#8364;5.9 billion at June 30, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with the company&#8217;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $73&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax gains of $2 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to AbbVie&#8217;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $402 million for three months and pre-tax gains of $501&#160;million for the six months ended June 30, 2022 and pre-tax losses of $126 million for the three months and pre-tax gains of $256 million for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 2 &#8211; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">Level 3 &#8211; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#8217;s management about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, probabilities of achieving the milestones, time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%- 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034 </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2022 are shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,137&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $148 million as of June 30, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of total net accounts receivable, three U.S. wholesalers accounted for 76% as of June 30, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie&#8217;s pharmaceutical product net revenues in the United States were to these three wholesalers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humira (adalimumab) is AbbVie&#8217;s single largest product and accounted for approximately 36% of AbbVie&#8217;s total net revenues for the six months ended June 30, 2022 and 37% for the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the company repaid $1.7 billion aggregate principal amount of 3.25% senior notes that were scheduled to mature in October 2022. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the company repaid $1.8 billion aggregate principal amount of 2.3% senior notes that were scheduled to mature in May 2021. In May 2021, the company repaid &#8364;750 million aggregate principal amount of 0.5% senior euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in May 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909811984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Post-Employment Benefits</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Post-Employment Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562913616416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">EquityStock-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 0.9&#160;million stock options with a weighted-average grant-date fair value of $22.83. As of June 30, 2022, $10 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs and Performance Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 5.8&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $146.20. As of June 30, 2022, $824&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/23/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the six months ended June 30, 2022 and 5&#160;million shares for $550&#160;million during the six months ended June 30, 2021. AbbVie's remaining stock repurchase authorization was approximately $1.4&#160;billion as of June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,899)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,470)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,196)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss for the six months ended June 30, 2022 included foreign currency translation adjustments totaling a loss of $1.1 billion and the offsetting impact of net investment hedging activities totaling a gain of $666 million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,938)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income for the six months ended June 30, 2021 included foreign currency translation adjustments totaling a loss of $433 million and the offsetting impact of net investment hedging activities totaling a gain of $260 million, which was principally due to the impact of the weakening of the Euro on the translation of the company&#8217;s Euro-denominated assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Amounts are included in interest expense, net (see Note 8).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Amounts are included in cost of products sold (see Note 8).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909910096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 22% for the three months and 11% for the six months ended June 30, 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to 34% for the three months and 14% for the six months ended June 30, 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The decrease in the effective tax rate for the three and six months ended June 30, 2022 over the prior year was primarily due to differences in the company&#8217;s jurisdictional mix of earnings and accretion on contingent consideration.</span>Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#8217;s gross unrecognized tax benefits balance may change within the next 12 months by up to $145&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909659776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings and Contingencies</a></td>
<td class="text">Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#8217;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#8217;s consolidated financial position, results of operations or cash flows.Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Niaspan Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#8217;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#8217; fees. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#8217;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#8217;s settlements with biosimilar manufacturers and AbbVie&#8217;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Humira (Adalimumab) Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Namenda Indirect Purchaser Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#8217;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#8217; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#8217; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Bystolic Antitrust Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States District Court for the Southern District of New York.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Proceedings</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,031 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prescription Opiate Litigation, MDL No. 2804. Approximately 266 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In May and July 2022, Allergan reached settlements with the State of West Virginia and its political subdivisions and with the City and County of San Francisco, California, respectively. Allergan previously reached settlements with other plaintiffs. Allergan is engaged in negotiations with representatives for the remaining states, counties, cities, other municipal entities and Native American tribes regarding a potential settlement, with payments likely to be made over a number of years. While negotiations are on-going and definitive terms have not been reached, a framework for an agreement exists, including an estimate of a potential settlement amount based on maximum participation in the potential settlement. AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to this potential settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the New Mexico Attorney General filed a lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#8217;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. In July 2022, the parties reached an agreement in principle to settle this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder and Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. One of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, a federal securities lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Holwill v. AbbVie Inc., et al</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May 2022, a shareholder derivative lawsuit, Ranney v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that certain AbbVie directors and officers breached their fiduciary duties based on related allegations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Allergan plc Securities Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The plaintiffs generally seek compensatory damages and attorneys&#8217; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, a federal securities lawsuit, Nakata v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois against AbbVie and certain officers alleging misstatements regarding the potential effect that safety information about another company&#8217;s product would have on the Food and Drug Administration&#8217;s approval and labeling for AbbVie&#8217;s Rinvoq. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the same court, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties based on related allegations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and General Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, a qui tam lawsuit, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Silbersher v. Allergan Inc., et al.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allergan USA, Inc., Allergan Sales, LLC and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit. In May 2022, the parties settled the cases and they were dismissed without prejudice.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909687056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562913933552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SupplementalFinancialInformationDisclosureAbstract', window );"><strong>Supplemental Financial Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of interest expense, net</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SupplementalFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SupplementalFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910006480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted earnings per share, impact of two-class method</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the impact of the two-class method:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings allocated to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911422624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of profit and cost sharing relationship</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Janssen's share of profits (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International - AbbVie's share of profits (included in net revenues)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global - AbbVie's share of other costs (included in respective line items)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of profit and cost sharing relationship</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the profit and cost sharing relationship between Genentech and AbbVie:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech's share of profits, including royalties (included in cost of products sold)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie's share of development costs (included in R&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909073056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of changes in the carrying amount of goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of definite-lived intangible assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of indefinite-lived intangible assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>carrying <br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>carrying <br/>amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911127168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of charges associated with integration plan</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.372%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.240%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total charges (benefits)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of cash activity in the restructuring reserve</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the recorded liability associated with the integration plan for the six months ended June 30, 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and employee benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other integration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges (benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember', window );">Other restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of cash activity in the restructuring reserve</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562913675520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of amounts and location of derivatives on the condensed consolidated balance sheets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of AbbVie&#8217;s derivative instruments on the condensed consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211; <br/>Derivatives in asset position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value &#8211;<br/>Derivatives&#160;in&#160;liability&#160;position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;sheet&#160;caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement&#160;of earnings caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury rate lock agreements designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as hedged item in fair value hedges</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable <br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in active markets&#160;for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other observable<br/>inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of significant level 3 unobservable inputs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%- 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for unachieved milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for royalties by indication</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56% - 100%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2034 </span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in fair value of Level 3 inputs</a></td>
<td class="text">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of book values, approximate fair values and bases used to measure certain financial instruments</a></td>
<td class="text">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2022 are shown in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,137&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis&#160;of&#160;fair&#160;value&#160;measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Book value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in&#160;active markets for identical assets <br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other&#160;<br/>observable inputs <br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant unobservable inputs <br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, excluding fair value hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909746832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost relating to the company&#8217;s defined benefit and other post-employment plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined <br/>benefit&#160;plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;post- <br/>employment&#160;plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562907938496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of share-based compensation expense</a></td>
<td class="text">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax compensation expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDividendsPayableTextBlock', window );">Summary of quarterly cash dividends</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quarterly cash dividends declared during 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Declared</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/23/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/22</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/17/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/10/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/16/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/14/21</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of changes in balances of each component of accumulated other comprehensive loss</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and post-employment <br/>benefits</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,899)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,470)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,196)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency <br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedging activities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension&#160;<br/>and post-employment <br/>benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow hedging <br/>activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,938)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact on AbbVie&#8217;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) (brackets&#160;denote&#160;gains)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on derivative amount excluded from effectiveness testing</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and post-employment benefits</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedging activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on foreign currency forward exchange contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on treasury rate lock agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on interest rate swap contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Amounts are included in interest expense, net (see Note 8).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Amounts are included in cost of products sold (see Note 8).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDividendsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDividendsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562909659776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of worldwide net revenues</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details AbbVie&#8217;s worldwide net revenues:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rinvoq</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Hematologic Oncology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venclexta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aesthetics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Cosmetic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Juvederm Collection</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Aesthetics</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Botox Therapeutic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vraylar</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Duodopa</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ubrelvy</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qulipta</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lumigan/Ganfort</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alphagan/Combigan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restasis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Eye Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavyret</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Creon</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linzess/Constella</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910030240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense', window );">Reclassification of development milestone expense to IPR&amp;D and milestones expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense', window );">Reclassification of development milestone expense from research and development expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of development milestone expense from research and development expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562912270848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueOrExpenseNetAbstract', window );"><strong>Interest Expense, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,617)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueOrExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueOrExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911376096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 5,414<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Earnings allocated to participating securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Earnings available to common shareholders</a></td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 5,388<span></span>
</td>
<td class="nump">$ 4,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to AbbVie Inc.</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 5,414<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted', window );">Earnings allocated to participating securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Earnings available to common shareholders</a></td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 5,388<span></span>
</td>
<td class="nump">$ 4,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicTwoClassMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562904911664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing, Acquisitions and Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Cash outflows related to acquisitions and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (394)<span></span>
</td>
<td class="num">$ (345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Pre-tax gain recognized on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_SyndesiMember', window );">Syndesi | Collaborative arrangement | Acquired IPR&amp;D and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_SyndesiMember', window );">Syndesi | Collaborative arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_PotentialPaymentsUnderAgreementCertainMilestones', window );">Potential payments under agreement certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember', window );">Juvise Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssets1', window );">Proceeds from sale of assets</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember', window );">Juvise Pharmaceuticals | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Pre-tax gain recognized on sale of assets</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_PotentialPaymentsUnderAgreementCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_PotentialPaymentsUnderAgreementCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_SyndesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_SyndesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911704544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">AbbVie's receivable from Janssen</a></td>
<td class="nump">$ 11,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">AbbVie's payable to Janssen</a></td>
<td class="nump">22,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable', window );">Milestone payments</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty', window );">Share of collaboration development costs responsible by Janssen (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts', window );">Share of collaboration development costs responsible by the entity (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_OtherExpensesFromCollaborativeArrangements', window );">Global - AbbVie's share of other costs (included in respective line items)</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">AbbVie's receivable from Janssen</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">AbbVie's payable to Janssen</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements', window );">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Collaborative arrangement | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">International - AbbVie's share of profits (included in net revenues)</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc. | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements', window );">Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements', window );">AbbVie's share of development costs (included in R&amp;D)</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member', window );">Genentech, Inc. | Collaborative arrangement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements', window );">AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_OtherExpensesFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_OtherExpensesFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abbv_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abbv_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562995343152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 32,379,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Foreign currency translation adjustments</a></td>
<td class="num">(351,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">32,028,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Accumulated goodwill impairment losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908773712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 96,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(25,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">71,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets gross carrying amount</a></td>
<td class="nump">97,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">71,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">3,704<span></span>
</td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">88,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(21,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">66,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">8,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562905126128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Integration and Restructuring Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Integration related costs</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Severance and employee benefits | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember', window );">Allergan integration plan | Other integration | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember', window );">Other restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Charges associated with integration or restructuring plans</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring reserve rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance end of the period</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_RestructuringReserveCashSettledRestructuringGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_RestructuringReserveCashSettledRestructuringGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_AllerganIntegrationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abbv_OtherRestructuringPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562903754032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Financial Instruments (Details)<br> &#8364; in Billions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet', window );">Amount excluded from the assessment of effectiveness for cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet', window );">Amount excluded from the assessment of effectiveness for fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">236,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Net investment hedges | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of unsecured senior notes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Duration of forward exchange contracts</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1', window );">Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">129,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">256,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative instruments</a></td>
<td class="nump">7,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value - Derivatives in asset position</a></td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative instruments, notional amount and fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value - Derivatives in liability position</a></td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911557072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet', window );">Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense, net | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1', window );">Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</a></td>
<td class="nump">402<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income</a></td>
<td class="nump">304<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument | Cost of products sold | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Designated as hedging instrument | Interest expense, net | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Treasury rate lock agreements | Designated as hedging instrument | Interest expense, net | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Gain (loss) on derivatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative instrument net gains (losses) recognized in the consolidate statements of earnings</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ForeignCurrencyGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ForeignCurrencyGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562904784000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">68,223<span></span>
</td>
<td class="nump">82,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">8,521<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,293<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">15,178<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">15,496<span></span>
</td>
<td class="nump">14,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">4,212<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">4,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">4,309<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">6,027<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant other observable inputs (Level&#160;2) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">15,178<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">15,178<span></span>
</td>
<td class="nump">14,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant unobservable inputs (Level&#160;3) | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Foreign currency contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and time deposits | Fair Value, Recurring | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Money market funds and time deposits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562912161024">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.041<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Probability of payment for royalties excluding early stage or approved indications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for unachieved milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for royalties by indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Projected year of payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Probability of payment for royalties excluding early stage or approved indications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Significant unobservable input for contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforUnachievedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforUnachievedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProjectedYearofPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProjectedYearofPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910966512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Transfers of assets or liabilities between the fair value measurement levels</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers of assets into Level 3 of the fair value hierarchy</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers of assets out of Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract', window );"><strong>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers of liabilities into Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers of liabilities out of Level 3 of the fair value hierarchy</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">14,887,000,000<span></span>
</td>
<td class="nump">$ 12,997,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in net earnings</a></td>
<td class="nump">861,000,000<span></span>
</td>
<td class="nump">2,349,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(570,000,000)<span></span>
</td>
<td class="num">(357,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 15,178,000,000<span></span>
</td>
<td class="nump">$ 14,989,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911376048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying amount of investments in equity securities that do not have readily determinable fair values</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">11,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">56,674<span></span>
</td>
<td class="nump">70,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">68,223<span></span>
</td>
<td class="nump">82,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">11,918<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">61,202<span></span>
</td>
<td class="nump">64,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">73,137<span></span>
</td>
<td class="nump">76,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">11,906<span></span>
</td>
<td class="nump">11,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">57,471<span></span>
</td>
<td class="nump">71,810<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">69,394<span></span>
</td>
<td class="nump">83,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Significant other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Approximate fair value | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure', window );">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure', window );">Long-term debt and finance lease obligations, excluding fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562912163696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_NumberOfPrincipalUSCustomers', window );">Number of principal customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable, net | Geographic risk | Principal US customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk (as a percent)</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Total revenues | HUMIRA | Humira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations risk (as a percent)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_NumberOfPrincipalUSCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of principal U.S. customers of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_NumberOfPrincipalUSCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=abbv_PrincipalUSCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=abbv_PrincipalUSCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_HUMIRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_HUMIRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911710512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember', window );">3.45% senior notes due 2022 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member', window );">Floating rate notes due 2025 | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Aggregate principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term loan credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember', window );">Floating rate notes due 2025, refinanced | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt obligations, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.250PercentMember', window );">3.25% senior notes due 2022 | Senior notes | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotes2.30PercentDue2021Member', window );">2.30% senior notes due 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorEuroNotesDue2021At0.500PercentMember', window );">0.50% senior euro notes due 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDueInMay2021AtFloatingRatesMember', window );">Floating senior notes due 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt and Credit Facilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.450PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDue2022At3.250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotes2.30PercentDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorNotes2.30PercentDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorEuroNotesDue2021At0.500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorEuroNotesDue2021At0.500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDueInMay2021AtFloatingRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abbv_SeniorNotesDueInMay2021AtFloatingRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908837632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined benefit and other post-employment plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit', window );">Amortization of actuarial loss</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other post-employment plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined benefit and other post-employment plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost (credit)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit', window );">Amortization of actuarial loss</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910983664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">After-tax compensation expense</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pre-tax compensation expense</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911740448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock Options (Details) - Stock Options<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares) | shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation cost</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908832512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares) | shares</a></td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Fair market value of awards vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 146.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation cost</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abbv_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abbv_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562913902896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Cash Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562912337328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock Repurchase Program (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Payment for shares repurchased</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1,479<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining share repurchase authorization amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember', window );">December 2018 Stock Repurchase Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Payment for shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=abbv_December2018StockRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911567136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 16,314<span></span>
</td>
<td class="nump">$ 13,733<span></span>
</td>
<td class="nump">$ 15,436<span></span>
</td>
<td class="nump">$ 13,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">14,688<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
<td class="nump">14,688<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(570)<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,624)<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(1,624)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember', window );">Net investment hedging activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">575<span></span>
</td>
<td class="num">(530)<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,546)<span></span>
</td>
<td class="num">(3,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,470)<span></span>
</td>
<td class="num">(2,938)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
<td class="num">(2,938)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Cash flow hedging activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="num">(3,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (3,196)<span></span>
</td>
<td class="num">$ (3,103)<span></span>
</td>
<td class="num">$ (3,196)<span></span>
</td>
<td class="num">$ (3,103)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562911730032">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">255<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(924)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
<td class="num">(5,414)<span></span>
</td>
<td class="num">(4,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Losses (gains) on foreign currency forward exchange contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,170<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">8,222<span></span>
</td>
<td class="nump">8,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and post-employment benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amortization of actuarial losses and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Losses (gains) on foreign currency forward exchange contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Significant amounts reclassified out of each component of AOCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Gains on derivative amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(a)&#160;Amounts are included in interest expense, net (see Note 8)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(c) Amounts are included in cost of products sold (see Note 8).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562910970432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Potential change in unrecognized tax benefits</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562908430416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings and Contingencies (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>company</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>investment_fund</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>company</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>claim </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>claim </div>
<div>class_action</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>claim </div>
<div>direct_purchaser</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>end_payor_purchaser </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>company </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_NiaspanMember', window );">Niaspan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber', window );">Number of individual plaintiff lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyPurportedClassActionsNumber', window );">Number of purported class actions | class_action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of healthcare benefit providers acting as plaintiff in lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember', window );">AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws', window );">Number of generic companies with whom certain litigation related agreements were entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember', window );">Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_PutativeClassActionLawsuitIndividualNumber', window );">Number of individual putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember', window );">Bystolic antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws', window );">Number of generic companies with whom certain litigation related agreements were entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember', window );">Prescription drug abuse litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember', window );">Prescription drug abuse litigation in state courts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember', window );">Prescription drug abuse litigation in state courts | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Litigation charge related to potential settlement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member', window );">Elliott Associates, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of parties to lawsuit (in investment funds) | investment_fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of plaintiff claims dismissed | investment_fund</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyIndividualPlaintiffLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyIndividualPlaintiffLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_LossContingencyPurportedClassActionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purported class actions filed, pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_LossContingencyPurportedClassActionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_PutativeClassActionLawsuitIndividualNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of the number of individual putative class action lawsuit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_PutativeClassActionLawsuitIndividualNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abbv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_NiaspanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_NiaspanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_BystolicAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140563000167952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140562901526688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total net revenues</a></td>
<td class="nump">$ 14,583<span></span>
</td>
<td class="nump">$ 13,959<span></span>
</td>
<td class="nump">$ 28,121<span></span>
</td>
<td class="nump">$ 26,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abbv_OtherProductsMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">5,363<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">10,099<span></span>
</td>
<td class="nump">9,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">4,664<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">8,657<span></span>
</td>
<td class="nump">8,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Humira | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Skyrizi | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember', window );">Immunology | Rinvoq | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">2,318<span></span>
</td>
<td class="nump">2,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Imbruvica | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember', window );">Hematologic Oncology | Venclexta | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Botox Cosmetic | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Juvederm Collection | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember', window );">Aesthetics | Other Aesthetics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Botox Therapeutic | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Vraylar | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Duodopa | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Ubrelvy | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Qulipta | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember', window );">Neuroscience | Other Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Lumigan/Ganfort | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Alphagan/Combigan | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Restasis | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember', window );">Eye Care | Other Eye Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Mavyret | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Creon | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember', window );">Other Key Products | Linzess/Constella | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_HUMIRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_HUMIRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_SKYRIZIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_SKYRIZIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_RINVOQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_RINVOQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_HematologicOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_ImbruvicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_ImbruvicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_VENCLEXTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_VENCLEXTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_AestheticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_AestheticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_BotoxCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_BotoxCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_JuvedermCollectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_JuvedermCollectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherAestheticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherAestheticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_BotoxTherapeuticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_BotoxTherapeuticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_VraylarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_VraylarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_DuodopaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_DuodopaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_UbrelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_UbrelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_QuliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_QuliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_EyeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_EyeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_LumiganGanfortMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_LumiganGanfortMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_AlphaganCombiganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_AlphaganCombiganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_RestasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_RestasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_OtherEyeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_OtherEyeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_MAVYRETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_MAVYRETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_CreonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_CreonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abbv_LinzessConstellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abbv_LinzessConstellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>abbv-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abbv="http://www.abbvie.com/20220630"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exch="http://xbrl.sec.gov/exch/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abbv-20220630.xsd" xlink:type="simple"/>
    <context id="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib3edc6e25d594992851f6063814f5231_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia6d97026aba9492bbb24ab4366e9ed1b_I20220727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5695becc3594da099d28f6bd485f543_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibca39d7498d64a07bc02cb92ab8980b5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4bba3be992d1453a87a14f0fc2f2e003_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icd10bb64fb74478ca8debe7969144471_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieae5bbb2ee744272bd95a22daad94e1f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie23011746e9d454494e543e106a64681_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i331646900637403aaa44f99b19a7e033_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b62204439a646a58b785ecf93877432_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id749deebcb704c62b8d4183e0bcd069a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5349780f1cf74c438be36b3034549e8a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if5c48f78d5eb442ea02eb2415d1ad543_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia2313112557e4fc19d7b91b3581dbfc8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic21c67498e334a7c8353b31179d82f98_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i648a34fc11d2459da8234225c63c7180_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8bcf2868925d4b4c8aa4037dcd0e5af4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa3515fb6a244df8a64a70f4a299d580_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b5b734cf6ca4161852ec96132b5b371_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7fa65e7da4134abaaff3c9854cd90499_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d2e3d15040b43b680868217bfddc553_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7586872540c3447fb66b7b84c15458df_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e0c1adb73294f28ae198cc2a832474e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib43cafd566d444139ef47736b216cfb1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i63689aa1556b43cd941eb0a471e03f21_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iddd8b399923342659954704e5a03ca81_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if0fc5d280fb74f1eb96d3958d3310a50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99c4079c9e0b47618569cdc1a099cb9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c496813ec4c4dce8734e3932b3a401d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic18ec1eab6f64c5b8ad244778c1a7e89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06a455a093e74bb9ba124f24699eed85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i744bb82611c44753ad6906f397e5e897_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1816b7eac954956b4765afd462e3f73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9b644de3252423c91efecac801ba901_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17c01223096b48bebd06861e5feb9879_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i925631283eb246fca0b6016ff6e36dcd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5aa927ee5d642738ac384f97cdb27ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d7be7b002a544fc89aa3eff960ce4c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3c423a29ebb405295d44e99550f4888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i143fa36216244880b463624089eaba3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16b4a2ace56f474f9eb07fc6b9af67c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3894668cb74143f090cddbd16341590c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1b72292beef4cbf9fac74da6779e3fb_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:SyndesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i59db14e384674164aab7d20a75d7554b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JuvisePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38b7b50a66b144149f8c1287ceec7314_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JuvisePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic98df2b43008404b90c33af8edee6dd2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42d7c4579b3144d4a545b08d34ae8d8f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ied44bd1369ed4bdb88cabc67622ac9dd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia760c3d64fb74371a378c6623497a7ee_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i92651b474c794e5ca8ac957b8b9b0e59_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1717a97362f94154b97a937865fbff42_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaf29d7b949e14095835b529dec0be4b4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide6eb92d83444f61b91925e0d7f8ff5a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7107caab25d347ebaae1ee759946b263_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe6e878897e14d5ea3dc67ebfd22e441_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if1955ccecde54928aa0c73f282a2340a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d666e53ce1843c38b0611e7ba387246_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i520d59c123c940099b7566525c161f63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a1be3d4d92e4a689787ce9b5a84b41a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i17953cb362654702ad658e6a13cfb987_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i895042247e154437ae780eab2540751d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2fcaf1fd7b534884b238ec95d10826b7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i439ea03a9e384ea8baf9310fdfda9c21_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a65557623304acba06de330a83ee93d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4361107b3034a3c94e481eec57cf68a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abbv:GenentechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i32c025272d3c4c2194f440828c692e80_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifc9175130fd841a5a84a0d431d286267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98f7ec1f596843529dece3b7b59c127d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c7df08664994f12aca1518baebbe045_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic88c1ac3f5e440e784ff845b1c57c6e7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i812ac0d2871a40f1aafd158554ed5422_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fc63ba180b3456d81d30cf250f754f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i27fce41091494b70b87e4d7af3546c7d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8022aceb9c14776b862ea4d4d6d6439_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ab97e9e01f14b32910efe469af4e78e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c8d8f7d150e4296aee9bf18bd08cc12_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1a5b6a497ea346abad95173f039d362e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8eb1e9d02bf34f17b2a0eed52a00027a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0bcd977a37754942a73c727470b4f98f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9ccfe28417c469f8af551c99b927b19_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i61a05939f8244a33897e7422c89f7126_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e74bcc52335423cbc3f7f772ff0e679_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id282193bd524451fb438bb7e138e29ac_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19e30abb6a7a486f885ad340a96c5778_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb6915f306024be09472c7f5080f0fa1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6899f65d669d4afea3cd976e00ecbe6f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7e1c3dc13f54e42a2d2dc2c62ec8e91_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71d0d44f11db4eb99c11417e2743e862_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i87cf8b8c10db40639f8c71e5fa2e3818_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i37f4c1493f0542bf83279f44f2ec5342_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e06ca0731cf4d6a8f878bc559195695_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1654b4f6b905425eb698282a6331007e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i871d07741b564eae82a08aa0199ea0cd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib37c40029abd4cb58eba88c002702a40_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iceb8785d8ad7402c9c7f7eb39826f245_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7570209272a04303b295e10fbfbaa969_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d6ef1b50dd847ef8aafa94acba4e841_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b456e53d96948d096132c028d6d6d45_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaf06b1b60dd7473091c775a625e20ee8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b4df6c592544227855270f51208be85_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie235947ffd0b4fd494f966cfa005097d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib759084aea2f4496bf0b655de783f845_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cf0ce88a8a04b83934728dac91cf848_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9690c3dd790403b890e9214d1dca483_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8ca60bffa3784e57811f6fbbdf1b19bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:AllerganIntegrationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i641166a797c04452b983f67696448927_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie93c2d6ffcd9446ca4da0534ab40b4da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib96b0b1b9688402b88d483caeec8f26e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ebc83f6b36448f796534e54e707d893_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99ca5c0ed3734cb0b0a99ad300871adb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abbv:OtherRestructuringPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iae698ca482024ce3b8216d18a4baf683_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4524aeddacca4e89affea472fd4d9845_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2528382e46b44d108bf6d00b5efc76b8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i12ea8e2e6bee41e29619c4f66c42dbe3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7aa7cb14d24744b7acd20b1e031fb6b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba71512b143247428f9ba4531e9ff25d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i910af4ba6c4148dead70c8fa5c3026a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a19c3fd69054e33b86e0c727461ec6d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a04bf70fbd049c193fbd17df553937c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea76646782af496e869aa248190a44f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icadd7ee0185740f48c4b33bcf2366cfa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie930d15d61914f70acd5df79dc6f905b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i48bd044943e9493c89b9abd3d5e526a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ea75dcf12dd4babada42fe684de9583_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i50577511b38f48d9809921e16e47f00e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a4006483b344921a0461483796c88d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iae0ed5cfd5e041159ae295f44339cf2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fdb8595f8fc429f8bcbb4158edd7889_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d3b1067e45a4422969dfe03a89a0497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i315f4ccb8fbd487f8663eb19701710d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if3b21adb7b594e90b42f8a6d7c1542b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9a9fc635cec47649c6b29ca40ecc4f4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i10501d2d359c448ab6d314b187853a21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d1fd48dad064b5dbbcfd0c6de9a08b1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib7c14573e31f4f1faeb7cb5d171e2310_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i739c681a88d742ad8f180ae17ea5b87e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ebe4f90c08a4455a7f43925dbdae635_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6801e00c9ec84d40ab46635262d0eaf2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if3baae219b314a4b9cda87196725e47a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i386f36745a614aa0bfef448277833331_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i71872c61ab7c46989f11583bf3a1dabc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5156cbd23c04971a5dd83142a3d49dd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i37f9ab36c47243cb97c7b0b729b87202_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i755cc2dfdc554f1aa804588740a5c249_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i52aaa9318c7c4b838df81129cb70fa97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e16a7b014ce47f1b67466b07472b8a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i98e8e4a49ca14f008f133fdd5954827f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i709556ab9a9f465bade302574846826c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idffcc1ea976042a3b863cd853e3615c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b69cc0d9c0a4003bff5b8b142db53cb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3f3858f900834806a5d8b1b8a4ab8060_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i321bab6a8ec644378bbfac816a7f1529_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd1da7424536451694dbf819f1ad1afe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2887c0ea8ed429e81e55af1fe19ba49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d9c65ce995c41569b56cea1f111c6c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice9147234a7c47909a827383e386fa41_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i50774814001e48ec956e2b9c5f605ec5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fff8515f5964feaada59a50074f36b6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2242a34258674da88852f8da26f482ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4b9c1a3268b4e8490a003cc3c407a54_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3c18991cb0745f7bfde8bb5e68396df_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i34f3be30283c469288d3b140fb14f38f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4fa7e393d853413e8c347f6adc293a09_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2e974e271de4652b5cda15919ce55ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i60b2022fd9784fa1800afc801df52ab4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id93653ba690e49d188298eb65d621889_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7672ac59d1eb40d889784fa7661a5dff_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib8ba4ee6e978452e8a1317fb1eefa4ab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i014cf1d076d344b3a853244e7ff6f7e2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic92b470b9e9b4e9099e15d58a841ffa9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i585d1d66efc44ae9819fbf2a01450a74_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i708a87d51a194373a7ae0cfd26e60f16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1576b42347bd40ac95a968ddb28a8b73_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9466c79412984d2eb3f7d8ac357eecc5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42fdbf024af844d29c32652264e478ee_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5da9ec9481dd4073920e0859a42702c6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68ce7ad10c8f4e0e8549ad2454dcf4f4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia8cc41372ed3492cbdd0b1794bfc39fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4a5b327aee6478ca6d36a047ef148de_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ief6806c0a00d42728328e0c191cb6c46_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b17ef4e01764ead8e46800fa43600f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i48e376f561464510bf004ff1475b3177_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3967d0c84ef4ab5b092b438c43a6bb9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica001ccafca24ec1b40518c87036cbc3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i916d4573e04c4ebb82df425498689123_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38c5f2e4fd04481eb9c96733c3ab6282_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b6d1c3a9b9b43ed888b26722a1ef814_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i81835d73a8d24f9fbf352588b381f229_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib14b54f083414973b49fd17c21639430_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e90fc724a5a42e48ee6a1d195f84ab8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0ada3a46921346fd865f1babab324aeb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5306df8c08e44da98c277f0e759fd1ae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia0873fa6f786493d98f649f5b8df8913_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idc6789fba1c748ce81e02fec0c7a1680_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i374e011a12484720b013a8ebf2f11a07_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia351d42f430a4ed8b308f667517d9671_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5fb37261f9244543bd3e42841c253c3d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i870123ed29d24decb0df38ca4b783ed5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4de815be0be44e778d9f2b95394472e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i55b79104cfa54b9abca4b24b661bea9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b5a23680db6467891252a20dcb977d8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5130a9a2788493194f69310dd5fb80a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0856d184c09c4cb990892955581e79dc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idac4c3858d334f249fad7fb813cec175_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i18eaf40a654b457087ccb29d6d1bec0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7eae17c36c184345887eaf72ceb217e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cb9b6002b78431987a6b16d086053e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d3593e90c734bc2a603ee6d35d961d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48db75cf5be84dcebf25c3be860e8891_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa8175f7411740adaed89dd39b020a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5da0605afd0403a91a86f6fc2935d5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ad384a1ae084ceb824d660b0d1c00c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06facb13108b44fdb65aac8490d55d79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebba20d42aa84545b03550839e4d1ff6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i06c67c0260e9410f924a9a9f01b3ccc6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie0f761535955494a9972245ac0bfc828_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i50f71d020d2441aead5e84026b2c81c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2acaa96ed3e4d86ba6f80df2d1d23bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314e59ebff154934a9005087b9a2e107_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie09bf75182a24ca78e3c58dda4a972f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9667464bea64d7bad769b8345f8228a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie0bd307199034ef2b862a230a13fa5ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaed7fba9444e4475a8d1d1fe03296f36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i618ae073cb994907a536ff425fc537bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if01319674f9d40b28d7f32e4d0729277_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforUnachievedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2fb100f05394ac080c865b058757667_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0db82b411f6d44028dadc73a81fbddce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8e7e2cafe6f4f15bc1374d8dcb0e6b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3f97658421c74a6883a23a2e06b3ea74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9facac76db04d889e4a084485f7e2e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbc5716897864f0c9cc862e142a2ef79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcb4215fa5f64baaaaf01df3d5b4e8c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iae0da0e73d4249789bbdb7acc456ca25_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i939b4297b7084062a87e128f885293a2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if2e05916e33146c8ae338e992f86d223_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb38cc669ce545e9bfccb54b2b798037_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i889c9bd592d04c6ebb6f06b0687977ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProjectedYearofPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic282be83b0124b8e836b6f16a56eda8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb1927254a0845d7a42c9414c93e995c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i286cd5a8d73f41ecbe7fec3a2ee10763_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i876bd774408e4212b518335222b57f15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6cba587881ea4be1a6fcd26255e217ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i630843de12c0427290cca6b9829cfc34_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibaef6f99af86488d838a3ce30fbf6f87_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9692678e8ae94f98873e8e482dbe735a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia83a0493fb014bfb876176f16f9cb06e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd887f1676e449bba91f5fac45a6b160_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0e5774a49944c5ab537c8ac3146f7c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i641a3f2e695f488cb5096a3ed75f5c70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i986059b4f35d4a8daa2894ea55ad12ea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i599b7447e0804132a06303bb0b4a837b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abbv:PrincipalUSCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32d41cc6c1144c0eb773b14b0f419c16_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9583131a11e44e7aa0e4827ce3a411c0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i8e9e7fa9be3843a7a5bf54dd5d8ac7a9_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.450PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ibf34cf7670534dd3897946050fdaea95_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i704e3023cf64424fb2e548f19872b22b_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="idd94ae07eaed40088bbf3d7cfc1781e6_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i6a0fa7a03c79447e8db8a5d601b5fc8c_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDue2022At3.250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ia77710e9c10447af9cd57b70a76e9850_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotes2.30PercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ieb78cb6f6ae44cb296ba20fe69d1e6a2_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotes2.30PercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i9c46c9af7913451184bb8271e2852db1_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorEuroNotesDue2021At0.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i2610045aa69e4030bc8c18d427b52b41_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorEuroNotesDue2021At0.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ie0483da2eaea4022985712c39ea59d19_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abbv:SeniorNotesDueInMay2021AtFloatingRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i70516d291c55477c878b4b846af7180a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide690142a55247c6a2b03d88e336f404_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c4a5e696cef44729310622ff60e2500_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i80b10bd565e94cdbad34d4b699a9c302_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f8541a3fbd04b4aa7b0c71db6c67624_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcd274134e874c458ac8bb198e697455_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie39ddc4d4f8b4a60ae8112fec8a02ca0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i215a3d4557c14afebf2687d536e46e9b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84cd19c9ee4e484da629710856ae0ec6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4aeffb4bf7740e693e0cf853abfe9cc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i87c76652aba54b3cb73c859bfcc92d58_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i73323fc2811c4815be8a6fa8d6f92ebf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic74c227e50b7440cb0bf2fe1f16077a8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf3113d83c8f491b941990950d5919dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iebba8edab23541ff89c8b58adf3e8a76_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ca53a8519264b5a8bf940cc274a106a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abbv:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29287228cbed45f6968865ac190732da_D20220623-20220623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="i2ea99297cee64545990d63d337e0bd15_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="ic1a2a526c6f543e48795a4f1d12639ad_D20220217-20220217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="iac1d6f16dc8f42568eb8061858ff99c8_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="ibb37ae95313d475593909c6970fed474_D20210617-20210617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="i82eba66f65734def83204d704d5b47ea_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">abbv:December2018StockRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22b5f6d04f0a4544845c676987a1eeed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cd460fb97a943bea7eab54ac965aa60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icce33acdbe974160ad9b3dfc07ae39d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia710a25cb0c047998dd58eb85bc213f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae61288e27a24ce39bded79de1bf4095_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7f81fb701254285a4a206a18828b567_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ed8396560c44007a9c95309d6d3a6a2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib73a09f43445463abe6438c2b68a40d0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie041d69136f64b3a8a27ad04a132c273_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ec6491fd6214350bcd0866f550aa297_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia05002d950604d46a192beaa49081fc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35fed5ff539e43798107045d15730636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i403c50879b1c4e05a4a20ace89fd4c22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d626d0838c74271a9d49423686e77f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0e42ad98a314ebeb3aade819088d66a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if950e8b5b2df42df96087980787dec24_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7698dc329628476c963cdee26aa2812e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3822e99b0a044b3bb3488101e174bb2d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i995a19a6da744643b9b86cc7f1216901_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic97760527e754306a1191c6bc2573b87_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3a4d976678cf4540afbc6dc51554a787_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idbb0ed41b4e649d2a7d806f7497e41a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i32d84e38a2994c878bdc69755243817d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ccb01751b304c18af28a34833388cf8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic191f46d7d8e4caba4afd72c543fbcd4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3853f87f21c434890d33f2f2b77b72c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5bfb160d4b1643648262fd6a0eaae478_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3b9ff182e8741859555b210dca9a32b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i02110886faa542a89965a36d12b1be28_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic4767839908e4c3c981b0e75e52a508d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie51ac81d02ae4bb4bb4b631a36857242_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic48cb26fc77245da81fea6fc298e2334_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i608d6972b6ff4f3d8c222972b983496e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1eb4fc0c623c4f1ea81b83cb3bdba9ac_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43c0a79aa3464c16a02968bd63694f55_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia174e4331257480796e6106ea2a76cce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:NiaspanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icfa3a17240a84a5fb4378a6e0964580e_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i7334ba57c4e449f59500bd93a416fe9f_D20190301-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="if3a36967092e4074bf4a78063e79132b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:BystolicAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie8cb2800eae14237a93a3936c9e32a27_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i48ac34a8b8274cc9af2a8d06028995a6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1e04db914dad47f5b3d445d36e86ac46_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65d8e2a0e62b4729b3abeb9e927196d9_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="id7c685b4419c4e248155b129a874cf5a_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="id76475932981417e8c60761ee84327e0_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abbv:ElliottAssociatesL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ib1e751a39abb44d69bf6dde5f62f5da1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib18bfd7270ee4f79a082b091a1d91241_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cc2260464184105897c45f4f42c8c13_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8cf34e3dc9a54da193a3b587af7498e0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3665d816d7a49f7b2a2c250380955e0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id772f9666c5c4b569bff7bcce7ec09b4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2789587e0039409e85ee53a0e676e039_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70a7736453da40babfdf09cafbc6d8d7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaab62c95758e45988052a829d4196a90_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7dea9d6f70d4ec98a1e472f35d5c5e7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecc046d2283c4b17b9218d96bfe9f744_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i85dd0c7934dc4d97bade1ff5347b0cbb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:HUMIRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i613d7817d5e44951867e1c6db534f048_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3925d88e2c564017be693e4f33dc9fef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4fab7cbaef51414aaaf8cf3add2b35cf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5bb12764f7504661af49974aecf799fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i691d9600e9b043098e5c276598fee110_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i48a4b28633f342598240cdb0c3efa237_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i560e85f5cfab4fc3ac49d453b66f47fc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i768c6e087bc94398bcebcdec93f187ee_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d6c8a9d73f14855aeed15aaa74afcff_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia2b51a1c66954d9aaa0187e550ad0413_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9ea89bc103144a5958d2f2a66fe8098_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2a8bd49f99be462b96189ff1b51b483f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:SKYRIZIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i874093c1c0ae4f308272c783ac24326f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4e6208b6b4f4a0388ca9ada2c7cc625_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3fd758e6d37b4bc59135caf3c0de84d6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d868053bd8748d3bf614376fe813cb8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i26c02e7957b24efd9ccb2368a2201c6e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4f955f09f26347a4b61f9e1d792d9c52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4a3befe2196456aa7304c27b18e62b0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1c352b7e3b4a46d4ac9b0c8ae253c346_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iacefee9559c84a7f8fe1b97854abae81_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2cf6107ac310458ca74734c319137631_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4786d948d133499db74a085616fa1875_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4d29d5d87b2d4ba492379977f9b5ab22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RINVOQMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a916779feaf471db9c3dd44f2d0f9e4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i636fc0eccf124d9a800dd95dc70ad820_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c2b0f551bc049d6abd5b17ecbfd5a7c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i436d40cfe964413fbcbf9f712fc800e0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc0416b6fe5a4a28ad14a534ffeaf36c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94c20efa76564198871cbde27c4f3770_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76a3090d63854077932361ea0cda6045_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8046e68b530144f7bb14542e2e179616_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a43659878c5400aadd92c3684016238_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifcc5e412e1f94776bc76d6999c9445a6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a45a226af5241fa94c7236e40243ed4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id67c8e799778495794ae8022dd02b919_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:ImbruvicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if90678a4b1d64aa5a5d8b7d3d0f183f9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2ac78ef5437840d1851a7bb8a12f61ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i25b338d203ed4ed48104fb83314e02d9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c74555cc18a4bc1bd636f5aab45af28_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb374613bd8a41a8bf753c1018b7cb7c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i017973a311a149579a6e2d7f0bf65764_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84118bab402a49e5b84833a66c174d12_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21226e99e14c4ddbac60ef91e89cc530_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1dbbf979d6cd4eccb6057977d03291df_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iae072cee9e51472198a5efde9ab867c3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if64aebd25af841f1b7229554bc01f412_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5f15191fe14b4cfa89c7a4ae3911fe49_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VENCLEXTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:HematologicOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94c81ab58c08424a9e69f6265e734d0f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0605eac069cf4d81b845fd844cb58c8a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6eafd7ccb9f4f629d0ad43895286c38_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4567b8412c0f40aca0ba3ae7d82676bb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iccdc471eaf3645a69aa7fd3af900fa42_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i86af501659bb429a93b12bc11b5044ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34627b0f80bc47d4b2ee036c078502fa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if389f2dd00e545d28d559a5e75ab3f64_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic865d7480948423580adca162837e77c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id886288666fb48ccb61718e61df34b35_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94cddde0247f443b9b340a36d7ca29a0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9cbb654aee284bde985e29ed2a417187_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxCosmeticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e9b4bcd3c344d4caa8accace369889c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e6f7a1a1f1d4823b6772df289977ce9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9240ee581cc94c809d2e9975585d0e32_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38e9f078ec864353b22c3fdd238993cb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e70fb16dfd04148a41903925eb90981_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i85a3b9cd19a14173a8c66d72c61e2b31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07be0755a0ce42f09fbc795069473e02_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib2de83259a6941d8bd633aabc6f46bc0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i275a2f367c8e496799ea036748f953a9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id42a239b714e4f67893f359965c39442_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69c169ef01f945ee87a73716291f5111_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2ee77d1be804cf485a2836eb7067c67_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:JuvedermCollectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd3df4a45fab4f4c9278ca1bfce58738_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i75d432d522a94fed8847f371bc5981f2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84165bbb1f1347e897f9eab39bb8ea94_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1efa50552eb2412c8ac12c30f21c490f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07b03fece4c047a99bd000932229b9de_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea32020dfa4649129801589297294e8d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idaffe79a5455443aa04784d34e6c64ba_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idb2fecdd608d4d54b39f0ea275388289_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4e6ceaa8895481db504ab1693ffb3fa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i67ad21c8d5d444f39b0047d67697123f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ffaa78a8e1142b288e6e354c460254c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9128c44b088f4cab95566ad9edc2a8ee_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherAestheticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:AestheticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i37d523156e124aa2ab5e04ddb64884bf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice7f58287b6145d5a6823247454ddc45_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieaf6ab07195a4cca93acbe6ceb203e73_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8df2818c56ef42baaa8eb76d1b384c0f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i638a5ee6ee4c42fca17c06b8857fb5c6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1065d539abeb4072b769ab2d71e8944b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i04d1768636d746b4bab2547e1b9c9ce1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i67f61f08f40d4da3a4256963bc6f1384_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd8781577e0c4483a640bac78e68df6e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5f260375e939438fb809d92be390d888_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia3461140986e4666a08f4efef9f1b613_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07dc2f0df2044b08beb63c5086eb5739_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:BotoxTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1888ed0d9b0e438c8de2757d768f23f6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3305a5ca26ca4e7ea948f6a5cb50efa8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5cab0be8af14785bd28c582835b0cc4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaeefd3642f924fffbc846fad74fdad8c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:VraylarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e881c96a7684c80b5f00b2c241ce2ca_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9cf09146bec940c49881c105e2fde2a5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i061d2a55e7174d83b68a055cd5e369b1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i451984d626294d03858200463c69ceb7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc95ef169d984d27b48f3e697f6f4d3d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04dcb0e5c7634daa8fd3b1024c048528_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3628e0cef99d4acc818a521eb8fa79fd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2a341dab3c8b46f780c38988862e144d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d827902a8b74349b77862bc1ae1fe1d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7877be381ff54eeebefba91654c5bec8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d561bc963364eb3b42dc2bb43967bfc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05c9d7c0c1954f4a827422d7ddb71e44_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:DuodopaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib009e9f4ccbc4aabb0abf813ff1b9b9d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic91980ca8bba425dbf5ec17c1e6c8260_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66976616df8f45e4a0233eabd261afb9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5efcdbc4d1cf44e6b7ae58e964d94349_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:UbrelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i63415011c3e645908f7ec388df1bb966_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58a378f983e24296878b4a51a9ce87bc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3650cb2a09d0454bb935da1c661555e1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id488c5c2f38b4d9c87b2dd5a3c14dd52_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:QuliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f0aa8affc324889ba63c424cf09ade4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11d3ccb3b6564bcab939ffb027584e3c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8319fb8317f64500af0908643ad0632a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i486d629919554591943fc705452e1ffd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i910a16d51cdf46e69ab2f11998279fce_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac5ee0b393444da28b3de9ccb5848abc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e1c2e9044134fb283858ebe2b7015a4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1efe769f8be14215a0a43d2955581c8b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie341a38ca0504923bb7a4212d96ae509_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0338fe30ecfb43c2bb594866b36d0c38_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8baf06e41cac46ca890ff77bbde002de_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if334fd6f6ced463191edffdfc673820e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae918b7a7fec4e0f884db97d43014c3d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6361dbeea1084098930ecf34e1a2cd74_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie802121280734295adc561cdb0a46110_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e1d8a4f5a10492bb4bd12e2b4c064e8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia37fe742fa0946ea9ef53a300a8b5681_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i082bdbf7ba954da5b6a638b5ff634bd0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5d2dc14539945b28da637cec2804a59_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i065d8379e1cc41b4ad8f7251eaeeb1c2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78b0f0ce20724b90a4f7647bb9a8ef1a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iccd74e66f1b04b9ea3d575b51adf1c05_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaed7b5a1ebea48f093da2b0ff29eb4b7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id123036947d949b3b27454b60e9bb03d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LumiganGanfortMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06cad72124104e83a37813c7ca4d58bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b70cb0e5c7147579fa25e09acbf6291_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79667b913ce74f5dbebec3fe976825ff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i76d10096f8a24fccb83511987f26c69a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d2d4201e5e747079eb77993bb61fba3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i711eb0534e014c01be59768e65562deb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibec21debfbe341cdad1aac7ebf721a99_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad19468cf9d346b28980e07a20d6f5db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i15fbf82d23f3402dacdf01e8cf69b44a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3f1716e275a0412aa55aeb45b7eb6c31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf40dd1d09234507952e167d1479045e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3682c7c9fc8d4e37870dd6d2a55fffa6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:AlphaganCombiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83a5fbce24694e669e94f977e23e2355_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia2c7d12ad2714a6ea184eada5e3b70a0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dea495dc74647a89c9c075bf46494aa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib1a900fadd404c10ad147fafe8f4deb4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28b4ab1ba4784671a896ead7cb8313b0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8173b604f62e4076a3617362c1136935_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05e86aea9a594dbeb0b923716d380818_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83ae3512f1eb4610aca3449ed15dd8d1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if1412de7cca3427fa94e528b2abb50ea_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i201933aab6584d7ca5b8dbf08dbbac04_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifedaedd5de554534991638c4456c25b3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i17b9bd9ac4d044d5860a53c8b0380a1e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:RestasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d9e048450024856b06b4e78059095d1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iacd1758c8b804a44b870604e3de47893_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a3067379f7643989c5c6a9f5aa57e51_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i29b1aa17325b4c23ac4029b80c3b95d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i959da824f08a41469fcef4982237f0ad_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa9ca253be174199be0d0235e1eb2f23_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i335cd00f529e4f93912c67b5c142472f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic8a7e51d8bb049719a805c96ee4e3371_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i904652ab5bb343df953e359f58983c26_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f642aa7c52d4beca6b8434dd4031490_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0dc83404ae74a8097d23417e7af22df_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53336e17dd6a40f1990e05073d8317b5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherEyeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:EyeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9aeae0c651354131b671fc904166fb25_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04e57842484a485991d62e03a01d8e38_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i158d06c961ab4b84ac67732c15bd9b13_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id16f064354b64f688d1bff104fcffb76_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24fc70faba5c40f2b7c77bb2f65b318d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i51a52d243b364ceebafddad56040e1d4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b345afd17164d7d917c60019900d02c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7baadf51bd904370a6d282562978b306_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9ba200322b8f4fcb86619a36931e9175_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i88385ff780be4c28851e5dde7a7375aa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3842eb65438141e288a8210b375b0e59_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia67b59d6f5054f0f9504c3b750eb3e0f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:MAVYRETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb25c770cdcd4b8a84b4d8984b516ea3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7846dcf271946ef9f581063d57b1d32_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1be1c9ae69774509942fb2c801e8e0b4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5411bdc1d3b46c5a26a274c0c49de78_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:CreonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0fe1ad8786cd4ec9b518879507cdeefc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43669c40e73a46afb5e6f704a10e6d1e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9a8730959ce4f028d5538a29f222423_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id215663e03264d678a32b5af7a72e4d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd1f55c4f4fa4a0f87dd08291588f95f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18902dc3bd7b4eb2bf8e70464f318c7d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f331549442e46038a09afa23765f532_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia689063c9a8d4f47ad065d4cd5c51cce_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a165da7515149dc9f2231f0452f276b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5aa0784d769c47b1b61138f07a799e92_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b632bb7a6f44b95a3ba9242b438a9b1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib35991f95fd64801a6f989d5186073d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:LinzessConstellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abbv:KeyProductPortfolioAxis">abbv:OtherKeyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i676449a933204a9cb64a6f54570b2d60_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc8f4a95cb1b4c99b4bb5f312cef5b00_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5611e12d1194636a4cdc0e36968dd1a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibbe1892fc3014e6b8f3d56ee7c617da9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abbv:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="wholesaler">
        <measure>abbv:wholesaler</measure>
    </unit>
    <unit id="lawsuit">
        <measure>abbv:lawsuit</measure>
    </unit>
    <unit id="class_action">
        <measure>abbv:class_action</measure>
    </unit>
    <unit id="direct_purchaser">
        <measure>abbv:direct_purchaser</measure>
    </unit>
    <unit id="end_payor_purchaser">
        <measure>abbv:end_payor_purchaser</measure>
    </unit>
    <unit id="company">
        <measure>abbv:company</measure>
    </unit>
    <unit id="claim">
        <measure>abbv:claim</measure>
    </unit>
    <unit id="investment_fund">
        <measure>abbv:investment_fund</measure>
    </unit>
    <unit id="segment">
        <measure>abbv:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8xLTEtMS0xLTk3NjE2_8dfc04f4-30a1-4f1e-80ea-57afc8d8bca4">0001551152</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8yLTEtMS0xLTk3NjE2_5b248bfa-f1e4-409a-8ab8-2b2b0a2b827e">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl8zLTEtMS0xLTk3NjE2_95bd13fa-26cf-4cbd-9eea-b91d4df8f60c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl80LTEtMS0xLTk3NjE2_a9d447b6-a64b-407f-ae82-14467625c236">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80L2ZyYWc6OTQzMjEwNmRlMDNkNDNhYzk5ODlhNmFkNzEyOTZkODYvdGFibGU6MTMyMTA1YThiNGVmNGE5NmE4NjM3NTNmNzJlMTNmY2YvdGFibGVyYW5nZToxMzIxMDVhOGI0ZWY0YTk2YTg2Mzc1M2Y3MmUxM2ZjZl81LTEtMS0xLTk3NjE2_836b28e1-6bdf-4a08-9a23-0d15f419a12d">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xMDAvZnJhZzpiMTBlYzkxZmU4MTU0YTAyODQ1YzdhN2FiNDFiYjBlMS90YWJsZTpkMmQzZmYyZGMxMjA0ZDU3YjZhZTYyMDkxNTlmZDkzZC90YWJsZXJhbmdlOmQyZDNmZjJkYzEyMDRkNTdiNmFlNjIwOTE1OWZkOTNkXzEtMS0xLTEtOTc2MTY_602ac02c-1c11-436b-b4b4-155ff770bb7f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQw_8ee58896-be3b-4ce0-995a-e170d5da672d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQy_5e4e8e40-3a91-43c0-aa40-143d9de4d424">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMjU_48a6f8bb-8aeb-4cbb-8687-6197891a03b8">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ2_475d6fd3-6518-4123-81b3-71a6b627e415">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQx_365d7218-b037-49c2-afe3-e5d33a4af12c">001-35565</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQz_1b9804e9-4151-4798-9b27-56ba8a8219a1">AbbVie Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6ZjU5YzNiZTNhNjc3NGZhZGFmMTg3YzU4OWJjNzI4ZjUvdGFibGVyYW5nZTpmNTljM2JlM2E2Nzc0ZmFkYWYxODdjNTg5YmM3MjhmNV8xLTAtMS0xLTk3NjE2_3c27e32b-13c7-475a-a797-92175ceb04aa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6ZjU5YzNiZTNhNjc3NGZhZGFmMTg3YzU4OWJjNzI4ZjUvdGFibGVyYW5nZTpmNTljM2JlM2E2Nzc0ZmFkYWYxODdjNTg5YmM3MjhmNV8xLTItMS0xLTk3NjE2_63b79131-af62-4eaa-8a77-004ddb489bb8">32-0375147</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ3_7b4fd2c6-e1e9-4b63-99ec-29b7d97e59be">1 North Waukegan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ4_d9ee3f26-de06-47f1-a7c9-3eeb043fcdf6">North Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ0_9a08bffe-fb53-4678-934e-2b2599810e22">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUx_63d4f2cd-d26b-4be0-8779-5fc811732fd2">60064-6400</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ1_727715cd-a582-4d67-baee-93cc1a49ea34">847</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUy_72c46a82-61a7-47c0-b5c2-9e00a44f4a82">932-7900</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTUz_f8159a4b-994f-4a72-a635-b5a6f1f47a75">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTQ5_fabec1f8-b4a2-4092-b02f-bc6d37f4a8cf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8wLTAtMS0xLTk3NjE2_f19e2410-485c-45f3-bc6a-1a0e93627f53">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8xLTMtMS0xLTk3NjE2_84ae3fd4-de03-4d99-835e-2680a2076708">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NDcyZTVmN2JhZTcwNDRhMTk2ODM1M2Q0MWY3YmNjMDkvdGFibGVyYW5nZTo0NzJlNWY3YmFlNzA0NGExOTY4MzUzZDQxZjdiY2MwOV8yLTMtMS0xLTk3NjE2_06ceb342-5876-44b7-9f39-ad0d4fd5a742">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMTU1_0cbe4a47-9155-412f-8c32-025adc38cc9d">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTAtMS0xLTk3NjE2_b410f95f-b6a9-403a-b8f1-edc0ba445f75">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTAtMS0xLTk3NjE2_e53544c0-dabe-4796-86db-0730081d46cc">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTItMS0xLTk3NjE2_18aaa252-be8d-4a50-85d2-43969ea6d15c">ABBV</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTItMS0xLTk3NjE2_4249663c-09b3-45b9-b815-58f0c6fd567f">ABBV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia55af04cdf7d42c486e6593e0bfaa687_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xLTQtMS0xLTk3NjE2_d94f28a2-40b6-4bca-ae4f-f4eebc713d1f">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="id8bdf24ed6cf43238ba15aac9495c436_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8yLTQtMS0xLTk3NjE2_b7d792c9-e0f3-466e-a31c-2f634797e640">CHX</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTAtMS0xLTk3NjE2_f26d19fe-eb79-4839-8ef2-55cb7aa4da2e">1.500% Senior Notes due 2023</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTItMS0xLTk3NjE2_845cac4d-bba3-44a2-91db-28ae3fafc3dc">ABBV23B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib4d9dc7efa13452590b1c96f50fdc4ba_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8zLTQtMS0xLTk3NjE2_2a5fd6eb-3777-4a9f-a0c1-7faff89278fd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTAtMS0xLTk3NjE2_d3b0e1d5-f8e0-4f98-a15d-55ce65d5d961">1.375% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTItMS0xLTk3NjE2_0a4757f2-ff55-4ebd-9490-753131671e6c">ABBV24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib70ae72f577b4e0389d365303fad05f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF80LTQtMS0xLTk3NjE2_7722e382-1405-46e8-9dca-1ae8b8daf6d8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTAtMS0xLTk3NjE2_eb41bd48-57f6-4c8f-8714-9f94bc93c057">1.250% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTItMS0xLTk3NjE2_70e207f9-ef4b-46ea-a696-8c110fe82db0">ABBV24B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1cf5a920a9024f6bafd823f2d925ded0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF81LTQtMS0xLTk3NjE2_2c1fb0b0-ce6a-4682-aa2b-a875140f09f9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTAtMS0xLTk3NjE2_f250438c-7b9e-4552-92c4-95f0301db2d8">0.750% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTItMS0xLTk3NjE2_04b09a87-a028-4455-a17a-f8b69483ac46">ABBV27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib3edc6e25d594992851f6063814f5231_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF82LTQtMS0xLTk3NjE2_1641a08b-2f4b-45a4-9caa-d0a231a66768">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTAtMS0xLTk3NjE2_f2e08425-247d-43b4-aeee-1c05534e54fb">2.125% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTItMS0xLTk3NjE2_34a499fd-0d40-4ee9-abe7-35af1bc798c5">ABBV28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iec0750e073274955bf7b54c3f8d492be_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF83LTQtMS0xLTk3NjE2_98ddacc4-88d3-4f86-810c-42cdb467f918">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTAtMS0xLTk3NjE2_94625e7e-5cb8-41eb-a1f6-a3133e1ca925">2.625% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTItMS0xLTk3NjE2_01907a3b-93ea-4ebf-b428-3a8352637594">ABBV28B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i65602cc7042d4ccdb5cb1a1ffd9c1f05_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF84LTQtMS0xLTk3NjE2_e14432e9-8143-4fc4-b7b6-a062d5d95436">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTAtMS0xLTk3NjE2_cccfb16a-d684-4d33-b220-fe98f48f8bf7">2.125% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTItMS0xLTk3NjE2_965ea73b-1eb1-4d66-a9cf-6503d6a12614">ABBV29</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifa429b2ad3a143d6b769a639c9f7b88d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF85LTQtMS0xLTk3NjE2_837642c5-65fb-4f56-9389-a53b13ec7b9d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC0wLTEtMS05NzYxNg_dbde003b-58cf-4bb2-bfa4-6b26b613a726">1.250% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC0yLTEtMS05NzYxNg_eaccf544-b997-4bd9-b2c4-c88d578f698f">ABBV31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i90a7d89283b94ae6a724ccacdd639c4e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGFibGU6NGI1MDI3MzI1MjVkNDkxZWJiNzI1ZDEwMDgxNDcyNTQvdGFibGVyYW5nZTo0YjUwMjczMjUyNWQ0OTFlYmI3MjVkMTAwODE0NzI1NF8xMC00LTEtMS05NzYxNg_f3429f4b-5ac7-42a9-a671-7ebee15885ed">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia6d97026aba9492bbb24ab4366e9ed1b_I20220727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xL2ZyYWc6NmQyYjRmZWMwOWIyNDgzN2JlNjlmNGEzOThmMTIwOGQvdGV4dHJlZ2lvbjo2ZDJiNGZlYzA5YjI0ODM3YmU2OWY0YTM5OGYxMjA4ZF8yMDgy_9e3d691b-499e-4bfd-8a9d-bced3e79c9fe"
      unitRef="shares">1768096495</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi0yLTEtMS05NzYxNg_a2039004-9895-4ba8-8a71-26661928514f"
      unitRef="usd">14583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi00LTEtMS05NzYxNg_e13538a6-b329-465c-be93-362d6ea1c1e0"
      unitRef="usd">13959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi02LTEtMS05NzYxNg_a56d15d6-ace8-4cee-8932-ddefbbbf4a28"
      unitRef="usd">28121000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMi04LTEtMS05NzYxNg_006cc40b-9a32-442c-8f55-72a3e4c4a2b7"
      unitRef="usd">26969000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC0yLTEtMS05NzYxNg_aad12718-7181-4a26-992a-7790802966cc"
      unitRef="usd">4170000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC00LTEtMS05NzYxNg_04e1a54d-6346-4f2f-928b-64eeeb67f7d6"
      unitRef="usd">4523000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC02LTEtMS05NzYxNg_3bac7f8c-c638-47f3-a512-0d117cc75d0d"
      unitRef="usd">8222000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNC04LTEtMS05NzYxNg_5584c7a4-46f8-4378-bbb6-accf9dc77277"
      unitRef="usd">8736000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS0yLTEtMS05NzYxNg_9bb716cd-f27e-40ab-ad35-e9d0075e99c1"
      unitRef="usd">5412000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS00LTEtMS05NzYxNg_66009fdb-7fb4-40b0-89d9-afd300d28106"
      unitRef="usd">3164000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS02LTEtMS05NzYxNg_dc32c5fa-cd71-46f9-b153-1e1026234bb9"
      unitRef="usd">8539000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNS04LTEtMS05NzYxNg_f3e50927-cd83-4733-ac80-8185a9f0ab69"
      unitRef="usd">6006000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi0yLTEtMS05NzYxNg_5d35c895-768d-446f-b563-984269c6f51a"
      unitRef="usd">1609000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi00LTEtMS05NzYxNg_4ba467c8-2659-4556-8ad0-2fac599d70a4"
      unitRef="usd">1767000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi02LTEtMS05NzYxNg_b92480bc-9f9e-4dbe-8c92-8ee4508c8a46"
      unitRef="usd">3106000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNi04LTEtMS05NzYxNg_e5f8e273-afbe-4be7-88c1-1d5efac394c2"
      unitRef="usd">3434000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy0yLTEtMS05NzYxNg_7b3fe2f3-9332-4df0-b224-d8effebee342"
      unitRef="usd">269000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy00LTEtMS05NzYxNg_b4fac5b3-0177-4563-acb0-f17555a1a161"
      unitRef="usd">132000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy02LTEtMS05NzYxNg_785e14e2-489d-44b7-8c73-90a1cd92df65"
      unitRef="usd">414000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfNy04LTEtMS05NzYxNg_0a1319e8-8a88-47ef-8e44-fbbc606d4e42"
      unitRef="usd">317000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC0yLTEtMS05NzYxNg_2706abe8-7966-4efd-beca-3e4e7b78df65"
      unitRef="usd">172000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC00LTEtMS05NzYxNg_75b5f5c7-7497-4f90-9a8f-380f0fc96258"
      unitRef="usd">68000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC02LTEtMS05NzYxNg_7e32c9af-ddc7-4447-a171-8820b88060f3"
      unitRef="usd">172000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOC04LTEtMS05NzYxNg_fdf21a76-84a3-4873-964d-60d7c4175cdb"
      unitRef="usd">68000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS0yLTEtMS05NzYxNg_6cab7ca9-d5e3-45d3-b284-348b44c5b134"
      unitRef="usd">11288000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS00LTEtMS05NzYxNg_56842ce7-3300-4047-9031-7a2d28a1cba9"
      unitRef="usd">9518000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS02LTEtMS05NzYxNg_6fb3be44-5313-45a3-9192-2f859fc747ed"
      unitRef="usd">20109000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfOS04LTEtMS05NzYxNg_ab396aaa-9996-4d31-a53c-ec5ccd708357"
      unitRef="usd">18425000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtMi0xLTEtOTc2MTY_61b77116-86a4-40bb-be04-90423711f4a1"
      unitRef="usd">3295000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtNC0xLTEtOTc2MTY_5ddc635b-3bdd-4bb1-bb80-e366f7e87a38"
      unitRef="usd">4441000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtNi0xLTEtOTc2MTY_c9436d98-aac0-4fe1-9ea3-6e7f7fc3d3a2"
      unitRef="usd">8012000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTAtOC0xLTEtOTc2MTY_4234a520-b591-45e6-a4bd-41597dd74756"
      unitRef="usd">8544000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItMi0xLTEtOTc2MTY_e0ad69b5-2ad4-436b-9928-14afe7bf83af"
      unitRef="usd">-532000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItNC0xLTEtOTc2MTY_6e2457a1-5de7-4d95-b689-23a41905101e"
      unitRef="usd">-606000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItNi0xLTEtOTc2MTY_2f2b4b15-af46-4ade-8fc0-99194d1678db"
      unitRef="usd">-1071000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTItOC0xLTEtOTc2MTY_139a4ff5-a827-4a18-a940-040db425cf6b"
      unitRef="usd">-1228000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtMi0xLTEtOTc2MTY_d7d7427f-a2e9-4307-91a7-f50a10775ef6"
      unitRef="usd">-47000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtNC0xLTEtOTc2MTY_7f450690-4a10-4ceb-8dca-be30dd0783c0"
      unitRef="usd">-14000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtNi0xLTEtOTc2MTY_2d622c5b-cbd4-4428-814a-4f04cf035b97"
      unitRef="usd">-72000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTMtOC0xLTEtOTc2MTY_5b21ef16-d619-420d-9923-98359ecb22f3"
      unitRef="usd">-23000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtMi0xLTEtOTc2MTY_55e5c11c-70c4-4df5-ab85-1da6dc4e98d7"
      unitRef="usd">-1533000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtNC0xLTEtOTc2MTY_118cae42-6454-49b0-ba96-38deea6ab3e0"
      unitRef="usd">-2658000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtNi0xLTEtOTc2MTY_4d88bb8f-34bf-4d0e-a456-6cd5e5d940d0"
      unitRef="usd">-757000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTQtOC0xLTEtOTc2MTY_e4058584-cf15-46f8-b495-f4a134eba81d"
      unitRef="usd">-2263000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtMi0xLTEtOTc2MTY_dc34bc9e-c56b-4101-a6c2-87e7836857f2"
      unitRef="usd">1183000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtNC0xLTEtOTc2MTY_a8140558-3d4b-4c27-807a-1530cfce7026"
      unitRef="usd">1163000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtNi0xLTEtOTc2MTY_f4d411ee-a994-4b30-950c-4b5b5197cd3f"
      unitRef="usd">6112000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTUtOC0xLTEtOTc2MTY_5179109e-bf40-4f59-b679-66bd65040bc3"
      unitRef="usd">5030000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtMi0xLTEtOTc2MTY_bf418c32-75a3-42bb-bda9-8e2264bda994"
      unitRef="usd">255000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtNC0xLTEtOTc2MTY_2ac7796f-89c0-4cc1-bb76-cb08475dbff5"
      unitRef="usd">394000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtNi0xLTEtOTc2MTY_fe8dee4a-e663-4c6d-ab2d-9fb69088f42a"
      unitRef="usd">691000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTYtOC0xLTEtOTc2MTY_f2929141-3eb5-4ab4-a681-d851b7cea5dc"
      unitRef="usd">706000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctMi0xLTEtOTc2MTY_88281ca0-b770-4bc1-b6d3-704213300e11"
      unitRef="usd">928000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctNC0xLTEtOTc2MTY_bf929520-6cc8-4b52-962c-d4c46b3062f6"
      unitRef="usd">769000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctNi0xLTEtOTc2MTY_f4cacc32-05f5-4b2e-8e3d-acbb86218d2c"
      unitRef="usd">5421000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTctOC0xLTEtOTc2MTY_14524416-9beb-4066-8147-07bb5076e5c3"
      unitRef="usd">4324000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtMi0xLTEtOTc2MTY_00438504-9f1b-4125-876a-e8407e1bb358"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtNC0xLTEtOTc2MTY_573563f9-b9e9-4860-bdce-499efdbc13a0"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtNi0xLTEtOTc2MTY_698e4db4-c409-42ad-b3f4-5a6792e949ee"
      unitRef="usd">7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTgtOC0xLTEtOTc2MTY_48fc3c98-433a-422b-9a68-debfe07ef587"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktMi0xLTEtOTc2MTY_9ade95b0-1b8f-49fe-84ea-11f8bacfae97"
      unitRef="usd">924000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktNC0xLTEtOTc2MTY_fb9de274-2297-4d87-9539-27e8082f7db9"
      unitRef="usd">766000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktNi0xLTEtOTc2MTY_4c9fc1a0-7938-448a-9759-25a85c00cbe9"
      unitRef="usd">5414000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMTktOC0xLTEtOTc2MTY_599519a5-c281-445c-b89a-acc43b77293c"
      unitRef="usd">4319000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItMi0xLTEtOTc2MTY_bf05e2fb-9067-4e2c-ac99-500ed150d1ed"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItNC0xLTEtOTc2MTY_18d7c75b-03a7-4bd6-b313-334bfc41234a"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItNi0xLTEtOTc2MTY_d9b495ed-bff8-461e-bd56-9e3bbd056fd5"
      unitRef="usdPerShare">3.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjItOC0xLTEtOTc2MTY_af62ea5e-a4ff-4508-ad6e-45829f580763"
      unitRef="usdPerShare">2.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtMi0xLTEtOTc2MTY_3589b5ef-a2ad-4d05-affc-2dccad326316"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtNC0xLTEtOTc2MTY_79719a07-c2e4-43fc-b517-700a2d6ae81b"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtNi0xLTEtOTc2MTY_621a6f86-63d5-4d65-9f2f-a20871638b7a"
      unitRef="usdPerShare">3.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjMtOC0xLTEtOTc2MTY_44ec63b2-eda8-4ea5-a5a1-2bac18a1b7e3"
      unitRef="usdPerShare">2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtMi0xLTEtOTc2MTY_03aa0070-ad88-45a0-8cbb-c3850f9c1225"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtNC0xLTEtOTc2MTY_ff4b3114-9865-4d33-b17f-deadd2c4bcec"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtNi0xLTEtOTc2MTY_ba22ac09-4fe5-4b54-bf6c-3cb57bc3f385"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjUtOC0xLTEtOTc2MTY_cb96d079-9b3d-4ff3-b8f5-7656e39e10ce"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtMi0xLTEtOTc2MTY_bdef9785-4f6c-430e-a35d-b4ef8cb7a94d"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtNC0xLTEtOTc2MTY_7bfd76d9-3175-4633-8687-ea70a778a210"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtNi0xLTEtOTc2MTY_72fd12d9-daf9-4788-8642-be5499bdc998"
      unitRef="shares">1777000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xNi9mcmFnOmFlMjg2YmE4OTUwMTQxMGNhY2UyYzRmZjU5MTcwMTViL3RhYmxlOjIxNWNiZjcyNWI4ZjQ4NDI4OGIxNWMzMzY4ZWQyYzEwL3RhYmxlcmFuZ2U6MjE1Y2JmNzI1YjhmNDg0Mjg4YjE1YzMzNjhlZDJjMTBfMjYtOC0xLTEtOTc2MTY_7c3cdfc3-514b-4a6f-9738-06632cc95f5c"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi0xLTEtMS05NzYxNg_6360e1d8-8447-4e72-a1ae-b3a31dae40cc"
      unitRef="usd">928000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi0zLTEtMS05NzYxNg_78ea868f-3f5e-4503-9ed0-8ba87534f448"
      unitRef="usd">769000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi01LTEtMS05NzYxNg_bc340364-dcab-4f55-93a7-5236da2697fe"
      unitRef="usd">5421000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMi03LTEtMS05NzYxNg_bb06d16c-7e3e-4f4e-b0f6-ab5d7e99c5d4"
      unitRef="usd">4324000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzE2NDkyNjc0NDE4NDM_9683602c-28bf-4723-9354-0fd0bb92d188"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzc5_aff4dafb-b4d8-4960-bffa-74f46e31f63f"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzIxOTkwMjMyNTU3NDI_0684b794-fc30-4a9a-9d8d-49b8b50c8698"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg3NjVkNzUxOGY5MjRlNjViMTRkNmE2NGExODk3MjQwXzk3_c0ff6c4a-621c-434f-9471-8e14939b9dd1"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0xLTEtMS05NzYxNg_94314b1d-1676-4e78-a8fb-6d163d72699f"
      unitRef="usd">-823000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC0zLTEtMS05NzYxNg_301726b5-5640-4748-b1cd-517e7c2301ba"
      unitRef="usd">244000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC01LTEtMS05NzYxNg_dc466c1e-23a1-4a4b-8c23-09eac7a0f979"
      unitRef="usd">-1054000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNC03LTEtMS05NzYxNg_40025649-4832-48d5-b382-4eb3068902c9"
      unitRef="usd">-433000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5XzIxOTkwMjMyNTU3MzE_a58044c6-ff8f-4c5e-a261-94a64c9d29cf"
      unitRef="usd">146000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5Xzcx_1ccd4986-f4ae-47e0-b2ab-24bc9b1aff94"
      unitRef="usd">183000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5XzIxOTkwMjMyNTU3MjQ_650afba6-9cb2-4eba-bee6-9c50c9d6d086"
      unitRef="usd">-31000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyZTJmY2RjZDJmOTRhNDJiZDcyNjRlYjkyNTdhYzA5Xzg5_b7b74176-bdef-4cd5-ada1-23165e3fbce6"
      unitRef="usd">72000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0xLTEtMS05NzYxNg_c8fd878d-5859-4e3d-a59b-f4501038f499"
      unitRef="usd">536000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS0zLTEtMS05NzYxNg_b802e493-30e7-4a54-8d6a-c1f9108a11b4"
      unitRef="usd">-114000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS01LTEtMS05NzYxNg_7cfed901-5605-4edc-a044-a57fee2c1481"
      unitRef="usd">666000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNS03LTEtMS05NzYxNg_e4eb11d8-75d4-4e40-be92-cd858983ca7a"
      unitRef="usd">260000000</abbv:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1XzIxOTkwMjMyNTU3MjM_d8c3508a-b1c2-4e90-b6a2-306d6c8edc0d"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1Xzc0_fde2a83e-b1a6-4ab3-88dc-6a07009fcdfe"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1XzIxOTkwMjMyNTU3MzU_6bd7ee17-8181-41f6-be3d-a74545b142d5"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOjY2YjVkYzBkMzYyNTQyMzM5ODI1YjllMDUxNDI0YmI1Xzky_cc23a128-bae1-4483-9e7a-b957e1151f82"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0xLTEtMS05NzYxNg_2464ac7c-6a6b-4fca-a847-6b4ae4227afd"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi0zLTEtMS05NzYxNg_30263cfa-6fdb-48a5-ae03-29b8f6633a34"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi01LTEtMS05NzYxNg_312910f9-5e87-483d-a357-35513c594e84"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfNi03LTEtMS05NzYxNg_22330252-793d-4150-ad07-3393bb84124d"
      unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzIxOTkwMjMyNTU3MTU_bb460af0-d0f4-46da-8ffb-b34e9d2a0dbf"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzY2_2542d6e3-40ec-4019-9844-77c3b14c8c54"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzIxOTkwMjMyNTU3MjI_26b170fd-d21b-4af4-b4bb-c79379fe1edd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0wLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQzYmIyYTFmNmJmNDRhYzVhYmZmNDUyZjgxNzg0M2ViXzg0_b29f7731-03f6-42c5-8f8d-1766332e8bd7"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0xLTEtMS05NzYxNg_2762cfd0-ac24-4729-b604-08502bbe9ac9"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC0zLTEtMS05NzYxNg_d09595c9-e709-469d-89dd-01ae9038440c"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC01LTEtMS05NzYxNg_0b3ca9ab-f7fc-4a91-90d4-47e830d7cdee"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOC03LTEtMS05NzYxNg_310abab3-5995-46a0-bf6f-b6a1812bfade"
      unitRef="usd">58000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS0xLTEtMS05NzYxNg_228c6d1e-1569-449f-9315-2e66e610c45c"
      unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS0zLTEtMS05NzYxNg_150fd686-7a0d-428a-883c-a343a617258c"
      unitRef="usd">192000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS01LTEtMS05NzYxNg_65b013ea-6fb4-4214-a2f5-88dcdd91ba8b"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfOS03LTEtMS05NzYxNg_df24e683-c9cc-4143-9f48-95c2591b6cdf"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtMS0xLTEtOTc2MTY_0e7bce97-1e99-4129-8efb-14188198f2db"
      unitRef="usd">716000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtMy0xLTEtOTc2MTY_33eee592-cdc9-45ad-aec0-4448bfc8d413"
      unitRef="usd">961000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtNS0xLTEtOTc2MTY_202d7324-3953-4da5-9898-925f0ba55576"
      unitRef="usd">5124000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTAtNy0xLTEtOTc2MTY_c29b7a75-cd9c-477a-96af-f0405cb445d5"
      unitRef="usd">4338000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtMS0xLTEtOTc2MTY_bc5f79c5-5dbc-4603-945a-d18d6374ba30"
      unitRef="usd">4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtMy0xLTEtOTc2MTY_98a27352-000d-453e-acda-df81b545c856"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtNS0xLTEtOTc2MTY_f390e436-c9f9-424e-b51e-e6cc74dfe315"
      unitRef="usd">7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTEtNy0xLTEtOTc2MTY_afc27ed5-9d97-499e-8a3c-75b50336a761"
      unitRef="usd">5000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItMS0xLTEtOTc2MTY_6d120320-1c59-4ce0-8799-f937e682f66e"
      unitRef="usd">712000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItMy0xLTEtOTc2MTY_ee30185a-6596-4414-9168-2d21bba86985"
      unitRef="usd">958000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItNS0xLTEtOTc2MTY_330fe575-2e8c-4094-aa04-ec06df137480"
      unitRef="usd">5117000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8xOS9mcmFnOmRkNzk0MTk4ZGJlNTQxMzRhMzBlYzE0ZDU0YWUxYTIxL3RhYmxlOjY3N2IyM2Y1MGI1OTRhZjRhNjYyYjYyNjJhMTBhYjc3L3RhYmxlcmFuZ2U6Njc3YjIzZjUwYjU5NGFmNGE2NjJiNjI2MmExMGFiNzdfMTItNy0xLTEtOTc2MTY_1e33e671-600f-436f-bd17-79e0f3e857de"
      unitRef="usd">4333000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNC0xLTEtMS05NzYxNg_a07f98db-cbd7-4415-bd19-c45b67e1691a"
      unitRef="usd">8521000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNC0zLTEtMS05NzYxNg_bc186d6b-3548-4df6-a8ec-1fc72dbf6a60"
      unitRef="usd">9746000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNS0xLTEtMS05NzYxNg_3d8fef27-f8b6-4372-ada0-beff0b69f7d0"
      unitRef="usd">1440000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNS0zLTEtMS05NzYxNg_19df8528-75a3-4651-83c3-d3fb995806b2"
      unitRef="usd">84000000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNi0xLTEtMS05NzYxNg_0cf2c294-c6d0-4efc-9421-19b5740ebf81"
      unitRef="usd">11237000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNi0zLTEtMS05NzYxNg_68d3e698-66da-4eb2-8949-f0b49dc7c31e"
      unitRef="usd">9977000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNy0xLTEtMS05NzYxNg_ef6031b4-f2ed-4760-a4c7-a9d11ed708b0"
      unitRef="usd">3396000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNy0zLTEtMS05NzYxNg_f6bea658-a445-400a-9021-df3c3e2d24e9"
      unitRef="usd">3128000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOC0xLTEtMS05NzYxNg_240d239e-9094-46f9-8498-8ef87483f3ba"
      unitRef="usd">4506000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOC0zLTEtMS05NzYxNg_707e8a86-919e-4d69-a89a-6a90cb984572"
      unitRef="usd">4993000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOS0xLTEtMS05NzYxNg_db37f34d-631c-452e-b206-696aa2ff390d"
      unitRef="usd">29100000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfOS0zLTEtMS05NzYxNg_dce48b95-987d-4ef2-b0e7-39c1bceefcc1"
      unitRef="usd">27928000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTEtMS0xLTEtOTc2MTY_a4fdfb44-8584-4dce-9d63-4745ab060d59"
      unitRef="usd">244000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTEtMy0xLTEtOTc2MTY_0d22ae6f-f15b-43c0-84d8-1f331b13edc5"
      unitRef="usd">277000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTItMS0xLTEtOTc2MTY_1bb6a2e0-fe82-4aed-ac51-84c915101af9"
      unitRef="usd">4958000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTItMy0xLTEtOTc2MTY_94a1cf21-8e0a-41e6-b7ac-41bda81e33f7"
      unitRef="usd">5110000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTMtMS0xLTEtOTc2MTY_377d33cc-df70-400d-bb86-354e17350502"
      unitRef="usd">71823000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTMtMy0xLTEtOTc2MTY_6d306640-c1de-4480-a7c9-c5a32e8f6ac9"
      unitRef="usd">75951000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTQtMS0xLTEtOTc2MTY_8a989df1-7d43-4b31-9241-0e82cbbc8fa9"
      unitRef="usd">32028000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTQtMy0xLTEtOTc2MTY_1449c5e0-cc9d-410b-be47-72cf8d3a2ea9"
      unitRef="usd">32379000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTUtMS0xLTEtOTc2MTY_898c5757-e29f-499d-97e9-f1d48b1d6dad"
      unitRef="usd">5033000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTUtMy0xLTEtOTc2MTY_f88d7473-4c14-4323-a5c5-d3cc3a36a15c"
      unitRef="usd">4884000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTYtMS0xLTEtOTc2MTY_a269e77d-c4a1-43a2-b12f-cc6062c3e375"
      unitRef="usd">143186000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMTYtMy0xLTEtOTc2MTY_402d31e8-36ea-4dbe-84ce-786f684f1655"
      unitRef="usd">146529000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjAtMS0xLTEtOTc2MTY_d2fd64c1-6faf-4640-bd7f-e49fbe6c10aa"
      unitRef="usd">17000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjAtMy0xLTEtOTc2MTY_36a9e02d-0ad5-41c4-b2a2-6548046172c4"
      unitRef="usd">14000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjEtMS0xLTEtOTc2MTY_da8041fb-f3d1-4b1d-98db-11f7edb8bb38"
      unitRef="usd">11913000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjEtMy0xLTEtOTc2MTY_e86efddd-a997-487a-b3e0-c4660fa29808"
      unitRef="usd">12481000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjItMS0xLTEtOTc2MTY_e920c2c7-1ad7-4c7a-ab4f-b9ca0bf931a1"
      unitRef="usd">22543000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjItMy0xLTEtOTc2MTY_aef76514-c38b-43f9-bed2-8ddf4fa4f12a"
      unitRef="usd">22699000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjMtMS0xLTEtOTc2MTY_8d52b450-1fc4-4c16-be8a-45186cf81b07"
      unitRef="usd">34473000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjMtMy0xLTEtOTc2MTY_6cd43a8d-fbf7-4e01-a085-273ddadb63f3"
      unitRef="usd">35194000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjUtMS0xLTEtOTc2MTY_0a2e1286-2bdc-4e2b-89a7-f573d2a61a4b"
      unitRef="usd">61002000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjUtMy0xLTEtOTc2MTY_7e987439-8be3-49c7-a7f1-aefb6377db9a"
      unitRef="usd">64189000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjYtMS0xLTEtOTc2MTY_74397eb3-d99a-4c8d-a109-6b10e9cd2575"
      unitRef="usd">2255000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjYtMy0xLTEtOTc2MTY_39329da7-4592-44e7-9282-e3fde8bc651a"
      unitRef="usd">3009000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjctMS0xLTEtOTc2MTY_aaa20c64-fdb7-4d97-b9be-0a897aa866fc"
      unitRef="usd">30768000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjctMy0xLTEtOTc2MTY_bc4e4f92-cd3a-4db5-a1d6-7fd709cdbeb7"
      unitRef="usd">28701000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjktMS0xLTEtOTc2MTY_c97acb6a-a452-47d1-8caf-2c426e4bb4bc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMjktMy0xLTEtOTc2MTY_bf9cafd2-22b8-4b61-9ba0-0cae60e2563d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8xOA_4eccd90d-f724-4e8c-b490-36221d72f991"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8xOA_d5ffd944-285c-4da1-b43f-ed19696fc128"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8zMg_456dc0c9-07b9-49b4-a6da-b0bc67047fee"
      unitRef="shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV8zMg_6bd1a1c8-2108-436f-98f2-2dc770058bf9"
      unitRef="shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV81NA_76bf0d42-4a74-491f-b0f3-ced873f8394e"
      unitRef="shares">1812622099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjowY2YxMTRiYTc3NjY0Njg2OGFmNjRmODMxYTI3ZmM5ZV84NA_0c945b07-b17c-4b32-a3a2-ed594aa536eb"
      unitRef="shares">1803195293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMS0xLTEtOTc2MTY_b34801c3-0c21-46b6-b1de-348363ba0bc8"
      unitRef="usd">18000000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzItMy0xLTEtOTc2MTY_4047dc69-f476-428a-8b41-a84aebd5ca1a"
      unitRef="usd">18000000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjpmZmE3N2RiNzk3YmY0ZjFiODkwYjk2NTM4MTc2YjI1OF80NA_d366f1c7-345e-46f7-a088-2f352308b4df"
      unitRef="shares">44595448</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMC0xLTEtOTc2MTYvdGV4dHJlZ2lvbjpmZmE3N2RiNzk3YmY0ZjFiODkwYjk2NTM4MTc2YjI1OF82Nw_2afa48b9-bfb1-480e-b3b8-adc2dfa56f4b"
      unitRef="shares">34857597</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMS0xLTEtOTc2MTY_0fb40ed7-676a-4d7f-9626-5badd8d0f449"
      unitRef="usd">4591000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzMtMy0xLTEtOTc2MTY_f20edd9a-02d8-498f-b0a3-1b0564f562ce"
      unitRef="usd">3143000000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzQtMS0xLTEtOTc2MTY_54ecaa99-d120-4fc7-9a71-13d16d820707"
      unitRef="usd">18906000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzQtMy0xLTEtOTc2MTY_9632d0fe-44d4-48b4-990f-919a82589e34"
      unitRef="usd">18305000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzUtMS0xLTEtOTc2MTY_c3187b0f-f308-4ff6-8f6d-ea9782c05517"
      unitRef="usd">3516000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzUtMy0xLTEtOTc2MTY_75755daf-9119-45eb-9085-af74e8cba16d"
      unitRef="usd">3127000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzYtMS0xLTEtOTc2MTY_14abd861-f690-4de0-a96f-a1f10da44363"
      unitRef="usd">-3196000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzYtMy0xLTEtOTc2MTY_853fd458-8003-46c0-a475-761a5500e76f"
      unitRef="usd">-2899000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzctMS0xLTEtOTc2MTY_6cbdfeca-9faf-4c69-a1e7-c8ccd6ab2694"
      unitRef="usd">14653000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzctMy0xLTEtOTc2MTY_9be714dd-cd41-4940-920d-375d725a5912"
      unitRef="usd">15408000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzgtMS0xLTEtOTc2MTY_d8d82e2c-799a-4dfc-b406-8235e268ec88"
      unitRef="usd">35000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzgtMy0xLTEtOTc2MTY_500adf41-392a-4958-9244-76d12977fa8a"
      unitRef="usd">28000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzktMS0xLTEtOTc2MTY_6c1be6ba-6a36-4483-a646-3987038531c3"
      unitRef="usd">14688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfMzktMy0xLTEtOTc2MTY_a0a546b3-cc4b-48e3-8869-5c07eaaad0a9"
      unitRef="usd">15436000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNDEtMS0xLTEtOTc2MTY_a042e605-711f-4fae-aef3-036fa1208485"
      unitRef="usd">143186000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yNS9mcmFnOjkzZmFkNDQ0MDdlMDRlNzI5NTg1MzU3NGRiYTM1ZDVkL3RhYmxlOjM2NzUyZDQ0OTgyZjQ5OTU4OTc4NjdiOTk3ZGYxZGI0L3RhYmxlcmFuZ2U6MzY3NTJkNDQ5ODJmNDk5NTg5Nzg2N2I5OTdkZjFkYjRfNDEtMy0xLTEtOTc2MTY_a23c1095-285d-4204-9283-5995a5133589"
      unitRef="usd">146529000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xLTEtMS05NzYxNg_c4fdbc32-7ef3-488a-85c6-4473a89c3bc3"
      unitRef="shares">1766000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib04a50b9f3f7472b87073a71d2b25fcf_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0zLTEtMS05NzYxNg_e6f10908-a2d2-48fb-bbee-112ae0cb33cf"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibca39d7498d64a07bc02cb92ab8980b5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS01LTEtMS05NzYxNg_1b5f7a5b-c5fd-4d1c-8741-24db5625c394"
      unitRef="usd">-3017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bba3be992d1453a87a14f0fc2f2e003_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS03LTEtMS05NzYxNg_68c286eb-355e-40bc-8dd2-bb720d673658"
      unitRef="usd">17712000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd10bb64fb74478ca8debe7969144471_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS05LTEtMS05NzYxNg_1e19c4f9-8ae0-4c1a-8298-622569cdf752"
      unitRef="usd">2292000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieae5bbb2ee744272bd95a22daad94e1f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xMS0xLTEtOTc2MTY_377f90ff-89a4-4374-8f54-9e86668c52a6"
      unitRef="usd">-3295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie23011746e9d454494e543e106a64681_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xMy0xLTEtOTc2MTY_53d3eaf1-d839-479b-be24-786e5498eab6"
      unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i331646900637403aaa44f99b19a7e033_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMS0xNS0xLTEtOTc2MTY_1deb814b-061c-4b81-b638-4b75d9f910d2"
      unitRef="usd">13733000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0zLTEtMS05NzYxNg_0c90b226-6e87-47de-8a66-564cda567e2f"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy01LTEtMS05NzYxNg_89bee6bd-e11e-4134-b208-6503cca294e7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy03LTEtMS05NzYxNg_0ea73bb9-c0f5-459a-bfff-4a905675aaed"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy05LTEtMS05NzYxNg_1a25280f-4d2d-4d20-9b80-b34b0ebaef15"
      unitRef="usd">766000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xMS0xLTEtOTc2MTY_87431fa4-32f1-4541-a7ea-82ea750c666f"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xMy0xLTEtOTc2MTY_1e7c9446-c62c-4483-8292-73dd811d1c7b"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMy0xNS0xLTEtOTc2MTY_afb7a8d4-2ad7-4077-a1a2-0cd30b1008eb"
      unitRef="usd">766000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0zLTEtMS05NzYxNg_33da4a28-9c01-474a-9607-914d747b5e96"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC01LTEtMS05NzYxNg_ae1c6368-3281-4fca-addd-54d0e28a7b6a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC03LTEtMS05NzYxNg_58c1977c-785a-4af8-a67f-5baf7564f5b5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC05LTEtMS05NzYxNg_ea633a62-5dae-4b21-9542-cd936be1129d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xMS0xLTEtOTc2MTY_3a77a409-eb09-472e-9dea-ac78d698f6e5"
      unitRef="usd">192000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xMy0xLTEtOTc2MTY_a8545dbb-4a4d-4ce5-881b-182aea15c388"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNC0xNS0xLTEtOTc2MTY_21f40824-48e4-4173-a352-64d2a4d0b17e"
      unitRef="usd">192000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0zLTEtMS05NzYxNg_3a48fd7f-6bb5-4e2c-8564-2b8ca3ff3826"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS01LTEtMS05NzYxNg_37b28c0b-d686-4397-ace8-2f5af77c8bec"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS03LTEtMS05NzYxNg_3d66d13f-b183-4efc-8b10-7b9a3d75c9d8"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS05LTEtMS05NzYxNg_8c80bc5c-1ed9-4296-81db-f6f822cfaf19"
      unitRef="usd">2318000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xMS0xLTEtOTc2MTY_282c538f-0f24-441c-8085-3de081205be0"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xMy0xLTEtOTc2MTY_ad5ab9fc-757c-4f0a-ad5e-80bd0fd120bc"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNS0xNS0xLTEtOTc2MTY_89927f6b-af91-4190-81d7-a05d01ba3ffa"
      unitRef="usd">2318000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xLTEtMS05NzYxNg_bcad14ec-ebe8-4ed1-8c18-db8a7363012c"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0zLTEtMS05NzYxNg_1cdaefd0-809c-4e43-95d8-d71a73c13748"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy01LTEtMS05NzYxNg_3b521210-86a1-49e8-a253-906a5e201fbf"
      unitRef="usd">10000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy03LTEtMS05NzYxNg_876222c3-2b99-47fd-8139-440507ccd8cf"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy05LTEtMS05NzYxNg_97ae8233-3fd6-4b07-9463-7149e0d0fd70"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xMS0xLTEtOTc2MTY_ebd236e1-a573-4fb9-a1f8-efad7b27a80e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xMy0xLTEtOTc2MTY_2da43918-6fe5-4245-8a3e-e05e490e200e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNy0xNS0xLTEtOTc2MTY_da31fb92-4746-4bd2-ac6a-49775041891a"
      unitRef="usd">10000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xLTEtMS05NzYxNg_18d57812-0634-43d1-8308-88b214c967fd"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0zLTEtMS05NzYxNg_1bfa3a48-f5a6-44ce-908e-786b7c468e7c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC01LTEtMS05NzYxNg_19627792-5411-4c90-b2f2-68fc92b5dd1e"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC03LTEtMS05NzYxNg_b771e8fc-510f-41b2-ae86-88e0de0bbc9c"
      unitRef="usd">224000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC05LTEtMS05NzYxNg_108009a9-94e0-46b8-8ea8-5140493b505a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xMS0xLTEtOTc2MTY_f4e065e3-33ea-4800-95a0-eebae60669ee"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xMy0xLTEtOTc2MTY_9e735159-af8a-44f8-a3b8-9a2a9092ca57"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOC0xNS0xLTEtOTc2MTY_2ceaf008-5d2c-4efa-942a-e91b0d8a9235"
      unitRef="usd">229000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ic4d6ca2cc7f64c069719df653ec28320_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0zLTEtMS05NzYxNg_70f997b1-360a-4569-8088-cf11bfaf6e5f"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i33c2da93ab00421c9e4c19c78563a448_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS01LTEtMS05NzYxNg_2fbd6ef4-3ab4-44cf-8f9b-777e4314968e"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ib0a54edfe70447a2bbf8c58ae7e6b9ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS03LTEtMS05NzYxNg_945cc086-7f79-4752-b14d-104ac3b8bbfc"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i5fd70a8075c3441ab222145bdbfa4d56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS05LTEtMS05NzYxNg_bd7e184e-831c-47c3-a1b4-a13217f98297"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="idd722bacdd3641538c632f514a2a40aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xMS0xLTEtOTc2MTY_34d89e8f-2dd0-49c3-94b8-894fad600e79"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ib9614e49d09e4960b6a1e32ca29eba26_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xMy0xLTEtOTc2MTY_53585c43-966f-49d4-87e6-12cea94f193f"
      unitRef="usd">2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfOS0xNS0xLTEtOTc2MTY_beafbd63-bdb9-47b7-ac88-d6df4e3788ff"
      unitRef="usd">2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i0b62204439a646a58b785ecf93877432_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMS0xLTEtOTc2MTY_b214bc21-7633-48df-9394-885247062d54"
      unitRef="shares">1767000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b62204439a646a58b785ecf93877432_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMy0xLTEtOTc2MTY_a0cb9926-82a6-487f-be65-07aa4dcdc918"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id749deebcb704c62b8d4183e0bcd069a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtNS0xLTEtOTc2MTY_ef869c52-602d-433d-8063-4d76065bb7ee"
      unitRef="usd">-3022000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5349780f1cf74c438be36b3034549e8a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtNy0xLTEtOTc2MTY_fd94d4f8-3bad-4520-8c4f-779675799080"
      unitRef="usd">17936000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5c48f78d5eb442ea02eb2415d1ad543_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtOS0xLTEtOTc2MTY_67a852d3-4e59-4a34-8a1f-104122b22c9f"
      unitRef="usd">740000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTEtMS0xLTk3NjE2_42f01f4a-ce1c-4b09-bea1-afa6ccf9833d"
      unitRef="usd">-3103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2313112557e4fc19d7b91b3581dbfc8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTMtMS0xLTk3NjE2_1259dfe8-9d24-46bd-bced-2c6896233a9d"
      unitRef="usd">25000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTAtMTUtMS0xLTk3NjE2_02352a79-8b6f-48ae-a3b9-b9b4603e1870"
      unitRef="usd">12594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMS0xLTEtOTc2MTY_9b22fdf6-3fb3-4dbc-a002-7c042431fa17"
      unitRef="shares">1767000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cae5f3b4e3544c9ad8af6d7421c6c58_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMy0xLTEtOTc2MTY_0ad86031-53ea-4cd6-a74b-25117d60c1e7"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i648a34fc11d2459da8234225c63c7180_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItNS0xLTEtOTc2MTY_f82a04ef-f13b-4707-a7ab-422966490565"
      unitRef="usd">-4585000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bcf2868925d4b4c8aa4037dcd0e5af4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItNy0xLTEtOTc2MTY_c8b00378-9c24-4450-a24a-8f2303104ef7"
      unitRef="usd">18731000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa3515fb6a244df8a64a70f4a299d580_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItOS0xLTEtOTc2MTY_f5c5818b-42ed-4f2f-a2ba-fbbc1e95cb8e"
      unitRef="usd">5103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b5b734cf6ca4161852ec96132b5b371_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTEtMS0xLTk3NjE2_bd3e9503-8c7d-4819-9457-55035d6e4a00"
      unitRef="usd">-2984000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fa65e7da4134abaaff3c9854cd90499_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTMtMS0xLTk3NjE2_9927151b-ed3f-4cf9-9750-81b9c5087c19"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d2e3d15040b43b680868217bfddc553_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTItMTUtMS0xLTk3NjE2_a69b014e-b868-4763-ac71-6eba7eee84c1"
      unitRef="usd">16314000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMy0xLTEtOTc2MTY_4796efbd-f6ce-4a88-a04a-318dc8303619"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtNS0xLTEtOTc2MTY_035f234a-8c84-4d0c-b5ba-be75d68d12a0"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtNy0xLTEtOTc2MTY_5bcb54d4-d8f3-4c0a-bf1f-0ee9bca7f382"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtOS0xLTEtOTc2MTY_267b7b22-3ad3-4ab8-824e-ba8794bfc08d"
      unitRef="usd">924000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTEtMS0xLTk3NjE2_96f367ec-6d2a-4833-b156-6a6f9655d8b7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTMtMS0xLTk3NjE2_a4f42ed0-6195-480c-80c1-fb34884b76fd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTQtMTUtMS0xLTk3NjE2_91c422b1-ef9a-4289-b0f5-5321b0362e6e"
      unitRef="usd">924000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMy0xLTEtOTc2MTY_7c0d1c11-fadd-4735-9684-0d0a5fa988c9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtNS0xLTEtOTc2MTY_73f1ad5c-b56b-49ac-b93e-b934a0e47d69"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtNy0xLTEtOTc2MTY_b2146763-c763-4902-81f3-6be212e44eec"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtOS0xLTEtOTc2MTY_f4012be2-d163-4d90-964d-6d4a9702bc5c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTEtMS0xLTk3NjE2_d5412bc4-69ca-41c0-8419-beee6b21e93f"
      unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTMtMS0xLTk3NjE2_1d29ad05-4016-4040-98e8-0a6e71e5ff3d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTUtMTUtMS0xLTk3NjE2_578aa314-1b1d-4c91-a943-0857de22474f"
      unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMy0xLTEtOTc2MTY_76956736-d191-4303-8350-2b5c138b046d"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtNS0xLTEtOTc2MTY_9fbf52a5-7bd6-4e5a-8295-87749fefb066"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtNy0xLTEtOTc2MTY_d3bcd14d-7741-451e-973c-a3c1ea5f3712"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtOS0xLTEtOTc2MTY_24c63317-0237-4dbb-9a24-c81d7220f8b6"
      unitRef="usd">2511000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTEtMS0xLTk3NjE2_f4f6ca33-2be4-4bbe-b892-cd960a930c1d"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTMtMS0xLTk3NjE2_87923900-b0dc-4c97-984f-04fce265c1e9"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTYtMTUtMS0xLTk3NjE2_96def73a-9dec-48ae-b803-2ec06317a89e"
      unitRef="usd">2511000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMS0xLTEtOTc2MTY_8e3a2770-dd64-473f-9d21-8a27ad3ba6ef"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMy0xLTEtOTc2MTY_a6e94521-312f-41af-85ad-afcc59912d87"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtNS0xLTEtOTc2MTY_86b0070c-553a-4f87-bdba-3aad8009787f"
      unitRef="usd">9000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtNy0xLTEtOTc2MTY_8f858355-e5d3-4fa2-a06c-6b7a3dbe8e9f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtOS0xLTEtOTc2MTY_7587af19-9da8-45a4-a80d-2b9c5e150de4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTEtMS0xLTk3NjE2_1080ded2-d469-4930-9434-58f5caa6967a"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTMtMS0xLTk3NjE2_0e2dc666-d110-4974-91cd-b437a636c124"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTgtMTUtMS0xLTk3NjE2_ee888579-5265-4052-80de-c672d1194387"
      unitRef="usd">9000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMS0xLTEtOTc2MTY_fbcd7144-6bf6-4ba8-93df-f5946080c8a7"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMy0xLTEtOTc2MTY_242e0bbc-5c22-4c78-b58a-331e067d9d0e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktNS0xLTEtOTc2MTY_f0aad404-96f4-4c50-a94a-2c5ffbae57b9"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktNy0xLTEtOTc2MTY_f4410d30-a655-4e4b-a40f-3bac792e4489"
      unitRef="usd">175000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktOS0xLTEtOTc2MTY_63e8b516-a9c2-470e-8fc7-953713e7ee78"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTEtMS0xLTk3NjE2_14b3e324-5788-401b-860b-19d16e1fb07f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTMtMS0xLTk3NjE2_e97cec4c-57bc-400c-a7d2-8c3772197bf7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMTktMTUtMS0xLTk3NjE2_a2c38341-79ee-4af5-8f57-bc600f030de9"
      unitRef="usd">178000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ifdf19a4b23244e10ad876e67d11a736e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMy0xLTEtOTc2MTY_63ae7d55-c5da-41ce-9fdb-2946c987ff38"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i3632a802676c4ec5b675b7def0b098fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtNS0xLTEtOTc2MTY_56f6fd09-5ce0-4d02-8f1d-8d65ca1a96ec"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i16d9e7205b0b4c22907c1fb088496243_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtNy0xLTEtOTc2MTY_eaf30898-f679-42e3-be8d-3f48686feab8"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i9252795fe7fa4f5993fe3dc975bae597_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtOS0xLTEtOTc2MTY_2a4a0bcb-ea4e-4a32-bd1c-1bd2fa1ceb00"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="iea31c8cae1fd41628a1b1a848c8630ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTEtMS0xLTk3NjE2_b3b0e830-56e8-493b-8df4-beeda180073b"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i7586872540c3447fb66b7b84c15458df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTMtMS0xLTk3NjE2_d144aaab-cb86-4dfd-83ea-a3d9502b4da7"
      unitRef="usd">4000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjAtMTUtMS0xLTk3NjE2_90f4bda1-b072-428e-a4a2-bc74d4ebbd9a"
      unitRef="usd">4000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMS0xLTEtOTc2MTY_d5e0d195-a74d-4b39-a86d-0169686471b3"
      unitRef="shares">1768000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMy0xLTEtOTc2MTY_f35cfa6c-9733-4de0-b106-ee98bb9df013"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib43cafd566d444139ef47736b216cfb1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtNS0xLTEtOTc2MTY_f4424ac3-3617-414e-ac0e-6ed21654dae6"
      unitRef="usd">-4591000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63689aa1556b43cd941eb0a471e03f21_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtNy0xLTEtOTc2MTY_11f88f4f-13db-400c-8b1b-5a3d55c62974"
      unitRef="usd">18906000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddd8b399923342659954704e5a03ca81_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtOS0xLTEtOTc2MTY_8613d92b-ab03-40b6-9e3e-10079255f220"
      unitRef="usd">3516000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTEtMS0xLTk3NjE2_d454fd4e-f476-40c6-8199-f938956f4c19"
      unitRef="usd">-3196000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTMtMS0xLTk3NjE2_e3c40fa8-b3a9-4464-9e38-f73c4039703c"
      unitRef="usd">35000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjEtMTUtMS0xLTk3NjE2_87a8711d-a215-4225-8407-3263dd3c4de1"
      unitRef="usd">14688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="if0fc5d280fb74f1eb96d3958d3310a50_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMS0xLTEtOTc2MTY_a22a92a1-89bd-487c-8447-726c61c4116c"
      unitRef="shares">1765000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0fc5d280fb74f1eb96d3958d3310a50_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMy0xLTEtOTc2MTY_efccc113-4c67-47e2-a82f-26c1e02bf822"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99c4079c9e0b47618569cdc1a099cb9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtNS0xLTEtOTc2MTY_15c20cd9-a732-40af-a0f4-08b04ad188f0"
      unitRef="usd">-2264000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c496813ec4c4dce8734e3932b3a401d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtNy0xLTEtOTc2MTY_b5bfa79b-0b0a-4749-bff3-56e2ac7846a8"
      unitRef="usd">17384000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic18ec1eab6f64c5b8ad244778c1a7e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtOS0xLTEtOTc2MTY_daf99927-8422-477c-909a-7485c73f2a65"
      unitRef="usd">1055000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06a455a093e74bb9ba124f24699eed85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTEtMS0xLTk3NjE2_2c85c8c3-3820-4d9c-aa19-ef0586bb37c1"
      unitRef="usd">-3117000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i744bb82611c44753ad6906f397e5e897_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTMtMS0xLTk3NjE2_6e48c0ab-b674-4685-a9f7-22bb32e466f5"
      unitRef="usd">21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1816b7eac954956b4765afd462e3f73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjMtMTUtMS0xLTk3NjE2_1b6b7fcf-a5d5-4860-b4b5-9b640a32659e"
      unitRef="usd">13097000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMy0xLTEtOTc2MTY_a80ed9e5-b6b8-4000-814a-599fd51a870c"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtNS0xLTEtOTc2MTY_d60d6ff7-e932-4a5f-9010-c37015b35f6e"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtNy0xLTEtOTc2MTY_c1974f32-27d2-45a9-b476-123d9dda61b0"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtOS0xLTEtOTc2MTY_8b874e2a-981f-4426-a110-4b0eac0f4eb2"
      unitRef="usd">4319000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTEtMS0xLTk3NjE2_d4d39964-2eb7-4ea6-9980-ec098322d258"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTMtMS0xLTk3NjE2_ba82e0ab-43a7-4a58-88cd-1e35124c005e"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjUtMTUtMS0xLTk3NjE2_92457dab-5a6d-466c-acb1-b8031f566e5b"
      unitRef="usd">4319000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMy0xLTEtOTc2MTY_965c130e-4037-4de0-8470-e631006ce24d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtNS0xLTEtOTc2MTY_3ae4b6eb-e260-4736-a612-f3f228bb7907"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtNy0xLTEtOTc2MTY_ade920aa-516b-416e-a02b-eb1712e8a9b8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtOS0xLTEtOTc2MTY_d181ca5f-e676-4921-955b-12d04959af12"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTEtMS0xLTk3NjE2_4675aa28-a471-4610-9df8-8232bdaae543"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTMtMS0xLTk3NjE2_3e18dfe7-a785-4dbe-ba9f-c39e0e82d216"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjYtMTUtMS0xLTk3NjE2_f0a601be-5eb5-49c8-b98a-487dbbc771f7"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMy0xLTEtOTc2MTY_a0aa0b45-a60e-4d32-8864-3c33d0d38808"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctNS0xLTEtOTc2MTY_d60b755e-2f59-4a9d-bcf0-8c90c4e3efb4"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctNy0xLTEtOTc2MTY_8e4c97ec-f58c-40f8-b3b9-1aa2abfae3aa"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctOS0xLTEtOTc2MTY_6a1b713d-f533-46a3-8b98-7e051575a583"
      unitRef="usd">4634000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTEtMS0xLTk3NjE2_990926d5-3fb3-43c0-ad1d-0bbb5a2a3bf8"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTMtMS0xLTk3NjE2_73d12d15-db33-47f7-80e7-d4c3654a2f52"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjctMTUtMS0xLTk3NjE2_607d2806-3455-4e7d-9a18-795ae0932049"
      unitRef="usd">4634000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMS0xLTEtOTc2MTY_4c944c87-ab90-41f9-a3c0-c1b9640e8942"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMy0xLTEtOTc2MTY_2810fe77-e08f-46c2-957f-980b22c88d4a"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktNS0xLTEtOTc2MTY_a1278728-613d-478a-ac43-cb0fcbed9583"
      unitRef="usd">797000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktNy0xLTEtOTc2MTY_c11841a9-7ce1-401e-a656-6db3f7dbc5e9"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktOS0xLTEtOTc2MTY_36d2ded6-b730-4389-9c9d-afce3d17569f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTEtMS0xLTk3NjE2_c21905b6-73d6-40c9-8bb0-271e4bbf23a4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTMtMS0xLTk3NjE2_9830432b-aef1-42d3-b9a8-8fffe3978bf4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMjktMTUtMS0xLTk3NjE2_efe833d6-456d-43ca-a4e3-81236f32eb55"
      unitRef="usd">797000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMS0xLTEtOTc2MTY_0e163e3b-0db1-46cf-8f08-5fc06467b633"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMy0xLTEtOTc2MTY_ce343bb6-b0ba-41e2-b965-51489f273ab8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtNS0xLTEtOTc2MTY_e5c494a9-a458-4d84-85ec-ba37d49f1cfd"
      unitRef="usd">39000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtNy0xLTEtOTc2MTY_a712b58a-ab7a-4741-9987-1a4151186d54"
      unitRef="usd">552000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtOS0xLTEtOTc2MTY_03313678-e48e-4012-962d-0ceca9b1f921"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTEtMS0xLTk3NjE2_0f9c0eb6-2551-479a-843b-89f637233670"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTMtMS0xLTk3NjE2_bcf65433-1c78-408a-9cba-2aec05326381"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzAtMTUtMS0xLTk3NjE2_55969472-f7cb-4ccf-92d3-128f802db6dd"
      unitRef="usd">591000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i4c12b516c34b40cab2aa82649d489df1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMy0xLTEtOTc2MTY_44621147-0128-4132-90ce-d483ee3a4835"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="if9b644de3252423c91efecac801ba901_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtNS0xLTEtOTc2MTY_e4770446-091c-4a63-98f0-8b08cc7246b1"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i4688a6cf74294eccb99920db10b0dcbd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtNy0xLTEtOTc2MTY_be2e5f1d-85d4-4383-8fb9-95794db70bab"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="iefea5da5e2da4aa3b5f1000df1d9ad89_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtOS0xLTEtOTc2MTY_0e31d86c-e8b4-4667-8a86-8978a6bd26cf"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i17c01223096b48bebd06861e5feb9879_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTEtMS0xLTk3NjE2_63db64fe-1206-4e2f-bb78-2e1e110a776c"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="if68f76f0cffe476fa09e2094f9085ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTMtMS0xLTk3NjE2_89d1e2c4-8599-4461-9d8f-09146e0c359e"
      unitRef="usd">4000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzEtMTUtMS0xLTk3NjE2_67d0eec4-1d57-49d5-9db5-2a5e188ed0fc"
      unitRef="usd">4000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i0b62204439a646a58b785ecf93877432_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMS0xLTEtOTc2MTY_f0cac12e-522b-4dff-9e06-f58a05a656e0"
      unitRef="shares">1767000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b62204439a646a58b785ecf93877432_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMy0xLTEtOTc2MTY_67987734-130e-4174-b987-4c076b38c628"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id749deebcb704c62b8d4183e0bcd069a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItNS0xLTEtOTc2MTY_867e4322-d6a2-483c-bf21-e21862e44cd1"
      unitRef="usd">-3022000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5349780f1cf74c438be36b3034549e8a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItNy0xLTEtOTc2MTY_1034e82e-5f18-4328-a6eb-a40b8f83061c"
      unitRef="usd">17936000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5c48f78d5eb442ea02eb2415d1ad543_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItOS0xLTEtOTc2MTY_db01ce23-2585-4429-9f34-85fdb87b407d"
      unitRef="usd">740000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60dc0ca7aa124854b483871a4bbc8ecf_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTEtMS0xLTk3NjE2_a25442d8-647b-46ed-84ad-d70d7146ba92"
      unitRef="usd">-3103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2313112557e4fc19d7b91b3581dbfc8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTMtMS0xLTk3NjE2_eee2aad9-bcb2-43bb-a622-dc42c54da0c6"
      unitRef="usd">25000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzItMTUtMS0xLTk3NjE2_095a656c-597a-46a2-8aac-e1a6ca6856c2"
      unitRef="usd">12594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i925631283eb246fca0b6016ff6e36dcd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMS0xLTEtOTc2MTY_fe753c98-5f93-4d57-8f94-bc90d486d250"
      unitRef="shares">1768000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i925631283eb246fca0b6016ff6e36dcd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMy0xLTEtOTc2MTY_fed1e230-5851-4862-b11b-5bbf4a5e6a1d"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5aa927ee5d642738ac384f97cdb27ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtNS0xLTEtOTc2MTY_455c86a5-e00e-4a25-94ae-e0b55d0e98eb"
      unitRef="usd">-3143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d7be7b002a544fc89aa3eff960ce4c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtNy0xLTEtOTc2MTY_9500cc8f-80c9-4fd2-8cf8-bc41d3939f19"
      unitRef="usd">18305000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3c423a29ebb405295d44e99550f4888_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtOS0xLTEtOTc2MTY_3e0c9e9e-83ae-489a-99de-c8dfb602ca68"
      unitRef="usd">3127000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i143fa36216244880b463624089eaba3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTEtMS0xLTk3NjE2_f29d6b56-16db-447f-8b80-d25ff192baaf"
      unitRef="usd">-2899000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16b4a2ace56f474f9eb07fc6b9af67c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTMtMS0xLTk3NjE2_bb086d7d-c1ec-4b9f-8cb1-bf7ab156190a"
      unitRef="usd">28000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzQtMTUtMS0xLTk3NjE2_03e57fe7-7145-44c7-ae46-e49535bf2ecf"
      unitRef="usd">15436000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMy0xLTEtOTc2MTY_1260604f-589d-4883-830d-4c57bba4b1db"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtNS0xLTEtOTc2MTY_5de8e06a-6b72-46c5-aa41-6d99d74351fb"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtNy0xLTEtOTc2MTY_979f0f60-4353-4588-b1c7-5e4394b8edad"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtOS0xLTEtOTc2MTY_66897d46-c1a9-44ae-b748-3224407970dd"
      unitRef="usd">5414000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTEtMS0xLTk3NjE2_52e4cd95-2e15-4eb0-abce-de81d91a5a7d"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTMtMS0xLTk3NjE2_646ec9c6-dd96-443c-afea-9b5f5d2f36b8"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzUtMTUtMS0xLTk3NjE2_5b626f2e-acf9-4ede-bf5c-a71aacf5f30a"
      unitRef="usd">5414000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMy0xLTEtOTc2MTY_706dcf4d-6b4b-4e30-93e4-90dd562788aa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtNS0xLTEtOTc2MTY_f45c4f60-e70c-4dc2-b1df-bf88c0723e98"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtNy0xLTEtOTc2MTY_81823495-dd9e-485c-976c-0525da67af66"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtOS0xLTEtOTc2MTY_28554a94-02e7-4f94-951f-27271c17e7f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTEtMS0xLTk3NjE2_eb70efff-82d3-4dcf-bfbf-eaf4fc473e2e"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTMtMS0xLTk3NjE2_b6243409-d4dc-405a-9d67-189c29cb2817"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzYtMTUtMS0xLTk3NjE2_8412c73a-eb91-4558-a22e-50f1a6108377"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMy0xLTEtOTc2MTY_374a8452-8e4a-43a6-b21e-355be74e2dea"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctNS0xLTEtOTc2MTY_73d167c7-0969-4e7b-a2e6-2e746f753ac2"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctNy0xLTEtOTc2MTY_d9a3c24d-dbcc-4d6a-9888-07d537b6ea1e"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctOS0xLTEtOTc2MTY_3902750d-2b5c-4b40-adcb-63d505d403e6"
      unitRef="usd">5025000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTEtMS0xLTk3NjE2_f8ef1a04-b29a-4b27-b36d-9410374fced7"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTMtMS0xLTk3NjE2_0cbe6753-2087-4032-9cbd-32820dbc4bb5"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzctMTUtMS0xLTk3NjE2_adec0863-2df6-4d40-9d0c-52b2063f6270"
      unitRef="usd">5025000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMS0xLTEtOTc2MTY_d82ef54c-03f5-4959-bfcf-7ab9d29f0101"
      unitRef="shares">10000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMy0xLTEtOTc2MTY_e90360b3-60fd-425d-aa57-7eb258332f0a"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktNS0xLTEtOTc2MTY_ea803f37-1e8a-4b45-a1c7-cf6f166ceb4f"
      unitRef="usd">1479000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktNy0xLTEtOTc2MTY_5d79eaa9-eeb3-40b0-ba19-304f668ba52e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktOS0xLTEtOTc2MTY_1be1fe40-9e7c-4ac9-8402-16f480c66415"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTEtMS0xLTk3NjE2_a0cbc27f-44bb-4439-81a6-8f973c7c438e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTMtMS0xLTk3NjE2_3a3359aa-c747-4c5c-8738-34020fd97630"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfMzktMTUtMS0xLTk3NjE2_36187b07-3637-408b-a9c8-89979f19885c"
      unitRef="usd">1479000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMS0xLTEtOTc2MTY_32ec0f83-d964-429b-9ed3-4f5ffef1f84c"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMy0xLTEtOTc2MTY_cdbf19cd-5e93-4c06-8a1e-d0d3f13e7b38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtNS0xLTEtOTc2MTY_1d035fdb-e520-4209-ab29-9851b954e6fd"
      unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtNy0xLTEtOTc2MTY_fcdf4cc9-e6c6-4666-b9ff-be6c1f317202"
      unitRef="usd">601000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtOS0xLTEtOTc2MTY_05dbfaa2-4156-40d2-a4b8-9c866f273879"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTEtMS0xLTk3NjE2_4a1f2cb5-376e-49c1-9e65-d3184d991466"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTMtMS0xLTk3NjE2_401e4619-573e-4010-a94c-6410d4aa1f20"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDAtMTUtMS0xLTk3NjE2_c5f0eef3-f213-4e22-a0be-fedcd7ec1173"
      unitRef="usd">632000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i49741c49c37a4ca29b8d6b32fbac0e3a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMy0xLTEtOTc2MTY_b0de06b8-413d-4c9d-997c-d64af0a4f41b"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i3894668cb74143f090cddbd16341590c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtNS0xLTEtOTc2MTY_c4a255d4-27c0-4589-8759-3c3048feb4c0"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i8f1b07a47b08411c92a204b4d5942aca_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtNy0xLTEtOTc2MTY_6878f28f-94b0-4414-aeaa-e7b4e26b89fd"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i0eb12747c1e541d4b28efa73ff33ab4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtOS0xLTEtOTc2MTY_da32be96-bc80-4b43-8498-d2faec7d0946"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i6a760ccd05ad4f9db15d33af07fb9afa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTEtMS0xLTk3NjE2_2bf95276-d71d-46e2-b7b2-5c78949480a8"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ic09d5b5c51824b6caa6e3df7852e0b5d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTMtMS0xLTk3NjE2_27a4f2fa-120c-430d-beef-950601a463dc"
      unitRef="usd">7000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDEtMTUtMS0xLTk3NjE2_352fe742-4fb6-4381-87f4-c442e10bd8a2"
      unitRef="usd">7000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMS0xLTEtOTc2MTY_e30117f8-a7d5-496d-9d5e-636756527e6f"
      unitRef="shares">1768000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0c1adb73294f28ae198cc2a832474e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMy0xLTEtOTc2MTY_380ba1d2-0323-4a17-a1d7-6cd822cdda7a"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib43cafd566d444139ef47736b216cfb1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItNS0xLTEtOTc2MTY_21fba1bb-9a1e-4987-894f-c5feb8158d7b"
      unitRef="usd">-4591000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63689aa1556b43cd941eb0a471e03f21_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItNy0xLTEtOTc2MTY_4cb4a0a6-886e-4b58-bf59-05239ce11c62"
      unitRef="usd">18906000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddd8b399923342659954704e5a03ca81_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItOS0xLTEtOTc2MTY_2ef51291-8d03-4911-b3ce-4d975aab291e"
      unitRef="usd">3516000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe0629a5a7bc4e44b6c15e6705008c35_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTEtMS0xLTk3NjE2_2276787e-5d1f-4207-99c4-f0b887bd9b08"
      unitRef="usd">-3196000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6a0df24a4f1470b8244d9f9c7fce158_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTMtMS0xLTk3NjE2_a65a8f3b-051c-460b-b1f7-7395da5a8ca4"
      unitRef="usd">35000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8yOC9mcmFnOjgzYzM2YTMzZjM5MDQxZGY5NDA5YzJhOWU3MmE4ZGVjL3RhYmxlOmRhZjkzMGU4MWU1NjRiZWM5NmQxNDk0ZWZjYTQ2NmViL3RhYmxlcmFuZ2U6ZGFmOTMwZTgxZTU2NGJlYzk2ZDE0OTRlZmNhNDY2ZWJfNDItMTUtMS0xLTk3NjE2_f0b26647-fac2-40d8-b053-b2d45ff986c8"
      unitRef="usd">14688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMy0xLTEtMS05NzYxNg_19210008-5786-4ffe-9740-ad81fa1c790b"
      unitRef="usd">5421000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMy0zLTEtMS05NzYxNg_43a470b6-60b2-4d6c-84b1-378d08cf51af"
      unitRef="usd">4324000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNS0xLTEtMS05NzYxNg_ce729471-cbbf-470e-aca8-6be251ca2225"
      unitRef="usd">401000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNS0zLTEtMS05NzYxNg_781c56f1-a2c1-4d3d-a0cc-f4870a3f54e4"
      unitRef="usd">407000000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNi0xLTEtMS05NzYxNg_8708618a-95a9-40b1-8805-cbd037858b07"
      unitRef="usd">3704000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNi0zLTEtMS05NzYxNg_7dc76575-5275-4c2c-8089-1b3761c9a63e"
      unitRef="usd">4008000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNy0xLTEtMS05NzYxNg_70365a30-2abb-4db6-803a-5951025d3863"
      unitRef="usd">-794000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNy0zLTEtMS05NzYxNg_b93605f1-6ce3-4350-9c75-e98e93b0f52b"
      unitRef="usd">-119000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOC0xLTEtMS05NzYxNg_4e619f7b-4e3f-4560-9a80-9f691c7f07ba"
      unitRef="usd">861000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOC0zLTEtMS05NzYxNg_14d9b0a8-4696-4aca-bd59-5e0ccf5abab2"
      unitRef="usd">2349000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOS0xLTEtMS05NzYxNg_a947f80d-0a13-4ba3-aa30-3d4bfd96e467"
      unitRef="usd">413000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfOS0zLTEtMS05NzYxNg_f6d09e3e-a94a-40a5-9f4a-de926a8276d5"
      unitRef="usd">428000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTAtMS0xLTEtOTc2MTY_89ff5fc2-2560-48ea-9836-92b68a4b3274"
      unitRef="usd">414000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTAtMy0xLTEtOTc2MTY_27b7dbd3-29ad-4297-8968-78947d5ac463"
      unitRef="usd">317000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTEtMS0xLTEtMTAwNTAw_6ad1dd03-7ee0-4d8d-9d8c-93ba482593e9"
      unitRef="usd">172000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTEtMy0xLTEtOTkzNDM_2f9b6883-f58d-41db-ada7-1484d1988a06"
      unitRef="usd">68000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTMtMS0xLTEtOTc2MTY_69866a13-bffc-4439-be2e-aba8cfa334d9"
      unitRef="usd">2190000000</abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments>
    <abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTMtMy0xLTEtOTc2MTY_0ca0ba6a-2ec7-4587-8c88-0b52f3e7b8ec"
      unitRef="usd">97000000</abbv:NonCashLitigationReserveAdjustmentsNetOfCashPayments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTQtMS0xLTEtOTc2MTY_e866b92e-0455-4efc-a1e5-5e07431bb4aa"
      unitRef="usd">86000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTQtMy0xLTEtOTc2MTY_c1f9afcb-756e-45d0-89e8-339492a6dc69"
      unitRef="usd">30000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTYtMS0xLTEtOTc2MTY_f53ca716-3e59-45fd-b402-6cce4c612d70"
      unitRef="usd">1396000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTYtMy0xLTEtOTc2MTY_961fe951-d266-47a5-890c-500279682389"
      unitRef="usd">1162000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTctMS0xLTEtOTc2MTY_cc56065e-23e3-4e68-bf01-9ea88c5cf532"
      unitRef="usd">499000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTctMy0xLTEtOTc2MTY_417d758c-c68e-43f0-8806-8067c81a79aa"
      unitRef="usd">249000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTgtMS0xLTEtOTc2MTY_b5934321-65b0-4b0f-8fea-2fccbd0c9b05"
      unitRef="usd">-14000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTgtMy0xLTEtOTc2MTY_e68a4e8d-a97d-42a5-8a1b-31eda3f3f656"
      unitRef="usd">281000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTktMS0xLTEtOTc2MTY_6855820b-72b2-41e3-97aa-08684824e977"
      unitRef="usd">-448000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMTktMy0xLTEtOTc2MTY_e239916e-f3e1-4e67-a6f2-8ba6c27bc6ba"
      unitRef="usd">308000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjAtMS0xLTEtOTc2MTY_93b7cab4-beab-4b7b-9c3a-2799a95b2546"
      unitRef="usd">-110000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjAtMy0xLTEtOTc2MTY_bd79532b-5077-44ae-a3dc-0afb33953d2c"
      unitRef="usd">-562000000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjEtMS0xLTEtOTc2MTY_1eb1be6b-c849-42d1-8e5e-f5b9f1f4680f"
      unitRef="usd">9913000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjEtMy0xLTEtOTc2MTY_65d0da24-7ff0-45a8-8532-4b7bcf1a6701"
      unitRef="usd">9767000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjUtMS0xLTEtOTc2MTY_3ec288ae-d5a9-44eb-9512-9c47c2b45a12"
      unitRef="usd">394000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjUtMy0xLTEtOTc2MTY_7c88a736-9a64-4d57-aabc-68cc44456277"
      unitRef="usd">345000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjYtMS0xLTEtOTc2MTY_eb440e0d-a091-477a-842c-895625c16bca"
      unitRef="usd">305000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjYtMy0xLTEtOTc2MTY_4c175ed0-f8a4-4a31-92e7-75de42420434"
      unitRef="usd">383000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjctMS0xLTEtOTc2MTY_b59874b5-1da2-4fb9-9568-8003a109c7ed"
      unitRef="usd">1411000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjctMy0xLTEtOTc2MTY_bddc7de5-4323-49b0-813a-5d8771666477"
      unitRef="usd">56000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjgtMS0xLTEtOTc2MTY_b9d0b3a7-777e-4d66-86ac-90ebe751d6cf"
      unitRef="usd">50000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMjgtMy0xLTEtOTc2MTY_87d10c45-bf20-414e-8618-f543012cafc6"
      unitRef="usd">65000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzAtMS0xLTEtOTc2MTY_940a5846-ffa8-485b-b7c6-c673775c9865"
      unitRef="usd">-599000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzAtMy0xLTEtOTc2MTY_9c7fd10f-1d78-4a99-a629-52d0341ceaf0"
      unitRef="usd">-135000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzEtMS0xLTEtOTc2MTY_337238da-b9f2-4437-a541-7336bca13746"
      unitRef="usd">-1461000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzEtMy0xLTEtOTc2MTY_091c2da4-2f35-4458-9978-e6d101e82864"
      unitRef="usd">-584000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzctMS0xLTEtOTc2MTY_ece7f9fc-e56c-4d6f-a4ab-9827af0e2229"
      unitRef="usd">2000000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzgtMS0xLTEtOTc2MTY_af824aca-e51c-48ac-8e36-283e6b20f949"
      unitRef="usd">4881000000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfMzgtMy0xLTEtOTc2MTY_b33b5fb2-47be-44d6-a845-bbdd017faf91"
      unitRef="usd">3461000000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:PaymentsOfDividends
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDAtMS0xLTEtOTc2MTY_ffea133c-2b64-487d-8ca6-863eab57c8e4"
      unitRef="usd">5033000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDAtMy0xLTEtOTc2MTY_8ea9ecb3-873c-498b-b382-81c44eecc2f5"
      unitRef="usd">4632000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDEtMS0xLTEtOTc2MTY_cc322db5-3163-4a14-b3c0-d31f2dff2b44"
      unitRef="usd">1479000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDEtMy0xLTEtOTc2MTY_47dc01bd-1ad1-4960-9fad-5ce0a4728c19"
      unitRef="usd">797000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDItMS0xLTEtOTc2MTY_80399773-6898-4245-9a3b-697fb647a752"
      unitRef="usd">198000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDItMy0xLTEtOTc2MTY_e5cf3ec8-9ff4-4ba8-8f71-2d25000c5f20"
      unitRef="usd">144000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDMtMS0xLTEtOTc2MTY_99972e69-4763-4cf1-a628-e070e8bfd863"
      unitRef="usd">482000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDMtMy0xLTEtOTc2MTY_8dff73a0-4a94-4f20-a85d-f7111a68f8f4"
      unitRef="usd">313000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDQtMS0xLTEtOTc2MTY_61a93cc9-ea68-4d8c-959f-9644e8aefcaf"
      unitRef="usd">26000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDQtMy0xLTEtOTc2MTY_7a0433b3-5298-4d65-b494-4bdd2de8a75d"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDUtMS0xLTEtOTc2MTY_6498aa0f-a6a2-48f0-b13e-fa9f751b19d3"
      unitRef="usd">-9651000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDUtMy0xLTEtOTc2MTY_1fb52194-0b23-4797-bc8b-31a560a29ead"
      unitRef="usd">-9058000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDYtMS0xLTEtOTc2MTY_b3a9049a-613d-44c4-877c-a8bd3b419abe"
      unitRef="usd">-26000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDYtMy0xLTEtOTc2MTY_cd808c46-4c98-4f99-9cc5-77c08366121e"
      unitRef="usd">-28000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDctMS0xLTEtOTc2MTY_74e95e89-1a92-456d-9ba2-ca862b47f8ae"
      unitRef="usd">-1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDctMy0xLTEtOTc2MTY_e27ee032-12bf-46b3-b82e-b1b0766a0455"
      unitRef="usd">97000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDgtMS0xLTEtOTc2MTY_4e93d1e7-883a-4268-ba98-d289396f2624"
      unitRef="usd">9746000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if1816b7eac954956b4765afd462e3f73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNDgtMy0xLTEtOTc2MTY_92e7cd46-7562-4158-8275-72313b03db8b"
      unitRef="usd">8449000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNTAtMS0xLTEtOTc2MTY_ea5ad3ad-f879-4a52-adcb-1bf82e2ea6f8"
      unitRef="usd">8521000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zMS9mcmFnOjhjYmU2YTUxOTFkZTRiOTdhZjEwMmZmYmU3OGMwNjliL3RhYmxlOmE3NjVjNTk4NWI0MTRkNWU4ZGM4NWMxNzRiOTFkOGIyL3RhYmxlcmFuZ2U6YTc2NWM1OTg1YjQxNGQ1ZThkYzg1YzE3NGI5MWQ4YjJfNTAtMy0xLTEtOTc2MTY_7b8d3024-b2e5-448c-aa57-606c12cd22ff"
      unitRef="usd">8546000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMjIxNA_04e15f52-8c4d-4b5b-a0bd-a2a4dcdf0e0e">Basis of Presentation Basis of Historical Presentation &lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules&#160;and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company&#x2019;s audited consolidated financial statements and notes included in the company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company&#x2019;s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. &lt;/span&gt;&lt;/div&gt;During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&amp;amp;D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&amp;amp;D and milestones expense by $35&#160;million for the three months and $150&#160;million for the six months ended June 30, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA3Mg_847812d0-67d3-44fa-a686-e479b8c5383e"
      unitRef="usd">35000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA3Mg_b60e3f1f-24dd-49fa-b8d0-47751da89209"
      unitRef="usd">35000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA4OQ_3c8c058d-81c0-48a6-9c8a-52088903e799"
      unitRef="usd">150000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense>
    <abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl8zNy9mcmFnOjVhNTRhNzViMjYxODQyMTRhYzJlNzRjNjhlN2U2NDFiL3RleHRyZWdpb246NWE1NGE3NWIyNjE4NDIxNGFjMmU3NGM2OGU3ZTY0MWJfMTY0OTI2NzQ0NDA4OQ_48627638-b8a4-444e-9c4f-1569e3e545b0"
      unitRef="usd">150000000</abbv:ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTQ5_2685580c-1024-4f66-9756-c43ca619d6de">Supplemental Financial Information&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $203 million for the three months and $401 million for the six months ended June 30, 2022 and $201 million for the three months and $407 million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTMy_78ce1abe-3592-4f43-be53-9e25e9cf1fca">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi0yLTEtMS05NzYxNg_0cec2356-66e7-4834-922a-0cb45befd0ed"
      unitRef="usd">556000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi00LTEtMS05NzYxNg_002620d4-b9ad-420a-a4af-39f6c16b8a91"
      unitRef="usd">615000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi02LTEtMS05NzYxNg_99a11075-8827-41a0-942e-1f97211cf557"
      unitRef="usd">1104000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMi04LTEtMS05NzYxNg_5ae04cd0-eeca-4f90-843b-f5456cfce6df"
      unitRef="usd">1247000000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy0yLTEtMS05NzYxNg_2f74ffdc-3721-483d-b484-bb28b93a7fbd"
      unitRef="usd">24000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy00LTEtMS05NzYxNg_3c43040f-4723-4efd-b7e9-3ac9c3ca6e68"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy02LTEtMS05NzYxNg_a9e2922c-48ea-4336-ba05-86d019fdb2bf"
      unitRef="usd">33000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfMy04LTEtMS05NzYxNg_3241c2a9-0d76-4760-a341-0d8ad28f0b23"
      unitRef="usd">19000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC0yLTEtMS05NzYxNg_5277d662-6387-45b4-b828-752517855025"
      unitRef="usd">-532000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC00LTEtMS05NzYxNg_3eaf50b2-3f5d-44cd-a507-5ac42ba2c32e"
      unitRef="usd">-606000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC02LTEtMS05NzYxNg_beb241a4-df3f-4f39-9b86-d5694f5f3d19"
      unitRef="usd">-1071000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM3NDAzZDc2NjYwMjRjYzQ5NmJmZWQ4YmJiMzdjMzhhL3RhYmxlcmFuZ2U6Mzc0MDNkNzY2NjAyNGNjNDk2YmZlZDhiYmIzN2MzOGFfNC04LTEtMS05NzYxNg_2d41c117-9c0c-4006-b76f-c7f6c00a83e0"
      unitRef="usd">-1228000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTUw_b03763d6-7dde-4ffa-a5b8-c7638663bad1">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMS0xLTEtMS05NzYxNg_b4a1ccd2-afe1-4c2d-bb4f-839a46146cb0"
      unitRef="usd">1158000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMS0zLTEtMS05NzYxNg_ca76b761-32ae-4f69-a215-35eabb949166"
      unitRef="usd">932000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMi0xLTEtMS05NzYxNg_f7c38e58-a643-4360-8721-f578ea2c5b10"
      unitRef="usd">1250000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMi0zLTEtMS05NzYxNg_5770591a-3b1d-4dc5-a070-f9bbdaa87153"
      unitRef="usd">1193000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMy0xLTEtMS05NzYxNg_d01d6a80-23d9-4b24-b137-c11d506f9ff4"
      unitRef="usd">988000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfMy0zLTEtMS05NzYxNg_eed4f73e-73ad-46f1-850a-7a3cfe928eff"
      unitRef="usd">1003000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfNC0xLTEtMS05NzYxNg_9b5a1824-39c0-4712-b99e-33a1cb1bc2b4"
      unitRef="usd">3396000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjlhZTU3NjUzY2IyZjRkMDdiOTkyNzdlNzQ3ZDQ5NzQxL3RhYmxlcmFuZ2U6OWFlNTc2NTNjYjJmNGQwN2I5OTI3N2U3NDdkNDk3NDFfNC0zLTEtMS05NzYxNg_e04cc3b3-039e-41d4-8ec3-7a2615deed5c"
      unitRef="usd">3128000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTQ4_8f3837a8-8559-40fe-8d33-0f251e88a1e8">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMS0xLTEtMS05NzYxNg_e47a4a5f-62e7-4bce-9990-b8ecc5c52f64"
      unitRef="usd">10827000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMS0zLTEtMS05NzYxNg_bf9563c4-5686-4383-9452-66b755089f1a"
      unitRef="usd">10727000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMi0xLTEtMS05NzYxNg_cd088809-67aa-49ef-8b13-d28a2fe267ef"
      unitRef="usd">5869000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMi0zLTEtMS05NzYxNg_c15b89e3-89f3-42fd-ab85-7bd768fc3de3"
      unitRef="usd">5617000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMy0xLTEtMS05NzYxNg_32bee0a9-0630-44c3-abf6-c92fc6599cd1"
      unitRef="usd">4958000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RhYmxlOjM1MzRiZTAxZjhlYjQ0OTBiNzU3MWQyMTM5YTFmZDhiL3RhYmxlcmFuZ2U6MzUzNGJlMDFmOGViNDQ5MGI3NTcxZDIxMzlhMWZkOGJfMy0zLTEtMS05NzYxNg_d96a2691-789d-4d79-b847-821352d811cc"
      unitRef="usd">5110000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTY0OTI2NzQ0MTkwOQ_8924e009-207c-4504-8364-343fb30ee20d"
      unitRef="usd">203000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTAx_ce729471-cbbf-470e-aca8-6be251ca2225"
      unitRef="usd">401000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTY0OTI2NzQ0MTkzMw_2f65fcd8-83cb-4df6-9d00-21320f67f7d7"
      unitRef="usd">201000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80MC9mcmFnOmJkZmVlYjQ0YzExYTQwZTBhZTkyYTEzZWUzN2I4ZTE2L3RleHRyZWdpb246YmRmZWViNDRjMTFhNDBlMGFlOTJhMTNlZTM3YjhlMTZfMTE5_781c56f1-a2c1-4d3d-a0cc-f4870a3f54e4"
      unitRef="usd">407000000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RleHRyZWdpb246NTI1Njc1NDJlY2E3NDYzY2I4MDliOTIyNjI4MDlhMWFfNjQ3_f4119463-87ec-4045-a9fe-a0af5d0578b1">Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the impact of the two-class method:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RleHRyZWdpb246NTI1Njc1NDJlY2E3NDYzY2I4MDliOTIyNjI4MDlhMWFfNjU2_d9604a67-da0f-4fa4-bcb7-4e8e17e9a23b">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the impact of the two-class method:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy0yLTEtMS05NzYxNg_37146fb9-6500-4a5b-a19b-7b2f5b5fe053"
      unitRef="usd">924000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy00LTEtMS05NzYxNg_32440a73-6dc6-4019-8662-cf7a1d39f70b"
      unitRef="usd">766000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy02LTEtMS05NzYxNg_1983de8b-dd95-45cb-ace8-6747fc95d3a6"
      unitRef="usd">5414000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMy04LTEtMS05NzYxNg_9cdad053-08b6-4eb0-aa10-87fcf2d94506"
      unitRef="usd">4319000000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC0yLTEtMS05NzYxNg_98d38408-d7a2-498f-86d0-a9c7e0c1304a"
      unitRef="usd">11000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC00LTEtMS05NzYxNg_92bdefb6-182c-4e15-90dd-f696ab81b141"
      unitRef="usd">17000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC02LTEtMS05NzYxNg_d7290f37-e1bc-4236-b5d5-6b210652f717"
      unitRef="usd">26000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNC04LTEtMS05NzYxNg_bc644469-df4e-4ba3-93cb-6f6ef2cbe8a5"
      unitRef="usd">34000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS0yLTEtMS05NzYxNg_505ea6f2-7735-4635-9c68-3f1f330a2587"
      unitRef="usd">913000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS00LTEtMS05NzYxNg_312c238c-a94e-4fa4-b707-a20c64fd7168"
      unitRef="usd">749000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS02LTEtMS05NzYxNg_73e0bce4-28a4-4576-91ef-29ee1d3500bd"
      unitRef="usd">5388000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNS04LTEtMS05NzYxNg_d0e5bd10-e483-4c88-bc1e-b6d373dec7f8"
      unitRef="usd">4285000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi0yLTEtMS05NzYxNg_75115a2f-6461-443d-95ca-6c69c0277405"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi00LTEtMS05NzYxNg_8ad16e4f-be9a-4f36-94d7-efa223625897"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi02LTEtMS05NzYxNg_fae4c8fa-7e81-4ba2-bbfd-1e126d260925"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNi04LTEtMS05NzYxNg_8fa298db-481e-4dc6-a761-c4e12d49117f"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy0yLTEtMS05NzYxNg_65aae81b-aa05-4385-aa36-8c7d014b5df7"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy00LTEtMS05NzYxNg_20bbcb6c-e7bc-4bc5-bbb7-99d9aad4a780"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy02LTEtMS05NzYxNg_a5058de4-f681-4dd9-a52b-bf0a9fe082d1"
      unitRef="usdPerShare">3.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfNy04LTEtMS05NzYxNg_1a369a36-c02a-4269-86db-baf98fa13ff8"
      unitRef="usdPerShare">2.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtMi0xLTEtOTc2MTY_0b3f8f24-59ee-4f76-8411-23140dfa86f5"
      unitRef="usd">924000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtNC0xLTEtOTc2MTY_cd265164-7cd2-47fc-a236-409cfeb60530"
      unitRef="usd">766000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtNi0xLTEtOTc2MTY_76f63a78-356c-40d7-8f20-c2e665f81b9c"
      unitRef="usd">5414000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTAtOC0xLTEtOTc2MTY_498a265b-b243-4a5a-94a6-936bb159e8ee"
      unitRef="usd">4319000000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtMi0xLTEtOTc2MTY_5df30677-e338-45cb-a886-0428cf173018"
      unitRef="usd">11000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtNC0xLTEtOTc2MTY_b34832b9-13a4-40b9-acdf-20bfa1b466e7"
      unitRef="usd">17000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtNi0xLTEtOTc2MTY_e9bb9f66-50e1-4eaa-94c2-fc9d73c02f95"
      unitRef="usd">26000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTEtOC0xLTEtOTc2MTY_35de705e-e798-4477-b1fe-ce3e3c705154"
      unitRef="usd">34000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItMi0xLTEtOTc2MTY_5e2f6128-de1f-44f1-a3ad-840e42bf7368"
      unitRef="usd">913000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItNC0xLTEtOTc2MTY_3170e559-e17d-4908-906d-216e3d5aa9bb"
      unitRef="usd">749000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItNi0xLTEtOTc2MTY_c899c0ea-0c58-4fc3-900d-fcc9dd65a572"
      unitRef="usd">5388000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTItOC0xLTEtOTc2MTY_632dc574-7d90-4c4f-807d-0dba7d56dbea"
      unitRef="usd">4285000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtMi0xLTEtOTc2MTY_5d166d1c-13b0-460f-af4e-375b25b1ba1f"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtNC0xLTEtOTc2MTY_25e420f4-9dd5-4e32-bb2f-9fe7a5f7bf03"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtNi0xLTEtOTc2MTY_49ac8c52-ced1-4d7e-a0f0-b6e125469b2f"
      unitRef="shares">1770000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTMtOC0xLTEtOTc2MTY_7a23a0d5-e60a-4089-9fef-2492649733d2"
      unitRef="shares">1769000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtMi0xLTEtOTc2MTY_e3894e3a-53e0-4346-8c91-eef1d29694a8"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtNC0xLTEtOTc2MTY_fa15dfb8-3a8a-4970-97be-e05c7bb11bfe"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtNi0xLTEtOTc2MTY_ade7ea5c-9e9b-4b15-9a1a-1ced95c4d709"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTQtOC0xLTEtOTc2MTY_00d2b0a8-de83-483a-aaab-2bed2e7076f0"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtMi0xLTEtOTc2MTY_a319a982-7cc0-46f8-99cf-4defa4ef56e2"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtNC0xLTEtOTc2MTY_590e06cf-c7b0-4bc0-ab4a-64280961f4f5"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtNi0xLTEtOTc2MTY_e5b73e62-1d58-41b2-a53b-cf4cf2f08841"
      unitRef="shares">1777000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTUtOC0xLTEtOTc2MTY_d76377fc-b890-4c08-bf32-da643ab65b7e"
      unitRef="shares">1776000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtMi0xLTEtOTc2MTY_691751cd-23e4-4156-a65f-892cf24fde24"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtNC0xLTEtOTc2MTY_e6b15e20-752d-4466-88dd-8c48786acf12"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtNi0xLTEtOTc2MTY_68a68a5c-2b50-491e-abc4-34d8f4aff4a4"
      unitRef="usdPerShare">3.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80Ni9mcmFnOjUyNTY3NTQyZWNhNzQ2M2NiODA5YjkyMjYyODA5YTFhL3RhYmxlOjNhN2EyNTBlOWYwNzQwOGJiYmJhOGZmMjlmYTljMjg1L3RhYmxlcmFuZ2U6M2E3YTI1MGU5ZjA3NDA4YmJiYmE4ZmYyOWZhOWMyODVfMTYtOC0xLTEtOTc2MTY_b1c4fa8d-ad7e-45a2-a133-fbabc22a2966"
      unitRef="usdPerShare">2.41</us-gaap:EarningsPerShareDiluted>
    <abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfODc5_55042e2c-79b8-4ff6-9a1f-650fa4c1ff69">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Licensing, Acquisitions and Other Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflows related to acquisitions and investments totaled $394 million for the six months ended June 30, 2022 and $345 million for the six months ended June 30, 2021. AbbVie recorded acquired IPR&amp;amp;D and milestones charges of $269 million for the three months and $414 million for the six months ended June 30, 2022 and $132 million for the three months and $317&#160;million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Syndesi Therapeutics SA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&amp;amp;D and milestones expense in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Juvise Pharmaceuticals&lt;/span&gt;&lt;/div&gt;In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the condensed consolidated statement of earnings in the second quarter of 2022.</abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNDk_227d1594-5b5f-4448-a12f-8f9dc8867421"
      unitRef="usd">394000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNjc_f08efd6b-f86e-4984-94b2-20319abb1406"
      unitRef="usd">345000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTY0OTI2NzQ0MjcwNg_7b3fe2f3-9332-4df0-b224-d8effebee342"
      unitRef="usd">269000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTEy_785e14e2-489d-44b7-8c73-90a1cd92df65"
      unitRef="usd">414000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTY0OTI2NzQ0Mjc1MA_b4fac5b3-0177-4563-acb0-f17555a1a161"
      unitRef="usd">132000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTMw_0a1319e8-8a88-47ef-8e44-fbbc606d4e42"
      unitRef="usd">317000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNjEz_7157db06-c503-4ddb-991a-3e022921ccf1"
      unitRef="usd">130000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <abbv:PotentialPaymentsUnderAgreementCertainMilestones
      contextRef="ib1b72292beef4cbf9fac74da6779e3fb_I20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfNzk1_dc717643-9e9f-4e11-9b4a-de53ebaa34df"
      unitRef="usd">870000000</abbv:PotentialPaymentsUnderAgreementCertainMilestones>
    <us-gaap:ProceedsFromSaleOfOtherAssets1
      contextRef="i59db14e384674164aab7d20a75d7554b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTA5OTUxMTYzMDQ3Mg_06b914ea-d5eb-4e8b-9dab-453569efe8ba"
      unitRef="usd">215000000</us-gaap:ProceedsFromSaleOfOtherAssets1>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i38b7b50a66b144149f8c1287ceec7314_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl80OS9mcmFnOjhlMDVhMGFhZjhlNDQ1OGU5MWRiNzY2M2Y3YTI5NzkwL3RleHRyZWdpb246OGUwNWEwYWFmOGU0NDU4ZTkxZGI3NjYzZjdhMjk3OTBfMTA5OTUxMTYzMDQ4OA_2cb7d27e-173c-423f-b3c1-10988e08c4a9"
      unitRef="usd">172000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDI0MA_3cece7bb-a642-4c2d-9a61-f694d396bced">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Collaborations&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended June 30, 2022 and 2021.&lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration with Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech,&#160;Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson&#160;&amp;amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton&#x2019;s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Janssen and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Janssen's share of profits (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International - AbbVie's share of profits (included in net revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global - AbbVie's share of other costs (included in respective line items)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie&#x2019;s receivable from Janssen, included in accounts receivable, net, was $310 million at June 30, 2022 and $294 million at December 31, 2021. AbbVie&#x2019;s payable to Janssen, included in accounts payable and accrued liabilities, was $389 million at June 30, 2022 and $509 million at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration with Genentech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie&#x2019;s net revenues. Genentech&#x2019;s share of United States profits is included in AbbVie&#x2019;s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&amp;amp;A) expenses and global development costs as part of research and development (R&amp;amp;D) expenses, net of Genentech&#x2019;s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie&#x2019;s cost of products sold.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Genentech and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech's share of profits, including royalties (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;amp;A)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of development costs (included in R&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable
      contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTM5Mw_6f820d84-3b79-414d-b592-425c90c314d7"
      unitRef="usd">200000000</abbv:CollaborativeArrangementMilestoneMethodPaymentsReceivable>
    <abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty
      contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTU3Mw_b8b380fc-f971-419f-b230-71e66160eacd"
      unitRef="number">0.60</abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty>
    <abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts
      contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMTY1NQ_a063e779-fee2-47db-8bab-ae5df91edec3"
      unitRef="number">0.40</abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDIzOQ_511052db-c424-4cee-840d-d897db5cc172">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Janssen and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Janssen's share of profits (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International - AbbVie's share of profits (included in net revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global - AbbVie's share of other costs (included in respective line items)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i42d7c4579b3144d4a545b08d34ae8d8f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi0yLTEtMS05NzYxNg_cd436447-818a-4b90-9ced-7068c5c626c9"
      unitRef="usd">404000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="ied44bd1369ed4bdb88cabc67622ac9dd_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi00LTEtMS05NzYxNg_2b58678b-df2e-4885-a8e2-b119466a92d8"
      unitRef="usd">514000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="ia760c3d64fb74371a378c6623497a7ee_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi02LTEtMS05NzYxNg_b03eacd6-b87d-4427-b466-1f3beb06da05"
      unitRef="usd">812000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i92651b474c794e5ca8ac957b8b9b0e59_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMi04LTEtMS05NzYxNg_7d8248f8-8d1b-4ef5-87f8-c2ac9d5fd47d"
      unitRef="usd">979000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1717a97362f94154b97a937865fbff42_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy0yLTEtMS05NzYxNg_1082f60a-fa41-4359-8539-bfc805bdba4d"
      unitRef="usd">283000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iaf29d7b949e14095835b529dec0be4b4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy00LTEtMS05NzYxNg_ee060a9c-a5fc-45dc-b853-44cb5cef01f8"
      unitRef="usd">282000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ide6eb92d83444f61b91925e0d7f8ff5a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy02LTEtMS05NzYxNg_4a1f7914-544f-46b7-aaee-0e0754f59298"
      unitRef="usd">582000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i7107caab25d347ebaae1ee759946b263_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfMy04LTEtMS05NzYxNg_23ffeb63-298f-4919-93e8-e81cb2c4f2f7"
      unitRef="usd">551000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="ibe6e878897e14d5ea3dc67ebfd22e441_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC0yLTEtMS05NzYxNg_633de1bd-9dde-49e9-846e-93a3f364e41d"
      unitRef="usd">69000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="if1955ccecde54928aa0c73f282a2340a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC00LTEtMS05NzYxNg_09b5cb4f-4e85-4a6e-a2c7-2ee549d50679"
      unitRef="usd">74000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC02LTEtMS05NzYxNg_10658a99-5b4f-4f88-ab53-ea56cd4a0767"
      unitRef="usd">133000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <abbv:OtherExpensesFromCollaborativeArrangements
      contextRef="i6d666e53ce1843c38b0611e7ba387246_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjljNzI3ZWFkN2ExODQwYTdhMzFhNWVkOGZhMTE0NDc5L3RhYmxlcmFuZ2U6OWM3MjdlYWQ3YTE4NDBhN2EzMWE1ZWQ4ZmExMTQ0NzlfNC04LTEtMS05NzYxNg_6fc8f9d2-0fde-4730-a86a-c61dd6efaab4"
      unitRef="usd">144000000</abbv:OtherExpensesFromCollaborativeArrangements>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjczMw_424aedcc-383b-4156-af01-5b67aa8ae9aa"
      unitRef="usd">310000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i520d59c123c940099b7566525c161f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjc0Ng_d5a3084e-af64-446b-b8e8-3efb93895375"
      unitRef="usd">294000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic98df2b43008404b90c33af8edee6dd2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjg0Mw_7d1c7383-47eb-41a7-8b3a-23f9a3a2896b"
      unitRef="usd">389000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i520d59c123c940099b7566525c161f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfMjg1Ng_02caaf9f-617d-4474-a428-997d494cd066"
      unitRef="usd">509000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i3a1be3d4d92e4a689787ce9b5a84b41a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RleHRyZWdpb246NGZmY2Q5ZTdlNzM0NGZmMzgxYjE1NmU3ZWYwNjM1ZDVfNDIzMA_482ba8ea-e410-420b-81dd-0c98b3d631dc">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the profit and cost sharing relationship between Genentech and AbbVie:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech's share of profits, including royalties (included in cost of products sold)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;amp;A)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie's share of development costs (included in R&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i17953cb362654702ad658e6a13cfb987_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi0yLTEtMS05NzYxNg_8373f176-1a62-472d-94b3-bd91c76271fd"
      unitRef="usd">196000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi00LTEtMS05NzYxNg_3e6dc4d4-90a6-4dda-854e-e2ae99e706c2"
      unitRef="usd">168000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi02LTEtMS05NzYxNg_b1779986-f730-475c-b068-52dfe6f4b519"
      unitRef="usd">374000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements
      contextRef="i895042247e154437ae780eab2540751d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMi04LTEtMS05NzYxNg_7d0b87d9-b549-4de5-aa4b-db3f5a81342d"
      unitRef="usd">327000000</abbv:CostofGoodsAndServicesSoldFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="i2fcaf1fd7b534884b238ec95d10826b7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy0yLTEtMS05NzYxNg_321685c2-42b0-4203-a53c-78e0ac642425"
      unitRef="usd">5000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="i439ea03a9e384ea8baf9310fdfda9c21_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy00LTEtMS05NzYxNg_a25584ec-4d4e-4ce3-9d6b-508afa097dde"
      unitRef="usd">8000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="i6a65557623304acba06de330a83ee93d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy02LTEtMS05NzYxNg_17ebc28d-8bf9-4456-93f8-fe01e7950e23"
      unitRef="usd">17000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
      contextRef="ie4361107b3034a3c94e481eec57cf68a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfMy04LTEtMS05NzYxNg_fb049d41-648d-439c-9970-897731059e46"
      unitRef="usd">19000000</abbv:SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="i17953cb362654702ad658e6a13cfb987_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC0yLTEtMS05NzYxNg_32539e79-c114-4d9b-a2e3-f32ad53bc48e"
      unitRef="usd">31000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="i9ecf91a6c8af4aef90a3e9d5d5a95150_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC00LTEtMS05NzYxNg_c986f9a7-b025-4cc1-83ac-9ec8805b2e04"
      unitRef="usd">34000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="ie73cd58045884c2989dcb5968dc2c44b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC02LTEtMS05NzYxNg_7674113d-1edb-498d-8451-271151f79790"
      unitRef="usd">58000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements
      contextRef="i895042247e154437ae780eab2540751d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81NS9mcmFnOjRmZmNkOWU3ZTczNDRmZjM4MWIxNTZlN2VmMDYzNWQ1L3RhYmxlOjAyY2MwZTUzZTFhODRjNGJhOGViYjk2MWYyNGNkMDk5L3RhYmxlcmFuZ2U6MDJjYzBlNTNlMWE4NGM0YmE4ZWJiOTYxZjI0Y2QwOTlfNC04LTEtMS05NzYxNg_37c9fb9f-25f4-41fa-bb73-dab52b60183b"
      unitRef="usd">76000000</abbv:ResearchAndDevelopmentExpenseFromCollaborativeArrangements>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODcy_f7989389-7686-4541-91b6-c1df2c476c84">Goodwill and Intangible AssetsGoodwill&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2022, there were no accumulated goodwill impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Definite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $1.8 billion for the three months and $3.7 billion for the six months ended June 30, 2022 and $2.0&#160;billion for the three months and $4.0 billion for the six months ended June 30, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODY4_01c8e8ab-ba09-48a0-a779-b912fa0294e0">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMS0xLTEtMS05NzYxNg_9f128b2a-848c-450e-97ec-3d75cc38902b"
      unitRef="usd">32379000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMi0xLTEtMS05NzYxNg_e14f539c-f458-41dc-a190-ad4f40700d0e"
      unitRef="usd">-351000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOmEzZDI3NDM0MjcxMzQ0MjY4OGZjNGFjN2M2YTU4M2E3L3RhYmxlcmFuZ2U6YTNkMjc0MzQyNzEzNDQyNjg4ZmM0YWM3YzZhNTgzYTdfMy0xLTEtMS05NzYxNg_25cbfde2-5595-435e-92f9-baedcc7e6299"
      unitRef="usd">32028000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMjQ5_c3c0774d-1984-41cb-a4f3-dc923454be6f"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODU3_0d3093ef-8def-471d-95fc-04e1b2121412">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfODc1_4339e603-a813-4086-9010-13a741e46ac6">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated &lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i32c025272d3c4c2194f440828c692e80_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0xLTEtMS05NzYxNg_d4730082-1652-4425-8acf-658ff27a5bc4"
      unitRef="usd">88443000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i32c025272d3c4c2194f440828c692e80_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0zLTEtMS05NzYxNg_b0e2c05c-61c1-4a80-8166-300346fa2f11"
      unitRef="usd">21679000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i32c025272d3c4c2194f440828c692e80_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy01LTEtMS05NzYxNg_c14aea42-c908-4e70-9b56-2d76b3489478"
      unitRef="usd">66764000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy03LTEtMS05NzYxNg_041b1fcf-531e-4041-ae6c-d7f59386f852"
      unitRef="usd">88945000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy05LTEtMS05NzYxNg_e5fbcb13-f806-4068-8632-6374aec48817"
      unitRef="usd">18463000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifc9175130fd841a5a84a0d431d286267_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfMy0xMS0xLTEtOTc2MTY_80b91642-75e8-4ce1-b8b8-324c7a2c6bad"
      unitRef="usd">70482000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0xLTEtMS05NzYxNg_28e8379c-5f23-4841-9af0-7db3dc236de4"
      unitRef="usd">8487000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0zLTEtMS05NzYxNg_a8fa0b92-db61-4035-b26b-0d10e96e9dce"
      unitRef="usd">4098000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i98f7ec1f596843529dece3b7b59c127d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC01LTEtMS05NzYxNg_68410c9e-bf76-4680-a360-684a397f660f"
      unitRef="usd">4389000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC03LTEtMS05NzYxNg_a670bf3a-7c68-4614-8605-fd9b56427f2a"
      unitRef="usd">8487000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC05LTEtMS05NzYxNg_873fbdad-c95d-43f9-b45f-4c480259f8b8"
      unitRef="usd">3688000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3502e3aaaccc48d9a643e7dc97219a2e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNC0xMS0xLTEtOTc2MTY_d6683703-dac7-4f26-9802-75a2f53eb9ff"
      unitRef="usd">4799000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0xLTEtMS05NzYxNg_6b258bc9-2cef-478a-b64c-091b1227db9a"
      unitRef="usd">96930000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0zLTEtMS05NzYxNg_ea8efac5-6ed9-44b4-98a9-7d126dfb607d"
      unitRef="usd">25777000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS01LTEtMS05NzYxNg_854de169-85a1-4805-9a25-eead2a5197c3"
      unitRef="usd">71153000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS03LTEtMS05NzYxNg_1c1d5a44-b864-402d-8f2b-aa4a4c65fd44"
      unitRef="usd">97432000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS05LTEtMS05NzYxNg_419c2c11-da8f-4722-8b19-a435150b240f"
      unitRef="usd">22151000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNS0xMS0xLTEtOTc2MTY_3fc39c54-191d-4fa2-9e85-b3776552a6ca"
      unitRef="usd">75281000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi0xLTEtMS05NzYxNg_249c2d20-c4f5-40cb-91d8-979593cc8ac1"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi01LTEtMS05NzYxNg_100101ca-eb67-4fc0-8d22-9ceb0f6f1d8a"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi03LTEtMS05NzYxNg_b50995ad-2dee-4feb-91c6-552187c4bb3c"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNi0xMS0xLTEtOTc2MTY_0db9e832-4ded-4b17-8ac4-0bc9971cc98b"
      unitRef="usd">670000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0xLTEtMS05NzYxNg_c8740b70-6c7e-4f06-b89f-8ac39ade8825"
      unitRef="usd">97600000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0zLTEtMS05NzYxNg_809f3362-104a-43f7-ad98-7a0d0c431623"
      unitRef="usd">25777000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy01LTEtMS05NzYxNg_f1883024-f5d4-4c18-a525-88da1c23a5c7"
      unitRef="usd">71823000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy03LTEtMS05NzYxNg_4159002f-b647-44a3-b1e9-569e3156a26a"
      unitRef="usd">98102000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy05LTEtMS05NzYxNg_205b9fdb-63fb-43d3-85b2-bc3168670b42"
      unitRef="usd">22151000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RhYmxlOjExODdlMzU2OWQzMjQ2ZGE4ZTg5NWIyN2E4ZWUyYWYxL3RhYmxlcmFuZ2U6MTE4N2UzNTY5ZDMyNDZkYThlODk1YjI3YThlZTJhZjFfNy0xMS0xLTEtOTc2MTY_ec32bc82-d275-438d-8e6e-83cff28a6e79"
      unitRef="usd">75951000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMTY0OTI2NzQ0MjYwNA_d9858c00-27bd-45d6-8ea1-0ac0bd3acc54"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfNDI0_b657da08-725c-49b6-a578-7b7e2d0c6054"
      unitRef="usd">3700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfMTY0OTI2NzQ0MjYyMQ_87b411ba-3e79-497e-b9d4-8eedbae7fddd"
      unitRef="usd">2000000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl81OC9mcmFnOjM2M2NhMjE4OTgwODRkNTM4MTBlOWM5YTg3NzkzNzc1L3RleHRyZWdpb246MzYzY2EyMTg5ODA4NGQ1MzgxMGU5YzlhODc3OTM3NzVfNDQy_38eb49c1-47f2-406d-9101-3a5b738b4f97"
      unitRef="usd">4000000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTcw_b7ff6739-4319-433b-a0ff-06a23af15df9">Integration and Restructuring PlansAllergan Integration Plan &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total charges (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the recorded liability associated with the integration plan for the six months ended June 30, 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie recorded restructuring charges of $36 million for the three months and $93 million for the six months ended June 30, 2022 and $5 million for the three months and $43 million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i2c7df08664994f12aca1518baebbe045_I20220630"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMzEx_90066e3d-168d-44db-a5e5-bafcffc10e12"
      unitRef="usd">2000000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTcy_27f27ae5-62e3-4d44-bd3a-b550e4c89c4b">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total charges (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic88c1ac3f5e440e784ff845b1c57c6e7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy01LTEtMS05NzYxNg_9fe5f03b-21fc-42eb-ae07-dfe5955fa5e6"
      unitRef="usd">-5000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i812ac0d2871a40f1aafd158554ed5422_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy03LTEtMS05NzYxNg_6e25bb52-860d-4e61-b82f-3d20cefa8fa6"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8fc63ba180b3456d81d30cf250f754f1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy05LTEtMS05NzYxNg_617d13d3-2cf5-47e9-b6c3-b92b8a769382"
      unitRef="usd">-4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i27fce41091494b70b87e4d7af3546c7d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xMS0xLTEtOTc2MTY_428afa82-35b7-4d7e-b3a9-21de59321199"
      unitRef="usd">6000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia8022aceb9c14776b862ea4d4d6d6439_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xNy0xLTEtOTc2MTY_db303e30-01fa-489c-8d91-ec95bc1b1a05"
      unitRef="usd">31000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6ab97e9e01f14b32910efe469af4e78e_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0xOC0xLTEtOTc2MTY_2a543c47-f078-4282-8bb2-bef1277f867d"
      unitRef="usd">25000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1c8d8f7d150e4296aee9bf18bd08cc12_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0yMC0xLTEtOTc2MTY_d321ff1b-bfe8-44b1-8d34-ff87cd1e5395"
      unitRef="usd">61000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1a5b6a497ea346abad95173f039d362e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfMy0yMi0xLTEtOTc2MTY_bb1842b8-c199-4751-bc88-ac9774ef7efc"
      unitRef="usd">40000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8eb1e9d02bf34f17b2a0eed52a00027a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC01LTEtMS05NzYxNg_c3454b79-8351-46e9-950f-42fe1e423f92"
      unitRef="usd">-2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0bcd977a37754942a73c727470b4f98f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC03LTEtMS05NzYxNg_0056b140-cc7e-428a-8e2b-76c436ef0c5a"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia9ccfe28417c469f8af551c99b927b19_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC05LTEtMS05NzYxNg_9f8f24b2-cdac-4d0c-88e1-192f2e9ee967"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i61a05939f8244a33897e7422c89f7126_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xMS0xLTEtOTc2MTY_53c5d8ed-b7be-471f-bca6-2c18ef1f9c99"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0e74bcc52335423cbc3f7f772ff0e679_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xNy0xLTEtOTc2MTY_cc300806-9af7-4d11-af67-c35ff1f1435e"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id282193bd524451fb438bb7e138e29ac_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0xOC0xLTEtOTc2MTY_89128a84-24d4-4880-be6f-56df197c9d60"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i19e30abb6a7a486f885ad340a96c5778_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0yMC0xLTEtOTc2MTY_71d0e9c7-e29e-452f-b75e-25740e56a56a"
      unitRef="usd">9000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibb6915f306024be09472c7f5080f0fa1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNC0yMi0xLTEtOTc2MTY_92908c0f-2d8a-4f4a-8d5c-94cf229ce24a"
      unitRef="usd">69000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6899f65d669d4afea3cd976e00ecbe6f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS01LTEtMS05NzYxNg_4beb07dc-59f6-4c72-bca7-47ef2e55d1f7"
      unitRef="usd">-4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if7e1c3dc13f54e42a2d2dc2c62ec8e91_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS03LTEtMS05NzYxNg_6938dbfb-d666-4e6b-97f9-24a90e5ce9a6"
      unitRef="usd">12000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i71d0d44f11db4eb99c11417e2743e862_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS05LTEtMS05NzYxNg_3ddf38bc-d276-4607-a8f0-a6e31a5e3129"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i87cf8b8c10db40639f8c71e5fa2e3818_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xMS0xLTEtOTc2MTY_b429060b-900a-4af9-86e6-9143a3a7891a"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i37f4c1493f0542bf83279f44f2ec5342_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xNy0xLTEtOTc2MTY_c39c1d62-9d77-488d-abf2-b1bb9dcd880e"
      unitRef="usd">80000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0e06ca0731cf4d6a8f878bc559195695_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0xOC0xLTEtOTc2MTY_642612af-6240-4874-bdb3-cb9e74f634cc"
      unitRef="usd">75000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1654b4f6b905425eb698282a6331007e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0yMC0xLTEtOTc2MTY_4f25244e-b29c-49a0-96df-752c6f196d51"
      unitRef="usd">146000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i871d07741b564eae82a08aa0199ea0cd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNS0yMi0xLTEtOTc2MTY_06218959-f3fa-4f88-b33a-a9739d7575a1"
      unitRef="usd">125000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib37c40029abd4cb58eba88c002702a40_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi01LTEtMS05NzYxNg_b13d274c-377b-4f94-8f19-91f293e51460"
      unitRef="usd">-11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iceb8785d8ad7402c9c7f7eb39826f245_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi03LTEtMS05NzYxNg_459d8db2-de16-4249-b47b-92bbaf5e6aa9"
      unitRef="usd">12000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi05LTEtMS05NzYxNg_6c901f41-e50d-48f6-bfc3-cbcf483489f6"
      unitRef="usd">-3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3d6ef1b50dd847ef8aafa94acba4e841_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xMS0xLTEtOTc2MTY_bc405da9-0bee-429c-8584-605ab8d47c88"
      unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6b456e53d96948d096132c028d6d6d45_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xNy0xLTEtOTc2MTY_90cab837-a229-4ae8-8871-bf520beda558"
      unitRef="usd">114000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaf06b1b60dd7473091c775a625e20ee8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0xOC0xLTEtOTc2MTY_a6074777-1a91-49d0-a0d7-38c4cbdfec94"
      unitRef="usd">118000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0yMC0xLTEtOTc2MTY_c8984ab6-b596-4002-a22e-d862c56de4da"
      unitRef="usd">216000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie235947ffd0b4fd494f966cfa005097d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjhmYTJmMDE1OTI4OTQ5MjlhYTU1ODBkNjNmMzU1MzVhL3RhYmxlcmFuZ2U6OGZhMmYwMTU5Mjg5NDkyOWFhNTU4MGQ2M2YzNTUzNWFfNi0yMi0xLTEtOTc2MTY_d73103b7-684a-4597-b9b9-057e583a9cf6"
      unitRef="usd">234000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTgx_3c8bc558-78c6-4363-8d76-a31f89b347a8">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the recorded liability associated with the integration plan for the six months ended June 30, 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other integration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ib759084aea2f4496bf0b655de783f845_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMS0xLTEtMS05NzYxNg_7328b8e3-489b-4e4a-b44b-f90fbea5eeb8"
      unitRef="usd">222000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9cf0ce88a8a04b83934728dac91cf848_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMS0zLTEtMS05NzYxNg_6b53bfb8-aae6-4d5e-bc50-f86458d8225e"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMi0xLTEtMS05NzYxNg_0b7c669c-07c6-47e1-98d4-617f10ce82cd"
      unitRef="usd">-3000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfMi0zLTEtMS05NzYxNg_90fbe789-821b-452e-aba1-b4af63de533c"
      unitRef="usd">199000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i7570209272a04303b295e10fbfbaa969_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNS0xLTEtMS05NzYxNg_6e5042d6-1282-4cb4-af6d-0091d84ceedd"
      unitRef="usd">90000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i1b4df6c592544227855270f51208be85_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNS0zLTEtMS05NzYxNg_8f66fbe4-15cc-42ac-ad5c-638138436800"
      unitRef="usd">220000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="ia9690c3dd790403b890e9214d1dca483_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNi0xLTEtMS05NzYxNg_fe222c8f-c69b-4ed8-8059-18b1d696b1b0"
      unitRef="usd">129000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8ca60bffa3784e57811f6fbbdf1b19bb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjRhN2RkNzI0MzczNTRlNjc5MDY5OWRiNTM5NDgxNDBhL3RhYmxlcmFuZ2U6NGE3ZGQ3MjQzNzM1NGU2NzkwNjk5ZGI1Mzk0ODE0MGFfNi0zLTEtMS05NzYxNg_f6963668-952a-4f59-8d9f-a3c7d7b30896"
      unitRef="usd">12000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i641166a797c04452b983f67696448927_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfODQ1_038bc44d-d712-46f2-9fb4-752dd265e946"
      unitRef="usd">36000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMTY0OTI2NzQ0Mjc0MA_400357f8-13c4-45b5-9fb8-3455b51b5cde"
      unitRef="usd">93000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie93c2d6ffcd9446ca4da0534ab40b4da_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfMTY0OTI2NzQ0Mjc2Mw_e86b80c3-207a-4c51-9dc4-964142655559"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib96b0b1b9688402b88d483caeec8f26e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfODYz_7092185f-af41-411a-9e4d-02259a402bdf"
      unitRef="usd">43000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RleHRyZWdpb246ZDFkYWYwOTcwNWM3NDNhODg1NDU2Yzg1ZmUxZjIxYjRfOTgz_f410ceaa-ce86-4897-b9bc-a011e5832ace">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i7ebc83f6b36448f796534e54e707d893_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMS0xLTEtMS05NzYxNg_f198a1a8-829f-4a3a-bbe7-edbeb3569f5e"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <abbv:RestructuringReserveCashSettledRestructuringGainsLosses
      contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMi0xLTEtMS05NzYxNg_115121e3-c901-45fc-b0e4-7e81df893ca9"
      unitRef="usd">72000000</abbv:RestructuringReserveCashSettledRestructuringGainsLosses>
    <abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i3d2107239f614bf1b0ba58e886522643_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfMy0xLTEtMS05NzYxNg_8f2df836-269e-4c75-af10-587cb1b5e3ac"
      unitRef="usd">13000000</abbv:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="i99ca5c0ed3734cb0b0a99ad300871adb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl82NC9mcmFnOmQxZGFmMDk3MDVjNzQzYTg4NTQ1NmM4NWZlMWYyMWI0L3RhYmxlOjE3ZmU0OWE0OTUzMDQxNzRhMjM3NmQ0ZGVlNWQxNTA0L3RhYmxlcmFuZ2U6MTdmZTQ5YTQ5NTMwNDE3NGEyMzc2ZDRkZWU1ZDE1MDRfNC0xLTEtMS05NzYxNg_3d307867-27ea-46d2-84c1-37e747dd56f2"
      unitRef="usd">92000000</us-gaap:RestructuringReserve>
    <us-gaap:DerivativesAndFairValueTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTM_1ea2220c-aebc-4dbe-b4fa-aa782b8096b0">Financial Instruments and Fair Value MeasuresRisk Management PolicySee Note 11 to the company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie&#x2019;s risk management policy and use of derivative instruments.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.7 billion at June 30, 2022 and $1.1 billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of June 30, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $750 million at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.2 billion at June 30, 2022 and $8.2 billion at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling &#x20ac;4.8&#160;billion at June 30, 2022 and &#x20ac;4.3 billion at December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of &#x20ac;5.9 billion at June 30, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at June 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of AbbVie&#x2019;s derivative instruments on the condensed consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013; &lt;br/&gt;Derivatives in asset position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013;&lt;br/&gt;Derivatives&#160;in&#160;liability&#160;position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain derivatives are subject to netting arrangements with the company&#x2019;s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $73&#160;million into cost of products sold for foreign currency cash flow hedges, pre-tax gains of $2 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to AbbVie&#x2019;s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $402 million for three months and pre-tax gains of $501&#160;million for the six months ended June 30, 2022 and pre-tax losses of $126 million for the three months and pre-tax gains of $256 million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement&#160;of earnings caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury rate lock agreements designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as hedged item in fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 2 &#x2013; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt"&gt;Level 3 &#x2013; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company&#x2019;s management about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable &lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable&lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, probabilities of achieving the milestones, time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%- 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for unachieved milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for royalties by indication&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2022 are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $148 million as of June 30, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of total net accounts receivable, three U.S. wholesalers accounted for 76% as of June 30, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie&#x2019;s pharmaceutical product net revenues in the United States were to these three wholesalers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Humira (adalimumab) is AbbVie&#x2019;s single largest product and accounted for approximately 36% of AbbVie&#x2019;s total net revenues for the six months ended June 30, 2022 and 37% for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt and Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to June 30, 2022, the company repaid $1.7 billion aggregate principal amount of 3.25% senior notes that were scheduled to mature in October 2022. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the company repaid $1.8 billion aggregate principal amount of 2.3% senior notes that were scheduled to mature in May 2021. In May 2021, the company repaid &#x20ac;750 million aggregate principal amount of 0.5% senior euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in May 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iae698ca482024ce3b8216d18a4baf683_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNTM4_c86c5fc6-4533-4633-9d8b-15ea6ac3db16"
      unitRef="usd">1700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4524aeddacca4e89affea472fd4d9845_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNTUx_d661f281-feb5-4a02-abca-49863ba7f02e"
      unitRef="usd">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNzAz_b5908299-3e8f-417e-a8d7-0d59f2d49985">P18M</us-gaap:DerivativeTermOfContract>
    <us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1
      contextRef="i06bd3af3b0034f6a901e8606cb000821_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODk4_177446da-16d9-4c92-a3a1-9c0c821ec89c">P6M</us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2528382e46b44d108bf6d00b5efc76b8_I20190930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTA0Ng_763e7e83-50af-4c51-a415-a37b66f88f30"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i12ea8e2e6bee41e29619c4f66c42dbe3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OQ_92fbaf3e-bc41-4780-b7b6-f96c54cfd3d0"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7aa7cb14d24744b7acd20b1e031fb6b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OQ_a0e76e63-97c6-4e4b-ad88-93ec19727133"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iba71512b143247428f9ba4531e9ff25d_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjQyNA_fb01b324-949c-459c-a797-11135255d29a"
      unitRef="usd">7200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i910af4ba6c4148dead70c8fa5c3026a9_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjQzNw_a779ef10-ecf2-4add-b783-ade1185de08e"
      unitRef="usd">8200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a19c3fd69054e33b86e0c727461ec6d_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjc1NA_501efd62-68af-4ba5-855d-a06267230063"
      unitRef="eur">4800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1a04bf70fbd049c193fbd17df553937c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjA1MA_748f681c-1d7a-4356-ab11-17854a9005ab"
      unitRef="eur">4300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iea76646782af496e869aa248190a44f5_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjg4Mg_b6a7b71d-9d63-4bd6-855e-91a42c5493e9"
      unitRef="eur">5900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icadd7ee0185740f48c4b33bcf2366cfa_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMjg4Mg_f51f39f1-f721-4c0d-ad1e-240e929be666"
      unitRef="eur">5900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie930d15d61914f70acd5df79dc6f905b_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzM4MQ_5256f2de-d6bc-46ca-909a-cf5872df00ee"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i48bd044943e9493c89b9abd3d5e526a6_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzM4MQ_b64ff904-981e-4953-b942-6d755a03cab2"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_83eafbf2-c5ed-43b1-8e82-8a3e339e81d8"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_8d6ff385-6bd6-45f9-902d-a17d47d8b6c8"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_a446347e-4969-463b-b295-b41a940371e9"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMzY1MA_e804acc3-6795-4fba-ba66-a89ac7e67add"
      unitRef="usd">0</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyOTU_7369f69a-da97-4c0a-93e8-2844d2e07179">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of AbbVie&#x2019;s derivative instruments on the condensed consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013; &lt;br/&gt;Derivatives in asset position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value &#x2013;&lt;br/&gt;Derivatives&#160;in&#160;liability&#160;position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;sheet&#160;caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5ea75dcf12dd4babada42fe684de9583_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy0yLTEtMS05NzYxNg_af6cbc73-d66d-49b9-a0b5-01a859791ff9"
      unitRef="usd">47000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i50577511b38f48d9809921e16e47f00e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy0zLTEtMS05NzYxNg_6cef5034-f67c-4cdc-9da4-6020742d9f31"
      unitRef="usd">51000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8a4006483b344921a0461483796c88d1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy02LTEtMS05NzYxNg_bd4a4164-42cd-4106-b43e-89781a435aed"
      unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iae0ed5cfd5e041159ae295f44339cf2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMy03LTEtMS05NzYxNg_331fbaa6-48c8-4f82-a0dd-c87934ded128"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4fdb8595f8fc429f8bcbb4158edd7889_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC0yLTEtMS05NzYxNg_d3621d0d-0769-48cd-b221-50a1aaadab39"
      unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3d3b1067e45a4422969dfe03a89a0497_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC0zLTEtMS05NzYxNg_24dd831b-a05c-441c-8af8-5617794a29a7"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i315f4ccb8fbd487f8663eb19701710d5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC02LTEtMS05NzYxNg_9999b9f6-3fa0-419a-8cae-0757d6dd5023"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if3b21adb7b594e90b42f8a6d7c1542b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNC03LTEtMS05NzYxNg_5ee6b137-621d-42d5-a34a-e9b93ebde3cc"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if9a9fc635cec47649c6b29ca40ecc4f4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS0yLTEtMS05NzYxNg_f9d35179-8f63-4f16-ad6b-396961863871"
      unitRef="usd">32000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i10501d2d359c448ab6d314b187853a21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS0zLTEtMS05NzYxNg_afef2ea9-5e20-4a1a-982b-ae2d36afff1b"
      unitRef="usd">149000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i4d1fd48dad064b5dbbcfd0c6de9a08b1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS02LTEtMS05NzYxNg_fb30368c-8da7-43c6-b26f-03e3f9c83f70"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib7c14573e31f4f1faeb7cb5d171e2310_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNS03LTEtMS05NzYxNg_4c08a46c-4b3e-44fb-bd0d-b1dee6c37c79"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i739c681a88d742ad8f180ae17ea5b87e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi0yLTEtMS05NzYxNg_289bc242-6f9d-43b8-b99c-ff0e911277f7"
      unitRef="usd">129000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1ebe4f90c08a4455a7f43925dbdae635_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi0zLTEtMS05NzYxNg_7c8e9eb6-7a30-47f8-ba38-1c1456a2975f"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6801e00c9ec84d40ab46635262d0eaf2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi02LTEtMS05NzYxNg_ecfaeb8d-67cb-4672-94f6-1e5ade214614"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if3baae219b314a4b9cda87196725e47a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNi03LTEtMS05NzYxNg_5aaabf2f-a63a-472f-bcb1-e06fa9e3ce2b"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i386f36745a614aa0bfef448277833331_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy0yLTEtMS05NzYxNg_4cdc60f3-0860-4b5a-b65a-7ca5dede5857"
      unitRef="usd">22000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i71872c61ab7c46989f11583bf3a1dabc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy0zLTEtMS05NzYxNg_afd8888f-4330-469e-9d5c-842e333c5a1b"
      unitRef="usd">26000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia5156cbd23c04971a5dd83142a3d49dd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy02LTEtMS05NzYxNg_2d0059e7-cfe2-4986-bb56-41c2c5b7bcdc"
      unitRef="usd">41000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i37f9ab36c47243cb97c7b0b729b87202_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfNy03LTEtMS05NzYxNg_033c8a75-42cb-434a-b1a2-fb0c81c7da1e"
      unitRef="usd">13000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i755cc2dfdc554f1aa804588740a5c249_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS0yLTEtMS05NzYxNg_8068acf7-3681-48ea-8c70-8e7a4b37d09d"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i52aaa9318c7c4b838df81129cb70fa97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS0zLTEtMS05NzYxNg_ce370a39-ebd0-4edc-a602-5ed8fbffdc78"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0e16a7b014ce47f1b67466b07472b8a4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS02LTEtMS05NzYxNg_32266bb0-69f2-486b-8e66-d7e6262d3ace"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i98e8e4a49ca14f008f133fdd5954827f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfOS03LTEtMS05NzYxNg_7c6f30ff-82f7-4ac6-9932-562b25e550a5"
      unitRef="usd">7000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i709556ab9a9f465bade302574846826c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtMi0xLTEtOTc2MTY_f74eb5d5-c8ef-4c5b-a160-5967e12d0660"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idffcc1ea976042a3b863cd853e3615c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtMy0xLTEtOTc2MTY_23ec152b-3015-40b7-aa2a-5821f047a96a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9b69cc0d9c0a4003bff5b8b142db53cb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtNi0xLTEtOTc2MTY_b38d69e6-c2cd-4fc1-983e-b6e85d4249a4"
      unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3f3858f900834806a5d8b1b8a4ab8060_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTEtNy0xLTEtOTc2MTY_466c89a8-b628-4d3d-939a-ccd8527b56f8"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i321bab6a8ec644378bbfac816a7f1529_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItMi0xLTEtOTc2MTY_7eab817d-b153-4ce9-9fa9-092593c8787a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="icd1da7424536451694dbf819f1ad1afe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItMy0xLTEtOTc2MTY_2722492f-7762-4a0d-bac6-524216240036"
      unitRef="usd">26000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib2887c0ea8ed429e81e55af1fe19ba49_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItNi0xLTEtOTc2MTY_e4b52d62-a946-4f0e-9dcb-9bc49a0ae340"
      unitRef="usd">256000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6d9c65ce995c41569b56cea1f111c6c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTItNy0xLTEtOTc2MTY_285ac5a7-4b35-47c6-aab8-c7c1c67fc534"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtMi0xLTEtOTc2MTY_852c67cf-5d98-4c80-91fb-47a747e66e2c"
      unitRef="usd">236000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtMy0xLTEtOTc2MTY_d7358c6c-a4f4-4440-880f-9931be51dab5"
      unitRef="usd">267000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtNi0xLTEtOTc2MTY_64fc97ab-623c-44ad-953d-6ba80ff9ce26"
      unitRef="usd">318000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjMwMTUzYzkwZmMyNzQ1NDk5NjMwYWJmMmY2MmJiYjIwL3RhYmxlcmFuZ2U6MzAxNTNjOTBmYzI3NDU0OTk2MzBhYmYyZjYyYmJiMjBfMTMtNy0xLTEtOTc2MTY_4e3658cd-b94a-43b9-9d32-283dd26dc9f2"
      unitRef="usd">37000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTY_e324d443-9899-425d-b170-7ab0fc10aaab">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyOTE_6be19a31-ba0d-40aa-9ace-9b1850b7e713">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy0yLTEtMS05NzYxNg_4499ba70-50ff-4e96-ae6b-c8ba032d1c7a"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy00LTEtMS05NzYxNg_648980a5-234c-4e02-8cb2-965a8a1fd525"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy02LTEtMS05NzYxNg_8f5db9af-f1dc-46cb-ae64-66793bcac427"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ice9147234a7c47909a827383e386fa41_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfMy04LTEtMS05NzYxNg_bc6f7eca-8e7e-4b84-b761-61a98cf9bd95"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id138d3c5e46c4abb92ef8430a4f26319_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC0yLTEtMS05NzYxNg_c4d6b905-bf86-42de-a6d3-257aa5237647"
      unitRef="usd">304000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie8dd7bc0e23d41faa184abda662497d5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC00LTEtMS05NzYxNg_ecaaf11d-2afc-46d0-b925-ce23f4907486"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7cd4a1e9a8ea4134ab52c2dd025069c8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC02LTEtMS05NzYxNg_976f1c49-aae3-4e65-87d9-68c62851efb6"
      unitRef="usd">386000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ice9147234a7c47909a827383e386fa41_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNC04LTEtMS05NzYxNg_1c48c8bd-d011-4fa0-9cb0-72353030c6e5"
      unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i50774814001e48ec956e2b9c5f605ec5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS0yLTEtMS05NzYxNg_49a19bb3-f0c1-4c00-829c-53c98b81b208"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0fff8515f5964feaada59a50074f36b6_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS00LTEtMS05NzYxNg_21158f72-aa24-44bb-a8af-63f56abbfc17"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2242a34258674da88852f8da26f482ed_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS02LTEtMS05NzYxNg_b9b40ef8-809b-4c35-8fa9-83d04d4f599d"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia4b9c1a3268b4e8490a003cc3c407a54_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmM4Nzg2MjQwMTNmMzQ0NjNhZDdlMjQ0Y2ZkNGNmNTY3L3RhYmxlcmFuZ2U6Yzg3ODYyNDAxM2YzNDQ2M2FkN2UyNDRjZmQ0Y2Y1NjdfNS04LTEtMS05NzYxNg_7859643a-7271-41d9-ac66-61eeba2cb9f4"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="ie3c18991cb0745f7bfde8bb5e68396df_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDI2MA_ac7b1abc-974c-4dba-beda-65fb08bbfff7"
      unitRef="usd">73000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i34f3be30283c469288d3b140fb14f38f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDMyNA_0161d188-a178-4819-85d4-5549f62e9dab"
      unitRef="usd">2000000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet
      contextRef="i34f3be30283c469288d3b140fb14f38f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDM5Mw_3e0f85ce-2d95-45be-86f9-b011d530b9f5"
      unitRef="usd">24000000</abbv:TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4fa7e393d853413e8c347f6adc293a09_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjEzOQ_b859fd9e-a66e-4886-8965-84543da7ea79"
      unitRef="usd">402000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if2e974e271de4652b5cda15919ce55ec_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDYzMQ_827cc6a8-d046-4f6f-9109-0f9542dc0218"
      unitRef="usd">501000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i60b2022fd9784fa1800afc801df52ab4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfNDY2Mw_17d58a29-8486-443f-bb1f-7ec2e9ed3ae2"
      unitRef="usd">-126000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id93653ba690e49d188298eb65d621889_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1MjE1NQ_42cb51c8-9ad0-4883-b005-19cc825d2682"
      unitRef="usd">256000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNTc_73ed1f25-8e08-41e1-a1ce-ff479f9c22cb">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement&#160;of earnings caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury rate lock agreements designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as hedged item in fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7672ac59d1eb40d889784fa7661a5dff_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy0zLTEtMS05NzYxNg_8ba541d8-1ea5-43ee-9e54-fff9baa17dcf"
      unitRef="usd">18000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib8ba4ee6e978452e8a1317fb1eefa4ab_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy01LTEtMS05NzYxNg_a439cf18-57c9-4f12-9a8e-f1c1b03f9d19"
      unitRef="usd">-22000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i014cf1d076d344b3a853244e7ff6f7e2_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy03LTEtMS05NzYxNg_53df2e10-640f-40e3-bce2-a0817ce89bad"
      unitRef="usd">26000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ic92b470b9e9b4e9099e15d58a841ffa9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMy05LTEtMS05NzYxNg_43329fe5-714a-4232-8349-771103a576ab"
      unitRef="usd">-34000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i585d1d66efc44ae9819fbf2a01450a74_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC0zLTEtMS05NzYxNg_5ac6e852-5275-4a95-b2aa-14e13bf4f22b"
      unitRef="usd">24000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i708a87d51a194373a7ae0cfd26e60f16_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC01LTEtMS05NzYxNg_4516d19e-69fa-43e3-a593-8f61518e6716"
      unitRef="usd">5000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1576b42347bd40ac95a968ddb28a8b73_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC03LTEtMS05NzYxNg_dd1974bf-490c-402b-a15e-f871cffa6fee"
      unitRef="usd">38000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i9466c79412984d2eb3f7d8ac357eecc5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNC05LTEtMS05NzYxNg_7840e677-e3de-4f28-9c30-3bd57642d74e"
      unitRef="usd">9000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i42fdbf024af844d29c32652264e478ee_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS0zLTEtMS05NzYxNg_b01b869d-ce07-400d-a76f-0ec81752d3f1"
      unitRef="usd">-123000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5da9ec9481dd4073920e0859a42702c6_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS01LTEtMS05NzYxNg_0ea3ce66-dada-4be8-a074-297bfbea28fc"
      unitRef="usd">-3000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i68ce7ad10c8f4e0e8549ad2454dcf4f4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS03LTEtMS05NzYxNg_f58bdfc8-79d9-459a-a38e-a6ce00821f75"
      unitRef="usd">-164000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia8cc41372ed3492cbdd0b1794bfc39fa_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNS05LTEtMS05NzYxNg_10f12dc2-1440-4f5c-a776-3f5311e0fa9b"
      unitRef="usd">-28000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if4a5b327aee6478ca6d36a047ef148de_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi0zLTEtMS05NzYxNg_cbfcb11c-699f-4570-aa18-0e80e52b143e"
      unitRef="usd">6000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ief6806c0a00d42728328e0c191cb6c46_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi01LTEtMS05NzYxNg_a7298e12-c356-4b50-80eb-ab5b6140e21f"
      unitRef="usd">6000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7b17ef4e01764ead8e46800fa43600f1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi03LTEtMS05NzYxNg_ee63d773-6aac-4e99-95f7-c50a221dbdc3"
      unitRef="usd">12000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i48e376f561464510bf004ff1475b3177_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfNi05LTEtMS05NzYxNg_79b634b8-4c8f-46d8-abd5-d5427a1ab45a"
      unitRef="usd">12000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib3967d0c84ef4ab5b092b438c43a6bb9_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC0zLTEtMS05NzYxNg_fad94b7f-bb6c-4ab5-bf80-f64c5a611021"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ica001ccafca24ec1b40518c87036cbc3_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC01LTEtMS05NzYxNg_5c2ee1d4-f9a8-4454-809b-eefe50ba7dfe"
      unitRef="usd">-7000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i916d4573e04c4ebb82df425498689123_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC03LTEtMS05NzYxNg_b5fbf819-b626-4e85-a49d-ebcd6a2b7f58"
      unitRef="usd">-3000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i38c5f2e4fd04481eb9c96733c3ab6282_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOC05LTEtMS05NzYxNg_230c13eb-13bd-4755-89c6-dd1c9342541a"
      unitRef="usd">-14000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6b6d1c3a9b9b43ed888b26722a1ef814_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS0zLTEtMS05NzYxNg_e9598eae-d186-46ec-a387-1ec398a5575d"
      unitRef="usd">-99000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i81835d73a8d24f9fbf352588b381f229_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS01LTEtMS05NzYxNg_b4c0acd0-8fea-4593-9044-9446feb49e39"
      unitRef="usd">-11000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib14b54f083414973b49fd17c21639430_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS03LTEtMS05NzYxNg_2c4dee88-7dab-468a-b00b-8e7829161435"
      unitRef="usd">-283000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6e90fc724a5a42e48ee6a1d195f84ab8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfOS05LTEtMS05NzYxNg_3429ecd8-769c-4a4d-84be-ffab2a9c2e01"
      unitRef="usd">-68000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="i0ada3a46921346fd865f1babab324aeb_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtMy0xLTEtOTc2MTY_76af0bbc-38a7-4f30-b16a-aaacd3560894"
      unitRef="usd">99000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="i5306df8c08e44da98c277f0e759fd1ae_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtNS0xLTEtOTc2MTY_5ff95616-8421-45ed-a81d-16470ea9dfee"
      unitRef="usd">11000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="ia0873fa6f786493d98f649f5b8df8913_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtNy0xLTEtOTc2MTY_87913ff9-5748-436f-8eb2-6ec13def183e"
      unitRef="usd">283000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1
      contextRef="idc6789fba1c748ce81e02fec0c7a1680_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjUzMTA0NTAwMjM3MTQ2NWNhMzFiZGJlNjQ0OWVlMWU2L3RhYmxlcmFuZ2U6NTMxMDQ1MDAyMzcxNDY1Y2EzMWJkYmU2NDQ5ZWUxZTZfMTAtOS0xLTEtOTc2MTY_cf2577e4-fccb-4123-8235-639e57231ff6"
      unitRef="usd">68000000</us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNjk_691bdbe9-ce6b-443a-a53f-58cf8e3705e2">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable &lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in active markets&#160;for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other observable&lt;br/&gt;inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy0xLTEtMS05NzYxNg_98095244-c311-4aa3-9fb0-bb98f6f492bb"
      unitRef="usd">8521000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy0zLTEtMS05NzYxNg_5b75fd93-6660-4b98-97b1-eb63d9d7b884"
      unitRef="usd">4212000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy01LTEtMS05NzYxNg_ae9da209-43d0-4b27-9f06-906999bf5008"
      unitRef="usd">4309000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMy03LTEtMS05NzYxNg_80887d87-dfa6-4436-a992-a5d13b858cd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i870123ed29d24decb0df38ca4b783ed5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC0xLTEtMS05NzYxNg_d3b8eba0-2620-45a3-88bb-0c24c62768c3"
      unitRef="usd">1425000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4de815be0be44e778d9f2b95394472e4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC0zLTEtMS05NzYxNg_0a61f3b6-cf84-4c81-8288-90fb16350594"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i55b79104cfa54b9abca4b24b661bea9c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC01LTEtMS05NzYxNg_d3eabc8b-571d-4e27-b8d5-d87f2b140fdb"
      unitRef="usd">1425000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1b5a23680db6467891252a20dcb977d8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNC03LTEtMS05NzYxNg_90dd0218-fd64-4f9d-b397-203f340a5bdd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS0xLTEtMS05NzYxNg_b2d92b14-b734-40ea-8c45-47f85ff25417"
      unitRef="usd">37000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS0zLTEtMS05NzYxNg_7179ace4-0ea3-4807-ad53-c513732a6c81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS01LTEtMS05NzYxNg_3446af62-3a03-4b62-a52f-8b8d22fab19a"
      unitRef="usd">37000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNS03LTEtMS05NzYxNg_8ca8db30-8bca-4bdc-b3cd-3192202390f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi0xLTEtMS05NzYxNg_8654b5de-07b8-438d-992d-32d073e9655b"
      unitRef="usd">74000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi0zLTEtMS05NzYxNg_4912a6b8-df17-4d61-9e64-264f86e5c161"
      unitRef="usd">54000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi01LTEtMS05NzYxNg_e3bdb2d7-f41d-4b29-beea-802c817ec6fa"
      unitRef="usd">20000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNi03LTEtMS05NzYxNg_41259d29-5f76-4599-bf9d-4822614f7684"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy0xLTEtMS05NzYxNg_2ba879ff-104b-4e76-a898-e39867a93576"
      unitRef="usd">2000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy0zLTEtMS05NzYxNg_62e8bab4-0847-4ba5-a241-d9aa262def39"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy01LTEtMS05NzYxNg_0b76c4e5-4991-4456-bc63-c60bfe07ea1c"
      unitRef="usd">2000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfNy03LTEtMS05NzYxNg_0eeb6d5b-6faa-4039-a86d-73d24190d379"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia5130a9a2788493194f69310dd5fb80a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC0xLTEtMS05NzYxNg_8098e67e-8662-4050-93ba-5a6c09858a8c"
      unitRef="usd">234000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i0856d184c09c4cb990892955581e79dc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC0zLTEtMS05NzYxNg_ff29223f-1ed6-465d-a99b-18e3df548bcb"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idac4c3858d334f249fad7fb813cec175_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC01LTEtMS05NzYxNg_e4099c5d-babe-40df-a2e1-3f0ea9a046ec"
      unitRef="usd">234000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfOC03LTEtMS05NzYxNg_9448c568-5fa4-4bab-b0a9-2f4f5b96f3ed"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtMS0xLTEtOTc2MTY_423ec9e0-b703-4e16-9776-022afea31b9f"
      unitRef="usd">10293000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtMy0xLTEtOTc2MTY_f3cd3c2d-e3ba-409f-a227-d8b5ad49aa29"
      unitRef="usd">4266000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtNS0xLTEtOTc2MTY_3ee31aaa-12fa-4949-aab8-bf181025755b"
      unitRef="usd">6027000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTAtNy0xLTEtOTc2MTY_8fffb873-b16b-407c-a02d-47fdbfa4ca63"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItMS0xLTEtOTc2MTY_49ae0764-6fce-44a7-ae98-5c8a2c5504e5"
      unitRef="usd">272000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItMy0xLTEtOTc2MTY_d3d91a69-6daf-4f0d-b9de-432b6a7c4b99"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItNS0xLTEtOTc2MTY_f588d54d-24f1-43b4-b6b2-57ed1e1eb046"
      unitRef="usd">272000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTItNy0xLTEtOTc2MTY_60d4cd52-6903-4ce7-aace-c6a947721d50"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia5130a9a2788493194f69310dd5fb80a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtMS0xLTEtOTc2MTY_44582c44-1c02-495a-9b1e-31faa11d41fc"
      unitRef="usd">46000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0856d184c09c4cb990892955581e79dc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtMy0xLTEtOTc2MTY_5af5425f-bc19-4fa9-a777-6fa6883f69f0"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="idac4c3858d334f249fad7fb813cec175_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtNS0xLTEtOTc2MTY_2c69e26d-f59a-4b07-8173-d8fee38aad5e"
      unitRef="usd">46000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5ec53bda543b4ce7a5fed2759a6f0d38_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTMtNy0xLTEtOTc2MTY_ed6b8496-79d9-4c81-87e3-5acff206071d"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtMS0xLTEtOTc2MTY_781ae6e4-b0d5-49b8-935b-77f4e4c66dfe"
      unitRef="usd">15178000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtMy0xLTEtOTc2MTY_5a7b5736-4cd5-4587-b0d2-06baaa6f85f6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtNS0xLTEtOTc2MTY_bc3ee7da-584c-45f0-8838-b26ac46b6cc9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTUtNy0xLTEtOTc2MTY_0e845930-a066-4d64-a153-6355683cf076"
      unitRef="usd">15178000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i374e011a12484720b013a8ebf2f11a07_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtMS0xLTEtOTc2MTY_85f38e1d-d41e-4113-ac78-94af0de03f8f"
      unitRef="usd">15496000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i05c6f0124b2f40bbaf2452a271dea1a5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtMy0xLTEtOTc2MTY_346a158e-c533-4598-a48f-295671fc39cd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia351d42f430a4ed8b308f667517d9671_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtNS0xLTEtOTc2MTY_388f90ec-6db1-4bbd-a078-35a17dd906ee"
      unitRef="usd">318000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5fb37261f9244543bd3e42841c253c3d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjhkY2E0ZWI0Yzc1MzQ1YTJiMGNkYWNhN2U5YjhjMjZiL3RhYmxlcmFuZ2U6OGRjYTRlYjRjNzUzNDVhMmIwY2RhY2E3ZTliOGMyNmJfMTYtNy0xLTEtOTc2MTY_6c2cd8a7-c3a8-4c4a-bdca-7add14ea90ce"
      unitRef="usd">15178000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy0xLTEtMS05NzYxNg_2f804824-3ca1-44a8-9ab1-7e2534663119"
      unitRef="usd">9746000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy0zLTEtMS05NzYxNg_0aee1297-21e5-431b-951a-12a08d9ce80a"
      unitRef="usd">4451000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy01LTEtMS05NzYxNg_a440da8f-b088-424d-b258-d6b4c444359b"
      unitRef="usd">5295000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMy03LTEtMS05NzYxNg_9a4f6006-f2c4-469b-a1bd-09b315ac36ec"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i48db75cf5be84dcebf25c3be860e8891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC0xLTEtMS05NzYxNg_95495420-9347-4ad4-bed3-649fe0d9fbee"
      unitRef="usd">45000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifa8175f7411740adaed89dd39b020a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC0zLTEtMS05NzYxNg_7eb9a2e3-f8b9-4af5-8f08-afb3a16111b4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia5da0605afd0403a91a86f6fc2935d5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC01LTEtMS05NzYxNg_5ac105c2-4f2b-4f30-9565-eca1dcfed5bb"
      unitRef="usd">45000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3ad384a1ae084ceb824d660b0d1c00c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNC03LTEtMS05NzYxNg_7aee09f2-da3f-4e8d-a3df-7e48cee976d8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS0xLTEtMS05NzYxNg_10eae950-4d98-4a18-88e4-65e688069aa0"
      unitRef="usd">46000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS0zLTEtMS05NzYxNg_9afbf466-f05f-4b5c-83fb-70cc769007ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS01LTEtMS05NzYxNg_01854a5b-383a-4ed5-9a19-cd84e97e512e"
      unitRef="usd">46000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNS03LTEtMS05NzYxNg_973e8092-08da-4685-8efd-7df30fe7cac2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi0xLTEtMS05NzYxNg_14c4a2c4-63f4-444b-aa81-a7675fc58997"
      unitRef="usd">121000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi0zLTEtMS05NzYxNg_8cf3463b-4446-4d8c-9c60-88d96acd5bcf"
      unitRef="usd">100000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi01LTEtMS05NzYxNg_e783a4a5-6a57-4f0b-a8d5-1759d9cd2b0b"
      unitRef="usd">21000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNi03LTEtMS05NzYxNg_fdec86b1-3ee6-4153-9583-8fced9ca6ff9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy0xLTEtMS05NzYxNg_a80f7d20-962b-47cd-88f9-c9a5c60b859a"
      unitRef="usd">26000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy0zLTEtMS05NzYxNg_dab04d89-2176-4c3c-9dd2-201ce7e971b0"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy01LTEtMS05NzYxNg_f59e9496-8aeb-40a8-99f1-4699e5b0458b"
      unitRef="usd">26000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfNy03LTEtMS05NzYxNg_eecae072-2d16-4b90-9dfc-b59e78d5cdd1"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC0xLTEtMS05NzYxNg_820f89e2-eecc-453a-92ca-0be8189890cd"
      unitRef="usd">241000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i06facb13108b44fdb65aac8490d55d79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC0zLTEtMS05NzYxNg_644982e5-0da2-4bde-a79c-b3b21915c442"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC01LTEtMS05NzYxNg_d95f64fb-11af-4929-bba1-18cff0c6ad53"
      unitRef="usd">241000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfOC03LTEtMS05NzYxNg_094bfed1-89f9-478f-b4bf-c8fba4db8434"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtMS0xLTEtOTc2MTY_36da393b-dd69-46fe-9dd5-3b507a9242c6"
      unitRef="usd">10225000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtMy0xLTEtOTc2MTY_d6cc48f4-36e0-48f0-9317-c66da6ce3efc"
      unitRef="usd">4551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtNS0xLTEtOTc2MTY_5e1afe0b-06c7-41a5-911b-586a6cffce88"
      unitRef="usd">5674000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTAtNy0xLTEtOTc2MTY_34f22ba3-805f-4550-b4bc-93c4f274377c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItMS0xLTEtOTc2MTY_c8ad1e66-9cb3-4d39-8a79-baf93102596d"
      unitRef="usd">22000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItMy0xLTEtOTc2MTY_526f3bee-bcf8-4087-a2d1-1900b02ebaa4"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItNS0xLTEtOTc2MTY_86dea381-7d4d-4dd1-bdc7-275d9686c8da"
      unitRef="usd">22000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTItNy0xLTEtOTc2MTY_336a4f8c-c3b7-4955-ba6a-1e69f0cf4cc8"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i96ff3e92c3264d63ad65a2f8a72aae04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtMS0xLTEtOTc2MTY_84661a7e-ca57-4601-99b5-f198cd4b71cd"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i06facb13108b44fdb65aac8490d55d79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtMy0xLTEtOTc2MTY_8c73c61c-c5d8-40e1-961b-14b6c551a353"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6b95b67cb2cc42beb9574e0fa0911f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtNS0xLTEtOTc2MTY_42704efa-34f6-45f4-ad0e-e00e5d5a96e4"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibe866ba9f76b487f8fea35f16cf05bb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTMtNy0xLTEtOTc2MTY_993b91b9-d0e7-492d-8276-f4626205324c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtMS0xLTEtOTc2MTY_f115a378-b44c-4f5a-bec1-d35c9a3f3ed6"
      unitRef="usd">14887000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtMy0xLTEtOTc2MTY_43651b98-0e0f-47db-ab9a-485f97b365fb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtNS0xLTEtOTc2MTY_5d97e5df-c832-4be8-9eb9-20562447319a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTUtNy0xLTEtOTc2MTY_3c0a17b1-793a-4ad0-8e88-d0bba7abc73d"
      unitRef="usd">14887000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i18eaf40a654b457087ccb29d6d1bec0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtMS0xLTEtOTc2MTY_73f2c119-babc-4f61-b711-05159691553d"
      unitRef="usd">14924000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7eae17c36c184345887eaf72ceb217e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtMy0xLTEtOTc2MTY_51f90691-6636-4f15-bcec-654be4733bd3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2cb9b6002b78431987a6b16d086053e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtNS0xLTEtOTc2MTY_5467070a-2d4e-4335-96dc-a2001b1547ad"
      unitRef="usd">37000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1d3593e90c734bc2a603ee6d35d961d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjg5N2Q2Y2U2MDE5NjRhOGE4YjZmMjAzNDM1ZDVmNTFiL3RhYmxlcmFuZ2U6ODk3ZDZjZTYwMTk2NGE4YThiNmYyMDM0MzVkNWY1MWJfMTYtNy0xLTEtOTc2MTY_d3593a3f-a90f-4551-85d2-ef872d70f784"
      unitRef="usd">14887000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODA_ca665da4-331c-4b11-bc3e-41fcba30be72">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%- 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for unachieved milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for royalties by indication&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2034 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iebba20d42aa84545b03550839e4d1ff6_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjYxMzllMmJjM2I2MzRhNWY4MTlkOTlhMTVhOWY4MmNiXzQ_b1f1d050-1b0a-433b-8146-62888a9af1c3"
      unitRef="number">0.024</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i06c67c0260e9410f924a9a9f01b3ccc6_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjYxMzllMmJjM2I2MzRhNWY4MTlkOTlhMTVhOWY4MmNiXzk_b0718a29-df9c-49db-b0ab-4cf47420dcbc"
      unitRef="number">0.048</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie0f761535955494a9972245ac0bfc828_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0"
      unitRef="number">0.041</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i50f71d020d2441aead5e84026b2c81c1_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmRjOTE5YzRkNDc1ODRlNGRiYzUyZGRjMDI1YzVmNWZiXzQ_23dc4b34-01a4-453a-a971-1694619fad82"
      unitRef="number">0.002</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic2acaa96ed3e4d86ba6f80df2d1d23bc_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmRjOTE5YzRkNDc1ODRlNGRiYzUyZGRjMDI1YzVmNWZiXzg_f2798496-ed41-44f0-bf06-944af38ad346"
      unitRef="number">0.026</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i314e59ebff154934a9005087b9a2e107_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191"
      unitRef="number">0.017</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie09bf75182a24ca78e3c58dda4a972f3_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjQxYTZlMzkxNjY4NTRkM2I4ZTc0ZTBiYWQxYjA5N2FlXzQ_3197b046-ab8c-41f6-8c03-4fcfb1b8bf63"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic9667464bea64d7bad769b8345f8228a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjQxYTZlMzkxNjY4NTRkM2I4ZTc0ZTBiYWQxYjA5N2FlXzk_98008e62-fa0d-4648-92ae-20d10a3948bf"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie0bd307199034ef2b862a230a13fa5ba_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716"
      unitRef="number">0.95</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaed7fba9444e4475a8d1d1fe03296f36_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmY3MWI4ZjlhMmRiYjQ3ODU4MTgxMzA1YmIxZDhiNjlmXzQ_655a23ed-be60-48ba-be7e-304589734971"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i618ae073cb994907a536ff425fc537bc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmY3MWI4ZjlhMmRiYjQ3ODU4MTgxMzA1YmIxZDhiNjlmXzk_fce19593-12ed-4fd2-962a-9bd10c6982f4"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if01319674f9d40b28d7f32e4d0729277_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa"
      unitRef="number">0.90</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id2fb100f05394ac080c865b058757667_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0db82b411f6d44028dadc73a81fbddce_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib8e7e2cafe6f4f15bc1374d8dcb0e6b7_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da"
      unitRef="number">0.99</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3f97658421c74a6883a23a2e06b3ea74_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib9facac76db04d889e4a084485f7e2e5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="idbc5716897864f0c9cc862e142a2ef79_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128"
      unitRef="number">0.96</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ifcb4215fa5f64baaaaf01df3d5b4e8c2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkMTVkOTA3NDUwMTQyYjhiMjg0ODExY2EyNGI3ZmFmXzQ_0b8b2c25-c1a8-4b7e-97f0-7f5753096f76"
      unitRef="number">2022</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iae0da0e73d4249789bbdb7acc456ca25_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkMTVkOTA3NDUwMTQyYjhiMjg0ODExY2EyNGI3ZmFmXzk_afd424c6-9f36-4f12-9c05-6ab95d2ef4ba"
      unitRef="number">2034</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i939b4297b7084062a87e128f885293a2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d"
      unitRef="number">2027</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if2e05916e33146c8ae338e992f86d223_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyNmEyOWIwZGI2MjQ5YzM5YzIzN2VhOWY3MGNjZjc5XzQ_596846ab-d06e-4559-9fb6-4026fdb144a9"
      unitRef="number">2022</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ieb38cc669ce545e9bfccb54b2b798037_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyNmEyOWIwZGI2MjQ5YzM5YzIzN2VhOWY3MGNjZjc5Xzk_ff5c88ba-feb4-478d-804a-f75226968e65"
      unitRef="number">2034</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i889c9bd592d04c6ebb6f06b0687977ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0"
      unitRef="number">2027</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic282be83b0124b8e836b6f16a56eda8f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0d36de35-e35e-4faf-9566-d2931da1b051"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="idb1927254a0845d7a42c9414c93e995c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i286cd5a8d73f41ecbe7fec3a2ee10763_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i876bd774408e4212b518335222b57f15_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_f8338e58-64b8-4547-a026-88f77f9fd644"
      unitRef="number">0.89</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_0f718875-1840-4908-9c19-035b9644bb37"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_24be8f45-ebbd-4383-a4c2-58910a394bcd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_ac97a54f-0ae2-4983-91b0-3af187bff0ac"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODA0Mw_e55f3188-ec26-4085-bbb6-9ba25e8a5910"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDg_e9c4b106-6f5d-473c-a06f-69a7fb930d9a">The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMi0yLTEtMS05NzYxNg_a517a3b1-98fb-4c54-b0f7-4d01f923fdfb"
      unitRef="usd">14887000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if1816b7eac954956b4765afd462e3f73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMi00LTEtMS05NzYxNg_025b9fd5-78f4-4582-bafa-9df73323e83b"
      unitRef="usd">12997000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMy0yLTEtMS05NzYxNg_7a927ee9-a23a-4bd3-9e9c-d2df34dc6adb"
      unitRef="usd">-861000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfMy00LTEtMS05NzYxNg_685135e7-a810-4555-87fc-2bdab00621ab"
      unitRef="usd">-2349000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNC0yLTEtMS05NzYxNg_2d58860b-4958-4242-81ab-9ff2bd52271a"
      unitRef="usd">570000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNC00LTEtMS05NzYxNg_08c21a1c-bd46-441b-86a2-e9fbb72b7337"
      unitRef="usd">357000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNS0yLTEtMS05NzYxNg_89874aa1-8340-4835-b696-73de73939334"
      unitRef="usd">15178000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic21c67498e334a7c8353b31179d82f98_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmNiY2RjYTQyMTA5NzQzMmY4ZDEyZDRlY2Q0ZWE3ZWRlL3RhYmxlcmFuZ2U6Y2JjZGNhNDIxMDk3NDMyZjhkMTJkNGVjZDRlYTdlZGVfNS00LTEtMS05NzYxNg_97bd53ed-9e8d-4a11-a719-3a198b68b864"
      unitRef="usd">14989000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyNzE_3a835962-69e0-458b-ad2e-d3c07ac69ec8">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2022 are shown in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis&#160;of&#160;fair&#160;value&#160;measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Approximate fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&#160;active markets for identical assets &lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant other&#160;&lt;br/&gt;observable inputs &lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant unobservable inputs &lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt and finance lease obligations, excluding fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi0xLTEtMS05NzYxNg_e1d2a03b-ca4b-4b45-b5e6-8752ad9a3c67"
      unitRef="usd">17000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi0yLTEtMS05NzYxNg_d5a1fd10-b1e5-48ef-ad38-92f6228512a3"
      unitRef="usd">17000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i630843de12c0427290cca6b9829cfc34_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi00LTEtMS05NzYxNg_0478e6a5-afa0-408d-b4c9-41cdb3b745ca"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi02LTEtMS05NzYxNg_b5485abf-5c49-40b6-8ae4-98c7e5f3e12d"
      unitRef="usd">17000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNi04LTEtMS05NzYxNg_d2df51e7-041b-4d13-bd93-82aea25c3f48"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy0xLTEtMS05NzYxNg_7577dfd1-a700-4c19-b5ae-6c307c99e68b"
      unitRef="usd">11918000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy0yLTEtMS05NzYxNg_f8539308-cd35-47f5-b5a3-f65446238912"
      unitRef="usd">11906000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy00LTEtMS05NzYxNg_e055d2fd-81fc-49f2-afed-f2ad2def6e35"
      unitRef="usd">11549000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy02LTEtMS05NzYxNg_22a40f84-2302-404a-8d99-35a8c5e85142"
      unitRef="usd">357000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfNy04LTEtMS05NzYxNg_ce2f5f70-5458-46c1-9892-da2636dd68b4"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC0xLTEtMS05NzYxNg_2fbb35e6-4b2a-4566-a9e7-2491fa35ee17"
      unitRef="usd">61202000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC0yLTEtMS05NzYxNg_4d8dd53c-d82b-4db3-b920-2fb1825df574"
      unitRef="usd">57471000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC00LTEtMS05NzYxNg_bce914ea-9df9-4322-8786-bd8d4290e1a2"
      unitRef="usd">56674000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC02LTEtMS05NzYxNg_5982f453-ef35-4fd8-96d0-8b45809e42dc"
      unitRef="usd">797000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOC04LTEtMS05NzYxNg_31ce231b-891e-4185-b0cb-c3d8fa877273"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8a130b1f3ea24b0d8fc2702c36680e9e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS0xLTEtMS05NzYxNg_42fd2c7b-efe0-49af-bf26-ce8bcac272fb"
      unitRef="usd">73137000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6cba587881ea4be1a6fcd26255e217ce_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS0yLTEtMS05NzYxNg_12b8295c-da4a-45d5-a3d2-fe3a0cc9615e"
      unitRef="usd">69394000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie36438b2d2a046c2bc0d3fac167d8b39_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS00LTEtMS05NzYxNg_140b9979-3ef2-4590-9c22-c51eb53a663a"
      unitRef="usd">68223000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibaef6f99af86488d838a3ce30fbf6f87_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS02LTEtMS05NzYxNg_8d50148a-d815-4390-a08b-f6950e5b0634"
      unitRef="usd">1171000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9692678e8ae94f98873e8e482dbe735a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOjRmMGRkYWIwYjJmYjQyYjFiMzE3MzJlNmE5Mjg5ZGYwL3RhYmxlcmFuZ2U6NGYwZGRhYjBiMmZiNDJiMWIzMTczMmU2YTkyODlkZjBfOS04LTEtMS05NzYxNg_83cc26b6-7ad9-42e6-9995-c6a13a8b12b3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShorttermDebtFairValue
      contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi0xLTEtMS05NzYxNg_b36d7d50-44da-4a4c-822f-08d0f7baf511"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi0yLTEtMS05NzYxNg_7d52a375-338e-4efa-af1f-429c318e4cee"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="if0e5774a49944c5ab537c8ac3146f7c7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi00LTEtMS05NzYxNg_8f5a9496-d887-45c1-8d02-83ae917c82e9"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi02LTEtMS05NzYxNg_66a318e8-51ac-463e-ad53-4293490f6152"
      unitRef="usd">14000000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNi04LTEtMS05NzYxNg_417245c0-d301-4fe5-b8d6-0a3d593f4a80"
      unitRef="usd">0</us-gaap:ShorttermDebtFairValue>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy0xLTEtMS05NzYxNg_f6dbd383-e09e-47bb-b9a9-5b63b13de313"
      unitRef="usd">12455000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy0yLTEtMS05NzYxNg_1b87484f-e7cc-44fc-b314-8add9b3b8c8a"
      unitRef="usd">11830000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy00LTEtMS05NzYxNg_83f1ecdf-3d4b-4aaf-b49b-f0c88d83130b"
      unitRef="usd">11329000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy02LTEtMS05NzYxNg_4cf426d6-13bd-4ff5-b87f-068873d26a23"
      unitRef="usd">501000000</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure
      contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfNy04LTEtMS05NzYxNg_155d3aa5-6a44-4c94-a3b8-eb0dda087094"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC0xLTEtMS05NzYxNg_8f2b948b-4f51-4b3c-beba-fba7cc01cbf4"
      unitRef="usd">64113000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC0yLTEtMS05NzYxNg_2fac798b-e9dc-4aef-9aa3-96d70d1616e9"
      unitRef="usd">71810000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC00LTEtMS05NzYxNg_bc1264c4-971f-47a8-b725-ed62f50f0380"
      unitRef="usd">70757000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC02LTEtMS05NzYxNg_fcbe0b9a-3955-4c2f-ac11-a1c0be3aec8e"
      unitRef="usd">1053000000</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure
      contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOC04LTEtMS05NzYxNg_a65da8b0-fe81-4c8d-a460-a8f7bfaa918e"
      unitRef="usd">0</abbv:LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia83a0493fb014bfb876176f16f9cb06e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS0xLTEtMS05NzYxNg_98ccca8c-8452-422d-bf5b-f60d6897b59b"
      unitRef="usd">76582000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifd887f1676e449bba91f5fac45a6b160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS0yLTEtMS05NzYxNg_01be99c6-b6cf-41a4-8acb-b82cca528ef2"
      unitRef="usd">83654000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic02e4644d7e34f3a9d61d9f81075f26d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS00LTEtMS05NzYxNg_0ea0d3e4-9f92-40be-9d9d-ceb5dbf85f5d"
      unitRef="usd">82086000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id1bbf73c55a34d1ab456aee0f16a6b14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS02LTEtMS05NzYxNg_51567f20-e313-41bb-b3c2-9d31fe2c113c"
      unitRef="usd">1568000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i641a3f2e695f488cb5096a3ed75f5c70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmE1Mzk0ZTZlMDhmMTQ4OWRiNGE1NGRhODM5MGVlYTYyL3RhYmxlcmFuZ2U6YTUzOTRlNmUwOGYxNDg5ZGI0YTU0ZGE4MzkwZWVhNjJfOS04LTEtMS05NzYxNg_1cad6f30-e57e-4171-af4d-7b66ec4d43b2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTA5OA_6e594fa3-ced3-490e-b454-bed18c233848"
      unitRef="usd">148000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id5695becc3594da099d28f6bd485f543_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTExNA_f3ad7dca-5a77-4b4d-a014-e8a4b570713a"
      unitRef="usd">149000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <abbv:NumberOfPrincipalUSCustomers
      contextRef="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTI5Mg_c53a3b91-02b7-4b66-a215-84a53fb082a6"
      unitRef="wholesaler">3</abbv:NumberOfPrincipalUSCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i986059b4f35d4a8daa2894ea55ad12ea_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTMyNg_b2929e52-50c3-4282-a951-0e8ad4ccd672"
      unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i599b7447e0804132a06303bb0b4a837b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTM0Mg_1d82ebda-221d-4039-a06e-436d5f5e28aa"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <abbv:NumberOfPrincipalUSCustomers
      contextRef="i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTQ2MA_c53a3b91-02b7-4b66-a215-84a53fb082a6"
      unitRef="wholesaler">3</abbv:NumberOfPrincipalUSCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32d41cc6c1144c0eb773b14b0f419c16_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTU2Mw_573b4830-5497-4acf-a228-bdfbad0664a7"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9583131a11e44e7aa0e4827ce3a411c0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTA5OTUxMTY0MDIxNg_7f60e00a-61a7-4a9d-8dec-cbf504d86011"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTY5MA_0de06eb9-6718-46b9-8da9-3ccdca6adef7"
      unitRef="usd">-2900000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e9e7fa9be3843a7a5bf54dd5d8ac7a9_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTcyMw_50cd657a-671e-49b8-b75c-1f9af4a11e50"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="ibf34cf7670534dd3897946050fdaea95_I20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfOTk1NQ_5d196296-39ed-48cb-af8a-eca86dc12c7a"
      unitRef="usd">2000000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentTerm
      contextRef="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDI_a7d7f7e4-2082-40aa-a795-75978962971f">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i1105765cd3c845ee84e3c9353184c1f9_D20220201-20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAwNTE_a3a2c0f3-862b-4165-a2dd-30925b7c067f"
      unitRef="usd">-2000000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:LongTermDebt
      contextRef="i704e3023cf64424fb2e548f19872b22b_I20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAwOTA_f57a98ac-2eff-44d8-820b-63ab3e4fa2bc"
      unitRef="usd">2000000000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="idd94ae07eaed40088bbf3d7cfc1781e6_D20220701-20220731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTIwOTQ2Mjc5MTcxODM_80f74593-4b1c-4b7d-bf03-c6054000ec52"
      unitRef="usd">-1700000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6a0fa7a03c79447e8db8a5d601b5fc8c_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTIwOTQ2Mjc5MTcyMTc_36692362-8197-40ea-b3a3-1ebcb4a3d1f4"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="ia77710e9c10447af9cd57b70a76e9850_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc0Ng_94961170-78b5-4002-b96b-5fef89e4852d"
      unitRef="usd">-1800000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieb78cb6f6ae44cb296ba20fe69d1e6a2_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc1Mw_ec994b63-4ede-4b29-bd80-6b86a3a5190a"
      unitRef="number">0.023</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i9c46c9af7913451184bb8271e2852db1_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc1Nw_809da677-6ceb-4a37-935d-b34132459229"
      unitRef="eur">-750000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2610045aa69e4030bc8c18d427b52b41_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc2Mg_4c4b690d-d597-42e9-af7d-5c60d42178b6"
      unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="ie0483da2eaea4022985712c39ea59d19_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTY0OTI2NzQ1Mjc2Ng_68b2214f-fe8c-4ab9-ba98-ea0b47acaf19"
      unitRef="usd">-750000000</us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RleHRyZWdpb246OTRmNTc1YWM5ZTE5NGI5Y2I2MzI0ZGRjMzUxMDI0YzhfMjQ0_a58392dc-ae32-489b-9e66-1c1fce4662e8">&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Post-Employment Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes net periodic benefit cost relating to the company&#x2019;s defined benefit and other post-employment plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined &lt;br/&gt;benefit&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;post- &lt;br/&gt;employment&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RleHRyZWdpb246OTRmNTc1YWM5ZTE5NGI5Y2I2MzI0ZGRjMzUxMDI0YzhfMjQ2_bbd1cfba-2221-4a28-ac76-fb93e4e2d1b1">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes net periodic benefit cost relating to the company&#x2019;s defined benefit and other post-employment plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined &lt;br/&gt;benefit&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;post- &lt;br/&gt;employment&#160;plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xLTEtMS05NzYxNg_8f774139-a282-4197-acd3-3c2c57037784"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0zLTEtMS05NzYxNg_461b8b64-a3f8-4fb1-aa2e-65e9c2aaf964"
      unitRef="usd">109000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy01LTEtMS05NzYxNg_06297e25-ac23-42a1-ae0a-33a839194a41"
      unitRef="usd">229000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy03LTEtMS05NzYxNg_85b1b300-6aa1-499f-995a-06326fadffb0"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy05LTEtMS05NzYxNg_065b7529-0e16-456d-9c8a-5d17979eab02"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xMS0xLTEtOTc2MTY_5cba41e9-398a-4b13-a5b7-e38ec0a631bc"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xMy0xLTEtOTc2MTY_b62ab35f-827e-4de2-9b22-34c94ea75873"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfMy0xNS0xLTEtOTc2MTY_d07dbfbf-9948-4b10-980d-4ab348de5c1f"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xLTEtMS05NzYxNg_62645d01-0b3b-4c1e-b519-f2753126e212"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0zLTEtMS05NzYxNg_0896e60e-1b69-45be-8ac4-57fb1357d3f6"
      unitRef="usd">60000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC01LTEtMS05NzYxNg_9f780a1b-ea65-447b-aa06-7877d2ad790c"
      unitRef="usd">149000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC03LTEtMS05NzYxNg_1ba04185-a2df-49be-8453-66d12b9d0cea"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC05LTEtMS05NzYxNg_3cd5b007-be66-434e-a679-90cc55938b4f"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xMS0xLTEtOTc2MTY_a39a7952-eb68-4250-be0b-5560879d42ff"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xMy0xLTEtOTc2MTY_4ac495f4-47b5-46f4-962b-5128b9a28019"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNC0xNS0xLTEtOTc2MTY_f4e15604-b4d8-4fb2-9a7f-c8283bd7925f"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xLTEtMS05NzYxNg_0a8f617b-8797-4753-b478-d831cdfcfaa1"
      unitRef="usd">179000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0zLTEtMS05NzYxNg_6156321f-68f8-456f-afad-4ab8ea9fb621"
      unitRef="usd">166000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS01LTEtMS05NzYxNg_e78264ab-bc90-4e3c-b688-f0b25320a7b9"
      unitRef="usd">359000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS03LTEtMS05NzYxNg_bf71e333-13c6-48b6-ad7e-f89e2ef6a03c"
      unitRef="usd">332000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS05LTEtMS05NzYxNg_d91de2cd-1223-4e2d-ba70-0ccc304dae95"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xMS0xLTEtOTc2MTY_c33a2c05-663d-48a7-8aeb-1689b420bcc1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xMy0xLTEtOTc2MTY_2f013017-9c94-4b3c-bad0-725e1b51b138"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNS0xNS0xLTEtOTc2MTY_abd8dc02-5b48-4d96-baca-9b5af06eeff7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xLTEtMS05NzYxNg_1da8e92c-dba8-4abb-93c8-d2459b4dc9de"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0zLTEtMS05NzYxNg_752983c4-73b1-4ae6-bff9-b6bd61156042"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi01LTEtMS05NzYxNg_d6b89f46-8e5c-4473-b0e4-100638e831b0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi03LTEtMS05NzYxNg_7a468700-0add-4560-b9ce-311c03d9d809"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi05LTEtMS05NzYxNg_692468d4-4a82-428f-a0cc-bac39e41f96f"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xMS0xLTEtOTc2MTY_e411d1fa-d9dd-43f6-af03-96f4c9fd706b"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xMy0xLTEtOTc2MTY_5e37e5d3-3fb4-4094-a4ca-b89b2cecb756"
      unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNi0xNS0xLTEtOTc2MTY_1d1aea42-bd82-432b-8f96-7233fe3cfce0"
      unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xLTEtMS05NzYxNg_a243cca0-6b9c-4091-9a18-267944157278"
      unitRef="usd">-59000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0zLTEtMS05NzYxNg_60c5693e-2612-429f-89bd-cab20cb602e6"
      unitRef="usd">-75000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy01LTEtMS05NzYxNg_88dc7f5b-cd6a-4a58-b01e-40c5dc9f1309"
      unitRef="usd">-116000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy03LTEtMS05NzYxNg_e736f13f-fe53-4cc1-8931-0dd3e964e2f5"
      unitRef="usd">-145000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy05LTEtMS05NzYxNg_82dc66c7-4440-4d85-9c27-2922e6382dc1"
      unitRef="usd">-6000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xMS0xLTEtOTc2MTY_bb095aae-c186-4c54-bd43-ca56cb596126"
      unitRef="usd">-8000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xMy0xLTEtOTc2MTY_110d1b04-95ff-48b8-a926-1535cddbea4d"
      unitRef="usd">-13000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfNy0xNS0xLTEtOTc2MTY_37a67c60-627e-42d2-a628-d047545eeb45"
      unitRef="usd">-16000000</abbv:DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i70516d291c55477c878b4b846af7180a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xLTEtMS05NzYxNg_cee6bf2a-4b29-482c-ba3b-082cecfe94b8"
      unitRef="usd">68000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id4c39941eba34bdaa387afb0e11a3aa5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0zLTEtMS05NzYxNg_31115a07-76e6-465e-a50a-350c19436972"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ide690142a55247c6a2b03d88e336f404_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC01LTEtMS05NzYxNg_ba850157-314e-4233-b926-dff386e037df"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id749d81368f94b2d80bd0233a5c9f6f5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC03LTEtMS05NzYxNg_a8e5996a-5634-4127-bd39-f2a23f3585f5"
      unitRef="usd">153000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i671edde9b26049c8b99ce0653f693a9c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC05LTEtMS05NzYxNg_3b35b779-ac2b-4f48-b3c3-19f91fd68355"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0ebcfea76ff14c39841082b7ec7ed278_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xMS0xLTEtOTc2MTY_c4b1520b-f865-45be-b991-cfa4de44de22"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0beadd0e15f74dd69220e8bc28f1bcc5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xMy0xLTEtOTc2MTY_665141dc-ae12-4f98-8ec5-d2c9c16e3748"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib6b5c74271a8441d87027162b9a9f6d2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83Ni9mcmFnOjk0ZjU3NWFjOWUxOTRiOWNiNjMyNGRkYzM1MTAyNGM4L3RhYmxlOjFlNjNhYmVjM2YzYTRhYjdiYTFkNzEzYjJmNWI5OWJiL3RhYmxlcmFuZ2U6MWU2M2FiZWMzZjNhNGFiN2JhMWQ3MTNiMmY1Yjk5YmJfOC0xNS0xLTEtOTc2MTY_25dea66b-15e9-4f91-90b4-90c842560133"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1MA_c2b0cc6d-d997-47ee-b2b0-d2cdc33d5562">EquityStock-Based Compensation&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 0.9&#160;million stock options with a weighted-average grant-date fair value of $22.83. As of June 30, 2022, $10 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RSUs and Performance Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 5.8&#160;million RSUs and performance shares with a weighted-average grant-date fair value of $146.20. As of June 30, 2022, $824&#160;million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quarterly cash dividends declared during 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/23/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/29/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/17/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/16/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/10/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/15/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/17/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/16/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/18/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/14/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie repurchased 8&#160;million shares for $1.1&#160;billion during the six months ended June 30, 2022 and 5&#160;million shares for $550&#160;million during the six months ended June 30, 2021. AbbVie's remaining stock repurchase authorization was approximately $1.4&#160;billion as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss for the six months ended June 30, 2022 included foreign currency translation adjustments totaling a loss of $1.1 billion and the offsetting impact of net investment hedging activities totaling a gain of $666 million, which were principally due to the impact of the weakening of the Euro on the translation of the company&#x2019;s Euro-denominated assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;br/&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income for the six months ended June 30, 2021 included foreign currency translation adjustments totaling a loss of $433 million and the offsetting impact of net investment hedging activities totaling a gain of $260 million, which was principally due to the impact of the weakening of the Euro on the translation of the company&#x2019;s Euro-denominated assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the impact on AbbVie&#x2019;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions) (brackets&#160;denote&#160;gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses (gains) on foreign currency forward exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on treasury rate lock agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on interest rate swap contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&#160;Amounts are included in interest expense, net (see Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) Amounts are included in cost of products sold (see Note 8).&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1Nw_41668d49-43ee-4638-87d0-7c8bc4323062">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After-tax compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c4a5e696cef44729310622ff60e2500_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi0yLTEtMS05NzYxNg_bef65f9d-9b36-43ff-ac75-5cee3c015021"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80b10bd565e94cdbad34d4b699a9c302_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi00LTEtMS05NzYxNg_9b7956c9-fd75-4638-a8d8-7c09ad5f8570"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f8541a3fbd04b4aa7b0c71db6c67624_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi02LTEtMS05NzYxNg_3ebaa9ff-67db-4628-b775-dd7bf34a3916"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcd274134e874c458ac8bb198e697455_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMi04LTEtMS05NzYxNg_da1b73fd-7790-4b9f-9a08-df50af7bc47a"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie39ddc4d4f8b4a60ae8112fec8a02ca0_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy0yLTEtMS05NzYxNg_02b50c95-f7fb-45b2-8572-434398f58dc2"
      unitRef="usd">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i215a3d4557c14afebf2687d536e46e9b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy00LTEtMS05NzYxNg_54d6c619-3769-43de-8793-73aed427dc20"
      unitRef="usd">47000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84cd19c9ee4e484da629710856ae0ec6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy02LTEtMS05NzYxNg_1cf985ff-52f5-4e2d-aec5-fcefd2549ec2"
      unitRef="usd">147000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4aeffb4bf7740e693e0cf853abfe9cc_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfMy04LTEtMS05NzYxNg_4c872ab9-c585-47b1-9405-9b9fbba4836c"
      unitRef="usd">134000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87c76652aba54b3cb73c859bfcc92d58_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC0yLTEtMS05NzYxNg_347a6d00-0fc4-4ac9-887d-eb4b29275bd4"
      unitRef="usd">61000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i73323fc2811c4815be8a6fa8d6f92ebf_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC00LTEtMS05NzYxNg_ce9a1770-a8cd-4827-8e68-18c091d6bde3"
      unitRef="usd">102000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic74c227e50b7440cb0bf2fe1f16077a8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC02LTEtMS05NzYxNg_db4fe38d-5672-4ba3-b29c-621c739d82e6"
      unitRef="usd">241000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf3113d83c8f491b941990950d5919dd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNC04LTEtMS05NzYxNg_5605e03f-9a7e-4e6a-90b7-fe341e5d5e91"
      unitRef="usd">264000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS0yLTEtMS05NzYxNg_21f070ef-1dd6-4df2-a43a-2f246344d2a4"
      unitRef="usd">107000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS00LTEtMS05NzYxNg_2e6941e5-8ea0-4624-91de-7ea65835c722"
      unitRef="usd">159000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS02LTEtMS05NzYxNg_2326df41-eab2-4b59-a56f-4c4c3705cb9e"
      unitRef="usd">413000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNS04LTEtMS05NzYxNg_215e0aa9-8a16-4ea9-85f4-7975e4844d26"
      unitRef="usd">428000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi0yLTEtMS05NzYxNg_c38124fa-beb8-4f42-9e97-b8764c7b76ca"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi00LTEtMS05NzYxNg_193165ec-06a5-4de6-b136-05d4b99ccb05"
      unitRef="usd">26000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi02LTEtMS05NzYxNg_31a62cf4-f213-4558-b5c6-ab74bfaf861a"
      unitRef="usd">77000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNi04LTEtMS05NzYxNg_d15a4bf5-ac6b-4692-a55d-da95a5d0d467"
      unitRef="usd">74000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy0yLTEtMS05NzYxNg_a3a9240d-996c-4c42-a6ae-8ae7370b7e72"
      unitRef="usd">86000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy00LTEtMS05NzYxNg_7f90063b-2773-43ef-8d37-fdc04a0af45c"
      unitRef="usd">133000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy02LTEtMS05NzYxNg_df5a60ab-f8f1-4dab-a8b2-4f79f3d271a7"
      unitRef="usd">336000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjZhY2Q2MzY1YTUyNzRkNGJhMDQ2NjVkNDRjZWQ2ZGNmL3RhYmxlcmFuZ2U6NmFjZDYzNjVhNTI3NGQ0YmEwNDY2NWQ0NGNlZDZkY2ZfNy04LTEtMS05NzYxNg_54af9790-63c6-4ec6-9a10-d9004b3b6681"
      unitRef="usd">354000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTEy_5af8e420-817e-4ffa-b1fd-b42e6e557884"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTc4_9fd8f6df-ff30-4832-8343-dc60d273758a"
      unitRef="usdPerShare">22.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iebba8edab23541ff89c8b58adf3e8a76_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNTky_7cd7e5b3-870b-4215-af33-2bbd087b4b47"
      unitRef="usd">10000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibd90914ea384473db98e01873e81a8f0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfNzIy_161da7ef-d327-41eb-b889-7eb22c1aa144">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfODQx_d598a9ca-16b5-443f-a956-6d7a675d45c2"
      unitRef="shares">5800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5ca53a8519264b5a8bf940cc274a106a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfOTIx_788a6d3d-4d4c-4938-99e1-0b776715d6ee"
      unitRef="usdPerShare">146.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i5ca53a8519264b5a8bf940cc274a106a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfOTM1_2529912e-3c01-4535-ac2b-f077f3c350c0"
      unitRef="usd">824000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTA3OQ_c1053bd8-3d3c-4673-be50-d122ce636768">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfDividendsPayableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg4NQ_40f73324-01d5-46ae-a6cd-8d70fb40e701">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quarterly cash dividends declared during 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Declared&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/23/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10/29/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/17/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/16/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/10/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11/15/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/17/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/16/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/18/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2d2926;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/14/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDividendsPayableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i29287228cbed45f6968865ac190732da_D20220623-20220623"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMi00LTEtMS05NzYxNg_7fc0c58f-2bfb-48b1-856c-249cc8cad1d0"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2ea99297cee64545990d63d337e0bd15_D20211029-20211029"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMi0xMC0xLTEtOTc2MTY_e187bbb7-e9a3-4cfd-86a1-6188522aa8db"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ic1a2a526c6f543e48795a4f1d12639ad_D20220217-20220217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMy00LTEtMS05NzYxNg_526da670-9598-463f-af84-99a20b24ccdd"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iac1d6f16dc8f42568eb8061858ff99c8_D20210910-20210910"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfMy0xMC0xLTEtOTc2MTY_3c229516-b2a1-43e9-b53c-bcb87e63e8bc"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ibb37ae95313d475593909c6970fed474_D20210617-20210617"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfNC0xMC0xLTEtOTc2MTY_29797af1-d607-475f-ab7d-6e2153f6f4eb"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i82eba66f65734def83204d704d5b47ea_D20210218-20210218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjE1YmUwMDIxOTgyMjQxNDlhOGI1MDAzMDE5ODI3NzJjL3RhYmxlcmFuZ2U6MTViZTAwMjE5ODIyNDE0OWE4YjUwMDMwMTk4Mjc3MmNfNS0xMC0xLTEtOTc2MTY_56ca1d70-2f9a-4446-adaa-4cbfd751fb68"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTYwOA_60c55929-844a-45f3-8e15-45c8d549feda"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTYyMg_92b1e4e0-0215-4ab8-83d5-229d76fecb45"
      unitRef="usd">1100000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTY0Mw_a6664546-098a-480a-b1a3-a30592184100"
      unitRef="shares">5000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifa9f97b1793b4987aea0c191ae077cac_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTY1Nw_7d7d3a26-d676-4d32-9a46-46d78135f663"
      unitRef="usd">550000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTc0Mw_4fae8c58-6d81-42e8-95bc-a23b87720c4f"
      unitRef="usd">1400000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3Mg_1519fd1f-e7b3-493a-b134-f59fbfdf1b82">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency &lt;br/&gt;translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedging activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension&#160;&lt;br/&gt;and post-employment &lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow hedging &lt;br/&gt;activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22b5f6d04f0a4544845c676987a1eeed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0xLTEtMS05NzYxNg_fa9f9b32-bf94-490a-967d-aefd55d2da64"
      unitRef="usd">-570000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cd460fb97a943bea7eab54ac965aa60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0zLTEtMS05NzYxNg_c5224d39-ea54-46e6-8bbd-26f9f5d97f63"
      unitRef="usd">-91000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icce33acdbe974160ad9b3dfc07ae39d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS01LTEtMS05NzYxNg_78b05413-8c32-4200-9b67-d3229e83760c"
      unitRef="usd">-2546000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia710a25cb0c047998dd58eb85bc213f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS05LTEtMS05NzYxNg_f2d6af93-905b-4da4-a483-64b968725bc1"
      unitRef="usd">308000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae61288e27a24ce39bded79de1bf4095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMS0xMS0xLTEtOTc2MTY_31efdab3-082d-4216-891a-a67a46864ebd"
      unitRef="usd">-2899000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0xLTEtMS05NzYxNg_74033597-e3a4-4eac-ad44-049a30d538e6"
      unitRef="usd">-1054000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0zLTEtMS05NzYxNg_230d112d-b922-4919-bdf7-297c7ada9975"
      unitRef="usd">696000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi01LTEtMS05NzYxNg_ffe441a0-e5da-4316-9ce5-9e905e033647"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi05LTEtMS05NzYxNg_cbd87258-efb6-449f-94ce-7ec24a4c5dd0"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMi0xMS0xLTEtOTc2MTY_d5c62edb-88c9-4cd5-abff-2beff3d0fd86"
      unitRef="usd">-324000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0xLTEtMS05NzYxNg_c7003c10-0b2a-4da0-b360-9ed638d63e61"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0zLTEtMS05NzYxNg_39d1f8d8-c64c-45bd-b99a-17d58804b362"
      unitRef="usd">30000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy01LTEtMS05NzYxNg_af43ff48-5d1b-4ac6-8bbb-f13780417e27"
      unitRef="usd">-87000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy05LTEtMS05NzYxNg_759978be-e9cf-444d-aae2-aaf44c0e8ad0"
      unitRef="usd">30000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfMy0xMS0xLTEtOTc2MTY_32f514ad-a5a6-462c-ba63-4888ef0f1621"
      unitRef="usd">-27000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0xLTEtMS05NzYxNg_6cf3577d-4be9-4827-941a-18438b23456a"
      unitRef="usd">-1054000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0zLTEtMS05NzYxNg_8ef38e57-df62-4334-902f-20922755533a"
      unitRef="usd">666000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC01LTEtMS05NzYxNg_46d634af-8917-49c2-9540-1a451818359e"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ife4c71302fe74de19e049ff21e1cedf7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC05LTEtMS05NzYxNg_70b2ee86-4f4d-4ac5-a289-af0500eaf350"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b3596d7d4e5429e8a38ec79c16c353a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNC0xMS0xLTEtOTc2MTY_a460b387-5ddf-48a7-9cbd-8c4460654afa"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7f81fb701254285a4a206a18828b567_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0xLTEtMS05NzYxNg_2903d814-7f65-4965-a600-0226a337be21"
      unitRef="usd">-1624000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ed8396560c44007a9c95309d6d3a6a2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0zLTEtMS05NzYxNg_7466e3e7-0070-4d5f-8a4d-8d5258d03cce"
      unitRef="usd">575000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib73a09f43445463abe6438c2b68a40d0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS01LTEtMS05NzYxNg_eb933daa-4324-40db-9111-65179384553e"
      unitRef="usd">-2470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie041d69136f64b3a8a27ad04a132c273_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS05LTEtMS05NzYxNg_6b7fef98-0d58-4db2-8919-6f42d27063a0"
      unitRef="usd">323000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ec6491fd6214350bcd0866f550aa297_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjBmYTU3NTczNTcxMjQyZjk5ZWE4ZDFiYTcxYzJiOWFkL3RhYmxlcmFuZ2U6MGZhNTc1NzM1NzEyNDJmOTllYThkMWJhNzFjMmI5YWRfNS0xMS0xLTEtOTc2MTY_e0bf1527-3f83-4afd-b953-d3c063681b4c"
      unitRef="usd">-3196000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i686413b61ad74247ae4174d66d6efda8_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTkzNA_42888a5c-fcb2-455e-98cc-360f8e844681"
      unitRef="usd">-1100000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7e72c2b1972444a2888dfec9f303af1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjAxNw_f555ad20-0dba-4b84-a67c-1ccb4be26f65"
      unitRef="usd">666000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia05002d950604d46a192beaa49081fc9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0xLTEtMS05NzYxNg_395eb1f6-6558-46e4-a78b-f0a7eec364a3"
      unitRef="usd">583000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35fed5ff539e43798107045d15730636_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0zLTEtMS05NzYxNg_9bf8ea21-e464-4ddf-9a9d-3e5da631272b"
      unitRef="usd">-790000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i403c50879b1c4e05a4a20ace89fd4c22_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS01LTEtMS05NzYxNg_b8ada3c6-9c7e-4078-94ba-dfe69e8e39b3"
      unitRef="usd">-3067000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d626d0838c74271a9d49423686e77f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS05LTEtMS05NzYxNg_1c16a6f2-9be4-466a-83a3-217bf48534f9"
      unitRef="usd">157000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0e42ad98a314ebeb3aade819088d66a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMS0xMS0xLTEtOTc2MTY_db2b6148-5198-4896-b64a-43565e741992"
      unitRef="usd">-3117000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0xLTEtMS05NzYxNg_a82bcdd5-f1b7-438f-8e89-1e2684ef7939"
      unitRef="usd">-433000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0zLTEtMS05NzYxNg_d8ffc803-4fad-4e13-9b7a-d10da19a912d"
      unitRef="usd">267000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi01LTEtMS05NzYxNg_a57867ab-bab4-4798-a5b8-07bb641b57a7"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi05LTEtMS05NzYxNg_235645e0-1cc7-4d2b-910c-fc702a72ba0d"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMi0xMS0xLTEtOTc2MTY_c3b65fdb-6262-47cf-bbe8-3b060cda7a2d"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0xLTEtMS05NzYxNg_f2f1461b-2288-478e-8378-319b2979b4c2"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0zLTEtMS05NzYxNg_3880db92-6c55-4ad1-8365-d1c5fa202d83"
      unitRef="usd">7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy01LTEtMS05NzYxNg_d0e274d1-3b83-41a6-bb29-9a64671edbd7"
      unitRef="usd">-113000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy05LTEtMS05NzYxNg_70ae6d81-61d8-49c9-b542-e696986b367d"
      unitRef="usd">-31000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfMy0xMS0xLTEtOTc2MTY_cb5c6bcc-858f-4af4-8e23-8bc30b1e2117"
      unitRef="usd">-137000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0xLTEtMS05NzYxNg_b9b5d1ae-1cfd-4d72-9403-0dd1c4fd44f4"
      unitRef="usd">-433000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0zLTEtMS05NzYxNg_a0554e5b-c561-4d83-92e6-c11ce717c46a"
      unitRef="usd">260000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC01LTEtMS05NzYxNg_025d34cd-db48-48e7-81ea-a8e771fe6570"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i10c25d18d66f4485a636d0c07cd58fbb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC05LTEtMS05NzYxNg_4e0e512f-815b-49ed-a001-9ec6d691b617"
      unitRef="usd">58000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i34830ac15f3a4232a373b99f3831f78d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNC0xMS0xLTEtOTc2MTY_1e0f5181-7c08-4ba3-839f-1409b57c0bcb"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3822e99b0a044b3bb3488101e174bb2d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0xLTEtMS05NzYxNg_e521acc8-de69-4aed-bc27-cf405a1a8c1a"
      unitRef="usd">150000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i995a19a6da744643b9b86cc7f1216901_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0zLTEtMS05NzYxNg_f7f14e8b-70c1-47d8-8e26-c8962f36f5d7"
      unitRef="usd">-530000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic97760527e754306a1191c6bc2573b87_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS01LTEtMS05NzYxNg_84bdafe7-f994-456b-9f37-f30b03232ef6"
      unitRef="usd">-2938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a4d976678cf4540afbc6dc51554a787_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS05LTEtMS05NzYxNg_cf12adde-63be-44f8-b862-6e55edb792f6"
      unitRef="usd">215000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbb0ed41b4e649d2a7d806f7497e41a8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOmZjYmEwZDYxZWFhYTQ5YzY4OTFkMzMyMzU3Nzk1ZGZhL3RhYmxlcmFuZ2U6ZmNiYTBkNjFlYWFhNDljNjg5MWQzMzIzNTc3OTVkZmFfNS0xMS0xLTEtOTc2MTY_ed72b362-5ea1-4917-b7a7-93df0b9a35c6"
      unitRef="usd">-3103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if950e8b5b2df42df96087980787dec24_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjMyNg_212395d7-23ee-4a92-845d-5e385b458a75"
      unitRef="usd">-433000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7698dc329628476c963cdee26aa2812e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMTA5OTUxMTYzMDkyNg_73bed535-84f9-45a3-9283-1be01136000c"
      unitRef="usd">260000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjgzNg_c3f71c17-6a24-4e1a-b03c-6cf425244e64">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the impact on AbbVie&#x2019;s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions) (brackets&#160;denote&#160;gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedging activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses (gains) on foreign currency forward exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on treasury rate lock agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on interest rate swap contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&#160;Amounts are included in interest expense, net (see Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) Amounts are included in cost of products sold (see Note 8).&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc"
      unitRef="usd">24000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c"
      unitRef="usd">38000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed"
      unitRef="usd">9000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC0xLTEtMS05NzYxNg_5d02a065-8df5-48e7-890a-3f73018f2b67"
      unitRef="usd">6000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC0zLTEtMS05NzYxNg_9153ff70-549f-4458-bee8-5b04cdfc8076"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC01LTEtMS05NzYxNg_237a261e-1bf2-440c-8bb0-9a0d3e2f955e"
      unitRef="usd">8000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNC03LTEtMS05NzYxNg_957a5994-2a49-4c71-845f-52f4eaee5614"
      unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i32d84e38a2994c878bdc69755243817d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS0xLTEtMS05NzYxNg_6a40b03c-517d-467c-a346-652d7a0006e5"
      unitRef="usd">18000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2cdec6a4002b4218a4ff7448a4d04be8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS0zLTEtMS05NzYxNg_8e550155-3a97-4fb7-a5be-9a30e4e05ed1"
      unitRef="usd">4000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3cf402716ede4d3baa606c9a353acc19_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS01LTEtMS05NzYxNg_f071484a-e471-4efd-aaeb-fdca676db98a"
      unitRef="usd">30000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ied56c23a4c9e47799a2c0292584bf693_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNS03LTEtMS05NzYxNg_9a35bf4d-3356-4040-8e89-ab6267a694a1"
      unitRef="usd">7000000</us-gaap:NetIncomeLoss>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291"
      unitRef="usd">-56000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381"
      unitRef="usd">-74000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196"
      unitRef="usd">-111000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662"
      unitRef="usd">-143000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC0xLTEtMS05NzYxNg_d1837650-6e1b-4abe-a1e9-218164627826"
      unitRef="usd">-12000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC0zLTEtMS05NzYxNg_d1e3c3a3-a103-49b8-b5c1-c2a6d98aa957"
      unitRef="usd">-16000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC01LTEtMS05NzYxNg_8e9af11f-3229-4eca-9d8b-cf456978251e"
      unitRef="usd">-24000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOC03LTEtMS05NzYxNg_cba12039-db97-46d9-ae53-cac6e189edc2"
      unitRef="usd">-30000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS0xLTEtMS05NzYxNg_839fdc5d-30a1-4867-97e9-eb6d1fd4ad16"
      unitRef="usd">-44000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i25bcb5bd496845bca04a24d5ee18a820_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS0zLTEtMS05NzYxNg_a9eea189-bc15-4d4f-b72e-45174c92c634"
      unitRef="usd">-58000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9973fbf3c6874fc9badea8a51511491e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS01LTEtMS05NzYxNg_8184adb8-7119-4959-83c8-54e32bb3a169"
      unitRef="usd">-87000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i26d515b757e04fe9919a0757df9fa8c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfOS03LTEtMS05NzYxNg_2ae717ed-fcc2-4b9e-a25e-d860854f0c7c"
      unitRef="usd">-113000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3ccb01751b304c18af28a34833388cf8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b"
      unitRef="usd">-18000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic191f46d7d8e4caba4afd72c543fbcd4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383"
      unitRef="usd">22000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib3853f87f21c434890d33f2f2b77b72c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e"
      unitRef="usd">-26000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5bfb160d4b1643648262fd6a0eaae478_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3"
      unitRef="usd">34000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if3b9ff182e8741859555b210dca9a32b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i02110886faa542a89965a36d12b1be28_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic4767839908e4c3c981b0e75e52a508d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252"
      unitRef="usd">12000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie51ac81d02ae4bb4bb4b631a36857242_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d"
      unitRef="usd">12000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic48cb26fc77245da81fea6fc298e2334_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c"
      unitRef="usd">-1000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i608d6972b6ff4f3d8c222972b983496e_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad"
      unitRef="usd">-7000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i1eb4fc0c623c4f1ea81b83cb3bdba9ac_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb"
      unitRef="usd">-3000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i43c0a79aa3464c16a02968bd63694f55_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee"
      unitRef="usd">-14000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtMS0xLTEtOTc2MTY_8972a698-9af6-4b91-90cb-9d3324f66484"
      unitRef="usd">4000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia174e4331257480796e6106ea2a76cce_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtMy0xLTEtOTc2MTY_90c47a2f-6c94-40b4-9ceb-8a7008963183"
      unitRef="usd">-3000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtNS0xLTEtOTc2MTY_646aa0ac-9186-4705-8967-567205b84ef7"
      unitRef="usd">5000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTQtNy0xLTEtOTc2MTY_b1804aae-573d-4ef0-9d61-c4cd19a76643"
      unitRef="usd">-5000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iff375e57376d4cb9adda4b15c604aa4b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtMS0xLTEtOTc2MTY_d7f7f225-b498-4465-bdf2-0d5faa612188"
      unitRef="usd">19000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia174e4331257480796e6106ea2a76cce_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtMy0xLTEtOTc2MTY_6d720211-19cc-4d28-88f1-0fd8ce4a8894"
      unitRef="usd">-20000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4b0006714b7343d59c6f0a73faeb8ce9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtNS0xLTEtOTc2MTY_a1837d16-c80f-4e6a-9ee9-3acd313035ea"
      unitRef="usd">30000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60b2ef3ee7824de6addcdf71e6725f48_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTUtNy0xLTEtOTc2MTY_8f14e6dd-5d85-4523-b7e1-c1ff3e145a74"
      unitRef="usd">-31000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfODY3_ecc0c8d6-6192-4e9e-96ef-b42c82222637">Income Taxes &lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was 22% for the three months and 11% for the six months ended June 30, 2022 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;compared to 34% for the three months and 14% for the six months ended June 30, 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The decrease in the effective tax rate for the three and six months ended June 30, 2022 over the prior year was primarily due to differences in the company&#x2019;s jurisdictional mix of earnings and accretion on contingent consideration.&lt;/span&gt;Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company&#x2019;s gross unrecognized tax benefits balance may change within the next 12 months by up to $145&#160;million.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjYxNg_22794a87-adb5-42e8-842c-c04b9378a74b"
      unitRef="number">0.22</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY0NQ_2b6897ab-c393-400a-8630-4adcaf8c199f"
      unitRef="number">0.11</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY3MA_f7d794b9-f804-4430-944c-6aade107b19e"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTY0OTI2NzQ0MjY4Mg_3af8fced-f67e-44e4-9a79-95e7be1e76e2"
      unitRef="number">0.14</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_36630c3f-3691-44b9-9fed-2d0568df4621"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_956b333d-1e5f-439d-bf23-d6c8c5690fa8"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_b04884a5-8fed-4795-8b12-61d262f5a9a2"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfMTYz_bc0b4aa8-a59f-4d08-a7ac-b44214516693"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84OC9mcmFnOmY2YzMxYjUwNjBmYTRhNTc5NWU4NmViYWY3MzZkNzVmL3RleHRyZWdpb246ZjZjMzFiNTA2MGZhNGE1Nzk1ZTg2ZWJhZjczNmQ3NWZfODYy_86ec5403-eb08-4601-82bd-3c12626e5fa4"
      unitRef="usd">145000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMTQxNDA_5e6262c4-3079-4c52-8262-7db4a7a13d4e">Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management&#x2019;s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie&#x2019;s consolidated financial position, results of operations or cash flows.Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Niaspan Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MDL No.&#160;2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney&#x2019;s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys&#x2019; fees. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#x2019; fees. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott&#x2019;s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie&#x2019;s settlements with biosimilar manufacturers and AbbVie&#x2019;s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Humira (Adalimumab) Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#x2019; fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Namenda Indirect Purchaser Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States District Court for the Southern District of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan&#x2019;s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys&#x2019; fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys&#x2019; fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Bystolic Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States District Court for the Southern District of New York.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,031 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prescription Opiate Litigation, MDL No. 2804. Approximately 266 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In May and July 2022, Allergan reached settlements with the State of West Virginia and its political subdivisions and with the City and County of San Francisco, California, respectively. Allergan previously reached settlements with other plaintiffs. Allergan is engaged in negotiations with representatives for the remaining states, counties, cities, other municipal entities and Native American tribes regarding a potential settlement, with payments likely to be made over a number of years. While negotiations are on-going and definitive terms have not been reached, a framework for an agreement exists, including an estimate of a potential settlement amount based on maximum participation in the potential settlement. AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to this potential settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the New Mexico Attorney General filed a lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico&#x2019;s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. In July 2022, the parties reached an agreement in principle to settle this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder and Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. One of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, a federal securities lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Holwill v. AbbVie Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May 2022, a shareholder derivative lawsuit, Ranney v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that certain AbbVie directors and officers breached their fiduciary duties based on related allegations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Allergan plc Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The plaintiffs generally seek compensatory damages and attorneys&#x2019; fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022, a federal securities lawsuit, Nakata v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois against AbbVie and certain officers alleging misstatements regarding the potential effect that safety information about another company&#x2019;s product would have on the Food and Drug Administration&#x2019;s approval and labeling for AbbVie&#x2019;s Rinvoq. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the same court, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties based on related allegations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability and General Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, a qui tam lawsuit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Silbersher v. Allergan Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#444867;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Allergan USA, Inc., Allergan Sales, LLC and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit. In May 2022, the parties settled the cases and they were dismissed without prejudice.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <abbv:LossContingencyIndividualPlaintiffLawsuitsNumber
      contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjIwOQ_db395bb9-f778-46ab-8476-8943cc1543fb"
      unitRef="lawsuit">4</abbv:LossContingencyIndividualPlaintiffLawsuitsNumber>
    <abbv:LossContingencyPurportedClassActionsNumber
      contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjI0Ng_ac5fdb8d-6d67-4b03-90b9-d73d3dd528d8"
      unitRef="class_action">2</abbv:LossContingencyPurportedClassActionsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjI4Nw_0e248786-7f8f-4e35-b8b2-25f7ec366d3c"
      unitRef="direct_purchaser">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMjMzMQ_9ae7b6bb-0cbb-406c-b91d-4fa5d32ffb78"
      unitRef="end_payor_purchaser">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
      contextRef="icfa3a17240a84a5fb4378a6e0964580e_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMzU3NQ_4641e0fe-9458-4bee-be8f-09cce82a8981"
      unitRef="company">3</abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws>
    <abbv:PutativeClassActionLawsuitIndividualNumber
      contextRef="i7334ba57c4e449f59500bd93a416fe9f_D20190301-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNDI2Ng_c0a59244-1c4f-4467-b77c-017bb5ccd1a1"
      unitRef="company">12</abbv:PutativeClassActionLawsuitIndividualNumber>
    <abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
      contextRef="if3a36967092e4074bf4a78063e79132b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNjQ1NA_f2e65836-6955-46c2-81a4-566fc1274d3a"
      unitRef="company">6</abbv:LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie8cb2800eae14237a93a3936c9e32a27_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNzEwNw_263ded6b-8598-42fd-8774-b7a29b0a2197"
      unitRef="claim">3031</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i48ac34a8b8274cc9af2a8d06028995a6_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfNzM4MQ_3b89dd25-2ccb-4a37-9677-d68ced254da9"
      unitRef="claim">266</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i1e04db914dad47f5b3d445d36e86ac46_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfMTA5OTUxMTY1NjI1NQ_257319f1-694a-498c-baea-15790df46b5c"
      unitRef="usd">2100000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i65d8e2a0e62b4729b3abeb9e927196d9_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfODM4MQ_7679925f-1a70-44a1-8b71-6b8d77fab327"
      unitRef="investment_fund">5</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="id7c685b4419c4e248155b129a874cf5a_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfODgwMw_cbe90a42-9c90-4930-b2b7-fdfdab647f81"
      unitRef="investment_fund">3</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="id76475932981417e8c60761ee84327e0_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85NC9mcmFnOjY4ZTFhODhhMDU5YTQzOTRiZjAzZjBhNTliZmU5YzA5L3RleHRyZWdpb246NjhlMWE4OGEwNTlhNDM5NGJmMDNmMGE1OWJmZTljMDlfOTA2OA_7b21aabd-5879-417b-b9bd-db5c9c168311"
      unitRef="investment_fund">1</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RleHRyZWdpb246NTgxMGY2MTEzY2YwNDBhOGFkZTFjYWU4MDk5NzJhOTlfMTEyMA_b0cb84cb-67ca-483b-9c3e-d5402cd818d9">Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details AbbVie&#x2019;s worldwide net revenues:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Humira&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Skyrizi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rinvoq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Hematologic Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Venclexta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Cosmetic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Juvederm Collection&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Therapeutic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vraylar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duodopa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ubrelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qulipta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lumigan/Ganfort&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alphagan/Combigan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Key Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mavyret&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Creon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Linzess/Constella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RleHRyZWdpb246NTgxMGY2MTEzY2YwNDBhOGFkZTFjYWU4MDk5NzJhOTlfMTEyOQ_9f9e4c00-9867-40f7-b6ba-6f0c89fd57f7">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details AbbVie&#x2019;s worldwide net revenues:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Humira&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Skyrizi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rinvoq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Hematologic Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Venclexta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Cosmetic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Juvederm Collection&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Aesthetics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Botox Therapeutic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vraylar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Duodopa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ubrelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qulipta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lumigan/Ganfort&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alphagan/Combigan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Eye Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Key Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mavyret&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Creon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Linzess/Constella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1e751a39abb44d69bf6dde5f62f5da1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC0yLTEtMS05NzYxNg_64a03693-7fe9-4d5b-aa29-3f85c68fa630"
      unitRef="usd">4664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib18bfd7270ee4f79a082b091a1d91241_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC00LTEtMS05NzYxNg_e80a775e-399c-4605-a6c1-62fcdc66a456"
      unitRef="usd">4257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cc2260464184105897c45f4f42c8c13_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC02LTEtMS05NzYxNg_c0f295bb-d909-4a1c-9484-ffe3d2b133d1"
      unitRef="usd">8657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cf34e3dc9a54da193a3b587af7498e0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNC04LTEtMS05NzYxNg_bb257d5c-1d40-42e3-9d54-0d3efab91f52"
      unitRef="usd">8164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3665d816d7a49f7b2a2c250380955e0_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS0yLTEtMS05NzYxNg_9971f27e-1f95-4b7e-add3-3b7024001b61"
      unitRef="usd">699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id772f9666c5c4b569bff7bcce7ec09b4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS00LTEtMS05NzYxNg_226c5a16-a492-42e9-b30c-8c224188c0e1"
      unitRef="usd">811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2789587e0039409e85ee53a0e676e039_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS02LTEtMS05NzYxNg_0d0b7b8d-5a26-4f6c-9d75-536e84736c11"
      unitRef="usd">1442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70a7736453da40babfdf09cafbc6d8d7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNS04LTEtMS05NzYxNg_78f426f4-6f03-4e76-855b-24400bb54c09"
      unitRef="usd">1771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaab62c95758e45988052a829d4196a90_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi0yLTEtMS05NzYxNg_e77d827d-f969-4604-984a-1aae4e02a16d"
      unitRef="usd">5363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7dea9d6f70d4ec98a1e472f35d5c5e7_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi00LTEtMS05NzYxNg_39ad4eee-e58c-4390-9c1e-3db2d958e7a0"
      unitRef="usd">5068000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecc046d2283c4b17b9218d96bfe9f744_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi02LTEtMS05NzYxNg_fb477a0c-a4c3-4398-806c-8d1954f6059d"
      unitRef="usd">10099000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85dd0c7934dc4d97bade1ff5347b0cbb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNi04LTEtMS05NzYxNg_2d726054-589d-49a3-9882-068312e8f1a2"
      unitRef="usd">9935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i613d7817d5e44951867e1c6db534f048_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy0yLTEtMS05NzYxNg_ddef2b8f-67dd-43eb-8c34-38ac461de5b0"
      unitRef="usd">1079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3925d88e2c564017be693e4f33dc9fef_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy00LTEtMS05NzYxNg_9e8524dd-6ac8-4aa5-8bf6-cb0c0cac5c8a"
      unitRef="usd">565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fab7cbaef51414aaaf8cf3add2b35cf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy02LTEtMS05NzYxNg_71051ca7-5e97-4c69-afc5-cff2ec70bddb"
      unitRef="usd">1860000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb12764f7504661af49974aecf799fa_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNy04LTEtMS05NzYxNg_cdb7882c-8676-4a0f-9e0b-dc8ef6574822"
      unitRef="usd">1046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i691d9600e9b043098e5c276598fee110_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC0yLTEtMS05NzYxNg_ea2c0f5a-a78e-42f6-8f9d-d14ecf824435"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48a4b28633f342598240cdb0c3efa237_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC00LTEtMS05NzYxNg_abb99408-abcd-4c55-beaf-744b6b8a6dd4"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i560e85f5cfab4fc3ac49d453b66f47fc_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC02LTEtMS05NzYxNg_a543854e-45d8-4595-bc7a-5482f3c67ce7"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768c6e087bc94398bcebcdec93f187ee_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOC04LTEtMS05NzYxNg_862e4d4c-403d-4192-92fd-79e533846f96"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d6c8a9d73f14855aeed15aaa74afcff_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS0yLTEtMS05NzYxNg_26cfc1e3-c993-4c30-8bf6-65dced8c0b62"
      unitRef="usd">1252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b51a1c66954d9aaa0187e550ad0413_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS00LTEtMS05NzYxNg_0982f315-5c0d-4879-908b-ea16e4e05460"
      unitRef="usd">674000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ea89bc103144a5958d2f2a66fe8098_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS02LTEtMS05NzYxNg_baf79386-7a27-45ad-967a-a02d964c3276"
      unitRef="usd">2192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a8bd49f99be462b96189ff1b51b483f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfOS04LTEtMS05NzYxNg_68947207-aa8a-4e9d-a882-696bc81ee914"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i874093c1c0ae4f308272c783ac24326f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtMi0xLTEtOTc2MTY_2f2da975-c4c3-4236-b101-9485168a0c3d"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4e6208b6b4f4a0388ca9ada2c7cc625_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtNC0xLTEtOTc2MTY_528161ef-0818-459f-b3c4-e71c53e6f1ef"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fd758e6d37b4bc59135caf3c0de84d6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtNi0xLTEtOTc2MTY_abfc70dd-89de-4024-b92c-9d345688506a"
      unitRef="usd">723000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d868053bd8748d3bf614376fe813cb8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTAtOC0xLTEtOTc2MTY_bf12d5d0-f821-4670-833d-3be564ef2c7e"
      unitRef="usd">541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26c02e7957b24efd9ccb2368a2201c6e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtMi0xLTEtOTc2MTY_beb16ec3-2af9-458d-b938-c3103e957b76"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f955f09f26347a4b61f9e1d792d9c52_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtNC0xLTEtOTc2MTY_150c350a-3579-4aa3-b02c-a2838fb8e554"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4a3befe2196456aa7304c27b18e62b0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtNi0xLTEtOTc2MTY_a0abf226-2c3e-46c0-ad51-5175b69bba36"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c352b7e3b4a46d4ac9b0c8ae253c346_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTEtOC0xLTEtOTc2MTY_f1a581e5-717d-4c2a-a428-7d3f4292d089"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacefee9559c84a7f8fe1b97854abae81_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItMi0xLTEtOTc2MTY_6f4a0cfe-707d-4890-a200-826edba6ab93"
      unitRef="usd">592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cf6107ac310458ca74734c319137631_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItNC0xLTEtOTc2MTY_3efb14f4-cafc-4f39-98cd-55c1f68e64a6"
      unitRef="usd">378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4786d948d133499db74a085616fa1875_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItNi0xLTEtOTc2MTY_64b5d5d2-3030-4733-888b-53bdf1bf0f83"
      unitRef="usd">1057000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d29d5d87b2d4ba492379977f9b5ab22_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTItOC0xLTEtOTc2MTY_91ef78a1-1acc-413f-a5b0-73739d35d20c"
      unitRef="usd">681000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a916779feaf471db9c3dd44f2d0f9e4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtMi0xLTEtOTc2MTY_2b6e76d5-fd19-40f7-aae2-46edb2eef231"
      unitRef="usd">862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i636fc0eccf124d9a800dd95dc70ad820_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtNC0xLTEtOTc2MTY_7cbd9483-29e9-447d-8328-325833b564c5"
      unitRef="usd">1099000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c2b0f551bc049d6abd5b17ecbfd5a7c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtNi0xLTEtOTc2MTY_299d5baa-667d-4bcd-91a8-8a87f795de34"
      unitRef="usd">1736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i436d40cfe964413fbcbf9f712fc800e0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTQtOC0xLTEtOTc2MTY_9c3de0fd-125b-4e11-8acd-b3ff9a844a70"
      unitRef="usd">2098000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ifc0416b6fe5a4a28ad14a534ffeaf36c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtMi0xLTEtOTc2MTY_1c0ff8f2-5c6a-4a44-991b-33ca31f2a080"
      unitRef="usd">283000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i94c20efa76564198871cbde27c4f3770_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtNC0xLTEtOTc2MTY_0db03636-85b0-4e44-9c2c-f59e121c57a6"
      unitRef="usd">282000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i76a3090d63854077932361ea0cda6045_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtNi0xLTEtOTc2MTY_2ec09024-4955-4593-a199-2565dfea70c0"
      unitRef="usd">582000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i8046e68b530144f7bb14542e2e179616_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTUtOC0xLTEtOTc2MTY_c6c7a34e-2914-4ef0-9cdf-9815e649ae67"
      unitRef="usd">551000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a43659878c5400aadd92c3684016238_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtMi0xLTEtOTc2MTY_fcaeb696-7562-40c1-904a-733b908ca825"
      unitRef="usd">1145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc5e412e1f94776bc76d6999c9445a6_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtNC0xLTEtOTc2MTY_2f7f0834-7870-4cc4-9a2b-08e0999e9062"
      unitRef="usd">1381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a45a226af5241fa94c7236e40243ed4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtNi0xLTEtOTc2MTY_2e0c277a-c85c-47ec-95e0-06f4fbd0b3d3"
      unitRef="usd">2318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id67c8e799778495794ae8022dd02b919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTYtOC0xLTEtOTc2MTY_71ddf78a-146d-4633-8f7c-2455bd36dde2"
      unitRef="usd">2649000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if90678a4b1d64aa5a5d8b7d3d0f183f9_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctMi0xLTEtOTc2MTY_66aee01a-80a9-41ed-bd63-de12bf5cbe35"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac78ef5437840d1851a7bb8a12f61ca_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctNC0xLTEtOTc2MTY_244e5549-d407-4cbc-9cc9-88113ef57df2"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25b338d203ed4ed48104fb83314e02d9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctNi0xLTEtOTc2MTY_4785691d-cc11-4242-a106-4def06657c1b"
      unitRef="usd">481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c74555cc18a4bc1bd636f5aab45af28_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTctOC0xLTEtOTc2MTY_c5213044-d0e6-4f21-b365-2556b5aa1c3f"
      unitRef="usd">448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb374613bd8a41a8bf753c1018b7cb7c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtMi0xLTEtOTc2MTY_2d009d52-117c-4947-b83f-1116609d8148"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017973a311a149579a6e2d7f0bf65764_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtNC0xLTEtOTc2MTY_609428e5-1208-40b3-ba5d-04cde05b2507"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84118bab402a49e5b84833a66c174d12_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtNi0xLTEtOTc2MTY_7b943514-e9b7-4990-b3e0-8a294b3c4fc7"
      unitRef="usd">497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21226e99e14c4ddbac60ef91e89cc530_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTgtOC0xLTEtOTc2MTY_1fcfd340-2522-4e6f-80aa-74f4143095a8"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dbbf979d6cd4eccb6057977d03291df_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktMi0xLTEtOTc2MTY_c6e961d9-5a90-4fa4-870f-b8e3c52ee396"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae072cee9e51472198a5efde9ab867c3_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktNC0xLTEtOTc2MTY_d65d50e0-f030-45db-bcd9-73e1baf62811"
      unitRef="usd">435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if64aebd25af841f1b7229554bc01f412_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktNi0xLTEtOTc2MTY_53df3995-f9e3-4d89-9135-e7f289240c0b"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f15191fe14b4cfa89c7a4ae3911fe49_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMTktOC0xLTEtOTc2MTY_4349acaa-9a3f-44b4-b263-b4b0f8462e45"
      unitRef="usd">840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c81ab58c08424a9e69f6265e734d0f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtMi0xLTEtOTc2MTY_2d568380-51e5-430c-8140-589378ce5368"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0605eac069cf4d81b845fd844cb58c8a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtNC0xLTEtOTc2MTY_0de6439f-aff3-41d0-af4a-019d0fcbe660"
      unitRef="usd">366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6eafd7ccb9f4f629d0ad43895286c38_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtNi0xLTEtOTc2MTY_957dfead-e1eb-4ff1-8128-22c139fc84d4"
      unitRef="usd">862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4567b8412c0f40aca0ba3ae7d82676bb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjEtOC0xLTEtOTc2MTY_ee48a53c-29da-4c61-9ebb-13d47033a235"
      unitRef="usd">671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccdc471eaf3645a69aa7fd3af900fa42_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItMi0xLTEtOTc2MTY_337ac453-e3d0-4ed8-a916-a8b0348cc341"
      unitRef="usd">246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86af501659bb429a93b12bc11b5044ca_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItNC0xLTEtOTc2MTY_198ec91f-e0a4-4e3b-990a-b764498e48f1"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34627b0f80bc47d4b2ee036c078502fa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItNi0xLTEtOTc2MTY_c11c9287-161b-4687-9e0b-aaadb91243e8"
      unitRef="usd">474000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if389f2dd00e545d28d559a5e75ab3f64_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjItOC0xLTEtOTc2MTY_0832755a-5211-41cc-bb45-1db21bba00d7"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic865d7480948423580adca162837e77c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtMi0xLTEtOTc2MTY_a10eea4c-478c-4b11-b20c-65e7b1b5caa9"
      unitRef="usd">695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id886288666fb48ccb61718e61df34b35_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtNC0xLTEtOTc2MTY_341fc55e-29c1-4733-a42d-1f3cff4a133b"
      unitRef="usd">584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94cddde0247f443b9b340a36d7ca29a0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtNi0xLTEtOTc2MTY_294f180d-77b7-42b1-a881-1ab0f263233b"
      unitRef="usd">1336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cbb654aee284bde985e29ed2a417187_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjMtOC0xLTEtOTc2MTY_ad321713-c494-4504-9cb8-a8c065325510"
      unitRef="usd">1061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9b4bcd3c344d4caa8accace369889c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtMi0xLTEtOTc2MTY_6df3362a-f930-45f6-b128-f28f15501e6e"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e6f7a1a1f1d4823b6772df289977ce9_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtNC0xLTEtOTc2MTY_ebd85f44-4b0b-48bf-b9e4-c55ee042e4f7"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9240ee581cc94c809d2e9975585d0e32_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtNi0xLTEtOTc2MTY_4547939c-9c39-4c27-a17c-b44b929f1d2d"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38e9f078ec864353b22c3fdd238993cb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjQtOC0xLTEtOTc2MTY_ac18fd16-d926-4d34-b9c8-dd6961c46282"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e70fb16dfd04148a41903925eb90981_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtMi0xLTEtOTc2MTY_5e94f191-c207-407a-93bb-a3264b2cf47b"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85a3b9cd19a14173a8c66d72c61e2b31_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtNC0xLTEtOTc2MTY_9d0faef8-28a3-4fd0-8d41-791e36c25164"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07be0755a0ce42f09fbc795069473e02_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtNi0xLTEtOTc2MTY_a7642394-3ef9-47d5-b045-276b3364e269"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2de83259a6941d8bd633aabc6f46bc0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjUtOC0xLTEtOTc2MTY_cf44d69d-8a34-4c88-bc67-aecd528e3459"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i275a2f367c8e496799ea036748f953a9_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtMi0xLTEtOTc2MTY_1de04a36-f8dc-487e-94a2-a579ceb42fe2"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id42a239b714e4f67893f359965c39442_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtNC0xLTEtOTc2MTY_297d38e9-337c-4599-8405-0163d6c753a5"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69c169ef01f945ee87a73716291f5111_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtNi0xLTEtOTc2MTY_80dea705-d37d-4aff-bb60-5d2fcf2dcebb"
      unitRef="usd">754000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2ee77d1be804cf485a2836eb7067c67_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjYtOC0xLTEtOTc2MTY_8576dd0f-f1ab-4f54-b087-d6ce60285477"
      unitRef="usd">749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd3df4a45fab4f4c9278ca1bfce58738_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctMi0xLTEtOTc2MTY_d98124e0-a535-4f16-be5e-4e55b7923e61"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75d432d522a94fed8847f371bc5981f2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctNC0xLTEtOTc2MTY_2e97e84b-d8f6-4bc1-9944-b8c04cf48e6a"
      unitRef="usd">363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84165bbb1f1347e897f9eab39bb8ea94_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctNi0xLTEtOTc2MTY_7a07df88-2fd1-4e5b-be7f-44c1d7fd18a3"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1efa50552eb2412c8ac12c30f21c490f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjctOC0xLTEtOTc2MTY_951bf74c-b856-4c06-88a3-65c75a79c726"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07b03fece4c047a99bd000932229b9de_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtMi0xLTEtOTc2MTY_8b12a51b-4ccd-418a-a022-3d40e84676ff"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea32020dfa4649129801589297294e8d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtNC0xLTEtOTc2MTY_e34f0f82-d9b2-463f-ac8c-efeeb517c640"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaffe79a5455443aa04784d34e6c64ba_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtNi0xLTEtOTc2MTY_b759625d-a659-446a-9a97-e0d94ee48b26"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb2fecdd608d4d54b39f0ea275388289_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjgtOC0xLTEtOTc2MTY_3aa28ee7-fed2-4a5b-abae-fb197ce469e5"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4e6ceaa8895481db504ab1693ffb3fa_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktMi0xLTEtOTc2MTY_691f5a4a-d081-4785-b313-7ec951215156"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67ad21c8d5d444f39b0047d67697123f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktNC0xLTEtOTc2MTY_8106fac4-6153-49e9-a68f-10e506307e7b"
      unitRef="usd">422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ffaa78a8e1142b288e6e354c460254c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktNi0xLTEtOTc2MTY_31ea9902-d401-4658-a163-25d47bcb69d4"
      unitRef="usd">655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9128c44b088f4cab95566ad9edc2a8ee_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMjktOC0xLTEtOTc2MTY_0b5accff-9a8c-412c-b349-49d805a2596b"
      unitRef="usd">765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37d523156e124aa2ab5e04ddb64884bf_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtMi0xLTEtOTc2MTY_d8b59dc5-feca-420b-b9d1-b58ef14070d1"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice7f58287b6145d5a6823247454ddc45_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtNC0xLTEtOTc2MTY_25826992-5f19-4a13-b684-6e0f4b7edd96"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaf6ab07195a4cca93acbe6ceb203e73_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtNi0xLTEtOTc2MTY_e058be82-4031-402e-94ae-2cef92926c29"
      unitRef="usd">1057000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8df2818c56ef42baaa8eb76d1b384c0f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzEtOC0xLTEtOTc2MTY_86954eb3-274f-4c55-b933-4e6f4ba522cf"
      unitRef="usd">917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i638a5ee6ee4c42fca17c06b8857fb5c6_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItMi0xLTEtOTc2MTY_824b3f4d-24df-431f-be27-bd6f7aa08b7d"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1065d539abeb4072b769ab2d71e8944b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItNC0xLTEtOTc2MTY_01403eb3-e508-454c-86ea-3981b8795575"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04d1768636d746b4bab2547e1b9c9ce1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItNi0xLTEtOTc2MTY_81c448e9-8cd2-4d0f-acab-f830412a9845"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67f61f08f40d4da3a4256963bc6f1384_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzItOC0xLTEtOTc2MTY_ff122fc9-a4fe-4ada-bda2-d46f76603219"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd8781577e0c4483a640bac78e68df6e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtMi0xLTEtOTc2MTY_b7d4e55c-16f2-4e5b-b373-4d84225c4bd0"
      unitRef="usd">678000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f260375e939438fb809d92be390d888_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtNC0xLTEtOTc2MTY_48dd492b-1969-4652-9740-b01ec141f7c6"
      unitRef="usd">603000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3461140986e4666a08f4efef9f1b613_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtNi0xLTEtOTc2MTY_9900f7ba-6a70-4778-8b88-619f850fe039"
      unitRef="usd">1292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07dc2f0df2044b08beb63c5086eb5739_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzMtOC0xLTEtOTc2MTY_9c12a026-8044-46c6-8b83-99033f538baa"
      unitRef="usd">1135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1888ed0d9b0e438c8de2757d768f23f6_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtMi0xLTEtOTc2MTY_14c5f67d-2ed5-4c61-8806-e90544341f75"
      unitRef="usd">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3305a5ca26ca4e7ea948f6a5cb50efa8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtNC0xLTEtOTc2MTY_ac09a279-42e2-4dfe-a405-1c026ba86173"
      unitRef="usd">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5cab0be8af14785bd28c582835b0cc4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtNi0xLTEtOTc2MTY_8ef2d6df-0067-488f-bbdc-678986e89468"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeefd3642f924fffbc846fad74fdad8c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzQtOC0xLTEtOTc2MTY_47817034-fef3-408a-9e8e-428fc4a392c4"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e881c96a7684c80b5f00b2c241ce2ca_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctMi0xLTEtOTc2MTY_733d5f19-8ed0-4514-bb6a-e477d4118a46"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cf09146bec940c49881c105e2fde2a5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctNC0xLTEtOTc2MTY_00a7fa44-cfc0-44ed-8734-9a5e5ced5d32"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i061d2a55e7174d83b68a055cd5e369b1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctNi0xLTEtOTc2MTY_19152e1f-ab39-4462-8287-83f91a7fdee1"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i451984d626294d03858200463c69ceb7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzctOC0xLTEtOTc2MTY_6ccf24ad-2330-480c-af82-da1710eccc77"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc95ef169d984d27b48f3e697f6f4d3d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtMi0xLTEtOTc2MTY_d04983f2-c696-4e29-b17a-688e46988c10"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04dcb0e5c7634daa8fd3b1024c048528_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtNC0xLTEtOTc2MTY_5af0c7ab-be13-4507-84c1-6ee4b2d1a1bb"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3628e0cef99d4acc818a521eb8fa79fd_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtNi0xLTEtOTc2MTY_50a6e5b6-fa4f-4085-851a-da7c3ac5c94d"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a341dab3c8b46f780c38988862e144d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzgtOC0xLTEtOTc2MTY_f3730ee5-fc1f-42e1-a197-6788a5f2d713"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d827902a8b74349b77862bc1ae1fe1d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktMi0xLTEtOTc2MTY_3c185fc8-867e-4dd2-b2d5-9919ef5b52ec"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7877be381ff54eeebefba91654c5bec8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktNC0xLTEtOTc2MTY_a68d78c9-4060-424a-aec1-7cb8b7099bf5"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d561bc963364eb3b42dc2bb43967bfc_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktNi0xLTEtOTc2MTY_96efa6cc-bb52-4c86-8530-6586d4ab76b4"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05c9d7c0c1954f4a827422d7ddb71e44_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfMzktOC0xLTEtOTc2MTY_17e1f0e9-a157-4d37-9af1-b9754bdffd42"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib009e9f4ccbc4aabb0abf813ff1b9b9d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtMi0xLTEtOTc2MTY_0c2e92b8-894a-4f5a-90c9-5d8fca0fd373"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic91980ca8bba425dbf5ec17c1e6c8260_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtNC0xLTEtOTc2MTY_4e563549-6e19-46aa-bac1-c278e1d16add"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66976616df8f45e4a0233eabd261afb9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtNi0xLTEtOTc2MTY_7e9585de-c223-4f1e-aa4a-5b03675b0c49"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5efcdbc4d1cf44e6b7ae58e964d94349_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDAtOC0xLTEtOTc2MTY_f8865457-24e0-4c9b-84c5-9fad2b0ea455"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63415011c3e645908f7ec388df1bb966_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtMi0xLTEtMTAwNjY2_3c1f5e1f-5910-4ea9-9ee3-dbb6122eac91"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58a378f983e24296878b4a51a9ce87bc_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtNC0xLTEtMTAxNDgz_61f9227d-184c-435d-8ac9-d671aaccecfc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3650cb2a09d0454bb935da1c661555e1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtNi0xLTEtOTc2MTY_255311e1-d97b-4922-a917-65ec3402e957"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id488c5c2f38b4d9c87b2dd5a3c14dd52_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDMtOC0xLTEtOTc2MTY_cbe1cead-45ce-4e42-9eec-90032d5d0144"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f0aa8affc324889ba63c424cf09ade4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtMi0xLTEtOTc2MTY_cb2a50c5-d7f9-462c-aaa9-21981e6311bd"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d3ccb3b6564bcab939ffb027584e3c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtNC0xLTEtOTc2MTY_5cc7b5b7-046d-4420-af9d-28cd96e3167a"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8319fb8317f64500af0908643ad0632a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtNi0xLTEtOTc2MTY_93d1f3c5-9b90-4cc5-b957-49ef6083d6f9"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i486d629919554591943fc705452e1ffd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDQtOC0xLTEtOTc2MTY_540758da-7ad2-48e6-8a4d-2ab98a799687"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i910a16d51cdf46e69ab2f11998279fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtMi0xLTEtOTc2MTY_2aeb7d74-b0d5-4c09-aa0d-5a1944b4021b"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac5ee0b393444da28b3de9ccb5848abc_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtNC0xLTEtOTc2MTY_91e147c0-29a8-44c5-a0e5-bdc54b6e0a49"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e1c2e9044134fb283858ebe2b7015a4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtNi0xLTEtOTc2MTY_b456e81e-f0ae-4209-92e6-53f97ff68c4f"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1efe769f8be14215a0a43d2955581c8b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDUtOC0xLTEtOTc2MTY_0d3560ed-116c-4d12-bc80-9b77bcf724bf"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie341a38ca0504923bb7a4212d96ae509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtMi0xLTEtOTc2MTY_dfc13883-d883-4a0d-bcea-5a8ed0b37552"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0338fe30ecfb43c2bb594866b36d0c38_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtNC0xLTEtOTc2MTY_7db2268e-aca2-4a0b-9b5c-0a81f8471104"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8baf06e41cac46ca890ff77bbde002de_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtNi0xLTEtOTc2MTY_6c6143c3-19ea-4886-bc74-8d04e05ec5e9"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if334fd6f6ced463191edffdfc673820e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDYtOC0xLTEtOTc2MTY_f4980fc2-6df9-4855-ac86-cfae59f1f055"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae918b7a7fec4e0f884db97d43014c3d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtMi0xLTEtOTc2MTY_84b397ce-c7d1-4c4e-b379-36151d9141b6"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6361dbeea1084098930ecf34e1a2cd74_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtNC0xLTEtOTc2MTY_180c3519-14c9-4198-96c4-17a3675a9a58"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie802121280734295adc561cdb0a46110_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtNi0xLTEtOTc2MTY_d5823426-931e-46b3-9b5b-a6ba5db5a0c5"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e1d8a4f5a10492bb4bd12e2b4c064e8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDgtOC0xLTEtOTc2MTY_b670cafb-87b8-4439-85bd-831ff006cf54"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia37fe742fa0946ea9ef53a300a8b5681_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktMi0xLTEtOTc2MTY_e46348ad-8695-464e-9c16-7a2c040b84bc"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i082bdbf7ba954da5b6a638b5ff634bd0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktNC0xLTEtOTc2MTY_3ea2d10b-333a-46bd-b021-4d82bb77cf33"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5d2dc14539945b28da637cec2804a59_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktNi0xLTEtOTc2MTY_6e68aab8-8d3a-479a-b910-499b965b9b1e"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i065d8379e1cc41b4ad8f7251eaeeb1c2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNDktOC0xLTEtOTc2MTY_0ed6f1c7-6d7d-4332-951c-3249f4ed92c5"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b0f0ce20724b90a4f7647bb9a8ef1a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtMi0xLTEtOTc2MTY_1de3c64a-b742-49ea-b000-c9cb39bbca5f"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccd74e66f1b04b9ea3d575b51adf1c05_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtNC0xLTEtOTc2MTY_3b612395-5959-46e8-9ad5-9849d8996832"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaed7b5a1ebea48f093da2b0ff29eb4b7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtNi0xLTEtOTc2MTY_7b86eeca-7169-4c66-80b7-8bf3dbc6285a"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id123036947d949b3b27454b60e9bb03d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTAtOC0xLTEtOTc2MTY_800b1f28-bcb2-4375-a602-7e204838632c"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06cad72124104e83a37813c7ca4d58bc_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtMi0xLTEtOTc2MTY_a8214fe1-5fa1-4f0b-953c-6cc7c27ae32d"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b70cb0e5c7147579fa25e09acbf6291_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtNC0xLTEtOTc2MTY_f065e199-917a-4078-90d8-fcf328b17432"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79667b913ce74f5dbebec3fe976825ff_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtNi0xLTEtOTc2MTY_2c0f0bd3-9467-43a6-bbb7-0b878ad47cb1"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d10096f8a24fccb83511987f26c69a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTEtOC0xLTEtOTc2MTY_6bea63b5-7d6a-4ed3-923d-553da088f5b3"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d2d4201e5e747079eb77993bb61fba3_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItMi0xLTEtOTc2MTY_a9e37ec1-471f-414e-8a57-fbca0a286d80"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i711eb0534e014c01be59768e65562deb_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItNC0xLTEtOTc2MTY_c4384ef9-6b55-484e-8c1f-058ee8ac00fa"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibec21debfbe341cdad1aac7ebf721a99_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItNi0xLTEtOTc2MTY_fab87913-11e8-4ebc-aeeb-da6cd63fa345"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad19468cf9d346b28980e07a20d6f5db_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTItOC0xLTEtOTc2MTY_4310cd06-c9ca-49d8-bc0d-77e81403862e"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15fbf82d23f3402dacdf01e8cf69b44a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtMi0xLTEtOTc2MTY_7aa93c84-8a0f-4021-8de5-26549207a38d"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f1716e275a0412aa55aeb45b7eb6c31_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtNC0xLTEtOTc2MTY_2ee3f8d1-cba3-4f47-9c7a-d1b37c7e9136"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf40dd1d09234507952e167d1479045e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtNi0xLTEtOTc2MTY_24df0e3c-3a1a-43f2-ac9e-78f892874120"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3682c7c9fc8d4e37870dd6d2a55fffa6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTMtOC0xLTEtOTc2MTY_d13bf133-829c-4573-8dce-15b557e2dd37"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83a5fbce24694e669e94f977e23e2355_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtMi0xLTEtOTc2MTY_47c2aa33-9726-4a07-9a4a-0c7d68d6dae9"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2c7d12ad2714a6ea184eada5e3b70a0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtNC0xLTEtOTc2MTY_555f1a4c-459a-4730-89f9-bad1b8288188"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dea495dc74647a89c9c075bf46494aa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtNi0xLTEtOTc2MTY_b2768cfb-7540-4f62-b944-f875a54740c6"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1a900fadd404c10ad147fafe8f4deb4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTQtOC0xLTEtOTc2MTY_d8d0524e-de86-4d1f-981f-345450fb9208"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28b4ab1ba4784671a896ead7cb8313b0_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtMi0xLTEtOTc2MTY_0ae005f6-b15c-433e-9ef6-32767e236e03"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8173b604f62e4076a3617362c1136935_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtNC0xLTEtOTc2MTY_baa4e2a8-92b8-468b-8014-182547a60bd4"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05e86aea9a594dbeb0b923716d380818_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtNi0xLTEtOTc2MTY_b56f4f68-74f2-4799-9eb7-30bce652164d"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83ae3512f1eb4610aca3449ed15dd8d1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTUtOC0xLTEtOTc2MTY_549451c7-ea49-4ad4-8ac5-c452095da368"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1412de7cca3427fa94e528b2abb50ea_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtMi0xLTEtOTc2MTY_4136a226-3e02-414e-88bc-6153ac8d553c"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i201933aab6584d7ca5b8dbf08dbbac04_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtNC0xLTEtOTc2MTY_ebb311f7-1eba-4b7e-974a-2d73fc9c1c64"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifedaedd5de554534991638c4456c25b3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtNi0xLTEtOTc2MTY_798bf791-4c8c-4dc1-93e2-d0f1affa339e"
      unitRef="usd">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17b9bd9ac4d044d5860a53c8b0380a1e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTYtOC0xLTEtOTc2MTY_6cf77d7f-32ef-4107-b696-da7d26f3c3be"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d9e048450024856b06b4e78059095d1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctMi0xLTEtOTc2MTY_c87dbcd0-de65-419f-ab49-81724dd80a23"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacd1758c8b804a44b870604e3de47893_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctNC0xLTEtOTc2MTY_31863350-4f26-41ab-a7b0-15fbca0c03df"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a3067379f7643989c5c6a9f5aa57e51_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctNi0xLTEtOTc2MTY_2ad7f700-17ae-4440-8cc2-2e227f88c455"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29b1aa17325b4c23ac4029b80c3b95d4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTctOC0xLTEtOTc2MTY_73b7df3c-327f-4f7c-b6ae-bf25e16263f8"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i959da824f08a41469fcef4982237f0ad_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtMi0xLTEtOTc2MTY_7da863d3-b190-4e10-a1df-cd186bb2da25"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa9ca253be174199be0d0235e1eb2f23_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtNC0xLTEtOTc2MTY_090e951b-0696-4059-8891-7b53df98dea1"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i335cd00f529e4f93912c67b5c142472f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtNi0xLTEtOTc2MTY_58f0db2c-39f0-4f85-b2d1-5c9631727da4"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8a7e51d8bb049719a805c96ee4e3371_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTgtOC0xLTEtOTc2MTY_428b08e0-ac21-46fc-a64b-8ed2c9414332"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i904652ab5bb343df953e359f58983c26_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktMi0xLTEtOTc2MTY_40c16537-5f7f-4c66-8341-d8587462b307"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f642aa7c52d4beca6b8434dd4031490_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktNC0xLTEtOTc2MTY_b592dccc-7521-43a7-baaa-a64a54b404b4"
      unitRef="usd">301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0dc83404ae74a8097d23417e7af22df_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktNi0xLTEtOTc2MTY_c89a6fdc-14ba-48e7-b310-990201a07d3e"
      unitRef="usd">605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53336e17dd6a40f1990e05073d8317b5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNTktOC0xLTEtOTc2MTY_22761a8a-e412-47f0-bc73-e104e943a76a"
      unitRef="usd">577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aeae0c651354131b671fc904166fb25_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtMi0xLTEtOTc2MTY_fc754735-02a7-4036-a160-32a51cefe86d"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04e57842484a485991d62e03a01d8e38_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtNC0xLTEtOTc2MTY_1e7a269f-b1d9-49ca-a1d7-3f70359caf61"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i158d06c961ab4b84ac67732c15bd9b13_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtNi0xLTEtOTc2MTY_48a37d03-d476-487f-8a84-3d2bcd0721dc"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16f064354b64f688d1bff104fcffb76_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjEtOC0xLTEtOTc2MTY_ecf2c581-06de-4e79-aa17-bb9358656643"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24fc70faba5c40f2b7c77bb2f65b318d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItMi0xLTEtOTc2MTY_6b7e585f-2dff-4c5d-84d6-a042fac205d9"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51a52d243b364ceebafddad56040e1d4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItNC0xLTEtOTc2MTY_21bfc808-502e-45f3-b42d-326a4661835b"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b345afd17164d7d917c60019900d02c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItNi0xLTEtOTc2MTY_c806dd80-513b-4411-a161-7748114f203b"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7baadf51bd904370a6d282562978b306_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjItOC0xLTEtOTc2MTY_6b8dbe44-f651-424b-baa5-09d0bcc686b6"
      unitRef="usd">483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ba200322b8f4fcb86619a36931e9175_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtMi0xLTEtOTc2MTY_32b01c59-4d4e-48bc-9a98-d2af2c1a4a8c"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88385ff780be4c28851e5dde7a7375aa_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtNC0xLTEtOTc2MTY_92c49cb8-7735-49c6-88b1-4df0799c6cbb"
      unitRef="usd">442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3842eb65438141e288a8210b375b0e59_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtNi0xLTEtOTc2MTY_66872b25-76d8-4618-bb65-16b676afd549"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia67b59d6f5054f0f9504c3b750eb3e0f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjMtOC0xLTEtOTc2MTY_cab17eb3-b59d-4213-bf82-88375584593c"
      unitRef="usd">857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb25c770cdcd4b8a84b4d8984b516ea3_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtMi0xLTEtOTc2MTY_86272246-dbd8-45de-b651-06a1aad463f5"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7846dcf271946ef9f581063d57b1d32_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtNC0xLTEtOTc2MTY_4df0694e-c0b2-49cb-9d45-e23fcc06d790"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1be1c9ae69774509942fb2c801e8e0b4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtNi0xLTEtOTc2MTY_7d4f63e3-2520-4a64-ae77-6e16b425ef63"
      unitRef="usd">605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5411bdc1d3b46c5a26a274c0c49de78_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjQtOC0xLTEtOTc2MTY_3f3f1a3d-74c1-4a26-86b2-f90641e38e4e"
      unitRef="usd">554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fe1ad8786cd4ec9b518879507cdeefc_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtMi0xLTEtOTc2MTY_8f348536-9351-478a-93aa-e4b716dc74e4"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43669c40e73a46afb5e6f704a10e6d1e_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtNC0xLTEtOTc2MTY_3edef42b-a298-4550-a824-ae34b10868b9"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9a8730959ce4f028d5538a29f222423_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtNi0xLTEtOTc2MTY_aecb4700-43ca-44f2-aa6c-8f5e520a1b93"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id215663e03264d678a32b5af7a72e4d0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjUtOC0xLTEtOTc2MTY_c5b837e9-6f2d-4081-948c-e538b175f497"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd1f55c4f4fa4a0f87dd08291588f95f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtMi0xLTEtOTc2MTY_2dc994d0-7a36-486f-bfd9-72c651434bb5"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18902dc3bd7b4eb2bf8e70464f318c7d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtNC0xLTEtOTc2MTY_50cb69ca-bbe4-4eb5-92a6-f63c306f2d19"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f331549442e46038a09afa23765f532_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtNi0xLTEtOTc2MTY_c171edbf-ee82-446f-aeb8-4f68fa05ee8d"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia689063c9a8d4f47ad065d4cd5c51cce_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjYtOC0xLTEtOTc2MTY_1f1fa58a-f9bd-49ef-952a-2d048af5a05b"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a165da7515149dc9f2231f0452f276b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctMi0xLTEtOTc2MTY_dde84086-4c71-40bf-ba42-24626690ffc4"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aa0784d769c47b1b61138f07a799e92_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctNC0xLTEtOTc2MTY_89a55987-d589-468d-bd3e-3709129c1ad3"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b632bb7a6f44b95a3ba9242b438a9b1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctNi0xLTEtOTc2MTY_aae6d916-f090-488a-8ae0-be87b4fb1937"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib35991f95fd64801a6f989d5186073d6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNjctOC0xLTEtOTc2MTY_552f7e24-2851-441b-9fb3-79d4b2dd27ef"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i676449a933204a9cb64a6f54570b2d60_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtMi0xLTEtOTc2MTY_b2e79747-3e1b-463a-aa67-410486b7aa53"
      unitRef="usd">1009000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc8f4a95cb1b4c99b4bb5f312cef5b00_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtNC0xLTEtOTc2MTY_29bda50f-bbf9-4019-a007-b2c66ad6abe7"
      unitRef="usd">1221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5611e12d1194636a4cdc0e36968dd1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtNi0xLTEtOTc2MTY_2e8765e5-59f1-4179-aa1d-1746061e743c"
      unitRef="usd">2220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbe1892fc3014e6b8f3d56ee7c617da9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzEtOC0xLTEtOTc2MTY_a24043f1-33f6-44e8-ad0d-ea31aa4a9c1a"
      unitRef="usd">2697000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i41938fd146174f26bcca56dd5e673fce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItMi0xLTEtOTc2MTY_6f3ea7c7-c6e2-4fb7-a2ac-6601a5d7df76"
      unitRef="usd">14583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItNC0xLTEtOTc2MTY_1f0c4e58-a1fb-420c-bd1f-c6d49dab4e3d"
      unitRef="usd">13959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItNi0xLTEtOTc2MTY_9102ac1c-7019-4a32-bf8d-2068cf2ab3eb"
      unitRef="usd">28121000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea7e77b534884501ab1d493dfa1340ec_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl85Ny9mcmFnOjU4MTBmNjExM2NmMDQwYThhZGUxY2FlODA5OTcyYTk5L3RhYmxlOjU4NjY5OWNhNDUyNTQ1MTVhMjA4MDlhY2Q3YzA1ZmQxL3RhYmxlcmFuZ2U6NTg2Njk5Y2E0NTI1NDUxNWEyMDgwOWFjZDdjMDVmZDFfNzItOC0xLTEtOTc2MTY_056eea93-0902-4683-8041-8be3da454228"
      unitRef="usd">26969000000</us-gaap:Revenues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at June 30, 2022 and December 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjFjZDhhYTdjODJmZjRlODRhNmQwYmEyYzc5MzRkNjcyXzQ_7c137692-df19-42d9-8e28-d6860a3425da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjQ4ODIzMjA3ZjhkMzRkOWU5ZTM4YjMxNDA4MGRlNzVkXzQ_98e22498-2ab1-4b37-b1a7-63d5b307a128"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(c) Amounts are included in cost of products sold (see Note 8).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNS0xLTEtOTc2MTY_eb065cdf-3ded-41a4-a28e-c6a9638c526e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtNy0xLTEtOTc2MTY_43576c50-2c1a-45e0-97e6-8db17ebbf9b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMy0xLTEtOTc2MTY_3896b97d-0b0a-40ab-aa9b-de9c3cd25383"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTEtMS0xLTEtOTc2MTY_ce1e38cc-b372-4ca4-a70a-70fd344e8d0b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg0MA_74c9895c-a040-414c-82af-51e924aaf073"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(a)&#160;Amounts are included in interest expense, net (see Note 8)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNS0xLTEtOTc2MTY_32544a20-ea6f-4d0f-9e8f-ce2507eeb5cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0zLTEtMS05NzYxNg_f444d290-b22b-4b7e-b3c6-68fc475a9652"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNS0xLTEtOTc2MTY_e6b45f20-8930-4b60-965d-8499dd4fe252"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMy0xLTEtOTc2MTY_a019f80f-4f87-459d-b31f-20133ee0c326"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy03LTEtMS05NzYxNg_eed23e34-0738-45d6-b362-0ded5f27f6ed"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy0xLTEtMS05NzYxNg_af66bb23-bb0f-45e9-8604-590f66031ffc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMy0xLTEtOTc2MTY_63a68d62-a197-4699-ba24-a86153b596ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItNy0xLTEtOTc2MTY_49f92d18-c189-440d-8185-806a5c09571d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTItMS0xLTEtOTc2MTY_38620e87-cc2c-41f5-9ee2-b87fe2c38e69"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMy01LTEtMS05NzYxNg_c3158be8-e1fd-439a-9097-5bc0e4bcb20c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtMS0xLTEtOTc2MTY_3f80df17-758a-430d-a4cb-31215072402c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfMTMtNy0xLTEtOTc2MTY_d7273da6-96ef-4e23-932c-6c135a2a2fee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg1OA_39c34e19-7806-4792-8f87-0814576cac3e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjllMmUzNjhkYTU0NzRjZmZhOTIzZjY5ZTI4MGI0YzUyXzQ_a0045b16-20aa-4778-a1ee-1520860881aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi01LTEtMS05NzYxNg_0b5f09d3-0238-42c1-90cd-e0af74dad7d0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjg0ZjM5OGIwNzE0NDRhNWJiNTE5NDRiNmY1ZGQ5NzI3XzQ_6d4b3397-230b-41a6-83b9-7af794ef0dc0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMi01LTEtMS05NzYxNi90ZXh0cmVnaW9uOjE1NTkzODYzZjc4NjQzM2Q5ZjIxYWMxNGIyZGI1M2Y3XzQ_491d6e49-24b1-473d-9657-49ba74377191"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNi0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjRkMDQyNGZmNmI2OTQ3ODc5ZTgxNGM2NDJlN2Q5OGI3XzQ_8409b619-865a-4a85-846b-669831d9617d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfMy0yLTEtMS05NzYxNi90ZXh0cmVnaW9uOjhkOWQwZjM4YzQzNjQzZTdhZjkzYmIzZDc0OWRiZjUwXzQ_25c8d3cb-4392-41a7-be0e-e824a6658716"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAzMDk_b69f64c4-0cf4-4896-a0f4-1b4a2dba948f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(b)&#160;Amounts are included in the computation of net periodic benefit cost (see Note 9).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy03LTEtMS05NzYxNg_5bd24adc-b560-48f3-99a2-7955b7084662"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0zLTEtMS05NzYxNg_d8944257-5870-42be-b305-c28324a5d381"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy0xLTEtMS05NzYxNg_27f1ada8-9bec-4363-b670-b7722c238291"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RhYmxlOjM3OWY3NzBhY2Y1ODRhZmU4NGQ1NmJjOTkwYWY5ZmJhL3RhYmxlcmFuZ2U6Mzc5Zjc3MGFjZjU4NGFmZTg0ZDU2YmM5OTBhZjlmYmFfNy01LTEtMS05NzYxNg_5f6a59f2-0d3f-422e-8b7c-6e611f52a196"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl84Mi9mcmFnOjQ3YTRkOTM1ZWIxYjQ1MWM5NTk0YTUzNWY0M2QxY2M5L3RleHRyZWdpb246NDdhNGQ5MzVlYjFiNDUxYzk1OTRhNTM1ZjQzZDFjYzlfMjg3OA_742f17c6-04f3-4dc3-b5cf-384540b20869"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzQ_a35e9ad9-b5fc-4f25-88b3-199218ff2c7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzk_2fd30863-6a03-4360-8552-413920d1ff18"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC0xLTEtMS05NzYxNi90ZXh0cmVnaW9uOmQyNTY5YTVjYWViZTQ5YjM4ZThhZmE2N2FjODgyM2ViXzk_46e0dace-6683-4af2-9c24-7a21073c42fb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwMw_0e9ddab0-f698-48bc-bed8-6688bf93da84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RhYmxlOmRjYzY1ZjJkYTE0ZDRhMTk4NmE3OGQ2ZjQyZmFlN2UwL3RhYmxlcmFuZ2U6ZGNjNjVmMmRhMTRkNGExOTg2YTc4ZDZmNDJmYWU3ZTBfNC00LTEtMS05NzYxNi90ZXh0cmVnaW9uOmMyYTdkN2ZlNjlmNDRjNWViYjdhMmFkMzQ2ZGMwZGFhXzQ_f2d35d84-9704-4c44-b3dd-5e7031abcdd6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfODAwOQ_9d0113cf-e78f-43ef-b940-ec0f0978af99"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgwNDA0ODgyMjRjZDQwZDE5NGZkMjI1ZWRjYTk2N2QyL3NlYzo4MDQwNDg4MjI0Y2Q0MGQxOTRmZDIyNWVkY2E5NjdkMl83MC9mcmFnOmI3NjZmYTYzMjRiZjRmOTdhMWEzZTk4Y2Q1ZjMyODVmL3RleHRyZWdpb246Yjc2NmZhNjMyNGJmNGY5N2ExYTNlOThjZDVmMzI4NWZfMTAyODE_aa43afcb-a411-408f-b934-b8952538ab45"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
M  @ +G\$50?X,.PU"0  TDL  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6RUG&MSFT@6AO]*EV9W:Z8JEJ"YV5G;53)Q$D\RMF-[)Y/]AD5;HH)H38-\
MJ9H?/\W%M,@<#A)JOM@@Z;SP=M,O#]?C)RZ^IPO&,O*\C)/T9+3(LM7;R22=
M+=@R2,=\Q1+YS0,7RR"3LV(^25>"!6%1M(PGU##<R3*(DM'I<?'9M3@]YNLL
MCA)V+4BZ7BX#\7+&8OYT,C)'KQ_<1/-%EG\P.3U>!7-VR[+_K:Z%G)O4*F&T
M9$D:\80(]G RFIIO?>\H+RA^\7O$GM*-:9);N>?\>SYS$9Z,C'R-6,QF62X1
MR'^/S&=QG"O)]?BS$AW5R\P+-Z=?U=\7YJ69^R!E/H^_1F&V.!D=CDC('H)U
MG-WPIX^L,N3D>C,>I\5?\E3^UK5'9+9.,[ZLBN4:+*.D_!\\5PVQ46 ;+06T
M*J _%)AM2["J JLP6JY98>M=D 6GQX(_$9'_6JKE$T7;%-72393DW7B;"?EM
M).NRTW=\MI:]DI$@"<EYDD79"[E(RLTC;^8#DBX"P=+C22:7EM=,9I7R6:E,
M6Y1=\AM/LD4J54,6-NLG<BWK5:6OJWI&4<%?U\F86,8;0@U*@?7QN\KC,:$>
M5-Y8':MN.:O0LUKT_ME84!N5&C:LD8_1M^DJF+&3D1R$*1./;'3ZGY],U_@O
M9%"36,.N7=NU,76UH=R]K!CD%"\WC8,OD"6TJJ<EI[;D;&?IRSH0&1/Q"[EA
M*RXRR!XNE8DUU"@^6M73GEO;<[>S=\U$Q//1'1*9$6#GX4KUR&L=>FA]3Y]>
M[=/;<LL4@=R]%+'5WH^XUD,0IV!'HF4]#1[6!@_1E:J2YGT4,W*Y7MXS 1G#
M-0S#/+ <QW4@<VAI3W-'M;FC;<S=L'F49K(#,W(9+,%M%->9WM_+?;R,X]D8
MLH@6][1H&FHG:VQCTI=;J0ABN9(A>R:?V NX5\6E#-F3CF.:#C@.\>*^/C=@
MPMQN*+Z/TIDT^HT%@KR7'\+\@(NU90U>UM<C51[I3AZK=&UWB<M]@3VB17T]
M*K0Q490XG4J#86DR#N:@*UR@-4?QNK[&%,28.(;X:R%^W#ZQ_6*'W,&!20\L
M$S0Z!-F8"FU,'$AJ.IUQ(7>%!9^^(;>9]$FX(#Y?RRB2B<1#V'<'.9V#EH>@
M'5/ACHE32F7Y+G@F%Z'LY.@AFI4',>T[S0Y)BQX8EN>8M@?Z'8)Z3(4])LXJ
ME=]I&$KU],WK!/DL?T>N$KA?<4F37$IL6I"OP?H[FP>2HW@0@M:'X"%3 9&Y
M%1'5UOU\3F[6=_P)/ KKD"M-^PNYO<PY:'<(0C(5(IE;,5)MMQ[&UX(_1LD,
M[FI<\^(S:'0(3J**D^A6G%0;O>9I)F/Z_]&J-:DZ%%W#<.T#US8,\(S!$+A$
M%2Y1G'"*S78J6-#N#A<XA(,)K^IK2Q$2Q9'F,R^X:,$3['BE0^1(9J]WU-)M
M0] 1571$<;AYI?F*)<ICS2B9%^,2AL .Q6_@"38?K^KK4\$2Q>FF9HB,B?)T
M:\Y)P:MQT">NV.9S"%:BBI7H5JR4'U]+,I+1.N<"/#3KT/D<B#DCT]F,22$I
M$Y:2H.,A4(DJ5*);H=+M,HAC<K9.Y=<IO-WB.JV8C]?U]:?0B&Z%1N=+)N;Y
MP/P@%?(]/%^N@@3NVI[GA?"ZOD85"-&M0.AVP61'8O9PF79[0X /5>!#MP(?
M:6PI,?XVX[/ODGZ*"Q+D:IU).$A"V;^@8TTD4[5#J>84:OFEL<=3TW,/C2/7
M/G*.)X^ 2TM1CX4SRN7Y5_+MZN83N;V[\C^1\S_\C]/+#^=OR,6E/R9_O=I/
M<_O@-09-%%-=9!B"B2S%1):IX[**)L*I+ _!2Y;B)0M'G5LV6XLBKYYGBR"1
M^Y"V4Z =0I??;L$#<[RLK[^-"V4XW=Q%62P/5QZ(27^^_X6\V@4-XDK-(%@%
M@CP&\9J1?QECPR0KN?LNKE:";3 $2UF*I2R<?.Y$$!:(^+*\YS%H'1>8GIW]
M#OH:@ITLQ4X6SCQ=V24[FYACQS#D5!+)0]9+GLGP?B<[C1K4 AM"$QM5[3,$
M:5F*M"Q71YQIPJ7*\A#P92GXLG!6VB'.<*'6.!N"N2S%7!8.2[O$&:Y4#(Q_
M-T=&V#XR?%RNKW%%8Q9.8UMD6,<U.IEAU#H#K0UQXLE6"&;OAV!EC%F> \:8
M#=X/H97*=*DUVT=1F:V#RFRM5*9+K6E949FMB\HZA-IB#"_KZT]1F:V-RCJ4
MBH$!QQ@T,GQ<KJ_QC1N9]D6Q#H$BQF!G0\"8K6#,U@%CU(%A#$XQK3"F2ZW9
M/@K&;!TP9FN%,5UJ3<L*QFQ=,-8AU)IB0\"8K6#,U@9C'4K%P-@EQ8: ,5O!
MF+TOC'4(E"D&PAA>V?>N3 5CSOXP9HR]EAB#KHB=X4O<=4SK4FNVCX(Q1P>,
M.5IA3)=:T[*",4<7C'4(M<487M;7GX(Q1QN,=2@5 P..,?!:,2[7U[B",6=?
M&.L0*&(,=C8$C#D;-Y?O#V-T;%('[*M#L"FTPI@NM6;[*!AS=,"8HQ7&=*DU
M+2L8<W3!6(=0:XH- 6..@C%'&XQU*!4# TXQ:&3XN%Q?XPK&G'UAK$.@2#'8
MV1 LYBH6<_=G,3IV?TRQ=TB*X4O<=4CK4FNVCV(Q5P>+N5I93)=:T[)B,5<7
MBW4(M:487M;7GV(Q5QN+=2@5 V.'%,/E^AI7+.;NRV(= F6*@8>4>&5?:PK&
MW$%@K(JQ([ MM,*8+K5F^VP\*J@#QERM,*9+K6E9P9BK"\8ZA%IC; @8<Q6,
MN=I@K$,)@3%H9/BX7%_C"L;<?6&L0Z"(,=C9$##F*1CS=%RE_,?Y_;*OP,>4
MSO E[CJD=:DUVT?!F*<#QCRM,*9+K6E9P9BG"\8ZA-I2#"_KZT_!F*<-QCJ4
MVL_OPP_PX7)]C2L8\_:%L0Z!/,5:G W!8IYB,0]G,?_CA3_]< 6%V!8WN^+B
M.X_>(;#+4]CEZ< N3RMVZ5)K6MYX68,N[.H0\C_^ =H;@KH\15V>-NKJ4-KC
M7E=<N6\;* #S]@6P#H&V>UWQLEU]33;>FI0_*%*\3"HEL_S1Z/(%2O6G]0NK
MIL5KFB;JY^7;KGX+\N=,4A*S!UF:7X(9$5&^0*J<R?BJ> ?3/<\ROBPF%RP(
MF<A_(+]_X')_5,WD"ZA?XW7Z-U!+ P04    "  N?P15V?$;:5(&  #Y&P
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MHB:>W0.7&"H,CM0R91U=-DCW6FH!^[M^6M\3(@7:N1H_!YW:+L\Y HKLIK1
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M*C0 VI><J^>"[J!]C1K_!U!+ P04    "  N?P15L&1?CG0#  !;"P  &
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MR#IH=B+;'1$)>MW1IR]9Q]U[SY?@C9J-4T1*.DC=(E*WF-1-4+D]5]KHZ.L
MFB^@^)A4]YF\U.;IG;1WWT[D6:R>O]/A^4E=/NR_(>"VK.MRLW^X3I-56C4"
M^?^[LJQ_/FF^=.#PS1HW_P=02P,$%     @ +G\$56TL/%1B!P  _R   !@
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M%P(][X5>>DG%U$X$)")/=4Y07Z/':AS*:<=:&&79_!.OA[97F[I<-W6Z[XB
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M=]C%CV#WH*2?>F:&/71-I_VC$Y\5AH%U ^X@C.,0CJ,,N_1$_8VJQR9T>W6
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M+0UU!B<VU(I1607ZOY+2[!;V@+&Y+W\ 4$L#!!0    ( "Y_!%7*'3>K+00
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MGOJ<,"VHL43+ G2>&^-W"[Z@;U67?P)02P,$%     @ +G\$53*A$GP*!
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M<MRX$?T5U*SC2%6CN>MF2ZJ2[%W'KMV*RXHW#ZD\8$C,$#$)< %0H\G7[VD
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M:BW *F?9/VZ7UAGPXI^[[ YJ%[O54JZ\L25/Q/4 R6"%>1"#F]<_3,\F;P^
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MK7D!KL.. L8YO K@-+*;Y\3S>973%*"^&3*GK[(B@:= HRPW/?;3$O2Z(2(
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M&F-"*\=PJ&HM)+??@F08]U4 +2@]BIFYJC\:_P: :O>F1,O_H%?RW? Y8LQ
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M1.T,:'VNE-T,W ;M SOY"5!+ P04    "  N?P15N"M<%G$)  "J&P  &0
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MB+KPWU_VP_U7K(_2+ D%A5I -!A,1AUA_)<A?^/TAK_&S+5S>LV7*R5!#30
M[Q<:AM8W-$'S>>[\OU!+ P04    "  N?P15+JR"43@#  "M!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6R556M/VS 4_2M70>,3:MJT/ 1M)1Z;
MQB2DBL+V8=H'-[EI/!([LV]H^^]W;:<!)BA,JAH_[CD^U]<^'J^T>; %(L&Z
M*I6=1 51?1K'-BVP$K:G:U0\DVM3">*N6<:V-B@R#ZK*..GWC^)*2!5-QWYL
M9J9CW5 I%<X,V*:JA-E<8*E7DV@0;0=NY;(@-Q!/Q[58XASIOIX9[L4=2R8K
M5%9J!0;S270^.+T8N7@?\%WBRCYK@\MDH?6#ZUQGDZCO!&&)*3D&P9]'O,2R
M=$0LXT_+&75+.N#S]I;]B\^=<UD(BY>Z_"$S*B;12009YJ(IZ5:OOF*;SZ'C
M2W5I_3^L0NQP&$':6-)5"V8%E53A*];M/CP#G/3? "0M(/&ZPT)>Y94@,1T;
MO0+CHIG--7RJ'LWBI')%F9/A6<DXFEZK5%<(=V*-=AP3,[KQ.&W1%P&=O($^
M@ANMJ+#P6668O<3'K*23DVSE7"0[";\UJ@?#_@$D_239P3?LTAMZON&[Z<&5
MM&FI;6,0?IXO+!D^$+]>2SDPCEYG=)?DU-8BQ4G$M\"B><1HNK\W..J?[= [
MZO2.=K&_6XZ/H^&N0, \1W_L@7@'C""$E;"0))^ [S,0AU!A$*$*910J@\'@
M:=+*]78*786!ZX-=?8!7JX7A8=(P'.WB''V0<]![2[=4@"(MH$8C=0:9Y!"W
M=&YTY7GO>_,>6!+4D#:;)Z#.(>&4:B-5*FM1EAO(&G22'4IR!BFY(-;'5U@!
M^QWCV#$LK K)*[)-. ^Q_\2SG:%A67[+MZM9I[/4:4O +FAEAD&?DL1ZY^3"
M#CR"P:A<FAXV:]"PJEN9:K]IFE&FD^7B?S=&VDQZ/V.*16/Y %C++O3([EJS
M5U*P.4D2P\Z+-#7H_8]_*6^[5$L7QDVG+&0:-CU##F6#<UKH]2*\++#C?^>$
MZ$<,"-Y^QFY0&'\"N<MO@'RJ15M/WA"[7=^?+K79WSM)!L=G]D7VHF0S7+LR
M,*/BG/XGV]?N:?S,0BLT2_]06 8VBH*;=J/=6W0>+/@I/#QD-\(L)1>_Q)RA
M_=[Q800F/ ZA0[KVAKS0Q/;NFP6_IVA< ,_G6M.VXQ;H7NCI7U!+ P04
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M4<L-&'.(!(+E.'PY,E'Z@X>SB.DF^-)8_+;08$NWQ#SI;@8AZ2 "8$>IR<M
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MX&4R\4SY)6Z0K%D5VL04^$(G/B@GU<U7'9BNU5:.VF<8<2')D\R(6MX#P1$
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M>L?6(-;&V04BX3CWH@J]A!5/(B@/L8'<=,0@V47+_ZH]IP$)'LB$,^_,?."
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MP3GEGD+F?E^=>$SJ%RXV/6FSH7_[XCOP[:L-GUUMW%]M".?>+/^DM-2H]JZ
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M'9F7>:)=7J20["1LS66*!;?AVE[3I7NGN"+1]7J"H-BJ7[4NWX)2Q;;=+H
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M]@(3"TT/RLVW>?)H/)U$Z=@=1D,QVFI]'F =#07\MD*K#5A6"']04&[9HY.
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M"WR[(IV$OM=##T2HW:!BO1;=IM4!<6\)[4M8O26\U0Z%YRJ$@&HF] 501;>
M35DR#6A_Q<9%%4_H.4_\(YT6>3GQY6X6WF?S^83]>L 7. 9T)]B8?#)!08(G
M!$X$)(.U<BEK7WTL&R?3N,@GK)R7&$-*7K!QEF*&;"9B&#=>H7,$ER=R>'!I
M=/>BB+ OOYBE2?H&?&',K K/M/(2@HO=ZXTP4A_FL6_)5N$2A;5$Y847YM7D
M$V?NA9<\E4Q+,NH5*ZHB>"X/KLU2*KCC;)K,X=G_4X0F?R%"/P^-=- 6,^^J
M:AXPF4WCLJ)14E2#"Y/J?P-CGF5 1HD#M22 C),T^UN "#43'-<9*G3VN3@<
M=(U9DL[A&O071S#HZWD1^Y3.XB&7Y]F,1FE2#.Z+L\F1>E]MZWUUO-[C4MCT
M "Y!S"-KI;R3@0O>Z5ZAA]IS(.Z!?^TI<%R_0SGF>PA2C!26'1H+**"&QM2'
MK7IC(1V9H4+[J] &RL:K9AT>G2?W9A@%QM9GUM]K^^>TN.,%;C/OA:.N1]$-
M9X#TH=;WSY/Z.R(F3^'F).]"\QKL1&-9MWWSF!]BN13^<JT$$L&!)7$:\P!%
M7QG'14CK63AQ)KZ3?6Q/46G9C*5#K?B/U-VM:;[<!B:![P!X)-VQ4W+HF2UN
M&-HX^7MHCWTD'!I'";%#%2#J$)+QPI=T:I;182/%$I]H>;;7A:.,T+F!\NXM
M]?J\S(X\]V6/FO/*L\\.E,^=</RT7Z:@__+30HT)NHM1>/Q!0E#V%UR0U9,G
MWX5C*PVG??X4:&<$MSW:.4-];$M7-+X"" /^*:#C<O@%L_$WJ 5JJ=" (_B!
MVM[SS:Y\$">L8AG5LMW@CP=/HCN ]R:L\%AY*13FWISX"0DHNR3J<LA':KY1
M6P-8Y8Z.@_C <&R1:/Z3P&QRX@/_'+T_I)&KO=M"B!B$RB[K+2QJNE@^L9T3
MV_IYMO7!>^B>6H>*=[3SW:<39N6_;E$I@Y#P"6@[N_V =AF^&SUM#U_??N9F
M12AHQ1*D\4F%*YH)7[3"B],;_Q5IH9W3G1^N!4=IH U87VHH.KR0@.UGQ8L_
M %!+ P04    "  N?P15??F6OPX&  !]#@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6RM5VUOVS80_BN$6Q0M8-3BBR@J30PD:=>F:]<L2;L/PS[(
M-F,+E427I)RXOW['HR/;D9M]&>*(DDS>W?,\=T?S^,[8[VZAM2?W==6XD\'"
M^^71:.2F"UT7[K59Z@:^N36V+CP\VOG(+:TN9KBHKD8L2>2H+LIF,#[&=Y=V
M?&Q:7Y6-OK3$M75=V/69KLS=R8 .'EY<E?.%#R]&X^-E,=?7VG]=7EIX&G56
M9F6M&U>:AEA]>S(XI4=G(LS'"=]*?>=V[DE ,C'F>WBXF)T,DA"0KO34!PL%
M#"M]KJLJ&((P?FQL#CJ78>'N_8/UWQ [8)D43I^;ZJ]RYA<G S4@,WU;M)6_
M,G<?] 9/&NQ-3>7P2N[B7)X.R+1UWM2;Q1!!739Q+.XW/.PL4,DO%K#- H9Q
M1T<8Y=O"%^-C:^Z(#;/!6KA!J+@:@BN;(,JUM_!M">O\^%K/@6)/+IHH<&#J
MY4TQJ;1[=3SRX"',&TTWULZB-?8+:Y)\-HU?./*NF>G9_OH11-:%QQ[".V-/
M&OS8-J\)3X:$)8P]88]W<#G:X_\!]THOC?5E,R=_GTZ<MY <_QR"&ZV)P]9"
MP1RY93'5)P.H"*?M2@_&+YY1F;QY(E;1Q2J>LCZ^A@*<M94FYC:D=C6#S-"D
M@4*U>J6;5KM#$3]I\W#$-PM-;DT%]1D(\4%\2&Q?E)4CIY,)5,*+9XK1[(W[
M11Q'Y&9AM29U%%\'\<EU>;__XF790 97%:28>X6"A@O=N;NHZ[8QE9FOR8>V
M+FU!OC:E#[9\X;4CSXD82BEP9&D&HQK*S4CA_47CM6TPB8N*R#PGBE)"AT(P
MN&89)3?&PS?/23KDDN.82 4C388)3'].\F'.4W+]?6W+GV7//1TF69B5RA2?
ME$SB6R$?.:<9!Z,YX1RQ=8XI!,Y@E%F P88T9_&M4.2J;%;F1Q\S#5-8+N&:
M,8Q:T,?N5$(4 V^"4)%L8:)UGJD8)5(E%24?H+/[0'0Y)5^:::3\HI[8=E5.
M^ZPK&8.,% &37&+P2:X(M,.JF!@;6\=#1A"F./PSDH;_E.[@IR)RQR&.8(13
MA:,4.?FFFVFE[WT_!)8&X SA"UPI@+%]$@*S#,@2>49XON4\38)'P<,U1RX4
M<'2JG5]H7TX=.3/>W ,25X?GO@ BP.92=E3([+$ ##*  1(!NO)\JX#,@]=4
MB8@9B0,B)24?VY6>:5LC@YL]JI=O(BA&47J&ECC-'TL/:!EDF4ASP+CUS 46
M"@MXLS3<9X#C"V"VN]A[1*L,P6*>90@6[O==@H+@3(4,W[(<,CWXPR5IB#6#
M*OE#M]:X:0G"Z@W/T&YLL=3M(:I33%&A=A,VI]ECR- K*$T!=HJD=V2CN#+A
ML:0VI45AUC=;K*O"]J7%.0)#SVF0.0,;;ULS,\L#28@ZH*!)O.S'E0MDA.:A
MJ<EMSC/L$BR 80*S/I7DZ\3J:K7N:ZZP/M 7QWQG24;^;*MR>: N>)B [9F]
MP53=>8Q:[RG03S!T)E%S+,3@<A]52@0!M;=P$#S-*,[&E9S^3SO N[4FYX75
MY!/T_WG1C-X7X8>)[P6.C1?3,_)*^>-ND"6@)0"$+(7L[X+G&#Q6-,L2K"M&
M3JOEH@CNSDT]"7[[B8D%G$2'> ^-;=\A1 !M)4M)MN4JIJ# *S9/!H%?0?45
MKNS7'DV14^SW7$FLP%ZY R;(>A4^'2BI.BT$%4A/MI&_8[0O/>OX8-C;F.@5
M&N1B$)KSL)/M])8H>T+1%19$]N#P=[TFE];,VJEWY'.Q6EO=EX\E,;$%;D]Q
MDWJ\?],\5'@@54)'X%OGN<),9YMJA:8,?>+<Z@,-=+.YJ&0;*"CYJ6Q^:N=
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M,\7(>^^1#'*ZYF8NMQ^AT>,*3"77[DNV36S@D72MC2P;,%90,E'_Z5/CPQX
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M&E4A]J#G9I*]U2E4KKQY8?8=,9!@!!(L @(SN!C57(P )6P$20@D&($$BX#
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M+PT.'P3;Y(_2SYD0+,[?K@F6%T UD.>7C(F'#RI!^7N/R;]02P,$%     @
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MI6]6VTQU60W"3-#?EYRK;<<8J OUZ1]02P,$%     @ +G\$51HU-7R@!@
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MVZ6EW;[7G+GX.RQ4<<-;3S-(6@"EA5 :@](XBF8O5*L=7NJ]5II"H18OE!9
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M4N4WF.O7J9G=JD)>P?K_$XS_!U!+ P04    "  N?P15P%XO&G8$  #1%@
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MA[AVB!UO'\BQO".:)%,I=B"MM4&S R?5>1MRE-M#66EI=JGQT\F7UXKJ/5S
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MVX;2&IC]M1#Z,+$!FM<R^0M02P,$%     @ +G\$5=%24;O> @  +@<  !D
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M,(T&3N_1,B[,V7_T3B &$Z9<PE)R:\X;@D<N!.T$R4Z:RVEL*1&'$V<5]&V
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M-\3K0=:78SW1HK*]>2DT=GH[S/%[ J1Q0/M*X/_334R[;[Y0DO]02P,$%
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M(A)G;_R6\U!2D#C5"E:N8)TJM-]1:.4*K4LMM'.%]J46[%PA#5W/8D^)<['
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MI#8&6">6=XI5<71T<'1D=%36!7+5C^6BF*8\7CP@D?IQ)A>LHMY8_B?72EG
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MX?Z-2+;%R;IY(D02%2\WW%_R-#>0WZ^21#R^R3LX'/^<_@]02P,$%     @
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MS(!K [6?,E7?>J(=-+U>\ =02P,$%     @ +G\$5?TQ-=3E"   2&,  !D
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MM6,%)UN\GFR1/-GWF\VB[>^:CCO'Y*%3!QL29I P"X(%G[]^_?PU[LNOD?5
MP@P29D&PH![E:SW*Y/?AOT:^]L]'%_X7.LO(]WG)B 3].IM8)(3(R'>>$>FZ
MY+_RU>LI5LE3_+#=/NS:37O[;?&_BQ\>MNMNQ9UI$C)UL"%A!@FS(%A0B?JU
M$C7NRU\CZX&$&23,@F!!/?+,7:MGL[[^+X?[7\A":OJO/J?*=$4: *,Z]A+2
M3"PCJVM9\#T@]UQ)/K4+'/[P\V[=-S>+3_VJ'_@ DM2IPQ!*,U":1='"^@A7
M'X'K#2\L5%60- .E610MK(JS:GG2>8SW!QE]6976BO8'1B6*DO:'6%5IJK*<
M*O?>,3Q1YX'RM GBV\.'7=]TNZ<1N=JPYY^D3AZ(2)J!TBR*%M;'V;:\ +8'
MJ)&#T@R49E&TL"K.S.5);S+>'G3T9=7T'_PE(ZIRZAX84:Z4H,V!495E/M <
MG$?*TR8I: Z??OW6K?^Q9D\WB9D\[I T Z59%"TLB'-T>07L!E!G!Z49*,VB
M:&%5G+O+DV9EO!O4S'V"0M!V$*MTJ6@[B$4BKZ-VP+VAJOAV()QI$FG3Q+6#
M<[Q$&CMU($)I!DJS*%I8(.?U1(YK#P+J\* T Z59%"VLBG-X(NE51MO#R^'A
M_8&27BTPJD(7I#UPJ$K3FXWL&RH]T!Z<9Q)ISS30'D:]1!H[>2!")[N@-(NB
MA05R7D\H8'N .CPHS4!I%D4+J^(<GDC/S(VVAX*YMJ=W(CD1G:XPC$A*>NW
MB$0F!GJ#,TPB;9B"WO!QO7ML_\Z>*W3F"THS4)I%T<)Z.&<G2F K@-H[*,U
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M"35]4)J!TBR*%E;%F;YR7I*R9**-- W!:*(-;!@-?:##,II\: &IRAFH:LQ
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M9\C=O#/L=MY0G,'B+ Q':N-MZ9W-W-,[8V*.],["DE65=/,,3B7I74[+JN3
M^C%Y[MFM?%*T,FX59UU?I-]D\O"$X@P69V$X4C//..; Q.4)!JL-UBM"<1:&
M([7QO&(^+W=Y.CY\*#SR(YQ*TZD/3A7ON\.JQ,!3&WGN6:]\4O:2;1VC]SM'
MWF3Z\(3.R6%Q%H8C-?,\9 Z,8)Y@L-I@;2,49V$X4AO/-N;S@IBGXX.IBJAQ
M,$',J&TP"<NH:<2:@?1$GGON*T^[+_NM62Q7W;$S_.5AN[Y=[2[_8[7[TG8]
M?\+0"3DLSF!Q%H8CQ?%<8PY,79Y@L-I@W2(49V$X4AO/+>;SLI>GX\.5:B-'
MPJGHHI>&4XF2SINRJJ&5L//<,U]YVGP-]XCSK ATJ@Z+,UB<A>'"8@G//@I@
M%O,$0]4&BC-8G(7A2&T\FRCF)3)/QX>/=]&6P8CH<^&&$T5)+<NJY-!5A? \
META[KF3'&'<@:?KT48F=L(/B+ Q'BN6Y1@',:YY@L-I@W2$49V$X4AO/'8IY
MJ<W3\4$SB#L&(XIN73"B7$53J9S*6Q^3G*AGM43::GD=X_WF_FYU;!G+=OOY
MV#OX$\=.TD%Q!HNS,!PICV<3!3"U>8+!:H-UB5"<A>%(;3R7*.9E-T_'!W<7
MZ',>G"A7\64%MS9F=*N"40D]-(LJ/,\ETIXKU23.LB)I_O2!B9VT@^(L#$?*
MY?E& 0QTGF"PVF!M(A1G8;BP-M*SB7)FJ%/&&4NZ#O:2$S&A3DXEHN %IZJ&
M[EY(SW3)M.D::1KC;B3-GSPPH3B#Q5D8CI3+LXX2&>V46*<(Q1DLSL)PI#:>
M4Y0SHYV2B6/2)6PXD8JR6HRHI,^;LZ*ANQ?2,UTR;;J\CO&QV?>K_7K@;+&3
M<5"<P>(L#$>JXCE$B<QP2JP]A.(,%F=A.%(;SQ[*F1E.&:<J<QUW!B;I&3U>
MRJE4'E].,"MC#F:^I>>V9-IM,<WA+.N1QDX?D-C9.2C.PG"D2IY3E,@LI\3:
M0BC.8'$6AB.U\6RAG)GEE%R6DRY;PZEDM(,PJZKH=J&<JB@'-NK(E>>R5-IE
M\<UBW'*DL9,')!1GL#@+PY$J>0Y1(=.;"FL'H3B#Q5D8CM3&LX-J9GI3,;E,
MNA8>*Z*/IG,BNCV8'1&1T_2<E4H[*Z]1/*<V3R_PYXR=@X/B#!9G83A2&\\.
M*F1"4V%-(11GL#@+PY':>*90S4QHJC@U&5F*):O*HN="&)7.HIL2C*HHAXR'
M\CR6.CNI&;:(L^Q'&CY]6&*GY* X"\.16GDF42&#FPIK#:$X@\59&([4QK.&
M:F9P4W&1S&B^E%/1>*?A5()N5VY9E1IL&9[34F<'-Z.6<88)P4[(07$&B[,P
M7%BKPK.*!3*W66 -(A1GL#@+PY':> :QF)G;+)@<9;RD!:>*GSYE5%)&$0M6
M-12Q*#R_5:3]UG.?^,_FV^*GKKUYN.Z/-RQ^7#U^ZQK^B9 T;_I(Q,[ 07$6
MAB/E\7QB@<QJ%EB?",49+,["<*0VGD\L9F8UBS@[*>MH$H11J3B(Q:A*NEN(
MY515,71A47BVJTC;KE27.,N.I/G31R9V>@Z*LS <*9=G'0MD>K/ 6D4HSF!Q
M%H8CM?&L8C$SO5DP84JZY<^25T7/F3(J&>TIR*N&,MZ%Y[R*M/,:Z1KCCB3-
MGSXRL?-T4)R%X4BY//=8(..;!=8M0G$&B[,P7%@;[;E%/3.^J;F%-"-'PJ@$
M#6P93J6RZ"8&IZJ&%K70GOG2:?/%=HUEU[3G1;[3],GC$HHS6)R%X4BQ//NH
MD>E-C?6.4)S!XBP,1VKC>4<],[VIF?0F7;QFR:E$%=WX9%3,7 FC*@:?)M.>
M%=-I*\;VC+^L=_]H]OO+9;O;]\UFP^X2,D*>/B:Q\W=0G(7A2*$\(ZF1H4Z-
M=8U0G,'B+ Q':N.Y1CTSU*F9O<Z+^!J#4='HI^%4BEZO6%XU=-=3>R9,ITW8
M>?WBO.L-[&0>%&>P. O#D<)YEE(C<YX:ZQ^A.(/%61B.U,;SCWIFSE/'J4M_
MVO/T*3,JNBB&X52*7I585E4.;'F<EYX=*]-V[.S^,7Z/(_U.D\<H%&>P. O#
MD<)YYK)$1C]+K)>$X@P69V$X4AO/2Y8SHY\OQVM_=H-VCW&-X30T'6I'1,\G
M>;F_:YK>K/K5U=MMT]TVR\/7?K^X;A]V_7$,>J\>SNS+\3-X\UY<7$:O?Y^_
M6>;,ZR9_8Y]>OW3XJ[?WJ]OFQU5WN][M%YOFR^&MLN_*0X_KUK=WKS_T[?WA
MX[]8?&[[OMT^_?&N6=TTW5%P^/LO;=N??CB^P=>V^_7I=*[^#U!+ P04
M"  N?P15=F\IQ'(#  "J%@  #0   'AL+W-T>6QE<RYX;6S=6-UNVC 4?I4H
M7:=6FAI"UD!60-J0*DW:IDKMQ>XJ0QRPY/S,,1WT<L^SI]J3S,=.0J ^B/9B
MA05![//Y?.<[]DGB,"CEBM/;.:726:8\*X?N7,KB@^>5TSE-27F1%S132)*+
ME$C5%3.O+ 0E<0E.*?>ZG4[HI81E[FB0+=+K5);.-%]D<NA&C<DQI\_QT/7#
M]ZYCZ,9Y3(?N_=G;'XM<7KUQS/GDW<E)Y_[\:MM^IH%SU[.27NY!>M'!>16&
M48>;U'KXJ2(RCJ>86\^NZ,^OWYN:6I+66"T*(^];-*D4.HTLZ&#.D=WYM.V,
MI=7K[)76CJ0P8M^JJJ4)<^SNM?0[5EX3>U7QC@9)GJUK.'"-044F*74>"!^Z
M8\+91##P2DC*^,J8NV"8YCP7CE07CY+B@Z5\-+!O>G!=53PIRW*A8YL(YG=2
M#=\"ZAX(9)PW KNN,8P&!9&2BNQ:=?1@;7P".57[;E4HA3-!5G[WTET[Z),*
M,LE%3$43QG=KTVC :0)R!)O-X2SSP@-0RCQ5C9B169X1K:'VJ!J*=DHYOX6;
MSO=D@WN9M-94UUC6-)6@JFEH3 ?XVVR&NTT;OHC7*=A#+C\M5#J9[D.MT!M!
M$[;4_672",#8?9R=% 5??>1LEJ74)+]WP-& U'[./!?L446#4IDJ Q6N\T"%
M9-.VY:<@Q1U=RKJ<E@FNN7N$FO_M/,]H1@7A;=&J]@]YEE^L..B]EF1]5]D6
M;-58[20.7>3E,8@,CT'D4=1D__!%!M'A:ZQVJ0<NLO=J=_;GB/2/063W($5Z
MU9ZRM7'=V+8V5@=>#X;N-W@1X>N@SF3!N&19U9NS.*;9D]VKHI=DHE[$-_C5
M^)@F9,'E70,.W77[*XW9(HV:43<P$=6H=?L+I*>VPO6[B8K%LI@N:3RNNF(V
MT4U'-534Z@"';>1:'W8$\S&8'0$,BX,IP'R,%Q;G?\JGC^9C,$Q;WXKT49\^
MZF.\;,A8?[ X=I]('?9,HR@(PA";T?'8JF",S5L8PM?.AFD##RP.1'K>7..K
MC5?([CK UG17A6"9XI6(98K/-2#V>0./*+*O-A8'/+!5P&H'XMOC0$W9?8(
M5A73AEW!.!)%& *U:*_1,$1F)X2/?7VPJR0(HLB. &97$ 08 E<CCF *0 .&
M!(%^#FX]C[SZ.>6M_YT>_0502P,$%     @ +G\$59>*NQS     $P(   L
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M.=V;+X\_+[]/HH2+,\X)_DJY_P)02P,$%     @ +G\$56(CYQC8 0  2"(
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M!5!+ 0(4 Q0    ( "Y_!%4'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +G\$51&$*L_P    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ +G\$59E<G",0!@  G"<  !,              ( !S@$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  N?P15!_@P[#4)  #22P  &
M        @($/"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ +G\$5=GQ&VE2!@  ^1L  !@              ("!>A$  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "Y_!%6M\#U+K 0  )D2   8
M              " @0(8  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  N?P15L&1?CG0#  !;"P  &               @('D'   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +G\$58+K_XYC!@
M@QH  !@              ("!CB   'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( "Y_!%6[6DDGP0(  &X'   8              " @2<G
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  N?P15=J9G
M%5H+  !E8P  &               @($>*@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ +G\$56TL/%1B!P  _R   !@
M ("!KC4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "Y_
M!%5?#W!#Z ,  !L)   8              " @48]  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  N?P15WR'JI#@#  #H!P  &0
M        @(%D00  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( "Y_!%7*'3>K+00  +8*   9              " @=-$  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ +G\$53*A$GP*!   S D
M !D              ("!-TD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  N?P15OW- /7P(  "\&   &0              @(%X30
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "Y_!%7J<?79
MF 0  (@+   9              " @2M6  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ +G\$55'%?E6]!   TPP  !D
M ("!^EH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  N
M?P15%N.!73X4  !!2@  &0              @('N7P  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "Y_!%5';WAE*P,  &P'   9
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M970R,2YX;6Q02P$"% ,4    "  N?P15]-J%!44#  !C"   &0
M    @(&5H0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M "Y_!%6691LW80,  ,4(   9              " @1&E  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ +G\$50?C%N63 P  ^0H  !D
M             ("!J:@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  N?P15#='.4*X#  "-"P  &0              @(%SK   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "Y_!%4QP&RE  0
M  8-   9              " @5BP  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ +G\$50!5*(3H"0  /"D  !D              ("!
MC[0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  N?P15
MH*HI1C@#  "S!P  &0              @(&NO@  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( "Y_!%7!!(LH'P<  &(4   9
M      " @1W"  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ +G\$57WYEK\.!@  ?0X  !D              ("!<\D  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  N?P15"68RE*L"   <!P
M&0              @(&XSP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( "Y_!%6/PXY.K00  -@9   9              " @9K2  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ +G\$53_'&#.#
M!   JQ0  !D              ("!?M<  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  N?P151S.N_CP%   X*   &0
M@($XW   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "Y_
M!%5.1 YF@ 8  "8O   9              " @:OA  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ +G\$5?"HKVNZ @  .0<  !D
M         ("!8N@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    "  N?P155=97?" %  "#(0  &0              @(%3ZP  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "Y_!%7]0@'9K0<  +U&
M   9              " @:KP  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ +G\$5?SZB=1)#0  Y;$  !D              ("!CO@
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  N?P15R*HK
M<L '  !K0   &0              @($.!@$ >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( "Y_!%5C<_%.VP@  )!&   9
M  " @04. 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M+G\$5:Z<N>BG!@  ^S$  !D              ("!%Q<! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  N?P153G-! O\#  "W#@  &0
M            @('U'0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( "Y_!%7]PWP#P@4  /<@   9              " @2LB 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ +G\$5<:31#IQ P
MM \  !D              ("!)"@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    "  N?P15&C4U?* &  "K0   &0              @(',
M*P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "Y_!%7
M7B\:=@0  -$6   9              " @:,R 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ +G\$5:717F$@!   A!8  !D
M     ("!4#<! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Y_!%5=8D]J<0<   HZ   9              "
M@3E( 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ +G\$
M54@Q1Y:I!P  +3,  !D              ("!X4\! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    "  N?P15H0WVN>H"  #W"0  &0
M        @('!5P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( "Y_!%7],374Y0@  $AC   9              " @>): 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ +G\$53R<)V<F @  M 0
M !D              ("!_F,! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    "  N?P15%,Y(A0@4  #>[P  &0              @(%;9@$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "Y_!%5V;RG$
M<@,  *H6   -              "  9IZ 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ +G\$59>*NQS     $P(   L              ( !-WX! %]R96QS
M+RYR96QS4$L! A0#%     @ +G\$5?VU.LNO!   P28   \
M ( !('\! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "Y_!%43)^RZ[P$
M *4B   :              "  ?R# 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( "Y_!%5B(^<8V $  $@B   3              "
M 2.& 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !" $( !1(  "R( 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>644</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>127</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Earnings (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements</Role>
      <ShortName>Licensing, Acquisitions and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114106 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - Integration and Restructuring Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlans</Role>
      <ShortName>Integration and Restructuring Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Financial Instruments and Fair Value Measures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures</Role>
      <ShortName>Financial Instruments and Fair Value Measures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Post-Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefits</Role>
      <ShortName>Post-Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Legal Proceedings and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LegalProceedingsandContingencies</Role>
      <ShortName>Legal Proceedings and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/EarningsPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CollaborationsTables</Role>
      <ShortName>Collaborations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/Collaborations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Integration and Restructuring Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlansTables</Role>
      <ShortName>Integration and Restructuring Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IntegrationandRestructuringPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables</Role>
      <ShortName>Financial Instruments and Fair Value Measures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Post-Employment Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefitsTables</Role>
      <ShortName>Post-Employment Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/PostEmploymentBenefits</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/Equity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/BasisofPresentation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Supplemental Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SupplementalFinancialInformationDetails</Role>
      <ShortName>Supplemental Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/EarningsPerShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails</Role>
      <ShortName>Licensing, Acquisitions and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/CollaborationsDetails</Role>
      <ShortName>Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/CollaborationsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Integration and Restructuring Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails</Role>
      <ShortName>Integration and Restructuring Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IntegrationandRestructuringPlansTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Fair Value Measures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Post-Employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/PostEmploymentBenefitsDetails</Role>
      <ShortName>Post-Employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/PostEmploymentBenefitsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Equity - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockBasedCompensationDetails</Role>
      <ShortName>Equity - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Equity - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockOptionsDetails</Role>
      <ShortName>Equity - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails</Role>
      <ShortName>Equity - RSUs and Performance Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Equity - Cash Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityCashDividendsDetails</Role>
      <ShortName>Equity - Cash Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Equity - Stock Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails</Role>
      <ShortName>Equity - Stock Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Legal Proceedings and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails</Role>
      <ShortName>Legal Proceedings and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbvie.com/role/LegalProceedingsandContingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="abbv-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails</Role>
      <ShortName>Segment Information - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="abbv-20220630.htm">abbv-20220630.htm</File>
    <File>abbv-20220630.xsd</File>
    <File>abbv-20220630_cal.xml</File>
    <File>abbv-20220630_def.xml</File>
    <File>abbv-20220630_lab.xml</File>
    <File>abbv-20220630_pre.xml</File>
    <File>abbv-20220630xex106.htm</File>
    <File>abbv-20220630xex311.htm</File>
    <File>abbv-20220630xex312.htm</File>
    <File>abbv-20220630xex321.htm</File>
    <File>abbv-20220630xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>abbv-20220630_g1.jpg</File>
    <File>abbv-20220630_g2.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1402">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="56">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abbv-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 644,
   "dts": {
    "calculationLink": {
     "local": [
      "abbv-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abbv-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "abbv-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abbv-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abbv-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abbv-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd"
     ]
    }
   },
   "elementCount": 561,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 25,
   "keyStandard": 259,
   "memberCustom": 64,
   "memberStandard": 62,
   "nsprefix": "abbv",
   "nsuri": "http://www.abbvie.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.abbvie.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Supplemental Financial Information",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformation",
     "shortName": "Supplemental Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Earnings Per Share",
     "role": "http://www.abbvie.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements",
     "role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements",
     "shortName": "Licensing, Acquisitions and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - Collaborations",
     "role": "http://www.abbvie.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114106 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - Integration and Restructuring Plans",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlans",
     "shortName": "Integration and Restructuring Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Financial Instruments and Fair Value Measures",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures",
     "shortName": "Financial Instruments and Fair Value Measures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Post-Employment Benefits",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefits",
     "shortName": "Post-Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Equity",
     "role": "http://www.abbvie.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Income Taxes",
     "role": "http://www.abbvie.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
     "shortName": "Condensed Consolidated Statements of Earnings (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Legal Proceedings and Contingencies",
     "role": "http://www.abbvie.com/role/LegalProceedingsandContingencies",
     "shortName": "Legal Proceedings and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Segment Information",
     "role": "http://www.abbvie.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Supplemental Financial Information (Tables)",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformationTables",
     "shortName": "Supplemental Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.abbvie.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaborations (Tables)",
     "role": "http://www.abbvie.com/role/CollaborationsTables",
     "shortName": "Collaborations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Integration and Restructuring Plans (Tables)",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables",
     "shortName": "Integration and Restructuring Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables",
     "shortName": "Financial Instruments and Fair Value Measures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Post-Employment Benefits (Tables)",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefitsTables",
     "shortName": "Post-Employment Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Equity (Tables)",
     "role": "http://www.abbvie.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Segment Information (Tables)",
     "role": "http://www.abbvie.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.abbvie.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Supplemental Financial Information (Details)",
     "role": "http://www.abbvie.com/role/SupplementalFinancialInformationDetails",
     "shortName": "Supplemental Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.abbvie.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireOtherInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)",
     "role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails",
     "shortName": "Licensing, Acquisitions and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Collaborations (Details)",
     "role": "http://www.abbvie.com/role/CollaborationsDetails",
     "shortName": "Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630",
      "decimals": "2",
      "lang": "en-US",
      "name": "abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "id5695becc3594da099d28f6bd485f543_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
     "role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "id5695becc3594da099d28f6bd485f543_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i2c7df08664994f12aca1518baebbe045_I20220630",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Integration and Restructuring Plans (Details)",
     "role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
     "shortName": "Integration and Restructuring Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ib37c40029abd4cb58eba88c002702a40_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ie3c18991cb0745f7bfde8bb5e68396df_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i0ada3a46921346fd865f1babab324aeb_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i374e011a12484720b013a8ebf2f11a07_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ie0f761535955494a9972245ac0bfc828_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ie0f761535955494a9972245ac0bfc828_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:NumberOfPrincipalUSCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:NumberOfPrincipalUSCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
     "role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
     "shortName": "Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i70516d291c55477c878b4b846af7180a_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Post-Employment Benefits (Details)",
     "role": "http://www.abbvie.com/role/PostEmploymentBenefitsDetails",
     "shortName": "Post-Employment Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i70516d291c55477c878b4b846af7180a_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Equity - Stock-Based Compensation (Details)",
     "role": "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
     "shortName": "Equity - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ibd90914ea384473db98e01873e81a8f0_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Equity - Stock Options (Details)",
     "role": "http://www.abbvie.com/role/EquityStockOptionsDetails",
     "shortName": "Equity - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ibd90914ea384473db98e01873e81a8f0_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)",
     "role": "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
     "shortName": "Equity - RSUs and Performance Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDividendsPayableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i29287228cbed45f6968865ac190732da_D20220623-20220623",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Equity - Cash Dividends (Details)",
     "role": "http://www.abbvie.com/role/EquityCashDividendsDetails",
     "shortName": "Equity - Cash Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDividendsPayableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i29287228cbed45f6968865ac190732da_D20220623-20220623",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Equity - Stock Repurchase Program (Details)",
     "role": "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails",
     "shortName": "Equity - Stock Repurchase Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i8d2e3d15040b43b680868217bfddc553_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i22b5f6d04f0a4544845c676987a1eeed_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Income Taxes (Details)",
     "role": "http://www.abbvie.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Legal Proceedings and Contingencies (Details)",
     "role": "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
     "shortName": "Legal Proceedings and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Segment Information - Additional Information (Details)",
     "role": "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails",
     "shortName": "Segment Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)",
     "role": "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails",
     "shortName": "Segment Information - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i676449a933204a9cb64a6f54570b2d60_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "if1816b7eac954956b4765afd462e3f73_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "if0fc5d280fb74f1eb96d3958d3310a50_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.abbvie.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20220630.htm",
      "contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 127,
   "tag": {
    "abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Net Gain (Loss) From Net Investment Hedges",
        "label": "Accumulated Net Gain (Loss) From Net Investment Hedges [Member]",
        "terseLabel": "Net investment hedging activities"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromNetInvestmentHedgesMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing, Acquisitions, and Other Arrangements",
        "terseLabel": "Licensing, Acquisitions, and Other Arrangements"
       }
      }
     },
     "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract",
     "nsuri": "http://www.abbvie.com/20220630",
     "xbrltype": "stringItemType"
    },
    "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for acquisitions, collaborations and other arrangements of the entity.",
        "label": "Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]",
        "terseLabel": "Licensing, Acquisitions, and Other Arrangements"
       }
      }
     },
     "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abbv_AestheticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Aesthetics, a key product portfolio of the entity.",
        "label": "Aesthetics [Member]",
        "terseLabel": "Aesthetics"
       }
      }
     },
     "localname": "AestheticsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AllerganIntegrationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Allergan integration plan.",
        "label": "Allergan Integration Plan [Member]",
        "terseLabel": "Allergan integration plan"
       }
      }
     },
     "localname": "AllerganIntegrationPlanMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AlphaganCombiganMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Alphagan/Combigan, a product of the entity.",
        "label": "Alphagan/Combigan [Member]",
        "terseLabel": "Alphagan/Combigan"
       }
      }
     },
     "localname": "AlphaganCombiganMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.",
        "label": "AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member]",
        "terseLabel": "AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al."
       }
      }
     },
     "localname": "AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BotoxCosmeticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Botox Cosmetic, a product of the entity.",
        "label": "Botox Cosmetic [Member]",
        "terseLabel": "Botox Cosmetic"
       }
      }
     },
     "localname": "BotoxCosmeticMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BotoxTherapeuticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Botox Therapeutic, a product of the entity.",
        "label": "Botox Therapeutic [Member]",
        "terseLabel": "Botox Therapeutic"
       }
      }
     },
     "localname": "BotoxTherapeuticMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_BystolicAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bystolic antitrust litigation.",
        "label": "Bystolic Antitrust Litigation [Member]",
        "terseLabel": "Bystolic antitrust litigation"
       }
      }
     },
     "localname": "BystolicAntitrustLitigationMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.",
        "label": "Collaborative Arrangement Milestone Method Payments Receivable",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestoneMethodPaymentsReceivable",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.abbvie.com/20220630",
     "xbrltype": "stringItemType"
    },
    "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.",
        "label": "Collaborative Arrangements Percentage Of Share Of Development Costs",
        "terseLabel": "Share of collaboration development costs responsible by the entity (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.",
        "label": "Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party",
        "terseLabel": "Share of collaboration development costs responsible by Janssen (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Cost of Goods And Services Sold From Collaborative Arrangements",
        "terseLabel": "Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)"
       }
      }
     },
     "localname": "CostofGoodsAndServicesSoldFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_CreonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Creon, a product of the entity.",
        "label": "Creon [Member]",
        "terseLabel": "Creon"
       }
      }
     },
     "localname": "CreonMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_December2018StockRepurchaseAuthorizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2018 Stock Repurchase Authorization",
        "label": "December 2018 Stock Repurchase Authorization [Member]",
        "terseLabel": "December 2018 Stock Repurchase Authorization"
       }
      }
     },
     "localname": "December2018StockRepurchaseAuthorizationMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.",
        "label": "Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)",
        "negatedLabel": "Amortization of actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_DuodopaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Duodopa, a product of the entity.",
        "label": "Duodopa [Member]",
        "terseLabel": "Duodopa"
       }
      }
     },
     "localname": "DuodopaMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ElliottAssociatesL.P.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Elliot Associates, LP.",
        "label": "Elliott Associates, L.P. [Member]",
        "terseLabel": "Elliott Associates, L.P."
       }
      }
     },
     "localname": "ElliottAssociatesL.P.Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_EyeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Eye Care, a key product portfolio of the entity.",
        "label": "Eye Care [Member]",
        "terseLabel": "Eye Care"
       }
      }
     },
     "localname": "EyeCareMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_FloatingRateTermLoanTrancheDueMay2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Term Loan Tranche Due May 2025",
        "label": "Floating Rate Term Loan Tranche Due May 2025 [Member]",
        "terseLabel": "Floating rate notes due 2025"
       }
      }
     },
     "localname": "FloatingRateTermLoanTrancheDueMay2025Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Term Loan Tranche Due May 2025, Refinanced",
        "label": "Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member]",
        "terseLabel": "Floating rate notes due 2025, refinanced"
       }
      }
     },
     "localname": "FloatingRateTermLoanTrancheDueMay2025RefinancedMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_GenentechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc. [Member]",
        "label": "Genentech, Inc. [Member]",
        "verboseLabel": "Genentech, Inc."
       }
      }
     },
     "localname": "GenentechInc.Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HUMIRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to HUMIRA, a product of the entity.",
        "label": "H U M I R A [Member]",
        "terseLabel": "Humira"
       }
      }
     },
     "localname": "HUMIRAMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HematologicOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.",
        "label": "Hematologic Oncology [Member]",
        "terseLabel": "Hematologic Oncology"
       }
      }
     },
     "localname": "HematologicOncologyMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to lawsuits filed alleging that AbbVie\u2019s settlements with biosimilar manufacturers and AbbVie\u2019s Humira patent portfolio violated state and federal antitrust laws.",
        "label": "Humira Antitrust Litigation, In re: Humira (Adalimumab) Antitrust Litigation [Member]",
        "terseLabel": "Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation"
       }
      }
     },
     "localname": "HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ImbruvicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Imbruvica, a product of the entity.",
        "label": "Imbruvica [Member]",
        "terseLabel": "Imbruvica"
       }
      }
     },
     "localname": "ImbruvicaMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Immunology, a key product portfolio of the entity.",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertains to the entity Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_JuvedermCollectionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Juvederm Collection, a product of the entity.",
        "label": "Juvederm Collection [Member]",
        "terseLabel": "Juvederm Collection"
       }
      }
     },
     "localname": "JuvedermCollectionMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_JuvisePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juvise Pharmaceuticals",
        "label": "Juvise Pharmaceuticals [Member]",
        "terseLabel": "Juvise Pharmaceuticals"
       }
      }
     },
     "localname": "JuvisePharmaceuticalsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_KeyProductPortfolioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information concerning the company's portfolios of key products.",
        "label": "Key Product Portfolio [Axis]",
        "terseLabel": "Key Product Portfolio [Axis]"
       }
      }
     },
     "localname": "KeyProductPortfolioAxis",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abbv_KeyProductPortfolioDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Information concerning the company's portfolios of key products.",
        "label": "Key Product Portfolio [Domain]",
        "terseLabel": "Key Product Portfolio [Domain]"
       }
      }
     },
     "localname": "KeyProductPortfolioDomain",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_LinzessConstellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Linzess/Constella, a product of the entity.",
        "label": "Linzess/Constella [Member]",
        "terseLabel": "Linzess/Constella"
       }
      }
     },
     "localname": "LinzessConstellaMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.",
        "label": "Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure",
        "verboseLabel": "Current portion of long-term debt and finance lease obligations, excluding fair value hedges"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.",
        "label": "Long Term Debt and Capital Lease Obligations Fair Value Disclosure",
        "verboseLabel": "Long-term debt and finance lease obligations, excluding fair value hedges"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_LossContingencyIndividualPlaintiffLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.",
        "label": "Loss Contingency Individual Plaintiff Lawsuits Number",
        "terseLabel": "Number of individual plaintiff lawsuits"
       }
      }
     },
     "localname": "LossContingencyIndividualPlaintiffLawsuitsNumber",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.",
        "label": "Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws",
        "terseLabel": "Number of generic companies with whom certain litigation related agreements were entered into"
       }
      }
     },
     "localname": "LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LossContingencyPurportedClassActionsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purported class actions filed, pertaining to a loss contingency during the period.",
        "label": "Loss Contingency Purported Class Actions Number",
        "terseLabel": "Number of purported class actions"
       }
      }
     },
     "localname": "LossContingencyPurportedClassActionsNumber",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_LumiganGanfortMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Lumigan/Ganfort, a product of the entity.",
        "label": "Lumigan/Ganfort [Member]",
        "terseLabel": "Lumigan/Ganfort"
       }
      }
     },
     "localname": "LumiganGanfortMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_MAVYRETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MAVYRET, a product of the entity.",
        "label": "MAVYRET [Member]",
        "terseLabel": "Mavyret"
       }
      }
     },
     "localname": "MAVYRETMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Neuroscience, a key product portfolio of the entity.",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NiaspanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Niaspan, a product of the entity.",
        "label": "Niaspan [Member]",
        "terseLabel": "Niaspan"
       }
      }
     },
     "localname": "NiaspanMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash litigation reserve adjustments, net of cash payments",
        "label": "Non-cash litigation reserve adjustments, net of cash payments",
        "terseLabel": "Non-cash litigation reserve adjustments, net of cash payments"
       }
      }
     },
     "localname": "NonCashLitigationReserveAdjustmentsNetOfCashPayments",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_NumberOfPrincipalUSCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of principal U.S. customers of the entity.",
        "label": "Number of Principal US Customers",
        "terseLabel": "Number of principal customers"
       }
      }
     },
     "localname": "NumberOfPrincipalUSCustomers",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_OtherAestheticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Aesthetics products.",
        "label": "Other Aesthetics [Member]",
        "terseLabel": "Other Aesthetics"
       }
      }
     },
     "localname": "OtherAestheticsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax",
        "terseLabel": "Net investment hedging activities, net of tax expense (benefit) of $146 for the three months and $183 for the six months ended June 30, 2022 and $(31) for the three months and $72 for the six months ended June 30, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Tax",
        "terseLabel": "Net investment hedging activities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeTax",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherExpensesFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Other Expenses From Collaborative Arrangements",
        "terseLabel": "Global - AbbVie's share of other costs (included in respective line items)"
       }
      }
     },
     "localname": "OtherExpensesFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_OtherEyeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Eye Care products.",
        "label": "Other Eye Care [Member]",
        "terseLabel": "Other Eye Care"
       }
      }
     },
     "localname": "OtherEyeCareMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherKeyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other key products of the entity.",
        "label": "Other Key Products [Member]",
        "terseLabel": "Other Key Products"
       }
      }
     },
     "localname": "OtherKeyProductsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Other Neuroscience products.",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other products of the entity not specified anywhere.",
        "label": "Other Products [Member]",
        "terseLabel": "All other"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_OtherRestructuringPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other restructuring plans.",
        "label": "Other Restructuring Plans [Member]",
        "terseLabel": "Other restructuring"
       }
      }
     },
     "localname": "OtherRestructuringPlansMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PotentialPaymentsUnderAgreementCertainMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.",
        "label": "Potential Payments under Agreement Certain Milestones",
        "terseLabel": "Potential payments under agreement certain milestones"
       }
      }
     },
     "localname": "PotentialPaymentsUnderAgreementCertainMilestones",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prescription Drug Abuse Litigation In State Courts",
        "label": "Prescription Drug Abuse Litigation In State Courts [Member]",
        "terseLabel": "Prescription drug abuse litigation in state courts"
       }
      }
     },
     "localname": "PrescriptionDrugAbuseLitigationInStateCourtsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PrescriptionDrugAbuseLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to prescription drug abuse litigation.",
        "label": "Prescription Drug Abuse Litigation [Member]",
        "terseLabel": "Prescription drug abuse litigation"
       }
      }
     },
     "localname": "PrescriptionDrugAbuseLitigationMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PrincipalUSCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal US Customers",
        "label": "Principal US Customers [Member]",
        "terseLabel": "Principal US customers"
       }
      }
     },
     "localname": "PrincipalUSCustomersMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents estimated probability of payment for royalties excluding approved indications.",
        "label": "Probability of Payment for Royalties Excluding Approved Indications [Member]",
        "terseLabel": "Probability of payment for royalties excluding early stage or approved indications"
       }
      }
     },
     "localname": "ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents probability of payment for royalties by indication.",
        "label": "Probability of Payment for Royalties by Indication [Member]",
        "terseLabel": "Probability of payment for royalties by indication"
       }
      }
     },
     "localname": "ProbabilityofPaymentforRoyaltiesbyIndicationMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProbabilityofPaymentforUnachievedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the probability of payment for unachieved milestones",
        "label": "Probability of Payment for Unachieved Milestones [Member]",
        "terseLabel": "Probability of payment for unachieved milestones"
       }
      }
     },
     "localname": "ProbabilityofPaymentforUnachievedMilestonesMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ProjectedYearofPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents projected year of payments.",
        "label": "Projected Year of Payments [Member]",
        "terseLabel": "Projected year of payments"
       }
      }
     },
     "localname": "ProjectedYearofPaymentsMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_PutativeClassActionLawsuitIndividualNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of the number of individual putative class action lawsuit.",
        "label": "Putative Class Action Lawsuit Individual Number",
        "terseLabel": "Number of individual putative class action lawsuits"
       }
      }
     },
     "localname": "PutativeClassActionLawsuitIndividualNumber",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abbv_QuliptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qulipta",
        "label": "Qulipta [Member]",
        "terseLabel": "Qulipta"
       }
      }
     },
     "localname": "QuliptaMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RINVOQMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to RINVOQ, a product of the entity.",
        "label": "RINVOQ [Member]",
        "terseLabel": "Rinvoq"
       }
      }
     },
     "localname": "RINVOQMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of development milestone expense from research and development expense",
        "label": "Reclassification of development milestone expense from research and development expense",
        "terseLabel": "Reclassification of development milestone expense from research and development expense"
       }
      }
     },
     "localname": "ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&amp;D and milestones expense.",
        "label": "Reclassification of development milestone expense to IPR&amp;D and milestones expense",
        "terseLabel": "Reclassification of development milestone expense to IPR&amp;D and milestones expense"
       }
      }
     },
     "localname": "ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Research And Development Expense From Collaborative Arrangements",
        "terseLabel": "AbbVie's share of development costs (included in R&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_RestasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Restasis, a product of the entity.",
        "label": "Restasis [Member]",
        "terseLabel": "Restasis"
       }
      }
     },
     "localname": "RestasisMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RestrictedStockUnitsAndPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units And Performance Shares [Member]",
        "label": "Restricted Stock Units And Performance Shares [Member]",
        "terseLabel": "RSUs and Performance Shares"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_RestructuringReserveCashSettledRestructuringGainsLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.",
        "label": "Restructuring Reserve Cash Settled Restructuring Gains (Losses)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringReserveCashSettledRestructuringGainsLosses",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.",
        "label": "Restructuring Reserve Period Cash Settled and Other Adjustments",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_SKYRIZIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SKYRIZI, a product of the entity.",
        "label": "SKYRIZI [Member]",
        "terseLabel": "Skyrizi"
       }
      }
     },
     "localname": "SKYRIZIMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec0.750SeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "label": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "terseLabel": "Sec 0.750 Senior Notes Due 2027"
       }
      }
     },
     "localname": "Sec0.750SeniorNotesDue2027Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.250SeniorNotesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes due 2031 [Member]",
        "label": "Sec 1.250 Senior Notes due 2031 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes due 2031"
       }
      }
     },
     "localname": "Sec1.250SeniorNotesdue2031Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.375SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "label": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.375 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1.375SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1250SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes Due 2024",
        "label": "Sec 1.250 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1250SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1500SeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.500 Senior Notes Due 2023",
        "label": "Sec 1.500 Senior Notes Due 2023 [Member]",
        "terseLabel": "Sec 1.500 Senior Notes Due 2023"
       }
      }
     },
     "localname": "Sec1500SeniorNotesDue2023Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2.125SeniorNotesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes due 2028 [Member]",
        "label": "Sec 2.125 Senior Notes due 2028 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes due 2028"
       }
      }
     },
     "localname": "Sec2.125SeniorNotesdue2028Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2125SeniorNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes Due 2029",
        "label": "Sec 2.125 Senior Notes Due 2029 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes Due 2029"
       }
      }
     },
     "localname": "Sec2125SeniorNotesDue2029Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2625SeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.625 Senior Notes Due 2028",
        "label": "Sec 2.625 Senior Notes Due 2028 [Member]",
        "terseLabel": "Sec 2.625 Senior Notes Due 2028"
       }
      }
     },
     "localname": "Sec2625SeniorNotesDue2028Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
        "label": "Selling, General And Administrative Expense From Collaborative Arrangements",
        "terseLabel": "AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&amp;A)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_SeniorEuroNotesDue2021At0.500PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Euro Notes Due 2021 At 0.500 Percent",
        "label": "Senior Euro Notes Due 2021 At 0.500 Percent [Member]",
        "terseLabel": "0.50% senior euro notes due 2021"
       }
      }
     },
     "localname": "SeniorEuroNotesDue2021At0.500PercentMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SeniorNotes2.30PercentDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2.30% Unsecured Senior Notes Due 2021.",
        "label": "Senior Notes 2.30 Percent Due 2021 [Member]",
        "terseLabel": "2.30% senior notes due 2021"
       }
      }
     },
     "localname": "SeniorNotes2.30PercentDue2021Member",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SeniorNotesDue2022At3.250PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2022 At 3.250 Percent",
        "label": "Senior Notes Due 2022 At 3.250 Percent [Member]",
        "terseLabel": "3.25% senior notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesDue2022At3.250PercentMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SeniorNotesDue2022At3.450PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2022 At 3.450 Percent",
        "label": "Senior Notes Due 2022 At 3.450 Percent [Member]",
        "terseLabel": "3.45% senior notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesDue2022At3.450PercentMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SeniorNotesDueInMay2021AtFloatingRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due in May 2021 At Floating Rates",
        "label": "Senior Notes Due in May 2021 At Floating Rates [Member]",
        "terseLabel": "Floating senior notes due 2021"
       }
      }
     },
     "localname": "SeniorNotesDueInMay2021AtFloatingRatesMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_SupplementalFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Financial Information",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "SupplementalFinancialInformationDisclosureAbstract",
     "nsuri": "http://www.abbvie.com/20220630",
     "xbrltype": "stringItemType"
    },
    "abbv_SyndesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Syndesi",
        "label": "Syndesi [Member]",
        "terseLabel": "Syndesi"
       }
      }
     },
     "localname": "SyndesiMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "label": "Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abbv_UbrelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ubrelvy, a product of the entity.",
        "label": "Ubrelvy [Member]",
        "terseLabel": "Ubrelvy"
       }
      }
     },
     "localname": "UbrelvyMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_VENCLEXTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to VENCLEXTA, a product of the entity.",
        "label": "VENCLEXTA [Member]",
        "terseLabel": "Venclexta"
       }
      }
     },
     "localname": "VENCLEXTAMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_VraylarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Vraylar, a product of the entity.",
        "label": "Vraylar [Member]",
        "terseLabel": "Vraylar"
       }
      }
     },
     "localname": "VraylarMember",
     "nsuri": "http://www.abbvie.com/20220630",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XCHI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHICAGO STOCK EXCHANGE, INC [Member]",
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC"
       }
      }
     },
     "localname": "XCHI",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC."
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r117",
      "r118",
      "r276",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r194",
      "r312",
      "r315",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r275",
      "r297",
      "r395",
      "r400",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r628",
      "r632",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r275",
      "r297",
      "r395",
      "r400",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r628",
      "r632",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r194",
      "r312",
      "r315",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r190",
      "r312",
      "r313",
      "r581",
      "r627",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r190",
      "r312",
      "r313",
      "r581",
      "r627",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r275",
      "r297",
      "r347",
      "r395",
      "r400",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r628",
      "r632",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r275",
      "r297",
      "r347",
      "r395",
      "r400",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r628",
      "r632",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r117",
      "r118",
      "r276",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r312",
      "r314",
      "r630",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r312",
      "r314",
      "r630",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r573",
      "r575",
      "r578",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "AbbVie's payable to Janssen"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r20",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "AbbVie's receivable from Janssen"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r65",
      "r73",
      "r74",
      "r75",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Pension and post-employment benefits"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r229"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r65",
      "r73",
      "r74",
      "r75",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r75",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Cash flow hedging activities"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r62",
      "r64",
      "r65",
      "r612",
      "r637",
      "r638"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r65",
      "r73",
      "r74",
      "r75",
      "r120",
      "r121",
      "r122",
      "r467",
      "r633",
      "r634",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r415",
      "r416",
      "r417",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r402",
      "r411",
      "r419"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Pre-tax compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "After-tax compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r106",
      "r215",
      "r222"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r75",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]",
        "terseLabel": "Net investment hedging activities"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r61",
      "r65",
      "r73",
      "r74",
      "r75",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r177",
      "r181",
      "r186",
      "r203",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r461",
      "r468",
      "r541",
      "r566",
      "r568",
      "r586",
      "r609"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r49",
      "r113",
      "r203",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r461",
      "r468",
      "r541",
      "r566",
      "r568"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r199",
      "r201",
      "r205",
      "r593"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r404",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r105",
      "r449"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Significant unobservable input for contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Book value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r108"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r102",
      "r108",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents, end of period",
        "periodStartLabel": "Cash and equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r102",
      "r549"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "verboseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r113",
      "r136",
      "r140",
      "r145",
      "r149",
      "r151",
      "r159",
      "r160",
      "r161",
      "r203",
      "r261",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r295",
      "r296",
      "r299",
      "r300",
      "r541",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r451",
      "r452",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative and license agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r247",
      "r595",
      "r617"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityCashDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,622,099 shares issued as of June 30, 2022 and 1,803,195,293 as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r84",
      "r601",
      "r623"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to AbbVie Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r83",
      "r459",
      "r460",
      "r472",
      "r600",
      "r622"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r82",
      "r458",
      "r472",
      "r599",
      "r621"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r194",
      "r538",
      "r539",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r194",
      "r538",
      "r539",
      "r639",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r194",
      "r538",
      "r539",
      "r639",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r165",
      "r166",
      "r194",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentrations risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r162",
      "r165",
      "r166",
      "r167",
      "r538",
      "r540",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r194",
      "r538",
      "r539",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r581"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Losses (gains) on foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r594",
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "terseLabel": "Aggregate principal amount outstanding"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r112",
      "r119",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r564",
      "r587",
      "r588",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r272",
      "r291",
      "r292",
      "r562",
      "r564",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Principal amount of unsecured senior notes"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt and Credit Facilities [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r112",
      "r119",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r112",
      "r119",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r302",
      "r303",
      "r304",
      "r305",
      "r561",
      "r562",
      "r564",
      "r565",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt and Credit Facilities [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term loan credit agreement term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Potential change in unrecognized tax benefits"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r114",
      "r430",
      "r435",
      "r436",
      "r437"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r325",
      "r363",
      "r382",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined benefit and other post-employment plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r325",
      "r361",
      "r380",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r325",
      "r329",
      "r360",
      "r379",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r358",
      "r377",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r327",
      "r359",
      "r378",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r106",
      "r227"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r487",
      "r579"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Foreign currency contracts",
        "verboseLabel": "Fair value - Derivatives in asset position"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r487",
      "r579"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Foreign currency contracts",
        "verboseLabel": "Fair value - Derivatives in liability position"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Derivative instrument net gains (losses) recognized in the consolidate statements of earnings"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r484",
      "r488",
      "r496",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r481",
      "r484",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r481",
      "r484",
      "r496",
      "r502",
      "r503",
      "r506",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Gain (loss) on derivatives"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative instruments"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r474",
      "r476",
      "r477",
      "r481",
      "r482",
      "r490",
      "r496",
      "r504",
      "r505",
      "r509",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Duration of forward exchange contracts"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "auth_ref": [
      "r517",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.",
        "label": "Derivatives and Fair Value [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measures"
       }
      }
     },
     "localname": "DerivativesAndFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivative instruments, notional amount and fair value"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of worldwide net revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r133",
      "r136",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r515",
      "r516",
      "r602",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Per share data"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicTwoClassMethodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Two Class Method [Abstract]",
        "terseLabel": "Basic EPS"
       }
      }
     },
     "localname": "EarningsPerShareBasicTwoClassMethodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r136",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r515",
      "r516",
      "r602",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Two Class Method [Abstract]",
        "terseLabel": "Diluted EPS"
       }
      }
     },
     "localname": "EarningsPerShareDilutedTwoClassMethodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r115",
      "r425",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and employee benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r158",
      "r204",
      "r301",
      "r306",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r514",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r633",
      "r634",
      "r635",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Carrying amount of investments in equity securities that do not have readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Approximate fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value, asset and liability measures",
        "verboseLabel": "Bases used to measure the approximate fair values of the financial instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of significant level 3 unobservable inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r518",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of book values, approximate fair values and bases used to measure certain financial instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r387",
      "r519",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r518",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r522",
      "r523",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r281",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r281",
      "r348",
      "r349",
      "r354",
      "r387",
      "r519",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r348",
      "r349",
      "r354",
      "r387",
      "r519",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant other observable inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r387",
      "r519",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r524",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in fair value of Level 3 inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Transfers of liabilities into Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfers of liabilities out of Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfers of assets into Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]",
        "terseLabel": "Transfers of assets or liabilities between the fair value measurement levels"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers of assets out of Level 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value recognized in net earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r281",
      "r291",
      "r292",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r387",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r216",
      "r218",
      "r221",
      "r224",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r221",
      "r583"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r221",
      "r582"
     ],
     "calculation": {
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyGainLossMember": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).",
        "label": "Foreign Currency Gain (Loss) [Member]",
        "terseLabel": "Net foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r542",
      "r544",
      "r546",
      "r548"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Net foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r53",
      "r348",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.",
        "label": "Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net",
        "terseLabel": "Amount excluded from the assessment of effectiveness for cash flow hedges"
       }
      }
     },
     "localname": "GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": {
     "auth_ref": [
      "r494",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.",
        "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",
        "terseLabel": "Amount excluded from the assessment of effectiveness for fair value hedges"
       }
      }
     },
     "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Gain on divestitures",
        "verboseLabel": "Pre-tax gain recognized on sale of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r164",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r207",
      "r208",
      "r568",
      "r585"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r209",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r481",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D and milestones"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r177",
      "r180",
      "r182",
      "r185",
      "r188",
      "r584",
      "r596",
      "r604",
      "r625"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r426",
      "r428",
      "r429",
      "r433",
      "r439",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r176",
      "r424",
      "r434",
      "r440",
      "r626"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": {
     "auth_ref": [
      "r484",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.",
        "label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge",
        "terseLabel": "Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "terseLabel": "Income tax assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r151"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r175",
      "r560",
      "r563",
      "r603"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedLabel": "Interest expense, net",
        "negatedTerseLabel": "Gains on derivative amount excluded from effectiveness testing",
        "negatedTotalLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap contracts",
        "verboseLabel": "Designated as fair value hedges"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueOrExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Revenue (Expense), Net [Abstract]",
        "verboseLabel": "Interest Expense, Net"
       }
      }
     },
     "localname": "InterestRevenueOrExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r206"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r48",
      "r568"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r206"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r206"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r174"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Money market funds and time deposits"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Proceedings and Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r113",
      "r203",
      "r541",
      "r568",
      "r590",
      "r615"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r113",
      "r203",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r462",
      "r468",
      "r469",
      "r541",
      "r566",
      "r567",
      "r568"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r280",
      "r290",
      "r291",
      "r292",
      "r588",
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt obligations, gross"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Legal Proceedings and Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r256",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of plaintiff claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r251",
      "r255",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Litigation charge related to potential settlement"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of parties to lawsuit (in investment funds)"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of healthcare benefit providers acting as plaintiff in lawsuit"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Length of Time Hedged in Cash Flow Hedge",
        "terseLabel": "Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold"
       }
      }
     },
     "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r47",
      "r113",
      "r203",
      "r261",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r541",
      "r589",
      "r614"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds and time deposits"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r102",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r67",
      "r70",
      "r75",
      "r80",
      "r107",
      "r113",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r147",
      "r177",
      "r180",
      "r182",
      "r185",
      "r188",
      "r203",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r516",
      "r541",
      "r597",
      "r619"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "Total reclassifications, net of tax",
        "terseLabel": "Net earnings attributable to AbbVie Inc.",
        "totalLabel": "Net earnings attributable to AbbVie Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r70",
      "r75",
      "r131",
      "r132",
      "r464",
      "r471"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r148",
      "r151",
      "r177",
      "r180",
      "r182",
      "r185",
      "r188"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Earnings available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r135",
      "r141",
      "r142",
      "r143",
      "r144",
      "r148",
      "r151"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Earnings available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r306",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument",
        "verboseLabel": "Not designated as hedges"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r180",
      "r182",
      "r185",
      "r188"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating earnings"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r57",
      "r62",
      "r543",
      "r545",
      "r550"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1 for the three months and $(24) for the six months ended June 30, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r76",
      "r551",
      "r553",
      "r558"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Cash flow hedging activities, net of tax expense (benefit) of $5 for the three months and $3 for the six months ended June 30, 2022 and $\u2014 for the three months and $3 for the six months ended June 30, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Cash flow hedging activities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r62",
      "r486",
      "r492",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r55",
      "r63",
      "r547",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r73",
      "r74",
      "r76",
      "r81",
      "r301",
      "r551",
      "r556",
      "r558",
      "r598",
      "r620"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Pension and post-employment benefits, net of tax expense (benefit) of $11 for the three months and $21 for the six months ended June 30, 2022 and $14 for the three months and $33 for the six months ended June 30, 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r60",
      "r63",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedLabel": "Pension and post-employment benefits, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]",
        "terseLabel": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r483",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other operating income (expense)"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r321",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other post-employment plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r233",
      "r234",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other integration"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "terseLabel": "Earnings allocated to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted",
        "terseLabel": "Earnings allocated to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Acquisitions and investments",
        "negatedTerseLabel": "Cash outflows related to acquisitions and investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r320",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined benefit plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at fair value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]",
        "terseLabel": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Post-Employment Benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.",
        "label": "Proceeds from (Repayments of) Long-term Debt and Capital Securities",
        "negatedTerseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Sales and maturities of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherAssets1": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities.",
        "label": "Proceeds from Sale of Other Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r94",
      "r414"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "HUMIRA"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r67",
      "r70",
      "r75",
      "r101",
      "r113",
      "r123",
      "r131",
      "r132",
      "r177",
      "r180",
      "r182",
      "r185",
      "r188",
      "r203",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r458",
      "r463",
      "r465",
      "r471",
      "r472",
      "r516",
      "r541",
      "r604"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r228"
     ],
     "calculation": {
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r230",
      "r568",
      "r605",
      "r616"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Significant amounts reclassified out of each component of AOCI"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r551",
      "r555",
      "r558"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedTerseLabel": "Amortization of actuarial losses and other"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r73",
      "r74",
      "r76",
      "r551",
      "r555",
      "r558"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss",
        "negatedTotalLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r73"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "negatedTerseLabel": "Repayments of long-term debt and finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired IPR&amp;D and milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r234",
      "r237",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Integration and Restructuring Plans"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r233",
      "r236",
      "r242",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Integration related costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r233",
      "r236",
      "r242",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Charges associated with integration or restructuring plans"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r234",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Accrued balance end of the period",
        "periodStartLabel": "Accrued balance beginning of the period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring reserve rollforward"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r306",
      "r418",
      "r568",
      "r613",
      "r636",
      "r638"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r204",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r514",
      "r633",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r450",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaboration revenues",
        "verboseLabel": "International - AbbVie's share of profits (included in net revenues)"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r172",
      "r173",
      "r179",
      "r183",
      "r184",
      "r190",
      "r191",
      "r194",
      "r311",
      "r312",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r113",
      "r172",
      "r173",
      "r179",
      "r183",
      "r184",
      "r190",
      "r191",
      "r194",
      "r203",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r541",
      "r604"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenues",
        "verboseLabel": "Total net revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r165",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r65",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of changes in balances of each component of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/CollaborationsTables",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of profit and cost sharing relationship"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r484",
      "r496",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of amounts and location of derivatives on the condensed consolidated balance sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDividendsPayableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.",
        "label": "Schedule of Dividends Payable [Table Text Block]",
        "terseLabel": "Summary of quarterly cash dividends"
       }
      }
     },
     "localname": "ScheduleOfDividendsPayableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted earnings per share, impact of two-class method"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r402",
      "r410",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r216",
      "r220",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of definite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/PostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of charges associated with integration plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r234",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Summary of cash activity in the restructuring reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r404",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r170",
      "r171",
      "r177",
      "r178",
      "r182",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
      "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair market value of awards vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of the stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r401",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
      "http://www.abbvie.com/role/EquityStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r12",
      "r568",
      "r587",
      "r610"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r591",
      "r592",
      "r608"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShorttermDebtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.",
        "label": "Short-term Debt, Fair Value",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShorttermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r111",
      "r113",
      "r136",
      "r140",
      "r145",
      "r149",
      "r151",
      "r159",
      "r160",
      "r161",
      "r203",
      "r261",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r295",
      "r296",
      "r299",
      "r300",
      "r301",
      "r541",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r73",
      "r74",
      "r75",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r158",
      "r204",
      "r301",
      "r306",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r514",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r633",
      "r634",
      "r635",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r158",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r301",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation plans and other (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r306",
      "r403",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation plans and other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining share repurchase authorization amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r113",
      "r198",
      "r203",
      "r541",
      "r568"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r74",
      "r113",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r203",
      "r204",
      "r306",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r456",
      "r457",
      "r470",
      "r514",
      "r541",
      "r551",
      "r552",
      "r558",
      "r634",
      "r635",
      "r675"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r559",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r559",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r559",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryLockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
        "label": "Treasury Lock [Member]",
        "terseLabel": "Treasury rate lock agreements"
       }
      }
     },
     "localname": "TreasuryLockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
      "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r45",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Common stock held in treasury, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r301",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of treasury stock (in shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r307",
      "r310"
     ],
     "calculation": {
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common stock held in treasury, at cost, 44,595,448 shares as of June 30, 2022 and 34,857,597 as of December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r301",
      "r306",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payment for shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
      "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CollaborationsDetails",
      "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r151"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average diluted shares outstanding (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r151"
     ],
     "calculation": {
      "http://www.abbvie.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average basic shares outstanding (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
      "http://www.abbvie.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r668": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r669": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r671": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r672": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r674": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001551152-22-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001551152-22-000030-xbrl.zip
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M7=S_6.RX//,:8@Y%F'W(4,GD7!VV6"I@: '.GH"USMMA/0%[8-V!MUMX L4
M!5-R\TT]K2N83/*4;'7%A<;M[ D8?_5/X(]*S@_TX)W_/>G+C1='QXMY7[ER
MC7-\EZ Q?DO0,/E<$V2L$<BDTE>1E.RH8$93PMY \V2Y<6RG8P('2B%?)&>G
M2C%XPJ1I?S.-77-BC-\;<&[6.NOKD>CP)YK5N_-;=#Q;T^%(8.)J32D16DD
M"9FP2I&48[:@?[![ ],C6=-L+O4.+><]_1X)/D(2>LXJHO@XC3\U!W*N$M4,
M8O<G_-QD/CDZ.>Q;^QZN7\BRG[>4%_UJK^3NG!=',A;(G#=64V/-T"H$ ,5)
ME9)H,D$1(NZ/23U8S/L/7RX.#]6B[NHC4"V^'@E*^O@5C6Q4O2<PJN@)H.5<
M;-844<&Y/I1VYOJA1J8^F],BL(DYV5PUK_'"#KTS.QA#&+/$W?W@AO>L@2%[
M*L9HRLU9@&WFA)JJ*KMQ_P"]8F&\>TB+H0!2FR2C:HQ<*0TY($F2J#EIVS](
MKTU.[Q[<T&HRA"8%]@"6BG-.<Z522R.H(>X?N%<OPG>/:JW)N=(G)WT$&SQR
M]*X%"^0(#-'^H;H3Z;Y[H$N.%@1R-1IH<S0EDA7O5%)E*>3VT'RO2_#O'EL%
MLT]A@L\]9Z. 1564<,L>4P+OSK.#\4-ZC:.^VYJ22&IR(H6+:B*.KF %BWUS
M#U=-8FAOH+G64=\M@1,\Y(2F66X)&#P6\;%XXR% %MP?<'8TZKLEF%I@P):P
M!BD 3L@X*4[52K54WTSK[0%,USWJNR5\HJELF!*1=8 !"J &'DM0"J.\F70<
M/SX#&/7=$F3DO/76NA"20&.;:RK9%A_0:C['N#>0[6;4=TLHL;,<^XRQ> ^4
M&'WP16%+N:)K^1I1VM434+<BH?D"X@, 9ZI(+:JHZD^& YZO:1G_[,1U*5NW
MM0'Y"$B^^PY;'81<"9T'YP)'S\FBV1MHKD_9;@\<+-P<1NQ[,S4>]V668'RJ
MFG1(H 9[ \XNE.WV8"+RP896(CGHA<$T?:=D&I#+N88]LJ%K5;;;PP=**,D#
MM\@$-EH,3CA'ZYT>\.?K3?8!GUTKV^U!EAK%(*DJ7JJ9"E%KGK-F)5RS@9SW
M!K(=*-LMQJ?JQ%<;#)@"OD0T&JR<3:75RB'XZT-I5T^@U6:SILC.J^L7:U39
MIB@Q56LI^;B+?2ECEK@[V3!S>3U#]([0N)@B@W H,6GPJ-),,1G;'@)ZG>L9
M=@*IC35+<B84]5+L7#:);2L&$7)TX/</TMVL9]@)N)H:N91#$U4,T$+.OFE(
MXJQ62Q)RVC]PKWD]PTY0%?*6D4ELJZK8'9(MEA"040%\4QQMCU#=_7J&G0"=
M@BK&Y *8OAPI:0X=2RH(; ,$K&W_@-[)>H;=8"N&+55-O5V&IC8L-B.SRBL5
MRPGD^G8RCED27\D62\W6F%H-,58 3;&S-$BIE\FVD5NQ>P/-M8[Z;FLBUD?,
M1/K08L>I9K!2#$&R8GQS^P/.CD9]M[4FJ%8L/N?LO <757H&2 8DD%'CPOV!
MZ;I'?;?EX\1$ERE0*IK)0R];87NY$!.,0?9A;_ 9P*COMB"+9'K1=<WDK-I2
MP3Z?DEOFU%CLFWGB\4.VFU'?;2WD,HU#=6CZ_MVFL2G'ZK.J=>^MH7 VW66N
MHS[#GN@ZL[7"$3DSF)0YBRF0^DQ7S%Q5A1L]4C+O#337I^NV!PXPY(C6"^NK
MRH+)@_CL7?&D"6[=&W!VH>NV!Q-;%+9")?8MJJ$@50U#*:&:41+,>P/3M>JZ
M[>%C(D%0D9V])"@EE[Y>545#S%FD8M@;?':MZ[8'65+UK6(N6LMJ2<%3C=G$
MYG.2H!:5]@:R'>BZ[:'4+-I8DA!K)IO[X$.*@5J%Z,2WY*\/I=U%:.M*L)$]
M%#!,Q1$I;2%7P%S/&VM<;Z6^,4O<][?474L)P<N4SB5J"BG>!0?.<[;2A(G1
MV$+9["&@UUR=X/HAA8A(L6_U<AF$-:O)V9E:K"FF<JG[!^G.JA-</[AJG10J
M!7&5@,B7T*P^>W6]M6\:R/L'[O57)[A^5&UBE0W.FZR: HN4:B)&*Z%)R9CV
M$-7=S^;O)MQ&;"DVPZV)BL>F29HXDZ%E@X$*[A_0NZI.</W89A>BMPY]W[0;
M&Y,IT=C86A0?*]?KJ\H[9DE\)>6"6R#*+HF$&L$EC\0>U>@2U^(2R=Y <YW5
M";8%CJNI2"K&. H C?O4OI?6<C0LP'EOP-E-=8*MV9!G31 W970T]0\NAPH@
M.8=@&B#BWL!TS=4)MH6/!=_(1V>C \7#%(CZ#@QFH5[T>6_PV?6H[Q8A4[5/
MCEA";) T'DDQJ7$LF5I,O#\FM9/J!%L;\\P)+$-FGPAZ';&"-1;O6B$VXL?0
MAWI( N_]9;?7WWS*8X88D8OBJD[39,.UEFJC!QOTS?X!>LT[F*X?4FQ672>!
MRD@$:SD[<@8*]$:\ZF#WT$9WMH/I^L$U4JQ+D-A* %NA.)1&R;?F/2G&^P?N
M]>]@VD'36DJ:X'$U@:I*GUILJ(IG4P74]<\^FNS.QSQW C2;7$,)'"RZOL:8
M*(JO+?4B$Z:$/33?7>U@NGYL+1GT+,DE$R&74J*HMZZ;CAI&/?7[V ZX',69
M ;Y!^-Z"J<?7R\C>G?^T7+"L5H]D);3D%S?UV<DK.5P<]P_]#L2??"]/3H_E
M8;NY7/96M/W"[^OSPT,JBZ7>X"MYYZS/_?K5<JW7/NE\/5;VG#Z@(WFW1>WI
MO,IJ-B@>OUNEXG.J1MN2G,NNB#3@TG(C3E III3%MXM^M,[A4.F[0\H\>MLP
MN;^]3Z]G1R='8R7CY1T![L#A%L800M<W(!XA:M(9@:BDZ@RE4%,(;_SDD'?Q
M_@X>?SMY-5O)3R]H>40L)^L9T^%>[KSW6%()AF)41,%";LC686(13M[""*#\
M0R%O(U4?'O<VL!LQTS]RY_6Q7NOWU.I$J4]5R!EK<P6\,0@&2C;<,R&4*A)K
M=</?U35,P?(WFJ]6,O]^ME@+OU#JCF3_&!D?)7+(OA$DU2*&"2C:A+V7%,<1
M94Q?+#%VDIN]Z0X^/^DW_D%S^_-KZ,N+"WQR;WO//B,WJSD>@)*3BND]D:JU
MUD4,'V1Z ^3D%TJ*RY-9KB:&D')1J0(5*$ H!JL'$JPXAG(R'<8WFN5'63Q?
MTO&+K@W.L.2.\/+TQL^/]S4/WP%1=U#@J@*H=_$QZRMU-(CJ<CBFZ!QQKG4$
M?9PFHEXS47?2E&HSC>'K6;-NGRSYA!RCZSUW*(F,)#!.1-WWT)]=#+9  DZ]
M^343]GV,J6#)Q4@8PR:#B:C7[U%WL1O&)LK)1]<RV !%'6E6KQI#*ZV!&[]&
M?6>B\.??&]&:&#M\L4K-;3I+018+)@?TH03]D[ I @7&+U8GQNZ7:JT2I617
MT0- B[9DFUT04U/#UL(85M],C/VBY&NR)C%1<:%Z2%*(Q(JDD#/$XJ(?OWR=
M&+M?.K:HC\6$F).J@AJ$?.6HS&W5.0&P(]"Q$XMVKBV;S2$P"U<)D!T2&4Z^
M.73D/!@:@;:<6+1SO1=KC%&"9[$(GCT6$ZV55,AC<A!'$#TG%NT\H@5G:LAL
M>Z$H,";GDD*,P06VT;;HA[]A\8LESY5LC?1DB_@*-:N@H:A*IZ^#RR400@$[
MEBSR/R#SH_3U_6>@?+./:95-6:-"\='%7IW?48T!)9+UW'KMH4FDCHM!.V@P
M)MRRI<A(#4A:-N0EUU #Y6"#F03JB!BT$W$JR7-O PT!$=AES)5+R!$K.X8/
M=Q%-#!HP@W:S_SL' \Y!$AL ?")):*0/%H))P8ZIYN7$H)VD-JXQ-=MJ*L&#
MNJ'B/ KG4*U!%\L8=- 7OSIB[Z46^"QD/.6^DTP("[7LK6FU5<KL[ BDUD32
M?5=SD6(((47GO0'B0B96T=>$7B3[,>SWGTBZ[X)1P$=K32K>>* ^G"F 5H1#
MXA:11B 8)Y+NNR;UCDWOWNZJ9\V+;88&H'(4.68G:(:_+_2'V7RVEGM*BWIW
MOE9>S,JAW%RM9+WZ_O0^_;)8WCJDU7OE4\X+:DA]HMC.%X>+YZ>/9L]?K,?2
M5[-QMIIT>M5E");Z8#B9"MY6A]'%-/Q9DA'!MKW)C(PM"=O6!Y[ GRW?%-\W
M^_<9KU3WU-KNS;A?9_[\YO.E;-SV6.S,!^/$$Q$S ]9,$;RDRCFIJR0W@JK>
MHP!LBY6^.=5F,$;(&LIL+\QH@]4L5DH1 R-H./Q(5NOE":]/EOK\?SJD^3MR
MY.;AH2R?T[S7^WJ^W%32Z&>,Q)A<YEI2+3&7!L&(^CWC 'I# PUC;@Q3N8,"
M:?<I#F-OR,F^!5'5* FA-810;,]QHHQA1//J$/WDK_ZD&CFW%JOUP_:8#F5K
MZW8O_>1^_9OSVHO.+5_)Y>^^<W1\N#@5>:SR2S,OOH8:DM<_\(D]6!C5S\D2
MF&:)6K4!0P"I 9P;P<#GQ.7A<7DGXZ/8./I"%DWQ$&)%6[WAYH)I*4"S7W2D
MG;@\*HWA4F,!:[*%#"69@DF@)FH^0%2U/X)AU(G+P^/R3D9;"4VO+2,ELX64
M8L'HA*!"C36"SY->W@LN;^I97CI['P5SI)*39#&V62C>96ND"<1,#305E$DP
M3V0>C6*VW$O3)<WXC(#+D41R:19+-<ALW:28)S*/1C);"B42J'<F#^JFJ>9@
MDV_&Y^I5<4R2>2+S:#0S2K&2JW&E>6@V%4=&I ;]QQB7:-+,6R/SQSN.W-E.
M)?;!9X0[$=&F<,TID4\I0&\DESRGWHG,%&CYO%CN)*(G=H]255-F;N(0;&)-
M#!M24]YQSB6[5&R>5/7$[O'*[&C)A.R5U@Z O.]5>!(XQYA;LFY,!2\F=@^9
MW3O1W4:Y7)B#\SZ \US8M]12<JT9B6D:J]YQ,C<< QNE\*X.G<V^:"()$&PK
MX+&4)-:CN$P\">^)WB-6WC:+-\J 2(D 8T,,5'LMMQPYI(23\I[H/6+IK<3.
M-C1OHG%0Q&1(CE,+!DTSC>PDO2=ZCUA[1\RYQ5!CS!6H"?D^2AC%&.$B<0PM
MM 9 [T_BUF/9=%#O&SV7=*@,NUF/9O.9WO1FJ^DYR?9_/=1N"L^JWF9?V?H6
M0,"1JZX79(I.&"6/H=C$Q/-Q\7PG:CS9:BI L[86D)(S6PLVB4O@!>.TNF3B
M^5[(<DS<L"!;HSQ7%O?&Y<E*:.3$H\5)ED\\WP=][E,#MI!],P%<:>A=RDT=
MO.J6X$?1/FSB^<@67^UF>8J8R&22M]R@1L*&"0N'D&T.,8=)H$]$WPN%;F.
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M8LGH,C?V(^A-=KVX_9G;&FCED2VN+B%IL>5,#2,@5O1(GL6;5O3O..#5)5\
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M?1)3JCV?$K'&Y8.+%T-[;O; F@.7/TU+73KU<S(D2XZ"BQQ; "^ *0>"9C4
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M2R/*N_9R#&P N4,H7$*ID"."OB8#Y* &$<TCT)D1Y0[[SY =Z5\NQJ9@BS?
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M7@?,5FK,( 5*FXU,N8"E25W<(F4(=8I>26VIFS<C<T3G'*%3$9N8#)&(.F@
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MK=D3ZQMX>3*FT9SLS78?!!+5^H$Y%>7JQBY4ZK3%2E/9N"BS5NT72!T@6Z7
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MFFS7&[?9&T]7^HO])RN+SWLL5M?65Q<'*VO]KW1+*S93_-&]8G^P'ZZ.E?_
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MLR+N&"WUSGA4"^Q\=*&J!8^%#;KJ_:@<<#<.:'HU8F8B*<,AV!! 4,'!9F'
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MWW][2/;?'K&7/_UXLO_VMY.7S_?.#@]V^>N3/?GZ#W/V\ND;@4I M"1"UDR
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MN"04!TU1-I,2!=+M!7$KF#L'YM;3,"J85^C?:J9D)!\95XF"DYJ#R-Z"H]E
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M:+!&9" BA\24+/W^*X37#,(K#DQ6-?HA@-PLP50Q9<T=6%Q2$,8564Q0-*>
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ME7VJ3+00$[V;"WIG'Z*F0H#R68'P:.-;'C-D:85"6R$8AT1T[^GN-6^N<Y;
MJN [TR%N0F^U"]I!]8=F20I+Q/L ,C &(F@#7AH'G--$<(MM)*GFQ&XNMEN/
M?=\%VQ7#"V&X&0G/Q+DH"!KT*@O$L"2E7X\#%F3.)9*BO=W:X16]&X?>UL/A
M%;W+1^^'9M=:04GDB%DET<!/PH,3) /'HZQM:4)M$+U4RXK?C<-OZP'PJED_
M&*Z;X7#%D_&2*I3% 35K31*8'#18R37E2:>D3=6L-Q?;K8?#*[8?SFJ>"XX+
MSQ-G J0VIC2Z]6 4\4!MI"H5%4RWE[E6P=TY<+<>'*_@?D!P-T+ER>J0@@@(
M;A\0W"2 TY&!"5QK1JWVN4[.WF!PMQXIKU;U"D#<B)L[%KCA@H*V*8%P6:+Z
M+37XH C)A).89F:UZ1" -[A,_-FQ&QZE7G_8PZ4N:!N/!OBN(_S+-(W39/HX
MBL7KC-XN[\Y#QD3W^L/1N#_]L'N!AW,1L3L,)<LJ/4_G_Z]*7QORXNW3N3BH
MXB[I*"4$&6>CAQ+8'#TP*U2P1N?,V_/65#QW#L^MQT$KGE>*YV9,5*JL<B06
M9$@$1"R3/3.-8**2P5%G59WLN<EX;CTR6O&\6CPWY'-RF1-C#62E+0B6./AD
M(O LC#(J)^>K?-Y@/+<>*:UX7BF>YUIA.^&(#QZ2$\4]PQGX2 -0'UEVJ'Y[
M0BJ>-Q?/K4='*YY7:S\W(Z*>>Y(,)R!5,J5<V*.NG469W1L=-81H[BN@-Q?0
MK4=$;POH"MP%@=N(=D8JA'/.0_!&H:6<T4CFR8'CT4K"O(BEKD=4R&X<9%N/
M<U;(+@FRS?[7) N/4A4\T0R-89, U6G4H(,6423OHW7=@NQ="X/]:!S3&*:C
M]]^5KYZ,!OW8N\1.I\*>^EHT_N &;AA2STU[/Y\.4X^3[5[!TGVJA&^])FM*
M5->6$.M$ G71:\XL<I5!P\&:$)@SO,RC3F]V;YF*,;OXR]/I9.J&9:5JJ_[V
MJ.K%7-$PRA(2J97@D)E >&[!&17_/WO?VM1&DFW[5Q3<B1,S$:0GWX^><XAP
M^W7==P"[F^X.]Q?'SI>1+21&$K9QG!]_=Q8"0PEL! 5(<GYH-Z!'567F6ON]
M-Z%,.VVU-,R+C2VV:717>1B+,,9]9%E=ZW[:JLG=4L"RY(3\[<[V=H$]70;&
MN\2:ZHKN2N;9_FB RS9Y]I^C1C<+@Z.R4*]&XW(7CZ?3<=\?3<$/TMYHYT)R
MSJD>5VEP41ILUW@)%3+H4,9V"K2Q$B6>44U2<M9[%S-EA08K!U8.7',.7*1C
ME9<B0(Y*ZRBE9,*E+(T1VG.F0_;L:A*<X./A3W?%AE5C[(XJYXK9I>02@B!"
M,T,DDVC;!IJ(3A&W7<D(2:-MNZE<![.=*E%6HEQ2HER )[70U@$PI72AS.@D
M2YX"&E>)BLR_P9.5'I>>'EN:)&/9VBPS82+ZD]HDZYDG"D14*FCNC"R:Y*:C
MNFJ3E20K2<Y(,L9HO7#.<2$DU\HY)0V520%%+=-6DEQADFPG%UF-[.BX)^ I
MFMO4:^*22 0/C7%<J8P;O;$E-A6K'%DY<LTY<B&+.U'4($"!\4$F*;T.K$2#
MJ:+4!J&JQ;T&;#F7NA6EDCFBH9VET4B701/+G"/9">N4SC*PTC]ND[EYNJPF
M=V7*=6'*18A2 XV92Y"9H1KI+9<RNNR"R2$Q96M\9LDIL-WR0P1),UCB!3@B
MI99%8[0DF_*"< :-!*3 KGKP51*L)+CZ)!@< \XRRTH8F1.#(+P0$ 5 UDJ+
M:E*O,D.V<@ZM 6L8BP2W7!')N2)64D,$UR)&9,F8V,86DYO:KDP8>Y:5>'HC
MISA0#<TMF&5\[F8%WDX<'>%9_2Z'UBO4*]0KU"O4*ZS<%=9BUM5WL]:?II .
M?!KW!&LRUVF=;W7)?"N:@XK<TNQ1$6;).QV%4S8*P2@HVBC"E''!:G+Z@^FT
MVW/)Z< Y. Z,6.<CD=8$5&FE(8;KH%F0C.EPDIR^AKWW;XW5E370U\H&[XQZ
MJB/R02BIW>8FAQ 8$T0&;8@TB1.P/!-D))8H]]ERWF&B>.6CRD<=AY"="Y(:
M%URB7AK-K-(NQ," XBO>A:L)J8:05X:VVDG;3 5.0W0$C.!$4L@$:):$6D\E
M1&9MIAM;?)/K^:+DA2/(E;0J:77<""%(IRT3I>F_C"%9(V023G O0%(6[UN)
MJE35(56U-"RO? ;C/*&> FI8TA&?LRAMBS@$8Z4&6_K";PI[ZP8*E; J8=U-
MY)79A 8!>)VU#,I;B%Q*8RSJ62995PEK=0FKG<P<(9>L=4.L+!.:C0G$40?$
M2*N"$9F#5L5+157U4E6^6E*KD&J02J$-*)*1WCL/C,O,I78NI6A5M0K7@+GF
M$HMY0(JRI9;7\M*$W04"P!Q)F2JKO1<FL":QF)EJ%E;66C8MRTBD*LLU8P&5
M*R4@:D=U%LXDA4J6J;[U):>C5I*O3M(&"IYX;221VBH"+AO".5(13U+KC)H4
MG^\K4-6H2DC+0$B96::]21"<DJY4^QNM($>I>1+9B&KVK3);M1)NF<>MSB$3
M4%$1:34E7GI%G->2@B@ES GM/K%)W;SVM+0S#&-_<CB XW*SZ=LD5]]9WWF7
M[USC89L[:=I+,![B;4YZ<([*>]-1[['W?_13#QG_49VYN>ANUW[E#QJF8]PK
MIH.07M( G@.@>29=E-;%S)I^Y8RRDW[E[/N%1X@3A,'H(/U[-)G4T2"=:#*_
MS^4T@:4INJ30[/*VM"RBQ#()1#F7HV)@#:VC^-88MKEHK#(FP1677 3'4DX!
M@J7,@Z,5MLL!VW9.3]0TZIP-2:[D](#*!#>+DB ,9<H+E76JL%U?V$IM+>B0
MC>1.IA!\B4+2Z!GU- 8?*VR7 [8M:1N8,S(C8KF)"%L%CA0W$6%<1!<C:.;K
M8+TUABW*5E 15.(1)(#P*N-W4%2/HX-H79>PK3Z_VV%WKF^=MT8F#L19EHF4
M7!-@*'*EIPD"S3)Y7GH?"^8J<M<.N<P$RC@7U&DOK4\^4FTU2RHG[ZSI%+E5
MX-[<O)UOGQ:%<UH2GKPA,H$FSEE*4J#."LXC5W4T]1KC-FN;C<XTY)Q0T\I
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M$!Q).FB";*R)=SD3C[^S+)C!G=O8TG2=\7NGVN*-8JM56WQ8E+1#JE2AN@C
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M1$0=8[1>..>X$))KY9R2ALJD@**V;2M1KS!1M]/5RCP_QATC-E*!NC1CQ(N
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MLDF],DLR3;KZ3Y9>D?@6EBM<%X-KNQV/B8$R'PF#R%!UT)2X#)&HD"A().#
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MD16"1]F,5I&+E!(4S9QF;3+BM?##-<['K?BA\QG7]31\_S0\4V^-94&5#@;
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MDUX^Q2)V/G)$-> A%THB0V)"U,1( A,8NY 3GIB><_'G HL%%I<:%I\VR:K
MXK/"XJ2S-. H7" 81:X9XEYKY#R)R,G %(-)5DGG-"RJQ;+ XD-SM,8&=DVI
MZ&7PIGZOOL2 +(S&[L6:J_;V5G[47JUSW._U;3N_Q6.2M^XW38\)-=U_(98U
M$#58D:=V-X[(X=V &AK'N6OW9JHJAO4V+ZFAH.Q\4;8YY8E4@A!A:4(2%A=Q
MS@(RPELDO30>4Z4X%BOK9%6I1Y>^?PB8/4<,NL#&$\'&W+UU!39>"C8F'7G:
M!B(C3\A%8Q%/#&Q6'A2*R5+*)!7:J HVKFE*66"CP,9ML#%W9U>!C9>"C4E7
M5[(1#+EDD8J:Y 08BIQ+ 9%(J Q48D.+ME%@XT&P,7=G4(&-EX*-25<0( 8U
M.CC$-8F(Y[($5H&YXCG@!BPR(2HMF[;Q9A/K!E7=KJG;_D3UJDIPH007[A5<
M&)6LGZ_SB][5$.5J8@DN$N)N"3%=%4L*:T&E=,A:+!!G6L G,$JU5P$3[D1(
M8(_B-4&7)5904*Z@W#.BW"-]=07EG@+E)KUN%#OG88505'D_F/,"S&>GD#'!
M6!NX51IGE.,%Y0K*%92;1KE'NA8+RCT%RDTZ":W 0H?(49+921B"0590AUS"
MN5D>UC20E76VAN=5_ZN@7$&YUX1RC_2$%I1["I2;]&D2,$]--E$]IA9Q*G.5
MU0 H9Y/1>:523F^C2Z3+7=]ZDXC;>F\^492D/*$\X:T_X77TN;B^,\RPF^A]
M>\/,6H6UW..5WN,U%\E\TMXO=Y3K>72)GH69Q?O;%]>]VO*9$*7WRZ+:#/6M
M=_UZ$Y]FNV%SR]/ZUO8N=BSI1#D2)N;]TTHBS0FL!2,<@WVG91)S:?ZR>!7!
M"L2\$H@IS5\6"F(:?UR%&!^H%$1RI. 3RBT7D,V%!SDV/D4GL8#UF$?WEP(Q
M!6*6LEQ"2?6<*_Y,J#A*)LFLTH@)Z0%U@D*@\6#D:912)$V<\7-J_U(0J"#0
M4E8F* @T3P3:G-" N-$6=""''.4L=]BTR' KD6'2.0*6EXYQ3OU?YHA K\/=
M^V+]7^[K>;QM_\U]>W0M):(M6/^7802@@-U,8/=^RJ,D0F)8*H4B6.+#;GM:
M2X0YU3X1Q3#1\V@!LWBM]@I++U@+F,+2#V/I20^. Z6346<08;F>'(9/UH<$
M:^A _71<RJCFT06FL/3BL?2"=8$I+/U EIZ0T@#3SB0ID<"1(!YM-DD\1<F;
MH)C'%%9Y'HU@"DLO'DLO6".8PM(/8^E)+P,3(2HL(HK*@.+-005W)$7D(XO,
MPQ$B^#QZP2Q B]FEW[+^M+U@9IFE61W&;R[K?^;W7GKY\(*]8(HL>(@L^#3M
MA(DT24(U"I$DD 6)(,ML0!KD.Z<N*9;;(LRA'<P# /F9:R(5Z"O0MR"I1 7Z
MG@#Z)IU5C"@<A3 H$A40-U@C@V5 E,C(@K 6+-^Y=(0IT%>@[Q5!WPMVA+F
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M*FF8IBOKO*AY!>9>&<S-LG%&)1\YP89PPYW"3JO(@[*)"2Z]"G=58GFXFE?
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MV-];'?]C.5FA%?_WR]G.]W#D*)<[&Q]^;'_?/@$R/6E\K[/&1F,?QDL:&]^
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M+# /V>ZN@HQ66K<;@>>Z&_-TD%51@SHQPW%8DC8%IW3BW@65-54IJ!K7\WA
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MD1%J3_F _+0?VA#&J3/Z#,<-[Y5%KZ?E=V:-GZ_D?]:\<E:G='P:LU,!9QW
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MAD8%NPIVCQ7L6BLYLAK850?MS7%N0:FS.6=OC2">:8]*G0D$*.IXTN3H,\@
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MHE; LP7# 0E;K@I#9]!S"CEO\P(>5:Q9 VO>+B>46TZS=8D3!)U I!) <..
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M>"S5F$0IA9@L<0GM-+3)-)?2X#9#9>HGS-1MQ414%?RA.7LQ/B)08,8S8IQ
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M'Q&4:B=K?F=;MN,?OY_QI(#-;8IQ;9$G^K\F)W9^S_W[9,QY(1[X#CYX (-
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M0'5BCYU;SXU('(&?"MZJA%<F=X05A()!9*G&N1W"PS.)"E87#ZM/L%%<L/H
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M?'H?V97XZ'3IMS%X?V'WSE<2//!*[,V?CJ\5A=D+D>/RE\EKA@H:OG_I[_Q
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MMGM%;,<!&)Q8EES W'%KE<->D>"DETK2N]?V*6SW&&Q')\\[1V>M 8-.JN"
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MD'X.2$]&,X"HB131(RRM0#Q$B1QA$F$1>.ZH[AT6>:.G0/KU07KN48<"Z>>
M]%2]"6(E]>![)$H8XD)HY(27R#K%7;))2P):6CUXJZ) >O$@/??H08'T<T!Z
MJJ@"$1:P*Y#U,I>0,119(0(*U@@K @Y<*H#T*\K&F$\_S86,/GS(/<P>,V&C
M]%-^YF(]I9_RHN2]-.)@(X%Z*@KH+@IHN@B&9=90C@,R1OJ\OP4*2-J(M(V*
M*>S ZJ!+*_K!;N+"-%4NS%N8]W4P[S.E&17FO1_S3@;H5#(8UL0AJA3++> 2
MTH$IE(+'W&*;N*@.6<\YQZ!0;Z'>0KV+%F MU/N8U#MU<"V)7*;/H:0303S
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M>N88L_#:%NQFR6[HDKBT3Q49N[81:A/AS\E+/*F'',/U-4^Z8(V-2+-[K99
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MU_F@'\8>+H#=-,SAUT<EJM[QC\==6'=?_9XY7KLW+H);R5Q94 TOQK6FE/O
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M5<O]U1LF88X]2XA)0T#2 ?Q, L&G 0NI0^*2DH^$IAYP-VM6^?:K;(1TC+&
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M1@$"81V84Z/+_9)GU\E,?%S="'AZ_C-0!A!?WRZ\)7H@B5/R6S'H;H5"%<F
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M;.W63RYW?N%'?4"&/$Y9W>Q%%55ZF@-'E_NM/$D@4EFRIB+WI";JTW#'BY3
M2FBE=J>\6,VU<ES$Q3/;2:69-MR[B';^9>:NU^'.?,5D>3]AB,V/LO5R7*H=
M!I6N9'? ,+]KM@4K7_F,?-?F3K:8XJB*]$R#E)-QS@SOQTE^89[YWP?]!#^7
MZ,+3?HC%RJDT>,&@*1$>N'WMG_! 2$M(P':NLQ(GYDX]C;71LV1Z?S%Y)K12
MLSG172F;3WIAT/\Y=A97?+_UOWDVG@W&IS _!_G2YS#<G-%8F<#[K3@"V_N@
M]?Y@8I[/_GG_([;[)D%R?\'^+W;WQT2N6K&).VL:/"KI="_[<-/+3YO\D\C2
MQ/*'%WH>W6"<[>.\MY=']/H7K7?P3R^[LNI)^'WB.OOMMZ??5J'-FPV8ZF&+
M^7O),DOR^=@VIY0GQW/AKHQ -+C0N%3J$(-UX1?Y!T;6L%TFY.+GRAGQM P!
MI/S)L*AG'&0GW^6+= W4?U83^60ZCW]7?HOPM(KB93NY(2BK",K57^SXCS=<
M<A)QBLC \H'9$R-R^4Q6;+R/FEIM- &S)R<H+U.4>9]11J/::Q1FO$8SOJ+*
M8PJ"T%_2&D)6:,VU1ZN(*AA?*QYYC?I3+,DIT<,SVYV]UR3)=E83"T;WAW'F
MND^]PF?P4<V#-J#FD;TL6_0^(,U@T#[MMYY.?'TST)'3CJM0[L)>>2/P+6)5
M-;?3K;<LPG0.)ZM1W[1^2'WKR;A63'1Y@Y?Q?!2[%1N84(M;P>TLS!['B]:O
M.3GBLG4*>W3^<O5*_S6<4)'\M;?C<%KV\GX%Z^>=:"LF6N/\9+#3G26TA]WV
ML'CCV[5H 96%^P#S.)A>?I8C .?GT79J*E1_#3:77?%I_UC[D8_L(,<60! J
MT<J[\9JXKQCCS@KE>>3<)&$$QBX89CF1*9I4XSZ;X+[X..[_7MIPO8\S/JK:
MHWGMZYSXK+Y2@#Y^]@L]/GWCL16&<HZ(YRF?(*&04\HC3)1SPOM +  T66Z:
MT3JOYWC.$77MO2Q1L4JMUR%$Q_U!!I-Y1O1+!X2OWRXD)OM,"]'[U[C;'M@9
MOK<"?V8SG6:1N2BE:_>';5 'FY,.>^,$;S >3'PD"U^>/*Q"K>R!2V"G]J_1
M?*8&8Q6N3RSJ:1Q@:N7"VPYG@@>Y^<PV6;'UBW_S),#WNN.N==]NC44[;W'.
M69@5EM;(.C??,WOV(C2?%'B?;K]5+MUN0_1'PX[/^Z41YF_6]0<6V$().@-U
MSSQJLKU?Q_3V;Q.?!/O$E.N*G?!Q0V4F2@G(W0MV=92R'F6^Z3([N\X;AD4N
M*<@ $?4WENZ_OZRNM2#O;V%L<9ZWS488]V^* M1X.XN2"ZZ:R41D<9A3BVW#
MG8E(_#)YD=\G+[(U\+/6OO:R/U[>US(%?=4?O'L<</($D&!P"H.I'"490R9_
MF461FZ!C<O%TSYUXO<H5_>N.(+]7J%*[\K+./._W0_FA^'.>A)Q&#[-\;9DM
M0<1T9-<@\2=@AAVV5UIHVY2:L'\?X)CQZ@ZGCMV:NE7@,><*O0%&)E.U D>J
M<HFIXS[CU##>WR<VT90;W/^M&C6F:_C-T\O<A!- $F2X]>+\#$2LTX6MXZ?N
MN)/=HJM9S-1'WJ*:F%EKN;8RLX.H\@I8?Y9G<39!&X2TVM_@TO:P3J^JA'N^
M""?GV4^20H!@#/KO'SNEN!UW('3"'=BMN<./E\,12)^_D[LQ,<NDD0H;&CE6
MW"5N<U-R%I4AC+K[I4HT[L8O9\V^_8,</WF3:)1",XFD$0)QZ2G2Q'(DI$R>
M4,4#LWN'P_:'FYV-\Z;@EN\%GYU*SNT&]5Y050*NW!@FRK@#!'.*&PV=?+"$
MWI]SPY%>D?R9VN<'C"N*6W/<HN[Q?<&$2>'J+'!\)('W,K>E*06QG5)VVNT7
M_<@WS*W<<T:M'[3/J]+'\W:_':8YZ0>M)YDN?"@U@/#MCZ4'MKN+G;.T=U1C
M'&TDG#)E#>Q^ADEO(J.6JM6],99[!2SD U8S]+04>JW( [RQ#\97MT5=P347
M;ZAD(0;ID!;YR%Z: M)*<>24I<9A2XE1>X=L'Z\XGF>NI/DFT:P ?B'S>)K)
MLVFROM)?^^*LW5]@ZH,%IGYLZ\9 R\<3+!]'T%0$-A6!345@4Q&X]16!^2S@
MQU41^,D*OX6*P"2M5\1'F!_%I=:&!!H4$<GY8+26>P_ Z'Z?950OSMO92%OM
M\\'\7@R+:^L9M]II,#6]-S91JP.6F&ICA)4;9%A?+8DZXD=_O&%.FQ"H0-1[
MA[AE"AFI% I2^PA_Y\$:T$8I;T>A@/#,ML.KHXC#I8A@18R&=6;T?MT^I3Z=
MJ?IJ]K%FYTYQ?/FZD+,V$$!V2D_+:6[-?J%!8+0_*2V=0"-RI6C^.UR:\TV*
M69J 2<U&ND9G[4'.FAV,P'PHN;/[N>+T?1[X67]XGM&JNAY,C&$A6=D_,*B[
M,=A>-OL7' LER;0WM*71=OEJ%O0\M-K3,/6%Y@]_'7>*4Y3N7QM$$X_H4IA]
M+IWVG^P=_+N=MY6VK3P)N6*NG]U\(-'929KS,X;3QH736SPM5:ZE*U;)I(6;
MO83'PL+V?*Z]G4T +CFMYU4[S,[EP?4@@>R^S\O<N;QYO-4D7Z_ZS-?;N6WF
M*4Q'R6GHQ=-^W:*F_NH@UN60MFH3.B')@]B%NV5)6U]&RCNO%I.9W#0[TRGR
M^HWVZQ"WO:S>K]-^ES&M!%=+SZ&JXZ=M53UX\YSFGI_#29^;N3?,"M/OH=/^
MI%=(B*E="PEH5+<.F%<=C>)4(');HS0 ?+O([ONJ<'G&9UZZ],RU$<F%"'--
ME%:]V:0ADK/#RDO5M1]*YZ3BH,\S6&UAO84NFM=WF*;U3CL]E6Y @ZI/T3H]
M)TG$/#A# '0"5TDX%C@7@<FH83/D-Z ^TI^ _9_J27B1)OTEJ[-Q;V-;FZ]L
M6S@Z>2)>G/SUX>CD%3F&\>=#8(1BQ"2"I.$6<:,]<C9:1(0RN;6/=,+#%G&P
MPLIV5;/)*IZ34X].IWA9^55G HSOX^0@T>M&N#,6=M'W*GUPIOGMM,M/CDBV
M_CT&F:VTKY@2,[T(2AQII?3N2K2H9.AT+F?*2[*7\@C4WO>GY1FMG^O97<K2
MWPZ7\73[FAE[_) 7ZJ#UH^UD3\OPAD*!AZGT 0&;&>H*UPULG2/;>CZM2[DI
MJ7<VU>;:CYD[D8%4O8NE<F6VS&(:+[E^_#2>_U<5%_E]&@-YXD<+I3V3+*XZ
MPA+"I/QHKC!FYM6> Y;"OAB*M5A2;B<WG>$HGPS<MGN3AN-5)[?E*.[.N-1?
MPA86S_I9)LLJOKSNL;A[33.NT_MRS=<,+/R4 7H$XCH<]GV[HE2_'?Q^<]5.
MSB2?)D?=N+=7_2VS2+S)I'NQ]C4WZ*861TD=F,+&,>MB[KQ+%3$RF)*C++&L
M<I3E'6I?XT5EY#W/(VUJZF_<[E\\*U:@DLH8*A(B5F'$N25(.P4[OM-!J60=
MHVKO,,$>O:KUPF2I)_;5/ +66_33?O_=M,)PFH;\M#WPN6JAPM-56<<5N^ZV
MA[,FP<2FZ9?R@/Q;.<^WUXO^.A^UV$.#?O;$AQPU!J-LYM.78/O%@];+.F]Y
M5;;U)&]RLNVJ\LR9\DFS"NUA),/<L#+_W59]_>&V_BS'DN,' )%"=?HEYVHP
M)3 @S76$(3<G#*%=._479W<V^WE2;%'56 QGRR4*?:H[!GZD1\K'U30H+[5P
MG!/C>:ZF)T(X0HW5BOLD;)W302<Y'93J]=2TTM%GDQ3C1D\_HJ>G%T<7;[R+
M!EM.D?$&]-0PC!QU"J60@G42;*:/%(%=+S;*BSUCF$_\+R6D.LG3/FB]Z$VR
MM@OJ7Z>"SZ=[9QF>J4\NG*%T;JU\+!?]^B;#BC],=?\)_+63.<Y$^T$E!I-N
MF],$\=*#JU<>4E7'Y&=4QL.-UU\_?;[@DM*#N^L"S*XPC!I-.%%1>XF5)#%J
M#M@8\6)^$[FQK*;1A?OJPLD3^N+)&^4HL=8%)'3N)D^40\[ KP',4>.)U(R
M+KQ8U;&A$I'AG$=R$.L2F^S=J6OI:G">IDR^'(/0=^-"X/;:C3:Y,.M3WD9R
MT=J<XF1KHO]^6G"']^MJ1SN:$>#\E:ELPVY0W'YS3YY[U+4:/:O]?<5J^=7V
M9J3^AE*_J2[.;RBKJO>&XVXWWV]:Q3?9^G+CVVNWW,R,YHQA^&S>;3=IBSZ_
M5W575)#TA[>M(5G1=^^+%]#/L )=''5UUL!,9_;M,<7+H/_5[Y26B"NM[2]L
M;)<!S1D7FZMTFZ=H^Q]E8_7)/]ULKI=+KOMXUY<LEL95O=WK:$>5!U(7>H%@
MQG*0ST7FHKV96\$;%N?5A%^6+-TZ75=7!!0$NZZ.A:N\'0]CM3D#X1V5'*<\
MB$S]2K/,DHN_@@%?U]JUB\:6HN1VU^6V_T6'A^/SG+((4CIX/TVFK';.N3_!
M(E1,\KWMC.MCB^HA=$J)S-C#8":/FPD2#F^$GGG$N5;T3W4OJ;/(:5:RX8R)
M#O_+@9N\FE-%^]/VLD\,)/SG?N\*UN/JNNO$G*@]B_"=[)9_>I8I.\#<I*O(
MW&)/&H[7^E(E;O;K.L=:0&!9)YZ1RKV3VC [I95C&!<<F'K:I[TE\D,JJV9G
MO)&WS^V;3%K=\17@<# 1QEK5IC,WZQB[O*7A-]-5H'XJ[%N9MXU+J\VLGZ.<
M)MC)T;K%E-V*]LZ:?#,%+3/2!9>6_:>$8^;<TAM+-=VZM-[K4%_'?]SY]64K
M51<BR1\+O\[D=G^DB\,L.LUW;BJNSG+O*3.ZEK%KF*J)R$:A;@=P8-H[Z'S0
M[DPQ^6/$Y]B^LR/[$9?BY]KU%X!H$6[RZDW"2[.(,A_QK$_^*#O!T*8XRCM?
M99^5ZCB7.T;;WJRW_[I=UN1<GXMRP$@!D[H-QL=*[J9?G]0VE0L[-A]HDMM1
MPU0LE-?_F>MY_GU3CD$VQC^^:0+2G0#@@DG1>E[D!'[-EOW,'GK=N EN_K]V
MY//[KMYCESH77/NY[KFW7N^JUY2EZL7] +OL9XM!U&V@ '.GW<GA;2<QOIT,
M0TP,I'^/VZU1;DBS-591&6&IBYU$)%^V.X#DPUJ^%ZIR'S(JN4'$G.E[-\',
M237&](7G,FA6MRBJN.ZT+CCF\U-O*C2N^NE7@T\E[%B[JDL6?95B [<HR)PY
M8*[S7"H:.XNV,SKSA7Z6U*WR[4FQ^__W9YWMT[VR\*8+K $53(#+FY3Y)F6^
M29EO4N8?1\H\>6PI\[=+@=]2KI/-T>%J$[0Z[&(F#V>RO55).%4H*.??S.QW
MP)/@-]OIGXXGI<>3;YU>%W]>7W_]QV&.0W7*H3CYS+DLJ^]C;QJ8KPG8SG#B
M7V:/0_V]/@YU$UQX%@5R.3F8XU]89.I^LI>P6GY8]X]J78"M!F98_R(OX*J#
M8?9+3XRZ*W$^0#0;I3DLF_,?*N)5=+ ^FZF^"D8+AE*O[5H%'.#3;VPK9!-T
M?A0Y;W-65$OY?4Y9:_W2A5N\!YC\]@!89"YWO&.GNEDZ.O7$SL1[9_,L.N_[
MI['7^CTW(_EQD'-*)CTQCL$2[=>#;_TV"@?S/;GGG3%@\(]+1EP.T98VT-DB
M+C[,<J14[B6=?35E^G)V21KD.&UEJ(,=W@Z5"DZC8>=@KN;:!7C)F#(%S5\K
MQT7UW:B.?0WBZ;A3%P;,V_/CGC_+5^14]DZME</19/7BA_/VH*HFI9C)')B?
MO!?#^_6[S3SV.H+_*PCC$*;KQW9_%/U9W:"X+K885@>WGG;ZKI2W I$LO4:F
MX8-Y00!X!A.\-_&+!# 2.OWS*>K,93%.1:/(9C7MZ/I@EFGU1_$X/&3T+A<U
M3<V<OUX^F;2LGO[M98[B7#=>6=&5I?6O2G*R9[2;I7W_!I7-U\XH;1;R%5I[
ML\:"K=,^']BK+/H372UU[JN4\^^!O>S8 :CF;S-M^NYD-MZDGL^BOW:;3C7T
MY;BWT!<[=QX;YUO$Z115"973*UL_5S+X_/5//X!D#_JNW0O7NCSSG:4/IVOV
M0_G\]24\:K$O=^L;N.K;6OA+X8L-[8YM_>O:A*R?,6/D5^&MO'=.].J_KK/)
MINWS9I9D>MK=!"RF+JT)BE2=#@HK +"P@^L:H:6N(P>MGV%SAR7[$U0UI[3_
MWO%K:N_T3=91W%IL/J*VI?]2>[00BYM-#*YR?NN&D56Y?-72^7)ZP-],'E%V
MFE['_1N#O#'(&X.\,<@?AT%.US?(\PL5VU=CCKG6E'(?. [$\!0H%3%X:Z0*
M]$UN;K)M5OR-UA:;M[8(W:#92&]E-AX# VX1-LG_/!YWZP:X\[W3<Q5"5"HH
M;I5R.!D1DZ1:$:VH7MG$;CZK\V4L]L"?,>?5@$0#><KM$\>#> */^;'3]^\>
M.EWS<I*N^1<_.OFQ>_SVIP]']+B;[_'JY.SL]<]_?7A%GW=>/,N5@/X2GK6<
MKGER^N'HYU?TZ.2GJU?T%3S[Q[,7/S]_]_KD^=M7_\!]G[T3QU>_GKTXR16%
M/UT>/7GCL'>:>X>D\A9QS1PRGD44!,?4!TUT,(LM$)2+TGIC+;:8)^FUMHIA
M(3W1GJ8@]UIQZ.UYEM3!&."@GGR@)M.P["3YLU[OJ=3NSAZN#PR^^>,5N^T"
M=K.*LZR$W?K%BTJ>CUHEK:4U@<@))N.,R'NKX.M+^D96>P@_+2'S$B7@8\.$
M9XQ83@5U4?.0/',>LT!RPG =?\YNI6(4E>ZN.4\5Q*4FVY-#JX'I5O(6(I#7
MZTK3$N&*TZ,<9@CW_DQOLU(,Z_M=D,N<%=B^NFZRFU,'JZ:QO7X=GN_F1^2G
M3LCTP)ZW*T<@,/)JM%59_&!<.J>!09D7J:+Q3TLRXT_3?,<7TV3&22[D]1VF
M'I&N?0>&QS=/7SP[ N-I5(Z"Z>?7S*\'%N(D.3![2X;71WGG7@E%_<#J*#G
MTVDK_61S L:@V*MPP_SL7/<[S +5'N; ?J??.T6Y"KY5DB#B*8#T:3\G^8)9
M6D[]S3->-S/(QLCDA?>OGW33]%>3.SX_!^/<GY5<D&PA3::^/2S=#O)3,CA,
M[-]R(#FH^.7"ZLW>#1;KNK/<T^FBYIP1V ?J$]"OC^@K]YT:7OMUKF@9[<P9
MYS-YZA/;LK0.J,9<9:N=QOXIB +8A-F]5+XTJ,6CF+_Y&[:8M==WRVGP[^N
M;G9"5$F@U?UF+,K<S;(J'ITKTH:U2JGR?H68%RJ_43W:J:8LJ4C),5]<OL4F
M:M,,V=F\FLIK-BB-)MZWX\5U4GR6S"IF/.FWEH=0I+&DHE_+X?Y$=BLWW*ST
MYL3 WF0U<]0:3-;JK/=Q4:-RRES(3JHE8_0>#O.58/9)<%H ,XF]=TIS&S3L
MR5(81;TT3-H@*,8^5,_YC&0'R(T]/1W4:34OTI^@:C"ZDPP\7S/=>?''&Y-,
MY!YC9'0^I1@GA9QT%LF$O38I")74XGKFNDNK0I)6$>Z4,,8&(P7FS%J/ UZD
M.U]T_RT!)^!%_8OB2"KT"?3?MCO#Q1RTB_Z@$X">Y+8G.4.^",7P^YVC7I0>
M4,8V[CZAZL!0M?';$OBBN!U17.\S;OCG&"R_XQP\R&!W:V;96MZY95_/S0;#
M2IO@CI>"N3?H7U0_T]MX@BJWSJ+*5]J^*334MW*QG>0*V]Q#?'26&UD!_R\N
MD=)B@>']*3/X.F?G9?O#+>=FM02:+R2 G[CT$\[K>N>J]Z*;S>=;NC2G"S5#
M).M;H'Q]GI7J'FV8T][H>R0/E-A<5LOMEO:;=J\Z]+I;=78:?KO"Q7F_^;K%
M<GWJ5K=R:VRU"F7&?0L4V<A$-!->33C9P(0W<]H(\18)\<HM3*[G_EUW_]K(
M^YI;O>\OW>ZX!X\XO;R]F&U*C)K[;-U]/D78K']W.NB/>P'5<NE]C"EMEZ2O
MSBJH2NMO(^4[_))SV6B+[[K.^^'6%K_E?]SKS7Y8C,EOPRNMT>+7D:@$L<Q8
MYS@/TK@D0X@B29I$L*3V.O,;SHE#<M$'7?N<GP_ZW=Q-*0_AG_;H[.EX"-,0
M!S]]J+LA/REQ@1A.[(?;=?Z5N^FX/GO5_=#)WSE^^TJ\^.?X[/C97Y?')W^0
MHY._SX[>/H$Q=,[@V>S5U1/RNOO'A\EWX%GCU_2O[.RFQV_?"1@+/C[YA<#W
M/QS_\]/ET;/3BQ?_/(?W#&^/GOT-8WZ>CI_BR]].?AH=O<3B^.K5A^/3-Y);
MS*1A2*5H$ _"(6NI02QIX:5.-J_H(=^7DB\U9JI,R_OH1]XIUM23^X#IXC;6
M@-0C 2GM4E!4X1AY4L9B31TVQ))@".452)$)2)$&I+8=I/ "2$6-K5(B(F:,
M1UQB@:ST!,$FY(.7TG(A,TA1H1J0:D!J*T%*>T^IQ%QRHCG!0AOEN4@\<>JU
M)^P3)^XV(+5M($470,KC1(UP#@6#@4E9XI'AFJ.4(@O4$<8"V3O4^[(!J0:D
MMA:D$N,@KM[8?)04R0>E.J&538H;7;?-)1.0:IC4UH,47P IYX C!>$1"1PC
M3B-#)@B.<& Q66=($C2#%-DJ<V]M3V$J_[>6^_)3]]ABS,HE]H->?:[LC4Y'
MNMZ[KD3I7<0TQV0^P(+(H"PW23EJJ:<",XV-$--6X)_9A=7 UNUAZ^62E\H8
M11)5$9%D!.(.?@)198@YA2E("'$2N)4TYKZ@M5KI/RNSNBU6?:WZ&Y2BR4@I
MO?#<B>R"!B6&W45%CXWC7\:[T^CO.OJ[Z, !R]<+2R0"!*:9=ACD&/9(@TT,
M]K#V.&;;B"R?2=?H[Z[K+U7:@ D1,6:&8Q.UB%&P?)J4DA'^UC@^=DRY%QT?
M.&"GG Y(6"I1+NL#FT())/)!H%PQZ7.A'MGGG#;J_>C46V77/)-<L& Y=M:E
MD+#Q-CDO@PZJ<1GLF'HON@R43IS*Q',M%$,\*HFT$ Y1#K+CG.# PK)Z*[5-
MN_==DXLVE@YUKP=LI[.A*BSKCY:=#!M[Z<?E&[[]:^_Z+F"MD]0;H82.7!BM
ML:!64Q,X,=*:+^1D:7:!#>T"[24/3*X[UE0%!*:XR2%XCHSF%A%K(X^8@G$7
M]@[%/I-L0X[C=8#R2X2^[K0S-,#XE0.C5R%:$V12./#HC;8D<D43$T%X$563
MF[1CP+CHVF+&PL+&B*+0'G%F,#*>1,2"H\' =J@LSL"(I6Z L0'&!AAK8(S>
M8RX#I9IY[HARAN:>8M*E:)+BO'$+[A@P+KH%D^,*L,\CRSW+P*B1QM(C'8@1
M/$DL##!&@O?Q_<-V#3(VR/AHD%&+$+!7AO'@>3#*V1!)2H)QE;LRNL:CNF/(
MN.A1I4%1@#^.A#8!<6,9V-*:(IP/0:=1)V+IWJ'9-TSL"C#>-4-KA[VA5>^4
M=Y>#]E7[3I6>CV0*[E8&NN[+/Y+-;.W7WO7-3!(6E"8JB,BY$41+%8F7P<%V
MEC#7C6-XIS:SRR7'< @Q4:<3DBK 9L:B0]HSCIBVGDL2HG XAP>QVE1RWM:P
M_'7&<VN6WP#CUP&,S% 1M([4"PGHESMC&Q9Y8KGZ(L74I#5N'_8M^GYS,AOE
M 'O2>HVXM0)IER3R8*=A;_]_]MZU.<X;R?/]*@R>B(W="$.-!!) ICW+"*_;
ML\=SQO;VM+OW]*N)3"!A<5JW0TEN>V(__ &HB^VB9%NJHOQ4$=%MBF05J^JY
MY ^9?^2EIDIR?I'RWF[\(M\BW\F0#[MHJ2K6$R ,JY$^Z\[&(0:-J?:E_!X9
M%G>5WP(^097BDG%Q6#,[Z36YVGNP6KRVIM,EI.P7&!<8%QA?@C&I0B@9>TD>
M<P;IR%Q0K/;"W&4)OT<&QEWAMS8M1*$ZRB4/?]%WQ^;5M4K6<RI((5S'RIB/
M!8S[-O';)Y7V",31_4MS?VL#A6,$7F9HG+TW5H_1,UFJ X")J9L!K-+<K3'M
MZYL-Y$Q"]3V)DT+F,(SPESHWUP#'ND4!,:;!M'*HM- --3VY\_:+)*B!<HP]
M8AAF&]"/-<[7V4PBQ ^4W+CL]UWL=U?#$E5F].1$:QO!6DI.3;HKB)J5)+>&
M,TWG4#DZRWZW8[\I>Z/44^VBV&N4BMPP1<VY8^GUPR@QRW[?Q7YWQ19)&"GA
M6'I3H_&%A_W6(BZ-8*+'FDNU<GX1X]ZUM\M^-V>_)5/-YJEHY9E@J=4&Q*UR
M[$#%[,,(!LM^W\5^=S4!RL&P877HXUA_@8/CT)LK;"E&PMPY7X^*V)#]WFJV
MUS[-NHXXE^H]BFN7+GPW=.'2<B7A5@;6D5(2LP9)1 I*K[VO'*JC6@-NMC<+
MN?8*%EUECB,&B_Y%'D%.K5JCZC5?Z\(A':J#RMHP6V \?C!*T 0"-6=.V'@0
MT4^_-R4OS>/+GMI+?]H4^W;U)\\S3H7D4O7#_Z7"CCVI,X$\.PLDS/[\(I>]
M^]$N\BWRG0SYC$V(M8*/@"B)$[70@^3<C89)K1RJ(\/BKJRGT@M'RJY(* Z3
M-,>YB!,?&N?A(H8R98&/@)=+N,"XP/BZVZB0-N3.K(8Y*&<@[AV&HZA(L:\<
MJB,#XZY>FHFQ!%^<"(E#X^9D%L]FSEH)S!CP.E;&O?NM;#V'ZHC5SFNS_K?+
M1]\]_O_VF9)Z[&=@KQ&J=VTMNWN-( IZCA6JEUD8YBF44 M%J0%CR!](]UW+
MU6]>KK[\YM-G7U[Z[^>2-3Y#^/*;O_W[B,J:<$FN7K?!"3$[G=X'(R7()+[&
M=GZ!<*C]O<VX\:L'SD+?^^L;:#EXTJS8YX1BHBHL30;_:LTA+65W@^C[ZK.?
MHR\%@@S6G2>X3DWJ3F-%9P5JBI;[>.S\(O#>Q0X+?0M])X.^V-OLHIU;+(I:
M$T-,57JLOAEARRLI<XOHV_'Z1'LMOC5'W,RA#^B4PQR,$C%EHN2SG%^4L)IE
M+_0M]+W.1V^4R:>H;82^U*+V#!C+W-."6)56/NL&T??UCM>G'4)+S;M. 1SF
MXAW%V%Q42QFM#Q?>SB\2[CTM9NN]#=?TV34>ZS+DZH,53D7#N/D;UZHA9I+I
MPM5L2\/;'-(^OZ'AJ2EDJ]$%Z3P"66K#FXOD:@0?;5[;N1D/=*AV)FN^W78,
M&#NGU#WWD",60<W0V: 5#L.84UA*U 8->%>)@N1K3%Y<3(5GH[;HU(]P3 )%
MZDJ6$IY?T)I/>7KVVU&&Y]DM .<1>HN4Z+&&HD"6@_HEIVS1?G?E%"_:0\@N
MU&@CIJC>24O@$I2DF54EYEGD>J@DX67 VS%@&.0.6BPJ"N:&4EE]);&08HV8
MERBP00/>%04Z2"*PY J4V64BB!,,Y$J+'<-PI3S-(;*X)0]ZZR-D7WS:-[S'
M$6=%K1&S2QQ^6[%7'5[<"+835T(IG;J!<J&$HF($2TG9W#KPQ0TE)<]LCMK-
M%3_7 >+AR 7O'85L326+<CR_2/L7-:Q]L86^DT%?J#V#+S+U1DQ4I6").'YB
MB"5'6!K4!M&WJT%%ZPK8T57IU6&/[)AJ<RE5Z)DLH\P8MJPQL0M]"WVOY?="
MN3%2@QB1N6D9#@2E#+D+4$FKT/7HN+CK$J*FEEIPT4?OQL(6'1&IFVD@';3[
M3O&Z*78JBXR+C(N,K\C8 @^[H:*AH0IRB(6YE,Z:1$-8NN@&X;>KBS)8+R3@
M0.IP"B%V)TF]*[%$;G%@T=?SBTS'G2R53ZES7WFCX?[?-AR$\1;?7M:SKQ_-
M-_OVAUN?"GOKK1+7&]RU-]AWGL<F3/0MB8H/]>KY=^-#[%-Q?@3'N5=1^>EZ
MAB?E_!5AR*5P-^E8H"G7V!IB#\UW-ER;(9MS_OYTLS1<LY7<DNL-V*'OLZF)
M!8=S+R2,FS9$.+^@O*76SP=JW;XP=!(8RC'WZJW6#F$VX"3O6^/4:O'2*/@/
MLS&QU+G#,6IWUZ)4G?)K=(%M, I+<Q0#N1@2Q:@I8TW7ZAR?X("81:F3H%2H
M07U/";1ZY)9%6U(H5K6W).4#C;E9E#H@I78]*>9Q245<SC.M9$ZR8A!R)%1Z
M&0N2Q>NF<"4>JM?$HM2BU('U_)@;SMPHSCB%8!UXXEX@]#K<*O.K<^6Q4>J&
MV#]B=/.].0A)'1K  -1 E<;>A^^,*,7/GKZ>#Y4#LLJ?;]W"/WO\X('HXZOK
M NBSJQ<V=T-VN_-5'"-,1,B:NR5!"20-4%+$/A6LF.M^@M7K2_"=?7IU)8^^
MM8?VZ-EKPOT*"1?8W@EL?[DA9$'UO5,/+M4L#@71,8.Z&*M$Z$$\3;#1WMUN
M5GG6Y@R;L09O74I.&8&)"E1M%DK%'DO94P):AOU!#7M7_?%-?<PQ.YI)"6C3
ML&NHKB<V"%!3F3FK815.GZ!AERS1LV]YCI?UI7 ,,8.)KTVRQSTS+Y=A?UC#
MWA5,K(YK&] AIS1;<T8GP.Q"RJD-EZSX.E;LM S[! V;/&;+I"EZ0.Q%%3!A
ML&!0.,.>!=7+L#^H8>]J##77(A'-!89AW=;]6+%;=TR0+".+Y3(,.^V=4'B'
M"JV/("EQ%5*OQ/'?RG\O&'-B*E2'8^=E'!N'&C.-&"V'2&N<\'$M G^[H<?T
M*J:9LRLI!X>^@F./XDJ,RIZJ4+C>M!_K_K'DE:^2FD7&#R!2UV0(PQ'NC*5D
MK26WS,R5$9/DE<YT;&3<%;1"+]U31%>H>(>UHF,)ZCR9']?9V+^8M!Z/I^)F
MD7&1\?83/67P+X0L/06$+HRUA)AM3C:(UG"E4!T=&6\H@KZ&4L152M5AL>HX
MF7<^=^S:O,869W)"A-6@8I%QD?$5&5LNE>RZ\IJ04V$4HX' UGQ0!EYI6\=&
MQEU)M4!KLTC; >;F,,\&%;U4%S E;3&W9F&2,>.A4N W.]+BB 71:[O^JSVJ
M#\;'>K\2T!,Y">]7'_JN!W\BZ]D['_:QKV=]A, #=JC0,HHD28VTM-A\!XJ=
M5V7IYI:L>K/-9A8S#^+("SL$:TY;CL,E@* ]5;68QI*5#I60MQE7?I_&"@M]
M=QQ]06HAZPGC<.5] TH@194$0L]09;79W"#Z;BB\B'.:"[N&OCBL6AW7RHX(
M((Z+6UJ?WOK^DS<7^A;Z3@=]26.D%OP4<\?_:6"N*\4(:#XT7E-RMHB^':\/
M"Z7,,.[B"N P8' R5BF'S;K/.94*>GZ!^V]M+?0M])T,^GPMF%(:-C.CWF$B
M;78U22**27I80X>WB+X;::\I0/2(KGD;P.L!G,:<7$@IZ[B64&,?Z,.]]ZX^
M%/KV[<.W3]KK$6B8^P\=_JW-$8X1::JQ8(8Y1UT0A+27%.L@&&FI6O8LMEU(
MNP6D?7NS.USSGEL*#J!4AXS%#8>\CQ\AY_$( =+4\$ZP.]R=-V /A4N4""!P
MO:DLV4(KW6L?;GS&I41MT(!WE:AAI!C(DH/@R:'7Z%12<QYK,Y\T)%^& <,R
MX-,S8$(8B^T((7P09$M*2#%*SA4*-@A+3]FB >^LP$498P)TQEK&"LQ^!!7F
M'4E@U%BQUV' R(>:2[(,>#L&/+ <LC$;8,76QL%G;YW!B&M-\0-UXUH&_$X&
MO*L*0*^]1?1N>,G!H>4^-\3%%>P(&#TG&2YT/-BTR<VG9AU@EL":.KS4X3ND
M#D-3[5RXY=K0:M7L1SA62O,Q,+2^I)3-K0-_OR&EU+&29VCLD@P?#KN@H^*[
M4[)84S"+G,\ODM^[&G9MC"WTG0SZQ'P)P[$9X2M@"< DR7HS%J5<:EPBU ;1
MMRM"M9Q:\B-H[=?3-5-3IW60L$0#E9X# 8P8-B[T+?0M]+U.@L\HIBTDZ830
M04L(G!)J]3!"QR7?;1)].UY?BJU'YN0Z6W38B!U#3,Y*#\0!??5Z?L'[#UQ?
MZ%OH.QGTI0X)&+H!*M8NQ+7(H&%D&+_$#U3/NM#W3NC;%3XQ(DL5<2RQ.QQ7
MTFG(T2FJ'RM:#H;I_(+0'POZWGFL\-%U\'OS6.%/[>FS^S8^Q=LG"AQ-H\3U
M!G?M#?8=';()PWSSBOH_'C][_/W99X^?/IS6N4\Y^1$<[%X5XZ?K%)Z4W\=8
M"40354\84-@R]QQRLA*Q^;71L3F_[S\^?T/.:,H4R;L$EAQ&7QT!CA^)8Z%J
M*6:::?![-RIY,[M^S[;N"T,G@2&??3*I/G/MV B4,/5&B'6BB58-]A8Q='-L
MC&6,W)WT'AU"\^,[%.>!QTI2U7+VYQ<Q[SV,<V%H8>B6NKJ9]%9J5>XXW*!Q
MWTK#2)P"Y?JZ1_K: -@4AG:\(9[-'DR:,S!UV#L,;RB0"Z'"H%,E;'A^0?D$
MA]PL#)T$AC#E,CP@"-5W]%+%JT2QTBCDDE67&+]!#.V*\69(DF)U8Q41AS6#
M8U-U$!L6'Z.$V8PKEU,8R;/*CU?MQ&6MK6*!Z\&^<VP"BY3>HG3VO@N&)25M
MCEI?W)"28BQ2,45GL<W1GXV<,&0GI#XBU1H1SB\"[AW#K>*GS1DPS3[_'G)B
M50PL'!6"5@!-'G$UPMND >^*,,!DE:$[\S(G 49US%Z<EHPX'D/JTX /ULY_
M&?!V##AB#F6F>G@=*W%##68^YNH+)1^Z+/EBBP:\6[4"4#E0<9!!'>;Q'9M7
M)R)-&>;@E;F94W 9\,D9<(_$?<Z0\)8PM4 M)99D)8G&_KH!R K\MV3 NX&_
MIQA*2N)2F/T8H58W_*GDH&D 5?&^E5E^O'<6WATJ/SZ"3+Y57KRRK7^S5$(Y
MM8+D&0E#3.2E58$<*!8KJU/;!CG_Y0VI1,";"<ZI:32^Z("]!E_=S)W2$3-7
M$3Z_R+QJ[%:AR4+?ZRUVHH$YRCEWG7JB9BA EJ'UB!K3$IDVB+Y=D2DB])J2
MN<!UN+@E1B<8FH,>:^\H$*.>7R3:.T9=Z%OH.QGT,=;6FOF I2-&98WH)>96
MJ@06OZ;I'AT7=Q.Q&3N0;ZZ4V3HP*#@A @>BOH<<PS47X:,8#Y4#N<BXR'@"
M9*RJ.:&8!4)MQI0LL+4@.+W#LJ;I'AL9=T51:3&,2QE=14:'R:,;%YT&'JO/
M*8:4P$\R^GPT8VK>-UGJB"7-:[O^E^??V3B AV>?/7[PP*XOT:U7*6_X=+Q?
ME>2:$W\W5K9DK*BUQ1H1&U81DEJE6LQ,Q$OIW=[B]:>;<W5;'QY[$-?YNIM:
MSTYG14$/U"$E#Y9M+%YXJ([@FW'J]^DQL-!WQ]%7+/<B(-"A(86HN9309A,N
M+J4:+Z5W@^C;57I-&Z6.PV57KPY)NU,V=%/]-8_!L)>!/CY4/O!"WT+?\:-O
MMADT2P2US@8;GENP0;V4*#5O<362W"3Z=N?J)BP<>0X2C^RPAN)DSF131.7
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M'W$75G"S$[.&!@*JYQ?CJBX#/CD#CCF0^3G;@AM*K00D*8 I=2G<VU)/MFC
M.PMP\I(M:1XWT1P5X"DY2B CGB@U2DUUA(K#@'DUW3X] PX2$9IHK*2S0>0(
M)B,-GXMR,$!L2Q#8H '?:/D92_1FR?4*?9:?@!/@,M.O!X[[;*$>SR\&?3=D
MP*OEY^&-?[7\7"U.WB;\-@J%?1#2@A%92QF(UPIBT V64K(]SO_]AE(2*U#J
ME1SE8@Y;"VX$6,DQ UM/FH+5.1WEUI7?K6UUW<INUT+?::"O4"EJD:#WA&:F
MUE48<L*:U.H2F;:(OAO%U9E:H<HC/,U^N+@H3JR"*U7'BN:9M<^Y,N%0X^P6
M^A;ZCA]]U%(&K9QCS',8I&)H-:ABY%RTUR7/;1%]NUT]LW7)M3H=#I[#2ME1
MBM[E1+FA:,F*([K'O>6YA;Z%OI-!GT^56ZF^ B?L*"/\Q1!::4T+&*Y91EM$
MWZZP"<6@>V,GD,H(>&-Q+!V<<DFHK?>&UUGLMUZT\WMG.QVQ*/FBLE*O[,%W
M/[Q79>FIG(+5_'+U GGK<J7>LW''6K6BB*H7[02Q=U!67OKLUI:K<?PW]%E?
M@W%0<L0H#GL2Q[ZR2XUZ%=_'^A7/+X .-3MS,Y[Z:H.TT/?^'> 8F'P54IT#
M1YOV9!5*!<N50O9+G]T@^FZ,9+*48T)VV6".9!)QX]8&5T,A@P9YW+%3GSU4
M"L)"WT+?\:,O9RXY0VZ=.B9#\2%&$VTA@W3EI<]N$7V[C46,$Z5F@W4A#J\/
MS(D,_R^IC[G,+J;(YQ<Q[#V-;J%OH>]DT)>LUS9BW0:U(UK6(I;(.&/CF:"T
M]-D-HN]&XBE13IB*"VC>866=I1_)<9<6U)M@2C/Q=.]=^=7\\LX\<UV"W_V9
M=[+YY9^>/[A\\FPUOUS-+U?+D)_%J!$A>8 :+6-B3[U8C42M@RKG-99K>X[:
MEZ]W)K[\YM-_C/<,,W6\I]DA*3$,3\V$'9M%UU0SA&!2&4:0>NL3TS>50+0Z
M)"W<W8A+26*ASA0M8.!,A10E@7 U*EH_S&[$3V<!]\OOK;G_M*O'"X/OB,%7
MNQ0#@]^/8_O/?\_0.832'(PXU6%,S=% GVNY@,B(,FNOYX-Y%"!\LEBX6'BG
M61AS\E6#>&X>$PYW;QB,0,T94AK>Q-J>V"+S=K8G0DH1P, U+NIPX,\)0W$Y
M#3<>?3!.Y?P"]VZOM&BW:'?4M&M(5%,-/0Z/KW$=WEYH+<D(G7#\&S[,CL3R
M_ Y"P=V=BJH&U:0Y3-5&_(MAQK_5L?<QM-0\(!Z7XW?P5/)C$"F_?G;?KLZ^
MLN=7CY_62WM4[592RH_A5-Q./ODI+F/O=LS'OHR%[D5(>J\QC!6-57*L&'!.
M]9!FN/3:S2U7?[J123ZCKA%[)==*G^F4H3H181> "2P/AUYG.B7>>B;YIA**
M#I]-M'!W[+@#:+%6C9I31JVB'+EW]:$D0HL?2*]=N'LGW-UH(5MKT:3%><S#
M1<?@G71N+E!MG"U"+C)PEV\]CVCA;N%NT[BC"-QU?"T]8_)>AE?G*6.4-M 6
M9$FR6\3=;D>/V*#'F2>I/-,FQW?*L\"=K6=/L>4^,\;AUF>&+]PMW&T:=TBY
MY3#[&Z:$:?R#L=?BQ_=SW%=?[8FWB+M=[36A'\YX$U>D!8=DV9'@\.Z&LTY2
M>"99?) "F=^U<?$A>A,?@2RY_\"B-QSKR;1;9_ "N26HK6.VS**A S#/[KR]
MVA+G-L>SO]P0YX*8EE;0J6]IN&^>G8AO+LE8GU!Q+$1Z?G&HT;J_P[;Y7M,2
M3ME\I28SKY$C(C8)I+$9UZJ)D.1#)0<N\WTG\]T5FQ@,L%3O @LYG/5JXFV$
M8*TFU&Q>9KWNH?)AEOENQWRCP>S0XQ$A8M= <_ZIJ04M'I+@$D^V:+X[JZ]B
MRD9@KGLQAV&LOAQ&2)%BY])[IHK]_(*7^9Z<^8)U*YD[Z0!X& 8[2!U;X)02
M025=8L &S7=7#/ MINRM.8!<'38(3BMY-R>2:.TEH [SW5OY/*#Y[IEH]>+%
MWE"O?GN3C [Y ;8I-;S'I*-#GY23U),/<%J.?96QB""1JOCDD4-4+3)6F] X
MBR7/2Z+9W"KSMYLSI7N%2!1=FU]PJC-:35P2LC8"^))2.+^ M/>DI%M [0?<
MA#OLVK30N]"[7\_^&*E;]%:[8IR#2A(CY:PQMSF7=,EK&T3OKKQ6FH:0R9Q4
M"1.].GS[5)T7@DY88%S @=YRJ&G""[T+O0N]>^>5J72?#:%*Q5R%V/<^(G)M
MYGUHMJ31+:)WQ^O--<-8-Z,#'KXN$N7A]19TU#R:3U:377<B/7 :[4+O0N]"
M[WNCM\>(O>6>JS7,$1AL3C;J-9=(P=N2M3>(WAN=4)')]QI<;K-@BU(:_N_@
M;^UBB3MT/SNAQG@R7N^U*OZ'9Z(/[.+5,7WU?-Q>E_7%S_,>OWST_#H3;/RF
M77YW\4_CRZLC>VDM"8<Y/7G\]'(^[>,K>S">_YU]\H_+]NS^*U/ZR5^]/%[_
MXY^(CF-[_NSM?_)0KKZ]?'1])M(UN*\_\X\O>'V>QLE]($^>VL>OOOGD55_,
MRT?7QGW]1Y^\?*V7GV*\W.XYNCZ'+Q[^\0/=\R\^U,L]A)?O_/+A>]</[5SV
M%X]QO$>)W_JPOP=O?>R77C;>8WS[7_[T57]EY^,=MP@>7K;VP'Y^<7;ON4-!
M&N 5I:]?Z>/+9^/I]3=P>SJW9__\^.KA&7CWIU=6>>#/]/(3E#=^@K/_<_;J
M;2\??GOV]*K^]W-1_>ZUW_WOWX9[WU[V\S-Y\.QM#_W<R,8[?_\^]V[V3[X_
M_\,KX_T%C^NP=T*UF4-ZL%O!_^JM\.8+,?.17T+YQ^/_.?9>_/XG7^]?_7A*
MOC6G5R9_=]+'X7PL#_XA/SR=I_.G<!I7Y*<D?!O$WF(G%_^D5_/Z_.QC[I+V
MYQ>>QKO\!(ETC<0=7+]P ;*O50NA- J8<^(2:N:8I:7@?6UO^SM$ 2FM9RF
M6A*S-,[)8Q2IOOEC0G (]T*,!T=P*/<XE(._+(P_3&]_^)=>]I<?0\;;^+#X
MGN?@=_FPQW5FXSNM\#?7BVM'Z1=9_QLR$W[UJ7Q^=O7X'[M93;^PFKQ8&FXW
MP*/?M$Q_<__*[.SA>-[]IV?VJ%F[9O&_/']D9]%_]!O:TISRV?GSY?>_\=R\
M^0[D#W0#_LI3#^L O[X0/UF<7[Z$F\^_EA:N7^-RG+-'SSYV^5YY$;-\P$OW
M7R\?O0A)QTL^&(OZT__V!C=H[]/]OKE'V[G%I\_]6YI/'2K+ZQ1.&!P"BR=V
M3M9-M-=-]$9$YSU:@_[*J?CP@ON;3\3G/]C99W+U?OWOWN4<[%.ONMY@O<&[
MNU5O%;TW999OU@__]?G#RV_ET1_^ISSJCZ^>[=.=\@B.=J\>E*>[MWE2VY-B
M#*1%2K>*YCL1-N72,'K &MO*A][<]N2W-_*A"35RJ>9J:>!P7$BGL;"+&1(T
M!@3-YQ?Y4.G0OT-NQ_NF9RP*'06%\KA3FYH)>$+/Q-=9PA$-)-16<*4&;Y!"
MNZG!0+[&!.S&PL$.@<EQKNB@R)R4+2R)SB]*6!1:%-HDA8P&6\;_R)>(@9.T
MFC+4IEXP _B5);M%"NW6AB4*X^IEQQ',8=8X"Q34259)39/XFLXOX&!9L@M#
M"T.'Q5 Q:"38T_"&D(,J:H-@0;'ZC$8K8W2#&-K-&-5<?)6NCHK.-D21'25M
MCB+T[GVN/<TZJ7BH)K"K]^'J??C["DFQ="L8NGC&;,+64Y3HO9"F3+"$I,U1
MZ^\WA"3#')%D8"IS&LX3FN,*V941AH]+IX1:1PBWMY"TVB]MSGX]!6W:BPHG
M;)(T2X[#='L?MX0VOR28#=KOK@0334(#KR[&*#/X:4['Q7+8QM754FJ/<=CO
MWK'/LM_-V>\(;D.K@"DR8]) ;=AOJ58#>93$2[S8HOWNEOA:)I$1,%";]EM8
MG#)XA\S*.2DKV!P,MG<O]67 FS-@GU.C6-B@5@2=A1F]A 0F9@KU PVH70;\
M3@9\H_^AM=RA%I=;:0YC#(X35!<#<D=K'*[5Q[2E_L,''S6[=^K1N[S!-@6#
MO3L8WM&& 7>@(4 A]=U7"WYV0V4OV$O&HLI"UD&64+(USG_SZ0VA!)K%FG&X
M9P7#G.PUOALWEJM<-;)JE=2GO'O@#H1;Z[5R*[U4%OI.%7UUYO)8'AZ2^H$^
MD]A229I VG":?%H:TP;1=T-CT@PA<G*)TQQ>;>186G),R(WFN*\XFZ_BWCWZ
M%_H6^DX&?6*M:!(P-4'JGF.3,!S!'M@4M2QY;HOHV_'ZBE(VJ^(*Y(&^FK,C
MK\61]MBTYD!)SB_"_OMC"WT+?2>#OC;<!1\S8VF,K%%#P3F*R]L(E'Q<4UZW
MB+Y=89.\5^B!G%8= 6\LR4GVP14+'BE2CJ$.]/&ALKL_3(>[]TAV.F)1\MIP
M/WWPY+[,&L;/'C_46<QXZR7&&SX9[U?A^*X'?R(+USL?]K$O7#Y7:25 0/!H
M%"46@EA+%6R)7LX#74KMEA:NSV\HM4(!L!NXU 4<]CFP(,7J<AT7,A2Q&-KY
MQ<$VY#;CLN_3'V"1[XZ3+VKQ5;VE6@!+*MPE)/,L57L.#$NHW2#Y=H7:[G,R
M8'8,11SZ0HY](]=KCX$4"EX+M7YOEWVA;Z'O9-!7..>B//P\*]A34U.KL1N7
M3"'UOH3:+:)OQ^D+U0]'KT7'F(O#*-FI:G%>J9 T+%5A%H$NKV^A;Z'O-?IR
M&W_#N9,$[+4JQ03 5'K(-;,LH7:#Z-L5:K.:Y*C)E9:'UV<3@B$VEU)LXHEZ
MTCC01T?C]>W;3FZ?#-0CD##WKTK]K=T!CA%IOH6&PUNS-+RYX@N;EL(<53-T
ME;@DO,TA[8N;$AY;+%;!88'N$- <22JN:Q4O@7(C?WZQJ5+Z0[/JKMIO 3#U
M*:+-=H0>U-(,Q"RGE$,S74+4!NUW5XBJ& FML\N:DD.:]EN')?M$9B35^R[G
M%WB"[0GOO/VJU0##3KM:1*A-&HC4,GY1 @BOJM1-VN_.^MM%J3!$-V!,(Z30
MZF9-HFN2:\NQ2\1T?E'2LM^3L]]AKXR9:N<6,6L@)F^^2/ M3W%T20(;M-]=
M20 C^-I\GM5)XF:6OM/JFRO%"-!'RL&&_6[)?[[5[*Q;;X>_3;G@/6I2E_)[
M-Y1?2%T[A19BC^A#D]JZ'XM][9D5<=6D;@_S7]Z028H(QTKH2'QW./O^4+/D
M0D[(82S:D=KYQ?X9NFO/:Y'O9,@7.Q3(%DH2CQ!$4A)33#IBU%SCRG3:(OEV
M!:9@%CLU<%4E.NQ8'-<BKH'&4HN-V#7/DM2%OH6^A;[7VEQ'WQHTSR%B\H53
M,,BE 1;VF&QI<UM$WVZF$PY/W6)U46#$]K$')Y7-%>K$@<I8T_Q '^]=C;_0
MM]!W,NB+F4(ME7NEAA8+E4'"W,+P_L:)D+QDS0VB;U?6;!"U0XR. E>'J8SO
M6C4'25,J%EJ+Y?PB[#_V;.N93D>L25X;[K_9TV?R]/)& >9=.@=[S=J\:^O5
MG6NA0%%2UVH!,\\&6FR,G<N 7!S_3VGILYM;K_YT0Y_%4H/(6*^XA.Q0?'$L
M*,[7TC(-]T.,9V]8.)86"JM[S$+?[6<@A#G4-D@+!5"R"1":-$DVBU1ES:78
M(OIV!=HTXBH0G%XZS[[VT3OBSDZE@5(@ J+SBPA'TSUFH6^A[P,4+Y@@IU8+
M9BQ"7+GZDK2/'QE%ED"[1?3M>'T:RLR?4U<2>H<]!Z>,Z#J5) D+^IIG\4)>
MZ%OH6^A[M3<%PK,LH#7T6,'+W)7JTHTZ-E-< NT&T7=#H*7F4T!SS6@$O VZ
M8QI?(B9,OBL'/[R^5(ZF4_0:D+H&I+XWT@(IBH(*%L)<8/AS(YIM99;90U2_
M-+S-(>TO-S0\+^9]ZMDII#KG.YEC&S_&X>5--3:;G]7U:\#BZ=DO08F:_?3@
M#7W)$O/X30X5(&:.:WC%%NUW5XA2$;0@Y#C,L>R9U)$'=$!AQ&*2O;8YEGWO
M4K9EOYNS7Y^&%RHF+(EQMO7RPP&-!7*+Y EHJ2E;M-]=-27E/@A,KF /<T J
MN]G2PT6OU7(*D+&=7X2]2]F6_6[.?BF*Q02APXC_,WBI$A'9&J0V(DU8DL &
M[7=7$DC(F.9\U*EL.Y0VJY5J<A53\)S:<*IH8_:[QJ,>WO;7>-2E_+X%\QT0
M0K-2)]Y#Z<)H*9 &44W>5BGJ]C#_MYNI3B,DEA"RB^;#RXY=I-5E2%$JM91B
M'6%6/E3+@;7IM=!W_.@;P2?'**(Y$;92)2DU[7Y\&6?'XU*8-HB^787)5"-
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MM;$YM&R "W[OSP6RQP! *;&*"X%$M8 OSY'E.YCP%)@6ODH;>^Y,P>/<?4
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M()4;>D,D*)UE668,K4L)XJ^QJ$B&:;.(C<N50!9P.6)B'GHX*&3G I]U/:$
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MC;)&?>WL*_#PV$'R-!IC( X)VZY#W\I(; C_:([ \]@8%J8\&>WLR\V'U]K
M=H??J3!/R9!6-EQMRJ;."5<*0*;S?:&.P2JW'(%H?_P 4)8X89@<F/ULE8S2
MQX@'9S>*2!!_-^^_WE[52%A&4A)3Z0+AT++*M,U5Z4@XVE%&_FU/Z6@^*Q^E
M0A=-RY]2YC)M#@)B/$S:"I$BJB:CCA6/5%;6>5+$;I"L8#<2R-$DE)E(GCR
M0$G) Y>!?NB(G;U=!XP-F\N\I>S7RUT88DVS42E[!L_"4E7A$J".%#T\9;.$
M-Y8UW"?%B2&U+Z0VA,Y@O#<@;A-Q,4I]5!GAE+JO;%F5\9F,J?UVL0RI@>&\
M6TAM"Y]-$UEF#)6-+:TM>A1/55'2(J6^IC3>/JE,T9P0>70?Y%/9#E^$;?GN
M^3?>;2^9[[!B%DU0[,*7[S"(%15T^:+$[7NJV1.7;Y8ECU1I*I3*M)Q!^&<X
M,P<:;%L7^#M8P&J57V_>OFL;5]5__GDF A-/RX%<%W.+X@YV5/-,V=9X/&N.
M?SQ8>*IK,9>%8GS0,F881L!L"G^&;LHAQ@[LD$HBHJ-5OFL*M*.REC9%*X;G
MOPD8$<J''W.L&JH2)Q)!"SPM19FX>."64KY1 \%('RJT> I@IJI\1ZIV-6(%
M+Q42>&2G65B1DXP2,S:^5DM'KKB\(^AIZ+#&4N#N$&#U0]B[0#$*1Z'BH"RA
MQQ!Q)K54^-R$;\+I\Z#-RU8JE BXG@V\\!Z6CV7 "P0$2%</5(FV=3T=MTB\
M/%LVC!C!;O34,7QSA,7-J0#*LCAY9/PGXL"XN88@6F#7HKP9!]'VG*(Y&/%:
MR5;'IF6K6G])9YEMJ8-@_L(/\%SG\PRWQ)OD:C[$,Y0FB%7>)D>+2_PJ'-1C
M+GZ^T\[DWZ_7M::DQN1Z\ZGIG&.>I"IN&"M*%'E=4Y:B7 04'_'J:F?O0_>=
M.UJ<7[YO_KA\WZB_KFW>>7@VRAJ&-NPL>S&;3]V9J4<CQJT6:7FRZKXZR$1%
M<1-OPPNI.(BLI)JHM:U\,E94$C0Z=D1I_7C;/TU8+=6W0+TKOL>6U7['H4>>
M&W4<<_GTJ&XCIXERFBBGB7*::!G31+N<)LI:PR[GHJ( V4H4$46IC77>M'?G
MTLQ3,ERVIB#/P]"=8H4N)7BO/E]^NKW2;O[Q\=S $_Y8T6G=\E5F[YJ4K\GH
MRZKV 8K_, Q,1Z#).;#HI/J8U/C &H#^H5HA67Z4]I-4&T9BAF=%5+W=,1[>
M'2ZD*H!E5U""1C$=?S4W2,4S$Y:U*K$SPD"A#7I_H 4/F EJT9E[I>33:928
M1%'P9YG@.9Q:H%JHX4^$L[2\OTCRQH'/\OJ!+^(Z 56T</X9 @:P ,<E)O=2
MPAE;.B^;(;@Q6>:?7[]=O;^Z_4W[]NGCNZN/'R^T_[DD9=^:T161>4(M?UQO
M@/ &L]ZF[AG+C'$JD4)M$B9DVC>,2MKM[]R;+U>,XV-G$BZ=Q+)A[69'L?\H
M.3H698GR?52N%%91.[OX]>;<:!OM7F=+(&-BFP,0-J827"6..=XDZM"4<E\^
M<\KZFV<N8)UX9Q;1Y:P6)]YCYDBVA[Y?/Z1D_ANN& D9A[FG(!TY;!ZIG+(R
M)NJ9LE^E+!^*NJ*ZFS*-RNP_?@;OOX>V-0\XQ/*".>V/S+](*'V^_?3K[=7=
MG;+A$/5JN2+3;TX=Q!YO@"B$,K,FLK+R4K]:/P 1Y6,FZD'*DT/)BE8)%4[J
M:N@8WI3228$9W):JWQ&..:YL)9,\82LZG,5\=+?#L\PU@E;$7!6VS#3HXF4]
M=G+<RK+^=G&QGA+Y>%7=^12$Z!"S"U:%YOIJKCMG\(1#Y(D9NZ&WO&-D+F3;
M/2HY5TDY>?'NW;?S?MO@I)U<DW82\-U<.V>-247+H)V-P0HQO8$U<N?FS_#!
M%O<N_KW% INYZ/,;V]AH>%GM<W."F?;9]+Y;#LBIO^504>K%3;:KA= N0=&M
MXK;\AAW=RB%TUL-XQ18Z#;W=3'5P+E):OUW?_OKI<=0A4;^>JM=&_A1R"*[E
MBCY80W$^,BU,Q5\M# A7TXIKAMYH_R6AU499>?Y@X<XMD[1<ZN$=:;G1^R)=
M]0E_/W/R'3AY!@4SAW4M$A=^ICDJ'C^B?#2T>CPQQ5Y TA,Q#.,C,.OEK),E
MP*/:UC6PM#8WUKF0'4EOA6Q-[U "@FS):]3/_Q4+0DJRD^V.WXNA;"[5-*CE
M\1/.=<ZTX4P;SK3A3)L"9]KTTF?:C';O[F&TX^X>!<[/0;9I-([?5>3J[NO'
M+W?:IP_:I\]7MQ=?KC_=W&5NI&+T2M!(Y09TREOTB86B2%7GG^V5D'"[DBJE
M&J]3GTB?NE'([AF@'7O45\\38TRT4#=*!Z#L219?Z @\G"UIH9FQ1QD4#E0V
M8@T%-! 8#;;%'DY-9R+D"[#( /9VDGV!4.NYMT:4#P37JZJTJA&EN@T;8ZZ\
MT??#F30KS"!^2SRZU==17A$6:I-?CN(&G\M!4YDZV4($_5B6.UHV:!A@S\-[
M[%$4F3IX#N?7BXO/\0S()[IYH%NI7(N+S)&W':Z2L2P\6!:UQMS])=CL++D^
MZA78"TJ1-ZF.VB(0LIL)CHSRI-SQ1A4ST16*: 3('9M#:IE*S>I,>X$5;;;<
MO;&]5$WU+<,$==F[)F$FPE6$@;@K'I[LD"M"!2P<JL:WJQG07-U^[57!%TNQ
MTNB;#;C3V$TS3/=;J]_*78OMZ#VCPV/-?:Q]O<EC/7$,E&FL9<( C+713F-Y
MK]MQ4A%_V@:KHP66>$>62_NO-,]]D'\W=K'RI+!;ETY2,.6ED_9V,I^_4.*=
M;$XEO5)D[9!#L5FOQ:)]/^J4B2*?A8>#D9X[J>/E1(6R8N3.^L$(28&0+=S(
M.!(W2G?I!E JI9M\&?- \UW;&FD1-4NQ0A=J<90A1H"-K#'Y"YED3V$W*UU.
MEM:Q9;U";>U90C.L&=8%IO7.L-Y#!]TQ#A"385MXO+\>'>_HW79^7L[="'<V
M0A^-APY$24%XM(VNIM<;X@-[\X+R PV#43OPQ[UW:94(9AQ?H%2)?(RW8^'M
MF92 QZU=AD,AQN.W6:F626PTZGJC?5S1L3F;X*MC83#L+E@1KL])B_V(N [A
MW%:FKJ5=GR-2^J=U0.<W[;?K8?0BS-<P:BVC+O61@TT=?TU) H8UPWH?6-=K
MO7KKA&$=OZ"1HTS="/'"K'E;[Q1OP8\X_[_LHKPRR!ADY0(9"^@J"NB&4>NV
M>\7;2@QKAO4^L*[7VFW6.T],)>@7;\$KK1(PR$X<9*F]QZHQ>&4=Q-<8$W#4
MT>0]',1K=,JT\3;0NMA[JUDSNLV4NVLSH XJED]U;=IM7IM"KDT]M2\DGY4I
MO&YSDFCH,AH8#3&I.K5FAV5J4=>F9;!,+>;:G-7UWFOFH(P$L/A?AG^6QZA?
M]7"HP\V/G1RGF3)VDSAZGUO&V'XTSA@"V7]A*QDBR8$LA60*1JO6[J5E?0=@
M!4<,L?"VXFUU\&W5K/7;^\403GM;90@Z'6B+%093+3VM&5D 0!7>VF$0']<;
MHAL,XE*!F!4<5G VE=FL&8T2;F7>5KRMBKRM.K5^A^T&5KERM1M*Z-\Y:96+
M0;PA/M-E$*<+[JS6.^<F#JEJ/G(3AZQXY28.R4W&31R>AL*66B?]]$T<"MR.
MH4B%_\? 9=T'*I-/S'@D M.R_?6N0P^N9X\>L$1\LJK\FVB^I6'D1EMO=[)5
M&C[08U^B,'2C4YX"\64::[O9*\E8NWH]XU,9 ]49:YGP:M0;:33E=;WK6$77
M3Z/V-M=GY_KLSU&$Z[/G4I^]53S&E5?-Z]R3AHNSV$_5Q'Z^^/BA2,;+5/(J
M\2>P%+QC2K%,^Q:@?RS6.CM3D0O4;XE*[DBWW>MC5QC(Z0J.'XZ+G!+!=RE8
M7A2"\]KQ9CG!S;(QT/Q(-.=[G/.(=+V>S4('7C%9%*W9!#^'G\//.='G9#U]
M7RB.NSF-YQ_AS/+,?7(J2S#)S2UB]IAKVN,!U<WP+WZ2?JO6Z62L.OP":?:,
ML#(BK-'.F.]<((2E26,O3R9Z/VM/BK(FDS,:& VLWYR0].G5.A60/HRP(B/,
MJ( &74V)UM$S-J@\<8G&:*@$&O9M=K&+NS#OAAE')-;FUA=[S/4TRLMV^FF+
M.G )Z".I(D;:*C:\,L=9F3.CR=6Y&0H$A:[>9"0P$E[]8M1:K08S[(*N3;?+
MPK28:W-F]/0.LU"&@M2KC).!PIY]+O;/#<JC56C!/ &RF(@;9/0 <"/OW%W^
M)2][V<[0OZQ*?;P9U=5$=;W3.V%4IXF(5*9,90$7O/!J.(,L94R.0<9:)\OG
MO?U5]5H]=5RN2@*:85U%6/=K_>9^G:+*C>H3U B,/:NCLT; ('N6R T&60YY
M8B5V^\HJ?]\7GO6GM4^XI>PDV/_P9QI"[*RTI:5N192VU-,N)',Q:O5NQA3!
MPBAMC&I&]9H[M)/6$*D2IM.D#U1$1^P;J?N['F'%"V^),,H89<5&&<OG*LIG
MH];KI#W?524)S:BN)JKKK;15&:J$ZA/4"+K=U#%QU@@898RRETBMSB-[N@1N
MXOV/2I]DQ0&CFS$3F"N#'#Q?)F.R#*_,H?VL_=0.D9*7Z6 X/*6G-/67V:D,
MAR*2JME,>V*:^?:14FKJO#+%7)E.*VNV$[/0"L*AVSLU!>N@^6W[%$DK<?;8
MGN>F.=+!D8[U2$>CG;$:3B4B'8SJ*J*ZTTU;&[A*F#[!N$JOG=I?4>6X"J/L
M,"CKZ6DC"XPREL\LGQ]YK6I&G[5.1G6U4 VV5*N V1VL$1S0J]=.[>1EC8!1
MECYKC*V;_;/&2NSW)2K<6LZ]^\?!"Q44F *Y-<WE8C=<[";JE&IDC* 71F=C
M3#.FU^SK?L:>HI7 =)H$@HIHB,V^GK$;8B4U1$89HZP:*&/Y7$7YW&UPK7K&
M=+4PW6YES&^L!*9/41MH<CE'UCD99<7V?:M 0!YYTR5P$'-SZ6R1ZU[&&CXO
M$)H^K97I5:A5Z7XLIC!+\M=)\!;^TNO:85M&,KE.=]LWFQD3V(NX[RNU,D:K
M0J*260R3ZTAY-3DTNI6TVO".$J>U<"-<=L/F7,B'TUD8T]7"=+-;P':5[/0]
M9->'U ?MJNST990=A,B=.H<66.=D^9Q'N?1V 7<2HYI1O8]XZ'%"RTGI ^UV
MUA)MK \PRE)46BZ@AZ98"2V=*A7QZVZDPC_$S S@%1-KJ'UR\&63Q<N=I>87
M\ OX!?P"?D%A7[!OKYQ"R,(M69NS@1?>PR#R*"==X'GF5KX@JR.BNKZ&XKL3
M>IWR5^IG?!477T:MWN?N2L6T^<\:AMYY?2J%_QD*# 66.Z<C=[K-C-5F"B1W
M&&'%15@#-)N,"6 %0EA%Q9G1U1LLSA@*IP8%/HC])+$N7=LV!ZY'1[$U3]P+
M)\SH\SK)8V:-7L9.$T4\9E:QE:G0D>Q*K4Q=;[_(RA1>'6$T,!I.' UMYMI%
M79EVVJ1+7IDCK8R>UJ_'')314!DT%+T<0@E27[G<0>'=_R4_I&/4C%9:/;]*
MQW08U=5$=9,/GYW6L2",GABIHR>5/!+$"&.$E1]A+)FK*)D;M:9QRL6(&-75
M1'6GE3%WO!*H/DEMH*&W61M@A#'""NA*3G-*M,!R])MPAC8,*]O!SHH08?]3
MG_L<2LZ-NA51V%)/NY#LI='.F!Y8&'6-,<V87L-TZJ:85<)TFJ2!BBB(1C-U
M.^$CK'CAS1!&&:.LV"AC^5Q%^=Q*'9*NDGQF3%<2TZVTP9PJ8?H$M8%NUE,A
MK PPR!ADQ\RCSB-5N@3NX?U;5I]DM8%&N_SE]"JZ,@:O3#%7QNAG;7!05MG#
M<'AJH_:S=EEC.%00#JU^QAY.S+</O#+-K#U=>64.S4([^LM4IF,66D12-3M9
M.TJ6%0X'S6S+H<$"]XSG* A'09XK[5 OH+^2,<V8WL>::9XRID\PZ&)T4O=5
MK'+4A5%V&(//8)2QSLGR>>_Y]KNGG'G#F*XBIGNM^@EC^@2U = Y"VAE5%H;
M.$&4@<Y9P,SK8KF<G^H87[JRF9L[QE\(/Y@*&,5>K6.+49V47\ OX!?P"_@%
MN;]@W\94A9" F_6 =V[@_M N77^&8C"/TNT%GFQN94.R^B"JZV8HOB>AE;H<
MVV9@OV13#,97<?'5[+Q,,X<\\97&$U B8[^1M5Q!6>UYA@/#@;6;4Y(^O4[Y
MF[$QOHJ+KTZ76\H55)SU4A\Y8W'&<*@.'+@8 A=#., ^:J4UY_F X+%B]R]S
M/I!7YMG<G8:>L>5%664/P^$I./13)W8S'*H+AU8WK=N-^?:10A?]M$FVO#)'
MRU/,V(J766@5X=#E8@C%*H90@M17+G90>/]_R0_I=/H%/++!F&9,[U/ HU?
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M,8++@F#6:UBOV92+M5\V_VGK-;RG>$]MJDK$M@)K6ODFO*5H_5P ,)VTHL4
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MZNDM#J0PP@Z*L#HCC.4RR^4]2MX::7MB5$DN,Z:KB.E.G77-T]($FH;>94V
M$790A+&N>?@RF@66HI^"J?"TJX70+DU/<!MH;@-=#)TM];0+R6-.NT@B8[J2
MF&YR,::3*I73US,F-U=24620,<@J 3*6SE64SHU.V@/159+.C.E*8KI50-G
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M!L,96X&NKOZ;KTVD/I8<^B91:N0D2XDC VE"FQ"T?(?: 2,QDZKR2"D0CG@
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M/3QJ:*,.Y08"QMZXJ*G!X;OP>;8P8:*N+88A7'?W_OK<,'HU[6%J@2)H^=I
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MKZ"X5F9'-) XDU<>4LS4R!@'VX3AC-P0DWMS*3'";^ WG,(;LGH!RF#HWX@
M#U# 5P[8^K+#E&:[_E[%Z;+*T@J+RQ)(Q*Q!K1?0Y!A@9028D3$;@ '& -MI
M3MV,;D4&& -LM_JJ:>M(YPBPK*D=52BE+(^O[AV+2DF1?8*K%2J<9M3:S8SU
MTXM4=)47/Q/'JW7::=UDO/@56?QN.ZU)R$M?D:5OU!J= C/]4M6NW)A,<Y@J
ME/@GS!7&KHU"006L5)U&$^B)I2A'8A!H ].F6DAKE9Y&PA9T&2Q/WJ5-#D;=
MQ[KALL"++'"U4I)2NCBQ I@V-BU/P^)15-]E"&^">6,M'/C3MT9"5;6T+7.
MU5ZP#B:5RM([VD!5C5E=.K5DN((_]3K&RB'U^-)GUI9N;NC='5[1T-4.7;_T
MF=I26.TJR^0M_W'I4M/W58G5P)I)\,X 3=8<B^;0REC./ S\9&DO"5EW()^\
MP)O]<$@5U:C<V-02]WC=LB3;SXE*1\O"9S5M9/E#X$"!!J/%S_AD^!&V ([1
MG-%O\,QQ2!61L)1/7(?,C.JJP5!&(59OP\'+,0.@OXO@?""W)\S8]7P=BS^F
MVJ=R/,JGOHJWN( =W#,%,"."XW'??5]XUI^6&N[(L^X%%5_R \^%1T7#TWQ
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MK<LWHCK\X'J@PZOMHQ2J6K0YU->8W#8,UK\%,%N8_A(\NAZTSW\G;Y!5?(#
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ML!)<E,R9]'RP&4)OF? 0:7?+ZEWS$*S=H385&,9"K8-\(S <,0=\SZPAV4?
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MUW+,D4 :;;#),_9[+1F0SP9J=2]@,.9$*+IXUE %J#^;H#_1E_-HQ6FEY7=
M4/D=4G67]JF5H]\PN3ODGW)W2 *YXP3-U.Y %-*/$HJ*SG$!5_K)]"/R>T&T
MSZ(+U1$ENNXB*B^M?J1RE_+-:F4^RPJSV]L*Y;TX^_*U7?3J%V0A([5@OYD_
MK%DX>\P0X^6]P+S0'[+F)WWQ'G5,==4WTP[%Z^TL=&5G1?P*HTG1VU4)[_\G
MU#?OQ!I/BVX?15@$$SV!$O5J+]KQ:RC)Q CW;.55WHZY%W//LC5#E2H\U^3G
M*"$FAXY>SY.FX&V=&KU:K][/UDPR#3R.T<TT3[@FHQ8YK4A';^^P)!OBHSBA
M\Z:^P;S%@#D^ +LWOMZ91^1.P.+ ^2>CT]";_5T:83.*LJ#HA%@C99@UWIX0
M;]RE7WN5>4>MV6_6ND:KUC>Z!V<A^VEH)>JIC'V[EBH8?E)'L+,I8.7KX-MK
MIE6P=NWBFR.?R :HZ@FX_6A4'-#]9+0-O;]]BS$6]E-VRL>&LNDS+\^*]G-[
M%8?^.>@73U$FJY.G#"H$G6-:ZA KQYKV\>*4:/?V>QF]-"]@;)R\X-B/1L4!
MW4]&JZ-W>_O80B>/A6JQH;V<(B_(BO9Q;91DJ^;EO<C50:%<(<O$3FWDAICO
M%5&B]#$FBC#OHH3D1HF"LPA0S#K-[M,<(D]4Y,E&CHG6ZHFZ(Q"R.##_R>@8
M>J>^"Z=E5.6D0)T*"]U)RZHT#]U%7SL%'I.7R^@ J[+Y@$::,P!;CUI%+SQ'
M#O>FT2 6DCRY<2Z_._+)#>,%"LVLDL)HZ7TZ#77MQ(W=ED45H][OR;[SKCS+
M[\Z%$Q5E5A4,DE755;9BU/=^6;%#EH%7SZ72%]:RVF?\PY.OBXHQJW(IU!7
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M=AAIL.4<TFP:_OA$/!;U-!M-L]$RXS4Y;$T6KZ9S$CX\,@!C!(T#!N\PF=U
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M(4,'0U+%FX1/TUQ(*';#S!8F?03&R$/B+#6?XF%,!@'#;JAN[+(I7(-\09
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M]SO'F\0%'EVWR3L0BQLC? L@BQZ-PPOL>2/!,6*56FC&.6& +$NT4=?S()D
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M+<R/#MRLU'&N_&JB[YYJW<H.#P,RQX2;9D^,A%U;+FM42S K(;Z[O+\&"^A
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M)(E2/ &,6L.\)D*4 ALPG#C)D>21:FN#IQE<$P[= VQ(=7)-R5-3074]Z,M
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M XOW@AM25J$^6RHII3Y;WOLOOZ'%[]#OOH9+!"I%#HK$9-'GL#81&ZE!4IM
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MQ7*;'<7->+XC'_ AQ*FHC(9NWKO9?/$:G:U97X+W J:0QWLY97=_X?XNU Z
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M /&46>TKTWT4Y];<_3_&9*=,\LO)@BR46H)T,>KW]O>_X:)'\>[#'M2[N'>
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MQM4V#S'7]%X-,J#A02<EFX]PZ@1T_YO=X+JT.60Q/%5-YX=]!?=2)#]]N:A
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M' U&2.3)>"7:=)]X0BT6=^)OEQ:+NPB_P2W:AK9OP<4<D\_@A2R@%*M)Q#P
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M&F[JV=WG'\E9W%.P S9 JFA^"V?XNGR%:15PZ !J\)-X(YS]G\1]>9JV$O+
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M)NPBZP8:<./XNCRC9+)>,BFA%#H.5:'5DBEK(.LBHI76.LV;D'\'R@'&7P_
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M%G0[_!G-V"[/_/;BO7Z*;Q_IZXN82)JE\11"[,JSE05#0P*E+,O.A$QL[B6
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M@H:!A8-' " B86(A8U/BL.,248FKZYBLX7&XN 8G9^(34--QRG^#-#7S2VB
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MP8%8L,,\5C_94X/@S_EJBTX($F7/\]4Q29]3D!*%1H1$672<R%X:6QL[-D'
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MXW"[3R ]A='!%!C!G>!5>R-461UL6"K(JD-/T_[;/!&F(; E/,LT[^HBVK\
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M1?=TMRM,=UQO%U.<3Q&J3YK]8I$:U?MZ.C$Q."N%*%F3\22JN+MR7>OPJTG
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M8URRXP7+:?T!*-45*5!UZA#F(4<W(GIZ:S0\>2GZB=-K1G$4$_K@*6037IV
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M2\ !>I;(H:Q8\37MKPM!59&Y3_W4%$4&Q'IN!1), !0%404$ #M02P,$%
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M;_Z^SNOG18R]5- $P2Q6U]43XL/4HR&,TX +%/ $9YZ-X^I2A_/T7RVW4NM
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M&H!I/2R88<#P&%#HN*"/S+,[>"OI@18?;.67EJ6N_"M H\(02AX O 5OCSL
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M@%0"2HY\!%RJH6-;LGQ%5(K:I1Q1 0JZ;%,C6V[UK8;+](C3,?I3'7.V8BO
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M>9'4C$,A.Y6K<7![@Z^WDOO[4MRW[K9/XJM8K:7MV07(,B*-P2@F,,M"!E&
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M0\ZCV$\)R4CF&6]+C_<Q-YIH%F8I)NCDM-A G8#18-]Y/3B3&"Q]7(;L,$\
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M19B=R>J4 !L5]%U7#:\!DPM.R;X FZWT%H<MMZDQ.)2.#OC8]JS'6@?8E09
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MG+Y8Q3\FF%@SN_;*\S2-:=P%;A=@_WKW3ZDHV->TO?#5090]71=@JRW0ZB[
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M'&IB,S2D[K$A&7S:S12T 8BWRD))"],%\76$XN.V626/8Q21*(",)JH54YA
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M!8FC&"*1Y1"+)(%1A#/*J"HAL6HI;3JPE>68H-&TBDT_=&*"[JH#4"FH[9'
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MU0A0GZVA&F,LMPU&;U6?JO;:<]VTFU;/<8I9G G!Y>07<I]($8$XY$@>JKG
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M2^2F. ,T9BF <:9$+#3)B%-6]>6FID8:]MQJL34UNC>V]C@ ? Y7-^H(@];
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M:&">V,+3&#C :DLG!$%9X71+HY)!I[//.:#[XMXUU+^WI_M%+!F!W!8Z3B7
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MF!A9&ST2.4] UTT\ 0 9F%D.L>B3W7H"%(]TUNO F5+^ZC,DF\, 9:C,U?-
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M#GV8Z@)@G2Q][M[QN/>"]0>,>NG:OO+^K912HU+!E"0J%B#),P9PFD- 6:J
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M^A2C[0&\Q_&>83M@_)+?C][?0*@S.OV1[#R=T^.QXYW+Z>_SP8F<*Q[3LUS
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MVOV^*.PW94;)M>LIL#U\NOFJG]<#D\[WC^^_O7L;??UV^^W=U^NIX]C'CFS
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M&A[YE*P[%,?G9#WN[5T06]GZVO/W"ZE^_A_U-),PPSGB N1"FK _M:G,7'/
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M_4GO\=G9XHC%0KU?JX=RII69=R5FYD5X$INX"QO^H6;ZQ8F2A,4,99E7?FI
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M>FK$WUC>;@O69PNK#']/F7MW\-T(>AA(!R;>%LUW^V@V>?F-^&%M^1!B]]Z
MA=6Z=V]^7*E[;UB.E.[]GQ#BB./31_77FSDK'LK?BKF2'S?5QY-+GF ,.8@9
MLIN@.@5480)PK*'*I1(Q<\J<]VAS:I156V777Q[9RLHXVGR'.?NKW!3KZ%6Q
M:.H/5?%-=5[ZEVL.19[N!C<."PSNP.3U[+CDTTUD#(YJBZ/*9/.;RNBACD]V
M(C3@6<K3[;[@P<I.(+I/67;?ZD=,Y6H]^V+#M=N?13F#&D.1ZP30W)Z<3)0
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MZ<!^PNSI"_IFRR[%G_?+N;FCM+4.UT\?S81Q^W(E2$/%I0(RQ11@F<6 LIR
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M20-S<V-S]&';-];L>BFSQME8'EG3Z]\%S+?P12ML(H9SZ^-F:/B"<I2ZX?V
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M1$+6,C*597SJS=_ ^!JW$K*)XK<!UTY:Z!!*&P%-!,8814% 'D.=WI3!92&
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MX*KH %Y?Z<[)J6#I3'>1Q=KG2$ 0+@ 3-D073,Z-1G/M!)/&CO$@,-E+I!U
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MD'FDO''#C""P.V8S2$9^H%)"47QI$W"7,#.T*KHV-<M/DC5NNFAX& VG@PX
M=;>4<<,%+\P[] A!,4;!!&G=^4#!!'VQ%%\(@6VF7#],S[BYHN$A-(#4.\#.
M%G6(&\:,\MX+%T%K5B_(B:?@F0+GN,T8>.&-ICUN3>*XA:(-C%03W70 NH=+
M<JYX83FH0&<XXX%.\Y1JHWA&X8CRKO#(,38R6T]1-6[%Z/#0&DP#':#I:SC[
M"YGC-_3M<A)%)OQ["5&&"$IJ#2[PVB @40R!(?A&MNH^+9U<W0Z8)-I/S!T
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M>X"J0\W6N\6\3%?K^Z"L"M?&%S 4?(&RM%N\8N1J&&&X8M8GWJ;WU#4-G=3
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M"C@T)^,6K78-_5%!T\&F^3E,9U7J;V<?PAF^+6MF-R&*SDQH%6ME>:D]:66
MH"09 2&B\R9HXUP3_#]!U+BEL%U#>2A5CCKOM%Z<UK8/57"_D&Q.UKJMNW3Q
M&6^*'S=W!>_"E_4/)CPD)S,%U*[4R2C9FOI<T-6[<!TR4YCNCC^]?SN\]^KC
MUL%V"<OC:+(#$[K>9U=R7PMY$TA/<D'%4T20T1A0G'MP@?@*:$1A/EKFVO1
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MR\:0/#AEZ?P45M(7[DTA++O2IF[R3_7F<UB0'>%1YRYJ[_%19V36*D&V7YI
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MR*C:\Z\.JC$\15EUP.YL@ATO_)\EX4]4PK,39.9'UU^O**US@E-5^@D9DO7
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M 5+T$)ET("Q3P@>3R>-[V7;P^LKGD277?=8O[WRBY%)$PR!+1QO'2D.^B Y
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M+W'Q&:^SR3P[FR495Q.Y)L"3O$)@"-Y*+-)X'5D;?WH;ZGJI1#NBES.$GCK
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MJ7L^O.P[@-#]LWS#!XIDN-(:,C)#047)X")IW&;F:>/)$G.;<^\QBL8]\-J
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M;?,DK 4W6^T&^W)WPUB*[PG\WW_Y/IQ5_^[#*>+JY\7\XA/Q?LT7=[2KM5-
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M]^8ABL9%SA#:?A) 1XB^ PAM&<#\8K'AZ<8EV+3Y*BTU2Q@@>%/7P/,(@9L
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M8,$Y&UV;^W=0-CJ.+([$V:ZYYJ,HO7/$WW-L]I. *'37)>,!,4E0B0R,E[9
M\@&M<;6ZODT5T_"\=%QXWA[[9U!_!P?@SK/DS@/_Z^R'6]QB_O%J3G?P6_QC
MR<4OL^GR\^*"9Y2,Z0A)R;IESTN(&@-D*[D0,3O&V@P#&H;^CJO\A@'Z"&KN
M -RWN]N.9+E.[](EHPHH($?B5=4YVB%4OY%%FU60#AN-PAR&_HZ?PH<!]PAJ
M'GO!PNW6NYTL+V=Q#Y9S]":[Y$%$NJ(44Q9BTAED%O0#1R_2G7K6!U8O#$-/
MQX]/IR%U+)UU8(-OI+IE\]WTU@QX8HBY%$P=<1M%XG2I, F>F0)!Q,!#TJ&4
M-KG^)TGK.!4RC.4<5CD=H(W<]WK*\$=<__OU]-:\NLW$;I+:Z^GM.^/[X9V<
M>&8H,"BHTQ+K"3/@/=9!=MY8ZQ,OL<V3_1#4]S+YLN%M?V85#P;K4884WON%
M,\P@?/ [SSAB<#^^SS%!L"AA(@5.@)K3A5U\ .>1TX_>,&-YS(VVRK:<('C]
MV>MMFB^FW^]J78D\OYN2.T,A)WDQ] ?>SJ;S[8\_A,5DL4[#!XHH0PF)&) "
M%(\,@E<9E.&:>Z%C4KFM>$YEH>/Y?X=@[\%'N;.JN LG8IOVNRZ69=IK$4T&
MK2+6C6D%G.")Y$C^MG$BYT9)W?NT=(*V\X+BG@]PDH:ZP]A+<E$^S>:3?Z[T
MN&TV*C$SD>H$G12)(_*/O+,,.)UE;Y,V*-O$14_3-G;+X&G:?Q1,)ZNB W#]
M,IOBMU_"_&^X_.EJFJ]W70N514P,Z&R1D+2BR\#&"#'XF+,QTJ5&ZZ-VTM,3
MB$[7^MV%4:>KH ,@75O['[YM;/MJ1]$<_WY5GQ%61T\:KQ%K\7Y>66]3FVJY
M@5)$LB4$*5V;33U[$#?N V8?=^70.NP)EKL8VI2CB>QBT"&",9Y.FJ23%J+V
MH+/!X&TA;AM7[3U,7"<NW%" > AP VFG4\ MKL_MQK8CDU(8\D%,R#55:B0$
M8P+PZ#-'&3&;-@,G]Z&N$\@-!8D]('>2?GK"W _?;K*7$YP349^_O<'?\7+=
M1"*8"RD'\":6.E&*@R_!0Y'>D,0<2M,F,MV/OG$K*[J[@8?29$_XO'WF[O.W
M'7Q6-+G3%)M%+B4Q1VZT\QE!"^ZB,%BL:#,YZ2 R.[&2 ^)D'T,YB-)Z0N3K
MZ=>KY6(E,;X=3"RM1%,]&*X-Q7*E5BXI"26FQ$SQ*HG&6>;[1'6"MN&A\!#H
M3M1+IQ 3VVXGYDIV3H./ED1D@@"G)0/K YU(SJ/-C=]Y[A/520 \"L2.T4NG
M$)-;%];[DD-MJ$OH05E'PO*VFGY30O8BIG ^B,D>^M'&A=@Q>ND 8H\NN]'>
M2*ZU %$,Q6'&*HC*<LB*VVRY<5ZWR>>=O+^J60UK'V'$8%KK"H$[=E*4PK(O
M*('YVIC'?("8"2_.B9(]JV6Z;1(ISW0]U4&Z/V0]U2&*Z !4=[8B;1G:KD7*
M)N0D"D@4B6RT)&:*D9"R5DYB%#PV6N3Y&%F]P.I4[3^^H.H$5?2 JP',_YOK
MVD>O<Q!:%_(5ZJA'9<@=53$ SZI$QG,LL7'";@@VQBW5[^-"'@\7'1R*-<\[
MBL^N:\^4C.@=)RAFK'OHD@0OK ,CF2@>"V.VS3J()TGK)/%R?MC,6NJP U#6
MMAH25_W7J[]?T=5V^5TX>,/@A0ZJ<+0%3%84"<:L26P603@??/9*"=TF'[TW
MB>."=&!H[!@^-;R>.@#@3571;F[0J"S(/V?!6Y)93! -"C#6>PP80LFM2_J.
MAEJS+&%;J VHD0[P]>+W,+FLC@LYV'6SP<=Z*ZPNCCJJ]>:G"^]JAPU:T PC
M*)\81$<BTYF;(#"KB&UZEO>E<-RT85O,-=%2!^BKMGKY[8;^GWY_.UF/%%BN
MG92T_N$"I?26:XKHO$-068O*EP(=34S.:(.-GD+VI7#<?&);]#714@?HN]W/
M=Y.XV#C1RVMI7H2HN%?1@8VB+B_F GQR$3C]Z)@W(JHVH]_W)'#<T+GU;3N\
MCCJ W@TKMWI-[_!W(="*DDL"$5F=9XX%7+7H#+,)RDA#O]DX;?TP=>.VLK<%
MW>#:Z0!Q#TKLHC G4^V8UC8'4$ES("^!N,FZ%,NM4JQ-_O!!DL9M.6_LR@VB
MA^,!-5N&RV'VI-SDF!Z3E5 E2N])5M)Y4$4K" $-<.V53#KKZ-I$J/O1UTD]
MR^B9NP;:[,#H[?8>;O%ZVX40PA3-6 :IO $5Z&@[XS4$%476=!Q%:/.>=PB5
M(Z]Q:8"2O1R^ 536 1R?\"NV3'Z[B#%;.K((TJ5:D1LU>"0VO4]>9I>4:E1<
MNB^%XYK-,\"PB:HZ@. /5PNZ+Q:+E[,O<;+>)%[?TNDR(;G3?RTFI+K-#)4M
MBUY*.F5)04)#<LP^45@O+4DTHS(.O5!MKO CB!TW"W@&8+968!=+.!Z7XX5B
M,?@L!>35&/]4UX8E4V?Y*R]]R1YEF[[SQ^D:-P=X!NP-J);! IA19F!]G'R:
MKN8T3Y?KLMW?IK.XP/GO-4>_+N<]PU2L Z@XXYRL8V4S].2L]5?]UQ71,5EN
M*AW+;/YE?2"WQ\%IE;7W 7P,ME[?"&0M%3A+SJ26CFG5YEGK,#I[J#BK?W]%
MU*^8/D\G?[_"3<E3RLQP;QG8R!TH';#NO4@@HY!&,6Z]:V..6W+524G/\"AN
M470V"#1&](X7\^7%AUI7NEYD*Z33UDJP)FN**J6AJ#)Z*"6K$CQB9GM%7_2I
MM[!,/]W%\7=?VPG@1D?![%25]("C35TREQP%"@T<61U!X!@XG0U$D8N461@7
M]K*,^R-IS"+P$U1V5^E'R&]DM?\W3CY]7F)^07%0N&9 F\B<,!*T"JF.2V3D
M;7-5]]=9X93V3LC! +"3A)&A<(PB9T-*=618_#*93KY<?=D0'I'B(28]T-D@
M0VBB L\P@,F2;G#O#<>]MIKL!8?OOGJ<A-U0,#A>BF.K/_QQBW"3,_.,3*)4
M-?8VR8)#P8"YZ+3.:##N52.\G_IO?_4X:;'!U'^T%#O(N-[J(UXY\]<C)IUE
M46?K(*@L0#D2A%-6@'%2>.>CB;I-.\-#%#W_M]!!/=!!%=@I$#>=>58DSC))
M)EM!G-0>/1\*AVB906'0:]OFZ?-AFL8-AX;1^1Y .D(!'4*I)H%G5]/5H^W&
M2KL8I8I: 5<D+54*^6B8+<B,R1KM,V\T;/AIVOJ#UC$H> )<)ZID['U4[^>S
MN'F^FI7WX5OEJ\SFOTT#B1=_Q_S+Y!(7R]D4MY-P5VN,8@CD39C: ^SHOX)A
M@#PK7K0LIMR)M1]8/77P5X][;PZ,IS-(OU-L?9A]"Y?5V8C?7D_S9@GGUG,-
MJKB(A>R\K>M= H? :[]Y]E$&U(Y<T5/ ]<AWC_NB?49T#27_#N#UOYB6F/\'
MP_R:P>U!J6-P;4(*>J*B@^*17(E$T9#717'&C2UWD\L/(^GAKQGW*;H1: :2
M:@?X>!3^K_Y(EU>Y1CA?O\YG9&QO3L.6W6"M#8X7"F>J%YJ")<:=!!4LMR4G
MY+X,8HZ>IF7<YI,QS-/ ^NG G6\4>K^YJ4QF,7**C "]##5E4Q<4,'(_210N
MDX*L:K3-N3%GG<RJZRUETA6@.CA@1Q3MW;5L%R'$I%U6X$MM.JF];BX'4Z^X
MA,)&0[KJI0KS+O%_RK?M(]%X>CWG2=!XWLLG?YV'Z8*(7LS*6IFS^2U=OIXN
M9[/YNZOEK*Q+SV9E^?G6JL[KX9WM:_.&)?2,Y7L-)7R.W9C<:/2^O@NI0$<A
M(WE>NDC(/ >9BZ%?;O.H<I;=F+=._G]/EI_O5U:2#9N1EB\G*WQ\^,Z$K=1Y
MK=ZWN+P66K9HM2+[P9SCH"*+$*S*0&&4*E*9K!O-QVS,6"?7SJDXW6?F_EAP
MZ,"Y:B&.:N?6!N["^<1%J'T3H::>ZK3OD*4#B5PD^@V94J,QGTWYZN1L] #A
M,QRO(_'T)SU=Y#^\*UMQB."2\&3^,&503DIP7M,_&#IM0C"A--ZCT8:Q3HHI
M_D7.U[&(^M,<L.O@<*>ZE&?D5%!LZ$VH+H<G33GZ41C+?$U4BNPZ/F2/,M?)
M0>O3R1L.%L_XI-P7PJWK6%)P7W@)$)0F:U%K>6(F'3G!O1$D!^,:IZ8'Y.;/
MX-0-"-F!CM1@^/E3G:';5ZXU$HV1'E)@=?J:UA X$N2+$SD65HQIG'49DIU.
M;I0__2DZ%D$]':/'7Q)6JK@GF._E\C)<IJO+M0IGEY<_S>;_"/-\@5B*9\J#
M$26"2A0P>M01N)9(_JT7)37>@MZ*M4[>3)LY;%U HJ<S<J"A6#Q@R=8CGU!&
MPR0SD&R=WZYD!"]=@A*U%LR6$-/Y]KZ>S$XG#EL?D!WHHAD./T<?HJ\XG\SR
MQV68+WO,$?P<)M,WLP6YL;62J18PO0KS*?VQQ84IP3OE!"BL2].33Q""BY R
M,L8$T\FVF75\-A8[\>[^5$>N+<X./X9^?0RG^"DL-W^VLR/X$9?+R_5RT0M#
M+JZ*PH#/L:XD*08<%E)@4#&47')LM""S'4^=^'C_"H?L6"2=>JI^[=Q1-"B5
MEQ+!^%@7L=$)<)X[T/1?05J9@NGK5)WN*+;?5_NG.E##X>=$1_'5]/8=-4IA
M'4D %[\MZ%C/-K_TZV=<%;C_,?E"Q_WZ+RS>E5V?>8:2NJ%(/&,Q71.IGJ.,
M3KKL='$*;(V-E!06O*IC0VU.6NA<>&X\TJUE&=W)2SZY,+Z$.O8_60VJ& '!
M:@.&"R=D)"?6]]O/T--XNU.QUZ+QX' 5]Y1L^^%V>?BZ4F(UC:N8K#)=9$(S
M$FJ4#AQG"")'GM%B#JV653].6"<X/"]<'@+M +KK"8HWA[NV2;SX4L<1++;=
M>9I'I@-%_5I2I))B!N)"0"XE1:<CMEKHM@]UG8!R"#@\!+6A=-,!WM[/YBO5
MW.R%V,'E=G280TS<!I#)97+JI0"7BX.D(F>A2.%]FZDD!Q#9"?H&0\CL/.KJ
M (DOPWS^C>Z%#_B5F,2\%MK#[*'T@B0H(#&L^Q(S71_%.BC!!,51F<+:E.4=
M2&@G*?-6B&RIM@Y0^6JQ7 6;%&(^?>)8HD.F.0+W-2\?1 */F4/V7&IROY-M
MM%#Z$"H[R2ZWPF,SA74 QEO.S?VNP54MT,K'R1F3QV#!&:=K.9"#&$B0F@>A
MG#72A38["?>CKQ.#V$O4,I0F>\+G+==[<9^_S2DG]T1)% YXJ)-HO<W@A6+@
M2B[*\JQ3:YCN0V8G#N6 .-GC 6 8I?6$R/43QDIB?#MU33LLT2;@6$AH61@(
MWDL0T4?#E94!V]S6CQ#5"=J&A\)#H#M1+YU"3&QGK5OA;$QT)P@1-B612F6P
MS"OZ=6&S.,N"G-M$=7+]C@*Q8_32*<3D]K0$@2R%7-=V\CJ\C4$PWM2]8:((
M1W=!HSWGCQ#528@Q"L2.T4M/$!MDF7)U.")R";FN2U1BY9EP!L59ZUF009B]
M-G>,\L3WYL\SGVS 0.7LN'@&NS1O6H(R=\6'!!'K3A7B!:)W=.*9C"5XQG6*
M3? ^X)[VKM\)CX30<7O:#]%F!Z;[X^?9?$D?]^5'C+?6>[N,4EKCP&I7%XK2
MW1/KECM5?/$Z9L%YF[;"W?0\B]WK!VE^-K@:QAZN^V8V_?3KA@,ZA2_#UTG=
M%TM'%-_%R\FG=>'?2SJ7N#/%?^$UD[J8 B:Y" KK&+VZT]8PJU5 9\K=E6T/
MC-8]E9)GL6+]&+2=7T^CWL,'L+N+3Z=D4MQ'<(SG6M+M(=35GD5AD<JK(+,9
M$(_' G'LE>J-@7BJ9IZ!)WBA3&+,EM4,=3+NM>^U+M0"[6R,V2ETC6HC_@1;
MU4^Y=0=4RV!;U4]X;?[[U:HIA5S?%4NU$']6FP!"GES6N:!TUB;3&M3=.-6K
ME],+'9B.B7C4H=0IM@[!<?104&"06GOCVI2$'4UR)WG(T8.2\^C\>4\N?CF;
M)OJ]]2CGQ:Q\F"S^=H:FB<>^]HR-$'MS?X[FAL@4UK4QD!VCBYNI BZB!>^4
M,,IJH5/CU%Z#YH;O)%S%NYWBKX(Q:*#PVFS+;02?4@!>1(D2O>&Y3=WW;GHZ
M2>.<BHI[%62G"[^#+,P]+G[X]@-.T^<O8?ZW=>5Q3G0/: <FYMJDYS*XH U8
M'GFR6 R9[O. Z0YEX\)J".T_!:A35-$EM+;<;-ZP"OD700H-Z)"#DG5CCI8<
MC+;DXAJ+6,YDI^Y0UAFT3L+!DR [02D=@.Q%6FV\K&V].%EU_6X>,A47(;/H
M(/OH*3KC""%D UZEP#$6P4N;"_\ABGH#U2EZGS500@=@^A@ND9CX':=7^!:7
M&R:$2LR(E" +6^H*50K&R54@)@0/W@J?&[4M[21GW/BS*8Q.%W\'&-IAO:\7
M23/A;)(8 %'6C!%SX%(I@$EE'3&2Q]FH]^-AHCK#4Q,WZB@%](BE6ZL.C2<G
MP#EBH- 94X[LJZO#,ZU&X3SQP76;M_M'B.KMBCM2\4\&>L=IH0- _8RS3_/P
M]?,DW6-JNU25BSKG)%7[32=/.F*H3F=ASCN)$FVV;2Z[)TGK#%S'@F#64B,=
M0.S]?):OTO(A;I**66IR 8T7Y!$*68=HVSJ%F"OG$^,9VUR!C]/5VRTX#+@&
MU,6(R%K,EUM.WLT_XOSW25H;=6%3\KD(L*5Z"<EH\$%DL%9RQ56T)>XUL(:^
MX!:.Z*>[&'J(@G%?R0?TG081<1\0J6]B&PZV?9D"O10H&216YXQ3X$DX=X1S
MX5ER3)L0]YH*=PA.[I,QSOTUC&;OP^1$,8]=,O8?O_WR^L.+;9;"$N/.9\B*
M1U ^*'!8-PA9IYUDZ$.X@X\'RFUN?^KHZCY50[,AQ#6R3?@E_.]L_O)JL9Q]
MH<];1P),)\TB<<[J<G:N$SCF$ Q3W A?$JJ]\H)[&8/[WS]N9<O 5\:)XAT9
M'&_#%WQ7ON-A>TZRLQB-!<S5YU+*T#DA>20=O5*NN.2&<RP>)&,\"W*J7F=#
M"WGLZ^+]?#)-DZ_A\K>/UV+9.M$V9Y=% 8MU<ITO&;RB\ Q+=%PHDTW9[_)X
M^#O& \) VIL-+\H.(MU[QO3-=6$59\:S8 (4X0PHNE;!FVB!4;A%EZ?0Q,YY
MDG-O#NH*T\_@XAE8_&.;EK=7%?OORJYS04XZ3TPF.@*!:U H,P7_@@$7.L>Z
M(DE%MY=Q>>Q;.DNL':G&60N9]FAEWN.\_D+XA/PB:;1:$QMF];Z:M8>H70&>
MN,;,HV6^S2+=QZCJ+)=V&IX&5\/SKFBM'1/TZR^)Z,GRIY VE<=G*&I]XIO/
M6-=ZB S.4=J:R"\R-KNZ\:$N, L%0A3UW3UJCXS^'\\V5G6PTM8JY!L];+P%
MQDO47 +WA;P%1@?.\Y! %Q90**X"MBGIV4%,QT6MA^#AKID[5>P=7)C?L[ *
M7BE0"8Q[!.]CK@5S&J)4I&DT3,>Z?<*> SCC5ZV>K-Y'X7*PK+M#2XUWMP-6
MC @*78 <R3E4(2-$)NI:^2B*912HLC8SD!ZBJ"?D'*[I1X%SI-C'#MT^XG0R
MF[^=+>GRO\+JU;Q8RK\HS3:^X2:M$82U,1@/25F2D_/U@"D!'FUP)D?OF7S*
M2SK@^WK"R;&*G;65\MC ^>ER1@J9?OH0EEC[D-_,PK1N2$Z?D5C\)7PC+O5V
M(),)1BB2&Q,^UR[3 K&$.H(XLA HP/"2[X6> [YTW AN> BUDO>SP!&%@*O
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M0FT(_72 N=W9G0]8_8S)]-/6*\!\RU/X,KN:+OE%4%HFP1"\I&!;,8*,M^@
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MF'^[^.WC!8]*A%JHY(VC8+=D"X%Y#=D%E:0-6OO'MNXL,/WET^SW_WOSB6N
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M"$G*1I)D-V:;,4JE(XKW*9PX)T$(E,'")= [A2 %X +B(6" FN"K7K 2R*<
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M$6/B!D9*-!#B%5Q@NS1#P!BSH$#),92_86>FKAUFH@C-WNZ_R(<Q]MNP\'P
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MEEPW1W^:4CWO)/J(!=RG>.&QY'SBPX,@G]@$?=$#_E N\(LL]K00PW)$#$(
M1G/G.B&8"E\#PG,]+P(-TNPIF:B@W>K5FUV6/5N,<FV$7NI*%2[BVVMX.J!B
MLA9"@<2@O8=X$-Q.,;R-:@#%T$.VH31#MC+@8#.=0J$;OFBP+#,#]207L+-7
M1[+A(YK[Z*B@,L\$V\?* ,,<#>PW+ A!NZ&(/I94I_ITV* *7M4=U4UP#WR>
M4WF^H38O-%8ZZ/FU[F?5E1F)>-&2^7Q"@6*+D7Q4=Y\0$=[#U \NUXD67F^<
MN[7E&U$R?Z]RG):]H.APG:D8^3Z(\+J>C?C,8\&;5+<490SQ&5,!1.+EX-<!
M@PB!\Z1?82VME,*EBJF1#.G=7M5@QG[$HJ9B&K!T $M"Z WFJGA=L+R4@T)]
MWO#[&S:T&_4OB:\4K712Q,VMW *?GAO-SY\U^?^5N7O<6,!V$RA-$P'*!<+3
MCN F1&+3;EJ=G8>;AU$GO$27IFC'USW@1 * $7M=%JN>X#!XYW!S>ZO;<X')
M,-1$6ZG91VR3TSA(4%]5]3HJO9D<D.L:PN;T]<US0TP3VM"4<V64&/(#:T>S
MYS[@KF2T?6MBK3N@G99,.*@1"T 2I0L^9O-.=04U^'X,,6<)/'+&>?A\^9V'
M1^]/SM[ _Y?1T=F;Z,WIQ?'YV>7IV:]'9\<GRRY._CY2B0R$=J @ %V%MM_H
M*E 6[$&2'&.GD%2B.X[59%3]<N[G'G,'(*0H?>\+0F"R "%M'[NXG-H,1(2P
MQ)FM/=-:>0(5$\NL@^%,>Y:ZL@&#63*"BL)$&F*9)MHKYMBI,-F7H4^GR><8
M6B^TL8&\0<[_*+QX;]OV$E;,M,;P+Q-/?UN)7/9;>I*]="B5JTUDU5/2GV><
M1$5#LWU# PU <V)V#WV'-.?P"="<=Y<G'\^.+D^B#T=_$.TY?QN]/3E9T>"%
MPQEY66%6%M:.9PG)6'\YD!(KT,\R!1OO[3\%8 U(K]N]:&=K^^"A?9YMK%:8
MKU!IZVS:2S9U<R;;79A21%*@336M)2@UF\N:E/I#ZHH],V'HT(MMKW4KY[!F
MOWMU8])4$+ 6IE%Q8>BLI5FUC5#@K7<\(ZD)TA#4;<)K>MYPZ<U7:QM=[&XU
M]EFO1W$06+E6ZE1;/?58%RH:J++!'X6O'?2]+F(>T-!+?O6N)M6IJCL-NIT=
M;&F^K%T*EZ&#HS-P(6>3::&U*N=!"'./R.A#4?Z)9$>'5FT+5)G(-]FDL06#
M-';@?5(4MM5!>#H,Y)^60"N=F=#8))K:^E4S.*W%0LM2A#[5/O97(+ 57D!O
M6VMY+F&%P6(FH-@4AO B=G2]$G)-:,-DT/_.%%CS<]DJ(5!>+2Q=AW-:E,8Q
MPU%7872QB2A&[N%54Z3P(]=(\&%;]7?6LEB+$>9\::BV%[U$V=2L*+ )N*:(
M0PFH+Q+,>^#N:W&4 '=(O!8<:$-"SE&*SY):QU,POG%1N:USYC*N*^QQ'W"C
MG:CC'7![BTZ$N;TNZ_-IQIU&];;<P5:"TL-FB!60"<YG;51>:J-RI;P@1>%X
MJ58:]SVC(-*^0T#-P$YFR($HO.*BZJ[&SGZWLX<,NW,THPK24_9(';:'&UQZ
MDC#)<I:R:C^\(C,XT,UI[JQ@.N'7-IRA"$^3S!$(^[;+K*@)L;[\*DQE%FZ6
MZ:C_AUQN7(K/?FT#=^NI*R4,-]_^7'6PI@('VAM5'['QX0Y<7<)6BD1WZC$O
MZJ.Q[K-[B1S+&\$WN_)EPW5IDI[+86)L-6568I"#Y:,(?(ZU&)Y)0H ?PA<T
M[&T0<@+FX#>7<YZ"1^61S=S18XQLOCJU9OVLFDWO[;=YB$/MC6T$^,I)$T7T
M198BS#HWN,WIJ2A&T*#HLNF+0A6;=V@)_/W$J?I0'J8VSX=SSHZ>D^;<=/'[
MRPO-9.3U\F1G:!@O-BNP.^O\'@%ZGS9(ME?3I$,U'-G7C&8(Z;MDLAXZ&S=(
MWTIZNHX)\7"NRL"* @([*U8L.6<IU0HG\5[[ :T2;Y?F![B0!F-,+]@O3"U<
M&O7)E_4[G!'+Y8+;FXJHL%&R[AY@! S%+\L6FWAR1=Y:IXZ\/?UX<=F+.!"Q
M9X(X0TMHH%^J(H@GM?;A,&N>G.,C[EN'0; 5$:5%=Z\/H0FRK;3C43\OZMLS
M:#JONHD-#5<_K+ ,%TC!41V@L.O^CKYBC\$J+N9!ILXT%(KTNV1&68L/]9]G
M)_]",.-2(2W77S4SA>(QTVQ1:F* -KHY(H5QQ^8M"?Z=1MG"2=M:R9LM;UN;
MV3*()MU6$+;VO>\7.-L%B;>G9T?OWOTQ#SZM J.=/@%$MIW\#(_MJG'WUO#?
MQ^#NS9K@//Z^R'FN#:6AH73Y,?O+BC<J9:EFHIU*IE_2%Q!P)GD63[G!E6G\
M%(RZ/(),SQ2?T:4&=>^I8<X9%XRNZ72,44I9[GIB<.E9ZT!J8Z&MV!O2"3XS
M=-$/58'<DBFMYK@ =YR4-V,!E8S8><H!/8YQHFC8C:E'6Y- ][09X<.D-!)"
M%I"^JL*799154&YS9;7)6_,DG._' +*@W.*0[9X2S!,/'SCX%E:'T,97]?.L
M&(@^1?O"@WFMM6Q_(9;K-$G/K#PR;]'**E5$U\RI>L.M'K:0TEG6-(^'<56F
M[\5VP%&",+07CQK2L4;[VWVL#D\;2-M9\B) FDIFP+"WHE5 #0'%."P0>M>F
MG!F=K!84B5YGV:?H-ZH:>N116_9,$ZE=2#1Z\?T8=]K[PSZJ<6>F&+5VWRR5
M>/5TK!MW%[6^FCVD!O!?VR+2O(#Y-I&U^?0+F4^?*I7Z F:E;V52NJ?@N[9%
M+8G@^[0/=7FDV4>/?%R2(S^<W6!T,6\!8/>L<-1:SPY;=F(MQ=Y'A6@(?&Z/
MNFX_?%/WR9C"3;RZ:>+E,BUS%G5F7%!PUB0W+,M9JYGU9H4NG!DFG8!8.99Z
MUQSM#]_;<RLD$>/2]L-XG609YM9>11=PU" VO[Y\_QX5!LQL%#G9GG1M] Q;
M!V6ESG74M7G::\; M"8AU@BVC;V)"$HX+T;OQ).)=8F&9%H\_/KN@''+!04S
MP. FBT8@Q%!5HQM8Z.T&=PS>V<$V(!A)'%&2\HQ*I(]Q?DM%L=HEVOM2K#LQ
M#,\R##.<UC%1EXVO:*98"1STF6E1T:%-@+/++;N;89E( YO$Y7B29)QW:[[H
M1AT_&ZCF<FS/"UI5$>/%8[&[BH8>R"%-J05]Z7J%B<)EWGKULO8W]ZI%S_PJ
MC:[ZC$B*+!B0C$@N]0/ !1,/)><MZ=]-80BAL)UH_@D N-JQ*2A\&G0;6BRG
M=A^;O\O/ SG1E;[0 D7EG=$$1 '^QDKEMR4R9>S-,+S)L01!NZ%VA(<Z81F)
M>C$NEW30<YW>12B<A[[YEIO358X;,SVX6:@_JGVM4EA<HV6SHC"WOOC3QL/M
MK=;R :Z@&IU3$&^\0*Y=+:%SQZ^LUVKY1A2B:KZN&'/'96!:.J\K8EL!M9ID
MTIQTZN?!B 9EFMZJ&XC#!SD*C@M4ZLR[ZK+T9K0>2F0#13UN+T;5SIMK!P2!
MM'X.8.A>#2LW>L$HH$9T8?!K:?J)/<BDX),VDW*/YZPI%OR2E\!2=[>Z&]3?
MC$LD]N652JE=R1$(S4ED"41+Z1NL95/K&,X'4SW67JC9MQSJ&>S:O@DD(\=7
M'G F7H^>.[JP>TY4,0;F)G]Y:\$T/0D70;"E(.YQJWA2,BY:CZ?7Z..H@[Y'
M0771S]F5'/;I<FN+:[PAJIRJD:^8'ZVU-K$O=2F'N51LCM0?VN1F0MDAJ"*K
MVH<><*BU@EJ%08=Q+'.9K[4>U'A7;+N/:15J42[M*BJ H*LF@+5+PJ5[#5GU
M"WHQ +"XTGEU3XNP^.?[R!0'7FGBNI3/S'P1*?X >Y#J<>[GK\PJ@KOAB14'
M;.NQN**5\WQ&#8[1KR9-O#7YR]4">PY4R&+FE_H-F)\IB669X)S==E E@I7T
M''+1UF&<?]&?1:5$'3UBM%QF[D#-KZ1%4(U3 $TWU//U7\9/3:>93ND&80 >
MG*JUUDI>=7N!1N?Y[:N% K<7@67@155@G@>$;>K;UX6[%68-[;VA&@.'JF=5
M2%\I5NFU++@E#973TY>BJ.2U5J!M-?'^K7Z>8 MKLTM<8=%4@\V643,Z>>.;
M6-9Q(/WW>Z:4/W<LKH]7K9.&_$EW-W:EZK##2=A-P&)@ U(&5$*/I6RQHMA-
M.)SFR"2<5-Y\3D'I\+#G15MQSUT09QR1R\?X>T6:GW7&JPKKK<6JWE;,2Y:P
M-9H)M56W:KGU53S3B:'/Y:U'L X4CX!K RO"KDG:7NR&:K('6^'#53YM9$<"
MOQB8(F0-!%H%OFKBH16#M#,_WW$7!3NQ%EI^95*OP4_MC$' PXKXSHW%?=>G
MM=UJS.J12FL#TOE4R9+'R84%H4PV+;U\0](6X7%\<R F"B/;DPQ(6K%9:]_!
MN%;M.\7<+0C^H^KAT0!$ZO_(E'M,TDXLQ\- &SC6"SP+H%A>$&#-$W"'JZA[
M$:C) =)@[-$N;0N)VDG; _+@AJJQD)2L303\75O XMW.=E6I2VOM%>IR[%FG
MVLJH5AI6D'TT/.?6@DDEMK^".RBT_L:]*/3EE=SEHR(WE]P#N\5*HS$6E @9
M<K3;Z$:ZVO8=M2DW>TYO-*8_^#I1"*!&3&UN/&.*/#L_-8UB)6EDDHWKZQ3=
MAEFI$>\=I_;;JPC0$D"N++QBWI6V,+Q(3^KO1;(<;)I>5H$*,..F3>U]W0%!
M=RB"C[CT]<)1Q96N-%Z3; =&BS1GK)[MRN+H?H3_'?7[ORG9,_V4O8I46;ZH
M/3=HFBBY9I4D'YB#WIK5W0*S)M?&5%T-_X9/268;9ZG$;A#8U$Y)QGN 2)Z1
M,I$0<EF@,]B.R$"#:O=(Z'/T!PLF0:,)EV7VZ$^P^);JSEO($E #Y.YOUH.G
M48*7Z7&R!0OX[K;#X-HZVQP _<1Q\^ KX*9!'@#3/)ODZLMF_^&KW)/6&%\6
MQJ2"^3CA$PY#)A63J.B\XBC?B2DP^EQ1XS/ E;X$W!I6C^;+8]_3J>SRK)_%
MM_#/J!PGO_P_4$L#!!0    ( "Y_!%5*.2=VH@<  ,PC   7    86)B=BTR
M,#(R,#8S,'AE>#,Q,2YH=&WM6EMSV[82?C^_ E7FI,F,;M3%%]GQC".[K6=Z
M];C-G*<S(+$4,08)%@ E*[^^NP!UB24E<NND25T_:$Q@L5CL?OAV ?+TJXN?
MQC?_^_F292Y7[.=?7W]_-6:-5J?SIC_N="YN+MAW-S]\SP;M;L1N#"^L=%(7
M7'4ZES\V6"-SKAQU.K/9K#WKM[69=&ZN.Z1JT%%:6V@+)QIGI]2"O\#%V7].
MOVJUV(5.JAP*QQ(#W(%@E97%A+T18&]9JU5+C74Y-W*2.=;K]GKLC3:W<LI#
MOY-.P=E"SVDG/)]V_"2GL1;SLU,AITR*5PT9<3@X'L3=)#F*!H='P^/C[@'O
M#P_C@W[<&\3I_R,TLH/B88QU<P6O&KDL6AG0_*-!KWTX+-W)3 J7C:)N][\-
M+WIVFNK"X7P&QX=_@YH-90[N7(LK.2E&?DF-,'31G6BES>A9U_^=4$\KY;E4
M\]'78QP5&_EUTZ+[6Q:,3(. E6\!;4&S_.,LF'J(XY4L8&%ZU"-C+^\R&4OW
M_%ETT#WI1^WH77.W&YJ@9\$T=BYRCU&?:GUC,$ZF,N$$3Z93-LXDI.SR#I+*
MR2FPGU+L!?/9+N :?J^DP9T0S]EUI2!$*NKS5C1XP5^&QQ?1(1M_<\UZ@VY[
MV?7RD4+YL=8[V+K>JR:[EDG&C6#G;?:M+MYR!6^;+/&!G#.7<43K\.CDD8%:
M<B&0:EH*4C?J'Z"M7H\L!.H8M:CEHT5^NR>B=@CNYN\5RSA"U\!4P@RAX3)I
MV>\5-[A8-<?V4AO'$._?:)/7@.FV?B'XG\?Q;Q+859&@]N'Q;B_N[X\OS:^]
MG7Y]S2UZ$_V6S]EMH6<*Q 2:P;VU4X4&RPJ-"0KGX;)@O)BSJG"F K0?4Y;/
M7NAHSG)\,I(KEO($FPS3N73,Z2"W(5!  M9R,R>1G-\"SKNFTV*;0&-P2N53
M'\Y! HDTF.I0K,#A:(D PV89[B!F*_I9C9^!@5H)+2"75F%.I/0ZDR[#!=H2
M$F\@Z2W1-"UPF5.HV6?-#4\5.OV'0P=8*@L,#L5Y%8PFX@;%L=NL]<LBQ0T;
M4I4L$E4)U(D!7_-\$\$B:9.7&"^"&D%0J166ZC#:>U,C7(4OT9HD42D40 !I
MC+*?SGI[$FXSEBH]LVM4P>DAV(O6-=? 81=&;%CY5/$QV(F/X,SGSXYZT>&)
MK2-?YS3:@CJ4(=[-5XP;\('$P,A8 3F> :(G5M)F)$YB.=(/41 ]"VD3I6V%
MXXB8C%8AHJ71"0ALMNP%!E( (B)$Z_(.DVPQ 7:.>YX*"[M660Q?0%U9D))H
M*$+32Z]34DXM J9H)D84L0:U  &RZF%3IIM3IC@EK7T!1>RAS/?^_/]1X#4<
MW-<3'7UR>"W*O<W?"[!8[Z";/>E_& U-RD<)K^S^0R@QQ(#QK&<*J497!A4@
M'TRE]>R"4E!X/52IK7AIG=L,*.X!@L(AM,V:[ZA1(C>A#58K*?P9T%:QE4)R
M(\EP&3*A9]F"-%26LI/?4=:G,L]%>,A$0_#TYP>56!O)I%*<J!.7XR=?93D<
M$7+F>JK'_V(@060Y' _B :SV7KA\:;"+]X3=WL2P@;[]*65O$")PIU(0C7*K
M"TXLRBWBDNHD;)S@ 6,! H2CY+%4TLTI[VV;EK:"QXN'PO(PN2VU![*^JQ=4
M5J9$*%J?IY-$&^$-\!77! I,OPH1B3U0$M1)!*O)@#K<$K+T+/DT<9?LQ-WE
ME*O*<P,%!=(4*QX\S!=80*\JEV6RW8/;PN/V8L;#"P<B/]E0*L6Z<MMGIL9]
MV)<OI8'JP/3#)3>+%Q6FWS$0/(#V>'30!$\0(6(W,X4@; :3SFMU&8(]]Y#R
M !ZBY*:3I#(4JCJCW-.6:^MP"%U"H Z;H(+ZD!Z&9]PN\R.1@ <3",^.WN":
MN>9XXKL%51\,[\DW__0:_B;@?!:%^O"1"G5_#R,66&NN-BEQQGK\5_N5=OL#
M,N6R1%J:Q+%,<MK895+R#:@JSZ5S %L8,-9TGX;M0J(]-/C?$GHC\'B*IJK"
MWQ:C071P221@0.K\L"QE9\!OB?!#5O>4[^L1?\>S.%$_*,QU]1F.?5MV/1<X
MT,)RTV] HJY>4!3CBT5&,V0;BZG&5GF.I?/;<'RJ67#KG<-3SB2[:]QS3!BI
MP3W6Q"B!IP.,L[]!JP'1#'0NBZE64R!.+_BDO@@T-8- 7BH]!^R=93K0!G\'
M;@B/OY21VH]\'XZ8F<BBY70Y&OIH.%]#U[TQ8@Q,"Z.B>&EAM/CG!+FP5'P^
MDH7WL1]T4NN*M7,Z)W4G4R)43(BU7=[$T%V_2CLZ;A]$Q_0VS:&13BPFKE^T
MM?V+MHX3FWV#]G%_N+.WVXYV]KU7Z[!]=-3[.&K[>ZGM>$<$9Z"[;<F+5XU^
MX]Z6&O7*.Q8M-E3P+NVR#8_K\M/M,/]:] )WR[M9IU[QE[B8\VI287(?-/T;
MZ'_"BIX_&R#?^-]M+^#>6>*>4.S22AM[N64/T9IRB)!0EOGK(;;PQV?OWJWO
M-,<9EYA[B\4!\#65:7^_IS][9U(A\Z'W^$OO=7P.>J2WX._/F?<^"BEU^"IF
M%.X[I[#QF<@*VSXS=E=#>(P K]SFD ]\65+_AN]<_!<W9W\ 4$L#!!0    (
M "Y_!%7VZT-+M@<  !LD   7    86)B=BTR,#(R,#8S,'AE>#,Q,BYH=&WM
M6MMRVS80?>]7H,HT369THRZ^R(YG4MN9>J:7U'6;Z5,'))8BQB#! *!D]>N[
M"U 76Y(CMW::3.H'C4D B\7NP3D+DL=?G_U\>O7'VW.6N5RQM[]]]\/%*6NT
M.IUW_=-.Y^SJC'U_]>,/;-#N1NS*\,)*)W7!5:=S_E.#-3+GRE&G,YU.V]-^
M6YMQY^JR0Z8&':6UA;9PHG%R3'?P%[@X^>KXZU:+G>FDRJ%P+#' '0A665F,
MV3L!]IJU6G6O4UW.C!QGCO6ZO1Y[I\VUG/#0[J13<#*W<]P)U\<=/\EQK,7L
MY%C("9/B54/NB[X8'N[UAWO#P> @2@[3PR@=[G?[>W$OBF+Q9X1.=K![&&/=
M3,&K1BZ+5@8T_VC0:^\/2W<TE<)EHZC;_:;ANYX<I[IP.)_!\>'?8&;-F(,;
MU^)*CHN17U(C#)TW)UII,WK6]7]'U-)*>2[5;/3M*8Z*C?RV:3'\+0M&IJ&#
ME7\!^H)N^<MI<'4?QRM9P-SUJ$?.GM]D,I;N^;-HKWO4C]J]V^YN=C3!R()I
M;%WD#J,^UOI.P3B9RH03/)E.V6DF(65O9,&+1'+%?DZQ%<PGNX!+>%])@SLA
MGK'+2D'(5-3GK6CP@K\,ER^B?7;ZYI+U!MWVHNGE(Z7RJ=8[V+C>BR;[-='.
ML:LVNP3TSC99XI,X8R[CB-3AP=$C@[3D0B#-M!2D;M3?0S^]'5D(M#%JT9TG
MR_KF*$3MD-CUWPN6\0DP Q,)4X2%RZ1E[RMN<+%JAO=+;1Q#K+_1)J_!TFW]
M0M!_'<>_2V 718+6AX?;HW@K'M$!>CR_8X*/!_,0K89Z:] ^M^#WM@;_.VXQ
MY!C<?,:N"SU5(,;0##FH(R\T6%9H5#"<A\N"\6+&JL*9"M!_U#0O;Y@-SG*\
M,L1!*4_PEF$ZEXXY'?JM=2@@ 6NYF5&7G%\#SKMBT^(]@<[@E,IK(\Y!'1)I
M4 NQ6X'#T1,!ADTSF63,5O2S'#\% [416D NK4+1)/V=2I?A FT)B7>0[);H
MFA:XS G4]+02A@?@Z]Z4?V[0Z3\<.L#2A1@MD]%$W&!W;#8K[;)(<5<'+9-%
MHBJ!-C'A*Y%O(E@D,4&)^2*H$0256F*I3J.],S7"5?@:KDD]*H4=$$ :L^RG
ML]Z?A-N,I4I/[0J?<+H(_J)WS15PV+D3:UY^J?@8;,5'".;S9P>]:/_(UIFO
MA8^VH YUB@_S!>,&?"(Q,3)60(%G@.B)E;09=:=N.=(/41!="VD3I6V%XXB8
MC%8AHZ71"0B\;=D+3*0 1$3(UOE-DO%B#.PU[GFJ/.Q*Z3%\ 77I04:BH0BW
M7GJ;DM2@")BBF1A1Q K4 @3(JX=-F:Y/F>*4M/8Y%+&%Y/'^(N%)X#4<W+5#
M*OF1X36O!]=_S\"B4F.8/>E_& U-TJ.$5W;W(20,,6 ^ZYF"U.C*H 'D@XFT
MGEVP%Q3>#I5S2UY:Y38#BGN 8.>0VF;-=W13(C>A#U8K*?PAT5:QE4)R(\EQ
M&930LVQ!%BI+ZN1WE/52YKD(3Z'H"!X/_: 2"RB95(H3=>)R_.1+E<,103-7
MI1[_BX$Z(LOA>! /8+5[X?*YP2[>$78[$\,:^G:GE)U!B,"=2$$TRJTN.+$H
MMXA+JI/PYI@;,0<!PE'R6"KI9J1[FZ:EK>#QXJ&P.&UNDO9 UC?U@LK*E A%
MZW4Z2;01W@%?<8VA0/E5B$AL@9*@3EVPF@RHPRTA2\^27R;NDJVX.Y]P57EN
MH*1 FF+%(R<83KM2N2S$=@=N"Y>;BQD/+QR(_&1#J13KRFV>F6[NPKY\T1NH
M#DP_7'*S>%YA^AT#(0+HCT<'3? %(D1L9Z:0A/5DTGFM+D.PY0Y2'L!#)&XZ
M22I#J:H5Y8ZU7%N'0^CXC#9L@@;JDWP8GG&[T$<B 0\F$)X=O<,U<\WPQ'<-
MJCX8WNG?_,=K^(^ \TD4ZL-'*M3]PQHQQUISN4F),U;SO]ROM-L?H)2+$FGA
M$L<RR6EC%Z+D;Z"I/)?. 6Q@P%BCW-%](=$?&OQ_";V6>#Q%4U7A'R>C0W1P
M221@0FI]6)2R4^#71/A!U3WE^WK$/^.9GZ@?E.:Z^@S'O@V[G@L<:&&QZ=<@
M45<OV!7SBT5&,ZB-1:FQ59YCZ?Q7.#[5++CQF<.7K"3;:]S7*!BIP3W6Q"R!
MIP/,LW^"5@.B&>A<%A.M)D"<7O!Q_2#0U P">:GT#+!UFNE &_P6W! >_TJ1
MVH_\T!PQ,Y9%R^ER-/39<+Z&KEMCQ!B8%F9%\=+":/[/$7)AJ?AL) L?8S_H
MJ+85:^=T3N:.)D2H*(BU7][%T%R_:SLX;.]%A_2ZS:&33LPGKM_$M?V;N(X3
MZVV#]F%_N+6UVXZVMMUK==@^..@]C=G^3F8[/A A&!AN6_+B5:/?N+.E1KWR
MAD6WG]_3+EN+N"X_W@[S[TW/<+?<5IUZQ9_C8EY7XPK%?=#TKZ@??T5A+WSD
M13U_-D#*\;]W7]+=6N&.2.S20AL[166'KC7C$!]A7^:?#K%Y+#YYO*R]\_P5
M"HGB\#O6DNPM'@DE*5_SOP_S)Q_)#[W@7T2NX[7GR;]TN.^E^OT6[WQC4NKP
MD<TH/!V=P-I7)\NMX'6TNQS"8]P/E5L?\H$/5>K?\-F,_X#GY&]02P,$%
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MH]HM9Y)+-=T+W5]B5[R"K!G?3I\M4"M5[%E?8_@]314K&@'-KBAB05CN==-
M/4!]S@3MH$>Q!7MR6;*4F:=[T3A,!K$??0KW;J 91I:JWF>=O(?6U_)O095A
M!<N(I2>\J96N">Z^E(\6<70([_QS?^'#.<TLZB8WT6 4/EK,<PWS7%;VP'X+
M(?XDL)-P#+( 4U(X)RHE@FKO]26G6YAGQJ[$81@_T*GX4FX.[W3S5$ FA6B<
MA0TSI?/R;4T4 N5;.*.55,['>9K^QBB<BLR'?2OT=.\PCL-D(=<5$5OW%B7/
M >W\(-6ZI63HO85"*F>U0HPR!RIR),'/M: P"/M-?28:"L;Q\S4$3$"ML&-0
M#43D<'*9E42L*!;V]9II;>'>1-'@[$#TF]U/^W#&4$_E,/?A1RFN"*=7?5B4
MA*DU$5U27THK8K=9E(P6N!EN;M@%A=<%%@:J.L'6USYDKF;@CZKCLI'P\5C:
M[0\2L >R;WTC+?-O2K<R]^)6']<)>C<Z3!ZX^%8DS[%]>IP69CH8(VF<'88Y
M$F;J18?5EVLW=U-R/WK>9&_WN<0@M80L:H[LS# ?W%+DFC:*_EDS16UCUS9Z
MNJ5V--@GK5UD8S3:S[NWXC;=KJG6)B":#(88^DEB&7*_0-JP)=T7U3AWV,7V
M9HX^&^UO+FOQWV:-"2P"ZZ;#8L$Q! WD^-7%ODLI'DK,::6HMMGKVV7".: :
M8B(<<ZLK3*?N.ZV""2(R^QT-YFZV=$<8I6K>)%]BQ7%[ZEL'V'_@4[0F:H43
MGY'5=.1";TC*:;>:2I53Y6$*.*DTG78_DISIBI/ME D74*>4M+92:8Q<6W/)
MA2TV&>$M+@>Q66Z'RE'LCP>1G2L-@C1YMW$[<OINY Q,OKLV.?0GX>>70S^Z
M7@N<[<8^>J QCB]Z@]XM2D[CZA*B3ZEN6;KCA*R^'D.=AT_WA@>)=L^[NL)U
M;N_A:YM0FVYT%;3D+(<.^:,/Q']T_M'[]Z^[^__*^WF]JK6!83-8[;H6N"KS
MQ?]Y>PS#[1PTXL(^([$%8[?@#2,8C@O8Z@T5" 1[B[M,:.>&'-(M[,S^)8YP
M*47Y2LD+9J=7G-]NSL.67!N&O2JU$TC;W=#2;9FB5H+ILC%PSRD7QQ6&[0RA
M%@74%7ZQ6*DV#]7$[I/F6W<9E6PN<Z:*<F*/TL[MQL=2Z=I8^%&%I%@O:[.K
M\@\7(NVSN9YQ%T5'?P%02P,$%     @ +G\$5?XAW5?*!   =!(  !<   !A
M8F)V+3(P,C(P-C,P>&5X,S(R+FAT;=U86V_;-A1^WZ]@':Q- >ONQ!>Y 3(G
MQ3)T:]JX+?8T4")E$Z5)C:3B>+]^AZ24IG:RI5A:I/.#(/'P''[G?LSIDY/7
ML_GOYZ=H:58<G;_[Z=79#/6"*/J0S:+H9'Z"?I[_^@H-PCA!<X6%9H9)@7D4
MG?[60[VE,?4DBM;K=;C.0JD6T?QM9$4-(BZEIB$QI'<TM2OPI)@<_3!]$@3H
M1);-B@J#2D6QH00UFHD%^D"H_HB"H-TUD_5&L<72H#1.4_1!JH_L$GNZ88;3
MHT[.-/+?T\@=,BTDV1Q-";M$C+SHL4%9%J-#&H_'\6 P&*?CP^$PR4:C+!GB
M,2;9'PF C&"[Y]%FP^F+WHJ)8$GM^9-!&@X/:I.O&3'+21+'/_;<UJ-I)86!
M\Q3P^U<O9D>8H5<FP)PMQ,2IU/.L';F47*K)7NQ^N:4$%5XQOID\FP%7H=BS
MO@;S!YHJ5OD-FOU% 0O <I]K#W4(_)P)VD%/4@OV]&K)"F:>[B6'<9ZE8?HY
MW-N!EF!9JGIW*GD/KF^EWXPJPRI68AN>Z+Q1NL%P^EP^6L3)"+T++\)9B"YH
M:5%[WR390?QH,1]K=$QD;1/V>S#Q9X8=QX=(5L@L*;K JL""ZN#U%:<;=%P:
M2TGC^*&RXFNI.;A5S3.!2BF$5Q:MF5DZ+=\T6 %0OD%O:2V5T_&X*-XSBLY$
M&:)]N^GIWBA-XWPF5S46&_>5Y,\1R'DIU:H-R3AX@RJIG-0:,$J"J" 0!+\T
M@J(L[OOZC#6J&(?E:PC@@$9!QZ :84'0Z56YQ&)!H;"O5DQK"_<F"H^S ]'W
MIY_UT44I#01:"(J [34L4,$ SWM64G2NJ&8$UOMHMF2T0B^9P*)DF*/7%50$
MJCJWMTKV4>F*!;S471 ;B3[EHSUWF".;B7VK%&Y#_N;N=L^]@JH/= QJ'8SR
M!ZZZ-28$^F; :64FV2%$BY/#A+7')$A&]=?K,[?'XG[RW+MM]SD'([616#4<
MPK($?W ;&]?QHNB?#5/4=G1MK:?;F$ZR?=S*!;<G!_ND^ZJVX^PZQEH').-L
M *8?YS8"[V=(:[:\6U%>N5%GVYL^NM/:WYW7TG_T&A.0_2O?6J'2& P""*PZ
MVW<NQ<R6FAJRT><HD#'G"-@ $R0C$&IPI^X[KNHZ24$@<4.E*Q&PJ^'>^1)*
MC3M3;R5P^,!9M,)J :.>D?7DP)G>X(+3CEI(1:@*P 4<UYI.NI><,%USO)DP
MX0SJF/)65@$%2ZZLN/S2%IL2\Q:7@^C)[31YD(:'66('2@,@#>D.;F?-T,V:
MD2&[M/$H',=WD^,PN:9%3K:7#QIHL..+7M;;"LE)6E^AY/-0MU&ZK83'_^V"
MU"GY=&\PS+5[;G>$:]?>0]76G];;H"G2DC.".M1?: <0\HV-\!\4?_RZ?5%7
M_U^I?MPL&FW0P$]2NZI%KKI\]7]KCV&:/48:<$%_D=!ZP>G<5W\&8P*T>$,%
M (&>XFX/VGF!H&*#=H;])8QN!60)]"1YR>RX"G/;S0'8]ILU@QY5V,FC[6H@
M:7M/U2C!]-(+N.=8"W',H(T!U*I"30TK%BO5YJ&:UWW<O'5Y44M_>S-1E$-C
MO:0[UQF?:J1K7_$G%EQ H6S,+LN_W("T3W\?XVZ&COX&4$L! A0#%     @
M+G\$5>TNU,F_\@( OY,K !$              ( !     &%B8G8M,C R,C V
M,S N:'1M4$L! A0#%     @ +G\$5;-W@\SO$@  >LD  !$
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M2P$"% ,4    "  N?P15!?CF3?$"  #L @  %               @ %ISP,
M86)B=BTR,#(R,#8S,%]G,BYG:6902P$"% ,4    "  N?P15."8F*E,5 0#I
M_0H %0              @ &,T@, 86)B=BTR,#(R,#8S,%]L86(N>&UL4$L!
M A0#%     @ +G\$54 ]UCEMG   N1D' !4              ( !$N@$ &%B
M8G8M,C R,C V,S!?<')E+GAM;%!+ 0(4 Q0    ( "Y_!%5]I(GU;2H  'X>
M 0 7              "  ;*$!0!A8F)V+3(P,C(P-C,P>&5X,3 V+FAT;5!+
M 0(4 Q0    ( "Y_!%5*.2=VH@<  ,PC   7              "  52O!0!A
M8F)V+3(P,C(P-C,P>&5X,S$Q+FAT;5!+ 0(4 Q0    ( "Y_!%7VZT-+M@<
M !LD   7              "  2NW!0!A8F)V+3(P,C(P-C,P>&5X,S$R+FAT
M;5!+ 0(4 Q0    ( "Y_!%5<L4X6S 0  (,2   7              "  1:_
M!0!A8F)V+3(P,C(P-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0    ( "Y_!%7^(=U7
MR@0  '02   7              "  1?$!0!A8F)V+3(P,C(P-C,P>&5X,S(R
:+FAT;5!+!08     #0 - &<#   6R04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
